<SEC-DOCUMENT>0000950170-23-005111.txt : 20230228
<SEC-HEADER>0000950170-23-005111.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228161925
ACCESSION NUMBER:		0000950170-23-005111
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		92
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				822933343
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38792
		FILM NUMBER:		23685676

	BUSINESS ADDRESS:	
		STREET 1:		131 OYSTER POINT BLVD., SUITE 600
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		131 OYSTER POINT BLVD., SUITE 600
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>alec-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-28T15:36:36.4660+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:alec="http://alector.com/20221231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_a3866d38-7523-46db-8d9f-8bcd3b2d27ed" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef">http://alector.com/20221231#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric id="F_b7cff7a8-112c-4256-b606-e164953835e3" name="dei:DocumentFiscalPeriodFocus" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef">FY</ix:nonNumeric><ix:nonFraction id="F_98ac5068-7936-4fc0-9429-483bd823749b" name="us-gaap:CommitmentsAndContingencies" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9570da83-0995-4ddf-8004-16aa50d300a5" name="us-gaap:CommitmentsAndContingencies" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_5efed98b-6248-4e22-97cd-ede4e5c8887a" name="dei:CurrentFiscalYearEndDate" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" format="ixt:datemonthdayen">December 31</ix:nonNumeric><ix:nonNumeric id="F_06d00587-146f-4b77-9cfb-7f1be4902705" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a">http://alector.com/20221231#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric id="F_88011f76-3c2e-41e3-bb75-b765e6c07793" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b">http://alector.com/20221231#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric id="F_19d80ba0-b0e8-42a5-8784-39822104cb76" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_d7eda464-9214-4fe2-80f7-6b4a12c2cf10">P3Y</ix:nonNumeric><ix:nonNumeric id="F_cc21cf17-7429-486a-b806-104d61bd189e" name="dei:EntityCentralIndexKey" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef">0001653087</ix:nonNumeric><ix:nonNumeric id="F_0e7814e4-5073-4e99-b6fd-985c393ee224" name="dei:AmendmentFlag" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric id="F_494536dc-8307-42a5-8e8b-fe55a7199628" name="us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend" contextRef="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9" format="ixt:booleantrue">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="alec-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_5c63d7ae-a408-4aaa-b856-64a3f876dcd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea97f9ff-6baa-434e-8a41-03175d03a38c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6eb70da4-a1bc-45a1-8da8-c9552a0a4ac6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0120a0fc-9112-4e54-9638-49d731099e2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67cf0962-6249-477f-8bc4-dab96a763b98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_338e36e2-ef61-4f44-861b-3a1b978b8228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a90b3f2f-9462-46f0-84ce-63965231a711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd06c0e7-b9e9-48e2-9fd2-99b651c4b5a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e759e0c4-57cc-4d3e-90d2-e3c5076206fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2c6f352-9d45-4576-a18a-112160c86b51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59b9e1be-3875-4c2c-8688-02e607d91e6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_180fddf9-2bc6-4a44-a946-c3ac0b3b7336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59545206-883a-4aa3-a49c-906caa840899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_816d6294-b950-41ec-954c-c41ce41aab6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69eaec9d-be8a-46cd-b047-8697f5e418ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0994610a-2693-49ff-a322-fa66e5902607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eebe0049-dfc6-425d-8d39-93f33680d12f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-30</xbrli:startDate><xbrli:endDate>2020-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed1f3bb7-c84d-4b92-a5a6-e2a94d7ac051"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-22</xbrli:startDate><xbrli:endDate>2022-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_319ea842-0000-481f-8857-4a411838770a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43db021b-c8f9-4318-82fe-8c0ec28ec33c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d16d809-66ff-4090-8fd8-8bb44fd13bcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cf5d0c4-ca22-4be2-aa95-e9fd5130a84b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2057c28e-bb01-4164-b42a-733be6be9aad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c3e6d3b-2fe3-4f9b-923c-d40ea56722bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e29ec8b-8d03-49b6-84f6-bb02efd765fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51b97a6f-177d-4792-ade6-51b7eab823e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cee82e6c-ce42-4848-8ad7-b247c43c8a26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f82b000-4be4-479f-8d5a-48258e77ae0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80e23df0-dda9-41ff-b7a3-932c8bf26d7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4670a0e4-4053-442e-b19c-76a0ef8da1fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6f138ff-488b-4b84-a7d2-f77486a49d63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b3e5c54-3f8c-4714-8434-7829b44103ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57f29121-2ac0-4227-aa7c-e698d47d2373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16a6dfb4-c570-4d0c-aebd-ef6ff61c25e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5506b44b-1aea-4b19-b486-8910d5fdf80a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e26edbee-11a6-44f2-9f0f-58d3b932feaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a436588-46b7-4c39-90f1-b29291faef62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d339045c-e830-4398-bf09-392c72a9d130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_591622e9-478f-40d8-a4c4-83e7718adf29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a99dc6-2893-4e9d-b0b0-79417c0a1aeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a365a03-f3eb-4107-9a82-26a3d4345ee8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc7bd397-63c7-41cc-afa7-7230b2cab7ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:InnoventBiologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9836c7b3-8244-4a0a-9397-0627ae5caac7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14db55be-444b-484b-9308-f5fa77d06c64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dad2a26c-287b-4267-9f7c-8a34fc96b55a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e9e000a-a972-4453-815c-7beddee684a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb53d62d-50b1-4820-8847-5ea059efb08f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_595ae80d-557b-47e1-8c82-0647e75f5492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48a91691-46db-40c9-a5b2-794422b8838e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bee6f6bf-d1c4-42f9-9ab2-0d5a9c70a44d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bdf40b1-3e1d-4b1d-ac05-25a671e15c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0630ba0-e9e8-4702-89d0-bdba73bdd2e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bbd6899-6eb8-4d93-b39f-c6d7afda1a04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7eda464-9214-4fe2-80f7-6b4a12c2cf10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eae11ed-31bf-4dfc-a698-681b39d46f70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2cef38d-be1d-484a-a61c-5428186c190e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2dccbdd1-17e9-485c-a5ee-03938c7e22f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf8d8382-eb79-4d5a-aace-511cc534b48b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92d78956-76c2-4167-b848-5449236c361e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c68a962-b28e-4960-a9ae-21e424ed19e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f8633fe-5aaf-447e-ae50-bc7154a4d0d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-30</xbrli:startDate><xbrli:endDate>2020-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b7ae830-6548-4c51-9858-5fd1f867e8f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e30431e6-e3b0-4a96-9bef-19773862a1a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a84f0779-d476-4feb-8427-952120804b66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc0ce554-adea-4930-b36c-ddea841a6c0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0060090-89cf-486b-ac52-984818190a96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a935fdcb-ad72-4392-9a72-8a721afa0563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1daf4bd9-70b1-46fd-8ea2-c3707e3a6d0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1389774a-b29c-48d6-a55f-f4bbb7532913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52877e94-eb03-44b8-a6be-a533ea71c990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79a8adcb-cfbf-4eba-bbda-4e86d5eee09c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5a26f10-025e-4a2e-83ca-fad8cfb00b35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d982249-1d80-47dc-833c-6f8db5de8881"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3b39a72-f9d5-452e-8491-11e893261ed3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_235ab5c2-cb0b-4693-a7d8-c6af3cd3645b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23fa1cec-8bf2-4e74-94f9-7b74111d38b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2eed340-5921-424b-b2bd-6f6e1a65315d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ede9fc7-3539-445c-b590-2e32ccf2dc14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45035b09-08b3-4500-b7a8-9c651c96035b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7aceb927-85b2-403a-82fd-27292ccc4303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8df03805-8723-4874-a2a2-8c93c5cbd3d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68921c7f-cea1-46f8-9606-82bf1ee5887d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8e32b37-b52b-4be3-bbcc-061f59815156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bca2306-c6f8-41f3-9a71-4b209e479578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98dece0f-6865-495b-b2f4-10ffd8b3e0d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e86e0f59-9472-4a49-b595-48701d364860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3b2caf5-7252-4732-8fff-6572963b403e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ae3112e-641f-46ac-8cd7-601ed0a853e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a249850f-9ff5-4ed1-8915-381e8e7d8c32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-30</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f4164fc-b4c1-41ca-8455-663b93759519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e21ea263-2f4e-4a53-bf66-2c7077518b36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0a599ce-bcb4-4bd2-baef-99bf600a266e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1066ab24-de91-4fc8-b8ef-54102a1ace80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a63e3081-f730-456e-b5ed-d6fc2de87931"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AlectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e8bb82e-dade-4bfe-bc72-3759b7ed3710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43d96e6b-e335-4918-832b-938ca6e7af68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe4d91c0-ce81-47c8-ba8d-75ea9ef9fb79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f138f916-581b-4f02-aadd-4cd12427fc86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76299c65-2f3a-4aa2-953a-8368c1d95f6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9cdc029-237a-491e-84f0-8ce387ab9c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1909874-9ac4-4faa-a605-aeb9628d2105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33d99e34-332b-4171-90ad-9a300bdceb05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_739d8fa6-0e40-445b-8283-8871a7bb5917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25d652af-cdb3-4c04-9508-c4f3acbb1dcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_493c7746-435c-403e-8f86-4bcdeada8dd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_558fd0f4-ad61-4047-b762-e6960a1f35eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b22c619-0e67-4a8a-9893-c4a93f9df158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_176df7af-82ab-480c-bae0-7332bb4be390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0aa7056-f119-4199-97e6-cbcd61a7b3fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fea33d6-9da1-41c4-92b1-404be25d8a1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f312b892-d20e-4878-bd76-21a8ad92aaba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfad70cc-a2ab-437f-929e-a3eb95fd5c88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aed28b8-d995-4247-8f88-dd02919d008c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_873e87e5-56d0-4394-ba3e-604f72c1fb04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-06</xbrli:startDate><xbrli:endDate>2019-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbc12a08-d369-441d-a256-6c6e5a6edbac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57a31f45-5c3e-4095-acf4-1177aeb8b664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30408e35-6b1a-4011-ac8f-7e1456941ba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f49c42b-493f-47f8-9739-cb8ff352f950"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07adf335-3612-4d8b-8411-b0ca428a8c48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d5342d6-08d3-4f1d-a440-effc09b14ff7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73e80b90-789c-418b-a25b-f51ca32e11ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dcbe690f-5774-4129-bd39-6000b70e20db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffc3dde4-e230-4e99-96ea-1e5e5dfbddfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edb4f89e-28d7-4da4-8c65-2ab76be71025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abf92419-83da-405a-8247-30fd4646394a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001653087</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bac464e5-91bc-42a4-b71a-f24347a6f1ab" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Wingdings&quot;, serif;"><ix:nonNumeric id="F_f6112d78-e83b-4397-9810-4cd8a71ffd34" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:DocumentAnnualReport" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_400c5e9a-a747-4ba4-a177-0e5e1f9c0bb0" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5f461f3-4da5-45a6-96fa-81624f08ffc2" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Wingdings&quot;, serif;"><ix:nonNumeric id="F_93483845-578a-47e3-a092-9752294ce3d5" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:DocumentTransitionReport" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d62b6e77-78aa-4edc-97f3-ec97f38817c2" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_46fc0ac1-8912-4ce3-ae39-9912bb703c97" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.433%;"></td>
    <td style="width:3.739%;"></td>
    <td style="width:31.783%;"></td>
    <td style="width:2.502%;"></td>
    <td style="width:32.544%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e971bbff-3f10-43a3-8ab8-adab29f4465a" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2c92e05-a750-44b0-90e4-dac3838f2df2" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4892758-22c6-4606-95ab-a55e06041f91" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82-2933343</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ff1a4942-5b29-49ae-8bc2-6e2006c02600" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131 Oyster Point Blvd</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cd830c8a-0824-48ae-8ad9-0273f148620d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 600</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e43addef-5226-4a76-8b32-bdcfbcf0072f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5eb0382d-4144-4111-82ae-44acdea6f43d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f96374f5-e4f2-4b55-89b7-83cf0f8b371c" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94080</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6f96e951-acc7-4ab1-bc74-11b17baeae2f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1d6bbd9-5701-4737-99ff-4a4d54ec8218" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231-5660</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Registrant&#x2019;s telephone number, including area code)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Former name or former address, if changed since last report)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:33.333%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.498%;"></td>
    <td style="width:26.224%;"></td>
    <td style="width:40.278%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_04bb1806-e8a9-4ee7-a4ce-70a0e7434e5d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c2b1fdc-ccd4-4699-b5c4-fd3da1769b7f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALEC</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_62b8f5c2-f461-4f0a-9f1c-e0f5c634d812" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_079840f3-0086-4e41-ad98-df83d491c956" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_00d17e73-e65d-4094-809b-114396915cca" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_016dda0c-00ff-467a-bbb7-4af27ebeb60b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fc121107-769c-484d-a606-3dcddf701c78" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.902%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:55.841%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.101%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_114402d8-2d5f-4c3c-81a8-8bc5f1a34b8e" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf0a8;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf0a8;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1ef09cfb-494d-40cb-a350-8cb3f5034acb" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntitySmallBusiness" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf0a8;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a028717-c0f0-4545-ae49-912de26912d9" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityEmergingGrowthCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xf0a8;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under section 404(b) of the Sarbanes-Oxley Act(15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report </span><span style="font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;"><ix:nonNumeric id="F_2a1b660d-0112-459a-bf01-67d7996358e9" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xa8;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xa8;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;"><ix:nonNumeric id="F_5601c700-a945-41a3-9271-81007280be13" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf078;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2022 (the last business day of the registrant&#x2019;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f484f64-8f2d-4c86-a953-f306b08eb39c" contextRef="C_595ae80d-557b-47e1-8c82-0647e75f5492" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">627.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing price of the registrant&#x2019;s common stock, as reported by the Nasdaq Global Select Market on June 30, 2022 of $10.16 per share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of the registrant&#x2019;s Common Stock outstanding as of February 21, 2023 was </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13d006c8-ac36-46d7-90cf-1b9bd3d20eaa" contextRef="C_7bdf40b1-3e1d-4b1d-ac05-25a671e15c71" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">83,027,910</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3d79079b-e6c1-4bce-adaf-189dc094234a" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the registrant&#x2019;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s 2022 fiscal year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Report on Form 10-K</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.944%;"></td>
    <td style="width:83.759%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.296%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_re_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;could,&#x201d; &#x201c;intend,&#x201d; &#x201c;target,&#x201d; &#x201c;project,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; or &#x201c;continue&#x201d; or the negative of these terms or other similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to the development and manufacturing of our product candidates and research programs, including additional indications that we may pursue;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our estimates of the number of patients in the United States who suffer from the diseases we are targeting and the number of patients that will enroll in our clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and focus of our future clinical trials, and the reporting of data from those trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the market opportunity for our product candidates in each of the diseases we are targeting; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to expand our product candidates into additional indications and patient populations; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competing therapies that are or may become available; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug designation, for our product candidates for various diseases; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">existing regulations and regulatory developments in the United States and other jurisdictions; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our continued reliance on third parties to conduct clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the need to hire additional personnel and our ability to attract and retain such personnel, especially in light of a competitive hiring and compensation environment; </span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and additional financing needs;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our financial performance, including potential volatility in our stock price;</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the coronavirus (COVID-19) pandemic, including recent and new variants, on our business; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effects of inflation; and</span></div></div>
  <div style="margin-left:5.731%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements.	</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this report and are subject to a number of risks, uncertainties, and assumptions described in the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this report. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Supporting our scientific approach, our research and drug discovery platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines. As a result, we have identified over 100 immune system targets. Three product candidates, latozinemab (also referred to as AL001), AL002, and AL101 are in clinical development, and we continue to develop our preclinical and research pipeline. We recently completed a prioritization review, focusing our development resources on our progranulin and TREM2 programs and extending our cash runway through 2025. We are advancing our clinical product candidates and research pipeline with our existing resources and in collaboration with our partners, Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK) and AbbVie Biotechnology, Ltd. (AbbVie).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> On July 1, 2021, we entered into a Collaboration and License Agreement with GSK (GSK Agreement) to collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101. Under the terms of the GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in the third quarter of 2021 and $200 million was received in the first quarter of 2022. Together with GSK we are pursuing therapeutic candidates for frontotemporal dementia (FTD), Alzheimer&#x2019;s disease (AD), Parkinson&#x2019;s disease, and amyotrophic lateral sclerosis (ALS).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latozinemab modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. Latozinemab is in development to treat FTD, a severe, rapidly progressing neurodegenerative disorder that affects 50,000 to 60,000 people in the United States and roughly 110,000 people in the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latozinemab is currently being studied in a global pivotal Phase 3 trial, INFRONT-3, for the potential treatment of adults at risk for or with symptomatic FTD due to a progranulin gene mutation (FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). We are preparing to engage with regulatory authorities in mid-2023. The purpose of the meeting is to discuss statistical analysis plans based on emerging knowledge in the field that may enable us to complete the pivotal INFRONT-3 clinical trial with fewer patients and/or a shorter treatment duration. The company is targeting a data readout from the INFRONT-3 trial in early 2025, pending regulatory feedback. In prior clinical studies, latozinemab successfully demonstrated elevation of progranulin levels back to the normal range and encouraging early signals of biomarker and clinical activity. Latozinemab has been well tolerated in healthy volunteers and FTD patients in our Phase 1a, Phase 1b, and Phase 2 clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we presented data for latozinemab from our ongoing open-label Phase 2 clinical trial, INFRONT-2 in patients with FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. INFRONT-2 was designed to establish the safety and tolerability of chronic administration of latozinemab at therapeutic doses, and to measure biomarkers of disease and clinical outcomes. Treatment with latozinemab was well tolerated and restored PGRN in both plasma and cerebrospinal fluid (CSF) to levels seen in healthy volunteer age-matched controls for the duration of treatment. Disease relevant lysosomal, inflammatory, and astrogliosis biomarkers trended toward normalization over twelve months of treatment compared to baseline and age-matched controls, and mean levels of plasma and CSF neurofilament light chain (NfL), remained stable over twelve months. Volumetric MRI suggested slowing of ventricular enlargement and brain atrophy in latozinemab-treated patients compared to a matched historic control cohort of participants from the Genetic FTD Initiative (GENFI2) patient registry. Clinical outcome assessments using the CDR&#174; plus NACC FTLD-SB scale found that latozinemab treatment slowed clinical progression by 48% compared to the GENFI2 matched control cohort.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we presented additional data from the INFRONT-2 trial of latozinemab in FTD patients with a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> genetic mutation (FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), building on the results in patients with FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Clinical outcome assessments using the CDR&#174; plus NACC FTLD-SB scale found that treatment of FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">latozinemab resulted in a trend toward a delay of approximately 54% in annualized disease progression compared to a matched control cohort from the ALLFTD consortium. In addition, latozinemab treatment was well tolerated and resulted in a two- to three-fold increase in progranulin above physiological levels in cerebrospinal fluid (CSF) and plasma respectively, and a decrease in the neurodegeneration biomarker GFAP. We intend to provide additional data updates on the FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cohort in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In September 2021, we initiated a Phase 2 study of latozinemab in ALS patients with a C9orf72 mutation. However, in light of the evolving ALS landscape, we closed that study to additional enrollment. We and GSK are currently evaluating plans for development of latozinemab in ALS.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL101, the second product candidate in our PGRN portfolio, is designed to elevate progranulin levels, similar to latozinemab, for use in the treatment of larger indications including Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. Mutations that moderately reduce the expression levels of PGRN are associated with increased risk of developing Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease. In animal models, increased PGRN levels have been demonstrated to be protective for these diseases. In 2021, we presented interim data from our Phase 1 clinical trial testing the safety, tolerability, pharmacokinetics, pharmacodynamics, and bioavailability of single doses of intravenously or subcutaneously administered AL101 in healthy volunteers. AL101 increased progranulin levels in the periphery and the brain persisting for one month. AL101 was found to be well tolerated at all doses administered. We completed enrollment of additional cohorts to test multiple doses of AL101 administered intravenously and subcutaneously.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, we presented data from the multiple-dose cohorts of the Phase 1 study. We demonstrated that AL101 was well tolerated and increased PGRN levels in plasma and CSF in a dose-dependent manner. The pharmacokinetic and pharmacodynamic profiles of AL101 support future development in larger indications such as AD and PD. We and GSK plan to advance the AL101 program in 2023, with the initiation of an Asian pharmacokinetic (PK) bridging study followed by a global Phase 2 clinical trial in early AD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our AL002 product candidate targets Triggering Receptor Expressed on Myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation. We are currently developing AL002 for the treatment of Alzheimer&#x2019;s disease in collaboration with AbbVie.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our Phase 1 clinical trial, AL002 demonstrated tolerability, target engagement, and proof-of-mechanism in the central nervous systems of healthy volunteers. In January 2021, we initiated INVOKE-2, a randomized, controlled Phase 2 clinical trial of AL002, in which we initially aimed to enroll approximately 265 participants with early Alzheimer&#x2019;s disease. We now plan to add up to an additional 64 participants in the ongoing INVOKE-2 trial to replace discontinuations, including APOE e4/e4 participants, from the study, as mentioned below. In January 2023, the first patient was enrolled and dosed in a long-term extension (LTE) of our INVOKE-2 Phase 2 clinical trial. In February 2023, we and AbbVie amended the AbbVie agreement, which will result in our receiving a $17.8 million milestone payment for the dosing of the first patient in an LTE study.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amyloid Related Imaging Abnormalities (ARIA) have been observed in our ongoing INVOKE-2 Phase 2 clinical trial in AD. ARIA are MRI findings suggestive of vasogenic edema or hemosiderin deposits. The incidence of ARIA has been shown to increase in AD patients with the administration of certain Alzheimer's disease therapeutics, namely anti-&#x3b2;-amyloid antibodies. In our INVOKE-2 Phase 2 clinical trial, most ARIA cases were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred almost exclusively in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, consistent with recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an Independent Data Monitoring Committee (IDMC), which is allowed to review unblinded data and to make trial recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL044 targets membrane-spanning 4-domains subfamily A (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), a major risk locus for Alzheimer&#x2019;s disease. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene family members encode a transmembrane receptor protein that is expressed selectively on myeloid cells in the brain and associated with control of microglia functionality and potentially with microglia viability. In September 2022, we commenced our first-in-human Phase 1 trial of AL044, with the intention of developing that candidate in Alzheimer&#x2019;s disease and potential orphan indications. Based on initial PK and tolerability data, we decided to close the trial. We are actively pursuing a back-up MS4A program to develop an IND-ready candidate with a potentially improved dosing and tolerability profile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The neuroimmune system of the brain is part of the body&#x2019;s innate immune system, and based on our pioneering work in immuno-neurology, we have identified potential oncology applications for several of our therapeutic programs. We believe that products focused on innate immune biology may complement and expand the efficacy of current immuno-oncology drugs that target the adaptive immune system.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL009, is one of our innate immuno-oncology product candidates. AL009 is a multi Siglec inhibitor that is designed to enhance both the innate and adaptive immune system response to tumors by blocking a critical glycan checkpoint pathway that drives immune suppression. We continue to conduct preclinical studies and technical activities on AL009. We own worldwide rights to AL009.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL008 is another of our innate immuno-oncology product candidates. AL008 is an antibody designed to inhibit the CD47-SIRP-alpha (SIRP&#x3b1;) pathway, a potent immune checkpoint pathway co-opted by tumors to evade the immune system. AL008 binds SIRP-alpha and has a novel dual mechanism of action that inhibits immune suppression and promotes immune stimulation. We entered into a licensing agreement with Innovent Biologics (Innovent) in 2020, under which Innovent would develop and commercialize AL008 in China, while Alector would retain development and commercialization rights in the rest of the world. Innovent will not be continuing development of AL008, and we intend to re-acquire the rights we granted to Innovent for the development and commercialization of AL008. Innovent submitted an IND with the Chinese regulatory authorities, and Alector is in the process of obtaining relevant materials and information from Innovent. Alector plans to evaluate data and documentation from that IND application to potentially support an IND submission in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our efforts to advance our programs through clinical development and execute on the strategic approach outlined in the section titled &#x201c;Business &#x2013; Our Strategy,&#x201d; Alector from time to time may execute partnerships with other biopharmaceutical companies. To date we have executed three licensing, co-commercialization, or co-development agreements for certain programs in our pipeline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Immune System is Central to Neurodegeneration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to neurodegeneration and dysfunction in the immune system. As a result of these genetic mutations, the brain&#x2019;s immune function deteriorates and subsequently would fail to carry out critical activities, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clearing or counteracting pathological neurodegenerative proteins such as amyloid-beta, tau, alpha-synuclein, and TDP-43; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">providing metabolic and functional support to nerve cells; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulating synaptic connections; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that restoring the immune system&#x2019;s ability to perform all of these vital functions in the brain is crucial to addressing neurodegeneration given that past approaches focusing on single degenerative pathologies have had limited or no impact on disease progression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The brain&#x2019;s immune system undergoes gradual deterioration of functional characteristics as part of normal biological aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated genes linked to neurodegeneration, with the goal of slowing or reversing the deterioration of the brain&#x2019;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple independent pathologies responsible for neurodegeneration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to develop therapies that harness the immune system to combat neurodegenerative diseases. The key tenets of our business strategy to achieve this goal include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Building a leading, fully-integrated company focused on delivering innovative immuno-therapies, validated by human genetics, for the treatment of neurodegeneration. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that building a fully integrated research, development, and ultimately commercial company will enable us to develop therapies more rapidly and efficiently for patients and realize the full potential of our immuno-neurology approach and discovery capabilities. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Applying our proprietary capabilities to rapidly advance our product candidates through clinical proof-of-concept studies and beyond.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are focused on maximizing the probability of success of our product candidates by leveraging immunology, neurobiology, and human genetics, as well as our state-of-the-art bioinformatics, to enable better and earlier target selection. In addition, we are also focused on a biomarker-driven approach, including proprietary tools and assays, to confirm target engagement, inform patient selection, and follow clinical outcomes. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Maximizing the therapeutic potential of our targets and product candidates. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the central physiological roles played by the distinct targets of our product candidates, we believe that there is significant potential for us to address multiple indications with single targets. Our goal is to expand the therapeutic and commercial potential of our targets and product candidates to additional indications, such as immuno-oncology. However, we will remain disciplined about advancing this strategy, leveraging our discovery capabilities to inform expansion areas of maximum value and highest probability of success. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continuing to focus on discovering new targets and product candidates, validated by human genetics, to fulfill the full potential of our insights and platform. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our discovery capabilities are central to our efforts to rapidly identify new product candidates with compelling clinical promise. We will continue to invest in our research and discovery efforts, including evolving our proprietary analytical tools and assays, to further investigate several of our identified immune system targets as well as generate additional targets and product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Role of the Innate Immune System and Microglia in Neurodegeneration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant evidence in the last decade has shown that neurodegenerative diseases, such as Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, FTD, and ALS, are linked to a dysfunctional brain immune system. In contrast to the dual adaptive and innate components that characterize the broader human immune system, the brain&#x2019;s immune system consists primarily of innate immune cells, known as microglia. These brain resident macrophages account for 10% to 15% of all cells found within the brain and are responsible for many aspects of brain health and maintenance. As the key innate immune cells in the brain, microglia respond to infection and damage, clear cell debris and pathological proteins, nurture neurons and the brain support cells, and control the number and functionality of inter-neuronal connections. Microglia have been our focus and new scientific advances have made it possible to understand how these key innate immune cells in the brain represent a crucial focal point for potentially treating or preventing neurodegenerative diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_0.gif" alt="img42979713_0.gif" style="width:421px;height:363px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 1. Our clinical stage neurodegenerative disease programs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Significant Scientific Data Support Our Hypothesis</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Understanding how the brain&#x2019;s immune cells affect its structure and function, in both normal and diseased states, is in our view, the key to understanding many neurological diseases. Human genetic evidence has supported the importance of the interactions between the brain and the innate immune system. For example, most of the top risk genes for Alzheimer&#x2019;s disease, identified using genetic linkage studies, candidate gene analysis, genome-wide association studies (GWAS), and whole-genome or whole-exome sequencing, regulate immune function in the brain. Many of these risk genes have been shown to express predominantly in microglia and to control the function of these cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Microglia have been shown to be key cells in overall brain maintenance, health, and function and are the brain&#x2019;s first line of immune defense. These innate immune cells are tooled with &#x201c;microglial sensomes&#x201d; which enable them to constantly survey brain cells to identify and respond to subtle signs of pathology or dysfunction. Microglia scavenge the brain for toxic misfolded proteins, cell debris, damaged or unnecessary nerve cells, dysfunctional or aged synapses, and infectious agents. In addition, microglia support the generation of new neurons and synapses and remodel neuronal circuits. Microglia also control the survival and function of astrocytes and oligodendrocytes, the main brain support cells which control brain metabolism and blood supply and replenish aged or damaged nerve fibers after injury. Further, microglia have been shown to modulate the permeability of the blood brain barrier allowing access to peripheral immune cells, to assist against infection or injury. Microglia can also change their morphology, functionality, and number in response to changing brain environment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analysis of gene transcription at the single-cell level in microglia from normal and diseased brains revealed that multiple microglia subtypes exist which may respond to specific disease pathologies in the brain. Our product candidates are designed to recruit microglia subtypes by targeting microglia check-point proteins that control their survival, proliferation, migration, and function. This allows us to differentially modulate microglia activity as needed to counteract a given degenerative brain disorder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Findings in the fields of human genetics, immunology, and neuroscience have indicated that as a result of normal aging or genetic mutations, the beneficial functions of the microglia deteriorate leading to dysfunction of neuronal connections, massive death of neurons and neurodegeneration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe our therapies that focus on harnessing the power of microglia may improve neurodegenerative disease outcomes either as standalone therapies or in combination with anti-amyloid beta targeted therapies. Anti-amyloid beta antibodies mark misfolded aggregates and recruit microglia to remove them. Our therapies, including those in our progranulin franchise, are expected to enhance microglia's ability to remove misfolded proteins in conjunction with anti-amyloid beta antibodies that tag these proteins.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_1.gif" alt="img42979713_1.gif" style="width:543px;height:295px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 2. Our checkpoint therapies anticipated to act independently and in combination</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Research and Discovery Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to: (1) identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases, and rapidly develop antibody therapeutics to these targets, (2) interrogate and prioritize those targets for activity using biomarkers and related proprietary assays and preclinical models, and (3) clinically test product candidates, including in genetically defined patient populations that may be most likely to respond to treatment. We believe that these platform capabilities provide us with the tools to solve the conceptual and technical challenges associated with development of drug candidates for neurodegeneration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on proprietary immuno-neurology bioinformatics algorithms and methodologies to analyze large genetic datasets from diseased and healthy individuals, brain-based gene expression profiling and proteomics, and human pathology. These proprietary capabilities allow us to rapidly identify tractable targets, pharmacodynamic biomarkers, and patient populations associated with aberrant immune function which lead to neurodegeneration. Specifically, the priorities of our platform efforts are:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Target Selection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our target selection capabilities address a wide array of factors that we believe inform efficient, optimized therapeutic outcomes, including genetic and mechanistic rationale. We leverage our bioinformatics expertise to identify genetic mutations in the brain immune system that we believe increase the risk of disease onset and progression. We combine our bioinformatic approaches with in-house functional genomics to discover and validate genetic mutations and targets of interest. We utilize state of the art techniques such as CRISPR Activation and Inhibition, single cell transcriptomics, proteomics, metabolomics, microscopic and biochemical readouts in relevant in vitro systems such as hiPSC microglia and in vivo systems such as mouse/rat models to elucidate the </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">immune dysfunction caused by these mutations. We then seek to engineer immune modulating antibody product candidates to functionally counteract the harmful consequence of these genetic mutations. We leverage in vitro and in vivo functional tools to validate the activity of our product candidates and their ability to cross the blood brain barrier enough to be therapeutically effective.</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biomarker Selection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are able to identify and employ molecular biomarkers, assays, and imaging techniques that are tailored to our product candidates to confirm target engagement and quantify their impact, allowing us to potentially interpret the clinical impact of our compounds earlier than would be expected using traditional clinical measures. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patient Selection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We utilize genetic screening and biomarkers in certain orphan disease programs to better align a patient&#x2019;s specific diagnosis with the targeted intervention in our clinical studies. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biologics Discovery.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We pursue a comprehensive antibody discovery strategy using in vivo (multiple species, hybridoma and single B cell technology) and in vitro directed evolution (phage and yeast display) approaches. We leverage our advanced antibody engineering capabilities to design and optimize biotherapeutics.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We employ gene expression profiling, proteomics, brain imaging, and data on disease pathology as well as our own preclinical and clinical data to continually refine our proprietary immuno-neurology algorithms and methodologies. Using our drug discovery platform capabilities to identify targets that are validated by human genetics, disease biomarkers, and responsive patient populations, we believe that we are positioned for greater probability of technical success on more efficient timelines relative to historical drug development in neurodegeneration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 3. The following table highlights our clinical programs, preclinical and research programs, BBB technologies, and IP portfolio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_2.gif" alt="img42979713_2.gif" style="width:624px;height:319px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:14.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical programs include latozinemab, AL101, and AL002. In addition, we continue to pursue a number of preclinical and research programs in our pipeline for indications including Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, and oncology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Progranulin Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our first development program is focused on modulating levels of PGRN, a key regulator of microglia function in the brain with strong genetic links to FTD and other neurodegenerative disorders. Individuals carry two copies of the PGRN gene that function together to produce healthy levels of PGRN throughout the body. Mutations in both copies of the PGRN gene lead to a neurodegenerative disease called neuronal ceroid lipofuscinosis, which is typified by childhood dementia, vision loss, epilepsy, and death. Mutations in a single copy of the PGRN gene result in a drop of between 50% and 70% in the level of PGRN and consequently lead to development of FTD with about 90% penetrance by 75 years of age. Moreover, large scale human genetic studies suggest that regulatory mutations in the gene for PGRN, which lead to a more modest decrease in the level of PGRN, increases the risk for Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease, making PGRN a significant risk gene for these disorders as well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthy levels of PGRN are associated with many cellular processes that include normal microglial activities, neuronal survival, and lysosome function. PGRN deficiency disrupts microglia-neuronal homeostasis in the brain and promotes neurodegeneration through the release of cytotoxic cytokines and complement factors by dysfunctional microglia. Moreover, these microglia activate astrocytes, which in turn, damage neurons. Thus, lack of PGRN leads to disrupted health and function of both neurons and microglia and if not corrected, leads to rapid neurodegeneration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_3.gif" alt="img42979713_3.gif" style="width:529px;height:229px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 4. PGRN deficiency disrupts homeostasis between microglia and neurons and promotes neurodegeneration during aging.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SORT1 Controls PGRN Levels in the Body</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human and mouse genetic studies have identified the neurotrophic factor PGRN degrading receptor Sortilin (SORT1) as a major negative regulator of PGRN levels in plasma and the brain. SORT1 is a sorting receptor on the cell surface and on the endoplasmic reticulum-Golgi apparatus within the cell. SORT1 binds to extracellular PGRN in the plasma and brain and transports it into cells for degradation by the lysosome resulting in decreasing levels of extracellular PGRN. SORT1 deficiency increases PGRN plasma and brain levels by two to three-fold in mouse models, while variants that modestly reduce expression of SORT1 increase the level of PGRN in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, genetic loss of SORT1 in mice does not lead to the adverse effects associated with genetic loss of PGRN, and PGRN continues to function as expected in the absence of SORT1. These studies and others have indicated to us that blocking SORT1 with a pharmacological agent could be a safe and effective approach in increasing the level of functional PGRN in the brain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed two distinct product candidates that target SORT1, latozinemab and AL101, designed to increase PGRN levels in the brain of patients to counteract the damage sustained due to low PGRN levels in neurodegenerative disorders. Our first product candidate, latozinemab, is intended to treat orphan disorders, including genetic forms of FTD such as in patients that are missing a functional copy of the PGRN gene (FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). Our second PGRN product candidate, AL101, is intended to treat widely prevalent neurodegenerative disorders such as Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease, in addition to FTD. We have partnered with GSK to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop and commercialize our PGRN product candidates. For more information on our collaboration with GSK see the section titled &#x201c;Business&#x2014;Strategic Alliance with GSK.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latozinemab and AL101 received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of FTD, as well as Fast Track designation for the treatment of patients with FTD-GRN. Generally, if a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the FDA may not approve any other NDA or BLA application to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity, if FDA revokes the orphan drug designation, or if FDA finds that the holder of the orphan exclusivity has not assured the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even though the FDA has approved orphan drug status for latozinemab and AL101 for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating FTD. Furthermore, orphan drug exclusivity does not prevent the FDA from approving another marketing application for the same drug product for a different indication before the expiration of the orphan exclusivity period. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and additionally, a rolling submission of the marketing application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Latozinemab for the Treatment of FTD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of PGRN in the brains of FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients. Administered via intravenous peripheral infusion, latozinemab functions by blocking the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. We are initially developing latozinemab for the treatment of symptomatic FTD due to a progranulin gene mutation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of FTD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FTD is a rapidly progressing and severe degenerative brain disease with no approved treatment. FTD is a form of dementia found most frequently in individuals less than 65 years old at time of diagnosis. Patients with FTD exhibit a range of personality-related symptoms, including compulsive behavior, lack of restraint, apathy, and anxiety as well as language and behavioral problems. The rate of disease progression in FTD is faster than in Alzheimer's disease. Average life expectancy in FTD patients is seven to 10 years after the start of symptoms. FTD symptoms have an insidious onset with clinical symptoms usually appearing between 45 to 65 years of age at an average age of 58. Hence, FTD is considered an early-onset dementia as compared to late-onset Alzheimer&#x2019;s disease, and is more common than Alzheimer&#x2019;s disease in early-onset dementia under the age of 60 years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_4.gif" alt="img42979713_4.gif" style="width:245px;height:198px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 5. MRI of frontal and temporal atrophy in FTD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although FTD was poorly understood and thought to be rare, over the past decade the scientific community has gained a knowledge about the biology of FTD as well as an awareness of disease prevalence. FTD affects roughly 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. There are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">multiple heritable forms of FTD; to date, researchers have identified over 70 inherited loss of function mutations in PGRN that lead to FTD. FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients represent 5% to 10% of all people with FTD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_5.gif" alt="img42979713_5.gif" style="width:591px;height:261px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 6. Mutations in a single copy of PGRN result in a 50% or greater decrease in the level of PGRN and result in a greater than 90% probability of developing FTD. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) Rhinn H, Tatton N, McCaughey S, Kurnellas M, Rosenthal A. Progranulin as a therapeutic target in neurodegenerative diseases. Trends in Pharmacological Sciences. 2022 Aug; 43(8):641-652. DOI: 10.1016/j.tips.2021.11.015. PMID: 35039149. (2) Dement Geriatr Cogn Disord Extra 2016;6:330-340</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients, inhibition of SORT1 through latozinemab represents a potential mechanism to compensate for the over 50% reduction of PGRN. Latozinemab is intended to reduce the ability of SORT1 to bind to and degrade PGRN, leading to increases in the levels of PGRN by increasing its circulating half-life. We have tested our PGRN program antibodies in various animal models, healthy volunteers, and FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients and have achieved significantly elevated, long-lasting levels of PGRN in the brain after intravenous administration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_6.gif" alt="img42979713_6.gif" style="width:352px;height:284px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 7. Mechanism of action for our PGRN programs. Latozinemab binds to SORT1 and prevents degradation of PGRN, increasing its circulating half-life significantly. A similar mechanism of action is also applicable for AL101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our PGRN Product Candidates Development Plan and Clinical Trial Results to Date</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latozinemab is currently being studied in a global pivotal Phase 3 trial in both at-risk and symptomatic participants with FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, named INFRONT-3. The randomized, double-blind, placebo-controlled trial currently plans to enroll up to 180 FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mutation carriers across approximately 50 clinical sites in the United States, Canada, Europe and Australia. Symptomatic and at-risk participants will be randomized to receive latozinemab or placebo intravenously every four weeks. Participants will also be given the option to continue receiving treatment in an open-label extension (OLE) study. In June 2022, the first participant from the INFRONT-3 study was enrolled in the optional OLE designed to assess the long-term safety, tolerability, and efficacy of latozinemab in participants who have completed 96 weeks in the INFRONT-3 study, and enrollment in the OLE continues. The primary endpoint of our pivotal Phase 3 trial is to measure the effect of latozinemab on clinical decline by utilizing the CDR&#174; plus NACC FTLD-SB assessment, which evaluates clinical impairments in behavior, language, memory, judgment, and functional activities in trial participants. In addition, our Phase 3 trial will assess secondary clinical endpoints, multiple biomarkers and safety. We are preparing to engage with regulatory authorities in mid-2023. The purpose of the meeting is to discuss statistical analysis plans based on emerging knowledge in the field that may enable us to complete the pivotal INFRONT-3 clinical trial with fewer patients and/or a shorter treatment duration. The company is targeting a data readout from the INFRONT-3 trial in early 2025, pending regulatory feedback.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we presented data for latozinemab from our ongoing open-label Phase 2 INFRONT-2 clinical trial. INFRONT-2 was designed to establish the safety and tolerability of chronic administration of latozinemab at therapeutic doses, and the study also measured biomarkers of disease and clinical outcomes. Results from up to twelve symptomatic FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients treated over twelve months in an open-label study showed that latozinemab was well tolerated. Treatment with latozinemab restored PGRN in both plasma and CSF to levels seen in healthy volunteer age-matched controls for the duration of treatment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_7.gif" alt="img42979713_7.gif" style="width:526px;height:202px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 8. Latozinemab restores PGRN in plasma and CSF to levels seen in healthy volunteer age-matched controls</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to assessing PGRN levels in plasma and CSF, we evaluated disease-associated proteins, including lysosomal (e.g., CTSD, LAMP1), complement (C1QB), and astrogliosis (GFAP) biomarkers along with NfL. In our Phase 2 trial results presented in 2021, many of these disease-relevant biomarkers of lysosomal function, complement activation, astrogliosis, and neuronal health trended toward normalization or remained stable over twelve months of treatment compared to baseline and age-matched controls.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_8.gif" alt="img42979713_8.gif" style="width:505px;height:198px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 9. Latozinemab treatment normalizes lysosomal and complement biomarkers in CSF symptomatic FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients enrolled in our Phase 2 trial.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (1) The control group included N = 44 age-matched procured control samples, (2) at Baseline N = 11 FTD-GRN participants, (3) at 6 months treatment with latozinemab N = 9 FTD-GRN participants, and (4) at 12 months treatment with latozinemab N = 10 FTD-GRN participants</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_9.gif" alt="img42979713_9.gif" style="width:500px;height:180px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 10. Latozinemab treatment decreases Glial Fibrillary Acidic Protein (GFAP) levels towards normal levels in plasma and CSF of asymptomatic FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> participants enrolled in our Phase 2 trial, suggesting a reduction in astrogliosis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_10.jpg" alt="img42979713_10.jpg" style="width:475px;height:180px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 11. NfL levels in plasma and CSF are stable over 12 months in latozinemab-treated symptomatic FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> participants enrolled in our Phase 2 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To provide context for the clinical outcomes observed in the open-label INFRONT-2 trial, a matched control cohort of ten FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> participants from the GENFI2 consortium was created using the propensity score matching technique. These ten GENFI2 patients were identified based on the CDR&#174; NACC FTLD SB at baseline and further</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refined by matching based on age, NfL levels, and clinical diagnosis at baseline, all done on a blinded basis without access to longitudinal results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Using volumetric MRI, we found a greater than 10% reduction in the atrophy rates in favor of the latozinemab treated FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patient population for the whole brain and frontotemporal cortex measures, and an approximately 50% reduction in the rate of ventricular enlargement, relative to the matched control GENFI2 cohort of FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_11.gif" alt="img42979713_11.gif" style="width:550px;height:201px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 12. vMRI data suggest slowing of ventricular enlargement and brain atrophy in latozinemab treated FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients enrolled in our Phase 2 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In our Phase 2 trial, we also assessed clinical outcomes using the CDR&#174; plus NACC FTLD-SB scale. The CDR&#174; plus NACC FTLD-SB is the Clinical Dementia Rating Scale plus National Alzheimer&#x2019;s Coordinating Center frontotemporal lobar degeneration sum of boxes rating scale developed for patients with FTD. Latozinemab treatment was estimated to slow disease progression by 48% in 12 patients at twelve months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_12.gif" alt="img42979713_12.gif" style="width:553px;height:214px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 13. Treatment with latozinemab showed a slowing of clinical progression in FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients enrolled in our Phase 2 trial relative to matched GENFI2 controls. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Random Coefficient Model with Repeated Measurements including baseline &amp; all available post-baseline measurements up to 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In prior clinical trials, latozinemab was well tolerated and demonstrated proof of mechanism. In our Phase 1a trial (n=50) in healthy volunteers, latozinemab was well tolerated. In our Phase 1b portion of the trial (n=14) in FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients, there was a statistically significant increase in PGRN levels relative to baseline when compared to pooled placebo in plasma and in CSF at the prespecified follow-up time point. In addition, results from these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 studies showed that latozinemab was generally well tolerated, with no drug-related serious adverse events or dose-limiting adverse events reported in the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_13.jpg" alt="img42979713_13.jpg" style="width:490px;height:242px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 14. Latozinemab restores PGRN levels in symptomatic and asymptomatic FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients back to the normal range as seen in healthy volunteers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potential Additional Applications for Our PGRN Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to treat any other neurodegenerative diseases and the broader FTD patient population with latozinemab, we will be required to conduct additional clinical studies to obtain the applicable approvals for that specific patient population. We enrolled an additional genetic subset of FTD patients (FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) in our open-label Phase 2 clinical trial of latozinemab and may expand to additional indications in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, we presented additional data from the INFRONT-2 trial of latozinemab in FTD patients with a C9orf72 genetic mutation (FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), building on the results in patients with FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Clinical outcome assessments using the CDR&#174; plus NACC FTLD-SB scale found that treatment of FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients with latozinemab resulted in a trend toward a delay of approximately 54% in annualized disease progression compared to a matched control cohort from the ALLFTD consortium.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_14.gif" alt="img42979713_14.gif" style="width:570px;height:247px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 15. Treatment with latozinemab showed a slowing of clinical progression in FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> patients enrolled in our Phase 2 trial relative to matched ALLFTD controls.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ALLFTD - One post-baseline timepoint at approximately 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_15.gif" alt="img42979713_15.gif" style="width:505px;height:200px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 16.Latozinemab treatment decreases GFAP levels towards normal levels in plasma and CSF of FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">participants enrolled in our Phase 2 trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both decreased progranulin levels and mutations in the chromosome 9 open reading frame 72 (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) gene are associated with abnormal accumulation of the TAR DNA-binding protein 43 (TDP-43). Excess aggregation of TDP-43 in brain cells is thought to lead to neuronal cell death and is associated with multiple neurodegenerative diseases, including both FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and ALS.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021 we initiated a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of latozinemab in people with ALS who carry a </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mutation. In preclinical studies using multiple models of acute and chronic neurodegeneration, increasing progranulin levels has been shown in the literature to reverse and be protective against TDP-43 pathology. In light of the evolving ALS landscape, we closed that study to additional enrollment. We and GSK are currently evaluating plans for development of latozinemab in ALS.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of ALS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALS is a devastating, fatal, progressive neurodegenerative disorder. In ALS, the motor neurons in the brain and spinal cord die, resulting in weakness, muscle atrophy, paralysis and frequently, cognitive impairment, before resulting in death from respiratory failure. Each year, more than 5,000 people in the U.S. are diagnosed with ALS and an estimated 31,000 patients in the U.S. are living with the disease. Mutations within multiple genes, including the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene, are believed to cause the disease. Such mutations can lead to an accumulation of TDP-43 in the cells resulting in neuronal death and an estimated 95% of ALS cases are linked to TDP-43 pathology. Approximately 40-50% of all familial ALS and up to 10% of sporadic ALS cases are attributed to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">C9orf72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mutation. Currently approved medications for ALS confer only a modest survival benefit and new treatment options are urgently needed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AL101 for the Treatment of Alzheimer&#x2019;s Disease and Parkinson&#x2019;s Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing a second product candidate in our PGRN programs, AL101, a human recombinant monoclonal antibody that also targets SORT1 and is designed to elevate progranulin levels similar to latozinemab. We are developing AL101 to target large chronic neurodegenerative diseases, such as Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Polymorphic mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2022, we presented interim data from our Phase 1 clinical trial testing the safety, tolerability, pharmacokinetics, pharmacodynamics, and bioavailability of single doses of intravenously or subcutaneously administered AL101 in healthy volunteers. AL101 increased progranulin levels in the periphery and the brain persisting for one month. AL101 was found to be well tolerated at all doses administered. We completed enrollment of additional cohorts to test multiple doses of AL101 administered intravenously and subcutaneously. AL101 was well tolerated and increased PGRN levels in plasma and CSF in a dose-dependent manner. In the two multiple dose</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(MD) cohorts, 27 healthy volunteers received either AL101 30 mg/kg IV every four weeks (q4w) for a total of four doses [n=11] or AL101 300 mg subcutaneously (SC) every two weeks (q2w) for a total of seven doses [n=13]. Three volunteers received MD IV placebo. AL101 was found to be generally well tolerated following MD IV (q4w) and SC (q2w) administrations. Consistent with previously presented data following single doses, AL101 was measurable in the CSF following multiple IV and SC doses. MD administration of AL101 increased plasma and CSF PGRN levels, with a higher elevation observed in the AL101 30 mg/kg MD IV group than in the AL101 300 mg MD SC group. Multiple IV doses of AL101 at 30 mg/kg increased and maintained the levels of PGRN at approximately 160% to 200% (2.6- to 3-fold) above baseline in plasma and approximately 80% (1.8-fold) above baseline in the CSF. The PK and PD profile of AL101 following single and multiple IV doses support future development in chronic neurodegenerative conditions such as AD and PD.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_16.gif" alt="img42979713_16.gif" style="width:520px;height:193px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 17. AL101 treatment increased PGRN levels in healthy volunteers enrolled in our Phase 1 trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Alzheimer&#x2019;s Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alzheimer&#x2019;s disease is a chronic neurodegenerative disease that usually starts slowly in people over 65 years of age and worsens over time. It is the most common cause of dementia, accounting for 60% to 70% of all cases. The most common early symptom of Alzheimer&#x2019;s disease is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, failure to manage self-care, and behavioral issues. As a person&#x2019;s condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is eight to ten years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While estimates of the prevalence of Alzheimer&#x2019;s disease vary, the Alzheimer&#x2019;s Association estimates that in 2022, there were more than 6.5 million Americans ages 65 and older suffering from Alzheimer&#x2019;s disease and that number is projected to nearly triple by 2060. Alzheimer&#x2019;s disease is the sixth leading cause of death in the United States and the fifth-leading cause of death for those ages 65 and older.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to its debilitating effect on patients&#x2019; cognition and day-to-day functioning, Alzheimer&#x2019;s disease places a significant burden on the healthcare system. According to the Alzheimer&#x2019;s Association, the aggregate cost of care in 2022 for patients with Alzheimer&#x2019;s disease and other types of dementia in the United States was estimated to be $321 billion, nearly two-thirds of which is borne by the Medicare system. Total payments for health care, long-term care, and hospice care for people with Alzheimer&#x2019;s and other dementias in the United States are projected to increase to more than $1.1 trillion in 2050.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of Parkinson&#x2019;s Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parkinson&#x2019;s disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Early in the disease, the most obvious symptoms are shaking, rigidity, slowness of movement, and difficulty with walking. Cognitive and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are also common, occurring in more than a third of people with Parkinson&#x2019;s disease. Other symptoms include sensory, sleep, and emotional problems. Parkinson&#x2019;s disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">typically occurs in people over the age of 60. The average life expectancy following diagnosis is between three to 10 years after the onset of symptoms.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no disease modifying treatment for Parkinson&#x2019;s disease, and the options for patients are limited to treatments that improve symptoms. Initial treatment is typically with the anti-Parkinson&#x2019;s drug medication levodopa, with dopamine agonists being used once levodopa becomes less effective. As the disease progresses and neurons continue to be lost, these medications become less effective while at the same time they produce a complication marked by involuntary writhing movements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to the Parkinson&#x2019;s Foundation, more than 10 million people worldwide are living with Parkinson&#x2019;s disease. Approximately 90,000 Americans are diagnosed with Parkinson&#x2019;s disease each year and an estimated 1.2 million Americans will be living with Parkinson&#x2019;s disease by the year 2030. According to the Parkinson&#x2019;s Foundation, the combined direct and indirect cost of Parkinson&#x2019;s, including treatment, social security payments and lost income, is estimated to be nearly $52 billion per year in the United States alone and is estimated to cost approximately $80 billion annually in the United States by 2037.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our TREM2 Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TREM2 is a transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia in the brain. TREM2 on microglia cells is thought to promote improved cell migration to the site of injury, improved cell survival, increased phagocytosis, and increased cell proliferation. Rare individuals with homozygous TREM2 mutations, or mutations on both chromosomal copies, may develop neurodegeneration by the age of 40 with an average lifespan of 10 years following diagnosis. A gene variant in one of the two copies of TREM2 is found to increase the risk of Alzheimer&#x2019;s disease by three-fold. Not only do mutations in a single copy of TREM2 increase the risk of Alzheimer&#x2019;s disease significantly, but Alzheimer&#x2019;s disease patients with TREM2 mutations exhibit an earlier onset of symptoms by three years and an increased rate of brain volume loss compared to individuals without such mutations. Evidence also suggests that a gain of function mutation leading to increased expression of TREM2 confers a protective phenotype against Alzheimer&#x2019;s disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discovery of strong genetic linkage of TREM2 to Alzheimer&#x2019;s disease in 2013 was one of the first examples in which large scale genomic analyses were used to identify a rare gene variation and link it to an increase in the risk of late-onset Alzheimer&#x2019;s disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TREM2 binds to membrane lipids and lipoproteins such as Apolipoprotein E (ApoE) which are normally found in the brain. Polymorphisms in the gene for ApoE are also known to significantly increase the risk of development of Alzheimer&#x2019;s disease and are the single highest risk factor for Alzheimer&#x2019;s disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AL002 for the Treatment of Alzheimer&#x2019;s Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidate, AL002, is a humanized, TREM2 activating, monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion. AL002 is a microglia cell regulator that modulates the TREM2 receptor</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and is being developed for the treatment of Alzheimer&#x2019;s disease in collaboration with AbbVie. For more information on our collaboration with AbbVie see the section titled &#x201c;Business&#x2014;Strategic Alliance with AbbVie.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_17.gif" alt="img42979713_17.gif" style="width:274px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 18. Mechanism of action of our TREM2 activating product candidate AL002.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently no cures for Alzheimer&#x2019;s disease. Two therapies directed at the underlying pathology of the disease have been approved by the FDA with evidence of reduction of amyloid beta plaques and potential clinical benefit. Other classes of approved therapies are for symptomatic treatment including, acetylcholinesterase inhibitors and glutamatergic modulators. These drugs are designed to help preserve neuronal communication, but only provide temporary benefit and do not slow or halt neuronal death. In addition, antidepressants and antipsychotics are often prescribed off-label to treat the symptoms of severe Alzheimer&#x2019;s disease in patients suffering from agitation, aggressive behaviors, psychosis, and depression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent drug candidates under development for Alzheimer&#x2019;s disease include those focused on blocking synthesis, enhancing clearance or disaggregating misfolded amyloid-beta or tau proteins in the brain, reversing chronic inflammation, and repairing vascular dysfunction, metabolic dysregulation, as well as neurotoxicity. Almost all of these candidates were designed to target just one of the multiple Alzheimer&#x2019;s disease pathologies, and most of these drug candidates have so far failed to demonstrate significant benefit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although amyloid-beta plaques and tau protein in the brain represent physical pathologies of the disease and are believed to cause a loss of neuronal connectivity in the brain and neuronal death, recent scientific data paints a more complex picture. We believe more efficacious therapies will likely require addressing multiple pathologies including those associated with microglial failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our TREM2 Clinical Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we initiated our Phase 2 trial in Alzheimer&#x2019;s disease patients in early stages of the disease. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center Phase 2 trial was intended to enroll approximately 265 participants with early AD at up to 90 sites globally, and we now plan to add up to an additional 64 participants in the ongoing INVOKE-2 trial to replace discontinuations, including APOE e4/e4 participants, from the study. The primary endpoint of our Phase 2 trial will measure disease progression utilizing the Clinical Dementia Rating Sum of Boxes (CDR-SB). The trial will also measure multiple fluid and imaging biomarkers, and assess several secondary clinical, pharmacokinetic and pharmacodynamic endpoints, as well as safety to generate data enabling pivotal Phase 3 studies. In January 2023, the first participant from the INVOKE-2 study was enrolled and dosed in an LTE of our Phase 2 clinical trial. We plan to complete INVOKE-2 trial enrollment in the third quarter of 2023, with top-line data expected by the fourth quarter of 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARIA have been observed in our ongoing INVOKE-2 Phase 2 clinical trial in AD. ARIA are MRI findings suggestive of vasogenic edema or hemosiderin deposits. The incidence of ARIA has been shown to increase in AD patients with the administration of certain Alzheimer's disease therapeutics, namely anti-&#x3b2;-amyloid antibodies. In our INVOKE-2 Phase 2 clinical trial, most ARIA cases were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred almost exclusively in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, consistent with recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an IDMC, which is allowed to review unblinded data and to make trial recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we completed the Phase 1a portion (n=56) of a clinical trial in healthy volunteers with AL002. AL002 was well tolerated in the single ascending dose part of our Phase 1 trial. In addition, a dose dependent and statistically significant change in both soluble TREM2 (sTREM2) and downstream biomarkers for microglia functionality in CSF were observed upon treatment, indicating both target engagement and proof-of-mechanism in healthy volunteers. Based on the tolerability observed in our Phase 1a healthy volunteer trial, as well as encouraging biomarker data, we initiated the Phase 1b portion of the trial with AL002 in people with Alzheimer&#x2019;s disease. However, based on the data collected to date in preclinical studies as well as in healthy volunteers, and in alignment with our partner AbbVie, we closed enrollment in the Phase 1b trial, which was impacted by the COVID-19 pandemic, and shifted to initiating our Phase 2 trial. In our Phase 1 clinical trial, AL002 demonstrated tolerability, target engagement, and proof-of-mechanism in the central nervous systems of healthy volunteers and Alzheimer's disease patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_18.gif" alt="img42979713_18.gif" style="width:490px;height:216px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 19. In healthy volunteers, a dose dependent decrease in sTREM2 and an increase in CSF-1R, a biomarker of microglial activation was observed in our AL002 Phase 1 clinical trial. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CSF samples were taken from the five highest dose cohorts. The data shown are derived from analysis of CSF samples from 34 healthy volunteers (* denotes p&lt;0.05 by T-test, *** denotes p&lt;0.001 by T-test).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our TREM2 Preclinical Data</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL002 binds to TREM2 on the surface of microglia and is designed to optimize microglial activity through the phosphorylation of Spleen Associated Tyrosine Kinase (Syk). With prominent academic collaborators, we demonstrated that AL002s, an antibody that is functionally similar to AL002 but cross-reacts to the mouse TREM2, can normalize gene expression signature associated with Alzheimer&#x2019;s disease and reduce pathology in a mouse model of Alzheimer&#x2019;s disease. Furthermore, AL002c, a form of AL002 with a murine Fc region, was shown to induce microglial proliferation, and amyloid plaque compaction and decrease dystrophic neurites associated with damaged neurons in a severe amyloid mouse model that expresses either the normal or genetic risk variant of the human TREM2.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_19.jpg" alt="img42979713_19.jpg" style="width:285px;height:217px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 20. AL002s statistically significantly improves cognitive deficit in a mouse model of Alzheimer&#x2019;s disease. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(**** indicates p&lt;0.0001 by T-test)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our MS4A Program</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is among the most prominent genetic risk loci for late-onset Alzheimer&#x2019;s disease. Risk variants of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> locus are associated with an increase in the prevalence of Alzheimer&#x2019;s disease and a decrease in the age of onset. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene family members encode a transmembrane receptor protein that is expressed selectively in microglia in the brain and is associated with control of microglia functionality and potentially with microglia viability. Our AL044 product candidate was designed to counteract the risk variants of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene family and to functionally convert the risk variants of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> gene family to the protective variant. In September 2022, we commenced our first-in-human Phase 1 trial of AL044, with the intention of developing that candidate in Alzheimer&#x2019;s disease and potential orphan indications. Based on initial PK and tolerability data, we decided to close the trial. We are actively pursuing a back-up MS4A program to develop an IND-ready candidate with a potentially improved dosing and tolerability profile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector's Emerging Innate Immuno-oncology Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Immuno-oncology</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also expanding our discovery platform to other indications, such as the field of immuno-oncology. We believe that products focused on innate immune biology will complement and expand the efficacy of current immuno-oncology drugs that target the adaptive immune system. Microglia display similar gene expression and function to the cells of the peripheral, or non-brain, innate immune system. These peripheral innate immune cells such as macrophages, monocytes, NK cells, and others, likely play a significant role in multiple chronic diseases including cancer, inflammation, and autoimmune disorders. We are leveraging our expertise in the innate immune system to develop additional innate immune checkpoint focused programs, including programs targeting the SIRP protein family and the Siglec protein family, for peripheral disorders, particularly cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_20.jpg" alt="img42979713_20.jpg" style="width:447px;height:174px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 21. Neurodegeneration and cancer converge at the innate immune system. We believe substantial functional overlap exists between tumor associated macrophages and microglia.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AL009, Our Multi Siglec Program</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL009, is one of our innate immuno-oncology product candidates. AL009 is a multi Siglec inhibitor that is designed to enhance both the innate and adaptive immune system response to tumors by blocking a critical glycan checkpoint pathway that drives immune suppression. AL009 is a targeted sialic acid trap that is designed to interrupt Siglec inhibitory signals preferentially on innate immune cells in order to confer therapeutic benefit in oncology indications. We continue to conduct preclinical studies and technical activities on AL009. We own worldwide rights to AL009.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">AL008, Our SIRP-alpha Program</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL008 is a monoclonal antibody that inhibits SIRP-alpha. AL008's dual mechanism of action non-competitively antagonizes the CD47-SIRP-alpha pathway by inducing the internalization and degradation of the inhibitory receptor on macrophages to relieve immune suppression (shut down &#34;don't eat me signal&#34;) while also engaging Fc gamma receptors to promote immuno-stimulatory pathways that drive anti-tumor immunity. By targeting the SIRP-alpha receptor, which is primarily expressed on myeloid cells, we believe AL008 may be able to avoid the antigen sink and on-target clinical adverse effects observed with certain CD47-targeting agents. Furthermore, AL008 is designed to bind selectively to SIRP-alpha without cross-reacting to other SIRP family members, such as SIRP-gamma. This specificity allows AL008 to antagonize the inhibitory CD47-SIRP-alpha pathway while preserving the T cell-activating CD47-SIRP-gamma pathway. We entered into a licensing agreement with Innovent in 2020, under which Innovent would develop and commercialize AL008 in China, while Alector would retain development and commercialization rights in the rest of the world. Innovent will not be continuing development of AL008, and we intend to re-acquire the rights we granted to Innovent for the development and commercialization of AL008. Innovent submitted an IND with the Chinese regulatory authorities, and Alector is in the process of obtaining relevant materials and information from Innovent. Alector plans to evaluate data and documentation from that IND application to potentially support an IND submission in the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Combination Therapies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our therapies are also likely to act in conjunction with each other or with other experimental drugs that are designed to remove pathological proteins. Therapies such as antibodies against amyloid-beta, tau filaments or misfolded alpha-synuclein protein are designed to tag the pathological proteins and recruit microglia to dispose of the drug/pathological protein complex. Aging microglia are less likely to perform this function effectively, and our immuno-neurology therapies could ameliorate this deficiency. We intend to explore various combination strategies in preclinical models and will, in the future, consider moving this strategy into the clinic based upon results from preclinical models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Alliance with GSK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we entered into a Collaboration and License Agreement with GSK, pursuant to which we and GSK will collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101. The GSK Agreement became effective on August 17, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in August 2021 and $200 million was received in January 2022. In addition, we may be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the parties will equally share profits and losses from commercialization of latozinemab and AL101. Outside of the United States, we will be eligible for double-digit tiered royalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The parties will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease and other non-orphan indications. Development costs will be shared 60% by GSK and 40% by us, except that we will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the parties will be jointly responsible for commercialization of latozinemab and AL101, with us leading the commercialization for orphan indications and GSK leading the commercialization for Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease and other non-orphan indications. Outside of the United States, GSK will be solely responsible for commercialization of latozinemab and AL101 for all indications. We may opt out of the sharing of development costs and of profit and losses from commercialization in the United States on a product-by-product basis. In such case, we will no longer conduct development or commercialization of that product and the Company will receive tiered royalties on net sales in the United States instead of a share of profits or losses. GSK may terminate the agreement with 180 days' notice at any time, but the Company does not need to repay any portion of the payments received.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Governance.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The collaboration is governed by a joint steering committee (JSC). The JSC may establish additional subcommittees to oversee particular projects or activities. Subject to limitations specified in the GSK Agreement, if the applicable governance committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> During the term of the GSK Agreement, each of Alector and GSK are subject to exclusivity requirements prohibiting certain activities outside of the GSK Agreement directed to targets under the GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Ownership of intellectual property created in connection with the GSK Agreement is generally determined on the basis of inventorship. Generally, we have the first right to control prosecution and maintenance of licensed patents, including patents developed solely by us or jointly by the parties, in the United States, and GSK has the first right to control prosecution and maintenance of such patents outside the United States. GSK has the first right to prosecute infringement of such patents by certain third-party products. The parties shall mutually agree on which party shall control the defense against claims that a product developed under either of the programs that are the subject of the GSK Agreement infringes third-party intellectual property rights, with the party against whom such claims have been filed having the first right to defend in the absence of such mutual agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> At any point during the term of the GSK Agreement, after a specified notice period, GSK can terminate the GSK Agreement in its entirety for convenience. Additionally, GSK or we can terminate the GSK Agreement in connection with a material breach of the GSK Agreement by the other party that remains uncured for a specified period of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Alliance with AbbVie</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, we entered into the Co-Development and Option Agreement with AbbVie. The primary goal of our global strategic collaboration with AbbVie is to co-develop and commercialize therapeutics to treat Alzheimer&#x2019;s and other neurodegenerative diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the AbbVie Agreement, we granted AbbVie an exclusive option to global development and commercialization for our TREM2 and SIGLEC 3 programs. The terms of the AbbVie Agreement included initial upfront payments of $205.0 million and $20.0 million from the sale of shares of our stock. We are responsible for the design and execution of Phase 1 and Phase 2 studies, taking advantage of our significant in-house expertise in running clinical trials in Alzheimer&#x2019;s disease. In June 2022, AbbVie provided notice of termination with respect to the SIGLEC 3 program. In February 2023, we and AbbVie amended the AbbVie agreement, which will result in our receiving a $17.8 million milestone payment for the dosing of the first patient in a long-term extension study. If AbbVie exercises its option for the TREM2 program, we will receive $250.0 million. Additionally, under the terms of the AbbVie Agreement, we will be eligible to earn up to an additional $225 million in milestone payments related to the regulatory approval for up to three indications. Following AbbVie&#x2019;s option exercise for the TREM2 program, we may opt out of sharing in development costs and profits or and instead receive a tiered royalty on sales of products. Following AbbVie's exercise of an option for the TREM2 program, AbbVie would be responsible for certain development activities and global commercialization, taking advantage of its global clinical trial expertise and commercialization networks. Through this partnership, we aim to leverage the strengths of both organizations efficiently to best achieve the desired outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exercise of options.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> AbbVie may exercise its option for the TREM2 program at any time until the expiration of the option term. The option term ends following a fixed period after AbbVie&#x2019;s receipt of the data package after completion of Phase 2 clinical trials that includes certain information relating to the TREM2 program&#x2019;s research and development activities. If AbbVie fails to exercise its option during the option term for a product candidate, we will retain all rights to the TREM2 program. If AbbVie exercises its option for the TREM2 program, then AbbVie will lead development and commercialization activities worldwide. Once AbbVie opts in with respect to a given product candidate, AbbVie must use commercially reasonable efforts to develop and commercialize the corresponding product globally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Governance.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The collaboration is governed by a joint steering committee (JSC). The JSC may establish additional subcommittees to oversee particular projects or activities. Subject to limitations specified in the AbbVie Agreement, if the applicable governance committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> During the term of the AbbVie Agreement, we and AbbVie are subject to exclusivity requirements prohibiting certain activities outside of the AbbVie Agreement directed to targets under the AbbVie Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Ownership of intellectual property created in connection with the AbbVie Agreement is generally determined on the basis of inventorship. Generally, each party has the first right to prosecute and maintain its own patents. We generally have the first right to prosecute and maintain joint patents prior to AbbVie&#x2019;s exercise of its option for the program relating to such patent, and AbbVie has the right following its exercise of such option. AbbVie has the first right to prosecute any infringement of jointly held patents developed under the AbbVie Agreement and our patents that are licensed under the AbbVie Agreement. Additionally, AbbVie has the sole right to prosecute its own patents. AbbVie has the first right to defend against claims that a product developed under the TREM2 program that are the subject of the AbbVie Agreement infringe third-party intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> At any point during the term of the AbbVie Agreement, including during the research, development, and clinical trial process, AbbVie can terminate the AbbVie Agreement in its entirety, or with respect to TREM2 program under the AbbVie Agreement, for convenience. In that event, all rights related to the TREM2 program revert to us. Additionally, AbbVie or we can terminate the AbbVie Agreement in connection with a material breach of the AbbVie Agreement by the other party that remains uncured for a specified period of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adimab Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview &#x2013; 2014 Adimab Collaboration Agreement (2014 Adimab Agreement)</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2014, we entered into the 2014 Adimab Collaboration Agreement (the 2014 Adimab Agreement). Under the 2014 Adimab Agreement, we are required to fund, and we and Adimab LLC (Adimab) are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">targets selected by us. We are developing antibodies discovered by Adimab in our latozinemab and AL101 product candidates, and we are developing an antibody optimized by Adimab in our AL002 product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Governance.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from each party. The research committee prioritizes among research programs and prepares and finalizes new proposed research plans, among other activities. If the research committee is unable to make a decision by consensus and the parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then either party may seek arbitration of the matter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Pursuant to the 2014 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Ownership of intellectual property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. For example, patent rights relating to improvements to Adimab&#x2019;s background platform technology that are invented in the course of the research are assigned to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a non-exclusive license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research; and except for Adimab&#x2019;s retained rights to continue using and licensing its own libraries, each party agrees not to practice or license the patents arising out of the research that it owns for any purpose other than to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exercise of Options.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The 2014 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extended to ownership of patent rights specifically covering the sequences of such antibodies, and the right to obtain worldwide, royalty-bearing, sublicensable licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. These licenses are exclusive, except as to Adimab background and platform technology and Adimab&#x2019;s retained rights to continue using and licensing its own libraries, as to which the licenses are non-exclusive. We have confirmed with Adimab in writing that key patents we have filed relating to the programs partnered with AbbVie claim inventions owned solely by us, and do not include any such background or platform technology of Adimab. All of our options under the 2014 Adimab Agreement have either expired, are in the process of being exercised, or, with respect to multiple targets and hundreds of antibodies (including the target programs partnered with AbbVie), have already been exercised. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target. The assigned and licensed patent rights we obtained from these option exercises are described in more detail above under the section titled &#x201c;Business&#x2014;Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial terms.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We fund Adimab&#x2019;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2014 Adimab Agreement. We also have potential milestone payments per program for use of antibodies and low- to mid-single digit royalty payments for commercial sales of products incorporating such antibodies. However, if we enter into any transaction granting rights to the inventions or sell products created as a result of a collaboration with a third party, we have a choice to pay a share of the resulting revenue instead of royalties from such sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are able to terminate the 2014 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on three months prior written notice to Adimab. In addition, either party can terminate the 2014 Adimab Agreement in its entirety, or, subject to certain limitations, with respect to specific optioned rights, for material breaches that remain uncured after 90 days&#x2019; notice to the breaching party. In the case of a termination before expiration of the 2014 Adimab Agreement, we would have certain continuing payment obligations to Adimab, or would be required to adhere to certain restrictions as to the fruits of the collaboration. The 2014 Adimab Agreement expires on the twelfth anniversary of the first commercial sale of the products created under the collaboration, on a product-by-product and country-by-country basis. The licenses we and Adimab granted to each other do not survive, subject to certain limitations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview&#x2014;2019 Adimab Collaboration Agreement (2019 Adimab Agreement)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2019, we entered into another Adimab collaboration agreement (the 2019 Adimab Agreement). Under the 2019 Adimab Agreement, we are required to fund, and we and Adimab are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We have not yet identified any research programs under the 2019 Adimab Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Governance.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from each party. The research committee facilitates communication regarding research under the 2019 Adimab Agreement and has the limited authority to amend a research plan in a manner not substantially affecting the resources required from a party. If the research committee is unable to make a decision by consensus, no decision will be taken.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusivity.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Pursuant to the 2019 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual Property.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Ownership of intellectual property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. Certain intellectual property relating to Adimab&#x2019;s background platform technology including any improvements thereto that are invented in the course of the research are assigned to Adimab. Patents covering antibodies that are the subject of the collaboration are owned by us; however, prior to our exercise of the option described below, we are prohibited from practicing such patents for any purpose other than to perform our research obligations under the 2019 Adimab Agreement. Upon the expiration of the option term described below, in the event we elect not to exercise our option right with respect to an antibody, ownership of such patents is transferred to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a non-exclusive license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exercise of Options.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The 2019 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extends to ownership of the applicable optioned antibody, and the right to obtain worldwide, royalty-bearing, sublicensable non-exclusive licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. Upon our exercise of the option with respect to a target, we are subject to an obligation to devote commercially reasonable efforts to commercialize products using the optioned rights to such target.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial terms.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We fund Adimab&#x2019;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2019 Adimab Agreement. We are also responsible for certain development fees and, in the event we exercise the option right, we are obligated to pay an option fee. We also have potential milestone payments per product for use of antibodies, subject to certain limitations on total payments owed on any given target, and low-single digit royalty payments for commercial sales of products incorporating such antibodies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Term and Termination.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are able to terminate the 2019 Adimab Agreement, in its entirety or with respect to a products or antibodies directed to particular targets, on 60 days&#x2019; prior written notice to Adimab. In addition, either party can terminate the 2019 Adimab Agreement in its entirety for material breaches that remain uncured after 90 days&#x2019; notice to the breaching party. In the case of a termination before expiration of the 2019 Adimab Agreement, we would be prohibited from using the fruits of the collaboration. The 2019 Adimab Agreement expires, on a product-by-product and country-by-country basis, on the later of the twelfth anniversary of the first commercial sale of such product in such country and expiration of the last patent covering such product in such country, or, in the event no product is optioned under the 2019 Adimab Agreement, upon the last to expire option period. Upon expiration, the licenses Adimab granted to us with respect to products for which we have exercised our option will continue on a non-exclusive, royalty-free basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview&#x2014;2021 Adimab Collaboration Agreement (2021 Adimab Agreement)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, we entered into another Adimab collaboration agreement (the 2021 Adimab Agreement). Under the 2021 Adimab Agreement, we were required to fund antibody engineering research programs with respect to targets selected by us. The 2021 Adimab Agreement also granted us an exclusive option to obtain a specified number of engineered sequences discovered or optimized by Adimab and directed against the targets that we selected. We selected one target, which was the subject of a research program conducted by the parties. We did not exercise our option to obtain any engineered sequences in connection with that research program, and we did not nominate any additional targets for additional research programs. The 2021 Adimab Agreement expired at the end of the option period for the research program that was conducted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We must manufacture our product candidates for clinical trial use in compliance with cGMP regulations. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet cGMP requirements and FDA or comparable foreign regulatory authority&#x2019;s satisfaction before any product is approved for human clinical trial use. Our third-party manufacturers will also be subject to periodic inspections of their respective facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may include review of procedures and operations used in the testing and manufacture of our products to assess compliance with applicable regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture our product candidates for use in clinical trials and commercialization. We rely, and expect to continue to rely, on third-party cGMP manufacturers or our collaboration partners for the production of our products for human clinical trials in compliance with FDA and other foreign authority regulations for such products. We rely on CDMOs to manufacture and supply our preclinical and clinical materials to be used during the preclinical and clinical development of our product candidates. As part of our broad manufacturing strategy to expedite the manufacturing of our product candidates and minimize manufacturing risk, we currently have established relationships with several CDMOs for the manufacturing of our drug substance or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have long-term supply agreements and we purchase our required drug product through development manufacturing services agreement. We expect to continue to rely on third-party manufacturers or our collaboration partners for the commercial supply of any of our product candidates for which we obtain marketing approval. We have personnel with significant technical, manufacturing, analytical, quality, regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with statutory and regulatory requirements subjects a manufacturer to possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercialization Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have any approved drugs and we do not expect to have any approved drugs in the near term. Therefore, we have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing drugs. When, and if any of our product candidates are approved for commercialization, we intend to develop a commercialization infrastructure for those products in the United States, Europe, Asia, and potentially in certain other key markets. We may also rely on partnerships, such as our AbbVie and GSK collaborations, to provide commercialization infrastructure, including sales and marketing and commercial distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our strategy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates and related components, their methods of use and processes for their manufacture, our proprietary reagents and assays and any other inventions that are commercially important to our business. We also rely on trademarks as well as trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product candidates. We believe that we have substantial know-how and trade secrets relating to our technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our patent portfolio contains over 50 families, which include 42 issued patents and over 500 pending patent applications that are directed to over 20 different targets and/or technologies and that are solely owned or we have rights to exclusive licenses by us. For our product candidates, we generally pursue multilayered patent protection covering the composition of matter based on binding epitopes of the product candidates on the target protein, functional characteristics of the product candidates, degenerative sequence of the product candidates, and/or specific sequence of the product candidates. In addition to composition of matter coverage, we also generally pursue claims directed to methods of making, nucleic acids, formulations, and methods of use of the product candidates. The method of use claims further include claims directed to patient selection criteria, biomarkers, disease subgroups, pharmacodynamic and clinical end-points, and dosage regimes. As further described below, we intend to strengthen the patent protection of our product candidates and technologies through additional patent application filings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PGRN Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own six patent families directed to our PGRN programs, latozinemab and AL101, which include seven issued U.S. patents, covering the compositions and uses of our PGRN program product candidates. The first two patent families are expected to expire in 2036, the third patent family is expected to expire in 2039, the fourth patent family is expected to expire in 2040, the fifth patent family is expected to expire in 2041, and the sixth patent family is expected to expire in 2042, in all cases excluding any patent term adjustments and any patent term extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TREM2 Program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own seven patent families directed to the TREM2 program, which include two issued U.S. patents, covering the compositions and uses of our TREM2 program product candidates. The first patent family is expected to expire in 2035, the second patent family is expected to expire in 2036, the third patent family is expected to expire in 2038, the fourth patent family is expected to expire in 2040, the fifth and sixth patent families are expected to expire in 2041, and the seventh patent family, assuming that the necessary non-provisional patent applications are timely filed and all other applicable requirements are satisfied for the U.S. provisional patent application, is expected to expire in 2043, in all cases excluding any patent term adjustments and any patent term extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A Program</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We own two patent families directed to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> program covering the compositions and uses of our potential </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MS4A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> program product candidates. The first patent family is expected to expire in 2039 and the second patent family is expected to expire in 2040.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a non-provisional patent application in the applicable country. In the United States, a patent&#x2019;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent is in force. A patent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it, may be extended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and other factors. Expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be available to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biotechnology and pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Some of the pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including FTD, Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, and ALS, include large companies with significant financial resources, such as Biogen, Eli Lilly, Merck and Roche Holding AG. Some of these companies are pursuing product candidates for the same or similar indications to ours and in some cases acting on the same targets or through comparable mechanisms of action. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, method of administration, cost, time to market, level of promotional activity and intellectual property protection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate our product candidates will compete with therapies approved for treating the symptoms of neurodegenerative diseases and therapies approved or currently in clinical studies intended to halt or slow the progression of neurodegenerative disease that are being developed by a number of companies and institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Drug Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA) and biologics under the FDCA and the Public Health Service Act (PHSA). Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any future product candidates must be approved by the FDA through either a biologics license application (BLA) or new drug application (NDA) process before they may be legally marketed in the United States. The process generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval by an independent Institutional Review Board (IRB), or ethics committee at each clinical trial site before each trial may be initiated; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Submission to the FDA of an NDA or BLA; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Satisfactory completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#x2019;s identity, strength, quality, and purity; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA or BLA; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The data required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory requirements for approval of therapies for the treatment of neurodegenerative diseases are evolving. For example, two new agents, aducanumab and lecanemab, recently received accelerated approval from the FDA based on a surrogate endpoint, the reduction of amyloid beta plaque in the brain. Under the FDA&#x2019;s accelerated approval pathway, a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients may serve as the basis for an accelerated approval, subject to subsequent confirmatory studies. By contrast, the FDA declined to grant accelerated approval for another product, donanemab, in AD, based on an insufficient number of patients with at least 12 months of drug exposure. FDA also recently granted accelerated approval for sodium phenylbutyrate/taurursodiol for treatment of ALS, based on efficacy data from a single 24-week Phase 2 study. The FDA advisory committee that voted in favor of approval was presented with survival data for the drug in that Phase 2 study as well as biomarker data from the drug in a separate Phase 2 AD study. In addition, a recent publication of disease progression models for genetically inherited forms of FTD, including FTD-GRN, may help inform the design of clinical trials for such forms of FTD based on more accurate estimations of sample size and the potential use of biomarkers as surrogate endpoints to reduce sample size. We are evaluating the applicability of these developments to our clinical programs, and based on that evaluation, we may engage with regulatory authorities to discuss the approval paths for our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical Trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase 1, Phase 2, and Phase 3, and may overlap.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug or biologic, findings from animal or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the consequences of the COVID-19 pandemic, the FDA has issued various COVID-19 related guidance documents applicable to biopharmaceutical manufacturers and clinical trial sponsors. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the clinical trial, any disruption of the clinical trial as a result of the COVID-19 pandemic, and impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial, among others. In 2020 and 2021, the FDA has published a number of industry guidance documents, including updates to previous guidance, related to Good Manufacturing Practices, remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities, and drug product manufacturing and supply chain inspections, among others. These and future guidance documents and regulatory requirements, including future legislation, may require us to develop and implement new policies and procedures, make significant adjustments to our clinical trials, or increase the amount time and resources needed for regulatory compliance, which may impact our clinical development plans and timelines. The extent to which the COVID-19 public health emergency impacts our business, including non-clinical studies and clinical trials, will depend on future developments, which are highly uncertain and cannot be predicted with confidence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NDA/BLA Review Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity, and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#x2019;s 2023 fee schedule for prescription drug user fees, which became effective on October 1, 2022, and will remain in effect through September 30, 2023, the user fee for an application requiring clinical data, such as an NDA or BLA, is approximately $3.2 million. PDUFA also imposes an annual program fee for each marketed human drug or biologic ($369,413 in 2022) and an annual establishment fee on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA or BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the FDA may not approve any other NDA or BLA application to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity, if FDA revokes the orphan drug designation, or if FDA finds that the holder of the orphan exclusivity has not assured the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even though the FDA has approved orphan drug status for latozinemab and AL101 for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating FTD. Furthermore, orphan drug exclusivity does not prevent the FDA from approving another marketing application for the same drug product for a different indication before the expiration of the orphan exclusivity period. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#x2019;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication for which it has not been granted orphan drug designation, it will not have orphan drug exclusivity in that non-orphan indication. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In litigation in 2021, a court disagreed with the FDA&#x2019;s longstanding position that orphan drug exclusivity only applies to the approved use or indication within an eligible disease, and not to all uses or indications within the entire designated disease or condition. This appellate court decision created uncertainty in the application of orphan drug exclusivity. In January 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the applicable court ruling. The FDA intends to continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that has not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of orphan drug exclusivity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA or BLA approval, but ideally no later than the pre-NDA or pre-BLA meeting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patient Protection and Affordable Care Act, or ACA, signed into law in 2010, includes the BPCIA, which created an abbreviated approval pathway for biological products shown to be highly similar to an FDA-licensed reference biological product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product notwithstanding minor differences in clinically inactive components; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">animal studies (including the assessment of toxicity); and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient to demonstrate safety, purity, and potency in one or more conditions for which the reference product is licensed and intended to be used. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, an application must include information demonstrating that: </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar product have been previously approved for the reference product; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for the reference product; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure that the biological product continues to be safe, pure, and potent. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. In addition, the law provides for a designation of &#x201c;interchangeability&#x201d; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proposed product is biosimilar to the reference product; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proposed product is expected to produce the same clinical result as the reference product in any given patient; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#x2019;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount of scientific evidence&#x2014;laboratory, preclinical and/or clinical&#x2014;required to demonstrate biosimilarity to a licensed biological product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity and recommends that sponsors use a stepwise approach in the development of their biosimilar</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to establish the underlying safety and effectiveness of the reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that any impurities or differences in active ingredients do not affect the safety, purity, or potency of the biosimilar product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and preserve the biological product&#x2019;s safety, purity, and potency.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The submission of a biosimilar application does not guarantee that the FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case the sponsor may choose to conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for 12 years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its product in children, a so-called pediatric extension.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first biological product determined to be interchangeable with a branded product for any condition of use is also entitled to a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: one year after the first commercial marketing of the first interchangeable product; 18 months after resolution of a patent infringement against the applicant that submitted the application for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; 42 months after approval of the first interchangeable product, if a patent infringement suit against the applicant that submitted the application for the first interchangeable product is still ongoing; or 18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &#x201c;off-label use&#x201d;, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters, or holds on post-approval clinical studies; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other U.S. Regulatory Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state and local governments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Patent-Term Restoration and Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office (USPTO), in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#x201c;First licensure&#x201d; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#x201c;first licensure&#x201d; of a biological product is determined on a case-by-case basis with data submitted by the sponsor.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European Union Drug Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA), and one or more Ethics Committees (ECs). Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Clinical Trials Regulation EU No 536/2014, which replaced the Clinical Trials Directive and entered into application on January 31, 2022, is intended to simplify the current rules for clinical trial authorization and is aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">European Union Drug Review and Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of marketing authorizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned). </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#x2019;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#x2019; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for &#x201c;line extensions&#x201d; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. The Centers for Medicare and Medicaid Services have proposed to expand Medicaid rebate liability to the territories of the United States as well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices, including U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, under the Trump administration, HHS and CMS issued various rules that were expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of these new rules. The Biden administration and HHS have delayed the implementation or published rules rescinding some of these Trump-era policies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of approved products, which could have a material impact on our business. Further, Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases and allowing Medicare to negotiate pricing for certain covered drugs. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products candidates. Such initiatives and legislation may affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the demand for any such product candidate, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As noted above, the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scientific Advisory Board</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have assembled a highly qualified scientific advisory board comprised of advisors who have, collectively, deep expertise in neurodegenerative diseases, genomics, protein engineering, drug development, and drug discovery as well as translational medicine. Our scientists work in collaboration with these advisors to identify new disease targets, develop a biomarker strategy, and accelerate discovery and development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:36.998%;"></td>
    <td style="width:63.002%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Affiliated Entity</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adam Boxer, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Neurology at University of California, San Francisco</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aaron Gitler, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Genetics at Stanford University</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stephen Hauser, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Neurology at University of California, San Francisco</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Heneka, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Luxembourg Centre for Systems Biomedicine at University of Luxembourg</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Martin Kampmann, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Biochemistry and Biophysics, University of California, San Francisco Weill Institute for Neurosciences</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lewis Lanier, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Microbiology and Immunology at University of California, San Francisco</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liqun Luo, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National Academy of Sciences and Department of Biology at Stanford University</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Scheller, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National Academy of Sciences and National Institute of Medicine</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thomas Christian S&#xfc;dhof, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Departments of Molecular and Cellular Physiology and Neurosurgery at Stanford University</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robert Vassar, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Neurology at Northwestern University</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Berislav Zlokovic, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Department of Physiology and Neuroscience at University of Southern California</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees and Human Capital</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 273 full-time employees, over 78% of whom were engaged in research and development activities. None of our employees are represented by a labor union or covered under a collective bargaining agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors, and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. Over the last several years, the employment market in the United States has been subject to a competitive hiring and compensation environment, which in turn, has led to certain employee attrition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic and subsequent variants, we focused our health and safety efforts on protecting our employees and their families. We implemented changes that we determined were in the best interest of our employees and the communities in which we operate, and which are aligned with guidance from the Centers for Disease Control and Prevention and in compliance with applicable state and local regulations. This includes having some of our employees work from home, while implementing additional safety measures for employees continuing critical on-site work.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a Delaware corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080. Our telephone number is 415-231-5660. Our website address is www.alector.com. Information contained on, or that can be accessed through, our website is not incorporated by reference in this Annual Report on Form 10-K or in any other filings we make with the SEC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We make available on or through our website certain reports and amendments to those reports that we file with or furnish to the SEC in accordance with the Securities Exchange Act of 1934, as amended (Exchange Act).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use Alector, the Alector logo, and other marks as trademarks in the United States and other countries. This report contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this report, including logos, artwork, and other visual displays, may appear without the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#x2019; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Channels for Disclosure of Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investors and others should note that we may announce material business and financial information to our investors using our investor relations website (https://investors.alector.com), SEC filings, webcasts, press releases, corporate decks provided on our website, and conference calls. We use these mediums, including our website, to communicate with our members and the public about our company, our products, and other issues. It is possible that the information that we make available may be deemed to be material information. We therefore encourage our investors and others interested in our company to review the information that we make available on our website.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; and in our other public filings, in evaluating our business. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company, as more fully described below. The principal factors and uncertainties that make investing in our company risky include, among others:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are in the clinical stages of drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses in each year since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development of biopharmaceutical products is inherently risky, and our business is heavily dependent on the successful development of our product candidates, which are in preclinical and clinical development, so we cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to continue to create a pipeline of product candidates from our research and drug discovery platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our research and drug discovery platform, our commercial opportunity may be limited.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to carry out our obligations under our collaborations for our product development and research programs; for instance, without limitation, failure to complete in a timely manner or at all our contractual obligations to GSK and AbbVie.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to expand indications for approved product candidates.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen both limited success in drug development and evolving standards for regulatory approval. Further, our product candidates are based on new approaches and novel technology, and we must identify and develop new biomarkers that are signs of a disease or condition and that can measure the impact of our product candidates on disease progression, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations and financial results could continue to be adversely impacted by the COVID-19 pandemic, including the effects of subsequent variants, in the United States and the rest of the world, including potential supply chain issues and concerns.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price of our common stock may continue to experience volatility or decline, which could result in substantial losses for investors and could negatively impact our ability to conduct additional fundraising in the public markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business, Financial Condition, and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are in various stages of drug development and have a limited operating history and no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company with a limited operating history, focused primarily on developing therapeutics for neurodegenerative diseases, including FTD, Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, and ALS, as well as oncology therapeutics that focus on innate immune biology. We commenced operations in May 2013. To date, we have financed our operations primarily through the sale of equity securities and upfront payments received in connection with our collaboration arrangements with AbbVie and GSK. We have no products approved for commercial sale and have not generated any revenue from product sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We are in Phase 2 and Phase 3 clinical trials for one product candidate, latozinemab, are in Phase 2 clinical trial for one product candidate, AL002, and we have completed a Phase 1 clinical trial for AL101. We decided to close the Phase 1 clinical trial for our AL044 product candidate based on initial PK and tolerability data. In addition, AbbVie decided to terminate the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. To date, we have not completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will encounter risks and difficulties frequently experienced by clinical-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant net losses in each year since our inception and anticipate that we will continue to incur net losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses in almost every reporting period since our inception. We incurred net losses of $133.3 million, $36.3 million, and $190.2 million for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, we had an accumulated deficit of $579.7 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have invested significant financial resources in research and development activities, including for our preclinical and clinical product candidates. We do not expect to generate revenue from product sales for several years, if at all. The revenue we currently generate from our collaboration arrangements with AbbVie and GSK is variable and limited in amount. For our collaborations with AbbVie and GSK, we recognize collaboration revenue by measuring the progress towards complete satisfaction of the performance of obligation measured as the program costs are incurred. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2021, we entered into an agreement with GSK to collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101. Under the terms of the GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in August 2021 and $200 million was received in January 2022. In addition, we will be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments for latozinemab and AL101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing our product candidates is expensive, and we expect to continue to spend substantial amounts as we fund our early-stage research projects and continue to advance our programs through preclinical and clinical development. Even if we are successful in developing our product candidates, obtaining regulatory approvals and launching and commercializing any product candidate will require substantial additional funding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur significant expenses and increasingly higher operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue our research and discovery activities; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance our research and drug discovery platform, including our target, patient, and biomarker selections; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">progress our current and any future product candidates through preclinical and clinical development; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiate and conduct additional preclinical, clinical, or other studies for our product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">work with our contract development and manufacturing organizations (CDMOs) to scale up the manufacturing processes for our product candidates or, in the future, establish and operate a manufacturing facility; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">change or add contract manufacturers or suppliers; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek regulatory approvals and marketing authorizations for our product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish sales, marketing, and distribution infrastructure to commercialize any products for which we obtain approval; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">make milestone, royalty, or other payments due under any license or collaboration agreements; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">take steps to seek protection of our intellectual property and defend our intellectual property against challenges from third parties; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property obtained through license and collaboration agreements;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attract, hire, and retain qualified personnel, especially in light of a competitive hiring and compensation environment; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide additional internal infrastructure to support our continued research and development operations and any planned commercialization efforts in the future; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional internal systems and infrastructure related to cybersecurity; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">meet the requirements and demands of being a public company; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withstand periods of rising rates of inflation; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">defend against any product liability claims or other lawsuits related to our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large enough to achieve profitability, we must succeed, either alone or with third</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parties, in developing, obtaining regulatory approval for, manufacturing, and marketing therapies with significant commercial success. Our ability to generate revenue and achieve profitability depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completing research and preclinical and clinical development of our product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing impacts on our clinical trials resulting from factors related to the effects of the COVID-19 pandemic and subsequent variants;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete clinical development and clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, assessing, acquiring, and/or developing new product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing, and distribution infrastructure; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign countries where our products are commercialized; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining adequate reimbursement for our product candidates from payors; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining market acceptance of our product candidates as viable treatment options; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receiving milestones and other payments under our current and any future collaboration arrangements; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">attracting, hiring, and retaining qualified personnel, especially in light of a recent very competitive compensation environment. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, clinical development of two of our product candidates has been terminated. AbbVie decided to terminate the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. Additionally, we decided to close the Phase 1 clinical trial for our AL044 product candidate based on initial PK and tolerability data. Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the FDA or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our current or future collaborators&#x2019; clinical trials or the development of any of our product candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have required substantial amounts of cash since inception, and we expect our expenses to increase significantly in the foreseeable future. To date, we have financed our operations primarily through the sale of equity securities and upfront payments received in connection with our collaboration arrangements with AbbVie</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and GSK. Developing our product candidates and conducting clinical trials for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#x2019;s disease, ALS, and Parkinson&#x2019;s disease, and in oncology, will require substantial amounts of capital. We will also require a significant amount of capital for the further development of our product candidates, and if any of such product candidates are approved, to commercialize any approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents, and marketable securities of $712.9 million. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities, will be sufficient to fund our projected operations through 2025. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may be proved inaccurate, and we could use our available capital resources sooner than we currently expect. In addition, changing circumstances, including periods of a rising rate of inflation, may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global markets recently have experienced volatility and instability in connection with macroeconomic downturns stemming from increased inflation, supply chain and other economic impacts of the COVID-19 pandemic and geopolitical events, including the Russian invasion of Ukraine, among other matters. In addition, the public market for and stock prices of biotechnology companies have experienced a significant downturn over the last few years. Our ability to raise money in the public markets may be severely impacted for the foreseeable future due to these factors. Additional capital may not be available when we need it, on terms acceptable to us or at all. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale back, or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may be unfavorable terms, including interest rates and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Due to the significant resources required for the development of our product candidates, and depending on our ability to access capital, we must prioritize development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have identified over 100 immune system targets. Three of our product candidates, latozinemab, AL002, and AL101, are in clinical development, and we continue to develop our research pipeline. The development of one of our product candidates, AL003, was terminated in June 2022. Together, the development of these programs and product candidates requires significant capital investment. Due to the significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof-of-concept data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">However, even if our product candidates are able to gain regulatory approval in one indication, there is no guarantee that we will be able to obtain approval in other indications, and we may expend significant resources in seeking such approvals. In addition, we may focus resources on pursuing indications outside of neurodegeneration based on the same genetic and mechanistic rationale we utilize in determining on which of our discovery programs to focus. Our decisions concerning the allocation of research, development, collaboration, management, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. For example, Innovent will not be continuing development of AL008, and we intend to re-acquire the rights we granted to Innovent for the development and commercialization of AL008. Innovent submitted an IND with the Chinese regulatory authorities, and Alector is in the process of obtaining relevant materials and information from Innovent. Alector plans to evaluate data and documentation from that IND application to potentially support an IND submission in the U.S. Similarly, our potential decisions to delay, terminate, or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases, such events could have a material adverse effect on our business, financial condition, and results of operations. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. Our reliance on genetic screening and use of biomarkers to align patient risk profiles with targeted intervention may eventually require us to develop and use companion diagnostics, which could impact product development costs and timelines depending on the specific diagnostic and any applicable regulatory requirements that would need to be met to enable its use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Discovery, Development, and Commercialization of Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on the successful development of our product candidates, which are in various stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are in the clinical stages of development of many of the product candidates currently in our programs. To date, we have invested substantially in our efforts and financial resources to identify, procure intellectual property for, and develop our programs and product candidates, and provide general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our product candidates may not successfully complete preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors may develop therapeutics that render our product candidates obsolete or less attractive; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product candidates that we develop may not be sufficiently covered by intellectual property for which we hold exclusive rights; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the product candidates that we develop may be covered by third parties&#x2019; patents or other intellectual property or exclusive rights; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be capable of being produced in sufficient quantities for development or commercialization at an acceptable cost, or at all; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate, to gain market acceptance; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. For example, after completing the Phase 1 trial for AL003 and reviewing the collaboration program with us, AbbVie decided to terminate the CD33 collaboration program, under which AL003 was being developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to further develop our current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Most of our product candidates are in the early stages of development and all will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never completed a clinical development program. We are in Phase 2 and Phase 3 clinical trials for one product candidate, latozinemab, are in Phase 2 clinical development for one product candidate, AL002, and we have completed a Phase 1 clinical trial for AL101. Further, we cannot be certain that any of our product candidates will be successful in clinical trials. For any product candidates we have advanced into clinical trials, we may terminate such trials or the clinical program prior to their completion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates successfully complete clinical trials, we generally plan to seek regulatory approval to market our product candidates in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical trials, commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of our product candidates. We cannot be sure that our collaborators or partners will conduct these activities or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or other diseases, we cannot be assured that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if approved, successfully commercialize any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to continue to create a pipeline of product candidates from our research and drug discovery platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our research and drug discovery platform, our commercial opportunity may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of our strategies is to identify and pursue clinical development of additional product candidates. Identifying, developing, obtaining regulatory approval, and commercializing additional product candidates for the treatment of neurodegenerative and other diseases will require substantial additional funding and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop, or, if approved, commercialize additional product candidates. If we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are unable to successfully identify, acquire, develop, and commercialize additional product candidates, our commercial opportunity may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to obtain approval for additional or expanded indications for our approved product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof-of-concept data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication. Conducting clinical trials for additional indications for our product candidates requires substantial technical, financial, and human capital resources and is prone to the risks of failure inherent in drug development. We cannot provide any assurance that we will be successful in our effort to obtain regulatory approval for our product candidates for additional indications even if we obtain approval for an initial indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any products approved for commercial sale and have not generated any revenue from product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development. Further, our product candidates are based on new approaches and novel technology, and we must identify and develop new biomarkers that are signs of a disease or condition and that can measure impact on disease progression of our product candidates, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have focused a substantial portion of our research and development efforts on addressing neurodegenerative diseases. Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are limited currently approved therapeutic options available for patients with FTD, Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, ALS, and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our product candidates for treating neurodegenerative diseases. Developing product candidates and, if approved, commercializing our products for treatment of neurodegenerative diseases subjects us to a number of challenges, including obtaining disease modifying activity and efficacious dose in target tissue and obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our approach to the treatment of neurodegenerative diseases aims to identify and select targets enriched in microglia and other myeloid immune cells which are genetically associated with neurodegenerative diseases. We identify and develop product candidates that are designed to cross the blood brain barrier in sufficient quantity and potency to enable efficacious dosing in the brain and engage the intended target, and we must be able to identify and develop biomarkers and biomarker assays that can accurately identify signs of a disease or condition, assist us in selecting the right patient population, and demonstrate target engagement, pathway engagement, and measure the impact on disease progression of our product candidates. This strategy may not prove to be successful. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND or a clinical trial application (CTA) will result in the FDA or EMA, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in preclinical and clinical product candidate development; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in identifying, recruiting, and training suitable clinical investigators; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining required IRB/EC approval at each clinical trial site; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of delays to clinical trials, including as a result of temporary or permanent clinical hold by regulatory agencies for a number of reasons (see for example our discussions of ARIA in other risks described in this &#x201c;Risk Factors&#x201d; section), including: </span></div></div>
  <div style="margin-left:11.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.759008424780358%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">after review of an IND or amendment, CTA or amendment, or equivalent application or amendment; </span></div></div>
  <div style="margin-left:11.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.759008424780358%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as a result of a new safety finding that presents unreasonable risk to clinical trial participants; </span></div></div>
  <div style="margin-left:11.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.759008424780358%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as a result of modifications to clinical trial protocols or related documentation; </span></div></div>
  <div style="margin-left:11.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.759008424780358%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a negative finding from an inspection of our clinical trial operations or study sites; or </span></div></div>
  <div style="margin-left:11.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.759008424780358%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the finding that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical trials, and delays caused by patients withdrawing from clinical trials, or failing to return for post-treatment follow-up; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulty collaborating with patient groups and investigators; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to perform in accordance with the FDA&#x2019;s or any other regulatory authority&#x2019;s current good clinical practices (cGCPs) requirements, or applicable EMA or other regulatory guidelines in other countries; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our product candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trials of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we had been developing AL003 with AbbVie to treat patients with Alzheimer&#x2019;s disease but on June 30, 2022, AbbVie provided written notice to us formalizing the decision to terminate the CD33 collaboration program</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> under which AL003 was being developed. Additionally, Innovent will not be continuing development of AL008, and we intend to re-acquire the rights we granted to Innovent for the development and commercialization of AL008. Innovent submitted an IND with the Chinese regulatory authorities, and Alector is in the process of obtaining relevant materials and information from Innovent. Alector plans to evaluate data and documentation from that IND application to potentially support an IND submission in the U.S. Furthermore, we decided to close the Phase 1 clinical trial for our AL044 product candidate based on initial PK and tolerability data.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such trial or by the FDA, EMA, or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, impacts of the COVID-19 pandemic and subsequent variants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, which could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We continue to pursue measures to enroll our Phase 3 INFRONT-3 and Phase 2 INVOKE-2 trials. For example, we are opening additional clinical trial sites and expanding recruitment efforts to enroll the INFRONT-3 trial. However, we may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient population; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the study population required for analysis of the trial&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of patients to a trial site; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the trial; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in enrolling patients in our clinical trials caused by the effects of the COVID-19 pandemic and subsequent variants; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility criteria; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain patient consents; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that patients enrolled in clinical trials will not complete such trials or that we may not be able to collect data from such patients for any reason. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment of patients in our clinical trials and maintaining patients in our ongoing clinical trials have been, and may continue to be, delayed or limited due to the effects of the COVID-19 pandemic and subsequent variants. In addition, if additional COVID-19 concerns or restrictions arise, including as a result of any new COVID-19 variants, patients may not be able or willing to visit clinical trial sites for dosing or data collection purposes due to additional limitations on travel new physical distancing imposed or recommended by federal or state governments or patients&#x2019; reluctance to visit the clinical trial sites during the pandemic. While the impact of the COVID-19 pandemic is lessening, the effects resulting from the COVID-19 pandemic and subsequent variants could continue to delay or prevent the anticipated readouts from our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex, and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in healthy volunteers or one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen, and other clinical trial protocol elements and the rate of dropout among clinical trial participants. Open-label or long-term extension studies may also extend the timing and cost of a clinical program substantially. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, in our ongoing INVOKE-2 Phase 2 clinical trial in Alzheimer&#x2019;s disease, cases of ARIA have been observed. ARIA are MRI findings suggestive of vasogenic edema or hemosiderin deposits. The incidence of ARIA has been shown to increase in AD patients with the administration of certain Alzheimer's disease therapeutics, namely anti-&#x3b2;-amyloid antibodies. In our INVOKE-2 Phase 2 clinical trial, most ARIA cases were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred almost exclusively in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, consistent with recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an IDMC, which is allowed to review unblinded data and to make trial recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operations and financial results could be adversely impacted by the effects of the COVID-19 pandemic and subsequent variants in the United States and the rest of the world.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic, including recent variants that spread throughout the world, has adversely impacted global commercial activity. While the impact of the COVID-19 pandemic is lessening, such events have contributed to significant volatility and instability in financial markets, including a rising rate of inflation. The COVID-19 pandemic and government responses created disruption in global supply chains and adversely impacted many industries. The pandemic could have a continued material adverse impact on economic and market conditions, including a continued rapid increase in inflation rates, and lead to a further extended period of global economic slowdown. We continue to monitor the impact of the COVID-19 pandemic closely. The extent to which the COVID-19 pandemic will impact our operations or financial results is uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, such as worker shortages; supply chain issues and disruptions; facilities and production suspensions; increases in inflation rates; and spikes in demand for certain goods and services, such as medical services and supplies. While the extent of the impact of the effects of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. If as a result of the global COVID-19 pandemic and any new variants that may later arise, we may experience disruptions, especially supply chain disruptions, that could have severe impacts on our business and clinical trials, such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and nature of the patient populations for our clinical trials; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in recruiting, enrolling, and maintaining patients in our clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to new limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations in resources that would otherwise be focused on the conduct of our business or our clinical trials, including because of sickness or the desire to avoid contact with large groups of people or as a result of government-imposed &#x201c;shelter in place&#x201d; or similar working restrictions;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, or to discontinue the clinical trials altogether, or which may result in unexpected costs;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in necessary interactions with regulators, IRBs/ECs and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div></div>
  <p style="text-indent:5.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to develop, implement, and maintain additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus, which may delay our anticipated timelines for clinical studies and regulatory approval and increase our costs for clinical studies. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic. In 2020 and 2021, the FDA issued guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing, remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities; and manufacturing, supply chain, and drug and biological product inspections, among others. In light of the spread of COVID-19 variants, the FDA, EMA, and comparable foreign regulators may issue additional guidance and policies that may materially impact our business and clinical development timelines. Further changes to existing policies and regulations could increase our compliance costs or delay our clinical plans. To the extent our clinical studies are delayed or data from our clinical studies become compromised due to COVID-19 related factors, we may be required to expend additional resources to conduct additional studies and/or enroll more participants, which could adversely affect our business operations and delay regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic continues to evolve, and the extent to which may impact our business, preclinical studies, and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions, social distancing in the United States and other countries, business closures or business disruptions, the effectiveness of actions taken in the United States and other countries to contain and treat the disease, and the possibility of new variants. We may also suffer from any of the foregoing disruptions if the COVID-19 virus and subsequent variants continue to develop and experience a resurgence in any particular country or region in the future.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The spread of COVID-19 and its subsequent variants has caused us to modify our business practices including by employing more remote workers and operating under hybrid work model. In addition, we may take actions as required by government authorities and regulations or that we determine are in the best interests of our employees, customers, partners, and suppliers. Many of our employees continue to work remotely. Our ability to perform critical functions could be harmed. We may incur incremental expenses in connection with travel for remote employees, which we will continue to monitor; such expenses could adversely impact our results of operations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, certain third parties with whom we engage, including our collaborators, contract organizations, third party manufacturers, suppliers, clinical trial sites, regulators and other third parties with whom we conduct business have similarly adjusted their operations and assessed their capacity in light of the COVID-19 pandemic and the impact of subsequent variants. If these third parties experience shutdowns or business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, certain of our clinical trial sites experienced clinical trial visit delays, and we are aware that for a period of time, some participants in our then ongoing trials did not receive scheduled doses or assessments on time. These events could negatively impact the integrity, reliability, or robustness of the data from our clinical trials. We and our CROs made certain adjustments to the operation of such trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA, and we may be required to make further adjustments in the future due to any resurgence of COVID-19.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent the ongoing COVID-19 pandemic or other disease outbreaks adversely affect our operations and financial results, it may also have the effect of heightening many of the other risks described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#x2019;s disease, Parkinson's disease, and ALS, as well as for the treatment of cancer. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. For example, in January 2023, FDA approved lecanemab, an anti-amyloid beta protofibril antibody for the treatment of Alzeimer&#x2019;s disease developed by Eisai Co., Ltd. (Eisai) and Biogen Inc. (Biogen). Eisai has also filed marketing authorization applications in Japan and Europe. Additionally, in July 2022, Biogen announced that the FDA accepted a NDA for tofersen, an drug for ALS associated with mutations in superoxide dismutase 1 (SOD1), and in September 2022, Amylyx Pharmaceuticals, Inc. announced that the FDA approved RELYVRIO&#153; (sodium phenylbutyrate and taurursodiol) for the treatment of adults with ALS. Other competitors are pursuing product candidates that act on the same targets or through comparable mechanisms of action.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan drug exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our patents relating to our competitors&#x2019; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#x2019; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The manufacture of our product candidates is complex, and we may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The processes involved in manufacturing our product candidates are complex, expensive, highly-regulated, and subject to multiple risks. Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in large quantities. Our CDMOs may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our CDMOs are unable to successfully scale up the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risk would apply to our internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design, and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA, and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA, and foreign regulatory authority requirements, including complying with current good manufacturing practices (cGMPs) on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA, or other regulatory authorities, including recent FDA guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug and biological products manufacturing, as well as any future guidance and regulations, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved product to specifications acceptable to the FDA, EMA, or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in commercial activities with our collaborators for, some of our product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Factors that may inhibit our efforts to commercialize any approved product on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; and our ability to recognize revenue from such prices; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent commercialization organization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The commercial success of any of our products will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety as demonstrated in clinical trials and published in peer-reviewed journals; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages compared to alternative treatments; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to offer our products for sale at competitive prices; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sufficient third-party coverage or reimbursement; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to offer appropriate patient access programs, such as co-pay assistance; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which physicians recommend our products to their patients; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">convenience and ease of dosing and administration compared to alternative treatments; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which the product candidate is approved by FDA, EMA, or other regulatory agencies; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements of the FDA, EMA, or other comparable foreign regulatory authorities, including any limitations, contraindications, or warnings contained in a product&#x2019;s approved labeling; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on how the product is distributed; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publicity concerning our products or competing products and treatments; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of marketing and distribution support; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we may not become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any products we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulations that govern marketing approvals, pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted or potential future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid, and Veterans Affairs hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA, EMA, or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current and future CMS coverage restrictions on classes of drugs that encompass our product candidates, including our candidates for treating Alzheimer&#x2019;s disease, could have a material adverse impact on our ability to commercialize our product candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates for which we intend to seek approval may face biosimilar competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#x201c;interchangeable&#x201d; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is analogous to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its product as soon as it is approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get it on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any legal proceedings or claims involving or against us could be costly and time-consuming to defend and could harm our reputation regardless of the outcome.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may in the future become subject to legal proceedings and claims that arise in the ordinary course of business, including intellectual property, data privacy, product liability, employment, class action or derivative, whistleblower and other litigation claims, and governmental and other regulatory investigations and proceedings. Such matters can be time-consuming, divert management&#x2019;s attention and resources, cause us to incur significant expenses or liability, or require us to change our business practices. In addition, the expense of litigation and the timing of this expense from period to period are difficult to estimate, subject to change, and could adversely affect our financial condition and results of operations. Because of the potential risks, expenses, and uncertainties of litigation, we may, from time to time, settle disputes, even where we have meritorious claims or defenses, by agreeing to settlement agreements. Any of the foregoing could adversely affect our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased or interrupted demand for our products; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exhaustion of any available insurance and our capital resources; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any product candidate. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Approval and Other Legal Compliance Matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain approval by the FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not submitted for, or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, the U.S. federal government has experienced and may in the future experience shutdown</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or budget sequestration, which could result in significant reductions to the FDA&#x2019;s budget, employees, and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. To the extent FDA and other regulatory authorities experience any delays or limited resources in reviewing our regulatory applications or requests for meetings and/or guidance, and inspection of manufacturing facilities prior to regulatory approval due to the effects of the COVID-19 pandemic or other reasons, we may experience significant delays in our anticipated timelines for our clinical studies and/or seeking regulatory approvals, which could adversely affect our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons, including but not limited to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or the interpretation of the results of our clinical trials; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately or insufficiently effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&#x2019;s risk-benefit ratio, on its own or when compared to the standard of care, is acceptable; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval or resulting in delays in our regulatory approval, including, for example, in connection with the FDA&#x2019;s approval of Biogen&#x2019;s Aduhelm in Alzheimer&#x2019;s disease amid questions regarding the underlying data, as well as the ongoing government investigation of the FDA&#x2019;s approval process for Aduhelm. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential, or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of management&#x2019;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our product candidates, if approved for commercial sale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ARIA have been observed in our ongoing INVOKE-2 Phase 2 clinical trial in AD. ARIA are MRI findings suggestive of vasogenic edema or hemosiderin deposits. The incidence of ARIA has been shown to increase in AD patients with the administration of certain Alzheimer's disease therapeutics, namely anti-&#x3b2;-amyloid antibodies. In our INVOKE-2 Phase 2 clinical trial, most ARIA cases were asymptomatic and non-serious. However, a small number of ARIA-related serious adverse events occurred almost exclusively in patients with the APOE e4/e4 genotype, as previously reported. To mitigate risks associated with ARIA, we voluntarily discontinued dosing and enrollment of APOE e4/e4 participants in our INVOKE-2 Phase 2 clinical trial. Following these changes, a small number of ARIA-related serious adverse events occurred in patients who are non-homozygous for the APOE e4 allele. We continue to implement earlier MRI monitoring, consistent with recently published guidelines for ARIA monitoring and management. We are conducting this study under the guidance of an IDMC, which is allowed to review unblinded data and to make trial recommendations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may withdraw approvals of such product and cause us to recall our products; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to change the way the product is administered, monitor patients over the course of treatment, or conduct additional clinical trials or post-approval studies; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, requiring pre-prescription screening or ongoing monitoring for ARIA and/or other adverse events, and/or other elements, such as boxed warning on the packaging, to assure safe use; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently are and may continue in the future to conduct clinical trials for our product candidates outside the United States, and the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently are and may continue in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe, Latin America, Asia or Australia. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practice; and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction, as regulatory authorities in different jurisdictions may impose different requirements for approval,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including requirements with respect to trial design or trial diversity. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. Our reliance on genetic screening and use of biomarkers to align patient risk profiles with targeted intervention may eventually require us to develop and use companion diagnostics, which could result in additional regulatory requirements that would need to be met to enable its use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties, and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive post-marketing requirements and regulatory scrutiny.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers and manufacturers&#x2019; facilities are required to comply with extensive requirements imposed by the FDA, EMA, and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, BLA, or marketing authorization application (MAA). Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates will be subject to limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including any requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#x2019;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">supplemental applications and obtain approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issue warning letters that would result in adverse publicity; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impose civil or criminal penalties; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or withdraw regulatory approvals; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend any of our ongoing clinical trials; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to approve pending applications or supplements to approved applications submitted by us; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">impose restrictions on our operations, including closing our contract manufacturers&#x2019; facilities; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seize or detain products; or </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require a product recall. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have received orphan drug designation from the FDA for latozinemab and AL101 for treatment of FTD and may seek orphan drug designation for some of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. While we have obtained orphan drug designation from the FDA for latozinemab and AL101 for treatment of FTD, we may be unable to reap the benefits associated with orphan drug status. In addition, we plan to seek orphan drug designations for some of our other product candidates in the future but may be unable to obtain an orphan drug designation for any additional product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan drug exclusivity. This means that the FDA may not approve any other NDA or BLA application to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity, if FDA revokes the orphan drug designation, or if FDA finds that the holder of the orphan exclusivity has not assured the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even though the FDA has</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approved orphan drug status for latozinemab and AL101 for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating FTD. Furthermore, orphan drug exclusivity does not prevent the FDA from approving another marketing application for the same drug product for a different indication before the expiration of the orphan exclusivity period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed above, in litigation in 2021, a court disagreed with the FDA&#x2019;s longstanding position that orphan drug exclusivity only applies to the approved use or indication within an eligible disease, and not to all uses or indications within the entire designated disease or condition. This appellate court decision created uncertainty in the application of orphan drug exclusivity. In January, 2023, the FDA published a notice in the Federal Register to clarify that while the agency complies with the applicable court ruling. The FDA intends to continue tying the scope of orphan-drug exclusivity to the uses or indications for which a drug is approved, which permits other sponsors to obtain approval of a drug for new uses or indications within the same orphan designated disease or condition that has not yet been approved. It is unclear how future litigation, legislation, agency decisions, and administrative actions will impact the scope of orphan drug exclusivity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have received Fast Track designation from the FDA for latozinemab and AL101 for the treatment of patients with FTD carrying specific genetic mutation in the granulin gene, but we may be unable to obtain or maintain the benefits associated with the Fast Track designation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the product and the specific indication for which it is being studied.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, the FDA granted Fast Track designation for latozinemab and in January 2020, the FDA granted Fast Track designation for AL101, each for the treatment of patients with FTD carrying specific genetic mutations in the granulin gene. If our clinical development program does not continue to meet the criteria for Fast Track designation, or if our clinical trials are suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we may not realize all the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, in 2010, the Patient Protection and Affordable Care Act, or Affordable Care Act (ACA) was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research. In June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial condition, and results of operations. Complying with any new legislation or changes in healthcare regulation could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of approved</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">products, which could have a material impact on our business. In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products candidates. Such initiatives and legislation may affect the prices we may obtain or demand for any of our product candidates for which we may obtain regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, in April 2022, CMS released a national policy for coverage of aducanumab and any future monoclonal antibodies directed against amyloid approved by the FDA with an indication for use in treating Alzheimer&#x2019;s disease. CMS reiterated this policy in January 2023 in connection with the approval of lecanemab. According to the two-part National Coverage Determination (NCD), Medicare will cover monoclonal antibodies that target amyloid (or plaque) for the treatment of Alzheimer&#x2019;s disease that receive traditional approval from the FDA when furnished in accordance with the coverage criteria specified below under coverage with evidence development. CMS will also provide enhanced access and coverage for Medicare patients participating in CMS-approved studies, such as a data collection through routine clinical practice or registries. Additionally, for drugs that FDA has not determined to have shown a clinical benefit or that received an accelerated approval, Medicare will provide coverage in FDA or National Institutes of Health approved clinical trials. Current and future CMS coverage restrictions on classes of drugs that encompass our product candidates could have a material adverse impact on our ability to commercialize our product candidates, if approved, generate revenue and attain profitability. It is unclear how future CMS coverage decisions and policies will impact our business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the demand for our product, if we obtain regulatory approval; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to receive or set a price that we believe is fair for our products; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to generate revenue and achieve or maintain profitability; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of taxes that we are required to pay; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of capital. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that the above healthcare reform measures and others that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. This could lower the price that we receive for any approved product. The Biden administration and the states may pass further legislation and regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our product candidates, if approved. In addition, increased scrutiny by the U.S. Congress of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud, misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">comply with the laws of the FDA, EMA, and other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide true, complete, and accurate information to the FDA, EMA, and other comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">comply with clinical or manufacturing standards; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">report financial information or data accurately or to disclose unauthorized activities to us. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education, and other business arrangements in the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations, and financial conditions could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among other things the federal Anti-Kickback Statute, prohibits, persons from knowingly and willfully soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, impose criminal and civil penalties, including through civil &#x201c;qui tam&#x201d; or &#x201c;whistleblower&#x201d; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease, or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, require applicable manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments and other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as nurse practitioners and physician assistants, among others) and teaching hospitals, and information regarding ownership and investment interests held by physicians (as defined by law) and their immediate family members. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities that potentially harm consumers. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection, and unfair competition laws may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements, as well as submitting claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines, and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources. </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State laws also require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration, and items of value provided to healthcare professionals and entities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State and foreign laws also govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is subject to complex and evolving U.S. and foreign laws and regulations relating to security, privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A wide variety of state, national, and international laws and regulations apply to security and cybersecurity requirements and the collection, use, retention, protection, disclosure, transfer, and other processing of personal data. These security and data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. We are continually working to comply with these laws, and we anticipate needing to devote significant additional resources to our compliance efforts. It is possible that the new legislation may impose new obligations and requirements on similarly</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">situated companies, and these laws may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices. Our actual or perceived failure to adequately comply with applicable laws and regulations relating to security, privacy and data protection, or to protect our systems, personal data and other data we process or maintain, could result in regulatory fines, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, any of which could materially affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In the past, the U.S. government has experienced budgetary shutdowns and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business activities may be subject to the Foreign Corrupt Practices Act (FCPA), similar anti-bribery and anti-corruption laws, and other regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations, or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers who engage in our clinical trials or prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these investigators, prescribers and purchasers are subject to regulation under the FCPA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently use and expect to continue to use third-party collaborators for the research, development, and commercialization of certain of the product candidates we may develop, including our arrangements with AbbVie, GSK, and Adimab.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our likely collaborators for any other collaboration arrangements include large and mid-sized pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies, and academic institutions. Such arrangements with any third parties, generally provide us with shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of our current collaborations or any collaboration that we may enter into.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaborations involving our research programs, or any product candidates we may develop, pose risks to us including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#x2019;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities or collaborators may elect to fund or commercialize a competing product; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, provide insufficient quantities of materials for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership, validity, and enforceability of our intellectual property; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may own or co-own intellectual property covering our product candidates or research and development programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research programs; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that arises out of our collaborations, which may not be provided to us; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may control certain interactions with regulatory authorities, which may impact our ability to obtain and maintain regulatory approval of our product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may restrict us from researching, developing, or commercializing certain products or technologies without their involvement; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators with manufacturing, marketing, or distribution rights to one or more product candidates may not commit sufficient resources to the manufacture, marketing, or distribution of such product candidates; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control, and the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to lose access to valuable technology, know-how, or intellectual property of the collaborator relating to our products, product candidates, or research programs; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our collaborators; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders, or disrupt our management and business; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if our collaborators do not satisfy their obligations under our agreements with them, if they terminate our collaborations with them, or if we fail to satisfy our obligations to our collaborators, we may not be able to develop or commercialize product candidates as planned; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully control, and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration and; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished, or terminated. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, AbbVie, after reviewing the CD33 collaboration program with us, decided to terminate the CD33 collaboration program, under which AL003 was being developed. Additionally, Innovent will not be conducting the AL008 first in human studies in China, Innovent will not be continuing development of AL008, and we intend to re-acquire the rights we granted to Innovent for the development and commercialization of AL008. Innovent submitted an IND with the Chinese regulatory authorities, and Alector is in the process of obtaining relevant materials and information from Innovent. Alector plans to evaluate data and documentation from that IND application to potentially support an IND submission in the U.S.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may face significant competition in seeking appropriate collaborations. For example business combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop product candidates or bring them to market and generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not realize the benefit of collaborations if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#x2019;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this &#x201c;Risk Factors&#x201d; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored databases within certain timeframes. We may also be exposed to additional liabilities if our contracted third parties engage in activities associated with improper use of information obtained in the course of patient recruitment for our clinical trials, cGCP noncompliance or noncompliance under applicable privacy laws, which could result in regulatory sanctions and cause serious harm to our reputation and business operations. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of materials for our research programs, preclinical studies, clinical trials, and for commercialization of any product candidates that we may develop. Additionally, GSK, and AbbVie, have certain product manufacturing rights under their respective agreements. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have any manufacturing facilities. We currently rely on CDMOs for the manufacture of our materials for preclinical studies and clinical trials and expect to continue to do so for preclinical studies, clinical trials, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs, for the manufacture of each of our product candidates, as well as with GSK</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AbbVie, for latozinemab and AL101</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and for AL002, respectively. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and related reporting; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to produce required volume in a timely manner and to quality standards. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our CDMOs or collaboration partners to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocations, seizures, or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any medicines that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We, and the CDMO partners on which we rely, depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials, whether due to the effects of the COVID-19 pandemic or otherwise, could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and the CDMO partners on which we rely depend on third-party suppliers for the supply of the raw materials required for the production of our product candidates, and we expect to continue to depend on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. The dependence on these third-party suppliers and the challenges faced in obtaining adequate supplies of raw materials involve several risks, including supply chain issues caused by the effects of the COVID-19 pandemic, limited control over pricing, the availability of such materials, the quality of such materials, and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We do not have long-term supply agreements, and we purchase our required drug product on a development manufacturing services agreement or purchase order basis. We cannot be certain that the suppliers will continue to provide the quantities of these raw materials that are required or satisfy the anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials, including those caused by the effects of the COVID-19 pandemic and subsequent variants could materially harm our ability to manufacture our product candidates until a new source of supply, if any, can be identified and qualified. In such an event, we may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of the suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for any product candidates we develop, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our core programs and product candidates, as well as other technologies that are important to our business. As our product candidates enter and progress through clinical development, we continue to pursue intellectual property protection with respect to certain aspects of those product candidates. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in cases in which we have only filed provisional patent applications on certain aspects of our technology and product candidates, each of those provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors, from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our patent applications, or those of our collaborators, do not issue as patents in any jurisdiction, we may not be able to compete effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents or those of our collaborators with respect to our product candidates. With respect to both our intellectual property and that of our collaborators related to our product candidates, we cannot predict whether the patent applications we and our collaborators are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is expensive, time-consuming, and complex, and we or our collaborators may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our collaborators were first to file for patent protection of such inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our or our collaborators&#x2019; pending and future patent applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we or our collaborators license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we or our collaborators have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our collaborators may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or foreign patent offices or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review, inventorship dispute, or interference proceedings or other similar proceedings challenging our or our collaborators&#x2019; patent rights. An adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly with us, without payment to us. Moreover, we, or any one of our collaborators, may have to participate in post-grant challenge proceedings, such as oppositions in a foreign patent office, in which a third party challenges the features of patentability with respect to our or our collaborators&#x2019; patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection for our product candidates and other technologies. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such proceeding or other inventorship dispute, we may be required to obtain and maintain licenses from third parties. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with rights to exclude others for sufficient period of time from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our patents and patent applications may be co-owned with third parties. In addition, collaborators or future licensors may co-own their patents and patent applications with other third parties with whom we do not have a direct relationship. Our rights to certain of these patents and patent applications may be dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not parties to our license agreements. If our collaborators or future licensors do not have exclusive control of the grant of licenses under any such third-party co-owners&#x2019; interest in such patents or patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology to the extent such products and technology are not also covered by our intellectual property. In addition, we may need the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize are subject, in part, to the terms and conditions of agreements with others, including terms and conditions regarding intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on certain patent rights and proprietary technology from third parties that are important or necessary to the development of our product candidates, and development and commercialization of our product candidates are subject to the terms and conditions of certain collaboration agreements with third parties. For example, in 2014 we entered into the Adimab Collaboration Agreement with Adimab. Under the 2014 Adimab Collaboration Agreement, we are developing antibodies discovered by Adimab in our latozinemab and AL101 product candidates, and we are developing an antibody optimized by Adimab in our AL002 product candidate. In August 2019, we entered into a new collaboration agreement with Adimab for development of antibodies for use in future programs. In 2021, we entered into another collaboration agreement with Adimab, which grants us an exclusive option to obtain a specified number of engineered sequences</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> discovered or optimized by Adimab and directed against targets that we select. Additionally, in October 2017, we entered into an agreement with AbbVie to co-develop and commercialize medicines with AbbVie to treat Alzheimer&#x2019;s disease and other neurodegenerative diseases. In July 2021, we entered into the GSK Agreement to collaborate on the global development and commercialization of the progranulin-elevating monoclonal antibodies, latozinemab and AL101.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our agreements with Adimab, AbbVie, GSK, and other agreements we enter into in the future may not provide exclusive rights to use certain intellectual property and technology retained by the collaborator in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that utilize technology retained by such collaborators to the extent such products are not also covered by our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, subject to the terms of any such agreements, we may not have the right to control the preparation, filing, prosecution, and maintenance, and we may not have the right to control the enforcement and defense of certain patents and patent applications relating to or affecting our development candidates. In addition, the GSK Agreement provides GSK with certain rights with respect to preparation, filing, prosecution, maintenance, enforcement, and defense of certain patents and patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be certain that patents and patent applications as to which preparation, filing, prosecution, maintenance, enforcement, or defense are controlled by our collaborators will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our collaborators fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, our rights as to such patents may be reduced or eliminated, our right to develop and commercialize any of our product candidates that are subject of such rights could be adversely affected, and we may have a reduced ability to prevent competitors from making, using, and selling competing products. In addition, even where we have the right to control prosecution of patent applications we have licensed to and from collaborators, we may still be adversely affected or prejudiced by actions or inactions of our collaborators that took place prior to the date upon which we assumed control over patent prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our or our collaborators&#x2019; patents may be subject to a reservation of rights by one or more third parties. For example, we received an award from the National Institute of Health in support of our research into the production and characterization of novel therapeutic antibodies against the neurotrophic factor PGRN degrading receptor SORT1. As a result, the U.S. government may have certain rights to resulting intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#x2019;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve the practical application of the government funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in facilities in the United States in certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we option or license intellectual property rights from our collaborators or future licensors or otherwise experience disruptions to our business relationships with our collaborators or future licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into agreements with our collaborators to option or license certain intellectual property and may need to obtain additional intellectual property rights from others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain additional intellectual property rights at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, each of our agreements with collaborators do, and we expect our future agreements will, impose various economic, development, diligence, commercialization, and other obligations on us. Certain of our collaboration agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products. In spite of our efforts, our collaborators might conclude that we have materially breached our obligations under such agreements and might therefore terminate or seek damages under the agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these agreements. If termination of these agreements causes us to lose the rights to certain patents or other intellectual property, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products similar to or identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, disputes may arise regarding intellectual property subject to a collaboration agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of the option or license rights granted under the agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the collaborator that is not subject to the option or license rights granted under the agreement; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; and</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our collaborators and us and our other partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the agreements under which we currently have rights to option or license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. Moreover, if disputes over intellectual property that we have optioned or licensed prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting, and defending patents on our product candidates and other technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in or into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert counterclaims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we, our collaborators or any of our future licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our collaborators or licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We also are dependent on our collaborators or licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ongoing conflict between Russia and Ukraine, including the sanctions targeting Russia, could interfere with filing of patent applications, prosecution of applications, and maintenance of issued patents in Russia, Ukraine, and via the Eurasian Patent Office. For example, the conflict and sanctions could interfere with payment of filing fees, extension fees, and annuities. The conflict and sanctions could also interfere with enforcement or defense of patents issued in Russia, Ukraine, and via the Eurasian Patent Office. The conflict and associated sanctions could</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">therefore increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any future issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, under the Leahy-Smith America Invents Act (the America Invents Act), the first inventor to file a patent application in the United States is entitled to the patent on an invention regardless of whether another party was the first to invent the claimed invention. Therefore, a third party that filed a patent application in the USPTO after March 2013, but before us, could be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This possibility requires us to be cognizant of the time from invention to the time of filing a patent application. Because patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to file any patent application related to our product candidates or other technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain procedures at the USPTO under the America Invents Act could affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Rulings from the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we initiated legal proceedings against a third party to enforce a patent covering our product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, or enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing partners and the patent examiner were unaware during prosecution. If a third</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Protection Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking patents for our product candidates and other technologies, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and know-how to be one of our primary sources of intellectual property. Trade secrets and know-how can be difficult to protect. We expect our trade secrets and know-how to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry scientific positions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate and academic collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former employers to us or in their work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to obtain adequate remedies for such breaches. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in obtaining, through acquisitions or otherwise, necessary rights to our product candidates or other technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many pharmaceutical companies, biotechnology companies, and academic institutions that are competing with us in the field of neurodegeneration therapy may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we co-own with third parties, we may wish to obtain licenses to such co-owners&#x2019; interest to such patents. However, we may be unable to secure such licenses or otherwise acquire any rights to compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement, misappropriation, or other violation against us or our collaborators may prevent or delay the development and commercialization of our product candidates and other technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The field of discovering treatments for neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by various companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and it may remain uncertain in the future. Additionally, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">technology used in our product candidates is still in development and no products utilizing similar technology have yet reached the market. As such, there may be significant intellectual property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our and our collaborators&#x2019; ability to develop, manufacture, market, and sell any product candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, and we may become subject to, or threatened with, such actions in the future, regardless of their merit. In addition, we may undertake costly administrative proceedings for challenging third party patents, including post-grant, derivation, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others. We cannot be assured that our product candidates and other technologies that we have developed, are developing, or may develop in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing product candidates, and other technologies might assert are infringed by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other technologies may infringe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of our product candidates or other technologies infringes upon these patents. In the event that any third</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable, and infringed by our product candidates or other technologies. In this case, the holders of such patents may be able to block our ability to manufacture or commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing product candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, and/or redesign our infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates or other technologies, which could harm our business significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Engaging in litigation to defend against third parties alleging that we have infringed, misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continuation of patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, or to defend against allegations of patent infringement, which could be expensive, time consuming, and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensing partners, or we may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may become involved in inventorship, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide that a patent in which we have an interest is invalid or unenforceable, the other party&#x2019;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1), or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we license or may own; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our future licensors or collaborators, might not have been the first to invent the claimed inventions covered by the issued patents or pending patent applications that we license in the future; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">it is possible that our current or future pending owned or licensed patent applications will not lead to issued patents; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may harm our business; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, especially in light of a competitive hiring and compensation environment, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our leadership, including our Chief Executive Officer, Dr. Arnon Rosenthal. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to either find suitable replacements in the event of such loss or to attract senior management personnel to fill open positions, especially in light of a highly competitive hiring and wage environment, could result in delays in the development of our product candidates and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conduct our operations at our facility in South San Francisco, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, especially in light of recent competitive hiring and wage environment, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region and doing so may be costly and difficult.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided and will continue to provide restricted stock, stock option grants, and other equity awards that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to effectively manage the size and capabilities of our organization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 273 full-time employees. As our development plans and strategies develop, we will be required to add additional managerial, operational, financial, and other personnel. We will need to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectively manage the size and capabilities of our organization and any future growth through significant responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, integrating, retaining, and motivating additional employees; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA review process for our current and future product candidates, while complying with our contractual obligations to collaborators and other third parties; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expanding our operational, financial and management controls, reporting systems, and procedures; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing increasing operational and managerial complexity. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to manage these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates, and accordingly, may not achieve our research, development, and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have engaged in strategic collaborations and may in the future engage in acquisitions, collaborations, or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have engaged in strategic collaborations in the past, such as our strategic collaborations with AbbVie, Innovent and GSK, and we may engage in various acquisitions, collaborations, and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition, collaboration, or strategic partnership may entail numerous risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">volatility with respect to the financial reporting related to such arrangements, such as our expected variability in the recognition of revenue each quarter from the AbbVie and GSK Agreement based on the percentage-of-completion basis under the applicable accounting rules; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assumption of indebtedness or contingent liabilities; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential goodwill impairment resulting from such acquisitions;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuance of our equity securities which would result in dilution to our stockholders; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assimilation of operations, intellectual property, products, and product candidates of an acquired company by our partners, including difficulties associated with integrating new personnel; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">diversion of our management&#x2019;s attention from our existing product programs and initiatives in pursuing such an acquisition, collaboration or strategic partnership; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; that may impact their ability to fulfill their obligations under such transaction;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">risks that the other party to such a transaction may exercise its rights under the applicable agreement in a way that negatively impacts us; and</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to generate revenue from acquired or partnered intellectual property, technology, and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, especially as certain of our employees have engaged in remote or hybrid work as a result of, or after, the COVID-19 pandemic, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information, and a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third-party research institution collaborators and CROs for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or reputational harm to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions, including as a result of global pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our collaborators, CROs, CDMOs, suppliers, and other contractors and consultants, could be subject to pandemic events and other events beyond our control, such as the spread of disease, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, political unrest, including the Russia-Ukraine conflict and other natural or man-made disasters or business interruptions, for which we are either totally or partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster, global pandemics, or other business interruption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The majority of our operations including our corporate headquarters are located in a facility in South San Francisco, California. Damage or extended periods of interruption to our corporate, development, or research facilities due to fire, natural disaster, global pandemics, power loss, communications failure, unauthorized entry, earthquakes or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is subject to economic, political, regulatory, and other risks associated with international operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to risks associated with conducting business internationally. Some of our CDMOs and clinical trial sites, for example are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular in non-U.S. economies and markets; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing and changing regulatory requirements in non-U.S. countries;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in compliance with non-U.S. laws and regulations; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in non-U.S. regulations and customs, tariffs, and trade barriers; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in non-U.S. currency exchange rates and currency controls; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in a specific country&#x2019;s or region&#x2019;s political or economic environment; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shipping of biologics/drugs; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trade protection measures, import or export licensing requirements, or other restrictive actions by U.S. or non-U.S. governments; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative consequences from changes in tax laws; (including the provisions of the recently enacted federal tax legislation titled the Inflation Reduction Act);</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties associated with staffing and managing international operations, including differing labor relations; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential liability under the FCPA, UK Bribery Act, or comparable foreign laws; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, droughts, extreme temperatures, and fires. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other risks associated with our planned international operations may materially adversely affect our ability to attain profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had federal and state net operating loss (NOL) carryforwards of approximately $40.3 million and $203.5 million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed 80% of taxable income. Pursuant to Internal Revenue Code Sections 382 and 383, annual use of the Company&#x2019;s net operating loss and research and development credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. As a result of our initial public</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">offering in February 2019 and follow-on public offering in January 2020, and other transactions that have occurred since our incorporation, we may have experienced such an ownership change. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. As a result, our ability to use our pre-change net operating loss carryforwards and other pre-change tax attributes to offset post-change taxable income or taxes may be subject to limitation. In addition, the enacted legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (the TCJA), as amended by the Coronavirus Aid, Relief, and Economic Security Act of 2020 (CARES Act), also provides that NOLs from tax years that began after December 31, 2017 may offset no more than 80% of current taxable income annually for taxable years beginning after December 31, 2022. Our NOLs may also be subject to limitations under state law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are or may become subject to income and non-income taxes in the United States under federal, state, and local jurisdictions and in certain foreign jurisdictions in which we operate. Tax laws, regulations and administrative practices in these jurisdictions may be subject to significant change, with or without advance notice. For example, on January 1, 2022, a provision of the TCJA went into effect that eliminates the option to deduct domestic research and development costs in the year incurred and instead requires taxpayers to amortize such costs over five years for domestic costs and 15 years for foreign costs. The Company is currently evaluating the potential impact. Also, the United States recently enacted the Inflation Reduction Act, which introduced a 15% minimum tax on book income and a 1% excise tax on stock buybacks. Changes in tax laws (including provisions of the Inflation Reduction Act), regulations, or rulings, changes in interpretations of existing laws and regulations, or changes in accounting principles could negatively or materially affect our financial position, cash flows and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market price of our common stock may continue to be volatile, which could result in substantial losses for investors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although our common stock is listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. The trading price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. Some of the factors that may cause the market price of our common stock to fluctuate or decline include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of existing or new competitive products or technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commencement or termination of collaborations for our product development and research programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to achieve development, regulatory, or commercialization milestones under our collaborations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure or discontinuation of any of our product development and research programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments or disputes concerning patent applications, issued patents, or other proprietary rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of expenses related to any of our research programs, clinical development programs, or product candidates that we may develop; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our efforts to develop additional product candidates or products; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by securities analysts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcement or expectation of additional financing efforts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us, our insiders, or other stockholders, such as if we use our at-the-market facility; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expiration of market standoff or lock-up agreements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in our financial results or those of companies that are perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in estimates or recommendations by securities analysts, if any, that cover our stock; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, political, industry, and market conditions, including a rising rate of inflation or a period of economic recession; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the other factors described in this &#x201c;Risk Factors&#x201d; section. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors, such as inflationary concerns, may seriously affect the market price of our common stock, regardless of our actual operating performance. Following periods of such volatility in the market price of a company&#x2019;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert management&#x2019;s attention and resources from our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business cease to cover us or downgrade their evaluations of our stock or if we fail to meet their operating results estimates for us, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to decline significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock could decline significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain holders of shares of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We plan to file an omnibus shelf registration statement on Form S-3 with the SEC, which, upon becoming effective, will permit us to issue up to $400 million in common stock, other equity securities and/or debt securities. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our directors, executive officers, holders of more than 5% of our outstanding stock and their respective affiliates beneficially own 50.2 percentage of our outstanding common stock as of February 21, 2023. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred and will continue to incur significant additional costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform, and Consumer Protection Act, the listing requirements of NASDAQ, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and expect that we will need to continue to hire, additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel have devoted and will continue to devote a substantial amount of time towards maintaining compliance with these requirements. These requirements have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to maintain director and officer liability insurance, which could make it more difficult for us to attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of Sarbanes-Oxley Act Section 404(a), which require annual management assessments of the effectiveness of our internal control over financial reporting. Section 404(b) of the Sarbanes-Oxley Act also requires our independent auditors to attest to, and report on, this management assessment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. If we are not able to comply with the requirements of Section 404 or if we or our independent registered public accounting firm are unable to attest to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities, which would require additional financial and management resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our operations are subject to the effects of a rising rate of inflation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States has recently experienced historically high levels of inflation. According to the U.S. Bureau of Labor Statistics, the annual consumer price index increase for the United States was approximately 6.5% for the 12 months ended December 31, 2022. If the inflation rate continues to increase, it will affect our expenses, such as employee compensation and research and development charges. Research and development expenses account for a significant portion of our operating expenses. Such increased charges may not be readily recoverable during the period of time that we are bringing the product candidates to market. Additionally, the United States is experiencing an acute workforce shortage, which in turn, has created a very competitive wage environment that may increase the Company&#x2019;s operating costs. To the extent inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our consolidated financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish that our board of directors is divided into three classes, Class I, Class II, and Class III, with each class serving staggered three-year terms; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that our directors may only be removed for cause; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">eliminate cumulative voting in the election of directors; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prohibit stockholders from calling a special meeting of stockholders; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorize our board of directors, by a majority vote, to amend the bylaws; and </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, Section 203 of the General Corporation Law of the State of Delaware (DGCL), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court, or for which such court does not have subject matter jurisdiction):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim of breach of fiduciary duty; </span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; and</span></div></div>
  <div style="margin-left:6.796%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5760267799665257%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#x2019; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters are currently located in South San Francisco, California, where we lease approximately 105,000 square feet of office and laboratory space. The term of the lease agreement expires in May 2029, with an option to extend the term of the lease for an additional 10 years. The lease agreement also provides us a right of first offer to expand into available office space in the building. We subleased approximately 7,132 square feet of our corporate headquarters in November 2021 with a lease term that expired in December 2022. Additionally, we subleased approximately 13,150 square feet of our corporate headquarters in May 2022 with a lease term that will expire in November 2023. We also subleased approximately 9,275 square feet of our corporate headquarters in February 2023 with a lease term that will expire in January 2025. We lease approximately 18,700 square feet of additional office and laboratory space in Newark, California. We believe that these facilities will be adequate for our near-term needs. If required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation, or other legal proceedings can have an adverse impact on us because of legal fees and settlement costs, diversion of management resources, and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is publicly traded on the Nasdaq Global Select Market under the symbol &#34;ALEC.&#34;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 21, 2023, there were approximately 7 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments, and other factors that our board of directors deems relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">This graph is not &#x201c;soliciting material&#x201d; or deemed &#x201c;filed&#x201d; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Alector, Inc. under the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following graph compares the cumulative total return to stockholder return on our common stock relative to the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on February 7, 2019 (the first day of trading of our common stock) and its relative performance is tracked through December 31, 2022. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of the full amount of all dividends, however no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on historical results and are not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img42979713_21.gif" alt="img42979713_21.gif" style="width:624px;height:327px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:5.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> [Reserved].</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties, including those described in the section titled &#x201c;Special Note Regarding Forward Looking Statements.&#x201d; Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled &#x201c;Risk Factors&#x201d; included elsewhere in this report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Supporting our scientific approach, our research and drug discovery platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines. As a result, we have identified over 100 immune system targets. Three product candidates, latozinemab (also referred to as AL001), AL002, and AL101 are in clinical development, and we continue to develop our research pipeline, including AL009 and AL008. We recently completed a prioritization review, focusing our development resources on our progranulin and TREM2 programs and extending our cash runway through 2025. We are advancing our clinical product candidates and research pipeline with our existing resources and in collaboration with our partners, GSK and AbbVie.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations have been financed primarily through our collaborations with AbbVie and GSK and the issuance and sale of convertible preferred stock and of common stock upon the completion of our initial public offering (IPO) and follow-on offering. We completed our IPO in February 2019, and received $168.2 million net proceeds, after deducting underwriting discounts and commissions and offering expenses. We completed a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">follow-on offering in January 2020 and received $224.5 million net proceeds, after deducting underwriting discounts and commissions and offering expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have not had any products approved for sale and have not generated any revenue from product sales. Further, we do not expect to generate revenue from product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one of our product candidates. We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We have incurred net losses in each year since inception and we expect to continue to incur net losses for the foreseeable future. Our ability to generate product revenue will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $133.3 million, $36.3 million, and $190.2 million for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, we had an accumulated deficit of $579.7 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance product candidates through preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pursue regulatory approval of product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire, discover, validate, and develop additional product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require the manufacture of supplies for our preclinical studies and clinical trials; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain, maintain, expand, and protect our intellectual property portfolio. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not generated any revenue from product sales and do not expect to do so in the near future. Our revenue to date has been primarily related to the AbbVie Agreement and GSK Agreement for the license and co-development of product candidates with those parties. We recognize revenue from the upfront payments from AbbVie over time as services are provided. We recognize revenue from the upfront payments from GSK at a point in time for a development license and over time for research and development services. Revenues for research and development services are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of our AbbVie Agreement, in addition to receiving the upfront payments from AbbVie, we may also be entitled to development and regulatory milestone payments, opt-in payments for continued development after proof-of-concept for AL002, and other future payments from profit sharing or royalties after commercialization of product candidates from such program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of our GSK Agreement, we received $700 million in upfront payments, of which $500 million was received in August 2021 and $200 million was received in January 2022. In addition, we will be eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments for latozinemab and AL101. Alector and GSK are jointly developing latozinemab and AL101.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, Alector and GSK will equally share profits and losses from commercialization of latozinemab and AL101. We may opt out of the sharing of development costs and of profit and losses from commercialization in the United States on a product-by-product basis. In such case, we will no longer conduct development or commercialization of that product and we will receive royalties on net sales of the product in the United States instead of a share of profits. Outside of the United States, GSK will be responsible for commercialization of latozinemab and AL101 for all indications, and we will be eligible for double-digit tiered royalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our revenue for the next several years will be derived primarily from the AbbVie and GSK Agreements. The balance of deferred revenue was $491.6 million as of December 31, 2022, related to the AbbVie and GSK Agreements. The deferred revenue is expected to be recognized over the research and development period of the programs through proof-of-concept for AL002 and the completion of the initial Phase 2 clinical trials for specified indications for latozinemab and AL101.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses account for a significant portion of our operating expenses. We record research and development expenses as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of our product candidates, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with third-party contract organizations, preclinical testing organizations, and consultants; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to production of clinical materials, including fees paid to contract manufacturers; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laboratory and vendor expenses related to the execution of preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel engaged in research and development functions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to the preparation of regulatory submissions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party license fees; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense, and other supplies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators, and third-party service providers. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and as services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specific program expenses include expenses associated with the development of our most advanced product candidates: latozinemab, which is being studied in a pivotal Phase 3 clinical trial, INFRONT-3, which has an ongoing Phase 2 clinical trial; AL002, which is being studied in a Phase 2 clinical trial; and AL101, for which we have completed a Phase 1 clinical trial. We also have expenses related to the discovery and development of future product candidates and separately tracked expenses related to programs that we expect to move out of preclinical studies and into Phase 1 clinical trials. These expenses primarily relate to salaries and benefits, stock-based compensation, facility expenses, including depreciation, and lab consumables.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where we share costs with our collaboration partners, such as in our GSK Agreement, research and development expenses may include cost sharing reimbursements from, or payments to, our partner.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory approvals for any product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, information technology, human resources, and other administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, consulting, and tax services, insurance costs, and facility costs not otherwise included in research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net consists of interest earned on our cash equivalents and marketable securities and foreign currency transaction gains and losses incurred during the period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.173%;"></td>
    <td style="width:1.356%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.306%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.213999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.369%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.213999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended <br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollar</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,617</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">207,085</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(73,468</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,418</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">189,407</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,011</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,033</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55,038</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,995</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271,451</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244,445</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,006</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(137,834</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(37,360</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100,474</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,778</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,031</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(130,056</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(36,329</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(93,727</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,254</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,254</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(133,310</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(36,329</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(96,981</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue was $133.6 million for the year ended December 31, 2022, compared to $207.1 million for the year ended December 31, 2021. The decrease of $73.4 million was mostly due to the $173.4 million collaboration revenue recognized from the latozinemab FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> license provided as part of the GSK Agreement in 2021. This was offset by a $55.8 million net increase to collaboration revenue under the AbbVie Agreement due to changes in estimated costs to satisfy the performance obligations resulting from the termination of the AL003 program, partially offset by increases in total expected costs for the AL002 program. The decrease was also offset by $44.2 million higher revenue for GSK programs recognized over the initial Phase 2 clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $210.4 million for the year ended December 31, 2022, compared to $189.4 million for the year ended December 31, 2021. The increase of $21.0 million was driven by a $17.5 million increase in personnel-related expenses, including stock-based compensation, due to an increase in headcount and issuance of equity grants to employees. In addition, we had an $8.9 million increase for AL002 as it further progresses in clinical trials and a $5.9 million increase in facilities and other unallocated research and development expenses from additional rent expense, headcount, and other overhead costs. This was offset by a $9.6 million decrease in latozinemab mainly due to the cost sharing agreement with GSK.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.386%;"></td>
    <td style="width:1.371%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.062000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.384%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.127%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.384%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.286000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dollar</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Direct research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latozinemab</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,118</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,689</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,571</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL101</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,751</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,728</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,023</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL002</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,805</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,941</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,864</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AL044</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,546</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,935</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,389</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other early stage programs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,385</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,740</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(355</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indirect research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel related (including stock-based<br />&#160;&#160;&#160;compensation)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,063</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,519</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,544</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities and other unallocated research and<br />&#160;&#160;&#160;development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,750</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,855</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,895</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,418</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">189,407</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,011</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $61.0 million for the year ended December 31, 2022, compared to $55.0 million for the year ended December 31, 2021. The increase of $6.0 million was driven by a $4.9 million increase in personnel-related expenses, including stock-based compensation, due to an increase in headcount and issuance of equity grants to employees. We also had an increase of $1.1 million mainly related to information technology to support our growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net was $7.8 million for the year ended December 31, 2022, compared to $1.0 million for the year ended December 31, 2021. The increase of $6.7 million was due to higher investment yields on our marketable securities compared to the prior year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Tax Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense was $3.3 million for the year ended December 31, 2022, compared to zero for the year ended December 31, 2021. Beginning January 1, 2022, the TCJA requires taxpayers to capitalize and amortize research and development expenses rather than take an immediate deduction pursuant to Section 174 of the Internal Revenue Code. The increase of $3.3 million was primarily due to the impact of this new law on the cash received from the GSK Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception through December 31, 2022, our operations have been financed primarily by our collaborations with AbbVie and GSK and the issuance and sale of convertible preferred stock and of common stock upon the completion of our IPO and follow-on offering.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had $712.9 million of cash, cash equivalents, and marketable securities. As of December 31, 2022, we had an accumulated deficit of $579.7 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to our programs, and to a lesser extent, general and administrative expenditures. We expect our expenses to continue to increase in connection with our ongoing activities, in particular as we continue to advance our product candidates and our discovery programs. In addition, we expect to incur additional costs associated with operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will enable us to fund our operations and capital expenditure requirements through 2025. We have based</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We may also choose to seek additional financing opportunistically. We may seek to raise capital through public equity or debt financings, license agreements, collaborative agreements or other arrangements with other companies, asset sales, or through other sources of financing. We expect to need to obtain substantial additional funding in the future for our research and development activities and continuing operations. If we were unable to raise capital when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and progress of preclinical and clinical development activities; including, without limitation, our collaboration efforts with AbbVie and GSK; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if our product candidates are approved, commercial manufacturing; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain our current research and development programs and establish new research and development programs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addition and retention of key research and development personnel; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to enhance operational, financial, and information management systems, and hire additional personnel, including personnel to support development of our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and performing our obligations in such collaborations; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and amount of milestone and other payments we may receive under our collaboration arrangements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of regulatory approvals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our eventual commercialization plans for our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effects of inflationary pressures; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property claims.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.479%;"></td>
    <td style="width:1.192%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.288%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.315%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.315%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(20,329</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,551</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(166,734</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(159,014</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(49,663</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(105,051</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,514</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,295</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,113</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, cash used in operating activities was $20.3 million. This was due to the net loss of $133.3 million offset by an increase in deferred revenue of $66.4 million from the $200 million</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upfront payment received less revenue recognized. In addition, we had non-cash charges of $46.1 million for stock-based compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021, cash provided by operating activities was $298.6 million. This was due to the net loss of $36.3 million offset by an increase in deferred revenue of $292.9 million from the $500 million upfront payment received in the third quarter of 2021 from GSK. In addition, we had non-cash charges of $40.8 million for stock-based compensation and $6.3 million for depreciation and amortization expense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, cash used in operating activities was $166.7 million. This was mainly due to the net loss of $190.2 million and the decrease in deferred revenue of $21.1 million as revenue was recognized related to the AbbVie Agreement. This was partially offset by a non-cash charges of $30.5 million for stock-based compensation and $5.9 million for depreciation and amortization expense. We also had an increase of $12.2 million in accrued liabilities and accrued clinical supply costs, which offset the cash used in operating activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, cash used in investing activities of $159.0 million was primarily related to the maturities of marketable securities of $402.0 million offset by purchases of marketable securities of $556.9 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021, cash used in investing activities of $49.7 million was primarily related to the maturities of marketable securities of $286.3 million offset by purchases of marketable securities of $343.4 million and sales of marketable securities of $10.7 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, cash used in investing activities of $105.1 million was primarily related to the purchase of marketable securities of $506.8 million offset by the proceeds from maturities of marketable securities of $406.8 million. In addition, we used cash for the purchase of $5.0 million of property and equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2022, cash provided by financing activities of $4.5 million was primarily from the exercise of options to purchase common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2021, cash provided by financing activities of $30.3 million was primarily from the exercise of options to purchase common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, cash provided by financing activities of $232.1 million was primarily from net proceeds of the issuance of 9,602,500 shares of our common stock upon the completion of a follow-on public offering. In addition, we received $6.3 million cash from the exercise of options to purchase common stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#x2019;s judgments and estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under arrangements, we perform the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recognize collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. We recognize collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We re-evaluate the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in our forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or feedback from regulators on the design or operation of our clinical trials. We have had changes to the overall expected costs to satisfy the performance obligations from period to period. For the year ended December 31, 2022, we recorded a net increase to collaboration revenue under the AbbVie Agreement due to changes in estimated costs to satisfy the performance obligations resulting from the termination of the AL003 program, partially offset by increases in total expected costs for the AL002 program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We record accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, we accrue expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. We monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation is measured at the date of grant, based on the estimated fair value of the award and recognized as expense over the employee&#x2019;s requisite service period (usually the vesting period). We estimate the grant date fair value for options to purchase common stock, and the resulting stock-based compensation, using the Black-Scholes option-pricing model.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. These assumptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;We have limited information on the volatility of our stock as shares of our common stock were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry. These companies are considered to be comparable to our business over a period equivalent to the expected term of the stock-based awards. In 2020, we began giving weight to our own historical volatility in the determination of expected volatility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date with maturities approximately equal to the expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;The expected dividend rate is zero because we have not historically paid and do not expect for the foreseeable future to pay a dividend on our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.507%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation associated with RSUs is based on the fair value of our common stock on the grant date, which equals the closing price of our common stock on the grant date. We recognize expense over the vesting period of the awards. Expense for options and RSUs are recognized on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.507%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also granted RSUs with market conditions to certain executives. The fair value of the RSUs with market conditions are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and the estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.507%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for forfeitures as they occur for all awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and generally short-term duration, invested in compliance with our policy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had cash, cash equivalents, and marketable securities of $712.9 million as of December 31, 2022, which consisted primarily of bank deposits, money market funds, and short-term government marketable securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. Due to the generally short-term maturities of our cash equivalents and marketable securities, and the low risk profile of our marketable securities, an immediate 100 basis point increase or decrease in interest rates would cause a change in fair value of approximately $2.6 million as of December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for research and development services with payments denominated in foreign currencies, including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a material effect on our financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALECTOR, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.996%;"></td>
    <td style="width:1.122%;"></td>
    <td style="width:4.882%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:5.75pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="margin-left:5.75pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.0798611111111111in;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audited Consolidated Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reprt_of_indepdnt_registred_public_acctg"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ef82858a-f802-45fc-942a-3271e92e9b76" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statement_convertible_prefe"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financials"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="reprt_of_indepdnt_registred_public_acctg"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of Alector, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Alector, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.835%;"></td>
    <td style="width:76.165%;"></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:middle;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of the Matter</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recorded collaboration revenue of $133.6 million for the year ended December 31, 2022.  As described in Note 2, collaboration revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure. In order to recognize collaboration revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations. Revenues are recognized as the program costs are incurred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditing collaboration revenue was challenging as it involves assessing highly judgmental estimates with respect to the Company&#x2019;s determination of the total expected costs to satisfy the performance obligations.</span></p></td>
   </tr>
   <tr style="height:99.35pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls that address the identified risks related to the Company's process used to determine total expected costs to satisfy the performance obligations, including management&#x2019;s controls over updates to the budget for the relevant research and development programs.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To test collaboration revenue, our audit procedures included, among others, obtaining an understanding of the Company&#x2019;s estimated costs to satisfy the performance obligations, as well as assessing management&#x2019;s updates to the budget for the relevant research and development programs. We also tested a sample of expenses recorded to the development program, evaluated the historical accuracy of management&#x2019;s budget estimates for the relevant research and development programs, and inquired of Company personnel directly involved with supervising the development programs.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_49d14a54-a1ea-4f89-99c4-c45d5022c20f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2017.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5efff96-f60b-4c49-987e-174aa79f3a46" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LECTOR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Ba</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:67.608%;"></td>
    <td style="width:1.657%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.508%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.646%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.581999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0b855de-1ffb-4e4d-a91b-c833843f29b3" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d29cf376-bfb3-42b0-9973-0c365b69fec3" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6697372c-71ec-4789-9067-0c968a7207ff" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">558,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb850478-b1e6-4bec-bcba-ffad8ea93b13" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">406,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivable from collaboration partner</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9abe9769-b588-478e-9d8a-3b461311250e" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,587</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a454f0b1-e957-4606-a865-4b6cd70906bb" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,391</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4589cc93-62dc-43a6-bafb-fb57d9e73b7b" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32029490-21c2-42bb-8907-35ab5ad721dc" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,071</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5fa82d5-fe8c-437a-8d9e-42f960f1d672" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">726,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a55122c0-e715-46f2-b875-10cda4c1a00b" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">749,713</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_317fbbf4-bc5f-4387-9315-016dbc99dcae" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0deba312-4171-4032-8d58-b2d0b6762533" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c902e55-6f42-4787-a055-26f8335f9633" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,811</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4e54f0a-d840-44c1-8dab-176ef525ce91" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,569</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4875854-ec84-44d9-91f4-b3a0ccfb1906" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f97c547d-df5f-451b-9e91-ba29441e43e6" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95637662-777e-42a7-bd79-6875a3d982cd" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40ac6994-bb85-4a3d-b5f3-267008a9ed2c" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,574</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8109e9a-f6f0-4bfe-a16b-a4a047c015df" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">787,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b32936d-77bf-4fb9-82bb-d0d62b22d935" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">814,658</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_819caf4b-24eb-4d20-8b54-a30852ceb965" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23cfedf5-4571-4991-8da2-4fb3e87b3b85" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,749</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued clinical supply costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3650a029-d140-41b1-b030-41dd9871c965" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:AccruedClinicalSupplyCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,559</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d25911a2-5d9c-48f0-9a56-ea37fb58dc0c" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:AccruedClinicalSupplyCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,748</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff1ae905-3cea-46c4-9fe1-0d3ea79eefd1" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,771</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_203079bd-2029-48be-92ac-4cbd5d32bf9e" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f60b933-2f0e-4dd3-b0b8-ca6fe66bc0f6" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,231</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d325bd8-45bb-44d4-8c59-0da2ae5025ab" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,803</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e092bf1-9643-4cc4-befd-caacb83e3218" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7a20f63-8237-4e3e-b406-50177c277393" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37ca2f7f-4e07-495f-8e3c-586a5b9b17ed" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e14cba99-a885-4812-99c5-1c4913c57ec4" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">139,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, long-term portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24126d02-cd2b-4a48-ba68-27d45569be85" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">443,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68609b3b-a5a6-4166-b1e6-aab30e8e252e" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">334,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, long-term portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47907588-0e75-430c-987c-7090fea6358d" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db5eab8d-9f1e-46c9-bd91-d7ba1bd4acda" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b421ed-cb15-4342-9e20-ee2c3234620f" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1fa6adf-a9a3-4161-8956-56b45fb73a9b" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_745596e2-13f8-49e5-93bc-b004c6e5ba47" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">573,206</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be86ede3-fa5c-49df-ae1e-240d77ec9a30" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">513,934</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9570da83-0995-4ddf-8004-16aa50d300a5;"><span style="-sec-ix-hidden:F_98ac5068-7936-4fc0-9429-483bd823749b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54a293b3-7489-41d0-99ca-97dcb1a2ab9f" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_3f6a27e8-923a-4b89-9159-1bc9b8f98875" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac50ca2b-04dc-4b88-9e24-bc2cef05fa54" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_882f6b93-5f1b-4f4d-a053-acbcb5ce3523" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf5e3602-14d9-4d1e-bfef-3935abb56447" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c577f4fb-b456-44f9-a5f1-7ba684e52edc" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">82,895,718</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />&#160;&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a9144a1-336e-4719-a8e7-a038a1817a6b" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_3779249d-8bef-42ba-a16e-11b17f82d990" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">81,986,192</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding as of December 31, 2022 and<br />&#160;&#160;December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c0dc0c4-4e15-45ee-98fe-2b1a092089ef" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07ca0083-8d8d-40d8-b40c-664b3fab3da7" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d868411-0747-4882-a92e-26d177ae1946" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">798,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e18e319-0865-43fd-8d28-92459b796244" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">748,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61b566e7-4018-4364-a841-f5ce8f66e11f" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a0ba543-43d7-4b79-bae7-5784dbe6707f" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2419cdfc-5b64-4bdc-8559-7cf3adc0385e" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">579,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcebf795-4726-4c81-9d91-a0df001c926e" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">446,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e401b39-c94d-4e23-9ef3-439717894588" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214,442</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e31edbbc-79ae-4510-9e0f-b7bc0898cef5" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,724</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_726c690c-5dfa-4018-8154-403afb713636" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">787,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7577054-2aa4-4ff8-a728-fef003f00160" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">814,658</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LECTOR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Oper</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ations and Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.739%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.926%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.473%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.926%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.473%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.0%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_a3866d38-7523-46db-8d9f-8bcd3b2d27ed;"><span style="-sec-ix-hidden:F_06d00587-146f-4b77-9cfb-7f1be4902705;"><span style="-sec-ix-hidden:F_88011f76-3c2e-41e3-bb75-b765e6c07793;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9124d315-377a-4e0a-9e8d-7bc6462f9deb" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cdf0bbf-9031-48d7-a9fe-0bda3ca64fea" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,085</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3090757-59b1-43f9-b2e1-d9dd81f497b1" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_023bfd3b-9aa8-4e18-863f-7d33376a5759" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">210,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36001254-55f4-40e3-9f4f-3106eb6b3eae" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_317407be-7580-4505-8506-2c900574b69d" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156,869</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5426a2bf-2a6e-4c46-bdda-f09dea183062" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af920b35-e431-4bf6-8491-ddfe4854045e" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1665bf8-77e2-4ad3-bdd1-c3461ceb878f" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,403</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e718aadc-54b4-4302-a7c3-07461958578b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ed100f9-907b-4d15-a86c-9f66bb585f05" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244,445</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed001acd-50ae-4114-8945-83f8f02514c3" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,272</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b22e48eb-f811-48d0-a161-a71e80e08d42" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">137,834</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a85b84e7-9fc4-4f53-8c9a-e09c01d93b7e" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85d0f97a-6a4d-43c9-baa9-62d37aa20bfe" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">195,174</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cd9cb6e-84ab-493f-bf7d-70804a9dcb79" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,778</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_727efc33-5ac9-4f9e-ba85-58e59de7b31c" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f0e0f2d-1670-4416-860c-e8a027f77848" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bc2ea86-4bba-466c-81b5-08e35fd04395" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">130,056</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d969e68f-bbae-47ab-b98c-22536a13451c" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06aa0568-eeef-4807-836a-848cba5dc3dc" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e6c1c50-7974-44fb-89f6-158b0914a460" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a02b272-3115-4bf0-b004-15bc0d4837db" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">133,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bff49685-aabe-4ac9-b76d-db3851a1462c" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af5f00a0-afe2-4703-b3c3-ce1a1f295795" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain (loss) on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2c0baf0-3734-44e4-b7eb-b0035d9ca6c3" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca3ef75b-4b40-4816-ae9e-3fc9999b0575" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ab53735-679e-4300-bc57-3d3a5a61415b" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_691eb6c5-cbab-4357-b75a-559fcf0eb7cd" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">136,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e79f814-70e5-4f11-890e-0e0f89464ded" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37,886</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a49a3f0-aa18-4463-bd22-cc149aada2c8" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">189,756</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d873c8f9-d49c-482a-9578-ac396d44476d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_1c749ecc-b7fd-4616-8aea-e1f5350ac60a" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.62</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daa5aee5-84ff-4468-b88e-eab0974c2d9c" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_a3493b84-8c0e-432b-a710-a3f5009af262" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">0.45</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99db0574-dea7-4cfb-9600-d18931030523" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_032f5f62-7b02-4c37-ab44-edf379e24ba8" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.45</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares used in computing net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6b71838-4482-4bbe-bf8b-e1a0dc81954b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_681f72b8-43fc-4250-8fcf-150578f2684b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">82,467,587</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d83a4ede-79ae-454d-a308-00c9932d01de" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_32635583-9595-4660-8d5d-1a8094040afe" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">80,416,936</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f08418c-5e9e-4a5f-a993-71ac5320ba8f" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c4fd5749-6959-42d9-bc80-4cf8295f8888" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">77,758,806</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALECTOR, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statement_convertible_prefe"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(In thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.348%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.6259999999999994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.955%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.974%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.976%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.985%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.7139999999999995%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.985%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.976%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.985%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.529999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-In<br />Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019; Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e2e6d4a-80a1-4d13-94c3-eb60fc32a8da" contextRef="C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">69,052,873</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_457727d0-7cd2-49f1-a72a-14e3063d1b74" contextRef="C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aae3d6b7-5a9a-4d09-be6a-c52056c3f85c" contextRef="C_1ae3112e-641f-46ac-8cd7-601ed0a853e0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">414,414</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5159ece8-6c85-465e-87b0-bb61b4df7aaa" contextRef="C_d0060090-89cf-486b-ac52-984818190a96" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcf7743f-846e-48b9-a7df-8eb1c1098bc0" contextRef="C_e30431e6-e3b0-4a96-9bef-19773862a1a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">219,820</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82e7e39c-dd40-44a8-a8cb-391e980f2176" contextRef="C_52877e94-eb03-44b8-a6be-a533ea71c990" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">194,743</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon<br />&#160;&#160;&#160;follow-on public offering, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb2f192a-0271-41d4-96a7-b51dcde41f0e" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:IssuanceCostsOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc2f2a20-a6b6-4b25-9ead-5dbc22a354bc" contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,602,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a49f922-6cfd-427b-9323-4ce349e84c84" contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d716e52-d342-404f-b2ba-0269d1f69234" contextRef="C_0994610a-2693-49ff-a322-fa66e5902607" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,510</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e7b2206-f6d2-43ae-869f-ed593b40ac54" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">224,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b880c4f0-e345-4480-9cf4-f53c04742d47" contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">655,772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_121ad564-23a0-42ab-91ff-3f827cdc362e" contextRef="C_0994610a-2693-49ff-a322-fa66e5902607" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9dbb91e-fe2a-4adc-9eec-e349ed341040" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of common stock under <br />&#160;&#160;&#160;employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb79aaa3-82df-41a0-ad1a-589638302730" contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,870</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5e29720-9954-4a65-bdd0-e0bd4fbde3f1" contextRef="C_0994610a-2693-49ff-a322-fa66e5902607" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4694710d-1a88-4da7-a98e-49e9d77cde32" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e46efd88-0aa8-46f9-a397-0d4ba79ce16f" contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">81,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe5e9978-5cd3-443b-88bc-5e4927f2df74" contextRef="C_0994610a-2693-49ff-a322-fa66e5902607" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f00562ae-1a92-44a2-a3b7-4866c2cb6451" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ebb765c-9ed0-466e-9c61-d4de11709c2d" contextRef="C_23fa1cec-8bf2-4e74-94f9-7b74111d38b2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2a3c1d1-0bc5-427d-9e33-f8f45c6e5638" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">472</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75579dce-fcfc-496e-9896-efffb66f5863" contextRef="C_80e23df0-dda9-41ff-b7a3-932c8bf26d7a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9f1e4aa-966d-46fc-a8a8-de08ce18c08f" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fea63e4-821a-4263-9efd-fa45474e2421" contextRef="C_98dece0f-6865-495b-b2f4-10ffd8b3e0d8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">79,316,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cc7b087-e77a-4cf5-8218-e0b52e37c2ad" contextRef="C_98dece0f-6865-495b-b2f4-10ffd8b3e0d8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a9db2ce-a632-45f8-a063-9b944311c688" contextRef="C_7d5342d6-08d3-4f1d-a440-effc09b14ff7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">676,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ddc80cf-76ba-432f-8f33-4819bfa3410f" contextRef="C_7a436588-46b7-4c39-90f1-b29291faef62" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b87b223-d2b7-4cbb-bfbc-c277d1cce03e" contextRef="C_b2eed340-5921-424b-b2bd-6f6e1a65315d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">410,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b86c39d8-93b2-465a-8104-bbad4b3d85c4" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">267,530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64920d3c-22ca-4a05-bac3-8025443bf39e" contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,395,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56f36e41-cddd-422d-bf41-1332b0d0d6da" contextRef="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cc75d69-98c2-4d6d-b016-487f4bfef627" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5290fb3e-8983-403f-836a-18dd3dc70913" contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">156,420</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of common stock under <br />&#160;&#160;&#160;employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_599fab06-127b-4355-8c8d-0adbe0e713b9" contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">136,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12790951-efd1-45dd-a6cd-629eefb01815" contextRef="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de4c3ee7-790f-43a1-8207-146c3980e48a" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e5ffe08-e6c8-4655-9b9c-71e8a26e498f" contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaa61ae7-3cd7-4c35-9a09-0f38d95ceed7" contextRef="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42eaa775-e7c7-4343-aed8-c42b70a8bdbb" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b43f485-247e-455d-a771-d12bfe41cb9f" contextRef="C_4a365a03-f3eb-4107-9a82-26a3d4345ee8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca9b254e-fe08-4ffb-8b05-f37dbb78b85a" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d8b5461-cc70-43ba-a2d3-9515787258ad" contextRef="C_1daf4bd9-70b1-46fd-8ea2-c3707e3a6d0f" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea8a9b81-5e06-451c-aa8f-fa39f9a8619a" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10d78e87-8528-43b1-8303-27a04bd2119c" contextRef="C_2c3e6d3b-2fe3-4f9b-923c-d40ea56722bc" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">81,986,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50dd6c67-9b6c-4dba-ad12-3d3cb0fa86ca" contextRef="C_2c3e6d3b-2fe3-4f9b-923c-d40ea56722bc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e9b2d52-380a-47a3-ba70-9ea2918be759" contextRef="C_14db55be-444b-484b-9308-f5fa77d06c64" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">748,036</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07bfcf1f-8b76-4aa2-9117-755bba5794f4" contextRef="C_dcbe690f-5774-4129-bd39-6000b70e20db" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5d5c04c-a839-42a6-9b00-6cca5830b8bf" contextRef="C_0120a0fc-9112-4e54-9638-49d731099e2d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">446,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baa01c1f-96ba-4e56-8fd7-0f7db974db91" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,724</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6017e044-a767-44e8-ba48-a8d23c733dd8" contextRef="C_5506b44b-1aea-4b19-b486-8910d5fdf80a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">298,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33e492c0-f116-4342-a82e-eb8cf3df3228" contextRef="C_a935fdcb-ad72-4392-9a72-8a721afa0563" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b417b927-23fc-4b49-9a92-db56e4270ace" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e019e6e1-9800-4bd4-91a4-eb74210d6ed7" contextRef="C_5506b44b-1aea-4b19-b486-8910d5fdf80a" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">414,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of common stock under <br />&#160;&#160;&#160;employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac8fd1c0-aaa2-4e1e-b244-f8d2b9e0b9bb" contextRef="C_5506b44b-1aea-4b19-b486-8910d5fdf80a" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">196,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a223c40-776d-478a-ab13-e1c8a31a5c56" contextRef="C_a935fdcb-ad72-4392-9a72-8a721afa0563" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,455</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d85f7e45-7119-4ec8-94c6-dd4f6f6be6bf" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,455</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1a99ada-89f3-4f6d-86bc-81bbc3da1895" contextRef="C_a935fdcb-ad72-4392-9a72-8a721afa0563" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4241f4ea-29d3-45ce-82b7-0d571175f729" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_827856df-6651-4842-84a1-f89bd81f1fd0" contextRef="C_43db021b-c8f9-4318-82fe-8c0ec28ec33c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50783cc1-7679-4a47-916e-fc079b4f65ee" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad7183a6-eed8-4d80-afa3-5ddcd6d93968" contextRef="C_176df7af-82ab-480c-bae0-7332bb4be390" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">133,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0aa6595-9f88-48d0-ae49-9865458fda58" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">133,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9683d49a-d8a4-4e8f-a477-09a6f03c1030" contextRef="C_5c63d7ae-a408-4aaa-b856-64a3f876dcd4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">82,895,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfea04cd-7c19-40fc-ae85-df76d49dc7ff" contextRef="C_5c63d7ae-a408-4aaa-b856-64a3f876dcd4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ea9bcf2-748b-4422-bcb2-fa8ff14066b1" contextRef="C_180fddf9-2bc6-4a44-a946-c3ac0b3b7336" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">798,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_170beeb0-7e18-49aa-a1c0-0d90527f0a15" contextRef="C_9f82b000-4be4-479f-8d5a-48258e77ae0c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82071a3d-b23a-4f6c-b982-4940e142463f" contextRef="C_33d99e34-332b-4171-90ad-9a300bdceb05" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">579,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebd401dc-dc06-4df3-8b20-82de8585c08e" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">214,442</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LECTOR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NC</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ents of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(In thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.739%;"></td>
    <td style="width:1.462%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.926%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.473%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.926%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.473%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.0%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67c0cf48-4cef-464d-b84b-fcf04a74f464" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">133,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63f2bb31-b402-403f-8a55-8ded04f98478" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fd4eee3-be9b-40a6-abad-8ea13a647bdd" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating<br />&#160;&#160;&#160;activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba00a58b-1f35-4f19-83e3-98ef0b5db7c0" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,714</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd05a873-ea66-4d58-ad0b-83b1ffb1b1b2" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a665437a-2381-473f-9e17-713a9e007ff5" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,870</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9dd7617-c1eb-409c-ba62-dbb6c8d164ec" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2149bc04-5bc8-46e7-a957-2a9ff9c796f5" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c12e5b35-66ae-4d88-a676-e981fbf1b9d9" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of premiums and accretion of discounts on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd042337-f555-43cc-9a6a-5fe0176a69ac" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8b49d8a-422b-4968-9591-3c2f2688bfc7" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4721f4d-ee25-4737-81f4-a8febb58ce5a" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_301042a6-a635-452a-92c0-ec88c27803f1" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:AmortizationRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3662129e-e715-411d-b85c-dafe64130d95" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:AmortizationRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c11a9c8-211b-4d82-ae48-67dfaba9015b" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:AmortizationRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,395</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment loss on right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3994cf39-6e2b-4f81-853d-b583ae7f7d9d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bf731c6-ece6-4c91-bf4a-ac79a8d35580" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c001b33-2408-42a5-ae91-5c54cf4e1cd8" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from disposal of property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c661ab2f-3a66-4480-b8dd-29cd19127a8a" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8811b57e-e886-4d98-849c-97bbe0e07b06" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e84755fa-f894-4a20-bd50-584ffb43cdd3" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivable from collaboration partner</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2687a601-ed46-4bc5-a746-15e5da1a11d1" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abdf6569-2dd5-4023-a1b2-a605fc12c442" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,391</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe312059-2d9c-4eac-8cab-e5406f9762ee" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:IncreaseDecreaseInCollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73bbc66c-ba65-4108-9de7-b9e1e1e6ae7b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e917a66e-3eea-40b2-8d59-d03db9ecdbcc" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,132</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73f18ec8-025a-48e7-8727-e6a8d271d42a" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f76d3d48-f08e-485e-8db5-39c26f345015" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16ebacd0-449f-4214-8724-fad4d23f0815" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a01def6-1707-4998-bce7-f481161e9cb5" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fbc1125-06cb-484e-915b-4ceeb99b2791" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8684225b-efc0-4e0f-b555-63243cf96e4c" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b0301d2-fe75-49ad-9bb4-f78acb593df6" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities and accrued clinical supply costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75472904-e13e-471c-88f4-86440dbfe643" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c244747f-e07f-4473-a5d0-1d30b4e85ad4" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,391</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eed87b91-8fc3-40e1-874d-c7c523d07635" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61352ca9-44ba-4ad7-9beb-2f6fc0dafd2e" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,383</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b6144c5-8f19-473c-855e-e53ffe58519c" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292,915</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fed7faa-4bb0-4796-8a41-187ef3cceea7" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc632c34-a361-4861-9f82-f6bcbe889bb6" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f779fb-6be6-4f13-961b-5ff43873e41e" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78ca8a46-29a9-46a5-9261-2fbd0fafae9c" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afd46c96-eb35-41f7-a60b-e3a6e06d4eec" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c13c2d1-fc4b-4127-9511-9547e7bc1426" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba142384-7196-4ee2-b22f-a93d436c16d2" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fce8191-a3b3-48b5-9bb3-f2efee921021" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ab0f384-b516-4b8a-a046-c473d1d1e9d8" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">298,551</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f182e07c-c8eb-4083-a498-cb29c9bf96f6" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">166,734</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d12f410-1208-44aa-b59e-07926a3356a1" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,117</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a448ec2b-f35e-467f-9af5-4d93957a3ba0" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d769418e-c3c4-484a-952f-8d023d9f5b04" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19ea10dc-16bb-4021-a62b-791931e31b29" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">556,898</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8709b5-4df5-4c06-b7c3-b0c315572c92" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343,402</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6122f8e8-23cc-4991-b4c6-05ace496694b" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sale of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb165776-7384-4935-aca7-33540c34434b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25dece49-a150-48e7-9b3d-c5c3c211bc45" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ffc12f6-d615-4386-8fb6-3b2052db41dc" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebd2ddaa-70c8-4e20-8761-965b8d6c1e03" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">402,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_710831d6-012b-458b-bf1b-4db04e7c04df" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286,290</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18657b42-5bd4-417e-92bb-288df498dd2c" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">406,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6568069f-a7d2-4c0e-a65f-5d95ecf82e5a" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">159,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12b8c1b7-486f-42e2-b518-b9362da25073" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">49,663</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_230df080-a3a9-4fec-9a90-085c0874c52d" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">105,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock upon public offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d51e59c8-e46b-484d-9089-6a20cf6ee878" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15775f6b-6701-4583-944e-75922ae78a06" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f3c8ab6-26df-4af0-ad29-eee417385ca7" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">224,603</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from the exercise of options to purchase common stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae5879ab-21de-4f49-8fb2-785043d14fd9" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99d4a5c2-5dae-462e-9ab0-3c7e97f37afc" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,530</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a543bd0-c12e-4d51-8fb3-c5ec024260b7" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of stock from employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52450061-b80f-498c-ac22-7e091cfd310b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,455</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09c7cd2d-2071-40bb-9c3c-596067cf5f09" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bad1202b-6b23-45f3-b3f2-1394bacda434" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77ed2f21-fe14-4b7e-b950-aa4540c89779" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,514</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2261cb4c-4846-45f4-84cf-594888b6656a" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afa8d53e-59b0-4417-8919-da2601399517" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba0b15f6-79be-4cb0-9063-c22e33d8d94c" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">174,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_926de501-03f4-4c17-aa61-5b17c65cfa3b" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279,183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fce16d47-81c9-481c-9622-18444408ba51" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash at beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c22b7b28-edf0-4f26-979b-8116db0dafa9" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">330,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfd5817b-9618-42d1-aed8-e8740a5d533f" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38accf55-3ef5-4570-b5b2-56b6b2075b4b" contextRef="C_52877e94-eb03-44b8-a6be-a533ea71c990" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents, and restricted cash at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f63dd2b8-acee-4743-bace-70b57b34218a" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6578687-eb56-4ddc-a339-ea708b08df94" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">330,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41312248-fa94-4439-af62-43ad973cbb66" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,441</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment purchases included in accounts<br />&#160;&#160;&#160;payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4530f519-671f-4ffd-b375-96a6c5833b81" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">493</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_269712f9-1a6a-4430-9c0b-b0e834f041aa" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">705</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4871f6e-2acc-4c1b-ac82-e6d49674b758" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cee28058-a75b-477a-ab43-14cde552e037" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;" id="notes_to_consolidated_financials"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and Liquidity </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Follow-on Offering</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2020, the Company completed a follow-on offering through issuing and selling </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_698546cb-76c4-4d91-8b85-fbaf1ba6568b" contextRef="C_1f8633fe-5aaf-447e-ae50-bc7154a4d0d6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,602,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f9533fc-4fd5-4651-bc8c-fc29edcedf73" contextRef="C_9fea33d6-9da1-41c4-92b1-404be25d8a1d" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" decimals="INF">25.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_625c7e65-8f94-4d16-81e6-0566af2a6683" contextRef="C_eebe0049-dfc6-425d-8d39-93f33680d12f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,252,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares sold pursuant to the underwriters&#x2019; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaa4eeb0-212c-4cee-8c7e-af1d9e6f03bc" contextRef="C_1f8633fe-5aaf-447e-ae50-bc7154a4d0d6" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">224.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and estimated offering costs.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d1bcd315-bd1b-45f5-af0e-09e4594e15f0" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e012bcb4-6147-435a-8de1-515be9f90b4d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true" continuedAt="F_e012bcb4-6147-435a-8de1-515be9f90b4d_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_e012bcb4-6147-435a-8de1-515be9f90b4d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4d516e4-6375-4f64-8efa-16c2a1e87254" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:UseOfEstimates" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ebb2b064-3d49-481d-a1f2-542d3c9aa75e" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f59a3dd2-863d-4be0-b66e-488ac0417412" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of December 31, 2022 relates to a letter of credit established for a lease entered into in June 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_07fa97c0-51b5-40f0-a71a-297050cdb93d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.888%;"></td>
          <td style="width:1.291%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:11.017000000000001%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.318%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:11.017000000000001%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.318%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:11.15%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfc1ef78-32ac-43c6-a19e-e15587f4c822" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154,323</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c35698e9-dbb1-48dc-8fb8-27e61bb78a64" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">329,152</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1387a433-1b2c-432a-8861-2760470e6248" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,969</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffdceb9c-b79b-4410-9fc5-178f14152889" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56901086-7416-47ae-bd84-1a36752f1ba4" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a584ce28-0e6c-40d5-8e6d-bfbd480aa792" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,472</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0fb1f16-f0dc-47b2-9523-1878f1dc77b7" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155,795</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5377d2fd-2c60-49d8-927d-62c1971123a4" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">330,624</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a86d56b6-9f87-46e7-9673-b3b8bacdcfed" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,441</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_841fe1b4-35f6-4e00-ab04-663ce2cbddbb" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#x2019; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02b72bb6-aef6-489c-8888-942f903fa197" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:MarketableSecuritiesGainLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> credit-related losses recognized for the periods presented.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ca7d7dc8-fe11-4275-a3a5-09da5e9c1586" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_ca7d7dc8-fe11-4275-a3a5-09da5e9c1586_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#x2019;s financial instruments approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_ca7d7dc8-fe11-4275-a3a5-09da5e9c1586_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ef4b93f-ec50-42df-a1d9-002a8d3ac56c" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_0ef4b93f-ec50-42df-a1d9-002a8d3ac56c_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_0ef4b93f-ec50-42df-a1d9-002a8d3ac56c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_19d80ba0-b0e8-42a5-8784-39822104cb76;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a450bf5c-c9b8-4be3-839d-bbe8a9539f65" contextRef="C_7aceb927-85b2-403a-82fd-27292ccc4303" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d79ea052-c9b1-4e2d-9460-9c73249e9176" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da1bd203-d7d3-4f22-8b20-be9e29874ea3" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36e458e3-387d-4d89-bb53-40c2018ca972" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1a47d64c-a071-4929-9a35-aa468f1201d7" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize an impairment loss on its right-of-use assets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5c01deb-3d63-4692-b5a3-c6482fcf3d47" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million impairment loss related to its decision to no longer utilize certain property through the end of the lease term.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1da655aa-5c92-4a9d-9c4f-8337f271dcbf" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5743359f-5619-41b6-9d29-6faaf1d116df" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f81fe624-85b2-474c-8d65-b85c29261287" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company's common stock on the grant date, which equals the closing price of the Company's common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, the Company granted RSUs with market conditions to certain executives. The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for forfeitures as they occur for all awards.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8803af79-426e-449d-b87f-8e625bba5d4f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are the result of transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c20dc0c-300f-4d78-999a-4f26e521f3b9" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7abe557-cb8f-4ba4-96c5-cfeb901b7fe3" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:PostemploymentBenefitPlansPolicy" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee 401(k) Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;Code&#x201d;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8283c786-6957-4083-8e99-05addfa851a2" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#x2019;s contributions to the plan are discretionary. For the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020, the Company made matching contributions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_011a027f-ee19-48df-a6d5-8302771c9882" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f1e3abb-76f1-4768-897a-f221247820bd" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_231eff40-f628-4172-a150-3ad87a8ebe4b" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54f820b7-9ed1-4647-9b82-d1d982cccfb9" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates in one segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6199b44-8cad-4184-8173-0e5ac1cecdcf" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements </span></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aad6988f-9b48-4007-955b-6dba5739adb5" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.882%;"></td>
        <td style="width:0.826%;"></td>
        <td style="width:9.942%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.445%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.294%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.256%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Market<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fff132b-437c-487b-95b3-4b17f74ca7c2" contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_361d2a99-4604-48e5-bb48-10d6dfdfbfa3" contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab5a9da5-7658-4f05-afd7-01f5ea37c211" contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be6f3a7f-db87-49e9-8864-e1e9958e6f20" contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,848</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b197c5a3-7339-4af1-963c-d69023887022" contextRef="C_a84f0779-d476-4feb-8427-952120804b66" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c326d355-5f7d-4dbc-ba5f-1f27fbc05841" contextRef="C_a84f0779-d476-4feb-8427-952120804b66" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_153ba4e0-e188-4107-8443-f98ef36fcc49" contextRef="C_a84f0779-d476-4feb-8427-952120804b66" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73488795-f773-484a-82f7-142594440800" contextRef="C_a84f0779-d476-4feb-8427-952120804b66" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">501,810</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd83477c-7ed7-49cd-a55c-07592f272e6c" contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ca2da23-8c32-4d3c-bf6e-b41a632563bb" contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75c50874-27fb-4efb-8379-f1d39ccba00b" contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6474fe35-21e9-4c70-9bbb-edbc67cf8b15" contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9eba3b70-5d75-4cb1-976f-e2cbd54ddb8f" contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31730c6f-3bb8-4e1f-b5d2-874bf30a9b0d" contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efb826cd-1418-49d2-99b0-bb6131affec8" contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8872382e-a954-4b6f-9c16-73225d6fd821" contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,346</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents and marketable<br />&#160;&#160;&#160;securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a395f8c-65af-4bb5-803e-8e03ff8c378c" contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">655,010</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ed68213-427d-4a39-940b-202299e7feb3" contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dfa77273-c3a2-40bb-9219-1586965b90ea" contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61eed76d-b2ac-4dbf-b29f-6391e835a84e" contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.882%;"></td>
        <td style="width:0.826%;"></td>
        <td style="width:9.942%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.445%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.294%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.256%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Market<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b4103b9-bf51-49ed-a40b-cba8a89accbb" contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,451</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe90378e-3d31-43b5-8511-0241a05e30a2" contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7ffed52-2d19-4158-87ad-dd6e79632157" contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2b41df4-6eb7-4e94-8f7d-38dabacc72fb" contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,451</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eab55c2a-70fb-4ad7-bbaf-63f450717557" contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">407,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4541ca52-b56f-4f11-b20c-eb46caf7c92b" contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_325d631e-5f49-4e88-8909-b39380f12346" contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4be830c-44ef-43ab-ac60-5c0aee92a595" contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">406,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents and marketable<br />&#160;&#160;&#160;securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ceaf543-e78a-4b96-8d35-2d6e312f8e26" contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">625,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12e702ef-60b5-4cb9-95d2-6507516599e1" contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_254ae394-08ec-4052-b9bd-a93de13f3993" contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be63ca89-6d89-4094-a0af-f5ec25c02983" contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">624,550</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the remaining contractual maturities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22f59799-ed2c-4070-b88a-4012f40f2a03" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">640.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of investments were less than one year and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5ff3209-4fdd-4a30-bfb4-56a14c6e5639" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of investment were after one year through two years. As of December 31, 2022, fifteen U.S. government treasury securities with an aggregate fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d02b5fa0-6194-467a-9cc3-e4c674785411" contextRef="C_5ede9fc7-3539-445c-b590-2e32ccf2dc14" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">133.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an aggregate unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eda69cdb-338f-4490-bbed-cce63f47ee64" contextRef="C_5ede9fc7-3539-445c-b590-2e32ccf2dc14" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were in a loss position for more than twelve months. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is highly unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company did not sell any marketable securities for the years ended December 31, 2022 and 2020. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company sold marketable securities for the total proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e07346db-c703-47fa-b316-8c4a365a7aec" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for an immaterial realized gain based on the specific identification method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fae57147-5df3-435e-81b3-fb50baf2a666" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.       </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2021, the Company entered into a Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK), pursuant to which the Company and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab (also referred to as AL001), and AL101 (GSK Agreement). The GSK Agreement was made effective on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fd1aac3f-1263-4154-a114-4825738a63c3" contextRef="C_dfad70cc-a2ab-437f-929e-a3eb95fd5c88" name="alec:CollaborationAndLicenseAgreementEffectiveDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 17, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the GSK Agreement, the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5690e85-6119-4413-8192-bea980e46161" contextRef="C_d339045c-e830-4398-bf09-392c72a9d130" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b336d79-21f1-48f8-be70-ca68e617c886" contextRef="C_dfad70cc-a2ab-437f-929e-a3eb95fd5c88" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in August 2021 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d839e9eb-c765-4362-b7a3-160ab891c9d6" contextRef="C_b2c6f352-9d45-4576-a18a-112160c86b51" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">200</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in January 2022. In addition, based on the development and commercialization plan for latozinemab and AL101, the Company may be eligible to receive up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1622419-ebc0-4e94-a923-9d5d11f89c9a" contextRef="C_f5a26f10-025e-4a2e-83ca-fad8cfb00b35" name="alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the Company and GSK will equally share profits and losses from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialization </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of latozinemab and AL101. Outside of the United States, the Company will be eligible for double-digit tiered royalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and GSK will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease and other non-orphan indications. The Company and GSK will share development costs </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35921857-412b-48b7-b477-407f6fc94425" contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4" name="alec:PercentageOfDevelopmentCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% by GSK and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b23a3e78-205d-4c31-9a61-31f6ba10dfa4" contextRef="C_a63e3081-f730-456e-b5ed-d6fc2de87931" name="alec:PercentageOfDevelopmentCost" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% by the Company, except that the Company will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the GSK Agreement is within the scope of ASC 808, Collaborative Arrangements, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of AL001 and AL101. Certain elements are required to be accounted for under ASC 606, Revenue From Contracts With Customers, where the counterparty is a customer for a good or service that is a distinct unit of account.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) license and know-how to AL001 FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is currently in Phase 3 clinical development and (ii) the research and development activities, including license rights and know-how, relating to products in Phase 2 or earlier stages of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at inception and as of December 31, 2022, included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a93377a4-b7e2-4056-a077-b0cfbf3cfb55" contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All potential future milestones and other payments were considered constrained at the inception of the GSK Agreement and as of December 31, 2022, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The respective standalone value for each of the performance obligations was allocated to the transaction price. The estimated SSP of each performance obligation was determined using discounted cash flows from the expected commercialization of AL001 and AL101 and estimated research and development costs to be incurred by the Company in the initial Phase 2 clinical trials. The estimate of SSP for each performance obligation reflects management's assumptions, which may include forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. For the license for FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determined that GSK could benefit from the license at the time the license was granted and therefore, the related performance obligation was satisfied at a point in time. For the product candidates in Phase 2 or earlier stages of development, the Company determined that GSK could not benefit from the licenses without the corresponding development services that the Company has committed to perform due the earlier stage of development for these licenses. Except where agreed to otherwise, the Company will perform research and development activities through the end of the initial Phase 2 clinical trials. Revenue will be recognized over time as the research and development activities are performed. The Company will measure progress based on actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development activities for products in Phase 3 clinical development were determined to be within the scope of ASC 808. Both parties will be active participants in the development, manufacturing, and commercialization of the product and are exposed to significant risks and rewards that are dependent on the commercial success of the products. The Company and GSK participate in profit and loss sharing for each program commensurate with each party's cost-sharing responsibilities during research and development. ASC 808 does not provide recognition and measurement guidance. As such, the Company determined that ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provision of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue under the GSK Agreement during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d76200d-78dc-4f63-9b75-31ee54b766b3" contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">62.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f4cbba1-b978-48c3-9afa-9110ab1278e2" contextRef="C_76299c65-2f3a-4aa2-953a-8368c1d95f6b" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">192.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The deferred revenue related to the GSK Agreement was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a90f735-d147-4c54-b0b8-7981b5c5a12d" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">444.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_296c2957-879b-491a-a0dd-d45f8591a4f0" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">307.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of initial Phase 2 clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company recognized a reduction of research and development expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25d4d1a0-f610-4e04-be78-7dc4069ac70b" contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97a9afb6-0244-4fbd-bfd7-9ab27392cbd3" contextRef="C_76299c65-2f3a-4aa2-953a-8368c1d95f6b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, under the GSK Agreement.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AbbVie</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7876ee1-e37a-49ec-ab59-ba912f6a9442" contextRef="C_a3b39a72-f9d5-452e-8491-11e893261ed3" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">205.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85a11d26-f59a-4976-b3cd-9ee1e077d167" contextRef="C_a3b39a72-f9d5-452e-8491-11e893261ed3" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7913f05-4410-4944-a6eb-d94814fe4de8" contextRef="C_bee6f6bf-d1c4-42f9-9ab2-0d5a9c70a44d" name="us-gaap:ProceedsFromCollaborators" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were received by the Company in October 2017 and January 2018, respectively. The Company was to perform research and development services for the two programs through the end of Phase 2 clinical trials, which were each considered to be separate performance obligations. AbbVie decided to terminate one of the two collaboration programs, the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. AbbVie provided written notice to terminate the CD33 collaboration program on June 30, 2022. The Company will no longer continue development of this program and will not be eligible for any future milestones related to that program from AbbVie. The Company continues to develop the AL002 program under the AbbVie Agreement. AbbVie has the exclusive right to exercise an option under the AbbVie Agreement with the Company for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b248729-54c0-4534-b42c-7048224b38d9" contextRef="C_a3b39a72-f9d5-452e-8491-11e893261ed3" name="alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. If AbbVie exercises its option for the AL002 program, AbbVie would take over the development beginning with Phase 3 clinical trials, and the product candidates program costs will be split between the parties. The Company would also share in profits and losses upon commercialization of any products. However, following AbbVie&#x2019;s exercise of its option for the AL002 program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. In February 2023, the Company and AbbVie amended the AbbVie agreement, which will result in the Company receiving a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e5ed3f1-83a5-4828-8946-ddf729064889" contextRef="C_c0a599ce-bcb4-4bd2-baef-99bf600a266e" name="alec:CollaborativeArrangementMilestonePaymentsReceivablePerProgram" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payment for the dosing of the first patient in a long-term extension study. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_256b28e4-b127-43a5-b293-d12a981cfe72" contextRef="C_ea97f9ff-6baa-434e-8a41-03175d03a38c" name="alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in milestone payments related to the regulatory approval for up to three indications. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at inception and as of December 31, 2022, included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a1b1aa4-f5ab-41a2-9f21-48432ad8fe63" contextRef="C_591622e9-478f-40d8-a4c4-83e7718adf29" name="alec:CollaborativeArrangementUpfrontPayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">205</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All potential future milestones and other payments were considered constrained at the inception of the AbbVie Agreement and as of December 31, 2022, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc2bc8bd-45ca-47a0-a83a-fb06a58ac0d4" contextRef="C_591622e9-478f-40d8-a4c4-83e7718adf29" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">70.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c319fa2-76b5-4511-bd2e-4835f8d82d5e" contextRef="C_07adf335-3612-4d8b-8411-b0ca428a8c48" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23974d13-3a39-485c-9524-b86a63c882fb" contextRef="C_0e9e000a-a972-4453-815c-7beddee684a4" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The deferred revenue related to the AbbVie Agreement was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fb1675c-30f1-4d9a-85f8-7455878d41cc" contextRef="C_57f29121-2ac0-4227-aa7c-e698d47d2373" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">46.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_322e3fbe-7164-4c87-9f29-196086c1cc71" contextRef="C_bbc12a08-d369-441d-a256-6c6e5a6edbac" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">117.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The deferred revenue is expected to be recognized over the research and development period of the programs through the AL002 program through the completion of Phase 2 clinical trials. For the year ended December 31, 2022, we recorded a net increase to collaboration revenue under the AbbVie Agreement due to changes in estimated costs to satisfy the performance obligations resulting from the termination of the AL003 program, partially offset by increases in total expected costs for the AL002 program.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innovent</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&#x2019;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent would pay the Company up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25781380-4434-40e3-90d7-628654ec4884" contextRef="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6" name="alec:DevelopmentMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in development milestones, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06dfe578-8f09-4f24-b362-e74c32481657" contextRef="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6" name="alec:SalesMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">112.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in sales milestones, and future royalties on sales and the Company would retain the rights to develop and commercialize AL008 outside of China. The Company determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement were not included in the transaction price, as all these amounts were</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fully </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">constrained as of December 31, 2022. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e42260d-3e3f-44bd-aba8-0dbcdb44ebb1" contextRef="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenue has been recognized and no payments have been received under the Innovent Agreement.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_afd0f89e-ec44-400b-8b13-6cc2b86ef408" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Components </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_95cf66a2-00b3-457f-9b29-74e37be1bfc8" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.949%;"></td>
        <td style="width:1.32%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.714%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.304%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.713%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7055793c-8bb6-4205-b53c-4f2d76f0136b" contextRef="C_59b9e1be-3875-4c2c-8688-02e607d91e6c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e69416d-d057-4015-8189-d56b77f4a328" contextRef="C_51a99dc6-2893-4e9d-b0b0-79417c0a1aeb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,294</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d57b30e-7d4b-4012-ab0b-3592be4e29af" contextRef="C_cee82e6c-ce42-4848-8ad7-b247c43c8a26" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e800322b-fe9c-4740-b47e-db71d76c2a10" contextRef="C_bc7bd397-63c7-41cc-afa7-7230b2cab7ed" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,330</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab Equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bd2714a-d706-49ad-8c60-4c16c16836c6" contextRef="C_dad2a26c-287b-4267-9f7c-8a34fc96b55a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49374286-8b54-4466-9ebf-f28bd6783fc6" contextRef="C_4b7ae830-6548-4c51-9858-5fd1f867e8f7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,043</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold Improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69067060-5cfb-4b2e-b692-f0fd1bc29dc4" contextRef="C_d0630ba0-e9e8-4702-89d0-bdba73bdd2e4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17a7e8f9-9091-4804-975f-8bf7abc4a82c" contextRef="C_92d78956-76c2-4167-b848-5449236c361e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,949</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e106a37-33db-40ff-905f-64bc4cec2c4f" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_149efd90-dfc2-4d55-bf01-a47c542d4bdc" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,616</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9850ec9b-0547-4aa6-a7f4-230ee757f14a" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2704d81-899b-42e1-80ae-980f5abc4e03" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df035bb4-d8e4-4c1c-8592-82e494b690d3" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,521</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f0a3c42-cff5-470e-8499-180a0fed75f0" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,330</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2bba8ac1-b782-4f93-b8ec-df1cd16e4a7c" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.206%;"></td>
        <td style="width:1.489%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.393%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.489%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.423%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ee2aa0d-7f31-4e7a-84b8-35d9f7b39eff" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:AccruedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,321</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8c07ef9-f224-439a-81a6-8bae20fdf9f9" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:AccruedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,330</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dedc888-8d09-4a34-a3ca-05e4058430e1" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,758</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adf80a7a-8adf-4970-8e1e-612fba3416f8" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,664</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e0060f6-4f41-4ab4-9923-7082dfa09afb" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,983</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a4fa02e-9b4d-481c-a319-d723d10108bb" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,588</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed8468d7-b35b-4062-b18b-d08283f686e6" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:AccruedPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">337</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eab3662b-ef7c-49a2-b28f-c94940add6cd" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:AccruedPropertyAndEquipmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">560</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_020a0cff-9d8e-4526-8203-592ef2c1f9fa" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c15636dd-27d3-4fc1-bf52-030cdec5b15b" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37f9ff3c-4710-45fd-b3f2-88d77716b51c" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_789dc442-70a7-4869-9bef-c55b76c86613" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a071638-95d6-42ce-aca1-efe19e6d1898" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, the Company signed a lease agreement to lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5db62e06-58ee-4694-90ce-a8f863ee025a" contextRef="C_a249850f-9ff5-4ed1-8915-381e8e7d8c32" name="alec:AreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">105,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in office and laboratory space in South San Francisco which serves as the Company&#x2019;s headquarters (the &#x201c;Headquarters&#x201d;). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47b49882-644d-4f50-b032-eff58ec74db9" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a3776f2-ce6a-4d6a-96d8-e4dbb71c0b44" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:LeaseExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with an option to renew for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8b1b6155-1641-49aa-9b81-45d9f99e7097" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The landlord paid for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aeb2508-718d-4963-b91e-e7bafba22a65" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d3c87af-6ac3-4659-ac8d-43aa9fda0d63" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77665e18-b526-4c52-b400-ff433df03366" contextRef="C_69eaec9d-be8a-46cd-b047-8697f5e418ff" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company signed a lease agreement to lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdc03bef-319d-47e8-802b-93a06bd187aa" contextRef="C_68921c7f-cea1-46f8-9606-82bf1ee5887d" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">18,700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space in Newark, California. The lease term ends on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_207d8686-10cf-44e9-a74a-b23f76d254d5" contextRef="C_0aed28b8-d995-4247-8f88-dd02919d008c" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 6, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with an option to extend for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88d29fc3-99d8-4923-86a6-31470ca126e2" contextRef="C_68921c7f-cea1-46f8-9606-82bf1ee5887d" name="us-gaap:LessorOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The landlord is obligated to pay for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44b67a50-4a0e-445a-bd5c-492b5203da32" contextRef="C_0aed28b8-d995-4247-8f88-dd02919d008c" name="us-gaap:PaymentsForProceedsFromTenantAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tenant improvements.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The measurement of the lease liabilities for the leases excludes the options to extend the term of the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#x2019;s leases consist of operating expenses for the spaces.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2019, the Company entered into an agreement to sublease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf4f192f-65f8-48a9-a53b-7c633f4bdcff" contextRef="C_6eb70da4-a1bc-45a1-8da8-c9552a0a4ac6" name="alec:AreaOfPropertyInSubleaseAgreement" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of the Headquarters (the &#x201c;Sublease&#x201d;), which was amended to approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_383c269c-6156-437a-b4a1-d8711c6a7af8" contextRef="C_6f4164fc-b4c1-41ca-8455-663b93759519" name="alec:AreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">23,600</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in December 2020. The Sublease expired in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3109d8ca-6c66-47aa-8894-656cf52bdc47" contextRef="C_3bca2306-c6f8-41f3-9a71-4b209e479578" name="alec:SubleaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The sublessee pays its proportionate share of operating expenses for the space.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into an agreement to sublease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b91ff0c-c229-4c06-87b7-792a03d08e72" contextRef="C_a90b3f2f-9462-46f0-84ce-63965231a711" name="alec:AreaOfPropertyInSubleaseAgreement" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">7,132</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of the Headquarters, which was amended in May 2022 to include an additional space of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_936f8caf-7073-4489-9371-07dcfd8c0eba" contextRef="C_b1909874-9ac4-4faa-a605-aeb9628d2105" name="alec:AdditionalAreaOfPropertyInLease" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">13,150</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">feet. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,132 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">square feet of space subleased expired in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_58bfbbfe-c406-4f99-b80a-86b013a56fa6" contextRef="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9" name="alec:SubleaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the additional space will expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0c3aded-b09b-4b04-a20f-95ec910b9508" contextRef="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9" name="alec:AdditionalAreaSubleaseExpirationMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_252f2c92-fc22-4133-b186-15a6c3692558" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.102%;"></td>
        <td style="width:0.722%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.773%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.597%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.613%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cca9d451-c5c9-44a7-bb57-05b6e74da968" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,638</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5842bd1-d5da-4db2-aab2-efba91938cb6" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04d67e0c-df75-46f0-9bde-7f2ee801ef45" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f93e8881-fcd8-4ee3-8c0b-35f47fe0e899" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,785</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c61de42e-44f9-4ef3-a0e8-8e6fafb4fb60" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edc59773-6bcf-40b7-82a2-605062316940" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,255</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease income and reimbursement of variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a410081-0a80-45d4-a998-722fa2795927" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3f449e0-13bf-4220-9fe4-748688a79d74" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,141</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_821cc1b8-42eb-4fb8-afea-dd8c492c3c64" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ffbdb26-48ca-4a68-bd08-95855fc9efb8" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,551</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eaf21c23-7652-4a70-b684-fd72fb279c76" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24a1548a-16ca-44ed-b239-07d8b8178c54" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term for operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c815f2e-ff1f-4e90-8528-560ebf90a875" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and the weighted-average discount rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3b24d31-d2ec-451f-b672-699a3adb4196" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">8.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. Cash paid for amounts included in the measurement of lease liabilities for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88cf206b-9d7a-4067-ab5b-6c0ffdea477e" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bb8395b-d3a5-403d-aedd-40f502352b3e" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_075e85d3-77ac-4347-a602-c08c195b6f45" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cdcc6352-5c06-42ec-8402-b7169aa75adc" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are the lease payments owed under the Company&#x2019;s operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.114%;"></td>
        <td style="width:0.996%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.89%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37230356-c3f0-46a8-9497-dfd193c7fa14" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc16753c-a1c1-4471-8167-92aa8fafbaad" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fa7c0a2-9e1f-46f2-b346-91b751a0427f" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,037</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61e596c3-e407-4636-9f1a-626f5d34b06d" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf32c108-bb3b-424c-b2fe-2c4e481d4f60" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,681</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d6d428-d156-44f1-8c97-c745523043c5" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,096</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f08f0029-e6dc-4997-85bd-d1da994d4bc8" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,335</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Present value adjustment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfd3d66f-f01d-4aa8-9111-b3dbdf44f4f0" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,008</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1799339-3cfb-4e78-a78f-b217ac4088ba" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,327</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_195e5664-78e3-4bf8-b6aa-13bd12f20a2c" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation </span></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b1ee039c-3e70-466f-a34e-73c914974868" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized stock-based compensation as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.888%;"></td>
        <td style="width:1.291%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.017000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.318%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.017000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.318%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.15%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0652d4df-9d51-4629-873b-c99ab3826579" contextRef="C_4f49c42b-493f-47f8-9739-cb8ff352f950" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,895</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd46bb9a-a7db-4c84-b290-f8bad7dab4bc" contextRef="C_2b22c619-0e67-4a8a-9893-c4a93f9df158" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a66e0526-94a6-4fa4-8485-966349f1ff5f" contextRef="C_e21ea263-2f4e-4a53-bf66-2c7077518b36" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21f786c2-09a2-4677-8233-e13f603e64a1" contextRef="C_48a91691-46db-40c9-a5b2-794422b8838e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_822f61f1-8aec-43e6-a85e-4f0106a5be81" contextRef="C_9cf5d0c4-ca22-4be2-aa95-e9fd5130a84b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f89fc1e9-fd70-40af-8fff-942cfc098b4a" contextRef="C_558fd0f4-ad61-4047-b762-e6960a1f35eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,542</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00c3e5b7-f057-4bbe-acbb-32012628ac6b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,146</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_daec6c10-5632-45fc-82e0-015e23594c2e" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,785</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c968b69-0905-4a4e-beed-4406ffde3597" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Determination of Fair Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bbf278c5-9fbf-4834-b2b9-552e1e2b4237" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated grant-date fair value of all the Company&#x2019;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.034%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:16.8%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:16.8%;"></td>
        <td style="width:1.202%;"></td>
        <td style="width:16.76%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f97540d-2142-4004-a6d0-a4213e0ad0aa" contextRef="C_1eae11ed-31bf-4dfc-a698-681b39d46f70" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0bd0f7b2-8cea-407a-9443-c4a03bec4c61" contextRef="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4de86e97-ab01-4166-a4bf-a50ed662c517" contextRef="C_30408e35-6b1a-4011-ac8f-7e1456941ba0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9ffcaf3-eb32-43c4-8f66-ddc1c8005b10" contextRef="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e46834a8-f78b-4011-95f9-195bd8ece2de" contextRef="C_f138f916-581b-4f02-aadd-4cd12427fc86" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13436713-cacf-43f9-a7d1-f6ce35633c72" contextRef="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3bb1579-4830-47a6-a527-6e99c8d2649d" contextRef="C_1eae11ed-31bf-4dfc-a698-681b39d46f70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_439dcfeb-b211-4682-8102-53570ab10677" contextRef="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ca5c176-46e8-4781-948c-9cc612160681" contextRef="C_30408e35-6b1a-4011-ac8f-7e1456941ba0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">78</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef4c04de-f354-40ea-af8e-ccaeb2142362" contextRef="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">81</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc1b4c62-b7ab-47f4-ae63-9b20ec3ff4cc" contextRef="C_f138f916-581b-4f02-aadd-4cd12427fc86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">74</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99f0d22c-6101-47dc-bd8e-b968efb49f16" contextRef="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">78</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e29dd424-e56c-42a2-ad90-1d94cf89c7c0" contextRef="C_1eae11ed-31bf-4dfc-a698-681b39d46f70" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d637236-007c-4f2e-b571-86ccbf4436af" contextRef="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2445fdaf-7fd5-4832-a50d-3197a1eb9ff3" contextRef="C_30408e35-6b1a-4011-ac8f-7e1456941ba0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fa63f91-e97b-4329-9a8d-105922a945fe" contextRef="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0206935b-411e-45be-82a8-45ddc892c627" contextRef="C_f138f916-581b-4f02-aadd-4cd12427fc86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_baaf0fb5-b855-4213-b403-4dcb46c0ea12" contextRef="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e420fc67-aa4e-4c31-a8d9-2ba4c506b383" contextRef="C_235ab5c2-cb0b-4693-a7d8-c6af3cd3645b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b56790b-a5d1-492c-a633-933f49fbd37f" contextRef="C_abf92419-83da-405a-8247-30fd4646394a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9be491ce-b45d-4174-b845-bf2886b4f0e1" contextRef="C_25d652af-cdb3-4c04-9508-c4f3acbb1dcc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#x2019;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend Rate&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan and 2022 Inducement Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#x2019;s employees, directors, and consultants. The Company&#x2019;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64be59b8-2924-44bc-87f3-6d89f121298b" contextRef="C_319ea842-0000-481f-8857-4a411838770a" name="alec:PercentageOfStockOwnedByIndividual" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or more of the outstanding shares, the exercise price of each share shall be at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c0ae263-2576-480b-b547-eecd657f7311" contextRef="C_319ea842-0000-481f-8857-4a411838770a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value and the term of the award shall not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_217d4dd4-71fe-4a59-986d-b9ce7ba7e874" contextRef="C_319ea842-0000-481f-8857-4a411838770a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_32a5ef2c-f174-4c33-a1c7-6a2b0f0bf2e6" contextRef="C_873e87e5-56d0-4394-ba3e-604f72c1fb04" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The stock options generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d4b2141-3cd6-487c-adf2-426fda1582c4" contextRef="C_319ea842-0000-481f-8857-4a411838770a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period with one forty-eighth of the shares vesting each month or over a four-year period with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da9b36e1-c2ee-4e5e-bd70-561082696edb" contextRef="C_319ea842-0000-481f-8857-4a411838770a" name="alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vesting at the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de2e4e80-14aa-4348-bee3-42be43bc5983" contextRef="C_319ea842-0000-481f-8857-4a411838770a" name="alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cliff and monthly thereafter. The RSUs generally vest over a period of three years with one-twelfth of the shares vesting quarterly. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, the Company added </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91767744-9793-4d18-ad7c-4449888286a7" contextRef="C_dd06c0e7-b9e9-48e2-9fd2-99b651c4b5a3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,099,309</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares to the shares reserved for issuance under the 2019 Equity Incentive Plan. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ff1c73a-3a82-4521-9bfb-f318f82d9a1e" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">20,463,901</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the automatic conversion provision of common stock under the 2019 Plan, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e8df67e-5865-4473-85ae-12c15e78a70b" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,587,550</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were available for issuance of future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, the Company adopted the 2022 Inducement Plan (Inducement Plan) and reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10996163-e7ca-4046-aee0-94e4d2d5d7b2" contextRef="C_b6f138ff-488b-4b84-a7d2-f77486a49d63" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,630,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares for issuance under the Inducement Plan for the grant of equity-based awards to individuals who were not previously employees or non-employee directors of the Company. On September 22, 2022, the Company increased the number of shares available for issuance under the 2022 Inducement Plan to a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_566b77f5-e69f-4b60-883b-b22f28de587e" contextRef="C_ed1f3bb7-c84d-4b92-a5a6-e2a94d7ac051" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,300,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2019476-ba1e-46d9-98ee-c23cc3f7a43b" contextRef="C_739d8fa6-0e40-445b-8283-8871a7bb5917" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,401,483</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were available for issuance of future awards under the Inducement Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f53df731-9012-4cd7-80a1-9ee774422e5a" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option activity is shown below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.134%;"></td>
        <td style="width:0.081%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.927000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.081%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.309999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.081%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.862%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.081%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.442%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price Per<br />Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3ac7af7-80ec-4d12-8c15-103c191e0b49" contextRef="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">12,654,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20fbe5d7-a237-4df4-af65-bd4b0aa99a0a" contextRef="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">13.96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e71215c0-982a-4d85-ab87-cee5a20d8b82" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,264,059</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5308a91-57a1-44e7-9f42-60c87156fe10" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">21.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24256b07-80af-428f-8d97-ce8be6e8f139" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,395,223</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_337402eb-ca62-47f7-976b-cd0332917c62" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d6db0ca-626d-40cd-8cb5-d55acde50a02" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,879,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_349836db-dd0c-46b2-995c-411a4cfc1f1a" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.55</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54419dcb-1f7f-4c34-badb-1987517b170d" contextRef="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,644,070</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5942fcb-b054-4208-a262-eb2bedff8cab" contextRef="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e83649e-5d6f-4a69-a9af-8703233cd990" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,996,366</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fef8182-7a8b-4197-84b4-c894c6d8d34d" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">12.11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cdb9194-5861-4691-ab19-9493a86737f9" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">298,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_820c6b8c-9b9d-446f-800d-1ceb46d60693" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89c5a5d8-517f-4fa2-9ac7-d8d9301cbe15" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,628,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c66e94a-414e-497c-bd7a-cc7e30295928" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.28</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a3849ba-3a26-4b51-8c5c-7113cfbe0ffa" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,713,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36ee61a6-6f9c-4af2-8685-3727b1d87aa8" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3979ef9f-1816-4566-a4e5-705ad5ad0882" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d976191c-6716-402d-a6f5-45a174a8b09e" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_272f3dee-16fb-437f-83db-76f608c84c66" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,776,201</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9adea0cb-3725-4141-8da6-cbc695eaf1f6" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_54f1b99f-bd89-4e0d-9a7b-63b9bd336ce8" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b69c8faa-e909-471d-9bcc-f3769d40427c" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest as of December 31,<br />&#160;&#160;&#160;2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c14e7293-55ff-4a64-815d-c5f84e3c4eab" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,713,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18b1896d-b9c8-43f4-a2f7-0e7fc0a426fb" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">14.62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_94b5df01-a318-4802-8a23-e6b60d1323f5" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c64d49fd-e59b-4623-8897-9543ebd7abcf" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,583</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eefa7a0c-63dd-42de-a3b1-b4c26ddbedd4" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b26a879-3181-4618-bdd4-6823719144d7" contextRef="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b7d0e6a-2eab-4f2c-a31a-9681a073d206" contextRef="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020, respectively. The weighted-average grant-date fair value per share of options granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_766e19fe-2d50-4ac7-8acd-72227946a4c1" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="INF">8.42</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b6e4245-184a-47fa-881b-dd218a4828f3" contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="INF">14.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cecff5c5-b37b-4ee2-8ea1-e661eb13b9e6" contextRef="C_e759e0c4-57cc-4d3e-90d2-e3c5076206fd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.14</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested stock options was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2adf5b26-25d4-433c-a985-b7ce9d9d0f32" contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">64.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_47e5f63b-fb7b-446a-9808-f4735133ef73" contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Activity</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_38df48a3-9919-4464-a5bb-d719c8dc3acf" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true" continuedAt="F_38df48a3-9919-4464-a5bb-d719c8dc3acf_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity for the restricted stock awards and RSUs is shown below.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In May 2021 and January 2022, the Company issued RSUs with market conditions to certain executives, which are also included in the table below. The RSUs with market conditions are earned based on stock price performance and continued service by the employee. The RSUs with market conditions trigger vesting upon the company's stock price attaining a specified level over a specified period of time. The shares then vest quarterly over one year after attainment. The Company used a Monte Carlo simulation model to determine the fair value of the awards at the grant date. The Monte Carlo model uses the fair value inputs on the grant date to run simulations and take an average of possible outcomes. The total grant date fair value of the RSUs with market condition was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aff8a1b2-2d5c-43f9-8f00-efb37bb5104a" contextRef="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf" name="alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to be amortized over an estimated weighted average service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4d6a880f-10fb-43c4-bf08-f159b6da1d02" contextRef="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. Compensation expense related to awards with market-based conditions is recognized regardless of whether the market condition is ultimately satisfied if the related service has been provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_38df48a3-9919-4464-a5bb-d719c8dc3acf_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.585%;"></td>
        <td style="width:1.267%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.103%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.709%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.334999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Grant<br />Date Fair<br />Value per<br />Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards and restricted stock units as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_341d6709-e160-4d28-81b8-2e5b848a2ffe" contextRef="C_338e36e2-ef61-4f44-861b-3a1b978b8228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">186,425</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a60deb84-1d11-4584-ac4b-3cb6a8ff35b9" contextRef="C_338e36e2-ef61-4f44-861b-3a1b978b8228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eee7aeb-878a-42cb-be52-8a9d24df8c77" contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,822,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8fb8ec9-0f05-4502-9784-fe61bf56839d" contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">17.33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2d02e6e-50a1-4091-8f86-19f656837b97" contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">324,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efdfae21-4134-49e0-b3ec-53a63be9cc3a" contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3960887d-7d55-4584-88c5-9ddb41bd4b96" contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">310,044</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70fc51d1-ce08-4df8-81d6-bc204b8938c6" contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">13.85</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a56e332-a0eb-4877-8291-903340ea5fa6" contextRef="C_dc0ce554-adea-4930-b36c-ddea841a6c0d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,373,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfb02e2a-5750-4f1f-979d-0a8eca08661b" contextRef="C_dc0ce554-adea-4930-b36c-ddea841a6c0d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e89d3c0-9540-4e3c-ba90-8b61c7d43697" contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,539,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2acc8fdb-44fe-43e1-a926-90d667643ca8" contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.02</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09957d0f-9810-4b39-a895-53ec06fa1557" contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">414,577</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e075dbd-4673-4c86-984a-cec3a4786435" contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdec96e5-e3c2-4b39-b857-0f4eb29291cd" contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">453,693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1733ad58-72c1-4ead-9e65-5d74b525cd3b" contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units as of<br />&#160;&#160;&#160;December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f2d7daa-ff31-4de1-8a33-75b97b4509e0" contextRef="C_bb53d62d-50b1-4820-8847-5ea059efb08f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,044,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9e9fb71-09ac-4927-9784-27e98739598d" contextRef="C_bb53d62d-50b1-4820-8847-5ea059efb08f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">11.68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cebe2d2-71d4-407e-af85-51856dc84f87" contextRef="C_4670a0e4-4053-442e-b19c-76a0ef8da1fc" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78e70fd7-5edd-492e-9b75-b5d6fe9860d1" contextRef="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) enables eligible employees of the Company to purchase shares of common stock at a discount. Each offering period is approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2b3b3a41-7c66-4797-8009-1e2446c8c213" contextRef="C_6e29ec8b-8d03-49b6-84f6-bb02efd765fe" name="alec:SubsequentOfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> long beginning on the first trading day on or after June 1 and December 1 each year. ESPP participants purchase shares of common stock at a price per share equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0787a54-5d1b-444f-856e-00d528f9e61b" contextRef="C_6e29ec8b-8d03-49b6-84f6-bb02efd765fe" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb7cbfbf-d520-4df7-a580-39291150a3a4" contextRef="C_493c7746-435c-403e-8f86-4bcdeada8dd8" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">591,397</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were added to the shares reserved for issuance under the 2019 ESPP pursuant to the annual automatic increase. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a512444-dd86-46f4-8120-52ab212592c6" contextRef="C_6b3e5c54-3f8c-4714-8434-7829b44103ee" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in unrecognized compensation expense related to the 2019 ESPP to be recognized over five months.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_56f9330f-4fbf-465c-88d0-87fcea5cc2a7" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d1da5c35-6676-4994-b039-6b0a8ad0d357" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal and state income tax provision for the year ended December 31, 2022, 2021 and 2020 are summarized as follows (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.115%;"></td>
        <td style="width:1.963%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.235999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.974%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.248%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.974%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.491%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e06e28d9-a533-4e22-82c8-4a96a788843f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_062754d2-9dfd-4552-aec7-19211a4526ac" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_439f54ed-4299-48d3-88d8-4bc0c212cc4d" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2b48f6e-d22e-462b-9fcf-d6e4126f26d3" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,045</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_662d3bdf-ce17-45f3-a085-7c4abdb22a37" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14e44b5b-9786-4ed7-a1ee-504d2ba97d72" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Income tax provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c351c5b-0aff-42c1-bfaf-0666ee891993" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94995899-37fb-4bd1-9eb1-f3baef10762f" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cbe893b-d83e-42d5-b53a-8dee48b8451c" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77784388-8cc9-473e-b177-bca76332ca81" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.61%;"></td>
        <td style="width:1.464%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.988999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.464%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.988999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.464%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.022%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71c95db7-c382-4887-8597-859a8093aecc" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5dac097-7d31-4e66-b66b-b06892505f97" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36677caa-e2e0-4854-bcdc-ee18bed8f76f" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de1f6ed-da47-497c-9a81-6d5f4131357f" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">344</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1f496e3-ef5c-4dc8-82d3-b983da8e864f" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">398</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a40df87b-2be0-422d-8255-85aec5dcb19e" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,570</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06c17099-78ba-435b-b064-18d6240cdd64" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,184</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3c0d116-037b-4aea-96f8-9f0eadade874" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30fe3b92-c71f-4c15-a9d7-cf2252a885d6" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,010</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_902c5828-5f7a-4b69-b4d7-ad75ce44d71b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,733</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67c1b751-7c36-40b1-ae3f-0ad95b5c10ec" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,347</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c27a6cc0-49db-44f0-86a0-ea51d1d8c9b0" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf3a9e34-9333-4dd7-be8c-f0d90853587b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_594bc4aa-266d-4d16-aa37-5213f0aaf15e" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,368</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a769d2d-8089-44f4-b793-f9b5328f3b54" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e98e769-1cf7-445a-ad5f-57bf81e4987d" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,421</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba598f64-2758-49e9-bacd-a764635b1980" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,800</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4835f91-67a4-402e-8393-8ce09579dc51" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5574620-9f00-485b-b4fe-7264a9204434" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fd5ea7c-8c02-4cc9-bb2a-566998d4ab6a" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10efe741-650c-462f-a8cb-84c1a524ee0a" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d422b4e1-be77-45ad-8092-2fa0ab33b3af" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5dab44a2-cde7-4fc7-87b8-4f70fda64578" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f89bd48-d896-428b-b1fe-38b3fa1243c4" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3920b2f5-3962-4f16-aef0-47bbbb8a68be" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant components of the Company&#x2019;s deferred tax assets and liabilities consist of (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.182%;"></td>
        <td style="width:2.441%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.450999999999997%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.441%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.483999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f39076aa-aaa0-4bcf-9b9e-2704109ce9a2" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1168ee43-f1e0-4de5-a2e1-9a89f8e0175c" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,868</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bc5bea6-d0db-41f0-a283-c924729ec60f" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e928825c-08d7-4c97-b4f8-10076ebabc1a" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00e54b88-788d-4ba4-833a-bb67513609a2" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b0e5f49-8bde-4450-b363-7012728e6653" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,614</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e3839aa-cc13-433b-8a90-8c704a9fa007" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,351</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6940c21c-1f24-4c39-8430-37c55ab4c2fe" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,656</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cf33964-7404-4814-b614-d33c7760f22c" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,673</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc6177f3-76fa-48f1-b0a3-289a48b5aba8" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,849</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_030bb2b5-06fb-4b97-90d4-09251211349b" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,055</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1a86321-1f31-4ead-99df-e7e70f90fb6f" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,296</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 R&amp;D capitalization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15fa6b4f-8b51-437b-8771-7987fcfc7b01" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,150</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23a5d470-cc8b-4f53-8800-2c1fd9840591" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05dbe2e1-41e6-49a1-b62e-2c22ebebb09f" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,608</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2bafb95d-496f-452c-9271-282952421321" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">694</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cf6c7b9-d6f8-43c9-8487-b7c8f2526664" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cabf4766-04ad-4a9e-bd39-38f2ab5b1ea3" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134,788</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b606d0e-4205-41b0-805a-fa3df707cd23" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,316</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba691e31-d382-4d81-90e8-c5b03efabf3d" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46ec38bb-6d61-4d93-b3f7-4a8e80b45296" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c575c4a3-513f-4b0c-b322-f5eac8e4ddff" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2a289eb-fc36-4c9a-beaa-7b84d7549b51" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_719122c7-b680-41f3-9522-7057ce7f081f" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:DeferredTaxLiabilitiesDepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf579b96-55cc-46df-950e-712fc77bfb04" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="alec:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,454</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96f42371-0914-4c0b-a73b-4afa74a0a1d8" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="alec:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dd64c52-7827-484e-9972-5481d5a7c669" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c1cec5b-9c70-40b8-8f84-e0a28fc0f675" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,742</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12e1f047-f7b1-4401-8c2c-21f83bef6461" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f7f4e75-6f2d-4252-ac1e-9c2ef3ab8394" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2c10c56-c806-4f81-8550-b7bcc2f713de" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal and state net operating loss (NOL) carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_607bb9e4-3d9e-4bdd-b9d3-3c1c4f8cc6aa" contextRef="C_8df03805-8723-4874-a2a2-8c93c5cbd3d5" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbd6bc38-f714-4665-86a2-098d28dbbd04" contextRef="C_79a8adcb-cfbf-4eba-bbda-4e86d5eee09c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">203.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db8ddbc0-1992-46fb-b360-0ce8b8017716" contextRef="C_2dccbdd1-17e9-485c-a5ee-03938c7e22f4" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of taxable income. State NOL carryforwards will begin to expire as early as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dfb1a02a-98a2-4be6-b227-e276f3d81a57" contextRef="C_fe4d91c0-ce81-47c8-ba8d-75ea9ef9fb79" name="alec:OperatingLossCarryforwardsBeginningExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if not utilized, or have an indefinite life. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company also had federal and California tax credit carryforward of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23a0e581-2125-4dcd-97a9-f99bb085e169" contextRef="C_8df03805-8723-4874-a2a2-8c93c5cbd3d5" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0e96491-b0ba-411a-86a3-c42c1651d5ba" contextRef="C_c9cdc029-237a-491e-84f0-8ce387ab9c94" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The federal tax credits will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ace9f30a-7d4c-4e64-9525-6756fb847c77" contextRef="C_9836c7b3-8244-4a0a-9397-0627ae5caac7" name="alec:TaxCreditBeginningExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">while the California tax credits have no expiration date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#x2019;s ability to utilize NOL carryforwards may be limited as the result of such an &#x201c;ownership change.&#x201d; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c90e7831-c157-4c5d-939f-af7d469dec47" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.002%;"></td>
        <td style="width:2.048%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.95%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1febd091-ab9c-427c-b08d-b4b9399e734a" contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,592</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decreases related to tax positions taken during the<br />&#160;&#160;&#160;prior year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd31a57a-9904-4916-96fd-759d866bbc31" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken during the<br />&#160;&#160;&#160;current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06067c11-6010-4c55-b4a4-4b5f0d4eb235" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b844b693-049d-489c-83c7-da87e867efaa" contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken during the<br />&#160;&#160;&#160;current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3952cafb-79fd-4dc0-ac5b-425bb5d7463e" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,199</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46e82a15-6511-4ccd-9f4a-91a8ac47e2de" contextRef="C_59545206-883a-4aa3-a49c-906caa840899" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the unrecognized tax benefits for uncertain tax positions as of December 31, 2022, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended December 31, 2022. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company recorded an uncertain tax position of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e67b05c9-5efc-40a6-9b6f-e8275c97428b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e824884-f823-439e-ba4d-e5469d53f065" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The income tax provision for the years ended December 31, 2022 and 2021, included a reversal of reserves on uncertain tax provisions of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40aa4436-0ac0-4337-b422-c366c8f02946" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="alec:ReversalReservesOnUncertainTaxProvisions" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cb911d0-a100-40b7-a51f-b3e11c9a0e6f" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="alec:ReversalReservesOnUncertainTaxProvisions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company&#x2019;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d8e5958-7286-4883-a974-a0799a279930" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2014, the Company entered into a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its latozinemab and AL101 programs and is developing antibodies optimized by Adimab in its AL002 program (2014 Adimab Agreement). The 2014 Adimab Agreement also provided for the Company&#x2019;s development of antibodies optimized by Adimab in its AL003 program. However, AbbVie decided to terminate the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. In August 2019, the Company signed a collaboration agreement with Adimab for research and development of additional antibodies (2019 Adimab Agreement). In December 2021, the Company signed another collaboration agreement with Adimab for antibody engineering research programs (2021 Adimab Agreement). The 2021 Adimab agreement expired at the end of the option period for the research program that was conducted under the agreement. The former Chief Executive Officer of Adimab through May 2022 is a Co-founder and Chairperson of the board of directors of Alector. For the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021, and 2020, Alector incurred expenses of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_494e25c1-362e-4ee6-b090-5732675c6ee9" contextRef="C_e86e0f59-9472-4a49-b595-48701d364860" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12d8093a-fd92-4350-8ccc-a91d5ce4dd90" contextRef="C_0bbd6899-6eb8-4d93-b39f-c6d7afda1a04" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61f4a9cd-7e75-4728-9c73-cd022bea4cf7" contextRef="C_edb4f89e-28d7-4da4-8c65-2ab76be71025" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for milestone payments for progress of programs through clinical trials and other expenses. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afee6412-7720-49e6-b5e6-442dbf5d53c5" contextRef="C_e26edbee-11a6-44f2-9f0f-58d3b932feaf" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d8feff1a-7b95-4af5-84d3-ed5dffa5a282" contextRef="C_a0aa7056-f119-4199-97e6-cbcd61a7b3fc" name="us-gaap:DueToRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued liabilities due to Adimab as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021. Under the 2014 Adimab Agreement, the Company has made milestone payments and will owe low- to mid- single-digit royalty payments for commercial sales of the product candidate. Under the 2019 Adimab Agreements, the Company will owe certain milestone payments and low single-digit royalty payments for commercial sales of covered product candidates.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_277702b9-dd85-42f3-a12a-8625a6a3e226" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_69e65dbd-a850-4fae-bac2-e8a1a500774b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.897%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.309999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.309999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.3%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.584%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c35cf09-d544-438a-84fa-659f85119627" contextRef="C_67cf0962-6249-477f-8bc4-dab96a763b98" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,044,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78726509-8a92-464b-ad9f-32caa0af826d" contextRef="C_ffc3dde4-e230-4e99-96ea-1e5e5dfbddfe" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,373,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5c1a10d-dac5-4771-b5e6-f8b1b7ab6638" contextRef="C_2e8bb82e-dade-4bfe-bc72-3759b7ed3710" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">186,425</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17dd26e4-455a-4c85-ad83-7e7924d4b435" contextRef="C_cf8d8382-eb79-4d5a-aace-511cc534b48b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,713,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_207033e4-6dee-4d82-b967-d655881c6c7d" contextRef="C_b8e32b37-b52b-4be3-bbcc-061f59815156" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,644,070</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cee33ac-0562-4a54-b4e7-796518992287" contextRef="C_43d96e6b-e335-4918-832b-938ca6e7af68" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,654,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares committed under 2019 ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5900f29-3023-49e3-8302-85f1e2cd9249" contextRef="C_9d16d809-66ff-4090-8fd8-8bb44fd13bcf" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">167,133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e82c3e8-83d6-43b8-9695-6b51abd9be5f" contextRef="C_16a6dfb4-c570-4d0c-aebd-ef6ff61c25e1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">70,406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68651e79-eebb-46a3-a3f2-19dc78036945" contextRef="C_1066ab24-de91-4fc8-b8ef-54102a1ace80" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">86,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3ae58d6-adec-45bd-a85a-a1ad081cba5b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,925,023</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bddfa7c-e85a-41b6-a2da-26953af85888" contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,088,350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf8d7cdc-1db0-492c-ada6-c722becaca5f" contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,928,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c87372ba-e601-4a43-b41e-0d89015e925b" contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent Events</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, the Company and AbbVie amended the AbbVie agreement, which will result in the Company receiving a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fe92fe2-7006-45a2-a1cb-c8f20914b3b7" contextRef="C_d2cef38d-be1d-484a-a61c-5428186c190e" name="alec:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payment for the dosing of the first patient in a long-term extension study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, management, with the participation of our Principal Executive Officer and Principal Financial and Accounting Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including the Principal Executive Officer and the Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our Principal Executive Officer and Principal Financial and Accounting Officer concluded that, as of December 31, 2022, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#x201c;Internal Control&#x2014;Integrated Framework&#x201d; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effectiveness of our internal control over financial reporting as of December 31, 2022 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and the Board of Directors of Alector, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited Alector, Inc.'s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Alector, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes, and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#x2019;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_re_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in our definitive proxy statement on Schedule 14A for the 2023 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;) in connection with the Proxy Statement to be filed with the SEC within 120 days of December 31, 2022, and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors has adopted a Code of Business Conduct and Ethics applicable to all officers, directors, and employees, which is available on our website (</span><span><span style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">https://investors.alector.com/corporate-governance/governance-overview</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) under &#x201c;Governance Documents.&#x201d; We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics by posting such information on the website address and location specified above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2022, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2022, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2022, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information required by this item will be contained in the Proxy Statement to be filed with the SEC within 120 days of December 31, 2022, and is incorporated herein by reference.</span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are filed as part of this report: </span></div></div>
  <div style="margin-left:8.796%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.974562519187754%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span></div></div>
  <p style="margin-left:8.8%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements of Alector, Inc. are filed as part of this report on Form 10-K under Item 8. Financial Statements and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:8.796%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.974562519187754%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:8.8%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other schedules have been omitted because they are not required, not inapplicable, or the required information is included in the consolidated financial statements or notes thereto.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:8.796%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.974562519187754%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></div></div>
  <p style="margin-left:8.8%;text-indent:-0.308%;padding-left:0.28%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The documents listed in the Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.087%;"></td>
    <td style="width:48.37%;"></td>
    <td style="width:5.612%;"></td>
    <td style="width:12.12%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:11.375%;"></td>
    <td style="width:8.18%;"></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="4" style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing</span></p><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:3.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed</span></p><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:3.3pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:23.75pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312519033930/d702882dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/11/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000156459020045922/alec-ex31_6.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/6/2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Registration Rights Agreement among the Registrant and certain of its stockholders, dated April 26, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312519003772/d550248dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specimen common stock certificate of the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000156459021008860/alec-ex43_9.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of securities of the Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/25/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2017 Stock Option and Grant Plan as amended and forms of agreement thereunder</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Equity Incentive Plan and forms of agreements thereunder.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312522000212/d160293dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1//3/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:25.9pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000119312519019648/d550248dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confirmatory Offer Letter between the Registrant and Arnon Rosenthal, Ph.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/29/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.087%;"></td>
    <td style="width:48.37%;"></td>
    <td style="width:5.612%;"></td>
    <td style="width:12.12%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:11.375%;"></td>
    <td style="width:8.18%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022001979/alec-ex10_18.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter dated November 30, 2021 by and between Alector, LLC and Saraswati (Sara) Kenkare-Mitra, Ph.D.</span></a></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;10-K</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/24/2022</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-8+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022001979/alec-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter dated February 4, 2022 by and between Alector, LLC and Marc Grasso, M.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/24/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022004925/alec-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter dated January 31, 2022 by and between Alector, LLC and Gary Romano, M.D., Ph.D.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">03/29/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Incentive Compensation Plan.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex10_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside Director Compensation Policy.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:26.65pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Change in Control and Severance Agreement between the Registrant and certain of its executive officers.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:26.65pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease between the Registrant and HCP Oyster Point III, LLC, dated June 27, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:38.15pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amended and Restated Collaboration Agreement between the Registrant and Adimab, dated September 19, 2016, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:38.15pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15#</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001653087/000119312519003772/d550248dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Co-Development and Option Agreement between the Registrant and AbbVie Biotechnology, Ltd., dated October 16, 2017.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-229152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1/7/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:28.8pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16#</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000156459019042920/alec-ex1017_159.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Collaboration Agreement between the Registrant and Adimab, LLC, dated August 16, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11/12/2019</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17#</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017021000725/alec-20210630ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreement, dated July 1, 2021, by and between Glaxo Wellcome UK Limited and Alector, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8/3/2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18#</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex10_18.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Number One to the 2019 Collaboration Agreement between the Registrant and Adimab, LLC, effective August 16, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1653087/000095017022001979/alec-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of subsidiaries of Registrant.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-38792</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/24/2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:28.8pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on the signature page to this Annual Report on Form 10-K).</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.087%;"></td>
    <td style="width:48.37%;"></td>
    <td style="width:5.612%;"></td>
    <td style="width:12.12%;"></td>
    <td style="width:5.256%;"></td>
    <td style="width:11.375%;"></td>
    <td style="width:8.18%;"></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.75pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:36.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><a href="alec-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;border-left:0.75pt solid rgba(0,0,0,1);vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:right;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:4.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);"><p style="margin-left:4.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.8pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.75pt solid rgba(0,0,0,1);text-indent:1.1pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="margin-left:1.1pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"># Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.387%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:4.22%;"></td>
    <td style="width:46.378%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALECTOR, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Arnon Rosenthal</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arnon Rosenthal, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Co-founder and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Arnon Rosenthal, Ph.D., Sara Kenkare-Mitra, Ph.D., and Marc Grasso, M.D. as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his capacity as a director and/or officer of Alector, Inc.) to sign any or all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.415%;"></td>
    <td style="width:42.201%;"></td>
    <td style="width:20.385%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Arnon Rosenthal</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arnon Rosenthal, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Co-founder, Chief Executive Officer, and Director<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Marc Grasso</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marc Grasso, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</span></p><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Tillman Gerngross</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tillman Gerngross, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairperson of the Board</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elizabeth Garofalo</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elizabeth Garofalo, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Paula Hammond</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paula Hammond, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Louis J. Lavigne, Jr.</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Louis J. Lavigne, Jr.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Terry McGuire</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Terry McGuire</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:37.415%;"></td>
    <td style="width:42.201%;"></td>
    <td style="width:20.385%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Richard Scheller</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Richard Scheller, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ David Wehner</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">David Wehner</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Kristine Yaffe</span></p><p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kristine Yaffe, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:6.55pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:6.55pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>alec-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALECTOR, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OUTSIDE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(As amended on March 17, 2022)</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) believes that providing cash and equity compensation to members of its Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; and members of the Board, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  This Outside Director Compensation Policy (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) formalizes the Company&#x2019;s policy regarding cash compensation and grants of equity awards to its Outside Directors.  Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#x2019;s 2019 Equity Incentive Plan, as amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), or if the Plan is no longer in use at the time of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted.  Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to Section 9, this Policy will be effective as of the effective date of the registration statement in connection with the initial public offering of the Company&#x2019;s securities (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) (such date, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash Compensation</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Annual Cash Retainer</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Outside Director will be paid an annual cash retainer of $40,000.  There are no per&#x2011;meeting attendance fees for attending Board meetings.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Committee Annual Cash Retainer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of the Effective Date, each Outside Director who serves as the chairman of the Board, the lead Outside Director, or the chair or a member of a committee of the Board will be eligible to earn additional annual fees (paid quarterly in arrears on a prorated basis) as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:2.133%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:78.846%;"></td>
    <td style="width:2.707%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.447%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Executive Chairman of the Board:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lead Outside Director:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of Audit Committee:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of Audit Committee:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of Compensation Committee:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of Compensation Committee:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of Nominating and Governance Committee:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of Nominating and Governance Committee:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:15.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For clarity, each Outside Director who serves as the chair of a committee will receive only the annual fee as the chair of the committee and will not also receive the additional annual fee as a member of the committee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Payment</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each annual cash retainer under this Policy will be paid quarterly in arrears on a prorated basis to each Outside Director who has served in the relevant capacity at any point during the immediately preceding fiscal quarter, and such payment shall be made no later than 30 days following the end of such immediately preceding fiscal quarter.  For purposes of clarification, an Outside Director who has served as an Outside Director, as a member of an applicable committee (or chair thereof) during only a portion of the relevant Company fiscal quarter will receive a pro-rated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during such fiscal quarter such Outside Director has served in the relevant capacities.  For purposes of clarification, an Outside Director who has served as an Outside Director, as a member of an applicable committee (or chair thereof), as applicable, from the Effective Date through the end of the fiscal quarter containing the Effective Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) will receive a prorated payment of the quarterly payment of the applicable annual cash retainer(s), calculated based on the number of days during the Initial Period that such Outside Director has served in the relevant capacities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Compensation</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options, Performance Units or Performance Shares) under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy.  All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Discretion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Options</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Subject to Section 11 of the Plan, each individual who first becomes an Outside Director following the Effective Date will be granted a nonstatutory stock option (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) having a grant date fair value of approximately $550,000. The number of options will be determined by dividing the dollar value of the grant by the Black Scholes value of a share (with the shares covered by the award rounded down to the nearest whole share). The Initial Option will be made on the first trading date on or after the date on which such individual first becomes an Outside Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy. If an individual was a member of the Board and also an employee, becoming an Outside Director due to termination of employment will not entitle the Outside Director to an Initial Option.  Each Initial Option will vest as to 1/48</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Shares subject to the Initial Option on the one-month anniversary of the date the applicable Outside Director&#x2019;s service as an Outside Director commenced and as to 1/48</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Shares subject to the Initial Option each month thereafter, in each case subject to the Outside Director continuing to be a Service Provider through the applicable vesting date. Each Initial Option will become fully vested and exercisable immediately prior to a Change in Control, subject to the Outside Director continuing to be a Service Provider at the time of the Change in Control.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Subject to Section 11 of the Plan, on the date of each annual meeting of the Company&#x2019;s stockholders following the Effective Date (each, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Meeting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), each Outside Director who, as of such annual meeting date, has served on the board as a director for at least the preceding six months, will be automatically granted a nonstatutory stock option (&#x201c;NSOs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) having an aggregate grant date fair value of approximately $350,000. The number of NSOs will be determined by dividing the dollar value of the grant by the Black Scholes value of a Share (with the shares covered by the award rounded down to the nearest whole share). The Black Scholes factor will be averaged over the 30-days prior to the grant date of the Annual Award, as determined in accordance with the Company&#x2019;s then-current accounting principles. The number of RSUs will be determined by a 2:1 NSO to RSU conversation ratio. As a result, the number of Shares subject to the RSUs will be one half of the number of Shares that would be subject to the NSOs granted on the same date. Accordingly, the value of the Annual Award will be split equally (50%-50%) between NSOs and RSUs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Annual Option Award will vest on as to 1/12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Shares subject to the Annual Option each month after the date the Annual Option is granted, provided that the Annual Option will vest in full on the earlier of (i) the 12-month anniversary of the date of grant, or (ii) the date of the next regularly scheduled Annual Meeting, in each case subject to the Outside Director continuing to be a Service Provider through the applicable vesting date. Each Annual Option will become fully vested and exercisable immediately prior to a Change in Control, subject to the Outside Director continuing to be a Service Provider.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Annual RSU Award will vest in full on the earlier of (i) the 12-month anniversary of the date of grant, or (ii) the date of the next regularly scheduled Annual Meeting, in each case subject to the Outside Director continuing to be a Service Provider through the applicable vesting date. Each Annual Option will become fully vested and exercisable immediately prior to a Change in Control, subject to the Outside Director continuing to be a Service Provider.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Terms of Initial Options and NSOs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The terms and conditions of each Initial Option and NSOs will be as follows:</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i)	The term of each Initial Option and NSOs will be ten years, subject to earlier termination as provided in the Plan.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii)	Each Initial Option and NSOs will have an exercise price per Share equal to 100% of the Fair Market Value per Share on the grant date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  For purposes of this Policy, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the grant date fair value (determined in accordance with U.S. generally accepted accounting principles), or such other methodology the Board may determine prior to the grant of the Initial Option or Annual Award becoming effective, as applicable.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in Control</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of a Change in Control, each Outside Director will fully vest in his or her outstanding Company equity awards, including any Initial Option or Annual Award, provided that the Outside Director continues to be an Outside Director through such date.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Compensation Limit</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Outside Director may be paid, issued or granted, in any fiscal year, cash compensation and Awards with an aggregate value greater than $750,000, increased to $1,000,000 in the fiscal year of his or her initial service as an Outside Director (with the value of each Award based on its Grant Value for purposes of the limitation under this Section 4).  Any cash compensation paid or Awards granted to an individual for his or her services as an Employee, or for his or her services as a Consultant (other than as an Outside Director), will not count for purposes of the limitation under this Section 4.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Travel Expenses</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Outside Director&#x2019;s reasonable, customary and documented travel expenses to Board meetings will be reimbursed by the Company.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional Provisions</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i) the 15th day of the 3rd month following the end of the Company&#x2019;s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii) the 15th day of the 3rd month following the end of the calendar year in which the compensation is earned or expenses are incurred, as applicable, in compliance with the &#x201c;short-term deferral&#x201d; exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended from time to time (together, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply.  In no event will the Company reimburse an Outside Director for any taxes imposed or other costs incurred as a result of Section 409A.</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revisions</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Board may amend, alter, suspend or terminate this Policy at any time and for any reason.  No amendment, alteration, suspension or termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company.  Termination of this Policy will not affect the Board&#x2019;s or the Compensation Committee&#x2019;s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such termination.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>alec-ex10_18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.18</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*** </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDMENT NUMBER ONE</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 COLLABORATION</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment Number One </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), effective as of August 16, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), amends the</font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 2019 Collaboration Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) dated August 16, 2019, by and between Adimab, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH  03766 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adimab</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and Alector LLC, a Delaware limited liability company having an address at 131 Oyster Point Blvd., Suite 600, San Francisco, CA 94080 (hereinafter &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Capitalized terms used herein and not defined shall have the meanings ascribed to them in the Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Parties would like to extend the Target Nomination Period on the terms set forth within;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, Therefore,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in consideration of the foregoing premises and the mutual covenants set forth below, and for other good and valuable consideration, the receipt of which is hereby acknowledged, Adimab and Alector hereby agree as follows:</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 1.78 (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;Target Nomination Period&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.78	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Target Nomination Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the term beginning on the Effective Date and ending on [***].</font></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 1.34 (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;FTE Rate&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) of the Agreement is hereby deleted in its entirety and replaced with the following:</font></div></div>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.34	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FTE Rate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means [***] per FTE.</font></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms of the Agreement shall remain in full force and effect in accordance with their terms.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*** </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Witness Whereof,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Parties have by duly authorized persons executed this Agreement as of the Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector LLC:		Adimab, LLC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Arnon Rosenthal	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Philip Chase	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Title: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/23/2023	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	Date: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2/9/2023	</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*** </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>alec-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.065%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:8.52%;text-indent:11.237%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:8.065%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) Registration Statement (Form S-3 No. 333-238230) of Alector, Inc.,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) Registration Statement (Forms S-8 No. 333-237369, No. 333-253524 and No. 333-262990) pertaining to the 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan of Alector, Inc., and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3) Registration Statement (Form S-8 No. 333-261968 and No. 333-267597) pertaining to the 2022 Inducement Equity Incentive Plan of Alector, Inc.;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our reports dated February 28, 2023, with respect to the consolidated financial statements of Alector, Inc. and the effectiveness of internal control over financial reporting of Alector, Inc. included in this Annual Report (Form 10-K) of Alector, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>5
<FILENAME>alec-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Arnon Rosenthal, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Alector, Inc;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.0%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:44.963%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Arnon Rosenthal</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arnon Rosenthal, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>alec-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO SECTION 302</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Marc Grasso, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Alector, Inc;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and	</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.	</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.0%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:44.963%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Marc Grasso</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marc Grasso, M.D.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>alec-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Alector, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.009%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.917%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Arnon Rosenthal</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arnon Rosenthal, Ph.D.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>alec-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Alector, Inc. (the &#x201c;Company&#x201d;) for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.009%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:3.037%;"></td>
    <td style="width:46.917%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Marc Grasso</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marc Grasso, M.D.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Principal Financial and Accounting Officer)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img42979713_0.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_0.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M.*@CIQ!&0)%Y'),Y[P8\]+%*! %GUE==G5=L"@=!&W0VRK"+JQ>,K*>(](@
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M%=LI/1]E':\;,8>U8B27>XN]00QH>O!#JZ:;&NS_?F:C>D$_$/3\WN\_:_=
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M"_3 0.W[ZRTHJ6Q/OP?QG"R-CAJ+3Q-8\X3R5P'WVJR_S+PBD"$$Y_LRHXE
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MH.PQJ,^2P=Z^,[*9/5%6*/L@L-KB+19J\$VRH^;"T,)!!CTFK XP""<U L=
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M#.@Q#6BP%IB"#WBZ"Z\Y-XY8-04I,ZZ:*[O0([T@(1'RBL +H2E!DZ_C&KK
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M,^/,#VS#7OE0OC30OR#$=BK2B%7,*CU"M*V]([*.X?/92-,<PGVW=,$TD6#
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M:3 W86\ASJ":62,XT:KZA6#Q"6IO;HCL2P,?\#LV3X-^0EQ@) F]"13S]>-
M$<WT?.XGYRZ/1/ '+Y$%_PA/UXV8#LE@A< P>NLS\F3-\QJL_S##L&LJ\=8;
M;J50+XUT[/QC3 4?#<=2S(Z^NM02&O]U0B;TK!K*UM4(&%Z)$Y)UB64MYC3%
ME#I#Z6OLN2"&:/20W=;T6$K-GJ!I%"'UC[AR$UEEG_DE"%Q+YH"&-;:K&'*M
MT-[,%3[%0S[OL3U9D8ACZ9.NM2:_0O*W0N) H[3!,H^/@8%N(G?HE-5W8)32
MD9!T/#>X%'_C^B5SIB3?R # E6R$;;>Q\0J=H#41XUX)4<^->OF9T='1UUQ
M97 =EHS=.6,;%_?;> IT0Q:GO5'K98V^^;U+,W\IX1[/70%<RBKI_%X&8L"(
M=9=V0![BX%6\\"%//FE;3F7DIT[F#/^_=U=WIQVN&4L417SE>!M3O731!)*_
MC7#OB :W<EM?%-9,6F%U"!8ME8..[BR5JTK64GFG>NNS12-E$Q?>/>J.8@BM
M;BL]]NV(F7J  PLP@F6  R  @GI,DE3L80W="!C?/^BR[(]]5423Z@P!2 _7
M6?%+-+0&:QA\]C7VY#&0Z[#'*!<IK^  =9D0>93X8.)^#9/_&>1 K+<O25#
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M<603?MS,0X;W4@^!)9 ?*M%E<L.\%"+L0NL:CDMD516\"'&C!_G3DF02,H1
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M49GPS,6(DO % [Z5GG?_=%$ K45/0$0_%8TPM4P6_E(H)AR"#%BA%6/T691
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M%40%REC+;%1JF(\^W:2I7*AZ9I'ER .ZH?];.\BE6OE*M!X:$*@!6<B-,EA
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MIH49 7C6)C^9Z58HC=WPUE=JN06*PF=U=6,F8ZTT%FG[I'% =V".=1@T9@(
MBE9I9*E8 &/EUI69:7!T\L8YV9S6:J<E%DJ>BKW&)S%IM$L,H;B!%M2('*E4
M;DLB;7B11HURI!9WS!FT:;37"5@=J/VUYJS(K5H;D=B<-GM0=Z8.>U\P\\4S
MZQFZYG=?K.S<EY\PF3:'&;/6GFK@I@":*CAW$Y9:[>$"J7VJ0KE12%"B^W@$
M:4O"8>4AN?I<A9)O0?$FFTSM#FU34#%.'",H_Z[.>NLX+KRMZZQK_)F<8\7Y
MN6(K U#_9"ACI3$QC 3U%$I<.^&%\8QC36)[[?OHI'N6726F9B:1B06 8M&$
MJ0DT"KTQUAL<21*#)K/B@!,Q&^O45<JNO4;0SUR]%LIL>95I&T4FC;OMAQM)
M/2F2- US W34N5;"*F;]AU4)3% #_38LM3U00A-\H'6LLREVY T_B@! &-;1
MMOC01U?U 99V&$@L%%90@2E$S+6&12$ +3"",IQ0O3XWP $RS5';DI3D$E42
M9:AH=.T:0[W08J2)X4YV3&RB$X>R(X4\\5]JNHB3Z&01PL0@8-P1TC)HEX8K
MB@$UN^/)]@!P&;64!12:2$.8T"":&.QC3A>A(TYH9Z$YB>$B_\,;4F2Z8S*6
M*>-A@ Q3:KBRN[,$92R2P$G 5'/(U4RO*_13#&ITI@G9X*88N&D6TH(R+D<-
MYS<]O) !F2*IV'DK:D91I:%RN*UQ6>0^M%S'&=:DF3#,)SZO7&4.<=C+I,3.
ME<%!E$J*\QL- ?!"QFQ)YS9R0Z:IBS;M4M&[,&(DN4PI95/LIC=E%PTV]NR;
M]VJ,'/>A)N;MXTU">IYF2#,GS< A%(0Y#?@ $ .UW/,GN],,\ZIHD<;L$2=U
M.:<[.\82GM .,JE)#>VZMXRQC D4A %>:I1QQ6@PY&;.NXCZ>+<:N7C/>SQS
MC?QTUAU-K @W92)&)SDR+J45DT._Q/]<2$9R.0WQ)5P!M @T0OFA8P(G)2#R
M" ^)(TM':7!NB\!E96JURV3 U&E#Q9!/0S+*7_*T@,4TSO..8\I8SI1$X ))
MB&2JJ!ON@UVS65%-;B*2>:5N8N2LJUWQ=1HV+O&N-%J3Q^:DI8"=,V!QTF(]
M I:)4-P3>-@#0%S,J49\\@1[F5#,[0XZ,(Z0C*-9Z@[V$D.0U%0O&K3;3&3D
M$HV.M0\H%L$C3CR3LM=0<K9<^1F?&MJS90A*$YQD"*%N\S1F@HB9RR@)#TFT
MU5X><U+$%8H O875$0FG1"**VJ+VUR$"\J9MMX(; &!PAD6$81'A#4,DQ@L?
M]L@#N]=M[RG_F0D-FBY*:E(K;M-X(]U5&M>'.P0KN81;KO]-#E(&Q.E*W$7-
M%%FH65/2YD_VRM<(2_@I!=G)72-CHX"1Y0:?E.A%&)DNFP749ES<QT?A4+-F
MO>P4:M++,A+)1C;MHZ!!^>@G+T(8 .@E3'H"Y '&$CW-I*&AD9&9)*V$3A%?
MQ >%J6W/\#092U+R?7NZC:E<:N7< #BX18DO2/P7M6?6-*N,LJ\O220IGA(S
ME*[$ZH8TN,M@-'41ZSA&G==AJU[%*E=2725?F%;3J=4T1(<*-%FA2]6/4'=I
M(]KJ39\6RE5&^B4I:FOI]@$CG<1H)UZ>L*<_C4J\0/B):IV*:QUY_UF+9&E+
M2EZUB4E\N[K0#A1BB<%/9# :N"Q#+ :8&,D0&Q3:=9HCNTOL%6.;&#.)(3+U
M'.3M *EB@6GO1<NHB\=$L@QSW@FE?&(-)0]9TMJVQC;DSLUMDBO+,7\Y:KY!
M"2N9"<187BXHQ5T&/0"M*)@F\] @NNF'S#5+/.\J;GF[6WR$ 2OYJ&>L3O/R
MOK,['+0>YUP'G&HS+QXB_=YW<LSU*;^WW/&HS28FM!F##IS3X+3("-0L;[E1
M7B27NH[Z*801BHTM<D6^.&F@KP: A;AD4(GB<Q]9&@L<"&).N<"A+')9AI-P
M8$ZA #0HGH%#ML?2&BB=$66I>5AD=@>9G_^I:350.BTHEB<2G<A,W-U^3935
M,C^N^)*EMVDI2X5RW4F96=+,!&J_??G<,S^/&)E( PYR@ ,'X&#Q/TA#)H@A
M*0$NDS?X9>Z\'<X1A-=R5E#M%7U@-3<\SV/=3?N?<6DZ<8X,&U'-RL0/%I]X
MQ.? !VF0RH68UCGA9MSB9RTTFP>,W6/R1:4H&N),@J<63?N$F"YO?LNC4:69
M@[/43J%Q4!"KCWY^& "<80GMK#B:[:^ZL3=(3BB<9&LXP.!W!:%+98X>.]%<
M6V < \ *#+([LT#_BFD I$13<W8 ,"9XXB0!<%%Q)S,\H3!?]#*K80JK$4EQ
MUV/:A1.$DC^_Q4EY?+$YH$04DN-*)6%@P.0M[J8/FO!Z#N  "(""*YB"*:B"
M#N!X/F(N@6%49N4T4P5-%A%G\6%G> -"<],>]5%"?A9<CQ9,&^(HRI ).8""
M*NB$+=B"*H@#;P!7[Z9H +<2EB=*JI==%H=W)T)R)#<&E!!.P?,62.9\:?^8
MA@6A,,PG.]+'%!YV?9K1&&$@?@#P3T.G:GAX$6&"17[($3F&3R^C3?VT;/RB
M&_(78D(R+R,C)&B0%64B/9*A6A=5%M,6@*;%%4YR %JA,RCU9+6%0U5%=P)Q
M&]8"-48H:%:%*#-87_[5&],%<..B#&D0A;>( $^X@D\XA=3W-)?#&]*7'T(8
M'Y$@7I' 'O%P7AXD0J,7',018!AR$A^Q>FV$BTV(C2]XBV:A(2&!>1@Q3#K$
M*%XE2QN($G&B+BI".NNB:6A186:DAO&8ADRR4=ZT&C,";$)A)C% #$Z261^U
M1?O@)/,' ,. 8ZY&&)F%<Q)U3PH!)?N(&@YV%M'_$$<7D0EAL@*'L8"G(09A
M @,XT!VO03O6DQAB88"O\3NN(8E"D@;SPWZ?*%MRETK>LEQ14S1'0RB_Y6Y#
MD5^"5U-*(U;$=HM0"(4O^(1'"8,LX6_ ,6]YEX71N _SP![KX5V5T1Y^6"L_
M* SLM85%45T#I P^,)1&B8W9B(MFL9,<!Y6M>(/3=1&=5A+Q50]R211@F"(T
M00D (B\4XXORZ)=\56%H.$5PZ)=<L3"AT&)\XI 3HPE,ACY" 7W=%EM\4EN3
M\1J'=("N0633%H&4)&[0, 98MQ6PD3Q+PU5707GE A%7=F6\Y2,;Z(5(")L]
MM6Z!MTI2HPE%:99DJ8N\_YF"9L&!1>@T.WDHN&*<^"$DLT(68/!YP>",M_DH
M-KAQ2@,-:9"+NHF=O5F6+9@#!F.::EDYT<EN3H-OWW(H&S%-85AIPL-I\/B7
M[\ER"M@OW52:\ F9R[!T B@OIT$O70%CJA%."K.?JF&9K*(]T!9EEID:L $]
M"3I)7$$R\T-)T(F:WN@M7B9+GI23-XD;W7@1:9DTPTEYB9*:I0=P+X:40XF=
MV<F"23E L"DYOA1Y&K*#P1 )8\$>E1$&[+%!6YF*X[AH3J,,.:"-UVBD9#F6
M#B ^O[AQ ^1H5FB;6167%\%6* (H(=43:)%N]LFE=E5A=M)-BM&E1+%^!U E
MJ__A/E"R(V.Q36WXB:B5?'RB=:9QF6XW;<I0=N#VH-,S/V-76_$E*1:"$KRA
M&]IB>4;S'%=&*'UI2I#F7,'I<3F! TB* (G7A)/ZFU&(J;K)BW'B57+IEN4R
MDW3S@[/R0<<@#+.B FZS*PEW#,[X7!IR;ZSD&R1Q%9EPI(KGA)9:J2TH V79
MFPB0!O/&<&AF2B#XH>'IH4TS3:131&1@)^R9&&-*K8!I!SM"F/YRC]5JD6,Q
M#(9Y.MI4$ TH2?,3D7I"IYGY,ZEQ20Q:IWIZ4@M:6RQCJ.;R9S1IJUD8GJNT
M*3?)6Q!1=T?A0ZQ4<=CE94$:&,2PB[NIHMJIJ4FJ.L;_*H*T*0_Y01]-)3?Y
MT53(J' ]&ERD!#4RI0FZF*1FF:2_JHW:V)W)&GP"-)=<Q1$@ZE_I!@?&EV!J
MT(Y?P5K<RK/?5&%6UTW9.J:!61 2""5\0A!E)U)-QR?0@Z9>8AH*RJ<0."S3
M]H \(Z]=H1*81Z@@X7#YRG&%YE/$8!L(<1OD5GF/)K-(Q2B1!XNLE)M(R:N<
MBHV;ZIO B@.@X7O8U1+#5A*DFA^S @/F%08V\%WC%08[JI7.V)3YUF[$QIN)
MUZLI2K)(>HTJF /_AA120XM?QE]\.TUC,#3K:!-Y-3&KU[.IZT305R13M*VJ
M:RAJ5SSRTI]*RQ62:4GSHZ>:_ZDG=IJ@/H,G,0D;O>%?&:(1P0AI6?&=QW$;
M&YJHFK"E,#4BJE2.1;42D@NLVWBW9+FIN8H[ K8//R5<9;4/.W@,3>548Q$&
M&X0,EO.B0T67')$)E,JB2:J=+_BK99D#545 Y8*A!.8ML_DMIT= ;/6L*_*.
M*P>["]Q$7[JS3*0]#$QO%1,_I]4=3[87IQ%W.N$][@INEY2[P=O!D22OKF%=
M%VH2VA(2%6&H++%, ;Q*"-%2^',;MA=R1"% N@%-3;DM84&_16J4V'NY#TNI
M.&!F6\HT HQPQ'A+Z0L D5!GZ^&,,]F58;8/N<FBW"N%6XR"F!K$OJF"!R ^
MMNI5S/\5:044OT/1K)5V(KD!%A(,QTSTI?,IQXR:NJ=QIJS!GWTR+!)S)SMS
M&O!JF0>ZKI,$;K6U@4JI$14!'%+C9?$UJYN3$2)2Q1.RH:?(28\F2MO2+<$1
M35#S ]J9ORJ(LM@YRMN)I*?L #G 2KDWCDY3HWBV"\@8";-LH[<<#("+@TQ:
M>A>A#-?8O93+L%QLLBF[I#C1:5@H7*:7;Z0D.<XZ$\47+W8<Q]7\(ZQK84XT
MK=8<-10L%X@!R*SQP7_<NU#VQU1F4L'[QUV+FF#E92X,'"[<*".Q>O@5C'5W
M;C6L92&*P\3ZN&MIBR5;N73+Q:1<S%'8 '"%K/-6>1=!JGC_TZ.W(D(*)\4<
MLGL?ZRA,2- .D+\E2Y2YZL51:"$Q:H0@>U-E7),T@V!L7+K9S,TO[2^LJU=-
M]#,PC6U(XA7F&I+\*3]0-CUYRJ +NIE1)G>S^E,;P1)>IBV4,ZM?];*HBTPX
MT2SEUDFX(;/N*X+F.!1A092G'+EWJZ+V"ZQ*N2$ %'%7(96A%RN7(%Y@4"NU
ME#>WHG$?*E\66;]%*<3"3+\-BX+[^Y;OI<P QCD;TCGK:$W2+$4VK=CY4C$*
M[#KU:=.(V!T/>+OLPZZ5W3[DS!HF%5M3.SU/([Y9(2['*V ;^&<Y& VS&CM#
M)<-U9S2\%2?E252D!TI*O0],B)0O_YC7NSBW*:NBJGR4,],HRPJ^36.<W94?
M3:P9JSJ,Z[$.SWE?Q9U#O\R+8#R6V.O%>1W2#.L "GE5'"B^J/>=O$%\ZGB7
MT K9BZW>/X(DBB3'0LO T[PSGMET/\.@>7* LC748GJA(F)@\06HD_Q36_NR
M2ZTHQZ4A#?&OG53#<3*]_#RS/DG=*ZK7V_B;VEC*15R65<BD_741\S$W\8"^
MN)3+NH(,/EI5FQQ<D[#1',V">^VPNKC=IVS$-VB#3?V=@XH2[J8,LR$Z;86S
MZRWD]H+'"BAQ^-(5T<O-ADD0?6*@>*HSR/:@O$N:\HJ:]W;25Y$:5C67^:KE
MX>LM27UFJ%\9HX3*FK^%'2V"$^Z&A9X#;]$(<#G0 "T8TKI8RL-LI$.9X=C(
M&7P;4Y&Z#TLL0F11RY<PR\JI L3HG,RUDT$ZX419J=M;YPS;T79.MP.C$=!X
MX+0MMCA!:<9'$] ZY/^C?B6;)IBK$\%#'D45W'9W6IE3*]1[NN7R_%/Q57$
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M1:NW<M^RE?HDTI,835\]E3+WJ50YDZ5-F 7W":VG;U]+AA)7:B)&C&DQ3<5
M-46ZSZC!FQ.K5LV$P($#KU[!?AU+5FQ8L#C$ECT[%JW;KV??&%0*K>75A/*"
ML=L;;!<  ,&.K1.V[AA?P+OZLA-V4*+1H@MSE)41E^WEMF\O;W;;-FY!I72/
MKD2:E25>@_0,JAF3ALP8V*]A:])8V_9MW+EU[^;=VW?&@0)!/?Q]$2;,XLF5
MY_8()U3(DA]#II0NL9[-:/\T9=+$N9*[Q((XKXN7V'.G2X1*L:-7:?4@L5!-
MXS,EMHG@P:H)(Y=.G7!R6QQH0T@9M<!*0RB#E'D#+(6Z<B"-@W 8RZ TX$(
MPGU40PBFJY0J#)EU0!0&!L#"B"2272() S  Y!$FGA?G(2VAQZY+T"S+,#Q(
MF0J]P@&4JO31A$&$A SK( <=4(T8"P6$3"&CD-//IH,T@2TVU](8@PPU4%ON
M2S##%'-,,B=:!A3A[BMS)Y'6=!/,4-#TR*.03#))I#G/@TDI#LMK"3N=ZC*(
MIY;"R\XQ+^\:C33UB('**66@4J8^!*%<Z$^Z-"R0K4H/ FNNA;Q:2!D$0!TJ
M+@K_RR(K/X5:TG">Q0X+AD5:68RDL+X:NRHK@U@E%3-3$1K# 1P8$E4A)AU
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M,D V ]Q"7T/!L<HYGK,-CEB&4_@\S2.7E\BR8S,)K)@D^HD&8LBK-) Z"=1
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MFRUKFH6666B35?9E9Y<!-RXHVJ:VC"9,,N000_PYZ=%] 5XJ((DF*=8?56F
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MF?QL/+. BJ:KC<=K>:E$X?/;N^T2!6LME\'*;N4GW5KV2[#8FE:HO<"]F<
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MOO1H3(%/:E95N-DR'.Z4/>XCG_7TL90OT46)\X-L4=GT+5/>CR -&LS/5HG
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M2JQ^M4T^Y=ZT.J-N R'<D4[2AA@*=J)CU4>]TT>5^"Z;IF,_HKOJX:T? O1
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MR68DD'\&0E.@LF7UIXRUVTZ+44D'3NHK>,7:%Z!9%\IUX9WIVD=BAB-V&)9
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M1$H)./B!]P&>L-P7ZW&1C&&YH. CTYM&GJJ(U(,^99C!I((*,J"T?O^$3+1
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MB?=I5__7]$R.]0Z=I GUB<M6"I$QB=PKQY>0\1)7_#$HZ=#FY)%V_-FMTYS
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M&_8\]"N,A(A921-0@-9=H/*Y9U<^0:W2*:+IKDO$5/!S""5T!LZ!Z#0ADP!
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MOE$%4T!=U[!$2A!%J\0/@*2374W7"8+$ANC@1)$(#S($-.C,#PA<4M@( *R
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MQ5:&S[O)(&U.WZ:X(/#5*H(YHD< 2T00 ^ZEY1BT)&;F2'Y89:1HTY2>V6<
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MA+_I,VK%R7:V6]?352&7LX5=O;D%RO!<+(E:]33^O&R^?9F06?CE])*AE^3
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MLBHWRHEF,6$6Y3W>S=VTYR5$[*60C&R*Z=;.[0%WSTS2J")D,"43 U[H81C
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MHN&ZU+XZ:\%"Z;FGQ,Y=>T3-CXQFE*/Z9+DKU[R1G;%D&50UP74[ZX#77V/
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..A&:I$"K5EG#)&0$! #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img42979713_1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M^A:B40391_[V&QG F@-\,,'^]!G9YO*6+&^,V<0#KCME-%D&#C6ZK.#+\>"
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M*1/1/53EOIN)RPUN./4*5N-(25RZ_Y@J9()1$W+W]QS[:D0,I-2K1]!0SLO
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MAR@_*GP37S1&>6L(NSM&*.E"[G J>E &?FN97+.8^Z"__S+$1HLAAH,QMO6
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M6M-9RB78"%/"B&9V+,]1(*+AY&4OW1LQO(Y;^)Y7N=EH.6=[M>-M9F54@LN
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M+ES=\A #DP&0FY /,;1@/?2"+\28DKE*"Z;<ALU4/2V/QX'9&/:LWL$!MEA
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MB2S2R".13%+))5.;4;>3Z%FF'BFCO&\AC"R2CA(0!2+I1.X$,H\EQKB4::/
M6DK)N_,*6S.:\#!$RAVQVNF%*_V:VHJJ_K!RBK^I *WG*SJ+:J>=+X=12ZYA
M,D'++7:$X06H\UKJ:A]BB$GFIX<,(^_-F3KJ\LL029II3!,'BJXBZ:B3L36\
M6.L," M @>.'SUK%C,E=>>W5UU^!#5;888DMUEC3G.31HN@N&J,T$\?T5#LW
M?3UB[T29.NVRK,1(4@9#]6P"[R0Y>R'0'?_TLX\I/_U\*2NFKH)&OZ[<D8^8
M NOLY:1QUY&0T4EX6:>=!>7A93Q+!5)F&(5[L9-3#]5,L<L0L;-PI;(VFA3$
ME1J!S+'(<J4L6=XV@> S8D+Y# A0CFW9Y9=ACEGFF6FNV6;6_T8FKAYF'QNC
MF)E0,@@SQM"[ME-423Q):#5ILBF:B?S2R2.$;BI)OK'LM*JFK+3NTVN)^G2J
MSG/&$@NLDI(11E%>A"E'[4=Y0<E;D_3QBYZC>DD(**?M>BE:H<$D^FA3NRR<
M)$TL6G6,+37+63588<U,$SBHT\2(D#6+_.;-.>_<\\]!#UWT7AT7KL6,LF3I
M3+L((QRFE?9575O"*S;\TDPRL9@F332),21Z"O2ESG;NTQ-0XZV:*OG_ *T;
MW[",NJ4=EI39A1UY(G04^WGFRJDC:/R:1\.^6&?LPFDESD[]W[$C:<4U"T<\
MHXK4V*STT?'/7__]^>_?__^#<S_@+/_C(CTC0TWP<AVIA*0[&8.=5(XF.U M
M\%*:.)^'HN&7G&0G))D8QK/$1 _YF(T8>G(7\[X6I>/M22^" DM2ZF4H?57+
M08IRBX0&M@Y>R 0ARFA'7Q96$\#93F)?>A_MT!,MF310((B3CG3L%RS-!2D3
M +@! '-3Q2NN9A( F$3GJ@@ +ZKF!@"(46:4(4;:B&&,6.2-&,_(I"Y^,3EJ
MI!D;Z>A&7@GP-\18%9;JIY,$<@EHVA'<QKRC)DU@(A/$T%:T,-22AY5D> 3Z
MR0F74@]Y-<1=]0&;/CQ9%79M12H^)-LY1EBO<]Q$00,;6%H6)(QA# 0A\R!&
M7_1B*HU-BVC_B:F6I^@6-&AYQU1^;%9%*#'%??!1-1L<71>WJ$?:0),U:&BC
M:R:1B1]!(YNJ":,88A#-T\0  ([<##'L*)LRYM%7W0R6&,W)*VNRLS;H9.:P
MUBG-/?Y($UCZ(TR^5!.)]3(H).D.2-A#P<+!1!F32$-I!G/(;PVD(_<RBGR,
ME\*GG+!/^2F+"J>"E*' T%#GP O;)!0A6+I%&'N#ACN2<<MA< B!Q(P@!=5C
M*34ET7#[&H_$")BX+)7%5:]Q)O^Z& -]3A, 2N4B -#PFC26TT==O&<^65/&
M.%)FJK0I8U1_-=5X^@J.[81J;KI*LZ\NE4GWY U%7.28+2$&:+)+_\FV$$D[
M$NT-)4\C1DXT:2:;?@0:::BI0 2$RG+U)UTK=*SRF+<5_YP2*8D27B^RHP]'
MM0,9L!Q&+">U, U!I3Z K<[O@M(ZGJZ/J.[#8-5,I0SZ%5 -H1(96U-C33$@
MRZUNU&TU :!-U]AS/#RJHE-14U;6D'.LE[$G;<A)3^)84[BK(>X[J=HKZN;F
MN32++FZ5U-O8=(6\-:D))5XDG4D,,DTJ<:9Y//+ 4P&3(_6)ED! @08%VA6_
M/JA)[/;1#EN XUQ^VF@FDV>>=W&4E(&RBCX:]I6DC&4^)4$I+%^I%F$,I"_M
M**$R#KK0]0F$K]>Y8.V"@L@'/M(Z65)<<_\'(EX])I6WX-7,<5DS1\ZE<S5L
MW"I!TBH;/%;UK)U3+J]T7$<9^VK(-C[2DE.CR8<\Y"#->0@E/I:E0*;O8)72
MCB&E=M^:3B8:F8#H,GY G0N.9S'*\$$F5L(8$8*C7'D*U+L>VQ!V/264I-W*
M2(?2#E]8TD..4NE*9=D57^0ME]41VJ=X"E#"+>-+.CF?[+03*M4]D7X_7N:P
MCAHD:MH/ROT;M6J2?#,>JX:<GD;LJE^#51ZE>G/P-*MT9]/=F<G:R40J]684
MLI"#-&3*Q:#R)!2'3%/YS3J%&<GK;,+7G_I-?3/1A!LVX@;A'L8[W7( R[A=
M)[&8HX3J<NQ5EE?_CW1S;:-/2139 BT6?44C) Y:D$KOS0L.#:-A[J@/!\%,
M3 "W-WW5.A5>QG/0-]'U(Y&)3F3& &.!_+HWH;X--\D)  .(X8SDO%09K0AC
M8H \!@VU8N/$F/+@#B03;!1C#'!-$(]_<R C3_D-QHI.--3#F@!8 5@SD7&.
M7P8-&0? T 7R72"GDYLIA[FK$4MR8M"8($%/.=(%4L5)0,/E/Q?9#7@N1N'R
MF!@9CT%U4^/QLHOQ!I/I.MK1N=N:DWSL*D\G,5S>5'J6<:S*R'LF@ASUF\/8
MZE:LQUHUXW%ET)T@Z)R$,C(>HZ)?/496M?M FO[RQU?&24W=1^&Q+I#)_UL1
MZGYW.MR]F'DOQE'UNSWR90S?\^H6_NA;'3U4$0)K-H)U'[='PV2JR/NL&SWT
M:/Q[X)71\Z8*?YE*#6/M:4+R.";?Z<Q7O<KS:/J7HWWX;#]\D363=[DKG99V
M[*)?_L[5PF_\C%W49M>9O_:F<E_[\Z>,_,\N+(H#><I5]K<RC*W*J$P9F(59
MG&4[$D.3)BAA*H5:4JMJ3D(9B& 9,L$'DD9]CN@-_*LDX,NB8JB4I*+=H&*3
M6LBQ&,QXO&*D!@4IVH$CZ $MU (9%$4>9$DB;BF>4JQ$>"HH^,IPF VV$FD[
M<JIP4,+%I,.V*J.9?L3BI.KF7 ZY]N&KQ"COQO\JC,+IY8Y.,VX@XVX G(#O
MY;;PY8KK,M:IJ6Y@BZPP#%<N88[. )HJXR:!C:[0\VB)"T%N#7&LZK+0)(2.
MY$PC#=EN#P7"Y;HPY23OZ-A.Z"HC#&, YB9N1@#1C%9#"JTHY>Q)#>,IC:(I
M$FM"#;O0J=+0[&1.$MEP"MTPX_30##,.[9Z0Y*Z)#(-K"E,N^Z#*%!T)\MCN
M#H4K$VY@!<RP"V.B#U^.\RKC"N?020@1%<,/##,N$Q'1BKB0(.J!"\FI&>V'
M$1UQ'P@Q[V($%ZW(Y;Y([$2&%+D0'$7O%;?1$#=CJMJPJ>Z.&<5(^,QP'H_N
MF]0QZ^ 1_/9!Z,P.YTHU,9P4<2!:$0MC;A_<L!VOJ(H,@#*J2.ZLJ>?4D!;9
M[@D)@KH2D>U8#@R/;*H <@HSDAZA+DG_]L\D(D(AC&T ET(K5)(>T&M5HF.N
M$FK$B$E,"&('PVP[#.,-*A#<B/"^HL$-?$"",@0LY.UX/,F3L&)/,FD_/FHJ
MY"5*O@(IB )KOH=MKD<M4LHGCD)#.L5]PJ.0+DAV2L14E(:#OH1,2&0[]D8-
M5F55,&?B/ ?RJFNJJLOEY"X*3R[&KHDB2>W^Q+$4[Q(6!9$F?"Y&PF@\[(D4
ME4_NZ'(@RB@&VL3ES.OUR$FX$"_I]'$<\X@0!X+JSC&:K JYPJBZ4H[[TJG5
M$D8,)&X9!5'EW$[C:HX.]Y$4_2Z>>*PQ 5,@LPLO[]+RRF\%#/,=:3/CF(\@
M['(@>FXR$O.,_QXS,H],ZRCC,F>3]WAL%O4RC]()\C9##+".C1;RU93+GBI/
MXPJ#'3^!U-90(#RS]_)R'Y*J37"'/0,S#^70,(6KBWAO/:U)G*)3$'US^(*3
M%)?I+Q,3N<CI+H,N0+_P.S^O.G=3K,!S,KRQ./$10>6.,M<P-)$S._.O%*LK
M- MC-#%30E53+YTQNU"3)DH46/8/)4^R/J0$OB@M,,R#9Q*'.GII8U %+_:*
MHE["=<32)-R  MX@)G3*>[S#S8HT,8!'+.+#'?(D;)Z"L3R*SU((4,2-;-H!
M'<:F)*K'E;8'4EJJP_XK7.;KO^Y"<)8(VA(C+9TFX 0+)29A66ZT<?^(19E8
MH\EF,S!U;3WQDC_'L3\#LT%+AYSXT\?ZTYRFJDT&5/B:;*KBJ#(%0M;2*HV@
M\%+:DS+\M(RB"=;2R9HNE8WN4HRD*YU>;[D&TZH( AJRLSU/52\)HHP&-8P<
MDS;%: QI=5(%5%?-25;'D?M&<5!]4;@@=>D 8 QGL[KF:>DN%9TZM?/2DSVW
M")TN=358=48";S:Q,UHA%.7HR5-GY%4)$QG;2%S=,SW!53.F"E=A;11CY"\Q
M$PJUR#282SVC-47QDR'7T%<Y#UCM=5 '$?R"#%3'T=66]1Q#=0_%-5_UL.Y"
M<E=^S2 @@B&:)H0(*["B =D*:#K6YUJZ0TW_T>-UF/0CO.5$&,@ZWH "$.B#
M8*NXE+0@PD49B')XEI)/3DB%^ 2RL(+2\*0>6/!>#B0<AH%Z>"%,-4S?;HFF
MX@LE9-1VP(27!BO3VF<[TE)&3Z3$]@%+H,,B5G,DB27X:C6.TFGW-%4V9219
M7M76,H.-FHL9M] <,94_U18?M^C4.I,.T8E!&Q(?FTH,ME -EY'YJ(XC_Y8+
M0,Z<&#8C&;1=Q[:I'C8SM(H@['9 %54VZ_-L.6^KU);O\+%93545WS8>'S&.
M]!06X^BWXK9LJ]4S$Y=08\!O.S)<H96K9',*'Q?V9L19RQ:LLG5 76W5"/=U
MY_ 6VQ4S25,2>_=N_^DH>,'I<#,C#V/S?CCW$?M3^)(W; .6G::WC%;@$\_0
M%YWJ5$O76(NSBE8@(WLS,Z<W,U(-;!O/CBZ7,MBH>YNW%^DP?H>EU 3P(8IA
M4LAK2H1&H(2&'E3%Q7"4;\A$@D+B6H(T87S@64IE)7P@*/=!$[*I50X'#8@!
M%":@2%>+; BD3O1C*4M0LEB(>9;"/SPIA@S$* :D)(8A&!1%!@OF)T8+@:"V
MVBZ0,9K6+#-K@BH-)X>P8FS4,=[RTWB#"8-DZOYV6 <B16%55^FIBP"6&*VX
M8!-O5P?4[BR1#>5V5T>-UOY5+R>C7L^5BX<1<E_Q7.4N,=%8>6E7=C'WB?]+
MLS6@6#ZQ&%,#,^-6P#1G%W?+F!2I.([U$HVSZU1YC3+N^%RW*(T&58P9&8[O
MUI"1RT']\B[9\0;\55-AU^7*[U(/5M=,M"^-U9!?#5 S$A3Q-E,IXV#9\8W9
M=S#'E2'1P'!CP!??-5EX390_KY:W$)<[]R-KU9#!"I'7.!6A;Y3W 9CME9[N
MF(FWD/S$.,B,#NWND(MYKYKS-S8B B%F]"4L5MW0A-) 8A(*T"*220@!3*)N
MTHBP0Q-\@&7"8R/<C'<=:AA$Q"/$  TF00/A0%<V I4\;%!"<%WL0\'4!3^<
M,BK\PUWTP1W,P4"&@4OG32"&X2KO;1?&=%,TC9C_*"V29/)D%Y!Z)B9-#D9$
M?-(]48=CB^HR0@U/+P.F?^3[N'@S=Y-ZI;AL43F*R1AW5W-]1]<T+'4<QXKJ
M6M=>HXELTXA!)_<T$GG4KC<CZ4G7&#=9\.X>4X-M)==L*=>+&9(;>=IW?3I@
M$9>KJ5J+B;IZM_.F(QE3+_6HV[I!V:FI S6L"9,_"P\R;\R43UE?EQ=<?]>J
MBY<-JS5SM7$-AWJOP8J73\-/=4T9?)&+;3-92C?((!N-)QL:X75\TSI6,Y.K
M)B$@V7B6I5I^=_.:4RX_USCPKEJY$CDS6ANM(?8UB,TA2"6PR/DT'$&H6%IP
M5"<\-&:^4B):T. -=) F_XH@GNOKL  ##=) $B:89="$)8#6*) BA8O'A/4"
ME+X&0++;9U_(0.1C(/8B+=P">_1M?#KD+A(J@EUB=9[6O;FMO4*:F XN E5"
MJ""##+HV.&0Z,R+GOU%##N,IU2+WBLGO,VO,L//8=#M;,^*NP?%86HE.$*F5
M/?,(=5EMC?<3/$_C8%/9KG&:,J#A0%?CCB<W/%DY3$Q\Q,4ZCP^\PXU5F5$N
M4H\9>XVSC32QE5=<PT%\PDG9Q5/W,G SC@&/IQVY;/]Z9.86=PGYG 8;+\,1
M6P<[R:(Z,V2\_&;$#;'NP =4D5]1U[@\1@Z<BH5NK%Z;P>FX(%-10F'SQW]\
M-O]?,P8*/#VW2P^KM<3W4%)30\^KN*VD:B'\XIL%J@=-HR4W%J).HKA*;%I^
MJB<!["3L  ?(C": \EEJLJ118AB600.+-()$"(2_PDXDJ[$^RMRD%%UHPH7F
M1$[F(Q,F@=*$04)P2)808E,^!#/ C%O #$V$!EOF^X@0JB4VZ%0>3G&.V&MY
MI8S0SGWQLFTAD:OE<,'I>%9A<QF;2U2%FI6;?-08F\\?D1B8>5QO]UP3MI*C
M]3*2:@SY]<N='(VXVC2 .L6S*[&)W%6=I,5#G%=+45]G1-LWH]TQLR#U_1&)
MU:QA#=Q;MUB#W-T_63/@FC O]1W?&OR:G.'GN%]Y:S7_,346 [/)MYHZTWW;
MDR57'9[?A5PZ@VS5IM?C-D,AY5V6$SSFXZDRQ_U<F6][HS5QS9?=9=FK"74U
M[)VL7&-BHV35FT8S@G@?#'!5&(>@J(4P%MBU^ IP,D%EL\/-'K@K1<1D!^(-
M>L"#H60E(,S#\(47SD$K0K!K5J@I2@ND# )=P#M1Q (I: ('PF 2=F$>7"D2
M-F53<!@Q1%JP&CT]LN5-2.61TB/@^,N@.,TQ/$W9=^4RPRB/%KE5TQ/D_CS<
M4[&Z[&F3Y=S?X>XN=5?-X_H4,6_:*](=^;,:@<R=[CWS/?(<=Q76-]1Q^3:7
MYQCRX@G@DS7@=U7#@UJ/$X;._W5S5)U$1,&SNJ#8%^]2^3YR]#]20N$0^ 71
MDU\-8%$_3%3?7B_5]6D)]BWY?>4N#LE\Y#N>1%N5/^_\L)$K,3D>UI*SZFRZ
M[5B.G;"0%9NJN&R?/0$BT[Z!:   4#9P8*9)"1L.7 % 3,*"!A,:%#APDD&$
M RLVO & 84)B'O==3*CQX, 8 # Z'*C,H,2$RL1 4[@1)LN0+P?>$+DOIDJ<
M+&,X+.C2YU"6:!)F,@@T90R.3U4JFYI03,2!]0PVI6DS: QB6;<&S=DSK=JU
M;-MV=-N0WC)E<Y5%JP>M7C2Y+Y?I6[:OWCYZ^_QJ4C.&3)HQ8RCMN_MXX-UH
MDBL_%O\,.'+DR9(S^0 5F<AGROHHZ]T<&#)EST4$:\[L[EP[=\/<M3O7RQT]
M:/3H*>O=NU[PX?2$%S\.G#"]7K+1S<9-.6B8Z<*&L1-6>%@[91RC1R]L.?-K
MR8++@S]-&CSYR'A3NS>]F0QCQ8PYO@0 -[_^_?Q[D@2PP@T0L0245F0U5-(^
M%,4 4D0 &*665@ (B)&$ >XT4UH@'=@011,VB!],#SID$(?[/ 5A8 8]"**)
M9T'ED% L[I34408Q*-.$#>T4 XXZXB3A#3M]U5&()(8HHY!HF<136@8VI%&*
M16(4TPTB/MCCD@GN8Z&29@WTY$"?&!1@CD8JN.(-(.YHD)?_6A'YDE8-QF!
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M7.F;0LV%BHC"2,,<14'<P*E3D\$AWQ3UEQ"JL*#\TL0=W]6CZN7M8S*)"7_
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M\LC%E]"Z\)2ZE0Y/LB%74ZT8ZS+J93!Q#$^O8X!U#Y"F7*G9KD8,Q94N]'X
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MMFS+UU:D,KI*<<*K8[C+)I;_K=G*SP@WD1,[,8:0$"A23^5@!D%"\(GF;]O
MS$[^K3UVKH2^QEZ(3CY&[^9TI0LAL5+ZSMA(0P>OK6,*B[&4SW4JKBV^QLD\
M1_^DITSR;Q6%K_]$(GDR*\96A>O [ V;<4 T 8QB)+U"4+WDCYZX#B14ZMVP
M!Q2&8?M*XWK"KSV^3V]RI0:_ A0]D1[KT1Y[91Y/PN^^Y#1PS&N<T%G"$1PM
M9*M.\8PL:B=2SK:4T#2\D!A H>]P$1>=)!W9#&2(@V_:SITH8?\(0WGLIGT
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M8QS3"*M2]IJ#5 1ERBB&"M%UQ<W$"H5<)2$T_L+(3X8FE*)TFFE00XQ&G(:
M/$FE;H!F75@Z]Y=+%>D^_/11<^YRG/X[4./P!Q]E) A^!653A^K'3/'IKT,M
M91-V?4.C_'KS(P1ZTC\+!1QMZFFAW^3)V@ D''FR=T_SS6CH! 5,Y_IF38MS
M'7I[@UX=F;2I.(V/]1+J&00SRIPV+5ZH*EP<\PAU,["+ 0&GJ5[QTE> &Q9Q
M@C<S)Y_R=$__-TVHBN$GTYQNII;)>9*DVFG@04EI:US+WG@GRAEK:GA_;B+Q
M W>D7B"#Y[O0;=C*7O*:MEQF7(<9%\PTJ<=;C7!6M:),"Q73PEW=\"%I_15<
M&1(MMB+D(,=B:PQ]^"R*"%I;AL0(=DU5DL>P:[;H(@L5*08;4MFD71]I+$BZ
MJ Q]T,,JGWXC.Y("%:(D9=3!$$8<DT*O-#8E7VE$QCP6=I:VC.LE.U$L2URB
M6BSN93-410E(+&)(;N4E,]0AQA"5358UITMD>J3B86BU9L3T)63??4V8-T.,
M2?3L-K1!32.&5]W6K&82K-FN('&VSOO]F)S*HS+OM(:\N/ESPS(=__ #UQ2W
M?D<4WD#N:)=)[,Q05GB="?:2P%_ZI-[U.T%K<D]4M9<D\G:IQML63-_<+3TL
M$<@ 2I5R.K765.,X.#LK^I! E^K4T,F8QQGG2?0LV*;*R3S'G8%&23&V<[S5
M.Z+N50[5YJ<]!E\PP&-ZVLYM?F+MP>T&7/!:>QK.\#[)>Z:+MCB0YN2VJ&\4
M=TLU^<6?\W*KVY2<$&+ZGA:]\FK25+X2SEG,0_640*9P&9M$KJV.>\)IDY >
MB=&DKE#6%V4ONUH5<:0FW/HK9^WP5\5"O$)VV,,A4LL@E1>B,BA1EXMT; S8
MWH>N&TV6F5S:98(U%[0A=I(M4L9AC9UU%__9$91@Z&.-74SM:8TB%'J1EK3V
M L8\^L5JVZ>ZU)LQU[.;N-B;K06$6-6+QFBR$=QR1"$3_XAOET76>MP*D)T!
MJ[-E!E9%>C+;4J4HT$Z#BU.2TA'-[38NA(:TW.3ENT0G'WR2(Z7X3EE*\"0@
MR;0G 30U:&=V(U$DUR,&4.<[ 5=/ZQ-*!<<=^<--JS,A'+=C&<8F1;)SLR-R
M.&8\.,=Q6B9.C.-?4_8TM;0D*54RD]!O"Z9_,GA3+]@U,8AC7(9=?;-12C=W
M'R8VD\" J2--S&-BZ<5R]R0^S[$9;V)/H+-."=4^*]>#N(1S#P@[1;(BBM-E
M*?A)1?943?5?4_8B''&B%RBG80X6=*HS*,SS0 2D=FP"(9G @%%'3/ZW)R<%
M9O_?Y1*5<1,II#(R42LQ\WVPHD>M @V+-&>$IRO%8&=YEF<\]%8+H5;6@D-S
M10R?4!!Y=G@1<5=UY1<6P1&BJ :!02Y+-&DTT5Q5I#$91%AZ,0R[)@RB=WM$
M07OQHFK!\&K! !7"$ ^XJ [P4GOR$$9M-%KR$A3#-P_$81,1LVN6Y$3L<FL.
M<VD85!9Z00]TD1%VT3$V0QV$H7ADE1B#V&@>-%@@<6LDM%5D%4G9YX4YTVVC
MU!J.X&U.<PNIR#35U4JPQ':AHB!1UV\BY6/:$V_G]6*V%'5>ER:>\G9:=V1%
M]1P(=70917"30V+=02)-MG"#$E$AEI%?&".U4V4;)I#_&_F -->  *DZ)!EB
ME($&F ."6*@<*R(D_L$X,=E@;3<F&9)0<PA3\1$J)H9-\@%1A6*0/"$AV#5+
M%C8G%::4)AE3H'*1XL,@8M=T$N5@+9>1TH.5G=%S-;49:@>'^!,#7I<W!O U
MG?%>H_-O.KF64QD9#ZD< /5V(H8G>A@:R44KXV)"C"&(,W,8:X:.A@AX=5:8
MNE)X8P5#@J9##T$0.*0LFM!G"?%#<C5HRY97>=40U )<O4(7GU=]<M%!5:42
MGN%Z:H$N+A$7PG89NR8Q@^59M-<.R3",\G!'"@-&M >,N.A&QDA::C047(%:
M!4-J00$;9-8NBV55%&,Q6L1K_XX5;3-AB@ FBH7$E=JW;&857";!9JSU;! S
M,R;$EX(7>)R)?CR6,_507?DX--[V2I'A".8V-$,S2I-0#-GV/QWX-N^V<ON7
M8](1&C)2)-"$A/FW&8'"92YUE ,G@1492FM38"3F-E;"A;6$=/JE)Q(B3R8F
MEF!(-26X</EI41/Z9'''5&-C'01I(&)0*0M9=EV(-TLU0/85(7GXDP>&7AF:
MH(B"/]8Y@RO7AAC*=80BHT]9'4]2E?$S96?W@"S6E6VR@>;EA4BHI)MA'I 3
MAF62GR&Y&1*J809YAP6J8WZ#H/S93*#Q/^UXGJ&1,C CB&[FEV 5$S/S5=:V
MB.N8&?_C25:6N2Q[E5<[](V.IRR_\F>%]HV%L4,283*"!D.Z,@F%Y#' (472
M5Q8RP2Z(11([T1870ZG>B1:WAE7#]Q&2=7SZ8%JAU1+L8%FC95J\5WOR @SS
M@@P%$Q3 $%I.48O!$!2/HBJ#E3'1B"JBR6BN-T539!$=XU=D$'J-5!AHM8[1
M<%S$RACG&'V#B&8HE)Z9T8@MI(K9YH.!H9ZI$6ZKH4J^D&ZW<:ZVP:TX8V4*
M.CZ*0F"\@R5(>F3"$4#:0S7Z-B9&F5 JUW( MJ!F>E\:-S[BU:$[IE3U]"0&
MJ"<DJ:_70V)-^J$_>H'$D1TB.K$P)Y)-,D[)P8\2M;$IURC_'E9?JT-UH3)S
M91-16WA!0\8;39J R1$9/<H[%UN7%Q2%[02'2(FP5MFE3EI/$=6PO427#<E.
M>E&TH3&O8)E01@AP7[E2_AHZ;K=H!0)5[E@R?2%",R,S@5DK)R1)BKB.A)F=
M+V0SRK:8B4<0C^=#CPEHOK5G$L&L@68RQ!(MSD)$A[D0==%YR2H7A@5;>K%:
M552*4W0NYFA0@;$4F39\24$/T# /]!)'\/)JJ/9%HS59\P(,LB@/^!)'\L(.
MFJM&LX8Q#M-K?BMF5M48J>)!G.HRT8 1=^%7H<&8>+M(HA=MD7$6S842G#09
M);15?#&>UK9NZ.>M@8$T\5@;E( T_[V@#$DS";:!;J?DL?TXI> %-CGF?S<6
MI9T1IO\Z/G4#'S[+*%<:7A<DA6LWHQPX'?4P=4,EOL2T-D-W-S%U3>(UAS4B
M)A_+&1D(7J#2A.$DL7%HH*+C'!SE-L1!3]_+&;EC2VMR)9W1P$IU*/YWAS8J
M*?WIH73)P.B%IDI2<-.Q9#CZD9MB.=U1#S>0'OK;3),@'O_3(=VQ-B0ED?8[
M/O@)=E13(0PR)_ET=>ZEHS%E4_Q73]9;7CQ1H&K8(1SJ&4A:'1WR/UA"I 2<
M=ESH2R)EM3@8L##*EMI&'9Z4=VG&9F%,;8IQIS5#5HWH%XT($9:9F9D'F3L$
M5X?Z9\E"5__@&"P^M)EUI7DNM"L=DVC9(DCK)KB?RFC,."N/P;K'25SE0HW)
MX!)?L0_)H Y#\7M"07NAQ7N].3#TH+GRH@^RZ;FIYD;R4GR7+%FKZ*G >KNX
MVYR#"Q>$ZR:&4WT>TRV?8VB,JHB%[)V  1.LLG==Y9?2^D(H8YZ?\5U(TY[$
M &Z^4 S(>PND-+WFB;0\2Y+]FH!T,R%GZ*0B9T]+\CT@.*'9;!V-DE 6.%1J
M0R3V$0/M 3?*H2H;13AK*"'N3#HO%4X"2#L%XC;?$WX  '(#RSD^::,L4J+K
M-64^XD ?@3F2(W+_ S=K(\$]3(8M&%-O0S@MFZ_7[%3T+,_PX2/_*Q#.5_E
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M-P39OG42AJUAG=#=&A9:^\,)S34 W3'AW@71EK@!LQV3(#YAODUA*8%AS 6
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M69?7#P- &AD]KTST7&6R@O4BQ@##2C$PM<]<Y5_/E4ASW:6^UE"A9?T-/0*
MAJ?!SRCX T ,1$0]ZRD%>M9#T?P:*)*C405J*WG: \_W/@KNPX(9 9'ZY'2]
M#T*#>FAHR?TR2 S]981_ %Q) 5/8M)4<31D9+%I&@K:C#FGO>EE)X  +> .3
M'$N"V[.AL02(%[$I<8E,;*(3_Z>5I+/EQ4"5*YC*MF0N+\&-.Z2!2;M \C#>
M<:<>4/)6Y>2DH-7HHQB"&]Q.*.$2 QT'.UW$79\L=Q!ZY 5M;G,3EJZ#FG\A
MR#LG*<\ZE*&/BDCJ/OE)2#(FTLC7 8,=\GBD>8:!L6 L0@8(D $G/]E) 1R
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M);.AD#&1$FDT+P^9*EN$NVR#(&3DAM^Q'_VI9>R@AX<H.Y5%$0DA9L3K'<F
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M+Z_CAD,G.'2;GH=R0!G0EXY2%%2]+C&"X<KKM%3 D-D%&GLI%5=@%\$7P4A
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M4GRQG5X4!59^5#=I!3L>%5"$@A'\XR%% QRTRB9P8HQ8(J^59AFE 2AT)D8
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M&\]!&<11(JS!X\%-[213Q#Z$K3ZP0R8([B=K22?_ZT.>ANOOP@31RL0PS$-
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M04^X,! #)G"2T^[#,'S'4*DZ*MN!>H3")MS!)L#K4$R"# B # "]#"   K!
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MPU:#A5(#!#%]R_8I Q!C7R8 Q/;5@R8&@*:&:  HBU;_#X"8@A#W1:.W3P6
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M!$D9MK&-/%D"A_#XL8_TM8P^].&+1O3"%X[H12+GE1K4T,/=E.A%(\Z=)]E
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M'5:/FPILV]&?;7JMV)JM.U>=83%T.9*@4XJ(S*:(S8%^5C)7]88,B^08K+%
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M#F( F3*L3%AZ,.(S/DY:R!8B#BP$&4A3+5H2,9J$E(O,#9+\ 7/2$#B8P^A
M"@M0EN[9D)M[-5S;/U$\CYR;Q%5$Q)V$F:PCC_2+CE/#1$NL1."4#OCSCD-D
MQ*E+SNP0SNC@S58$@..D+9XZ#.IKC'O1*R=L)"<)QX*RGK0PQGWPA>1 +E[P
M%@C<-\%+)+Q1E% 8*\ ;BG"CB-/+&7+)#0R9&G))AOC9!Q2T$A3QCP$*MM3C
MF<%CB]I(AJ;YHG,4K[WA2N@8/5J<%V(8"(;+DC 9$@M]PE_;0E8BT>*0)?_E
M>"$S3)T6&I3+/)V!;$@R7"$733E:BBGF^ 01,XZ40<U]6$;OT9!C^2KM$%*D
M -(P>CI;TTV%.,1&L35&[#[H6+^3?,X]]#[O,P#?#+63-(#GW+XK!3^AF%+O
M:S5B.,FBDSJB(R8T $3=?$2A0(,5\+X8F(184P9; P #,#^RF 1 -  WM8XF
M_<0O_;[G) MBP%-4DU*;+(A/HS5;RPT\C0$O/=,P%8I,2%0Q&(M$O=)!K=3G
MS(0V_=(]Q8HK-57HN-,KG=3K@(9)Z+[K[,U]6+]0]3XQL-/UR[GRD[E,.%--
M78A/&PXN-53NF]-")-2B,]24U#EHV$,]-<0V%0K_5EP(8KW.\(-404W)1%W5
M2P5$4ZTZ:=T'<-T'7NU4Z%B!^]L'-OV^YNLY,)4Z5\Q55!.*-RV(F8P__HO7
M*\W20+S4Z"P(HC-5?C7$3$W6_C,Z*F52/[757[TU0MU65_6_A=B^5]73>1%8
M)DU.1"W7Z<"M>YPRP8I/<RF]_?&0T*,'>1 SY%D(>H"NY+JV@.,W$>RK@?G
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M$K-VR(>Q)09O(89&&(9I>4_"6I=#W:ZQ=*@A<=K(H"=[&H9(HPK1F#LF698
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M]9W$7+V!AMC#A#[>W$BZA?9G?N9?HK126GNU\#/*W,R;CM[GC2YG_B7I?P:
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MQ\]$0Y3"R"EP:1S8P7+,@VMQ#GA$@WZ<%M^V%FB1UMV&<=]:9YE"@TYJ&V_
M1T]6"#+H5E#@9E!J( B^C5 6K;S5A11A#*(RKD*RB.*L8%THR&'IV[ZMEPMG
M)LI"J'7<I0_05R)'LB1/,B57LB7OZEII0G(9JG%L[55E$8.$"/)NT5%LL486
MIQ,C!\:&+RIGZ7!JI/:)R*JA:TG&R"G@QBI+_R2WNE\]&&>R,2"H=LTDJ=HA
M5:=.>O%J)7/7F*D8ZR1\F)9 (L-GE4?]_I&"*%:R.:SE)L<-#R5O>:><'*S2
M&&K?>"9C79'$3A?%2BP8Z=+% LDE+^8BKXX3D@GLZ,!UM*Q;Q&X\][,__S-
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MA ,!P49#+$SL,&SF0M %K<FE\ D\(M"2;DX#$2A2JLD ;BQ.<N-4THD"&0@
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M)9>I0%MT\> 6)T-##?:B9)IT2?I#2:!-C )$9<NH)#@G,R:-9;]"?Q^"3"W
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MK\QRRRZ_#'/,,L],&<J)/6G66(Z81AU##'YEK*-5;<M05@U%>J"C79VI)IM
M:-+2F_O00TF<OOC22'K*G+>5??8YT@B^N#0BDWG0L",,G>O0$PR>:>,$,96#
MD?^LG-Q40B/Q@L@AI(Q99:51%B4BFXHAAWIELE<RALO%(<V.$V1SBRH_3GGE
MEE^.>>::MQCY8<I :U8.Q#!X$-XM/3SF5%N)&1A4$2=\57//\<U=F^DZ&/8D
MO3AR2TXQJ9<,3HWT@O4ME*1-YS[GE<>V/("")\]U"9H^4(%HBDGI10<:F[J$
MT8ZE1L<A<TSX^.9G4I?BK6[><N?LOP]__/+/3W_]E;EOV&^= D<&B=R3N3?
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..G5(,U@JP 2NP-1(0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img42979713_2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_2.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M/WN9V]JL)?<*[66;QC+1]V/IEG?J:*!!^LWN9'.=@P;+7N8Y:+;T9I^)=DU
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M(#6)QK.(G!B)O'B)C-B+O^B+N^A#/19!0ZA,; AG= -+RI &D+$VFD"!CG$
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MQ'61(EMP4G5@6:#A^94>-B<JQ4JCB3:()$ /&  /="N@P!B3@#0*& 9*4YD
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M85>2KOJIN[B?W0E99I>K):F2E_JKFBJ5OAJLN5JLO1H@HO=+_Q-3:19N1*.
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MJ/W1ZK(.*N\K Q*S#\8N$'(R[*>5[+XU)RP0EP/!:H<S=:5.EF1MOP&(,/O
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M !#9.L[1^%5X?*[%$(/G_W ;,3BE]J0V^E.^F$%$RV LV)@+1=.\JIF$XP"
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M_^3&[\SH2^E15(U@@HV97K1[1,7B^F/=3>20$1JJ$378/N*S6?B/N4>!G.8
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MNMM+=5(FTTJ-%AO4#5_.=-5?:%QYTE  H$'3)$"I!94R8C**5& WB $2F0#
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M.#2!8Y]ZW+,*JU*[*J:>:.J7N.D-D(!4\<NQ_+*"H;0%04.Y 0#:)K<#@0T
MUMI'LP"0H@2EI8'[&<FV[@4]B-R'&"?"T=X*$I[/1$X@D#L7O6:TPONL4""(
M><P8S 5#'AFD/ @I3T)Z2!!'I*:'YZK($ OR0R-&I(AJ4"(90#C$3#VQ/$%"
MXD"*",4C,N2)>-N)0_^ZR$,B7B2(.QEC"K>8Q(MXL8EA3.(8@9A&+"Y.CE],
M"!O!N$8Q^I",<G0B'9G(13TR,8]WW.,<XQA(/J)1D0)QHQ +N41'PM&1?LPB
M&P5I2$+R49.3Y&0E&_E'1@HQDTN$Y">U^$94EO&*HC2E&=6HR5,B4I*PI.47
MU:A*4.[2((A!X4H*&,RPS*,<ZO@>]W1FO62&KWP\.Y\ZY $TH;6OF,5DGU,T
M$0=-1*,>Q?!%4+*"%5WYHE39))8PT9G.HOPE;><<6UV"DI8;%$M ;9G0/LQV
M3@G",S_\"LI#"+(8!S6N( .EDD'UN<+[K8@,#GK1_203-Q3B"S'UL&%NLGC_
M$XUN5*,K8FCQ.!I2D8Z4I"4UZ4E1FE*5KI2E+77I2V$:4YFB%%LG.XZ%_@8;
M=>Z4*4;;A<_FP8YYM(,=6!%G4>C!CJ(.=1[R,*I3Y7'-H.GLFOM@1S/74=6F
M:&(3FEB&/GSQCEL9E7]0^Y\FO,I3M08S;4))U@8!D :BR%,H8TN#/=&6%@W.
M)VP4XM:.;.2D@VSB0T4RET'P=1"=_!-<.:KAAP02HPI!+B@D5$B0,!M0#$D.
M39@=R&)^Y%G.AE:SHQ5,34F#+=!2*5.K+5-KJR1:U\HVMJ6=K6UK*QG3OO:S
MN85M9W$+7-W>=KB^[:UP?TO:XB+WN,I-+FN;"]W=\-*6N=,-KG.CRUOK+A>[
MVWVN=HG[7>IV-[S9':]TR^M=\UX7O<95[U__RMD5O2:QO%WK?8F"-'6PXRGM
MT-FLE#)5] F%'>0C1]*PB:Y]A()^W'2//MP1SOO51ZR;@$-GTHI?#?M*+F(0
MRK*B-;>AO)6O$L(KL]*BS['=4S_9<<@8OF(8U.)P'R)ZWB\14Z*&Q*T>FG4<
M#0EC8\+UI" Z%(B#XF9"D[ADICO\J&*;'&4I3YG*5;;RE;&<92U7N2/96IB#
M;O3D#>/7:/MUBCYVIM6DZ&-[Y&#?5766U:=H0L%<W6:M[J._>?!O5SFZ<&$T
MP?^K,0\Z/VUAT%]*;,&@/#""[Z2@!3&HS[;(E3\??4A]>>0A&2%6/"W:3/.@
M))1ZP(O(G"E,D%3X0L"E4"@K&5+*3AOKU,KZ)0P9$F=/%%S4UIK6N_9UKX$]
M:V'S>MB_+G:PB9UL8RL;V<MV=K.A?6QI,WO:SZYVM*F=;6MK&]O;]G:W%Y81
M+QOLHMM)"*'5&HRC\9<H^J '/=S][J (F!WNMO>[[5T4\<D'SE2%2C'2:N$[
MNV<?4OO9.[Q)CVAT-<B4B!NZ(9Z>M!T: !Z6((OW\;:@M)."$=2X4+SF%D]-
M2; _SE9"(H.FA(IP8NH2=0DEX\*@Z*3<YX;L9:$+WY+_[YQ%/-?YCE#J<Z'W
MG.@_-_K0CUYTI"]=Z4U/^M.9#G6G1YWJ4[>ZU+%>]:Q?7>M=Y_K7MQYVKV]=
MOF"?[20ABO.81SR=ZR@FNX<BOC:[V50\:_/<R;$].0-M'=X(ZL[* 8VHT/DK
MH.BJ@\4:'W?PV2M^CALE&L]VR9.%;419D. 92)2T>5A! %!@QIU%8KAVL,7'
M*>-'BT124*,,RII3>TU<#%!P7WO6SJOU8KY->V[K/O>[]WWO@3_[WPL_^+PG
M_O&-G_SA*[_XRW?^KJ4S&PYMA+X;LG5#)B_,,L.=P#SSMU6]'WZ> 3AF.MN>
M_)Q""07#@?W+J)4O1G65HF[%_Q>VB@,</$0)-0@P^_V'2EOX*6W68FP8)"@6
MQ$"(!1HHCIX6L,4VBJ%*CLEPPK. [F(DL'0D9R.*: ,W"9=<B0/G:)>"J(@:
MH4*JZ ,EPQ&F*)<\$ 1;D 5'$ 87"9=>4 1G$ 11$)1RL 9I, 9M, 1[\ 9S
M:0=], B!$ ==L B14 :/< B34 AU\ F;, J9D BAD >7\ >M< JQT FK4 JW
M, S!< R_,):,T):D\"+RCTPXQ/\(2)FX;][ZSOSH[CW$+^]V9GO@KGK0I]_J
M\"D$PD/40 > 8!GHP1%PX5;,81%_QA<0T4. 0 ="887XSPTM,2DX;H&2Q= ,
MQ"[PXO\&)*U Q$#PX.K0/,A) DK<3(-#<.]?*B4F,M"CH&SZ(D8%>RL68ZOG
M?*R\+@2[-@=@<$\P.F>Y4)$8VXM;@JL8?TL9CXL9RPZ\=-$8H1$9I9&ZG''G
MDO$8KS$:EU$;O7$:MY$:NQ$<O]$:RS$;R3$=S5$=T7$=W;$=X;$:XW$<*5#H
M?"RTCBM@D.02I2=GS,PHW&V:VJU4X&U41$5\P"<HE(G?Z%#-E((2=. ^C  (
M@$ 9Z@$7>((>S($=-E(\< $7(!$($./(^+$D33(P< ,?H40V7(SH,J)NI"/U
MX LW+I#63 ;6<-+'-.+)2*8G3\8G<Q+V0B8H]>4F7>(HA=+_*).2]7ZR*8F2
M8882*8N2*9_28IQ2*J'R)J^#)JGRH[+H)%]F9^)P*-CLOYR"';8G(07LS;9G
M>QP2*4A2#2C2$!WAFS22$??!$6_A/BAR),E T, R,,&2HS8")ETO86QOW)Y,
M%75.)Q-& KNL8Z"/N$K#]L)M8")39*#/)CESV"[3.S*3*S53,DES-$U3-%$S
M-%43,UD3-%OS.U;3-643-E_S,VES-FTS-SLSV71S%9T2)Y.(>6[O(CI%,'W%
M>KQA'9 "&G1F+)/BJK9GWLQ/::#3&[SA9YJ"#")R0R+Q76XA$362(QOQ(P51
M)%=HY8PS/?M/&7=-)T!H^H)Q)4W#_S(O*UMD<2/&#2%6K[/T<W(XBTOJAAY+
M9AAE\<6*;DY\[AG;)$%]#D&+3D'%A$$/M$@D="8I]$$;]$+A"T+/I$)+SD$W
M-$.5+ )%U.DX%$1)=$)'-')*U.A.5$-3U$)7='-:U$/3Q$8G!4-SL4-W471<
M:X=&2CU!!3G)0:F,U$B)BAVJ2A^0M$F+*F;24CK=<BC0$@^Q<RDLDE[DLB+K
M 1$5$2_UDB_-D]2$M$RSKX],\$P,M (WBS0BL#Z!=!AKPS$G(J,\J:3RLR6[
M8T]IX]6B;RL!E4^I(U#_5%#UM% 1=5 --5\6-4\9-5$/55$A]5$EM5(C]5(I
M%5,==5-MJO]3C<-3H\-2,_4F\I0Q3>CZ#"+US)0_VF%[: $/PR\AAT+ [I .
MV2UHSH\H6M4ZKQ,JMM3]OC,:]&$C.Y(8R',?*'(25W59)>\V6X\VXG-T,N($
MG\@IG4=.>4XG_R4UVF1R@"X5*] ^HT0FY90XVN0E6_)<6T]<SP1=\T5=4S5=
MQ<1=V75.Z-5-YW5=\;5=]?4EX'5*ZK5([M5?\S5>W[5@ 79?[;5?/0=A68A@
M^=5@ U8QY35B$Q9B%U9B%59@GS4W*$5E8./5;&\Q?FAD58A9\:-[O.$;:,$Z
M:Z$MB[0HYL$;6I9FK;-F:Y9[A&)F\T[-T))7KY0I@. '*K(GON(++LVA$1UA
M+Y$U!Y3_%66A=LP,5B%L,2.B2) ^ @(;(C[_\_4RU<N4#!@WAB>GEFPUYU]0
M[S!EAW=>3VO9=&U!ZEG=%DC+5FY!M@(-LV[U=FM=+V_AUF_9-F[W-G '5W#_
M5FT#%W#C5G$-DW'[%G$7%W(-4TZ&<T>TU2+*B").-FK5HQV^01=FIA;(X1MV
M@735C!YL1A>^1WO*81=&EWN$85:1$_W>XQN\IU>WJOUF]2JN(B^/52X+AW.%
MEZ<2LQ@G0R4OPK6RA1+D]"!N37,\IUY9PR:RB(J.")!FR9;2P'H#:05'R9;L
M2" FX7I1Z6I7R9*P%WP?B0;_J)-LJ7UU\'TOJ8[6MXT&Z4[A_]<#Y3=]KRA\
M4VF6\M=\;XF5SNB5^K=^(RF5\)=[26D&_U=]!PF W6B!T;2!@?"!#SB"V7>"
M]S>1+-B5,+B4,#B!!3A_"9@%0;AZ"WB$T>14^S8A'FYXV<-5 *S=A(*&DR*&
MUPP]PA19S5.&@1B=V+0P[Q8B2I!N1><AQJ"++*0$$ZF2 JJ'AK%DH[$9+3=!
M>6M@GLQ/X]4E_/1-IS9+'K1CU62,P[B,-Y2,O_AA76^-?_&,W3A:*S".5X.A
MZ'@V[+CUY!A([]A=2<>,VUB/Z]AY!1F/"=E@]SB/$7F0.:60_5B,TQB.'7D6
M_Y@"SQ8BW/@T;&]S@[B3C14DHT$NG_^VDTF9:R8B;87M/S/B>8$C;?OW 5>#
M8H&R*:7R0^>SBU$Y>7&.B'7K<7EY9"E9D!NVB]4.F(E9F'VYF#&V39$9;VM#
ML(99/ILY3I^9F:GYEY>YEZ=9:[$YFJV9Y+*9/N,KF;<YF!?9F[7YG,EYD<]X
M,L#5Q6Q9V)ZLB#BYE&58+_?*GO7Y96C">;"V>=64;RTU;'^"0//QD ]:8<4-
MH$LKC*/W8F%#]E9$]AYS7_ 39"BZ8BYZ8S(:8#8ZHC$ZI#E:I$%ZI$VZI%%Z
M3DE:I4^:I5/ZHUTZIF%ZIBVZIBOZIC7:IG/:G2'WC+-E2*IH7QFBGO>9<S\Y
MGXLZJ3\E.^S#]$=WF2-XTC%[M*!#QI+Y5I5)3J(/,_48<Z=# EM'XK=RCOJ^
M.E5]C*S7=*P5XM6ZE@+1NC_'-63+.JYK@ZT]ZJS7>J[5&J$/VJWS.JVS^*W[
M&J_YNJT)NY$!VZ\+^Z[?&+'A>J\=>[ ;^X\->[+%N++WN(PQ&S9D\B&4:S6X
M&$X/.34T 3V5&F4=$21/>[59N[5=^[5A.[9EF^VX(O)F^[9Q.[=U>[=YN[=]
M^[>!.[B%>[B)N[B-^[B1.[F5>[F9N[F=8/NYH3NZI7NZJ;NZK?NZL3N[M7N[
MN;N[O?N[P3N\Q7N\R;N\S?N\T3N]U7N]V;N]W?N]X3N^Y7N^Z;N^[?N^\3N_
M]7N_^;N__?N_ 3S !7S ";S #?S $3S!%7S!&;S!'?_\P2$\PB5\PBD\OO>"
M&/1!792!'I3!H?3!0RX\P]-EPST<,4*\PSN<P\5C'RZ<Q:.!Q%%\Q5L<Q3E<
M&3X\&D!\Q5&<Q*$AQW.<QCO\PUE\R#$<R&T\QT\<R(5\+9(\Q1V*R%T<QCM<
MQG7<R8\<QZ%\QSF\QZ&\R*U<R'U<Q&&<RG\<R%=\ (=<RY^\Q8?AQ6L\R)%\
M/KZ<&+B\R7D<PWU<SF$<S(E<S&M</(3\Q$=<Q3'<Q %=S<G\PZ%!RM?\T.<<
MRV<<R.N<RHT<T,-<P_\<S_M<PTD<T W=RYV<S*/\S8]\TQ\]S]5\TEU$SVL\
MT"G=RBU]TP>]Q$T]U,.<SAG_W=4U[=3!/,,E/<]!O=7S?"\J7=,%W=;UX=-]
MW=;['-=)/=&-_,8U?=>=7-73?,ZA/5TR7=?%O-,+O=:]O=D7G=2Y/=J) <?Y
M/-6!7=&M_,D'L,=?',73)=GWX=W/?<?G'3'L?='EW4'6PL1QG-\['%[^73QZ
M7. UO-[%(^")8<?592]LZ. =7F\4GL[OO=_IW=[C?>!M7-\-'M?[7>$!ON%1
M_-P]I. MOM^5X>07/N4Y?N4K/N#QO>-C'N2GW.(KGLMWO!Z4@<OW';<=).A-
M)6Z$'O/FX^@5[N@=I%2$WD'^1^FA7N@3I^FCGE[^1T.HWNFM?A^,GNKU(6X(
MPT&Z__[HZ:4GCG[L"2/IP_Y6JO[ILQ[JI[[JA9Z;A%7N[V?KQU[HRW[M\W[H
MH;[OW1[IVY[H[5[OUY[JW27I[;Y4N*GLWW[OS[[JO_[OJS[IA9[IH3[PW[XR
M$L3NW>7J[?XK&K_OB87PQ5[R39_K*S_U,5_H-;_P@^+PX=[JZ_[M&?\K2#]>
MS/[TJ=[Q(Y_J+5_PJ?[U$=_L=]_NZ1[KVQ[O[1[R>1_J??_Y+Y_U!Q_V.=_Z
M:5_YAY_Y'Q_L?Q_J)[_H5Q_J6__HB7_V$T?VI3[[%Y_[E__X;7_>[!X:1B7M
MY_\K[/_MZ=_LR[_H :+>OF7[Z.U3=C APFC[!A;<!TUA0L."^P0BO)C0(,*'
M&#%"JZ>/H$:)"#\Z'-D18D6&*"521-@2(\.,*E-2C"E1($F)'TVF]*BSH="A
M1(L:/8HTJ=*E3)LZ?0HUJM2I5*M:O8HUJ]:M7+MZ_0HVK-BQ9,N:/8LVK=JU
M;-NZ?0LWKMRY=.O:O8LWK]Z]?/OZ_0LXL.#!A L;/HPXL>+%C!L[?@PYLN3)
ME"M;OHPYL^;-G#M[_@PZM.C1I$N;/HTZM>K5K%N[?@T[MNS9M&O;OHT[M^[=
MO'O[_@W_/+CPX<2+&S^./+GRY<R;.W\./;KTZ=2K6[^./;OVY62Z>_\./KSX
M\>3!CRF//KWZ]>S;NQ=_OGO\]_3KLY\?'K_]_?S[\Y^OGW\" BA@@0:VIX8F
M06W'8(,.8I6?=_%-*)^$%9)!(8879J@?AQ9J""*!ZN$G(H@7FE@BBA^&>&*
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MV3D)A+FS4 Z]UB:>T1!&7VLBLUX7'AP"T7Y/1&*("K<\S@&Q0RNTU[.^LSP
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M!0>;(&?[]GJ7RY3N\ [1X)3UM8Y1B7 Q\+&)^K 4!WP4]U1<&9\.IPS*J%N
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M5HO<-6M]6$AU30P2TU6CA*H>KF.7?7;9\=7_EW;<<X_TS!)_A(SA)24V?5;
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MC*DZ&IQF3ID9I*D:VAAFD>ZUD5NG 0L8E,<BFZRRRS+;[$H"DB/,2/HH Z%
M!M&C3SWZ-)AM/="60Q"T FD(88,KO:7_!A! +$,/+B7J<Z(Y%Q'S[D;J;E*/
MC,[RVZ]_2NI44"8R'54430 ,=/!,(4&C,,(#*:GPC;IZ2D:BNY$9Z#[ZDG$8
MQ[@YQJ:'BUG\T6@8I55,6FZ%_.58:);L5U-JC=57KFM2AIO.E&@IEV)*A4F5
M6PNM=5A63,68)LIDA#67/HOQ'"C/8O%&)JF"VGHUK9Q2JO/-[V$JVZVE=AIJ
M8WM5[*K:9A.;=:.GFIVVUX_**JII<V.M=;&C:LIWU[SE_=UHA5F:I;^'(YZX
MXHLK"V&%(NF3(#E-H\1.@N%.)/FY&GK#H4H>KLON,K<X8B([\^[CBR.W;+0N
M*'.%Q+CLLQ\T_S  L1.DI$T1TY2PP[$K<^22/T+L\,,U.F6;8&5BW3/L!_FE
MYI_,[RNRTFZ1R27,TE=/3)PFXSK50@1U&EWN%@>ZD=0%:5+6U.2O.= R"RU5
MT,?&:MGJJ7LGW^O96_L/:Y6:%:_VMS^OP4I2F@(<I,I"G/]MJF]X<Z"O^-:W
M7P40;!>4%)U U3^Z##"#L+J9&A)5EM#0+H4J7"$+%U>.!*V#)/I0T.,JMR!R
M#&2&";K6/BRW( Q];@RA^! 0E#&B$M%#7BJRUS[6=9CJM3"*4IQB09Z2FE[%
M"FW^.]4!>]7% '[1*:W*H*XR:$9#K2IO%#LC!4&FQ0?NQFP2G)O^1FX8N+"!
M\#(*-)4%#1A .7(*D )THZ/@6+@/)N\JK3*DH,9XQ@\>L&UX<U096Y,HY16+
MBIK<)"<[:9)RW#!%HA1E.U)TKAR2,I7L*"4HO1'#B6SHE#WL7.=X:)+Y#21T
M[<*%1))XNHNH#A>M T*8</_GR6,BLUD=?&09MZ@V+XZJF>6#X!R_]C]&(O"1
M9OSBK-"&&0P:*C2\BB#=$'E'5V%R;@RTX!LG2+8%QNUM#9SF.M,(0;B9DX]D
MW)49VV9';"K%D?-\%4'E1ATTA3&9"ETH0P_WH,[=4$+DP%Q!Z"'1BU+(0C>T
MY3[:04MO7&0EZOK!0QI1NB2>B%XL<D<T\-70E\+4/^$+:#9KRLY,85".=LSF
MW>((06+5ZI^PJ>:C]/?,5HU1D HDJ#:CT].")K*"_).C474JJD;I$U?% B<Y
MI\FUJTJ0J__48P05V4>O);6?-%TK/2VHU*;VC4X;<9D8#173N^(UK_?9!2UK
MT3G_6GR#'+0@1PT',@]OT.*OBD4L1"EZV 7)<B"6HV5(4[(N'<CE'=U28NIP
M<0LRN4ZOHAVM2?@G06EJ\)M8%11 64M-+$Z2G<_L'^">&DB?:E%0#,2F68$5
MPJYBYC/;$:YG6B,X1QAW*L@]SU)*PY3/(,<\SEV.<,/C&^;@9KG200YTP;,<
M[F;WN,ZQTV>RLUSL"&ZZYB'N=*9BGN",ASO8N8ITPQL;["K7NM.Y+WMF,YYN
MININAB,M@0L\VG9\@Z_EJ,4+=_&-<D1V(@S613G*L8N)*I@<WY 60?016" >
M9![?\,:(*WL236@"#L;4AT6 2:)A'L; ,M:K5\5)0C3J_VU3ZS1D3W^5536R
MRINS]<REN#E) )NS;&)[K8Y_^M1USG&G1%7G7A:)M:Z5:G] 36TY 2C))=/*
MM@/](S33*>2P0K/)::;D4HR*QS7[;\9RGO-+*5<2RIUK6_:Q<WY6U @7J4$'
MKZ,SH17ZP0=^N7RJU1D7]>)F)H-UM5"VLF_SB&:Y@7FLS?SMJ00*P BF<\=:
MCNU3JDI(K=:%TFWL)J75.FI22;F0-KUR;NO$MRV[E=3J!.<(I<DV2'?5I[L-
M\_\*;>QC(QM9]1+FASR2[&='\8!09FLW(0G;O2':;^MI3K"WZ53:HLJ=YR2#
MF[&LQG@"\M5EI>:T18C:2DF[G?];)$ZU<SMN(*N5;+4Z))GMV65\IC&$:^0G
M4]-ZS4>:[7W07CC#&ZX2U7W6X1*?W5HGX>U/MUFK@KSJ;[T61M:VL:=YNC:Y
M[7VIC4=9UUXU>%T^,T8'JINM"RSKCW-5J5;_!==>5%5.Q2W)19?Z434_H".1
M;-JZ$GS*.(TDL%V5UGC'U2DQGCC5J[[P94?%ZEIO5K]C7=!/Y1:UHZJ-9P1*
M;Z;B5%!S^C:WTP-&S0"R;4S?IJTCK=6O'[J0'LRXEY>J8P#[L=H,G+:Z]YAD
M1H\S;XG6,L"Y:G-M&ES)=R?5M.OM1CDJ=VYWV3KG.V]@B&?=\Z*G$1;A%)HI
M[YI4+W^VJ[WW<MZC,]-,_SV\:]U6;D?+O*VG?K3EO0I7')OJY'Y'NM"_#?PD
M<Y'=SIS\;S<N]GK>'8Z>_MO,%=U;ZR.>[ZTG^%2F/OKO@U^A[B@&,38?_O/G
M9ZV)KM5TV4O>Z)17O-J)OO8OR%KA"ABWD8_MDY7#;?:B5W+TGL&=G!6Q4W&
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M9$5:Y$5B9$9JY$9R9$=Z)&G9CO&(Y$B29$F:Y$FB9$JJY$JR9$NZY$N*9(_
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M?M/L$^_^^N^W#__\\M<?__WTXV]__OSO[[_^ .Q? /\GP *J+VZ+H$?R%LC
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M3@VWND7Y_^AGJO&IF3ZMJB4^<8I7W.*5(88!8( #SL Z-S=80?%JC1!8\PP
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ML4XJP[FC*?=CMRW<OX*K.A,[HG);MV]D2Z8ZI*H^DCNP^S>[RSY+.\.@HB)
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MB-"$%)S@"@ATB]I$$AH!">8D3AW)C1ZIJ-\DS61A"= LDBDAAHGL"@2,28>
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M\./.8'9N".$^DS@18;4';^:0%9!G> _*C:=6N0^RXA9Z&J)>G:,9C9K['<E
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M8'VYI9;>4\B]U9AQ .:%6U?NO7:@9%#=L,)3,0  E8E.90) ?%'=<*)3,1B
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MQS,1A)2)Y&,MRY014C4T3F,:J3GHT0Y=[K.G/OTI4'M*KZ 2]8XA!.I0A\K
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MKM@^!:V0+9=&!OW2SYK6Y=*PT*3!IEY0S^K2%XJRD&\,U5W:)K;<3&YH1\3
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M*=B 712!QP !?&)_61B*Y3* IWB"*[*"#YB)=YB!A]6%(5A()9A^D_B$?U4
M;KA'>5A.6QB$UUA^J7B,K7B)HP4!B&&%36B!N[A0OUB*B5B,:1B..2P-CAB=
MTD  ?,*)"4(39" -@O1]#WF(VYB W]B"45B'X1&-[_B!H2V"I[6$R?B*S7B4
M"WE27QB597A#%QF4$5A_"?F)#3F6V3B5JUB)<V>$8 2>4- ($6B94/\PK-Z3
MK<8U?&$GEGA'?#NHEL#5Z?[.LB8J8>E.B &J*/O*A 05/RGSKTR2B3BV?:TN
M"0MV!5%LA^*2ZG2.9STMU\1VB,AY!4/HG+TY[-2Y)3W,G9\)GM=*GBUWB!!
M!A   5C@D0?W8HTN8>=SP[[YZ&AL&60 !U;(P>YJB&PX"<5Y"^\Y8==J02?R
M9O?AAP]: !!@$C90'RQ9!N0XH>5Q#! :H1%@#&+-YJ*!!7*@1@1,"B_/H5TV
MB&CZK)80?3EL"T=(KAQL'SJZ.#$,[P9KV$9H#&) $VBW.'.DZ7I7C9>Z?UT6
MUA+6FN79I^.QH0?X[+2Z1&1@#- W#5@@$S3_36 #VDV1>IXS&O7L>2O-V4T'
MDW=LN-;6F2D-ZYWM6F#Q&I^K;J\ELJ])NCTS*!,"@!@25@980*[2\*N#Z>S$
M>J^CNCW/.E^%6JUM4@T=&:O'6F17D*E==A^R>#\0C\;^.K2#.JWQ.2_5<(0F
MX8@)XK2O$YDL.0U,-F%C6PP$0+''F:_SV:\#5^D$VY_;F:X9<4'OVH'H6:]C
MN[&7^[%YKY\U\)^E>PFI&[&M.Z\7.[O+>;O1F9^?^[NCFV?K>KP).ISK&;UO
M>Z37V[G+M2)WZ'AV\CS1<^AX4*[,%=38RM-VCK7+DUZ';9Q0ZX7B>[',TY[5
M]9S',)OZ<\+X*I^&_TC$'/4%'?2QHO6'MG 'G1:_,SR%-OP"A<+#8=#67%"P
M1IRBI58-5U:8G4D I(2F,9F$-E2LQ;1$J?:65AC6A%BPT*GF#@LA?W@%JQ6>
M09RB/->PJNFB"V(25MIU@KL@?M@A]:&H"8(8$" A$'0P92 AE!2%8!7((T\,
M$,"#U%64P6D2:VF8<& &8M;$-@C#=K!UUM$.-3(>@WPA$1*-(]+&&]Q!=8EA
M][S0$[9%9TS,>QQ 96C&H;P23]S"*?QB!UT&6[R792 'BLC1/7VD8\@^7RV?
M@NC)$3+*U\ES=TTH''D_S FL7!D.6U#0Y<G$X'!B.^C'7["/&QO+ _E @_^]
MCJ72?HLZZTY977W=QT/\Z)18(@GTM+753*G%D@]DSXU]'XP86868TRVJP\N0
MPT"<F&7\4$G<8VU\;]4UW%?\9C_=!LT=QI])Q=6=QC'=W8-XP^*]U%V\WE/]
MW@5WW6O\P3+]W?U]L#A\WJ_58(NP9S<1Q&R=)'@NK<"ZYWBG>R&(K2P"1E"0
MZ5[M'RF<XU<MU8/TY+%M*G-(Z[AXHVVLA[R)B]&W5OM37JL)Z59027G-Y0D9
MYO_Y)Q-XA6N^4X4>J%$4Z+WTI'/ Z9SZN)?I;!'^MIG:GB8ZME%]6W-R9)^Z
M9+,IM"K,B?#;46&MHV40!Q @@XCADE%4S,= !M/_  $>PIRR&+5]C.GG2@6C
MWI^-+H2^'4]Q?+ #<@6_;P,OVI:B[JZ@3O%4BVH1$B3;2I@RD/#?5\4U6P47
MG]#)NCAY1YY4/JF+$K>5H:UQTNBALM6='NB#=2(EF@5W'KPC^H>-CM%=E)Z_
MOH+1MUQUVB[7E^C%'B63_D=/.V /RU^5>M75T^I?$/J6EMPQJ**D_J&1GW?4
MB=@O]LCW>=7X=1_BGG9^T(:<7^_!CN^'.B>ISNY.VWI/UO+U0<Q9&IFOGE,$
M8 E]?H657M..GN;Y.UA/'^D!0M\^9?NB[:MW$-H^?0BCU8LFD"'$??0&%CRX
MSZ+ ?<L*,I0HL"*TAQD3_RY$V!%B/8'+(EHTB+">0H8%'T:T2?$E1HT94W[$
M*9)D1IDG.7I<R=$E09@F:3J<"#+GTIT$-W946)$H1GT=!9*L2M%@2H0ERYH]
M>U8AV;4E91(=J1#CR*$*"2(D2-5BV(0D.ZY\JB]:Q8*#.\K56I&>V,"*C>:<
M"Q<IT<$/258TF+$BP;E)D38V6-$P4H)X<7X<RW+K6XPM<W(U*K&DYGV<6WHV
M"-KQ:+VF5Z(VBI!AW9(.1R(8XWB,#(*:6&1*(T/ 4F((HL=(LU.&C'TY6"!@
ML9 B=&(YJB\4(";SON;5EZ^$+D#&=^ST,E7_7EH3@DF3XBO#(5U/^^ @PVM;
MS?^P'4QB;#>2)C),8I0R,F GF'($M32)#,1@=5 T8QR@77P0MI1#?#(@5Q%#
MFL2'WT)C(#"@=]N19>$8,?CGV7K119?)00+)D -C@IEXG&KVL1C=AA8*&.)U
M.T43GP XJ!8;@-HIH^*$-47#PI04':?/=PCDX%H.V[T8'V8YB5%=F@_1HTD,
ME*3!PG($MO?@/G3VN,^+RMB(GT,G11DB&A>AE D+FDPBIB8G&93A=P?4I!PE
MM/6YG'+RR8=<>)'MPZAUWA$CZ'V*G@2- &D0L^,8+CGTG7R6^JAJ)O'U&,V.
M14;#ZJ;F00/D4(+IVBE"+\9H7HJ5&42G,M#)1PQM]>C_1TE_RS%$G9B3A)21
M@P+L!YTF M'I:$<K0DB3<O%-V9QVW^$PDF JZ0/=NR11YYUS.2USG#(F%BN0
M@][QAP Q BGGJ(]MCN$@A!E1MV./^E#2WKL]T=G>112]F&1/'^V5FV@"D2;L
M3:\YE%IPJZ'$[6M="265M![?=E%H0XW,&U2^U90RJI>R[%I'+ZLY6VT??[;O
MS1:5IO/)2/GELUI)!0T;S$63U1%E!DF]64.3"6B8L@H9AE;99Y'5]7!X#<4V
M46M)G5%IPP47=D:Y!:9R7DVYG5&\/+/MXUY_D=5A;"VU=ME=.F$DF%%/^2@4
M7,!Y;%1*Z@G:-5,X/>Y7:DMK_]R0S8^O%#E14$\M]*$I#R<H74CM(\.47-%;
ML(XGA@>JEONP.B5!8Q"(W8 (D,0H#@YG=&)*C$;;)P()<[>=0!YV*GRTT/!.
M9K</MD9=IXJ]1F#<T)/E8!JME4]6&@5OY"?CN".0GL;PQPW_4YG(P*<F.#RT
M8.T23JF04 4/!S!*R1CTI2/D."1\""E?W+03&#V=2D(%R@ATE-$2911I=R>:
MG0SBEXDQ0"1U^C#3 PWBP!0!B2RQ\U_LC/([%@1//CLS3T:4PR?>I0=SM\/,
M\B"EG0$*8"'+^%]&%N0HTLU$/QWL$PLP>$,$X$4Y!H/= 1#2O9*8,#-/(5RX
M!O+"A?\00P .L\\D#.,N[6&G)0[<Q_W2T!CM;.=AM4O@1C*4,(1HQR)O'!D$
M(:*^4^W#/(#)R;/BEP8!) Q[&XD&HQRFC"Z)Y7Z=(I ,$H;'B+!J$D]A$_O2
M<+#ER$98F)IB&NIAGY) AY,_DD]&^N@0^U2R.J1R8\$40\%Q!3&6,(JBPTHX
M1XPLJ"0 ,J0HP]2XL< D-M(:VTY:DSK,),XB?HO)1#@7.,.0##.A<QQ)2(<9
MR9T.FHZ[G.*J6;@M <=SVV1;,M4)SKZ9[IFIL5Q.,"<MS5VS+]D4WU08-QMY
MT00A<;&,.U/TDL8$SFP,+0MGV*(6R6U&9I(CJ%O$QS@#-8;_((EK7''R*3C4
MX4T]E_F>O&!3MXH2!G<&I<G-OA8>9>&-6VL1R$B\TK*=?6PG0<%ICF::$YYJ
M)#BN&1Q-E7;3P,D49>&IJ;P4FK4BD04]VA-E1Z@3O,#@,2,XD&%&]-&P@F1H
M!D3DR@OUP2KL;.2#*'MAUJ2E(GU-ZTIAH4>P#G(_1\&M'B]$"'1ZU* \<62/
MTEK2,E*H$D'QE4R)48Z EI<1 2AP, PQ$_-*Z5?!HE)?8)7!&P+G)SW*;AE]
MS0BC-+&2VUE0!EEK7SW$X"6%M,]!251/4_>AJJ)0)*RE2H]Q-*1*#0FDJQ+C
M8/"65!7)TL9!".A*0=)ZSTSJ2;"Y_TL8=+2Y']!QY(UV&T9V.^LH7"* 0I2$
M'8,HXM:5XJP>.$#1=&OYP94>BR'FL:D,R'J0^$IKB_2HCK@,8S*WTDNX$PEC
M/3:X$FH=!(<G69Y7' .=R<(N/<IPD"AE EV+C =YLCL(@1RE#,B:Z[L42QC3
M+G@X];81=TK5('(0$A\BFK<D8?3P)<6C(8.\", O0I?*]"$AY'2$30N!",5(
ME25.PBY[MCV:S'Z"5,GD]#4[)4M/(=<RIE)&/54AZE)S5%.X*O4D5'Z=E<5,
MNBSG2*A=CBF9M;P3I"3UISHULWKF[&2@;CEF+@V<35J"3Y  VFM?1=NE&HIH
MO*1-9B9A"__?J$F6V25%)9?;<E*'NI6P3:0U@9M*;=2C4;&P;<Z F6=QB"(H
M>?$395W<VCPGS<^N8%.<'K,<:F;M%LP,6M2L7E8S';-K;^+M<1,E7)HY?"DV
M(9DZG$1*7A5SER::\,&QRVR/R!9&VHH/!S,8S+0/Y1$'J4$AS';,>V6+@ =+
MKJOWB0YL6-7N$S5.3_'.<8<> SLO&20'8G"N@RC1V1Z55,<L&,X/JPMH9G=D
M>9^!+C ;F*>3AG&\%CGXA@?I*O(!MSE!.NE3OJ>=E#0&ND2I-K(MDM:.*,<O
M"@%210C$&7I'B]D2N<NN*A*NS&JB<>6KR+%PJ27%?&\]SFE<D%?_JXRU<2%(
MQCH. GI$$OZ"+3R[V@?%2(, -6SDO0;Y8&6:IYG]M"Y#\-U?D477/+*<%B7C
MNY[8%0JD<4F1)+0%M$BJ.Q=]C&&(N\LN7O[-&1?70_!&^>)TQ;60AC$+/(K^
MZHLN6QA0U0[: K7<[5IN]BARY.A$V6IUAQN]AY"<U_D.S\HQ\O.2C/?E3TSQ
M2_CI,H\,NB;.;'5J #/[4^.F+[?_LX$^JDS4.6YVJ3;ULGH_PI'J7IWDQ/WO
MC;^8RLE>^=#'B3*)[S6_<0[YLS,,L4&Z9\K 36ROEQKA$,W0T@!.;I"F2YQ'
M6)+6_)EGP!=01QG#1?>]2=2D4R_L6SI[_U/S$4Q1950#:O>$%$=E@#]E%#(E
M5 :2$\IR-Y)1: 9"9W>3$V=F@3DU@1MQ3JA6&=!0)_GB)1 7/!W1+/F76Z]5
M0-+27@NA!L E'+B%'"%F*ILR)<-B=K8A-6&E(VKE%F&518_&7EX">HX2#3[8
M65/2$DOB(M\U. <!)K91,3*"/U97,,N4$$1F-Y"E##%X63[H6+FA01#"5UX"
M691Q.^SE*C<D2J7$0?(A)C&0A0,F)5C&-J$"7(F771BA7"-Q.WA1;L!49'JT
M0UYE$?1P03I""7<#78-Q<1?'*[JSB'/E,"KC2#?V7!1'#YHB'S*B0&@E'_'S
M$2_4>%[A$/&E&/\6,E>?&"NBU%_((3W#-(GM=A]XH5RM,R_+0&0C,1X385=>
MDB@)(W2WHW?'M R) G4"4@^2V(P,DF$RP2B-!SN@I'@;,1ZZ1"HF2!$Y4(+N
MAUP7,44)LE!G=F#I@1!@TCCATUG8,1?APA5?Q%="%C!YPB$TH5PD4D$*T3^Z
MTD,0<V,:16:PD8%<Y%(,J#@?8V641E*ZU64/5E9AIBSBHX#?(Y&W]9 \Q9 1
MZ) #&6FVH303R1-989 7^6 9N9!]EA@=J9!?91O<DFF$ 7\G97R (WZ'AGYE
MPQG#45$%=5"@D7R9AHHT,8!LP2W.U)% ^1,>:%-_(W)%D52BX3.^]A?_C7$X
M$:1I5ODWMG=2FC9L6\E['A<<8ID;CR-0CQ,63F,0L0$876F0P==1$?(S;(-0
M2U86?]&.'^-@0J%:W:%;'X2"E_1-I3==6'(VT#-OH((D^]$2Y48V R(#F9A'
M>*,0W 9M?9<>H@A*AK%*JU4,!@(@3G,II04[U--(;G1C6CD^C>-Y>'13Y0-(
M?#=R#])U.,!&-_91[15 SC-X4D4[I"(A6546@X$IM%DY$90[QV$N#S)1-59C
MT2 A2O8AE3%<V=-!#6%UP/6(N!%DV.F:U84R;11D!D%D5S$U^@$AFB%OTZ4F
MTD,3%K8_CV,F:..* B 0IP5&G<(J?-(W=I-O_V_2)T,$5HJR$5M7$7%W=OL@
M(^VA=I?D4B8T+>M#-CC0;US70 A@*<-QG\ZC$71B$(YI6JRE?D6280MW22::
M,->C.\IA45+SBY 3'NJ3ED(#5@C0;F2">??V(MR8/IKH>;%S&7V''1"')$%R
M1*R%$5OT5:.$FEUR,V8YEB1!DS+YE1]U;W;'31!!ECE#I;KX/<''&6W9&*&C
MI5*J%6&I4#:QI4S3I611>>H4IFHZIFVZ>P6U&"=5.&M*2A\5IZ(6+RW9DGFW
M&[0V%^>7DVAA%X#C-A*E6W,ZI?,&E[\V%H7VIV<F* IQ:N8W4DY!$G/!:E]J
MD"%U.5C6.FEI5 DH%/\ITCI5N1<(-4U%*90RYF2"DB)DPZIE]C$ %H4^TCBX
MBF\L0Y8RT4'U9XD7L0P9 @HK56[0<"P&01 4)WE5%!?*%:V=(3GZ<%?Z&"UH
MU8<.)!S&HB'>*&-^%D9KM1V'I3M9,J3M0T1+4I3Z\(=@U#L=DA7VP2>J^EK1
MXQ#P^%YVLTD'<4%61EL_DCV,(G!#(5665!UJY1#(M4$=,16MT7+1$U1_<4,X
M, P_>#-%0A#*Q5':1@_?UA&J0E\2IG<P$@WW<XD,H4&@U#CRF(W:,R+%4R<P
MHH"HA)N#%W2A]1H[ RP3HB6EF(/$61:Y0B#QX;(U"B%M9A=%$D'AH[&YIE##
M!_!B#N$@7@(]E_)%\A)&><5%!W9<4A0>&;*,]W9Q'8$#4P(G0?L0%T<0T.5B
M9!:)#@IQ$,*L-FMH)UL5N %M3IB G;D0+/!B-!A3T\8JR*$6&^9($LIMZA%6
MT/!(-)8>'3%M%;(=) ."V'A)2_%E0;,1;<:K*SF2-5%6&$$W-R%FTV21;8%_
M-'%33^.2$,FJ@P$6KRI_L>JZ.4*K&WFK%I6KL1MG^$>[;B8HDA83I9N[1VE-
M'P.K3E-[?.,W+P-J:GJH_SI).!-%C<\DDZ'[I(4Q9;HQO7Y3,E<A&8GY@?DD
M:2X5%(IJIZ&+ITAS=VP:I*FS%V^E4FNY:E&:&PKQ:6SY31'$5%UC-["[>S(6
MP(PV--ZT-UQ4ER;G4@+!; $L5:8EMONP('#4+8J"<Y<D*"UQ(J311*2+$7LT
M&,.J(ZP$HD6&51-B:'XSGT_!.P^C.QUA*XXR8,IPF02D3B7,=*L5+?CKK(+K
M- ># *V3<X>',M1!"0H!FXT!'8)"("7L)31\8Y'T/)2C/LH K@M%-4WG3?"W
MP2#&PJN%M3(0 ZAE006#;LV&F@ZC/E7T$$WD0%/!>:N%21S*'!-"GK+8-K@Q
M.__H*16JQ5NRFIV.<B4D<5^QP5$J(2%7?+Q0"WL3QA0K!WH/)3X?'*,79L$P
MHG,NQ6VOX:1XD5?O 5RWV8C$5Q$98IM^)$)]-R(/- :<MHB0>6_^Q<3&"9GF
MDSM*AA>!J<4H0SAFY):.]1JQ$QC8RG0Z%@.&D;8FH1V:0!">YR>-P29GA"D7
M$29D,EP%1Q9F5!+FYTS-<;#P!,"&=F^/BL"D.U+4E,Y]RJON)\"TYS[%*QK\
MRS>N)B#%VSH3]6GN;+$F$<\?A9WT['[WF\[ZW,+M[*:#.1$U:8&/4E3C*H&O
MISG5:S8DHY$FD50NQ32BZ:FK5JM"XAC?ZI, 93="QTW_MA5YP5:50?DUI5I7
MZC&I0[5,>.DVTJ,;'%(WDF87O6<2K\JJ<Q&7OON_,2VHHB9/TI. &L$4SDH<
M^\<"9,*WQ5%NR8$_1I9=E/O,,N&D8B5<AS8_'*$^ED(0QC,1%N*L#*1!6C)7
M0,A4<A3/*L..R%,[T!!6S.&D#^&$QYB>!ARR"5(1U*&VZY%N.K=;"3),K^%@
MDBD]#K02EK40>](3P>(0&:)6S<&P[K("\S$42V+7+R08E) @8^ JO (F174_
M%U%:!*(,F1B(@R0?>!T\[*4=UT9822=@A*6Q/M(1+_2.!$9V):&R .N*,C I
MKSL4PW@16+41'W89@JE!\>,@_]K\C!SEGP1E7@) A^JX66F %6DPN1@W@Y#L
M((C;C/%SC@+"7<RZ1^2672I1KM 1/)AM-WYKK^\W76S-VFJ$*L]X;=PE$Z*M
M5O<%7,*JMIKB,+D23&.@5J*->+[7=,R3!LCQ>'0]N/.SCG-T6(@8.WOX14"F
M6K^SHG2K'4)6K7-Q)7[Q=#IR$N$#$TF%%XG1U%^&?V0Z@%FQ5Y\ZOB%!:>J'
M4BYE=Z;*:%Y3XU3*JD2HXX6#.#T..%T!DI,FX[GK3D=NY#6>XZP*T#YC,T0I
ML6-I(&RI%T.L&E@Q$1:=%N>7.7XF8T]Y%-.K7JXA("),,RU,%+W<9S-:I4O]
M8RD=Y_^6D7S>1WG**R S"!/+]'%3^3=+06C#]A-2<\#%Y]>(OK]?1]"]:A'8
MV5&$=F4 ZE)@TG\;T3"M414"XU]+2F3NLD-A3*NE.6_WTQZG=&\$@HCM)B%+
M[,JP(2AOL$=8<\QHZRXR4A80@R?"J3X[XA^&43=T771T_8GN8RW5@</0XUR>
M)X^:N77UXAT7 GI!Q5S>(2Z"\CLEX2]B $BU0Q;5X1WP$AQF$D17>A&,4B<S
M$A>;LAV87)J1M+"@!2.HKC'(LRG9\[9!IR82$A^.@D<+A\>N#!$.LC85_A4Z
MD@E&=R)?]RPBLA!F D68HF2P,Q^-L[K\)NX("D8R0B9( =K_QC)$HD[O3"@0
MRED4SR)#UX41>H@0)F08K!(E$K,2H<7$BE+G8ULP',-W*Y'"VF,B>E42I)X)
MK*()T"0#WI$&93AO1QL#R8PIDO5I$*$<&4/$T:$)X=YR.4"<!]2KW:X)M 4I
M"# ,//0MR!&TD"D?FL!OG,8QK=P\[G)9B7(?K&$57SOI/FTT\S:84A,9ZQSD
M]V91XG-37DII@T_GAH]_B#^7A=\ZA^_XBK^K F5-AX'YD"_X3$'XDS'C3*$;
M0*P74-.SET*^1%G4YNE]&+$V9MX6GZ)4=TI4BJS11N'H#[_D08&4 LP6IR\D
MP;\;L?>\J%RZT\2KA$,3]8R N3'1_^7K?G'I@+H*.APB:K.:-_L,T4SUNT7!
M_3/8&LI;Z,(W_OZY:UL7Y\X54YT43&U1%D59YIUA%D7.37U&5(?&XTCA0!P"
M$/OJ[=M'C^#!@\H*(MRGCR"]:/4<,B2HKQZT@M'V+7,X4:#'BM$L.M1XL*1!
MBQHU.AS8<%_$DO6B&:0H4:!)B PM-J2$@%A#C6-D,,1(DZ+"BBX=HI1YD.3-
MEB8)7F21(RE0F6*&(I1X,6K294"GBO2*4%_)B2O'3MTG(,T^A?HTR=!TEN9,
MMB*3@C09U2'&@SFY:AP8;1+=A@.%;GRI$^9 FQ@[AJ5(D"-8A"65:B98]&%C
MAF$YIYRXD__QLDD^S8IV"M<U7\C0;)KT>+FRZZ^;K\;M>G5C:9=0TPIN/!!X
M8M -*7ML2=DW::<# 2?6Q[&I4[TREZ)M2AGOR)NR6>X3[UJ@R(@';2(-OWYL
M=;8+9:N7?/&F2,HM#<YO[Q"I]O2F\D\]\MP[#[Z;Y(O*/HLP*@Q!_0IDJ[S_
M\(NOP84R&ND[T6B*C#$-C6ON)>WL0VZ_KJ:[;46&3)3./LHN>Q$FELX2[J/7
M;&J)/><DPBM!V3!"BK?P7 L21.D6LLD@LBQS\KN9-$*)H["*(DLCWL[J;KO?
M0L22.IA>FE),+PODLD/ER*S.H2J[TE*CRR JT2X2T]M)M);L&[/_(YED,LC#
MG?S\;C:%\'1H# %^H]*N*!E+R<^$,I*SLX68+%!(QB0*R[F@9%"H,(C6?$R\
MRSJ,LD^]PHJ+HT8+,^XTUV RZ%,X*\4+QL;^I#&B\E!4;LU82^1OUHP82\/3
ML"0: P&(FCW/M4^'A15/*8.5C[R,4B1(AAQ*2]:A'&10U5K7K(M(RQ!!#/7;
M<0T:=T!E9'B+Q+DFN8])^VB5<U0]?TWV(\IH"M5'@PY3)DPQ$AU)TT<[PNJF
M@%UK]D=W_:T45CGG,P[-5?D<"<]LOW0H$[J #>MC".N<&%B!,*(8+UX'*A3!
ML];<%,=QG_TRYW)!5.A+!3$TMT_/*DY)_\/+%-K7799.=?"CZZ3$Z],<282O
MO V[(Y,Q_BA32&-&:6:5)J\E1!I=FYMNV>QUT1[;22,A"WNYMWUF&S^W@6W*
MOF'QMK/NLONV^;W\'*S5-%;E+E93,?4:\SS[ O0N-Q99=%' 'V7DL\M\ZP01
MSZ=[#1/4)A-$L$JHUGI\RS"9''@I$F^"+T E"4,.R0$==94MQ 4T[^3"$E0R
M=@6M?C;/\6S'T-'C*R)4S<Z;GSU#&D5CV?.;J6,,AZ$FRI/W VV*F:  X6OJ
MR^\?4E[B@A 8H^H$;7H*1].6?&_$!+.T<S8=BX-=I2*):'K].PC(S ,Y[=&-
M>.=JR%S$T)G4V/]K0AE2'T%^9K\-6>I:Z1G(R6*"$0$\\%]/$P,";H>A5YU,
M=H5+C/)H=Z#[Z"<:+/"41(B! !R\!#P$1-!"P/.L_-2,5<5*7'%>D@D!C*$C
MQWH#8P!HHIM=1C).Q%]3?F::8HD,5.1#%W((\\7SV4\M'HK(L301*23]:E $
MXMI-<N(<HU!,?9!QGHULL[8_^:YG+G%6AHH8DZ>@!(@Z; J^UL*YXI1N;1@!
M'A;M=J#+T"Y[3*'3C_I5/QOE26J:]"'R N2J+NIN/#[ZWKD^62U,VNY9DUKE
M[4B9EU<Z:8<?^:353ME)S)520^WY#'CJ%KGK"(:,>QM0TXJIK<HE$RG_8[/0
MVG"%NKWYCI)5>QJ-?"@C$F&JD>H+&Q%_U3]??B9,#)0-*JE$2$9U:5WW(].1
M+FBE+LJ(+)CZV6N*R+EYQDTCXFD5/C%4J,;ECW@Y8J0XG;63^D5IF@.RYK)@
MY<X"-2EFPTG,?(HV%4P=B6"2V\=<Y@4Z?4+JC8V;7;_4B3<G0K).5]-6F\!#
MM7)^QG4*)0N7&):FUHERC6&YH0P00,,S,LQV-,71C*CH/V+R[97V&0BW7*(Q
MC'!O1Y][TT+:9$'5H6>C \-CL;:% )_*X'T&L>)* ]8H:H%GG:4DH*YV$B\!
MR""N0:6.CGJ%'%2]M*(9HJ-&^;HUZRCH2PN]_Z;5;A8EAZ2&&'124$$3U"9,
MW2F3U#$5V2*Z2*UYR*]PLA'58-<CSLI.J'UBDR@71Q+W[)!.1/*K#+GFE=PQ
MU7<*B8LW.>K,6GU):L 29CY!>K*WH0TO,44=<.F$H($55+=G\VIRJ5A04:'$
M3L/5&G2#>U:A9=-1B%T<F1H5IO\$E))-.5IMUPDK"-4JF>OM[FPQ2K^!./>"
MG)6<EHX;QI)\#9Q 3!D""ZO=,)5*>RA:R>X^<YT(??*^$DT?&6G)% ;'Q\$A
M(LE.5"DBN &+-*!T'C<CMB8#$YB"UG/I6J@E0!@*TD,2KM98NJ)>W' 6F\=[
MVG%MHV)8PLZTWT,AT/_R@]4,]C+!X'.59OIV/J- );=' Y%:&W.T(E>R,H"4
M;2Z;Y&3Q1,Z0C\U=J.:(+>'%=#LU*I:%:5*>:&+Q03'*U0$9PL ([80_/O0C
M\8R#6%)J-2;-9,@ZK5GDWZQQ=$,-53.U ]F%_&ATX\'>43>$2_]25<',3=]5
MD?;D4JX8A=J##WLZ!R@=W@R>F;NLCK@T&<\1V) !9K03-:M/2)=/1IBBG: Z
MZ9F:)6F:+XYA!8,WS1:N96,QA!U"$>S"^W2R1M$,4$Y^K;U@2^]?#&1*M-,\
M5#H;^[:^XMPL\8S5,,T'FV'"D7EIJ5?VK@@^_RQUZ38UV5JB>:^Q-&T?FV/_
MQ]QY^"^XDI1EBBTBE:2YK(.;9^?THM\G;1%#Y<QU/&,GNG3RIII](M-^(LI;
MCJ:G/.?L9Z)!!"5G!SMIHEVI_7R54S;S*F[5C*X.?:AH0=ZKIM.M(G'-JC;@
MWKR?:!ZS)0E=JY@2*Z99"FRC-D?3X_*50I[+\F[[AQ=BT?;2@5ZGG/%K&@[N
M5>KC@3*"YM.VB$5SON7%ZL"]\B6$\S96%;%.D$A):Z;Z+:]QNA0B]W=-QA*L
MU-K;HKR?)7&\IRY=]<,JD/,,8EP7ML6HBPM*JWWI3V;4I(9<&$E+E4ZCOMO?
M,P[HOV 7375:N:3P^3"'SRW&0^O8TC@:*3\GU7'W_[ G)Q+-5'8:/?,IV;>F
M*;W9,1FY;YROE,(6\C*^<ANT6%G<LK6Z#,;7/:C<DK=?OV=0D;?T*V^R;(@E
M;HFTS.SO03D6<BX;MO#279D?F\Y$W 78F.49+,(X*&Q:BQ2F<*:^D/=0?$:I
MD!/7O:1FFC +8R->"Q_8 0Q#^1[L0CW/01XD<1R70(I:6;$F&Y32LK,-HS6F
M0$"!FH^LP8I]LHFT^ALNV2L'TZ1 F9 .(IZB Q"CT!R-TQ/-6*CN*ZP=B@E*
M:0F5^S''*QT(8S(4 YG=8QS.HR-6*R!I>A9^<A7/&"A88CNVF*K]Z3%@$;^H
M>#<:":;F:8FC*8]F8R?SP+HZ+OR*\@,1J D0S@ >?PN@]^H=PD@>YRJN^+@G
M%1JI;TL/Q)JQL[(;MP._U N093(>':2EN1.Y47(20&N3-RR>^%F+GS$^,Q&>
M&?N/8H,A)L0-,"$]=.(0 -,T#FL]$30/U@' O[L=J?M"Z<&=/$0(5C(:4DP]
M7,J/"T.7+ 0/\Q%$N,$SU1,VV4D/-%&K/?LK/'R=V9@V'IN<W5N=:M'!#DHZ
MRUI#'8D_!QS&9AJ[_<NQ!],+-[(EXCC_O\'((+R1Q16K)]"KOJ00) ,K)(MI
MQ*"+'5$1$>H3KT@T#3OT).W(%L_0+^B2P90B+8\[DAYSM4A$D7VTDC"R&O'I
MG 9)1*#80$+"P.,A)U&LJH34,75DM/Y[,0N;/GO"%H1[C85 BOO"OX J$5DZ
MNY)"G\.Y1*&++Y02H%OA1;12G<N*F*:C(I:@)VRY*VC9*]8@//@)"["[+P]4
MJAI+J?!A"X+L2:Y[E7WI.9;ZOB5L0MNH+)Q:F;.2KIQHO#SB*I5[$4B:B!(;
M$Y^3'=&:OX;$*113N!F#17PIP2MD- I<IDI\&V>;HE#TI9H!N0'[#)N++K\!
ME"F,,GEBF?D2_\@Y>:\+,DNK:\")>+5'5$L=8Y[$3*'W<C!/:T@M^CT-J:6%
M7(EFLCGVT9GJ&[6[[*2 "Q!^HKI(#)X2ZQ@+J3[44B]^Q+,F#*/RX*=W',C&
M,*!5T:&I<8E$W(Z9ZA+V>,?8>J^B AI8M+1F;)3\\T:*V,CXR"<V82SE0X_Q
M@Y5=01&;8KNY,:@T(41D"R\\))IZD[L+?,8Q?!@##)HLC*&3X+O8B4]O,LL\
M6LW &J2^3,&<JA:XJTOAN2"&RK.X>1.NRA&5#*?'.K#W&I$W3)9:J:<!;2$&
M-0TBF4?KP1]>DCF!#$QL@4D(8[V]0Z7[C JRNBSSO$B4!)Q(K*7[[/^X]@@_
MNUH[!\2JQ&FFIOD>3K(D\@G%S)G,T$.@'LJZWMDCDXJ[770PD"&-. $Z^E,I
M=:E)LP'$UI3'D\A#DO SKNJ:DML:9_M*BAPE;*.6$*TC(_*=0[,RZ%E#8B/1
M 9P/66&Q-S')'$%0YO2U,R&III#39XHMQ[.\!-FR+=NHT?,O.3E '21&SR&Y
M8+L^K;0DPJ/&'S*@_9+0WP! O;F=B%2[.D&>!(LR^?FE0_RBU[G/^/&>=90M
MB%J;>_*RJ5J;#'6FJI+.-UM*I;&=*EO,D*LMD*RV%1L=^VLP'XN4\,N4R]P]
M8VO .?1)K0LTTME(Q\*PK[DU*@I4,S/1:I7_PVVL.Q4[/M01'4*,'^6:/ME*
M&6EI1.'4KJ1<//#D1+_!K ^L#X]PJ_<;J9 1Q6'='Y&)&^VB1#^B1^4Q(#01
M3;T[3$WE..12P5U4PPJU,+V**;TK-W^UHP+J(J%ZHW4SRV&3(B,YT*G:N,]0
M4$4I+6OZ/]>S$$[TRRACGH)E3;TJ':?K)7^]TV;+#M^+(?NS%&*9PTD=CZ+$
MM2T*%F^#2;,3VLUAE9(ZF_A$SB$,P=(2V7+UC$OJ3N4!TA/41AG*I%JU']W!
M/OJQR2LTFU<A4+1RO_C($*5)D]GL10>SP!R-2M3$1/+)"<FSR-#*O>H!2?#(
M4VB]6[[B+/GYKJWL_\OQ\=!J7=OD(:9G+:="V]JA'=06$S%8O!SP,ANZLU56
M5"7*:Y6G\:J)%<J$T\[@ZBZ(2M??;%#6>\DO<K7-/- TZJ_2ND&++% <M%2+
M))_D,[%&#!2&0M9K)5%#,K#_P(@C(5'Z2Y(7"9T_7*?,5=HY$9D@6D10Q3:1
MQ%2.8[81]97)#*_7L$_/JTR<VIJ23"<,J;8I%,7 V*M::I+#^R-8=-U.<Q(_
MG=PS%<U[H5C(9*-@7=,B*JWO"=:4(2=UO+OSF*9O.24>(Z:93* 6(B ,BS[Q
M-"2;PS OI:[WDL7+;-;[K%9+T2_2.,_6?;\AL\TI/1V3K:X& [-[>Q+?P?_>
MQ?T?V7I%V^,@N519,2J^*SDOQL&[W+*LXJ6_T?N.]G L*+N='P/,+CF<;U&C
M%KZ+ZUC6!@T3B-U/.H(E+7+,HE*/ *.>!$T?0".26C&U^- :!N+3,DZ0<"/%
M2>(=&^8HLG,LA/U.!H+>W/52S<UC/=YC/NYC/_YC0 YD01YD0BYD0SYD1$YD
M15YD1FYD1WYD2(YD29YD2JYD2[YD3,YD3=YD3NYD3_YD4 YE41YE4BYE4SYE
M5$YE55YE5FYE5WYE6(YE69YE6JYE6[YE7,YE7=YE7NYE7_YE8 YF81YF8BYF
M8SYF9$YF95YF9FYF9WYF:(YF:9YF:JYF:[YF;,X&9FW>9F[N<69O_F9P#F=Q
M'F=R+F=S/F=T3F=U7F=V;F=W?F=XCF=YGF=ZKF=[OF=\SF=]WF=^[F=__F>
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M:[)6!K FB$D@ZTG(!#3@;#=8[!51:P H;338A](>ZWW(A-0FB!@H;;"^@9\
M +%&BK0&@+GV;-,6@](FB-M6Z[PN[;V>;.(N;N..9;U&;8+HZX-P PFJ[$QX
M[K-6:V)(;0  Z\1&"+5> <!@[$G(['U([NS.ZWW8[-66H*YF;66H!P"PEQL8
M[O">:S%XH,$^;ON^;_P>Y<Q.;F7P:\T^[=46@TD \,H6[;4F"-[N[7W([O[N
MC!6P(/^6[7TP  @/;^M6A@)7[O*VE\$6;K1&BNS;SF\1'W$2A^3J3FV_)@;P
MSO!)Z&RRCFX#[_#2]NO$)@8*U_#L5O&IN'$ : G'WH<5H"VP3NZ#( :R5FLT
ML!?&3FX)!_+'+G$HCW(IWV,B5^X&7V[ 5H;J)@C&YO(5,8!Z:/ MGW#IZ/&R
M?J#./HCL!G.^]NNO1H@,5^M)".WQGNL8.&UEN/$IWW,^[_-D H#I>.\3!P"_
M3G ),G373FT 9XCLONW,G@359NWK)@@#:&T)S_$(;^TXUVQ[D?05F.L;@/2W
M]G-2+W53/W543W557W56;W57?W58CW59_Y]U6J]U6[]U7,]U7=]U7N]U7_]U
M8 ]V8>]I2"]RZSZ_8B>(#$>()K^-3/!O6ZWO/R_OLQYV:[]VC*;MO;[R9%\O
M R#R95?S)_?C<+\-S,9V=$]WBE8&R[8@\'[O]6+W#"]P1T?K!(=K4>=PL([N
MTMYL!4?MTE:(^6YO\&[MOQYK"B_P$S_R@"]K@Y=T/#=X=9]XBE_GY*9N:&_Q
M@Q#K?D>(BU?VLV;R!WIVO@9PQV9N]49M4/\),:"M!Q(#:/]OBHB!G_CN /_P
M@VAYN(CY ==P+S_OB@]ZH1_G_9YKYI;Y9"IZOK[L"/\):'AP41=NE#]RF7_M
MUD8#^(8+W&:(PU5.[].&=*2H]-:6<7OA[<5.;? >>K5?>VN6]!F'BW>'Z_*V
M[D4?=$)?;0 /<M<6\K*&;V7@@IO7\#0_; 27>X]/>[4^]V4G[Q#W[9H/;2Z?
M!&EG>\JO_WQIKO*N/GK67B_,OWFL/P@)KP<*'_/E3G&J+^_3%H-%C^_;:/PE
M'_VS/O=09_:?F/W21^UQMWS=WWUA)GS9EO$'7R_?)X8"7P'8QOESM_" ;W#/
M_ODDY_*WKW($+^UJ[_ W;WZQWVL4Y^O2_G2 9^Q!ER#>'W_R+W_S/W_T3W_U
M7W_V;W_W?W_XCW_YGW_ZKW_[OW_\SW]S'G2&]W" V"=P(,&!  X"**APGYA,
M Y4E7"AQXCX RB@*7*$,(L:.'C^"#"ER),F2)D^B3*ER)<N6+E_"C"ES)LV:
M-F_BS*ES)\^>/G\"A?GIAD #Q/;%@+8/HL..$=%,PMCPI;(8'A0-!,VJ=2O7
MKEZ_@@TK=BS9LF;/HO]-JS8E,2X"IP*H)Y"85:<",XFI>##OOA4W $";NL)A
M0F5B8@"H.^F@0V((!4(]&!7-4;T1!ZX <$-C58&/&3+>EPGA1<< ^))>JWHU
MZ]:N7\..+7LV[=JV@2HC6O%BC(M+Z^XS?5"W9X$WH@[L7;&I&&(W''9VS/OB
MY8I*)Q%=O+1Z)C0*Q;C97J_S).]WD:\@B'??#=\,+^:^+7\^_?KV[^//KW\_
M_YO"FRJW3SU8.;670(L=1-U 8@#05$5+Z3;5#75UM@\TZ;F!7( " H#<0#=4
M9H""3+V%D$66Y;68;XA]UI^++\(8HXPSTEBCC3,F0UQQ=Q$'$4(Z5L<14@K7
M0J;B;\%%V!13S@FD3'J3(&> 7 2A41V(&4%3(4-6H>$@0U%UEUQ>4MY8IIEG
MHIFFFFNRV29!RLA04( ->A2D51#)=5E#3#Y8X51WY75B>?L,.J1"&XH!YHG5
M]88=E0Z)P9> 6(EAGIN78IJIIIMRVJFG;.F(5&IU%L1@8D0R!*D8G<7'$#$^
MGC@:  1VN2-DPQ6TUPWC664J7RP6=E ,WAD0FF6A?IJLLLLRVZRSST(;K;33
M4ENMM==BFZVVVW+;K;??@ANNN..26ZZYYZ*;KKKKLMNNN^__PANOO//26Z^]
M]^*;K[[[\MNOO_\"'+#  Q,,\# _(D@:L!YB]-=!E:VV(4%_PH2&I 5CG+'&
M&V?*YT >M^>9I11)+%)U!:V7TY7?>:E2)L!Q'+/,,]/\HI9- A>@DQZM+!J#
M1,D:4:*A(:3H0:*EQN)1D36(F&XQ(,B<@15528RI$?4,VFE-?7;<PU/+6M=I
M1PM'S'I5'EVSVFNSW?99L/(%,L35F6@E0O6,)E ]3^4E!E8[/[@=9'FE/$E3
M6&E'8@Q'W9#7SID\[1#4!=6Z(>2>.12R80QA-1IUO!U(6%250@@H086ZG;KJ
MJ[->D\=-$M?SR1)9SE?*\36W8T2WNP/-E\,'U5,KX!+Z)N6?@Y*YW</L00SE
M6T>92.E1K8((ZVF!A\EGF+ RW+KWWX,?_D2O'RE0@,00Z)F)!/6<\NU<<KVC
MU3@'9Y[$SON9>64K!-94)E'-Z2+$&PA4WD*84D&G+KTA7T3F5Z'U3 5UXIL@
M!2O8MILAZ4.5F5Q'0G87\P@I4:G279.$!B:^D(Z 4:D099#B'64@3C>+2@YO
M) >QRRG.2[7B$XB@$1>"[,YQNEG/E8YCP2,B,8G_&".?QZ[6LHGT;'X'PM4(
M \<@[R"(. =12F:.%J8!&9 AIJJ,PS3D&UD-ACWN84]B#*>\ZTV%3\H)V@%]
MEA&+S,\TPU(B'_OHQS_&)&N '"0A"VE(V93LD(I<)",;Z<A'0C*2DIPD)2MI
MR4MB,I.:W"0G.^G)3X*2;57ZF(Z4]A''0&PG#%SCFV"6DME))&4F.5$H:VG+
M6Z8D!G_2TN48\I%*7:PDY#LELB@"R\"9[".RQ"4SF^G,EU@M91[+A%M"(B4"
M6:U80PO67(@BG#<28Q(,(ES7HO8;IV$):6D[4ME@Y1 $K7 S"4$(:MY$1=*D
MS&%+&Z<ZGT(TI;"(E<\< BA!_S59JXBTRCBTG(N)8+8>Y4"$.GT#X$4**"AO
M#I% 0K(8>QR7'H@<97&&6JA!WD24"FU.C7MCI7*J0S$1SB5%AR,4A?B&3*34
M8Y@%W2E/)RFTQB!+,QY9E1TKE!31>.>A&]'-SEB('-X9:A]2:M54INK*\A5+
MJ!5*6(.TE#!4(2U$ZO'.[^*2(=.5;C,&4<KU>NK6MS;2>B>]ZFY*^",@KH]/
M&K%C1>HQUX%@A4_."T[<K+*RWK#0(?P;)AC%6;ZG= ^A$9FL0FY E+V:[G[F
MD2)=!.)#AR3/<W =+6G_2+&$>&P2TSNF>B15/=T0*)]7PM,^.-JJ281'<+6-
M2N."$YC8) UI;U-ZB%7<Z*@'P@RE=YJA0A)B1--%ZG3(V:B'E+J@)Y8VN]K]
M'@"6\:%,P(HHHZ((Q?!2H;UREI9APXQ%"CA%H8HQ01D<H7(2!D3UQ: N?X$4
M:<!8HEGEB7V2>:,RI @LI XDBV^4BY36N]T'0QB4.A6)!R-LX0MC."S/28D@
G,^SA#X,XQ"(>,8E+;.(3HSC%*EXQBPY;[.(7PSC&,IXQC3T2$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img42979713_3.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_3.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M0W/:5++:=+*/I[(FNS>/5[)<BG@=I$TQRTHO5[,SJUW2EK.)M+/A1;.48[-
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ML90TB#-%8K9 WN6;BA.GV-2_YJ-5BA/ W@5.I=E-TLA&T); #MS $&Q1$<S
M$ES!JBE+_@O A_HY:5K &SS <I,XD(11U5:G&(5((QR<ZG=1#=P_',<7RD"I
M(E52F5JI):6IEQ=25<B<W/8+47B0Z?5SX69?H!=3ITJ1+&61:06JZS8)^]"J
M)C*+";K_",":AG@GDCHV5+9JDI%@97N4 ]! !2?8:+^W"+4*?E3@>OJ0QMA%
MGRTI4'<G$+:%8\D:"C6F6J@K88Y&Q@0!8Q &80B *RTFH&CL>B^QE16Z+PBC
M)P1!(4:B'B\4R6%)KI0,KV+IBO.J/O7J*)S,KS?2KQH2H\MK)MG+'PR[.LQK
MF-R["0@KL>+[B]H[;10KL;/<I.8[<X_)-:]CL\ECA WT/ELK9JW3J%"K2$LK
M.51+-<;<.LJ<1,>L-"-\2.TWS5>DJ"-\S3W+I3;$M&B#S?6;S=3,S=\\SELZ
MS?%[L4KCM%T[PLP\SLC<OLK,75OZSB^7..#D-_:;P"@,1_X;_\W=#,_'W!<Q
MO&8':;96*%8VC)P)#59E]69;N(7IME;GML03V5ZI>B02!,4VP5MD-!/Z0 R9
MD&7#$-*I--(A+1.OZQ#0L#D"P;P&(1YULJZ>2!VH^,2[I"=<^:'UH(IZHFNM
M6*) K3,KVB:U4SL:8M3[4J/+:Y<V"@?,B\J(.<H1NZ-ZZ=2S+,N^^+!*"K&0
MB33V*[\GO*3)J+]3%$OZB[Z-A$1B[37 V;7B%4!>0\#1MD93%6U*]-;["Y 3
MO,!\K<!^_< 6W-> 3<$ >4/\S$%P%-<,C-=U+=<_4\_!Z3_9]-@9Y3-Q UXD
M3#T+3-=H2GA:09#)J5X+G6:9BI &K1;#:09TH+=NHRI?.'!3\P6JK]V%^Z71
M_QYB,IY-')'W/&_"R -1#U&Y6MMA(+J$KC/]E8S\4[_KKL$;O#BBBB4Z'[&8
MHFT)RKAX*[?2KTQ-EQ*R(4ZJ"7<0*#"RO8EYO0P;L-;;F.@+I.:KI.[\L)4Y
MF?B\3<(8STL;-TC+1O,[F75Z3=X$M"_G3=>SFP"N30(>2_S8LRCK,P/^LUKJ
MLY $LT9[18WTS3+[S1*.OQ3^X!<>X3K;X!MUL1K^WR+.I=9FUAT+A+I<X2)>
M/=3CPC2K3<^VS_8,T&2VM?[\-QV9%F K5HX@VB0%Q)PJA6@[Y#[<<XU >FZE
M;G3FMA'I5D-WJ@4H)+0['@PJ,X)R.BGMR ,A'@YJN_^XBZ&[FZZ>6"#D]*$A
M*J_P6J+'ZRC]L:)%3:,V*J/^VKRX&-ZW")@2@K"Q3)@\JK \VM6Q++[3UK#M
M_;[X[:3OVZ,0N\M35=:B@]G_[#D4M4; V7B4W8P9S$:BHYJ;KL&PZ< 4/.J"
MO==_;>J#G9D-7%$@#$!3-=EOY)MZ[;^Q;L+*LYLEF\Z<SJ@_,\*]SETW-,#=
M5(VVW14]KFVGW83:5JFY@-KXQ\-IUM!1WI"B.MM$5YU9V%(GO2.#LQX*N@_B
M6J$Y$GDQW>4" 952V94Y/4A>M:'NFLGT2J\EFJ+?XB:(HKS$$,JA_**DG)<P
M@N>WDICA#?"':=6$#IGI;<O_Z[WPMIS+Z6<V2*/60TOI3YK@K<.EYK="^,C@
M'2O91YC@&N^TC13R.4O@*K[-TIS-+GO.<P._:%W6^,OR5'6D.SMS,)M"7 :_
M,MOAOW[?+1O@?E,\$ _AW'7C:/V#LDGKO E.'%7".KNT7[9-Z;?C8W'L."S:
M0%QY"AU668^V)34&+S5N:16 2S>J8=]6]"6WN50C)D/UR_'MY\[2LZL07$[3
M#34LHC@L-ET@D:RN.,VN'JHS(/K3>(4B;EX[T]W)U@W*=BX?X?W4$FJDX.VC
M@2G+C1FP>(Z8 7O>[,V^C.[>GL/HD[GPZLNR,7?.C_W-%,_"R1@_6H5(NF/8
MASV:_TP_^PN<47MZ^ZR^^]:H^\.^^WJ-F;4)C>Z'<YENV*]$P)Q>XXAT/%.U
MS29NS@0<S3$OLS<$ZUB4_#93[%=Q[&%5?\FN7F0[_F.+?Y9W]<K^;6@UVZX-
M5Q*);J%WJFF@#.[6(O^U'N6R"?2!,"]-6P"QK]X^??L,%HRV+^$R@]$&1J/G
M<.&^9="6Z5M6<5FTC<HR9E06:IG'4"&7@1H9BEBH32%7:@H%4Y/,F#$W@=JD
M":?.G#=[TN2I:9,=H41]PA&JB:BF.#.;PFFJZ8Y0I' V(;VJR2I2K4R94JJ:
M-2P<L)K46%6C]>S5JD^1GMVZ1BL<NF<KP3FKM:F:.'SGIO^E"W8OTKY,U;"]
M2_@P7K:4XFR%DUC3&L)D T,U^[9IWTUK/>^-(]AQVL*</:,%+;HTZ<6MK\J%
MJIILZ=F6;:O5*C?O9[.#[X;&G/<R:KBVX8*%"O<L<-AX^]:%SGHN4\N@_SYF
M:%#[=N[=O7\''U[\>/+EMQ/SE5[]>O;M*>%JK_Y7_/7PT]MO/S^^?OJ^**G_
MS[W^U,-E#!EDF.% !&7 @8L#N\#A0#$D3!#!"+D8PR/S-N2P0P\_!#%$$4<D
ML400B4G(1!579+%%%U\,+R-0M+M)D_)23#&[BP9Z:)^(* (2FGJB409(C>K9
MB!Z0-!I)QB9!*::DEDJJ22:<E/'_*:B8@*HQ)CABLB,GK7+"*DRJNAJ**B_)
M7+,JK[8:DS"OGIHKJ\6 H^XJMC:;CK+,'$,+K[GN<JQ.OL"BK"HX$N6++^B>
M@PZOZ.B2M-*S+HT4TT63DQ1232V--%10*55.U.)*';545.%ZKM3G^GJUTL<\
M?:PX4)?;=%/AD*+LL<GH>NY7MFR%#;C0?(74.4T=E=3/O&"$-EJ#T!O0OVJK
M#3"^;*U-[[WZ .SOEVV_[6]<]AJ!D(L()UPP0AD<9##!"!M44(8Q,BE26GWW
MY;=??T74\%^!!R:XX)DVT4Z9%+];V*"!!-(.QWV$!-(A(XV$:*,A%4;2(HX\
M"LFCDY:A_S+DEFXJ!LHK<ZJR2YE83BI+,:NL<J:ILK3*JS?)/%//,7^&4\[%
MLGI,+#KI,NLKNCIC2UBDETYNKEK=HK2WLY"3S*[+C.U-6*V;HJRSN R[ZD[D
M,BL[-T,CHRLQMQEC[#2QWV:;;=?@OKONQ,3F6SCK=E,4K-8R,TRMU_0"M'#
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MXOBVL6Q*VKJV%1S'>!M'QYI L[2AKWQ ;534S:JM1!VMS9++$>S3/(V<W))
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MOP.BU4 4A Y%3S'8PY[\@G=F_>$A??S;GY3U#,$\(TY)A>U'X@@5BTAMZ84
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M328678NWZ4]LA(^9=='=&9=];)HRQ) :7*=HEDOTYCNV8&B&*:'*A$_(V4)
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M-X2A@@"G+#3/%@ 8H )$!K!0$DSF'H"#N0](2RT,$=D+$1#3*K("'(H H*X
MH0BC0@ &! #_@P/2[K-+P0_9&\"U @5CK4!/[=-341<OXR#'T505C3(?<[S5
M5R2+)58HQAI+3%HNHT4,7<>VU9;,>?5EUQUZV?678'<)9@=D/#_&6-&H48;8
M9)4U-MEC2T/F-&R:("=;;:/IQR!_>]VVM7+#3>W=;MH%=QYTUW&=VVG((;=U
M'.FMIC9LP,7&V7[K[96;:ET'N-QX6F?VW7Q6LZ><VZ#)%CA^<$?GMW76T7::
MWE*?9G5Q8,,VG'7IO5=:<L-EUC;BS74=&6VA4?Y:;KWIC7=PX>7&F4W-SBXL
M,2QFF.*(N6?XBX:[WP[\BB4"N2&06HZ!Y1B,=$&CDT9R":2-SDL_1Z.9QYNY
M98U7:J]CECDJ3SR)C"@9(R-'CF@C)8XHB26-;L[P*IY<X'EGJJENE,DD/64B
M.X3+9$*)114J@ #,A";^QS%#+8QV_PQLX*#&@"I>W<E5O5(5KFIEJCGE"E1W
MNM4$:\4K#:)I5O%SE0PV.*L/R@!8#FR64S@B$&.)I84TI%0PA++ ?1 , =M:
MB#!@D(!HY(,*!^BA1^BU" ,@ (8Q46(/GR4Q>L!0AS$(@!J*4J\ M(M; ( !
M DHRCT(8( 8)4PC!M&@386Q$6C^,01P4$HV@(. G^X &QIKR$WU@Y2<?^XE"
MJ%(R0'(E+%4Y8,O  @J5F84N+WL9(]TBE[O(["YE48Q:<"9)3=SL+H&Q"QQ
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MQWXJ<VV*=!8!^6UQD?]7 &@S![D)S95)AN%<#/D7SJ4)$$DT%<E)DJ1=4?.
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MPB%D\CTT8H8N]3PUTCYVV)=I&*C1HW24T#W,@R,@\F2-,)F8F:EAEGHF$6>
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MYF&0>VJV/TF>B+OB=2Z$T"O(]_%=1>ZY62L>+"'C<03G')>1WQ)O'\+0&,*
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M?=5Q7$4=%E(#6+$U-;@_M0(/$O,U!?0%[WH'IM@(\!B)?2@&IFB(R?$0 [S
M1@@>V+FA2FB8BA 7'TLL>GB2@M@L;KL136D<2K (,O^H#S#R!4T0&$<0$<VI
M#R["BG!S*(D:G0@,"9K(@?J@&810AFC8O$FI&-$;GH\*DJ%2+ID(&=+[D3&H
MBC0@'Z*8P888BO*!BEV#DJG(A%U#E8E+0@O*#,L(+YA#/L1HKT=KPT&1JN0;
M)9'+JE<J-,B8#$;#$\&(I3?\GY;3LZXQ0T@1@S%DM5U0BYN"$DS8@@   ,O#
M#78 @-T:%?<#@/B#B#(Q0/WK1$\$G*C;L+M)#N>()CA8+ DC#\6A!*Y3#V51
MP YCL5[SA5@<D-FBATF@!# *BB0[I[J[NP31!P3Q)_FSHK]#HFCC(7<*LG\B
MB7?!K"!SA%T;AORXEHD($/+_B*S?R9Y=XP7[2Q@S'+--"[T@,9E%XIJ62AE&
M:AF(RT4O;(K1V!*J" IZF+.G0(I5^:DS'(LDK!1/(AL$H O 6!2JL25$6QI7
M@B7C2QK^.A1#&XSUVD-(,QJB8<BKT;A&D9Z@*BI-LQ0$2 -]J+EUH,2?<[_O
MR\3:>(U*[!1]T(( 0,E/C$F9]"#DH 3LJ*M:B37IR [JX,2T:C'WP(41:Y9O
M(APP<H=9S$9B0$I<N(^)J(1U*2.#B)=]\3%E$Q$D&@.AI)PQ<,<SLA=H'(/:
M"@\?PYTT&H9B<9@S&H-;  ]B*(:.0! /R2SY* \1J8D<F 0TP!YR[$O@DHN3
M6:F2_\D!(\&!+HBN-W#'+K$N)UF]E?F)Q9JS7$R#EJ$*5#P5?33#K]H)7CHO
M.V0T0D$EQEBJ_0K- ,*:ACQ- D*J16,OU'Q#6IHTTFROK7F?.8&??@PKE[B7
M5YO$!&"_2UP_'1&#\[- 2="\,("!&#@ UVD'- @# Y !-"!.QI&$-"A)ZUS!
M[*2'18"! \ !2J('28@! (@)JQ &,8@!&,"!Z>P6-&C&AIB'\?P^@ONY>3"Z
M>0N#[Q/"F>Q/_\P-"MN5#"N.Z!#%XHPP<$I $..K$E,/%5M =Y++E( [CRB7
M _&7BR (,;BGM2PC!'F8#BV='2,/I\PL9/0=DV"$&VD6ARMZF ?5IQF10K_D
M,HI30K]\"3$0.$,R,Y%A$BMTI*. F<2LBJ>PI*I "O-Q_S-4(08<B),!DQ](
MZ21.JPNL&LW/E,@\*11*8TC^<C33G*^/FR7 .)J)Q$,&.HPO=26:Z,R-E!.T
M8+U6VP62S(KT.X &"8850(!3((E+M#QA6 $ P(&< P!4DU- -8 5&+HCI (!
M:!"(F <58($]W8=\J ($$ 88" #PTU1'C4\M  #E!( #>,F@(S] )<\<: A%
M4 $Y@HA1 X#R ]4 P(%.G40@D%-3 ]4'\,G_[%5?W0JVRI46,B$3*HX/;#5E
M",H%)+%C4= %%,O&TRM**!!]& ;/:80NT#L>5+(339&"T)S;0<9_(1:3Z +<
M(;=S4=$IVRO3*H_Q"#)TP2.:&/]'3+O1OJ0+(J$+TZLN=F3'+IF]HXBSH@"3
M+EFX\J&*6.04G+&,KZF@+8-#,"5-I$FOSZP:^MH3@X2E5 JT0LNJCP,4,D7-
M^1K(Q3C(6W)8H-K'HBJ+27"U=5"+^VO) +"\?'#)\YL'EVP015B!5MV'9# B
M98B$%7  *$&(FK53D@BZ '#4FHV!604%'0F#.64<19A51Q4&+:BG89!:(WB2
MC:"%F7U4+3@ _HPM&)A:=A"_%?@!V?A3%8C$7XU;N<T*"BO0#'LFO'6P!ZN'
MO@HQ9X50P"51N60MC:@'5%2(B1@/@QG7U0'7>WH8U;H1W,FV>B&8Q#$($7TC
M\#"8=0W_W/#XT(MP&)*RF-O$S7[K(^"B5S*[(Y%Y"&*P,]53/=FS,RQ\N$R@
M#S9CLY^P,[W=#F48 [-H4U[JC,%T +JHFD3CV-][S?RQ)4A[2%-ROKY &O^*
M&CXTFM0LTX1\)0!2*J>1H)09L'^4GO*2@=Y-J]? @9C5@AB(Q$50 ::#")6,
MAIH5@$G-BI%<21U9 :1]5/6;U$J=VGU(/^&<-_7K5)7XE . 244X +BM!0.H
M*)(@8$=E!T3MV7UHX%2=6PZ>6YVTM>:(JUC#JU<#2L$!-L]50(?J)XL@AGI8
MP660B-M9T13Y7 \QUQ.M07T91LS]5H/17/%0/$,H(]MRC[]U_P]',%&L-+,>
M 3V1&K/0"TB1RJ G[I$<;=TMG*XP<9F?8)DVHXJC  GK.HKKRL6H*!7@_4<U
MY+3IV1C=4KZ2124X),B0RQ_E+4CL95XY3LT[A%B/$]E"T1]#$XP9R"7I65F+
MPSV58;51^TVM4#H=: AY.."&,$DYFK^WW8IU"(#X;8B:75J2P%E09AR7O(-0
M=EI'E=-.SHI++,[WC429Q6!*I;]6)>"?&[55[F!=]L_C< ZJ2XX"/5\%6X;/
M)9S.]29@XR:RZZ96?$5PNH\672+0E6;%.PF4Z%RGS,KH\@4EYF%[L4K%P5 /
M.>84+IQSF;:^\Q>2"B0@<6(JAF**DO^)&\#-/S*9,5BC?5"&=MRNQ!03A!M2
MH(C'(\7"!BN5-:'BLLD]?N0:4-JXU02,]5*Y_:*JJT%>JZE(UDRJULPJZ?63
M6](+ (JJ0WE-!\(+4-), XN4C<0!>@@U.=5?^=,"GJUDF6Y52-73AM@%1 7/
MK'AI[YJ'%8@!!(94&0!@*NA?3S[J!KG$ -&*EEP!!C: 2,P'I4[@18#$AK!@
MF,[?7>YJ7@:"FD0.OH&5%()/5WL1]VA%5RP/M4:6\GA1$N7!-U(HW%&M<#TC
MQDV\A^'0-W($S3&8;0U=&SY7V"&09ME*S3KB90/7L,36=K91/!(2LH%GFP ]
ML6FNN?B0D!3_D(.ES# AXZ.@J4PH!IO2D.EBQTRP75+)A+'1S?JQB000R-<$
M6>>=:,6@OHA-WNG-XXYU0[T@-.;-V*SJ7AV@8T$C2#3=7LH0*H_$3;G@S0A[
MV0).VBW ZIR>TV" 7Y+@A4R-SO/#TU7^9%.&"*5E6D=$X/)FG*M&-4]9! -@
MX!6(Q'E Y:QP[T@>8!5P9(A(OP3P:O^.23CH"V:R&^O(NE<CYO30)L56Q1H:
MR@:_CQ-TRL,LB!2QB'#U$!+%G8=1W- Y";G$5LC=W(H R[]FT<&E'$>8L@3L
M4,7S,;Z,8A@OQYWPGN$!"I+0YP9C3"P$X\34PH)N""/EPG8\1.%@_U+S\HR5
MA12W\#VG\5(__.,[;LC:QJ\IC\CY4J^'SF/AEC0]'NDQA4-5NIH?X,R$9N[;
M/  X?;#TO3]V4,[QUI$#UH=">,D$E@27#!7Y5=1'#>K[A7.<IM2J?E0J0("E
M)H0 D&4^=4D&;E])5H$8>/-*WME(G$28%@9*_&],US]9LK7H@)4X(/)6,^$&
MK4L0(W7O:.L7?5"XKD$?;D$?&]<.G0@:=H1)J' /N1"4\ BK+$LBKG 6!V($
M!(\4CW6US/5DJ4%P+=>^FYUMM%>R.5W.XYB.F8M)&,.IF$'M$A-V_(F@6 :F
M6 H6$Y#M*A]AYHUZ"$0]XRJ&S1ZLB<U \_^?5&JEBJ8:/K[C@V0JV,38*^7#
M+9W(YTU->,^+1W%23U)=&6"!<D>F1KZ_UYANDP2"F^YS^>M. ="4=5B!\,[9
M4(:!%7#4^5L!2)=91[5OKG"_]U:)6K!NF87)^0. 6H;9"=;N3)_YIC,.(R",
MNS7PFD/P8FGK!%=APE%K;>KP'T;&Q*4(<RWQ;4U1>)T(SS'Z$3E!!&3Q;;J/
MV[EK>*7A*&IQ=,E*O3.(%[<)M%!#*,:8>SN9>\X*8DA,(->N20**>EB&>X0*
MNJ>9?+Y'R$23:#AH2H&?SL3+V7S-T8SHARS-P,<3ZDL#BZ9#C4;(/F[#B'0J
M .K>'T@4Y.9>G#C1,(K[I:+" 9U'JUV 7_8;M0-HZH8(!DJ,!!BX;ZV(^)P.
M /W5AZ-&R5W(TTF=AT#WY.]+915P $[\%#HG"460ZDHV]!]0B4D6ZM,7X'W8
M9 >@>>AWM<"X>5XY1?U#:U]S5@4WXFWZ-;+,>HN(T7EJ>LUE\:X79Y1PR@NW
M%T; (0Q%5P;W5JQL!,3N865;MEV?'6C+2H.P5X"((4,&#BX##\I (! A0AP,
M98C1M&\BQ7V3)FE:5C%:/67*B&F:E&D2I4QJ2&:B)%+BLI1O2F:J*'/_)LV:
M-H<-/)!P8<*!" ;&^"E#Y\\<0("H 9+FZ%$=/Y#J6,HTZ5&I3)4BS?I#QU&J
M0)YZO1KVZM>D.<[F(+.5+-:K.I*J^9&4#%.N<^5FA9L7J]ZQ98'0G0I$!PZA
M/H$^E+%0( (Q]6Q"CBQY,N7*-8.M0!"-(KU%, #DV%QQWA8#*PS$X2R1HKS,
MHMD!>%!1WR+0HH7!,! @U,1\6P+<J>A[]\1Y,%8 X1PF^<3:/V0J0DY1F(H#
MJ2?J"[/BP6L5"41/9.?=,OGRYL^C3Z]^/?OV[M_#CZ\>3E^D:L#+SZ_?9CU?
M_O]3\I\O ?KWBX '(IB@@@O^A\N!C30RQA@1_T8XH8053E(AA8WXHN$878AQ
MX1AB'&(AA8Y0**$8&OJGT3DF$I@@BBJF.(8OMTBXC#XX7DA,AXV$."$7%8KX
M8XA#2NC00SP=-M ,!"'$DY)*'F300 [AL)I,RTSRQB3Z4+0,2"F-Y"4E;Q S
M$AR3I!%2)L3LPV5)*FFYGS(](2048XHYD)A19+VUEUB#=H455V3I!596A5I5
M:%QZZ9 ##I)*.JE1<V45Z%B'\G744VQ]^A5;@^K%E**%2HKGGC\1U=-/AKVQ
MGZSJK1, ##'$H((! !P@'4W1&3 #>.(YD$8FDNBJ!D6[V%81=0?@($D8 ."P
MA0RG]$;% ;Q1- \5"/]P2YMI.* A!@PJ7+?/+M6E@<88$RER '/[Z*-%#-1.
M8JX*X%+$3K#X"0/:K ,37+#!!R.<L,(UP66$7ILL''%YRS3(8,4'QHB@@?]M
M+& E %KL'R4C$EDA(Q].Z&&(_M5X<LD2PAPDA!-V(>')COCWV# I+SACB!6"
M"&&'8Y Q42]CG+P9/3 W4K.(&N)<XX=B'(8EE(I12>756S,DD-80U5G12)JL
MIHPF(XUD+)T8<>FF2B=EHLP^9T^RIB:/R3H&0X;A>=!/00WUYUY^E=KI8&'5
MASBG@0XVU0^!-764I#,XE(,,E%-^UJB.UT?JX(!]WKE;]47E%@ZK)L;30D+_
MP2EQPNS $   NL6 0QJ@V 0[ //2NX@**@  0 PZ#!N#;#*M"T  *N@ S2+$
MT:N% -SV]ANVV$GRV0'5W4=1/F$< ( *QS,+QVR+Q+!K[#A0OX]XW%7TONOS
MTU^__??C'YG#BZH!A__YXR]!#O)%QS(6,@'APH"^&."!&"BR!,UL#(<(48G(
M$ UZW&QF->.0+V!F(92=[&DF\B#2),1 C0RC$3A+$"6(1#,1V:B#$8K&CF"F
M$7=\4&I(&I&-9@2D"G'M(%FKTN4.PJ2^\>U*::@)E]9$C):H1"0GT40:2I*&
M240C31>!FTA4HI&0B&02<MO/)%X%.,8 ;BA[&\B?_^)"%KR,10V<@L,RE!$-
M9=21;%<)E5=*!<=%"88JD\,!YAQ@.<M9JB]XV1S_V,*I47'E4WBABU\*M1<=
MJ&HGKW)53U8G!OP <'[Y6$$,@B,3:*1)$Z"$##TRD8E5EH<>P\A$V"@R2U5&
M1I:T'&,H>^G+7P(SF.W1"WWB0!_Z"%-A_3F@@G#1,?\DL)G,?.8#_>.(%3G"
M0B%R! V%1J,)^2*;)RO1""<DAIJMZ)M XIF )N*.%2)H1B-,)\D&)"$+[N-H
M$2(&,4RFHG*:J!$^PH4*)Y' IF&I"T%DR)2N]*3$")$@[Z))2RY"-K2I(248
MZ2)&8A*2-='RHRNI8]TFH?^&6K[G3HE)XF%T<B5+?HXI:0C4IY+2OHK0@Q)R
MA$LDX^C(O(0J!YC#P0-D,#D'#%5P;*%D5J3BE< X]8]R7(I>(">JJ@AJ5)):
MW=54YS<\32*9"PO&OF IUK.B-:UJ7:LOZ=,5__5O$_[3"%OW S)I(DB!!5)0
MC/3*S*%UZ&=B4-8^;D&@#]HH@B+ZF=.DYL(3">B&,GK9SY@60X**@9LUG)#/
M/-0TF?%00A",T RL]"2%0O0@E+O<$2$ZAM;-!&US&LF<VL0F*V)D;K1]$Y=,
M8M&YA3$F^K%<JQ0B%./VS2<XL(LEE>I3K_"&'OU30QRHIPE"(661C *D8-)
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M>[VKQ1QD0 -.I!CXZ0]=*?*. S6[(AZV\DS:,8EL1AL[O6!$S2R8:,Y$Z)Q
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M!35 LUV1 6\"YQQ) QI'$S>QH38+XCDM9V"SA',( AS51![:E%Z;@QSAI$W
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MJ9"! ,3' 9(Q4$&($'2H[M0'_42?7X6)3K$?%QL(M)#6_5E/##2Q]$&(JOC
M@1L(##N5AES7D1N5ET@53ZE/81F(=^T>E\,4<Z37[L6<'$1/JP@JCR3)$1+"
M=GDAO5#)%LH+Z*FAEY2Z^!V,Q3B,J/HA*KQ?AGG8LBM1SI"8,532JM@R,LM8
MH_0,L%H[+B*9*N(BU3 9F"DN,_2[O'K#RG%%.[*M_?C9O^/*Y0@<1-H;W-./
M]8"+\SB%=Y$9PZHC1%(#)=6'O%L:K-D.-EP.0<H-X2RUGJ6UX+*\,BT\MT7%
M04*/R(D127L:.2T0V#N0L^T;&9[_+,3IK<AZ&\<RK/U(D"5.$;5M4\2[LT53
M XVDUR%Y7.9;1NEJU,7=)6J[MDYUMN@#IDX-GF;*IMKI$O3BS78"L'0+)^*Y
M'GE*@[]HSD/Q+V5@-TK(6Q];!ER-*:5079 @SUY5 W8\J 2$,)HX N^,E3B(
MKSY)"#AX)Q0\B,Z B"# (0'6A!D#@E/0!X DB1R  WI1AC&PP)+(J(!2 U
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M])T+H-OV]A78P'A)^%6&;08":GQ"]\8Z+H,,J]NZ^C:BRV [(Y*8B@W@Z3;
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MY/A<$)P 05?)3TJJR$(6Y$*VR9?HP*#MHX4(FND@FSTB7S  @ S88&TP&P(
MY3X(Y46@(+UYQ"($P/'08+LI5A5<X$AH8 #\P$*8$ HM1"T8@ [\A#RDFT,H
MP@$\RJ+ VP\9(<-MP0%<5U;DFU#M0S(8G$;$BC!TFZ_@2F_U"OK@RK'@BK$L
M2Q>.H7*-'!A6C&"BW,@%4GA)RT7TW$F$0A^E',J)B\&4BV%LRS;-TGE-A+CT
MDDP<S"UY34KLQ$6$BW\\8J]PTM'(1KU<DV*0BQX"DFDXA7\%Q2G5U\>,W9'M
MW">%!1WJH6?,Q+K<$E+,4M"<$LZ,U_\Q65-J[!C<344Y 9EK\@12&,W'X!B,
M.08T9M,S)2?/2,4DSD8@8F<O;5.% =F)C8W:) ;3(!.&(88T;08T104'[:2B
M+$.6U=[J+4=PS)-_+M1V_$WL[8TX'H<YIIXO5 (ZLA[AL-E9*4-\T&-N$ ,5
M4JC;V2?HI,'R->"?_!D.R _TN62;U F)C(%+Z<"=T$CVJ8@04<F4H&C]F(6/
MQ$CYM(E"AHG[Y4 :((GU/(!/&165D$B6S*A'UJC%<$AB4<(/Y$"Y$82)!HE"
M>A4 KHX!6A^)WEJ***"QF51)M0>&BAX[P( 4XD9=JN!/,,H,%B58CH0BJ !9
M7B4,K,!4K57_ %360NR""OBH8EU*NLB;"CB )*!!&@3J%0G 5-&"" Y$/L0
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M] -#8"2@#HY( HP_[J])'BSAJ*]U6H3@',H6(PIW%,IUY.G@6N3"Z(WYW&_
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M#WPC=O660VV8C3JLXSDJ]FY MO;#)Q->>4L9=3YFF807L]^C%J^+ELCIX2^
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M=!(_L$T9D4W>Y!(ZT!;#D& )T'*GH ^4  K*H R9,!"N G2(@@-)Z"J)PB@
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M>%X1+UXQ#Y%7E^PB0;X"%+P  U$6%.QP.G*Q"VSV%B$$>&_Q#)$7!V9Q0LE
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M'4G  &,9Z<3[E9'^(8!]T(,,E8,!K( ! $ ,   B*W(,',%TJ, !3#( K
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MY<K48HT]MB:@+%C)*@3(.HD=& 08*A@5EHT3!A;6;$D?+1 04AX5YF0IF44
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M&&QLVE3$[4(%*DR)/"A"T2%=Y7B["$ ,;A!3%0  !\>CAS+220QBB,];Q3/
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M58EA#&F8A";X=]>MU&.#!-8P32+A0I70L(0?)N%0@&* %0 @ '@"DQ8 H((
M&"  H3 25N(4@YYP2Q(P\+"QZLJ2# [EAT-)5%*+B!;N^80>?3'R$@6+EV@
M#(I+G.)AE[&8*F-QJ57>XI:[B)G&5"PR</AR&<DH&LJ*N62P 9G(RLBSE9WL
M96_&31WI'#/9AJAG)YNSC)2#(INM33FU].V+7N,;2R8HDXS$37^,*:'\T%8W
MEMQD@XPY(0PYI]*9?J2*7$0?7B):/@42]:4%IYR@_ZURCPP2G' J_;=)=@@Y
MGNQD+@.9G_7<QM9! YNIE\/;G(4'TY*4&W1QA$Q@;VBN&S95FXS%"X!J+]G*
MEO:TJ5UM /YE2J"PG[;MQV3$#2O:UOXO4$28SQ&OA!<&"!\_8: #MK!D&)-X
M R;DO8QP(2!8F<@$)DB8"4VX9!<QB+$ +1ROF-25+(D*<E_E<B\FPJ4O3^X+
ME E3<;\HEC&,99AC2#+F+9,18Q%K#&I :[*2NP8U;7Q-R=UH,I.M&39PQ.S,
M?D-S8=\LV,3QXS$II,N?I69 /1,T(4<D2-M ]VA/"^YZ]>9=&CG=M^O%FG2_
M2UWN7CV\X"W;V(I-MD%;U_]NY(T;V\KV'J5'G;;<O?0QB1LUN_4YZB:2M,Y=
M1"-F)E7<HU)<?DDUCQBD :+[4 8O8L#WO!\>\8E7O+))LG@!@[#<4>')L_2A
MB  @B=PU$08 8@  %'^U\]+R[Y!44/C_AB5>^EBX7/:QKF&9)"XF27)=]B5X
MODP1RH<-S!0%0Y(J&X9A#$.894$16==4K#%DY&)FQ4AFSYX<9F268VA,%@HW
MHZRT-<<CS/"L_?B&,CTS,V^>AS9G$94:EX?4;8HJW1\+L?H^E6YE_-/C2T0?
M>D&1Y+2&5LGH C$H:'3CU.#+TO;HDA#$TQSD-AKMT5!M/VB).B)-16*)0U[M
ME^;_PSN*P^S<Z[>:X_^6(Y**C9!Z#9. [;B0#D4<R3<*SO&HJ5&,Q9I*YP9R
M(/!:T 9O$ =SD%2B@>-T<)IVP0"D"B7: 08F2B6<X@"V!0B%,";H(1,F0=_T
M31+6*@TR8:ZL@L:.)=R\8B7"[2Q\ E2:*,GDXJ\(:R30XJ]NS[ .*V *AK&N
MC# .ALO&K.,J@_B\S#-* \Q,H\T<H[2B+\YP0S/2:(Y:ALY6RX[H3/MTHY $
MK=%4A$1RYF:4ANA@Y$$4:6O(Z^SJYKF4Z[KB)FJ8*P6#R^J:P[M$D>FVSKJJ
M!A4'C;F B^SD9D::)@4I$>R:)CVJID%8K4#T9FP:;9"6_P:YY(_^R,,VL@;O
M?+"FZ$(9F]$9G]$',PX:!:@H(N_>NH(>%B&'5J<:1V4G;&@?>&&AM#'$ &BN
MDNTM^ KV6J\MAL@D[D)?W"+) JLOYG$9Z*$P]N4-XS Q?.]A$ ,Q&@-B+*N+
M*H.-1BOY6,.RT,PQ.DL/80.TXFPV3 9EX(@B0^LVW$,"38:V=JG\-#)%*.U!
MBJ- MF-EANZ20K)")-#5)M"UP@^6@(D$0^V]Q*,^4*DC60G]C..2YD[4"O #
MJ8,_".<GZR.74HT '^V2BJ;G>'+_?JD!(5&^!.T\H"XJ%PW83(01Q\/6E&9N
MCL:\DJ:^II$LR](LSQ(M46(LT_^R5#)/):AJJTBG\PQ AU1B%V   D8E7-;M
M)"SO[S(!H[8165CP)$3"X%("B-:2"WV",=<E&D3B7OK*#/D"'Z7(+_2Q,-KP
M]WX/8AAK( 'R#I4/#^60C/#0,US#Y6!CC5A#$U9CYEXCC7(C-0_1CFQ.D%++
MC]ZLYKH/UU:FYX[I &^$)H?FDLQ.NL:K$]E+O;Z.%CU1 TLQ$U=1.@'G%.=K
M%J&S%)_&Z3"1ZH0+:SK1%,/+[*;N.0D01X9K1801Z<X#1]3F%/NL_\*#F2K)
M.O^-+>\3/_-3/ZVM)/931W;A ")O'DJ/\SC/FS)(J^*I1T#G ;(D##P/Q<#*
M\&R*\LK_ E[8$3(9CBV0:(F2S.'N4>*BC,H4RS-#X?<BHXHL9HQ4M(PR!C-
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M)PW-AT_$F[%U?N5#J?&OAF5R 5=RT%+2N[04.M+:UCH1.OZXGEUP0MD$2,1
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MR',Z%R6N0V'PU4VR(SO64U]CLE_%\$UL\D,4H3WKPT'2,R<#YCLST4Y.EQP
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M:2\:2BYJ?844!CL3@XME:O-1-/E7'C Z&8K53U C-7Q35X(%6OO@E.:7?__
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M=!L<8K :8N"ID#$, R(#:0,ADO#5$K-&_ZG!&>V7#UBK',>1!KSAU06B"<G
M!6@TUF%SR.DA":N1!DY3-%S-I6%P4>41<8Q$(#$@ SB0"5+32+ U#P/B&9I@
M#EXCE)!TUV3SU?N (+JVV>W'"XH)!(\4-+F! VC@V)&A'=P1'B3(R;AM@O)$
M7;15A@"@;PCWVP<P'Z@<("P8QUH: XF[N!'3N"M(NOJ@"-UV6/#&,WB:')U;
MA@<P!IF0!@?WD@  NCVHN=9%I2CCE]8%RVUC $-*&>\10)'Q.9J9ASNWF8<3
M#5>R7NT5B%G2JK$Z7X=XB&6B)N:D3K<ZO84S8+RZ)PM>1R8&CAL4=AE!O4I1
M5!4]X<5)G/\,*?^8XD\&5BYS=REH)ZU+%2BNP:V!,A\589ZC>-2(%BY[PD4N
M?A.W A9KT9T'U8N:)\$'-59WUGK>^7A ]8YM=Q,'1L,[C#"@H5#I:Q;V24,)
ML6$:/9TO[<$UC./NV2UU5Q _0WOIF^1HEV57@1)B4>332-5*E-%47<-\!C!J
M01=G=;'B N5/L=BY?>=WWC=XON=\WN<J9N<K2@4'@ 8(6.B]Q#&76T@KM\K
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MYZ2S3CL12@[*.]D) *Z#M,IAJ%U@"""'3"2!00"=]%G$@ /2R"0,&!X8:B8
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M^G10>;[)X8G14[$:_1H5!9I9$IN6AYGE81!1.MLO$;3"-RM;E^3H6Z8)%Z8
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M48-$AP$CD]1"9@E!FDD^Y%&)OC2A"^WG2/OIG[3)@"?TX(G@:H$#.! #&L-
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MS>8-4"J]4I7:?$SAIDT]H<B&6?_L 9=7Y6RQ%UMD[^D&=TP';KEBJ%Y)E>"
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&C2L."  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img42979713_4.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_4.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M2S#*RYH>JC[ZVPZU&'KZ17PF=;W2E%K/U4O;LED[RS8XHE>9&(&O29[( 85
MP&U<'"ZC^X*%&Q^L* DK<[L(_ZB ,ME]MT8S9)LC9F8O X:]:-9P?).HR_<=
MII*?RS:SHM."WGM;Q\&:U_JU@#PDL?>'G=H>/A!I^B1+-(J(!/*UBR"DTSFJ
MM,.6<B6@[09JNKLH%H@D'^@<N2RKLXIFVH(R\#H==[D+;[FUNJ()L'D#J=M&
MM!G%U1L#UGHXQ-&F=(3"Y[HQ;>@O-W>[L HF"[82+?E<U ?+-Q)$)-:ER8&
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MTHKJ93L-)N=;,MJ=D\9FE0WQ1C&,0<J('%2?L_$I/T:J4U"L_V1)K0DD$NH
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M87#*I(0598"&>KC-15F+:*@46($&1ZE-I(3*:1Q#+P(G-UNR,,/$I1(X1#)
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M[#CT-0OO)4J'1F/7+M\8GQ" 1WB\;!@94$;YWN3['4JH=MC")<[:]F@(.^0
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MT)V* [<T1QK=/&0.\&I4)&;#AXXCS-68J$6ANT^!>8,Z6?%)F%$*0;R7C'H
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M<.:FF0=AA-G@-0^.! FU#!!-_5AC\,HTL<WIY=D-'-=/C"%@3&/&"%F<$,^
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M14DG5VB!]DH;8]>&)C16DU-,E2;J+N\28B%4UH'\,22,3O=FJF^5)K$.4<#
M)T\59$\)+E-$ T-00[9^(]$&I$"M:LJJ<#$5R3<=$\*,BQ&7.%9$%O^K_F1.
MW2>5 (!G!J[^B"]OXL-PD7A A&Y02*ECW654DU?AEN[36@>G+C<:Q#9[6-8]
MYHY*_-%"GVZ.KD79W@N/-MBR:L?J2,4[*34*T>+]:A06W2>]%.<&CG8_I.51
M'&%Y$+==4*?6. 7%1.N]BF)MCZ;<E!)J-.$_&T,H!ZJ@DH^@C!A<0\PK32]L
MQ^C_=*Q4S-1*PBAQ8OE)E<;,F.4 T\*3*6/V)F-&AJ$>H*&3<7.!5X#GU$/'
M0*IE,$IW!U'FWA)#?@N\?LG"EL)ARNUIZ&$21I30^BLRJ(DF>,8P*2WDD+75
M."1G/@4BICA,NE"&D RX[&1WLJI*Y'9&-,'_1H"&)E[S=_&19O:C7 ,0) XE
MV8YY4)*D.1?N<O/")^1T0Y["]6( B6E(MJ0WT$JOH43NH@?TG0Z+/(HBX/A4
MN;9JFYMO/,-S5R):]G*7;NA!+W3+@>#B(>Y70!=%B(^M03BW+UC")M(D6:P.
M)YCK?H[,)5"2"I^F-76ROV*45'OD'4$B]8@7USQD6'6FI#25=ERCD*,0#=3Q
M^=0(3,;K_<[4,7^24TN*A5VXYQ8"G8LB?DF)E^+-C%")0'FX)Q3$$1F$F[9H
M)CKFOXCE[][B,XP5)!;PP)8B5T+%,=EI0,QS$@S3J!BS)04X )<NL<-T)0!@
M<#QI)F;1;DB"DGK$_W#-*%"K1.#F-R)N]P*=PU]T:"E8L2QBXT#^*K+)]UQF
MRC]D;$8^\1/^BJM953OH<5P\$2N[,(TD=X^$ZIY$J&RD-5-)(GZ!!-=\IZ7@
M2TTEY1;_#C$5F)P(FFC@+&&*,_%8I4%:I++=15SB>T;@-:.-E?2&P4_=E"[*
MV"G@;$GH$S_:)'O=[Z7_,F2>*$SW&@ _ AH"ST$PE:IGDTC^RTSWE[AMA%>P
MI<@2*7UD0_V.XEC<@L(4$"08@20L)7\AP[96-F>!C)/WR\)#1EY%"P9\Y9:4
MU%\(-BWEQV"KIDW8S3=8]94A>8QPT3$*0B&4A_\F"6E_*.*>V$- %4P-4/]U
MQN_Q' K&;I@EE(;$.IJNYIL'E:81)#0%KY6EZMM]Q:JM5$Z&(%:@L!B>ES#7
MYM!]Z@.2\*-@%&5<GCE(PD4@PL+@_@(C%GJ9I>0MCQ#$F]7"F"Z@"HI"4"?4
MG!?Y9I"%+?UM>JQ\ 30E4)-)BN(6 :B'5$,ZDR@\W>)9T^9JO.)Z$W>T[#QX
MB&%T<B25PND@LNB3,L(?GV8D3LQ'!@5C_8O#ZTF(&&Q/<0^'TUR^/=J,O&J3
MCS5/MZK3R;:*UFH\"B0-TRC^-/6SX<6D-V].^9&1(.*T!3=HO"AH='$+W*6!
M_4[@ @_>(@-I/WAAGJWJK -[#7QV:,>4/.7NX*. OH0F1_QQ\E(9HX:22C!%
MX%6GML5$.M+.KHIL3-BB0K**-%9+?S$D>0=H&9*A1>P8 /A-4JHGP,5V0$[L
M?P87*^II7_P(6-K&MBY$V:5YC4JLJWJ+=DXF!P<4Z1SS*?Z])B1!\O(J3G#&
M@]@DHIK5XO\06R[#6R\"!N;/HPA.KAK_ D75 $-BA%(",1/L+==  S)N@!5?
MA]6LT=W2)+$02=N>;LZ@U(RWF(&XAD.)VVJ)\6,YU,_VQB@6_5YNHSBR!"R4
MB.R!-GWFD;1*Y;2-ES_. [QI9MB,8H 6Y"]1$],AMCGO9U)U]/H^ZV;^%')?
M648"KB!#KN1IXK_E.\4>5VXX3#=4DBXF%YB;0]O']G8M@CNB 9*BR]!6YGXS
M-7N<)0"367C\PR]\B2M(%T]836B;HDDD*D2HAL0\M(&P%7$#PSS%0$%D<D"U
M/_<BY+:7JU#-C&NKT6HFGE](>*IK_C^"?XS@8SSF6CWJ^E,$;ID56$9G:@E5
MB6)6R26**FH _T)2C!@'8JPP,#  C((Q8 Q\"/'&0XD08R L>$-,HTP<Q4A<
MN'"%0P #*59T^%"%Q8=;T&0:EBF-I#28Q(AI&"- C!MA<-A$(P:HT*!#'Y(\
M(++@PH$D<0Q3!HU8IILK5S T0&R?UGUDNJHA(]'D 8<'5.Z<!)783800'=Y@
M!%3,)#1#@_ZT:7>H1(0^)4V:.8EC&HDK5C8<.Q"&PK$*<SYTB$;J389+'QJP
MBM(@PHQW[TH".C<N73$X>@9-,QK-&*%T)]D]33I,W!ME#>-X'$-,IGU1)Y,<
MJ$*KUZ[$E:E NM/E/F53#5L^?!PEY]1!77L,(T92)JEH;H],_+@@8O_$%<LK
MM6KVADM-DJ@.3 J^O.&R8PL6WJQ;4R:XKKL/)+\37J+E]9I$OY$%@U4'#62
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M7XP7M5P:MJ29"*&*UI*/RVNEIBB8:2(*OV RUI"O0'LQ;WNOH4# T,"MSLC
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MG%9$D?6U8D,MXMJ\V2',8<CH3(@,6SY#9DD&424QCJBM (G?HE@I.UU8XZ-
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M"C9L*-%PPJL@;YB,1HRL 9ADU) 9(U-9)F7$,G&)\=&RR  B5_?=:SGHZK2
M8R 4W&BP0+&\@VH-"9PH0]9<@P:]V%'XQ87'0X:)K)$@U8)(*>)N+%!R]-P2
M'VND>IWQP;ZJSV])HZ\>:1FJ8;CT+!,WFM(-V>[3ITD,#-<A:\<@PU$9]185
M==%)%U%1P($D$7 -\>941R/]=)4!*QR@%TF9#*.)76B,$>%@]8WU_QJ&JJD0
MPT\'I/@11P6E(=!3@B'44%73/>2#1M(9IE2,(/D5TB3T1#,,#FK)%Q-H9)RF
M#&DWC%3<>5->&&20K&%YX64O)C584S(.Q%J47 !7VT=^<559<1"J"5)BPEED
MF50#G4%=01>)=Y141B6VT9Q5#2C&9)#%%B5#DYST9&O$O)0D&0R),0DQN)6V
MCV9H9"CE?Y#B1E)N-=X0W6SN80EI&&]R%)9!RYE'7*'O47I:&KY%A<:7D8K%
MF5YFC4341RQEYY1 2T7XJ:#-.821@=71.!!8:(1A(4.:*$-/)E9]!)-H,HE&
MVDV3'(E66:WUMV8,*_!:(9HA]6<6L,P^Q/\;6'$*=9ZA(I4[;D@$!76@1&$"
M"5*T 29$JG/93291G;Q!-*AXN?%XK'43Y7DLP\8=FN@DT688WSXQI1'30@(I
M<RBC^R@S2;YJ%6=1G@PYIY!E/_GWH' @Q4D1B#LG52)(>\E&W$?$N7':6P8>
M-*M!'R[$X@%$55BA>9 ^Y>6\8XT8E4(4I2G1C*%.IM177PX4[D(7WC!,/=%,
M$I0*,"VY)!G*H'%3)N,VO2E( (Q$%H,H-AAM4!C>JQB,!GGET=2OO9?A ;)E
MZ!_,_$KU*8,WO+F0X+.%2F.!E2<(&9D(X:FUH-HEJ^:5 69FK7O]>2Q33%27
M+$:E^J2<:7#964[_5JGB"K7"99!RA<,-6R#>51I8^WZF\.;E:WLFF11+&,.T
M!MSN1[;%D.*_S$/5I4.'6;4UA!"69Y#24($%5K@_'Q"&,M$H(TG \HWAR&B2
M?$L;NV6QZ$)G\5W 7.,<'&Q!9O4*'&5H];<@E>M$][+,0P@BB3=(HD!_^]OO
M;-0;QB3K15RC#@BC4CKQ/*0A4CK8#1"%,I6<*P:QDQW.T%"R&]3M):0YUY70
M!Q6(M6E*PQOB56XPNH;=*$)?XQ6Y,D4X2-DE1N21T?*4&*9\L6AO:F%10V85
MEA Q8E:[B<J,L',98\U); ?)(!IV<S.^B$$9[&G;WEZR+9F AAAI*,VU_\2U
M&LGIKGP'^Q]($H@#,@WG,O\23!@!QK*R^(<O9I&->="4F_I,;T9B <Z]G+:X
MQ=U@,E*D3$8FHZ/3>1 -$@F#*C/B ^4,)",*Y&!1*D6,27"!+P:8X6?(  .%
M2,H 7+#A/MAS-R%"*EX&XM?-%+*0(QDE9@)ZF'22PI19T:4R&&()48C#%V!%
MZD/- E,&:?0U ([$:2RA)"NQEL%9-:5ZA[G,Z,*GD1@EJV>Q9 TQB8&&X'AF
M2=M*ANU(<R1#94J2&1+>5JSBNS+1LSF(_%\^OY)!B.ZN7>-:#263*9;IG<8N
M=&$5(47R/+ZX:E\"N95@KE.GB71N.E7ARBNGX_\@!?V.))- F3^UR,O907$%
M]SE)D7"PJ^2 KT<_-)]#'5H\AS)D"U0Q(E? ,J.P]#%XKUEG6AI2%_*,!2'$
MVIE<2/I$K?3J  :91(B>$I91:J2,*N11A,*B3((H[8VV6P;NTF!2&'CFCC'!
M"5LRP3%V2>X_0$E@99"S$'1=YCC,G!(K!:,J!C&191]QS85&TL.EF483Q#B-
M&^H21+ZLJ'&L09-R/L<PA%3'078RBL1.Q[4!466!.,L$/?9!O:F=S%''DT@F
M^N9"T^0M)$@IEFXJB"=94K4BQ3M5$I="++JT[6P%]"S@8N"C>.+J+GAE(QM[
M$U:\H&BANFNG=<E:7B7_UNB,XTSA8GRDIAL(SW;%[..9Y".WN5$JJYKJS^H:
M!%5Z^H^!=M+7OW83(H)(:U/?U"R6O,H690S#2:;)9)@PJZ^]L"1%EC%>K9K5
M$/!4! TVBNV+(N(< 24+O^OR+C'HEU6SS#!DCRJ.)!Z'PYN@S"I1XDL8QB )
M32Z38:L<5 *Q,JCH&FXI<ZE/F(2G)<;]13B^&:4#(=4^@;053)7Q9%KR)9$]
MMN^=\ZU:!2'E.6,MIBFK%0,Q].%;SJP@26, S1A*5C<!;ZI7GY3.+,N7Y0:%
M\B+-@5-!CER9M%AF),)+2Q:K=!497=A#'3)-AR3Q/JW(AK/U.E,15T49.,N6
M_W*#NEC+3!W$D*!A&#S!UKE.8N>/R6YD,4@#41JBDWWT=#9HX'+U4G<<XPF(
M*[B5JGFMZI2Q-$TOCDN1I7$VT@PBN7S(\Y)2!C,7"$,R8&IIR)';*Q@NXZA&
MIQ[,>,YM%2MY-U%]U*6C1N/=#MWWT)Z$;%2I0JH58NFY#CK2<)O]:LLXKGN9
M@HUP6C@]TDQO>ATJ[)CO925*%DZ^XW0,OPXR4]))K".A@C'2(&RE%LK[T2UI
M%*[G$Q)):*D^)X'&)*BT APT157,FR]L,U(4!)+8W[35R'4OZ&G-1FDUW4SF
M^I1\*L,YJXW>7L[J@$6U3%01GO-Z[WL_1Z,D-JLI./\0\6-C((EE\/2Q>@GL
M?_VLB6$04.%1XB[#C\<@ZFH*.K*5I4.H1\ @/?!<OYI:E 3"%J.%L2X<\I D
M&.3$0X-D11V]2KM?Z_')R)(WIU2W;1GVMQ44%&5T/!<,@MMRT"RD;YFR73U$
M_TB<X5-\4$'R8 C$G=QV1S*K:N1;EG<7P6NHL[#"F:-S9<(\A6V<3[%+0JRL
M-_I0SZU&9I^!T%WL$MMWV =935!PD D=7HLO&7+4MDHFB;?_4RA99#B62_5,
MP2%'8M1<539I&6'HL7\UM@NI)H>M>.83$?Z]7IE91FN%%63,EBJ=#OE$1?)!
MBV+$B':]!^L!FXHUSD_M&*?_;(6D0$,]J(30]$WX[,8890W/3<1,]4EKC<B4
M89W]3 UJ35*YP)'??<Z-#-T]@5<;34]'/ [AG9%(24*() 4)-E"Z6=X]L=&7
M0$D,-!FER%'*+ 3-P T>Q00Q_)@RI,$-%)AE  U"_05L1 N@W)?+9$1&C!0!
M;<]9U O05%O\\1'6_!"F_=[-1%XZ;1<R&5C6,,89.""!1$5-*5OG[1/:_"!?
M@0(CC)V*E![+<<NC( >_Y5!1688!>-4'28CGZ*&=4,XE*86179.4'4U($ =Q
M0-I(($49Y0J)\0L7+-FP)(61F9=I18L!  NDA9-OV(H4*1-S,=>>3!U8C,%D
M&0](_^20?J2?9VF+[ Q6&$P"M4 $NR2<^01'IFB4H># -)$$LU6. _H=7BS<
M[_A%*<))2 VAK71)&&52W(E;I"'3@Q@ATA#(WFE'*QJ.SSQ/2*1!HL =?F7*
M#"W)\$3A;CVAD#6-4!7(6"25JXF!$'I=/EW3L!%+)BP%)LP*6LD&+?Y*0]&>
MGVA0LP0CK0R&7625TSP/#AU9"TJ1==$(4Y102]8*MD'%^PQ,#+A0D5C%B0"
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MVD+6Q92]E20L15/TY72D28%BWSG_:0J=I9REY>0^"):]U8VBK&.:0,RX*%3
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MUE5DT?!=QB1TB)(RQ#3)A8Q<\*=5R>3MZ[@Q!*VT#[CJ<NATQ (2BAJV4#U
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MJ]_4V"JGAL:2:#<TAGFJGDQPL(HIW082**Z"]%)M.NE>4H\FQ@X[#/^A3-+
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MS)E]=OFBZ5Q'$\KX1$BDFICT6%6;!A(GG="PA65F""2]&L88;O"G>NJ.K3$
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M3!DX1AF$2GLV+?F!,SCX$.&$3IH2=GF&3CK66;WF/MZ" VDP<,,P2PPC&\.
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M.M$?]':/=3&B-7XPY=":^RS:^GP-.!5V%GLY!&9HX"5W81:2, EB_WTC(BK
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MY++5:1$8(OH),03@8LVG.:R7Y\*N8CT);1/68JV64'M^"!](2IGQC-7:_FN
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M^A1*G3+5KS,W2Y=:T+'_4:\E#PI?C'5J==[$"P/&X88;Q+B!"[,FR602--)
M$*U,B$E+DV'RRF08M"914,&RQ ACM!A&(RB&R0RZ#KZBM%I).J<(<BDEAVI[
MR2/!&!N,,?U60JXSSWI*@PQ' +L!L92:0T@AD%HL4JG[O%KH/I@HHVY)Z#A2
M@3L1!;(R)P!4,F#+\+I+;L:-9"Q1N_<4$BFK& DBC*.H9&J)S3*/.TBD^SH2
MKCNM5"/-*Z:*W.DGT$ ;2B&+7E0,HI$>PNHU*V-SZJN'3MIOL1H%4Q2 $ $K
MZ"\<PHCATP$'+ N-LL;"H:Q/114-+-GX5%$W+*M+4<2&]G.)HBN+/-$A%FW;
M_VW7ES ]C2 =RPOM0XA2;*ZF1@FRL[K6BCILHJ7>?,C)6T?DCML#HNMSO/VD
M;5&C:./4:*LEH<RH) ..VBPY)<';2*!P"=KJS_9&O*I,XER,%]DQSB-#F<5@
M*W%97>W]5C4N6Z0M(WLO\JXVAZCC4D2NMAI/5TXY;;753I4%3"DS3=J,T6%I
M])57^\;4[0")6L+I.F&CG-10F9!\4JEC>1H42(QI2@[%+H<K";$9'R,S1=M>
M_),JIN$=;LMHHXJ,J*I2LM3=>;TTB2D9B[1IMK'KU6BX9J%=[K5*$1*RJ(<^
M(QB]H?A+K6V47X3I4).>PYM,&*1>%+MH0R13/826W?]T4[ FPHE)=PN"R:41
M&3=7-3D;A5$[IW?#24Z-3J)T5W.7*PC=A8CQ#&CSR/"06C(# ^"I^<;.<[CU
M--=8<8 77PZWJ@824S-*TTU[UA7[?$HU396F3S.;O.:52"NM+)MJZ33"ZKZQ
M*1-)=&1]?-U@7IUKS2'ZJ),IJS23"WMVX5'D$]XO3588@"-#7%)3>@=?C><8
M B_6:&Y=29$4\$12K,/LYS4HJ8]V^I,?ATFL2"KZ64\$Q2GK+41Q)'I,O39V
MDO[IKDBU>]=62$BVAZBI5G6*E]9"B+79*61MD3**1506PZ_@S$79V@@.4Z0?
MW@WK7SF4S[= <J5<+019/2+_%(K"8RW $(9+3LG*WPZ"(\RH:V\JR!K*BD+$
M*9($@38!4^ "()AT%;"$[M/.WR@CN(CMK3>L.8S$E-+%KH2/<BUL5'4R.*C1
M_,5>^9$88=Z6..68<3]S).#S!KBG)64'CX^\V<N^UR=,EK!;8*-9;$0DG<"$
M9%\NB\^?YM>\$+%H=T9!7W ^(ZA!*:-YX-$9 $@I'.QLC#5?2B*:1/A&OE&'
M>-$3X? PR3OI<2R 59E1M8JC%-[1:B)B J(NS50T&HG17D$DT6T",\AD=8J(
M!KA= %S)E)5UCT^/9-9Z[K,N)LZ$.FS<':2DU46B\0=NN^L6V]861!JJLU;V
M7!FW_W+R,-&IQ$QK[-L^FSD^#1:LA=UZC\H4M\+1\9 VH-,G^&S#IV'"[$;_
MD=-XPF.K=L:(*&#YE4NC]2\UB9$F9W/H41PS2C1=<WX7M.91R!D43@V+@#4"
MF+;:%<,&HFUW3VV6K)JWI/ LC7<!S:)4-0-"&L:H15C3W#UC9+]F\6YZV1%>
M35S#.R)II#SG.8_Y< :?T6'E/=3Y3JT6E<1HVNMMR"G,?BA6E4SQJ5LXL>3)
M$'D3,&GD=$1AETGFX[%QE7$KE'$E4!^&L/@\A)P]"9G],#43%)+&JS/+&%6<
M6K7';@>R5W7JZ,!C&7RRDS<N_4C_MD6QBGBPI0R=:I\.^$RV(<*RJ=,C(@#&
M1TME].=L9O2(I>0CV87$R;<711AM5=1"[IJIC<,9#L#"H\V5QFQ,"V2:UZ2B
M2F992ZSAC0Q>W6F8_<RGHZ[=8D18_[>CBG+J)@#0W[>4ALYA60U@1R&P3^>#
M,TTY!DP.1DQ3T[5"S$X&28<:FU9U^1@":RYYXF'D3ELHISWAZR2<G-2,8KBE
M \:O(X$:%*$<>"8,"T]Q^?4C%@\)V[&>J8&MW6D:#UO#$PMGI\IY&<P.PT(6
M)21C!'GE;=LK*Q'.AG<H.C!L/PN[L #XOP!.H:8" & $HW @ % GB]&\M&\1
M>'_S;.E\O/>2^V!I92NN6G#H[$&#8@G 7/-RC%96-:N4V2"'N5-#Y-R=VAEX
MC>H$8T/0C$[NX.E;R@4:7(5B+6Y.MK.$7J]E=];5>+%S;<FKZ_ $YUB&&<U&
MBTHGZAX%W?]8 >Q/NS,-$:>'-XS]24CP2AMW]DO1! +8V,=&MJ:.W24O(YO
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0*@DS@-.V+T/$@\B@@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img42979713_5.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_5.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MK*]@:Q$.<,L-Y,A!=.]'W,!DHX$N9T*#*$, ='/Z)@QC [ EXU?3Q9A0S"F
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MJC[P)AB&RIHO"F-EABI:6PY>,"!G@K("9AN);EB'!=^NY$^3_Z)0 _T3%,6
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MP)=Z86=67<I$SVAI%J0Q4=0Q!3E9I0:-=$UJ;N8-]_+2= CT[([SJA7:0G&
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M6Y!^P4RBV#C%:\.$,XAN$P/ D16"6%- S4QH8KAER-5)"%3L*(@;/+/HN,Q
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MJ]<WX+<MT#3C4()]U;=^9\)[Q5=GJY=G.V)D,\XW-.DW,@Y-X7<N[!=]6?:
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M?^CU,!HWQ3J6F7*S7MCY.9OUTB?3&W:MU2;^.ZL\O'5WQ<TUJS9CW&0::59
M M,:K%%><F$LQ40J$E-V\9=VO+-,I+)>K-8LBI9.AB4_4Y<MO[%S&[->OX-9
M:J<9LV)L'(0M3E$M1+<K>#8P[<=KAC9 Y7%/!81FW.)FJN--@^5*GO0KQL,K
M\K<OC'9VN<.# E1W_$,]T$(9&:,QY:(3&)52*Y1Y-4-$T+9YD5>%I*>%G5<U
M!^8T+O1>*4%20M1"7$AME$=Z# )3T- U%68ZL&=%2V(D%Z83Z>8U1A%[GD)7
MQ;<2.. W?R@&RB$&"#%4:E012V(GQ,!H8_\  P!P8SC 84RE?90($5D2 $ 6
M ##@1S21$I7XB:!X-W)(4U.4881A%T(A6\03(%*6@%'6<JQ!/S<'6.F2<K7C
M*NCD6NU3@ W$@ ?T'+R$2M5#,98U3Z>D7L*X64!8+_0!()'!.++S0.C',@QU
MA'VU= Z$2Z)"3<0&30*5C?D2/D 8C1RTBAB4+Z[D:@/#'DKG&71W.[=R<13D
M9\>2,-(56Z(Q2EA':'LF*O^T+6VV7G"F7=;2.X2Q6<C%@H'G%,_2@?9B,>-R
M:[(E'PB60\J A@M";A<9>=,6A9G';/*ED6JX0RLE1)K7D2/Y(E?(0AP2%'D8
M)3P!%#A%-G!X.E__@Q.X)V]:,V];]!* M ]N\H<>T8?#UR4OD2;(MP6#,PF2
MH E %8J@Z#:<,Y69P%5[<GU0F96AF%--Y'I1PF1QE4X,:8N.81W&I(V!%1JA
MU1<%)$L(18"XI"NU53S+=) IPV5^YR]W9VC0%8#1HS)RB7^MH11_YQ1E9G;D
MA8S-0Q@0^$UK1C\,U![PAX'60CMW 2]_YFA[1C_GE"HT)S&+AA6H1DYWYG/*
MN%P2Q(VL.%E^^6?OYUQ99FN]$EG<,2VWTCRWE3+V,82^05L=@VOZ83_+A#NV
M<1B7E9B]"1T@27KBYE]EJ#-16)$E@C4X\R/WA426QY$DR2/61FW.UE+9_XF%
M&1DDMK<ZZ393H\A];S6*EI)N.E%[-A$;01$3>90)8A  AR(HR@  >T(W3XD1
MRR )9Q0#6Q(#:P( ^Z:5E$B4D-)P"OJ@V)<I=/AN%Y830_$3O_4>QTB7?B=<
ML9@8#0E"UL6/1D>-O 5;:EE!% -=!DD9R7);L96A<_DK'OH?(#@9MUDQVG,?
MZ)%0!*0=M7*<2]A-3#=.5A8]X(&+3,@^QT$]/_AUL*D[Y1@]4K>"W\%UKU-W
M)Z> F:1I\[0JET0QSV*C$PF-MF- XV<PA:E>&H,RZR-/"D-,VH@_%S@5P5%X
MOI,^5H%*2-<OV=$?4SAZ3J-$A,J1$9*1Y39YV__FG"[">(BZ(6D87U/((-=)
M;@SVD>E6%.F6>F]54Q+JJ6PC)#;E?>[9DR^1)7&S)9GPB&*P)V'"H XQB0K1
M8U"E FQR #"P H((H=FW$6B05I""E;PZK FGGJ>S)$ZR:E)4A!)9F^ 3%@_4
M?_BG9;;S?YF%:/JC3>GQ363Q%=8E9B=TA-4$D-1T/TE(I;]R=0R5:LY#7*91
MA+F3F9DD,:B&:X?UH4#H6=%RIUYF/\J52?&#:WH!:<XRF,OQ9A1T<\-H?^'X
MIJ]F9:,Q&>(8:4':0*PDC>R$=(XUKHFU/\.%2_4JHAU$I>X230%C78'A=NLA
M'"#JA((WL+B&;"XUJ3S_@U(V>VUB"&#+*:EGJ&U2&)W:YE(>DH4C,B%0 R*-
M.C4EPJGS=IX6%D44YFXP25/O"130 9]2\I\R811\0C="!1%KY!#ZL!$Q4!!S
M$D<'@ 8L1JP(QWQ:<@-&&2F>R+9T2V02QGJF U<+,6\0!7:W1I %BZ-U-Z.8
M>4[/ B\$I!7'=#&YD5KG)#L),W(Y6%A^2SW%]2LCNTSH(Q6$T:(GLT[OM++2
ME*6[N(/58DZN1!EOZ7/ENJ22B;G2@HYT@;F/-5U1]U@EJ++TPH(-^Q40*8PM
M]QQ"R*=!6H+WJ%V:%:.MV"]\%2^P0CQJB;S("X^=AB^O$TWE=#V%!Z?M$X2[
M_P.M[;4CH !@^L4A-Q12E3IN1MMX(QEMU4DA-+22EP<C*V6T,Q)@HB=O$[=Z
M3H(VW2>U9B&J NRTF4I[6P.K&3%1"DP,82MB*S81PK>W1F%&3W5&NUJW$.<V
M!/J3CL(@LHK!(+Q(>=M]4#MA/6D33I9)M5%^&WM.-?>,D3FG C,:HAF#[P)=
MM,0^R_MD*"M_C.$RSW0O5T<R!)AXV04@O[D^J-0[9><4J:;"QQN;?^MSTJA;
M/IH?.Y>!RZAXESD6JO5R6*&M+>N-8)8O+A,SXR*-LIE-Z$$]/[<NJX@4YE(]
MJT1JLO66T9%!3Z:"=79-%33'<$:R<^%VF*E7LLF*\?^7+.Q1*_JJ#)5WOI9J
M0T4#;?@;R483;I),AH,*AO(57TID4B BGN[+R3[BR,KF,P_&)&BC9.GY>L=*
MM4GR1#E9M;$G$P1Z  :08U_4)T2%$44UN_K08S @$ !0?2&<<,/@13&0!@CL
M$M5VS-"\2-\WM5&+-A=J%"@T+Q #2S6,KJHX/N-%@K\R00W9:7E9/J3B730L
MEBI8K^LX<U2F=R&(3P9XF6?:28@,0G>A%RVZ67Z%O*E[:!U8=4]G3@&)FNFH
M3XG&NR[7'5,:?P%;06>BL@HM(/%A+IDV.R8*KG+&4/SQ9-Q1@Y*%+4JZ*N*$
M9Q1+=* A&U^!TJR13]4TC_S_.CVXQ*R5^</_I$^\);-4HU&?AU\G69$D$IWB
MJT(S*VW-5KX-@FTFLD08R<GS>R&5"B)[B)/GR9ZAJFYT*"5/@J&/Y"G'AL+*
ML),Q@09<HH@SY"C$QQ(-#!U5:6[1#''U(!(J\!'-W!%5V=9QO=>38G'KYGV4
M-$5.]ED/TU<1:8$OZ[BMJ+AF J:8E2Z:H7.<Y#U!&';+E&4+S:?;$DH?XVK>
M*G(268XC2S[8DJ$B4]/<^-$Z_6NU05W2]4U6+([K)3WCJ"_ F%#^08,CM(SX
M\3OU.GCTV-ILC-.Q(W2VQ#[]U'/W J3($<@?B%PEFYD%<UQMEW;:JYE3\:?%
M%L/-;B/([I$N&4H;OH9.I4$RR/;3H0R_*KE@7AA#HC=@]'M1U:8@]D7?&#+5
M,@3)ZWM@/2O?4HC)$J(H31:?!PQ74HM3ER))EB++LU>U+WG77<6)C^*?'>'%
M5P+A?(UPRM!CQ@P3(I+A(-XXFF)3L RU_PIQ;%PK:((V@B9XT5]'CW5)6*.[
M07$**H)I9W<E90VT+ND4/.G'.,K%''[G=WV&/[;$NKSE:3C8+K1&<PN=LD2H
MR#(,K:*RPJ0-E[.!CR3-/Q@ML</&3]WA=8-A@ 9[2K(53R=7N.\$:&%>T!AD
M<Q-]>'A6,A.(/Y@E*K-[KL0$9S?=@NQ#2KP2,+4VLID52R8-C-'K&B48<J]A
MD3'4W@SFZ#VSD:6<$E28DF&H(Y?'49L\J:<<U/^-Z3Y3-[8'-G?HRC2IGCLE
MP$$1UC)UGFTH4^#G$I/0JI,B1A$<$<005EA%?1@>XD7VZQ:1$A\,[,8^$PD>
MP'[MRJ5824Y6V/\A]SSBO)HKRHU+F# B.&C]&(/18C(J)W8ARS!'"$V!R1ID
MQEN<EC"!-8N?),?7<;EP21>5"6@ERRY >IRP/1WNDA^@B3^U]!GS/'CKR+A(
MRIO6E=OH$JYJ=^U"-X-/:EC=NX#0XYIR 690<; JPXP)]%#(,F;('2WCL\<+
M<UDL0ZV=9#L TFE J'6E$LCB;%U@<9$VPC,A&9[QG;20S+[WZU'H?;X]_WBB
MI[[-:2)+K=[CR=0?DH<Q><"*@GM.JU/SF>R29'NL4Q1-!I_8W"DQ$0TWX&&.
M[,@=[*##'D>:"  7?.Q%QB@,L>N_-U3)@/9P3Q,&/LU--%=L\Y<+[1?_W-&;
MUY2P$/6;-GKDT231<XX^U5KXO\2O O^0$.4QB'R-$QE=U'6"P6:"K_A=W*XM
MEODRZ0+F^5?0)M?P1BY;J%GN3-%R25KD%O/1X-2M2]J-Q*;$1Z=QVY*/[U%,
M+CCF[KQK_S,4(,W0W8W[#HV]*9M="TM^!P<NW:U.?!]0F,0L(ZLK_2[.3FQT
MG&NQ&0,5]4T,G/?IVHE#IJ>T-:3?^#6=[NWSCTZ^FCQ#[TU1ZGN=3.0U0&$4
M>RAOJ4QA)=S5&&KU!.S7 $%/F4!E^PP>1)A084(Q 6 <.& @A@%B"Q5F"F @
M0*:#DPX .,!QF<)AF>A91&F0V V',0"(*9A2_^9,FC5MWL294^=.E)EDW(@A
MT@ .H#Q3#M-D5.E2IDV=/H4:M:8R9?6H[JN:E>K5K%:M'E2V3."^:/I&TBL[
M<M])@R.CU7MK$.[:??7(PF5K-]I)?7;K&D1K]F[9>OK6$AY,%BM9LX:A^=T;
MK:Z^R'_=SO6[;V1,O7SUPH7;>/%CN7()2RZLF;+HNH0-WX5VU[#GUOOZUF:K
M=IG@NH\-UXM=$+7MD7UC^]T=&3A=X:F1[R,M&[IFZI)IQ_TK>'ALMWPO&Q;L
MN_K<D>)WTUUMM_SXW]#]?@9,^/%QN;/34K8[]^1CR='5=HZ,,K2H$RRU@MJK
M+J_;]D*OL+0 <^^@]_^(DRNVR::SB[>_,BPNM>]L2RVNN83SSJ"^E"$FDQ17
M5/$3%HG1!"FDDHD1%!EMU(3&&6/D4<8>?QQ&F1:)<5%%''4$\D<B5SPR22%?
MS.3)(I\<<L@:?<0RQA>7_#&9L+0:Z,MEH!%+&7VHVFTKJJ#I2ADVO<JJS&7"
MG!-.L>XD4\RFJ"(&13\EDTF9& S"B- #3AKF@*L2TF02"W'*) 88 G ))JDN
MQ31335-*(RB/A!3#H!N2@DK%34]%-5555\5I33"W DY-63.CA\TY_[JK0M7.
MX^NPO@PK+[71/(1M,>QHTPZYV0Z;+#._8BH1/==\W>T\NGR3++E><RM-M0#_
M]7-O.+\"(V^QV[A]JRP&U^OK/KH,FD_7]WX%=, 1*7Q7K\G>"LZV?>E5S]^3
M!DS.L(*X6Y:TU+@%&#$"':1-M=I&NO>V7UL3K+%I8U+KKP#=PM5!XW+]34#B
M3#[H/Q -:JXM]V*[S5C1+@-TW.V6.SBTQ7JC+K0.-<Z8YHO3I2XP!B]4JZ#R
M5IQ21:>)&0;'J'U,41DMG:9RR2B?+E)K*&%$$DNIF\PR2ZBE9O')),OF$4FM
MJ83[:16GCK%,JNB9,YHP"9K3[C:M4A-O-[<22&^!YC1S*S8#WSLF5A<2M" <
M)CDHJ(X/*NERFXB)806)7G+\<=%'5W62- R:9)),_RC?9_6H4B0]=MEGI]TB
M.*D"'*N_NV(3K#+A38TU86G.E5\0LWT-LV4?Q@_YN.@]B6BZ)(LL,-U(OLS;
M#)V-#;NS3*ONXIP1/ \S$&/C+SOG7$:X0;".GY ZA>55=\"W-"379>W(I2SD
M8@.^5F% =J'\B M8NB+:@<K5+G,1[3.QB=["W),\R0AG9Y"Q#'X@!+1Y44N#
MLG&0SPR"';O,QT#ALMAR!F::Y<1O.>)[&<_BEQ<"E<]@*<M5=I[G'.N Z(:X
M:MD!?Y,UN7E-16'+T=IZ1$0CI@UK19R:$9\DH[=5J8E6NI&,GJ2CL0WC:W)C
MXM:N2":\L4D@A_L2000'N/_%904K<Q*(51!')VB@\4YX0XO@YD1&HQ#C42A9
ME$S0$*I]W( C!A$#&M22"3$D$@>2R,Q-,G$# ,1 !0:P5.TTN<F<3 (-!DE#
M)D()2M8])4J<1&4J5;DG6+525JZ"U4$(4A4&<LQ8YI*@> "8%PA.!V0,[)"%
M2E@\]!AKA=U2H'WVQ18*W2<N^PD1+I?EP,&(!F(4H@_TLL68\ATO04=3B\;R
MIZW3T(56[^,,6:*5EYNACX?@R9XL*U,PD:7KAQ+TV,)0<\#@X5(ZR7G.@=3"
M%J,-K"SUF6=IXA7/9[WK82Q#3W)"1I^_< =\%?07Q)Q9P,6\YSC.M%]@=J:]
MMBS_ZX;1(=@$B?8? >U3.;])2]2JIJ(<P6A'8J,BUFKTHIW.[6I6R^(2B_@T
MMK$M;&2[DI:Z5L2ESK2*4 )JDFA$C%G*,8UU#(M98-DFQLVQ5E;EVQE?23B[
M&44,,4"#)D*GDDFP9*T)B=0!!F40&1QR'VA(PUNKIA-EI X-ILM$)"T2,^K@
MZZVK1*Q3!!5* ##R!E4Q9%20\IK$5M:REL4=K!8')\YJQ7?VRQ?,FI48SN '
M9LL!:*X\0QJ Q4<PT#1,NFRFSF^YC&CV"M?Z]F4^!GUFFPP:&0TK\QF8)JL^
MYJ2MQ#P#*%[53*'= E=_@"/"]_7R>=TYF?_L"1H?+B:=_S%3WO9J6$UMY; Y
ML>5N-<GSFU[JKUP;JMEP-YC:#6IT0:/!6,>V2ZV2#O>&OWJ.14/FF'>Y2[R[
MC=E_HJ/"\9#P0?E2IP_ERT"_\.<V* +C4%<$)*0&-:=<"MN+;IK$FW:1Q"1>
M4E&5Z",D*0,I3/L:%9/J8:GQ*"RSY-N7PK2[K>RE3FXZ'!KI%*8\52N. ]$;
MF@Y[$TV<%2)BN($8(G* &SAJ*B$I)*GVT<B%9.*4[X.<40"E&,I>ULQ1820.
MXCJ)&,A5*IJHR)GE/.?9%80KF5U<&V'I+#<1HV&W 6@/8W9>\'E46N;K7H65
MET.\^.N\SJ+MQ3(6PHQN5,(G.?*/>)"EW^5$)[O!.N[!Y'?!]FQS@ABS+\5:
M>K'O$?!\\>O0M!0\+&5"T]3RNY=YFG<\Z)7FNB6#:*_;=;'0//"=)^SE@2J*
MVM(89[T.)K8,7UU<["A05]>S9S>U6:!M<LO"E8E>A%DCTKF8=%CG\Q8["UM"
MG1EM>Q6T8H:)T:2I:AB)=+LWB4V,TR[!F:9THQI-N1C49,!8WD,%JI0,?C8J
M+I5*9QJ3'L]TQKZ]$N)J5).<[O8EB-]XQXB;HU7&PA1BJ"Z1D^A33L1 N94?
M)+(*29%@HY$B+Z]NR3:1.8?HO/.FS/Q2)>%YT(6NJ5<"KI73Y?\J6-RX0\G<
MYH3&>S>M'[S %B[S0AP[:6O&-<(\'O0YSTL0"I55G>QH/3&I]<V$3 BHTLHW
M.QVSW@2OB>L<WD; 83<MKE'3+_. 3Z#0%3!NA9VA=3/ZA[5A=R])8[S_((]
MM>',0='[T<+W<+^HMFC3A84SV[YPF!WKYMP-;)]H:X]Z\V*0K6FXH,Y,+\"M
M*=&'='[<2$>T/;RQ2P1!A&&&SWAM3Q7C$[_6U"(JZ6D\>E%3 5YC+QZ1PS?:
M,(MC%$:;KAA(,-XX')4<\8$\)DYWJ[B/"8)5[FL_QV&:N%;R%#M&L@S+F0
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M$M%$9ZTTL<E30;$+7/5G[8TXL%8YZX56AS"[9I1ST.(9X;!'-IF)2FF6T9:
MX<Q#R.%-6":S&ZKH)6?T8,_1&FB7P\C&+TQ#40!U]O\8MU0&@YE1"E'B\C#0
MW 8KMO$+7F*S&I&]IAY&J IE3#B4 !KM,3*T&;-()#>M_$5@8J.'6O[BK[\,
MA3W+&%HTU#(0I!0F8%:+!GO<LS43"B@QF*F+9CAT(H+ 02MJ(U!!IM8SIE%H
M.":CEAN3)Z"N=8= I<&:WE9T-JRIJ$/P(8X(+T*T$\G&9K99$7<ZQ#5])>A>
MTVED EGD-COJ<6TW4QPQTJ2)')VI<IH,7)K.!,K&?=)(@B,E*O^6.<PY:953
MDIPKK60CR"EC1Z#[TOOX,JC2W<E6;]J)GGBG*VCLLC8S>5WN (4G0LUD)9^2
M!#&(I Q-$ D4 J*4)C)QS8C_V"Q]WOQFI98T"3&@(1.<JI2/E+=-<+*SG>=K
MWTP 99.+N"]\N4OC8YI3E9R%RSH7@U$9(126W,U&!W! ECYU4T8@"$TXQ]J-
M7^BU0(9B:$7LV2=15 8$5:$D/1I50S^3LHS2\ PU.X/#1>QB4!,Q[3?"ZE92
M<O:4E:XP*M+2%M#*LI0LZA,J*R*+KBY2E8FIQ0B,B@Y(]Q&*=*$%6G X*$2#
MIB\0?<LK2E5*4S9APH%A!JDD\A>]?/47M:CMCCW,)V\,.E)E7#1#_L+8JN #
ML;81Q409<J2#./06O;5H/U4[)-*P=D=>K<T^6S,@W!QX'ZI9]9IRRY#0./0>
M?0&R_[$%@1L@):G'0V[';&F3BWRF*2;'H<EQ9B)EDBQ'.!V=-DVTC-SF)J>Y
M3.*HM6HJ4]\ZEZ//,8E&4>*;)DD[2AJY+G>W Z;LAA+46=4NF$&='9N@$4QB
M_N1VM!*4<IT)O0,$X  &B($!O*N]20UC$HYQ)WK3JUZ-U&B][GTO?!FBDUK-
MDU;1E4G\J@LB/V*1A?="BAITPQNQ6 5> )Z7::[BL6'U9FKR8HP$OX4:-1BP
M8PS,"78TTZ&%*CAG]2.B>3YC+" \UC]$E,M61U,T!5LE-!XBBT\3QA@"<?@P
M,L2?572P3Z>$<2 R9,^X/OB6V!!%7&/Y5Y'# F*D31 KN?]BS&'F5\(C:^4'
M'F)6:JBB!M;L,*9V&P@T/*@W^9 (D'5U*V1"Q)]\/NBN'!JS97O5,S>_)9(M
M_6P@V?C9,1JH/V K;&?U:%FDM<A!-B.;VOXCL-KHEDFF_*0H2UDCT+%2=)2[
MM*5A^20PO5*XF^P2I$>YR=Z*FG%E8E_I^.*^.>UR4-+=Y>Z"RNK4'?.Y0;6=
M0'*2NW7&-RV9*-]"XB0[-O6ZV,:6U*B4-[YC,[O9NYFG,NS[/F@3FT7W%*'<
MSFJ4#2YE(-[)EF8$&=7&I.5;,86984K<'"!CI<B,40Q@ME)1<Z,&#OVI&%G4
M0$_$?.N@,XV;A.&P+:(5TF+PZ1C_BA;(%='X!:4XE<V A:5/:W4,L@>^"'L$
MUE-KN>=MTV**Q@"8[VX7I6K.T9=6(R@5%1'CHB@=R,'_19J-<V5I^>R87U(S
MGV70.\!QBQL-R:-(D1WQ,6+SHU[ME9^FP.=K2U];@9*3U_OT&;2/^:O4K=JA
MP";/L">!+,S:7/+^5>:0;OZLTZXN=$EVML0@(HZ!FH+)R#4ZEJ^<7"SMGJ4>
M00E\FYYTX53;RL'/UM&3ICNE]2[XPH,.39!KDW#<))/=Z8G6M]NEZJ+MIMRM
MSKF\(R;GW=2[9I<75PVI!QJF)X8;;*I[SGX][!/"D58E+_:VAV\]Y_GL>L+/
M)VZ2<E['__?G@C0%>6KN#UK,]IJ"-%V ]K&YR>9#YTC!',#%<* FS(B8_1EZ
M^6'?D$%\8U7^B1!K8T=)?YQF^@LM7X2K&FSPJ;5F7+V11 9YD,9+U- :$G_Y
M\!'Z<O@<_I%?7O710=@&9 E,@JB'SD!(_OF&>J2'!++('04(!:;=BD79']5'
M?8Q1?XA-VLG-__D$O"3@&[$&TRD6?)A=A)3-!GH-\W6@QI$'=XP(HLT-UR3?
M\Y&'S<3(F"E=W0A(@)0&\@D(>?2+*@'.F%1.*G4)*#'>WAV>:I52DJ )F9A6
MZ,B2D(C.X<06%,Z6%V*.I(6)KM3.K9WA+M'*<8G><<W.(\63Z?_ 3N7]!.JX
M#TM 0R:85_RD00R<EZ1DDQ\N!*( P H8P K 0":8WNTM8K.=4ZN@T;XQHB2F
MSTZ0#N_1TQM66Z[LRHHHR(BL8'*(T<;L%[?TRM+ G"@J367(G?MER/@]$A#&
MB"IV1X&I" :YVU:@HL"XB)1-%@(FS2_:!]ETC23UE1W]T=L,B _"36&]V7^L
MW6'-(O*!1QPQS4745=RDG<-L#/J!S5E4B,-42-98%8C(3=OTA+[ AU HG=E0
M!S<"UH"47=?EQ]/8!X#Q23:>F1PEG8& 1YGQXYXIH]ZL(MN$30Q*#12=#3PB
M']21H#Y64D<IDM'MWR$U5BA65!%VEOF4O8C=;)ULC5:8A-(3AN%N+>&3\-87
M*N$6 HYOX5VCW1VEO5)L98XI11I(HA*:S,E,8)>@_,2K79Y7')-TG:$^U).<
M5-Z@"-,NW5<@3D0]W, *' "HT$/U8$]3OL3P7"5"0(,8%&(,J, !3,*R,6#[
MP8OK32):*L_L*434D" ['E)$( H.L-ZF*&):WN6EN,\\[67NY?]$?@&%$8$=
M?1@A_V5C*(IC(:U=V=09FA6:SCC67J7? B*1ABF=C)$%1_'@_%R=^T'@&3TC
M^#T2^FT6\FWF-@56G74'!SZ&97%6 GY=8L*+0LHF"YICW)GFUXG<1C&@TX0(
M&K%9"D+-*99@#!)C2Y&?0<#,(.D98OD$#=U,V5W@<)1B1?Z<9:VBNC5?-KH-
M$'H=C,R-8C$-(!EA(<U9TMF<8S9?KPB(&K&=F_6F5:$F\$52"MZ'3,ADWP$>
MXNC638I6CWP)@)Y6$K[6:B$>XLVD2N;GX!@HXM@2?QZ)X=':H'#>'/*>Y8E>
M&::.<@W3FRC7'-):G6@E1#S/18"$#-S_0*A82C;9I4(@BB&"5TDL!'5<7IWA
MI8VV2K(=!&NP!6"F1(: A JL  # @%C>J)%22OO8UW7YDCVQ#FE""-+A1X34
M2\G(AP$)'2L21YR0Q@8*VLR!1]Z,)TJP1S%<Z<11!4IQZ3/^G-/0D;?MASM.
M%235T V^QOTL$@MV9Z]@)P22QX:\W98NC==5IX+PX"J6C&0)IE=TB$/]BU <
MJF(]E@6*S1KU1+T<UAKE&8-TUKYU$0<BWWJ*E:Z0B(JXT7X@HR352WJ &6-1
MDIH"$DOETQH-8-149 K"71&2'X;0IRN:):!!IPPF7'-ZJB39G'D:R)RE(!ZR
MEH*:VHP4R7"5_QIPQ23B@9)IF=::\.=_/AIK@1*!?J1O'4YJP5:S&LF$PDYU
ML9KD86*'GJLE$HHP9>B; $51WDHEJH08I$%!5(_P.&)%=*4A&N(D$ 1'F),Y
M^808K-[JZ6'RC=^1%ENFB$1W<1?%#BPV#<-8$JP84 _U9(]"P&4:G24Q@-<!
M@"6D/"S*NL1\W01?MHERX9?OX9>KKE&RKLC6&"9"WED+.F#Y%6,",1W)'(@(
MKB;^&=JR+4ADF:)$[@>6!N;R)2-ZMF<G(B )=E/)A&)X@AG8'2K9J)L>:=P:
MX17<K5V@<>D=J28@J1ECZ171T"/5(-UC]"KR04AB.>#P3>T=;0AX"/_6UZ;=
M_U44)=F@>>I,=/:C8L+BF9'9(P4GU-'5_2#CV;:JEBZ='E$(?Y$'7N5L2SU6
M\2FDF:%1U\X'^\D-,3!>%V9AX66.Y]BD)H%.X!$>N<8NZM:=;+VD$TK:@D*K
M%88D*/42[U!H4$G;A8;H/.T24A**AY8ADZX$#H2*&+S!JV03KUEB,.U&HIB*
M"L0H-)0*(0) JNQ&&(B$2*#!/A!#&DP"&J"O)DQORJ+73$13WR@#)D#/,%3*
MFB@$2'QER=Z B#[M8^I+^4(E#!Q #%AL^QZP1O $RTH;JNVD>C03V&7NZ.X<
M^=AL!5=6"B[2#7XN< HN!=Y'7T7GT.SBF^W_X-2)H)2.R-%1()^NK5_%I^?B
M+6<Y4A_5)]Q4G9O9U8YNISK21YL)KLVP!=)&[O]]( R>S=QNG639YW%X73D2
M)PE7UI?ET1_U&>A^5HQ(GT-&))LV+M!JKF-**235BX;89\,6WQ&.1YIQ[EY)
M#=6&X$'.&496)W]$RY0V#?*Y7<^R$7"5VK8Z:*;!;N(A'J<=#I#T78"*B=\<
M,H.B4JC5I*AYVK=*274-I9Z GC#QI4Z^R9_(B4Z<#KT&;T_""?#FGT<D[. 0
MPPUD#S410_&0%_%\1,*&@1C@0!HHSB08K*I,@DB$!/^6[Z=DK_=F@AC    $
M@ IX;_\BL#MQ90"(_\$RJT0F:,)9EB]X74\ +$I7Y"$WN_)!* /ZDI,8Z*$R
M0 ]8JH"_,K,ZRY>=K X\V81?QNRCHJ!]2DB'O(A\(,?5V&V:N<T^DDVOH.;2
M5(@#0I8!G42%A&;83>W\.&S2\A=!)ZTQ)M;5C6?2:9:8TG%9N;$8F8W?_MS3
ML:+-Y5/2%7%!AR(1$DVJ)BM^'"XKD@VN#"Z45E1\Z*R7]EFT<. 1^I49XUF*
MM/#@-BT^$U8>00UHO2<,SA%:>&KD/B37Z1':8ITS=E%]HFK8&#1KS@V85N<&
MRPAN\4U).NONWM:.V-WKAL[EN)(5TDAI]3&:I"0QC/6H%2A-2JOC[!H;SO^$
MJKG/A0J3<7ER'.;U<FTH)K\)\\(H 5]/>!E -*<$(&)*2 2 ,4.S0D3#\X@O
M92O##8"E_H(720QP#%#V.KL7HA!PBE**CN"O ']E9D,EC)+O0:BR2 @I9:NR
M,,>H033V:!_IZM3)NQ)O;N-$ OH@$':6L>:54J,T_O%12TGM#]\9B<#Q#G_B
M_5RMJ@[';_K'Y"9F"[IB(54WB4 6F+99\,5)9]WL"WN&!?;@J9:9@"12U7A6
M2HOB$H](V^#5:SXU3--I"O=J UH6*\[J#I?B3HNQZ([/V (M.#8-0-9C%Q^C
M>].CU]T,,NZPK9H9.W)=&HLGGBDUUGE=UD -^O7_SZ(IL<T]:JAVXF:5>!LC
M$;:V-5GW\6SY'90$B91$ZZ.-TFQ9ZUQ'#B +\EF;6A4ZJT@^&K;:R*O96G6M
MZSS5Z^8-Y4XX^:TAD^P4Y5+6#J!P(K,-S_26RG=E+_:D+QJD@<&:4S%[]@WD
M<JD<P"&R.0Q$)0Q(MC+O=GI%0Z;@-JLP2<;N QK >0!\ESB#UYL?P!:@@3@'
M.HP" .L9NJDT.@X<.L/2^6C#4P/;RNXYQON0X'AC+:)ZXAR-."&9> OO-'E+
MJ2R:L0'=K-@!(Q%ZJ0F6,..N"!L_*M-V5OI-31L?:_VA8YMQ64SGD=9FJ=K]
MW&+YV7PD&IOIE0..WYRA_P1+H:?](>1"&^1RSFGQS#3>GDTB57 C"<S-,F2(
M8"T)OQW7YA-D3A(C!5K-XDJO;*Z9INKF6IUXTX?6\<H,CA%+H2I[6G764,T:
M*SBN1V-E8))<C]+BX2Z/BS6.#[EM!1?O]LCB&:C>Q?46LBZ.D\F$6CFZ8OE,
M(.50QNNP39ZM:/RPK>%1>K*S/?9!1(,DF(I(',";A\17!H"0?F54-KK,?]<
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MPF#S/#$R::*>F$L2MV7VW"(39V5Z*E$R/7.9N,N4X(+WZ$<O\K(O5A"(8,S
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M [>&2[,8E&SP,K^!JEE>V%:[JA72*3)B46<.*8!EMUW.16E)3!A![#K;E#G
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M\/9!8PM-(OKL/A%C($D,,3@B)H9,%$-1HN]4,J@[\32:4225 ,RQ(^_H(7#
M@KJ#2;4+&2)P1AT9Y$Y'BM"C"28C'9HI0(MD['$BE21J:<*(4L(P(@DW>M*C
MA4Q"24:.SJ0(2<44@E!"'-,TR2#YRFP)(@ 3$H@BB()TB:67=/2N(?DD2HFB
ME :=R2;N9DQ(O2<%]5%*R@"D4\_X)!S3.XD$XF@BJL#_8JHK4'BZ*A.L3C55
MJ[?.$G55LWI*JBNI:H7JJZEHS=6HL' 5]=>@VO*IU591W6FQP^:BI[J\EO$1
M,8,6T\LQ9Z,US"^_"KNKH+NZG<M9T8)[,3=B#E#A@ ,"0",B20Y8X8!P+1L&
M5>CJM?=>?//5]S*A>@/PI&:7W7=@@@LVV+:\"K..+\4<*VROCZX5$\.XQK@A
MADF$C,]', EZ4C2()O5HN$S6.Q#1^CZ"R+V,)2PHAC B&I A-$P$T#U)&-T"
M!\56;+'F&&*0(89U]_F,GL\X@^QC3E4#+40O&4IY)O<R@8@SE:'Y+#DTQ+@H
M$^2,%@/1^,"<20PTE&'D8C%:_^RTPJ#;;E-L99(.#2:!X :MQ;R"OF&+H)71
M1S5B)(D!.6B(Z3IH-(@Y2!]-8B#&/9CUZRYQNRVG"&[.W(Y4T38/A7'0#M6;
MU,I"<>33;) J-?LBBHR,5"8CNSLH0QY%UY.\00.]?;]%3Q^IP-%!9IVDAXC?
M]"5/7U*3=3)5,AZ][]JL7N3><7*5UJ%.396K64,5*_RGPK^U?+6(&I5\8&L=
M/_WRA356V+>^EW^KO91M=MK#[N+K6_]-IEO4(DQ?<,(MO_!%88AIUG)P\(:"
M:<)R!Z-@!2UXP=S0JS<&PF '/?C!X#!F+PN;UG0<DQV&I81 ^TA#& ['HIFL
M;CP=HO\,D'RW#]5( DMRPA.1?C<XC(&G02R*%$<T\9X!&0X'3R+&>U3DQ,F!
M9A*9<(W19"!%]VR!4^5)R.0.)P9B. ^',="$"L<XB<2!9CYC#-&&AO$BL+7H
M3J&3$(JDF(;#$4,E>&S;)!S4(HITY@9AF(0D;L"%-;$0BW],S6?2,$62-/$S
MDTA#<L*  S1D0A)7I,L^)/D>][S'32MZ#]SD6+,^_I%W,DF42<:3$(M Z7,'
MRA#M("2RY.V)CI^:D1E;,JF86.J'3.J.A#"52 &MY'5Y^A$LYR.ZZ7',(W^B
M"9SLU#$I50E,MRM0IK;I).*%9'W?LQ_XUG>45.7*5&M!7_O_N%>4I<RJ5V4A
MRO9*]4YV&F4KY805JM#I%OO(11]Y"<P(#8(7'^%$.^""#+@86JW_$;!:WKJ+
M ./5&V68B&#S>@T(/?I1?66B:#@,D;YT E*4IE2E&!5,=3 B0L@\9FZ* 5>G
MGH2T&.!@"Z*DS)G )),@::DFDO#,)*:8AF'TB"##Z:212+:>A6QM4'S*J!@^
M IHP3-,]4//92_9!M,I$0PQA2(/,MG9,ERF&<F#TCGL8$9&$;,B36 ,9RR)"
MN<:M*&-<6LB3Q"K*U(#UC%VJFU4A,DE.216(>RW,BU8FN8X-(X_LB<9>'TN,
MS<$L.7.UJD%P$+:(#(,DF>!"T>+BN]A%_92.L9,021HRS=/];FYQ@IYJ*9,A
M1LE.(6RBT48*)<S?<K,F(!&2C1[W)#-BZB75,PE$= =7XDVS3&)\+HUVQ['7
M<BH^4KII,Q6C/O*%12GUTXIXWZDJK9#%?+5:5:KJEY1XMO.<8%%53]*WJ_,)
M157SW=4P+,K0O!3$,?[;GV*2M5"<6,LN@1G@0!_#%^U<M#<.\DR%)=R<UEQX
MI1OF\&PFP;.(X,!M^=H)OO[5812G>#>->? (83K_PLHPS'H2:F%.620G&)U.
M9@!"">GV,9R+!3D-9?HQXMJTV-V69&M(BITA(XD<%B6D9@MI(GPX@K6$&BT&
M7UK1NM SG_)42(U(NV/2T"C)B(V10^69R(N&@8.<MD@D5W+0\+YZ-Y+YA!@.
M@HR6#0*1%4EB9"RB(C'V;*+-W>!"XJER22(TD49[$HG<<5":L#8>X=R *WR>
M&4UXBZ<9 JB5N"LNCU@RU2-GZDNPBZZ;C#>\Y@%7QY>;4X'$Z!!6XVF%RZMF
M37"-NYFA)WJ[]51S>U?LXGHL.U@RT[%OVJ-9#6M[Z!46^GQU7UYU3U96L>^K
MU-L5GP2E*D+A9WKO%SZ?_YCW5VC9"7C-HHD(!PRAC$$H@/]RX)C^A<5XX3==
M!'A0F"Y',S?PS&?N9J]A3(+-*F9XBM-@51'IT*0C;GC%+5XPZKQ8@2Y66%TB
MQIBY84H9:=AIR]C#VTL16R*QK(=<63<@"D'V3BP+ZF%!&ZCOQB"I%3):6;^:
M,8+(U2."!=!G;'?$C'T)9&FBD(. 7K<PW&!OD 6;5</UH<V2Q"-&SVCC:F:\
MHM\@20X249 /%^3-&MT[D--TV3ES]LG6PW#)D="&\)0FD:)HDBD!6\LX8O1Z
M:"(,? .S@X(<Y"V +':W) COJ+1VU043>"HL-H#04R5ETXAISP1ULJ\9)221
M!_]08@+=[(C78T=M<4I"2KF8@#K-.P$I]32DF&HAM?9"00GV^\G)_'HBJ_+E
MZMKJQJ?XV-<]@":_G[%ZMUJ&W\YQJR4MFN G>>7G7IU,M%H=EXNV(C.7A_D[
MP=<9C+X'$YF^2"O>,>WHA"$^L-9\ZN+S1^F'/R+B?6F0_OOG/W.FE>__TS@9
M8P@9PSSY^PC'BSP=P;GDF@B6N3O@N2M-.RX@\CGI.9R2>!3VB(&RZIH?PP%]
M6)$+ ;0;2(,G4:,><Y"RT:O:J921^#"BP2PHJ8RMBHA+DX_.R 0VB:,B(PEZ
M("+1":354 FQ>I _L@]#,[2/^(R0F:M).!%"RXDDY)3_^I")*IN9NGD[J<.8
MDPBBQ(J!E^@R'GF2FMD)0\N)$*$4[C*;/LD1G+NF"%F2)/N3U+.=EL@FT#&>
MDD">'9$];C(U8N*8.K&21*$30>F0012]4%,M92,07=*3YO*NA9"/'7F\7[JU
M9YL(K3@^3FRG5%&?4@&H=7(?ZMN):R,?:9N?;P,O6KF?8DE%?OH*^DE%LU@@
MA1D@!OH6:'D,9_$^:ED,!_L+99F,_=$^_UD.-/"Y@4DX#>L_9R28OGL#]Q"#
M-)"$1Z(XYQB* WQ&;NQ&V%B8Z> ^ ,R+F9J6+0*4_VB3/ID1D\ E3-N4Q^(0
MWX&MRI*YY2(976HY+MP2!'F1_\$;(V5P#YF!G"UHD8NX-"-1.YI .N%2"4TP
M/+;JF&)B"#7B"#AS+>\(@_>+%B[\L0>)!AAB0Z.Y@6VJ*H)H(:@IB>$ANR89
M!L#JFLU"E"E)@YM3LVV:1M'PF9Y!HB<QNA!4(S=9C[%*CMCADS>4M<8+$Y60
MIF$:GN^@I=63KAM)G@"9$=%(.4LAG<Q['0T,$M%IB-@C+N<R%"OADNJ9HP Q
MGMG3&$911-RZG#MTKCZL1,S3O-XK)^QSGU0QE6QCG_Z2)^YY/E8D1?@1+ZA(
M)V_;GE*<156L+U?<'@$D* )3J,;PEL70Q;H8J&7!3&FYM_NPBP4:0-_(J&:$
MCM9H/_]O3$U[J9""J[#.D)MZZ1?5G$W59+$1NLW(S!K$@!+DZ9)O8B9<JS7K
MV9W%>LHVE,!A8!Z:8)GR("6!DH]P 1L1C(C!0YMJDK0TT!.RDY*:"9!&RTH<
MVBFVDI.H00F2H0\6F1'50(,L$QN)4 T?!$*5"*0%>8G^@ C52!&)P H Z4Z)
MB+3\7!W^S"S7D \6Y!C52$[\%"R]8A MJR/)42'18CNO 1.LL+77&KTV_,HU
MLCQ7JJ49<\N.^)2-N:$[&3T@^1S564JO DNSF41,<= >D\MMLAYE@BUB.Y 9
MTCRHLDK6L2:/ 92%J#F5*U%E@D0] 4PE?9_C0TQ2D:]U(S[_OQ2?ME"&XO,*
M:B.6:@.*:F,+\VJ*!+*. ]/%P@ _T)RWA3(,:2%&C!B_]/N+_RC-V\ C PB
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MR@M?VI%@A/ 7@P/ (  '"(/^*/2O9C(PFM+D5R8".)X;/(@]F3@ -[.)!AE
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M-:[;G'$F2 (.4)I!3*<9ZUY#"/(Y.HBD(?$-A'%HB@%0N \ML@XQT*(F\ D
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M1"!73*'_3% X$6H32B4\GZY"@@S&"*KH_J0B"<N/5NI9H$+FEDA3F.:AQ,
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MT,E7.PP 59.$H?9V&I)/MQ8VR;F%TU%Y'C7&$#*&-S5Z0! Y.TJA$I=.D.T
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MXLD2&W+W\8A10[_<43 *=#'P98SGH5"/&%^W%Q_N]E$O$P Q<%\.H5_+S*4
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M.=#"96M!WXAC421R_6MF#FE9[,AD1$&1HH9^AA)I"(DX)W@W/VQ' :G5NX6
MKL44R$DYT.*?JS)*KH/%_TTXR8:DCV9%H3^HCN)I+:,UGYGE)J%[ND_26-GZ
M2CI7A.OJJYY&=\+$@M;B2D472XRS)SJI5F)A55J5*FLLJYLR@*8JQXYT9$8<
MNMCYJ2CX-@8!++#UR)6KH(6S:HW+1XO2AJMR5NUM<]ATL5J)O7UHL+DAE38^
M'*07OJ6<ON:B>6*9;#I*RE1Y:YX(0<4(>P U19SHL@T#S!?SM%*#B0H5'PHU
MV324"9C=(S#TVPK"0RM ?2$& Y/PBOZ!0B0V!EMA(\00!@<PL]:80?+<,6/K
MBQS\-%N^L[J](.\,YCFE<'Z91+AWBS1B,Y%:>__$S\>=5#OF$9-,/'!DK7&T
M=O]#O$HW][P6^M5$\8&!$G9^2TPBV>A9QY&Q,G?52DQ,A\7/F[M#IBLP47)W
MD3UO$54+;9)?7$P &CV:JCJ2"W@Y;<7Q"'.=TBFRA7AZ-A69BQ.&![ [\70^
M[=7GW<0RAY!P!4;9PY0<Z:N[I9+=6J&,AM(J,3J'=>H0^H&]Q'?(PS;9_ND*
MK5:J[28/$:/9R["':,KIH^-Y2);+I1NPW*-LS1P"5$YOS2]?:4^V 8KX(6X*
M91XB&S4B^UX+\Z0/3T!P^1XC9^64+<WL+-P:PD,&L +A# ,!,'$$L@R2@ .9
M8$,&@6 E-4,\5*4= U-?ZF*?-\UJP-H/D08A4R$\):C_).9#8PXB^%P4BOH@
MKYV+B.YQ$5-C$241M\Q;P[MI6Y4JF@%,F@Z >P*O<%0XJCK'D)6Z,7?=EJ3@
M;YNNF=1VK$N]P#/$)BU6W4U)B"/JMMZ16M,VO!N V<G0BR1Y[^TV*+%RTHF>
M 2B#U+D4<I=+OC2<<D\6OGHEHJ.I.4=,S>-&U5+'PHLWU]*0@4$W9PAS00V<
M0NDZCH&N+R$ZUBGY.]G&C1^O _$7I?J=T?KB@$AZ,9Y.>GW*^:Z5I:=ZJWP<
M C37_)Z5>8WCMF_O,@*)"/.T5'M>"./P^^M["10>1EXQ"T-[!A67%@\@ 6;S
M^0P$.9 B]+S,*G0 *I &KTYD_^;O'TZSBJ,M_EBN-"C#?G_.Y1)"Z"XF(I,)
M4UDN(,1@1!=\(0"Q;!@.%3'2U-N74.%"A@T90G.8,%I$B@L1[HM&KR+#94"
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M&+@UQVM$1ERF3)#$22@4Y=HE91@#&, 39BHMCZ $/DP( Q&UT=(E0UD-SC,
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M*SD<8'S2+H&O<9PW?QL,C(,[F4C'@&3-MH&> @VD@Z3'A'NT)!42?"S/RM+
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MV]7%QM=\ZC&N9U[N90WV'&4(1-46G(UHM;;\RF&(ADKQX(7@K=]V6<U^M3!
MS!T2 ^ZZKA0F"3E=;-'+I.9;AC302]B>DTJ)@5G+A(1"Y@<>+FCP#TJ41$S2
MDL(6M7[<5WJ+M\R<XE6)P/EFW%CV<#J,K^$$5B9&N=U3:$BOR-_$/Q[>V]\]
MW83#P%_E07Y['I<>[L/M$:1[NP65N:C;7<'6M$][2HXME9R^T/2<T X?&U4E
M0/S4W A-3>?45@/LZ/5]/HT5:DKKO^DL4JE;D@#WOU_/-&8=TG:5Q[PU$N<L
MS8[_],!!EJP-7>D!%\C0;&.91EL<O-8C%6(PM-&WLK,/0653'JRW'IK^6&6[
M(@:=W-XPLN2;'-A3GO>\>I"I^;?Y?&I4X<Q&9=O*(FI[5%_)'1(E=X@H#;P[
M'8FE()1GAN!),:WBJY05:$N@ )YZ*!0%YA, B;S=]@U)BA7=(0EV@_/ NR,^
MW(332W,NR;>%*%- A_A.0AR(=]2!$\Y^997*A<9"+\KQU&L=;D D]#F5=DB(
MM.'%96FV%6\9I-8F;FD%E.ZK-M>7B&.Y97BZ#7%K7.I:A]SBY.)J#])6__30
MM4=)"_N77MQOY#_KGO#7+1)][3W]$T>6DW#Q#$G3%7QQ_R_P(@[J]+3P.>95
M6XYE>X4_2L*^I6-'AH-[6P[-[FY=M7$Y?'0X .5UDQ#EGNE>*SSKKTD0/+))
MGQ'?AQU80>MDA V;N,+>F"RT[IVLS^7!;9I(&A10HIZT"Y7D[-9Y/ORLX?<;
MV,E*D;@(6<*U+*T3>DB#UGDNRZL=-DV(20B#@W"]5?)F/LD$-&!AB]@(81&)
M3CJ\DPT0Q,9@CWAYDN#RA9@$Z#)^^05GTO)YAT9-1\6TH;=[I@0(>LH&UANH
MK.# 9?26*=-W4%DT90P9+H3&L. R?0H-"D0X$)K$A0(=8I2HC!XTD0E%4F2H
M\6%&AA'K02OH4)G%AB<C-F1XTO_@LIP*-R9\*%"B198O]YDD:G E3J,_FPH$
M&91ARH$+D6+,^?3HUZP<8?ZDJ!6GP(E@37J,^I!F09I/C483V/'ARHU'1Y*=
MZS=K2;4;"VZ-.M%@P8AV:_Y$&1?O2Y\#(\HTR#-AY+)S558]C-#K5IYB/QX&
M&S?G8\TW*3_,:?6I58=;A[(DS;<@T[$LCQ++1&R8IF2:AH$:UONX[TS*?'_J
MO9Q8\^3(ITN/_MRZ=.6^AP?G#IPX\&3.F1]O[OW\]^[?BZ-G#[Y]^OC<B7EM
MJHSI6J!:%5X^:[>Q5$8%19A/B9ETWSX)*K@@@PTZ^""$$4J8H":9Z#,AAAE*
MJ P0'6K_HN$^F<1P  P'B+&,@B*B45 F:$R"AA@QP!# #?1-$@, ,2BGX"0K
MU @BD K6 R*"&L*A@QI %!DDDT$.UR24$VH"A!HZP!&EAIG<D.,D6'KY98-)
M>@@FF1/BY5=!(+5UWT$*TN;343GEUMI=3\'9&$C_^750?7>M*1F DM7UT4Y?
M[3F5?D3!>6=I $9%&%",Y8?H5)1I1,^@(16EUE1ZE548HO_5=EI@+'GED%D*
M"?7032$1I>9;A\9Z($Z PJI?8&,]QM1C):'UTTU!&80J9SV===BF?J4U%4D
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MPK2F0"JA#CYJTPW!A4^'BQ6OVO\6-YZD)9=;"=S=_J-*4T)D6G/!8*LNDDM
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MV58*A9J CAK1S;9$4H*F#I-510ARH;DEA4!15?,L:2+^'T"E5:H>#FA(!5:
MRO(TBZ#J(8-RH[K4#L#BV,^IBB1B8JBHSN;I))7-F1+\L5_]"<A_@%;,$54?
M<I!:VB+KR!LJ3A"AJ&'_C4Z+SL;EZ)]/7)ITS!/6,>!SJ)/[V)/DYM:C0=T\
MP0N\ J9R#2EB8AV[@@=92(K=6"U2U,GNG-G8>5ZS1 RIB<J=/EB%0(,)UEI
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M-]VN#EP;G&;<RBE6>&5G<,QY!71S9B!*UE*9W.D$CN)04$]A.#N-^+XL)OR
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M*;UB\+^##RX8N(B PU@VAE[D$CMP?<Q6WH+][:_D%>7C>5O[NEQ007R'6_)
M?DL>$#V=CX-:FDA'9U1//*F'\HBC/7.RJ*2BJH;SI3F)"AMLD<S4D\\Z:^HI
M[9_._*E&AUI>D=+\G$:NRI;EI2]BG6M3]E*X(O-;<+.BT>3581EK58U20<UN
M'R?)D@U!4'G]U551 Y-M\,W7ZHCSS^GJ+%55 5M\<5%-!RRP38B!#O3784/7
M8&:1U/]J-_J20R_%2"D-6D!*8Q.X/IT)VLM>$<U;R$B#DXO8Y',I73E$^"15
MOL!N-Y8.>(?<DU[DAC<.<D$5F=/NOX^;!U&94#5)J$N(L5(1Z0"GI*?$YG]'
MD""B$56H42D'9J#U 4$3O@$0?.KFHW4]9$G7D5Y$>"2A@5"H8!6R&,$FU)_:
M:"E&&E0@B&HSJ921YW>YVU^2G!4>D;UM2HT"&J7R];0P'4Q)N]O@N,##$C^1
M9"1!"8F<7M*2L?UI&!<!B=B\UK4==J1..'%3UGIX-8ND1$Y O(B<PB0<D;F(
M7F!1X7.ZM;<#$H=>C'J("UL&NT_%18V#6TABAM6KTHQJCJ;_ 59@BH&L-L(N
M$YK;XQ\!&<A;O6PKA'H6NJ(%+TI%@QB^$@R [$<DW/!GA<HHT;CL=QTX &%W
MU((1#&TC.]E)97D]F]@DZU?!V/S&7%KJD=Z8M92X+:4A2>&+52Z92K&H*V3H
M,6."I$6/QL"'5WQ92<$,]Q=-6,DSQG3/)I?90#$!834SRI8R%#.LE1 3<<8+
M2V/"1#]"*M"2WAD.O2Z9LHN)R(L"^EZ8^J,^54JL01.<$?G  C/MG0] 'A)?
M_-B#'N6 1: ;\\KR(!2_DKGOFB\[Y7$JQD!GM4TF:KNB$I-X1(RNQ"(A<8F?
ML!;$/EKDB6N[2$NH:+6@&+$H7!N&_WOD5<.9#6=G2G&AW1CD-/WY49!M&<8D
M>-K36S5D5]F\'+'BZ"L[%BM6K!$JZ ;U5*E.E:IK"9$Z65:;_.RF>MSS2JC4
M4$QJ&O0ZF?P7"5_$')?5PWA+LQA\J)F@?S$%2<^S6%I#J=#?Z29_25,*>3:Y
ME8@ZK![@Y-Y>5-@T!@G6.[&$7H#8]YQ043.;<(C8)E7'%SA4A9IP) 9N#&?9
M&C4-K.7\DC)>!0?%[ 4.&*('9@.CVI5$)+!,*BA5R!?#1B&P?R^+&%JEHC.X
M"?>$4#-(!+M**8;N5)<*(AF/'K38@QT*8+T1$;LH-*%W'D0K[PSNW$0DP=D-
MJ'Y5(<9'T/]&C">:J:(DC8E%H#@4EL#$BFQ+KT; %A*SW3=K%F6O16 $G6X)
M4+G6\LV)W.7!'KT3E#0+:E7)HHE,< K"RJ)*K$AGNCB:3C'&>N18*OPYBX28
MQ"5N(X >F*V4*0HA9.G2EZ!2VH/LI76[W1E60XFBI]020)N<KK2\!$Z#J"\B
M-SU2O[+C(@2/Y[%#6N49AZRMA1A/JXER&34=9C/L9.F"TPKP5:*3/OP$]BFJ
MC<IDEPF-1JK!*LDD2*A:U\C-"F2L6:Q2J%HK2=8";\\$@29-J\*^_EQEA -U
M5-R>5,G_U/-1)K1/]:*TRP5)4I*LG!F4*@0S=D9WT<==-),KA!__"K(SK2QF
MRBGS2;U*B;*KTI.=8IMR'"@Z<:,97>(2?XC1EGZ-*%CCDT79UMXV\5!K&O5:
M/O^ZG=_]BZ;E Z66!\24#%K91@^&\$_K86)M;QM74>7VM\%]*93%9MRT\^-X
M3'V4TE8%5E[I,L7T%1[W4-IXRSX(]L8*Y KI"Y->^:V+>/LQ'0F7V3!$;$.!
MELF%"!EO N6GO@T:-W:%,T#U3O! 8+60/R\%FM@$0GT(.)!-%N,K 18(6#T(
M5H(MA#07QC(F#0).:T[H0\[#V0OUTZT4.T=>+,M.]IZ\H1=%3(SGDJL+S4JD
M[UK*61J[CG:WUR#R]@Q15=Z?T<Y%,D1=_]*0-'01U$&I9*!LS8>][J-*T6[K
MLJ?]UD@D>]6$7;:RX4DGM[X3+P.*KHHI^7Q"1P^/:<BM?M<SVR:6L+7#G7C%
MNZ6/BW?\X^F"D'\1:KI8+0M]'H4;>H!U9=#8"RBDLTG-SO;DHO<+QC\NH+%.
MZ.!J-BH<-B$0S/:EFM!(9K%&UEE8@?62RFB,HH8,&&*(GLT>;\PRGX/80!,0
M,:&)2#%,GSEL_DH-Q4O]?.#8&#6 ?H+"KZPFDF+[Q< >>@O?K*(%TFYZ&*\K
MFGA,\UOG>\M"T^FQV0>>*[CQFW;\M>^7Z(#J[2C$"WC(*,FN2I08S;? RV+,
MI8/*QSG4!],<Z/^L)FVOR"5@HJ:@HLU;7"E&*&Y<GB6 9"9^7*MWJH1>Y@H[
M7@FO7(3M.D*'@*@DQ@XD?,W76$*_IJC6WDXGY*Z)>+ &1PK8=&)<AN334&P%
MR>J:>DX%B22@PD/;X +Q(&\*$\\C](@*L1#RWF4+162N=D.>&JKYJ@F.JF\@
M0N%5DFG[GL.8OD\AX$ '5@)$ABG]@  _1N]51J=8*.&14@NL/@XZ@D6VED'F
MWBCDBJP@/B.;4DOT0.:6".+^ZBR;$N.8F&HQ4@6S)M$-.:D0=>_XEN(T%+$@
M)BLPZJQ)!NB8&JZ<;FGA_I K(DO.DFDG0FYC(.WDP&G:V"KUL$(L.F[_^O*,
M1I8!FK3BMG:QGMYM[Z(&TK0GT[(#T1H$2F@*@V2I:/S%/ERM7J@$NN2&8KZ'
M2C@F.90M/[2H>G8KH4)FG2A&=Y8MRH9LT<A#2=B)(/#+V%2BBEP0;/:K;?J+
MUW)M[8#(I0#E)X:B3=#F3C!B&+>%YW!'\^[F$-'#>3+H'1GR*,+/7Q[1\-@H
M"S4RW(IH(STR\:X+Q?@*-R@O6IQP6L2/-/B"#%:#XT)./O"L$%>"((;)^L"/
M*U;/XPZBM:H"F@Y"R$Z._=(/,*#"F."CXX##XCZFSSS/L%[K)86)S9;OF)9!
M*==G/'QR( B1#AW"F';R]ZQ/M)X2^<@LX:0#__]$IF)8RTKX0BIL;PXG*ZQ\
M3PV<4)+J ?^ 9Q6O9(!6H_E4)Q/I([*>!@5!1+'$:.K,L4N"XV,8D)R8:<!D
MJ>C^"D7<XX8<[F-JRLL*Q:!,:VH\:*ZB2YTX\ZST0USRHSWJ*:WV \BDXT2&
M9.QBD!Y-XB=P B?0CJ76KDY4HK]RL(CL*VV^)AGRL4QTXB-8XME>"'ZD305C
M"I+V1=,F905[*A, X   H'W2 G ^<CN%*@ ,( !N "TR01,P@SO-,\3>15%$
M\UUVXR'2C2])$2I1BX HI[2P20>PHO5@15$,:SX94K+&*N;4 (0VSB#6;2YK
M)";I81-R4BFB0?EDC^SY4D5"?8^33@3/CF,O-$1[\,_\K&63Q"*R%*2MGG)&
M8G)]'@/BRND-;W)V#G00BZ^6T!)W@I'-LJ\O_6?YU"!BD((OK D\6%3D_D(E
MCTD3MRFOW.79,*T+TW):/,U0?LX9=P:%;BXBGX?F[D;JHHLB'^LKDD[P(.5G
MGB;1B$L96PC@L"5<UL. "L2 7L2:&H;@7$0VN28V7:H>-\I.4ZJ(* ).8"*D
MKD9-"M*^^M0C>'/LD@Q[O!&&>"X>NRAW0 E(W&4OQ4*0,B$ ,",38L#:)$PN
MSO-37R<&T( L;F ,SD*]0#55I6J<]*7*?/_.CXCN/-3E0&_)*H2E+R*"?7X2
M1SN.-F3N03^N92KG#?,,0=DM]<+%1[62S:;+,6SQD62DWD*4@&+L,1ZBK8*R
MFCSNYQ)#$?,L*H^+*SUN)I_$XDB4+V=L])A)9 13:GI1*Y'U6:\E5T/N^'25
M2"!16S,T]8)&T+"))2W$>E!46]-T>K8%,S6P&IV%,9EE0\J+EM)#>8*'NH#)
MK1S.V:)-,^&-K#"S(,)H7(;C-EP&8VAD8T3&7#C&6R1N>,H)AFA4(/94!\7F
M'V>VU@(2BO21-NL.O>[1[9)(3O['D_S--@8F>2:% @FFIJZI:1)*D'!@$LKB
M!M(@<,HB"E7U:I7_A1@.H"R(P0#.PB*N$&O%]G6.K)"ZD,5T(W+D25YD;(#H
M<CZ,B7)V A2ZDK+4;SZ+5/Z> D(M!S"B(]\L"5OE4 V<H\X$)+(.#D(.!D1[
MDH"<0T0K=$KP[#H.SD/V0B6-DLZ*[UHWT?V*5"QH["B4$G(W3Q(7EGW,XSJ,
M4F2PU2 VZ1=ML;4$TV\YT&T3Q2I8M##3=29?UWEFI,.H8E)X++HXS83VCH$N
MQ,L<U%G<0YIH)J)"J#1K1LM YK>*D3B KY*"*[IX+-DDR@C_ SPHA#P,<X+6
M-#O6M2H&#,P^B&_B Z7R*SCQL3?Q5"B$,P@SZH> HA_KEW^_9CCG! ;E_\N#
M9,I\1RL^/(1>%@T<$^Y#%NS)!"D&,J$LQ  -'DS""F]L-?@U,B$\R4)K>6HE
M-GB$-R<D5\Q5CX0L#J3:=.-$%VYSJ2PL%!*L%@/YC-1)HO(KA31S-F\6H_)%
M^$\AU@PGV:RLZ,P(Y S4$#'UZ/68\I4^L%490 %@FV(O# 2S0$$LB,%:8ZXE
MJ:*V8K);A D(0(3*E$-!OXHO1"TI7E?2-+=871+Y_"SDHF1Q[$?0?CB<>M@(
M:"88 W0J)BM+!/-XQA)D!@^>5BXD7Y:QMJ(6K:YA'0I'D# =&?(ZC"16(0I1
M7 B!_A,S&W49)5F6PD/ 2#9XWFEE8>R%KN6+!/]0> 9&?<+#]M[$B,A.3ZP&
M?IEH3?+44&U3[6Y6B?Z4[E"B[;J&(Q8UK99+:GH+X-236:*-4*C%2:40='!@
M@LDB#= @,D["(M! #,8S$\ YG,5YG,FYG,WYG-$YG=$9+L29G3.!G3OBG<$9
MGN>YGCT"G"M"GNMYG]]9POIYGB6,GO79G>'BGOE9G1%ZFFE%$V)@-S95)B1!
M#-P9H2FZHBWZHM59H/5YHPDZG#N:GPN:HSUZI$$:G T:H]/9)*8J/0_066ZC
M/0-O*U0.=^FX%Q=B)Z8,65-N%N<31]LJ2&GKC_O3+YDBB..*DGN:@#S&K$#4
M(10CFDZQ('Q2_*B)-FC_K#LV#AJ,FEFM0OGL,T)Y4B>7(K0P9+<61Y*:[W/G
M4K2HA/=2Y:S[X_."LH!0:S6ZJQ#ITIWF<K: 0R\HE%BQUUZ 6O ^4X:B!,68
MK%KXRF6 C[&:S2&*$("BL\%PJN"D!80"I%&KP^@D*DCB-&-J9H$.(JL89.(0
M#M9(1ELDZG9C2+BD1$Q&:MBPAMCL1&=Y#>T$&(GXUQZ-;=?R$6>%\&S*)FYJ
M<6:L!3(_3<=NAN+<JJ&:)X*M>1_$0 STB!APN8BL.[NU^[RR&[N]V[J+2%,F
M ;S)F[O-^[O-.[VW>[W9>R>V6R2L6R0R81*T)K[MV[V!PKUY-KOA&[^-*+]/
M_PJ^!?R^@<*;^;N]NSO!RQN[X4NA9Z6#=R, U.Q_X1N]+7S!,=S SQO#-[S#
ML5N]/QS!1=RZ,R$-_+N_4?S "3S%X[N(F&C%5?S$*T(2^GO$T_O#OYLGJ,J$
MG66!4J8L#@8A:0/_7$XJ?>\Q*$&U\LVHE,DA&JE8@H4NK6\@P$K)'>-;7U?Z
M:GA5PAI&2?,N_X))K@);Z^%=0RLP4RM8BA2VJJ_*O14Z8&O.:NLI'R,-XV\^
MU=?]YFQQ5(NU$(T@AOB+BR6V5*L[^M"8+ 2/8XX^>1HLDJE;$\,6*Q'1B:/#
MY.9!K)A]K5'4>L1(@&DB#=EYE5'PJJ5C+)#@- \: ?_*G6A*7&)YZ,I).@:&
M(?(F2UKV0'Y.E%)FXC(O>OG)@;\W-*VL8(@F-GY;9V,[9WM"[606!VG9?NN7
MEG/BOT)JB4JVG$BFH( &?_I'BYSD;>BIRAQ\<\0 :DE5A&^E\:1*W84*&H#*
M\90A ,H"PFEEQ*2J(LJSIUR"PLP3;G9= 7O\W$)R2+Z:*[^RR>DUK/H<R]XH
MM>2/(2#T]N"@D:#U]DC/J.12/%YN9S+.9A[%"(KX66=C<CGNT$G/^*0RF5B2
MXA_"XNDPDM8G$>>FJ652]A+QE'.Z2DY#)0\NJ)6IJP81CFU/] 0#>XECLH
M<X^>R1N'FXK>8.L,EB+IL?__:GJ9(IT8LN@2\%JX(YS6]M$F,)ZHU&Z@)C.;
MTYIXJ?=P6&XF,TZ?SM1\CFGK93%E";P6J;.-<=D.6"+T\2;N*[@-4J.(*.W\
M%Y?U]S=_,-@07R.<<8O$0]B5QLZD8[JL)>?"E=*L0I#>8&OWX5*5Q=Z%BA[8
M7:@L^/$.P-QCP-QGY=U7-;KU?9D^M0NQE-P4$#B G%PF99=J[F#?5$0"]"?9
M#$10\-,)B82XZP#5H]6;^X%9#P@^2^^!QTBDIM)@?=8C[9 ,1-C5HZRR?TDH
M<[1),WN@PB<__;-O+J8$2-P-BDO!!]L!#;RPKLWRK3L29HQ(.7YTQ/PW9K"8
MI?< _X+>,F7UE-$CJ"QA067+!"J+QC"AQ(('!3I<!FW@P((:$QXD"*TBQ(@%
M.9(T&!&EQH\*429LB%'BPX0A91;<-Q'EP94#<5)$69(A-(,K7WX<&.TB3:(.
M:3I,IFE8U*B@I XCE@DK5F59/VFUJ@DJ6+!BIXXUB_9JUK7$O++MVG:KU&1;
MWW+5RK9J76)5HPX4*1/AQHA#$;*T:#"C1YA-Z24-[+!>1H'Z>NZ[C#FSYLV<
M.WO^+.9 C #Z/IL^O7F8,M2L6[N^G&GUZ]FT,RN;1*RV[MVNZ1F(<2 -;]:9
M- T_;AIK/>3,-7-=UCRZ],TM%P:]&;@EYI8)'SN6V%!FX?^*$0<J@U9/$Q U
M*M6KZ;B3?/R7#"]^E"SSK\ZB'HT.-:\,,>M-UI]D155DGD40;83>4OHIU1%,
ME2&V$U$2*8;8?Q9:R!* R^A#WTGT#'61>IJ<]Q-&'3'5$41!@;AA=I+)YU)2
M!T;46(,2'5302 O!H08Q. KVT5 %D;BC2^"5=YY%-5FDXH7]#:;2A0LAA"2/
M""V9I'SC&;1@?O6A5!B2RL"H7X+@?=?=EBQ.R*1)W#'IDIDI 8BD?D;M>5B#
M5YX97H++#-/7681>Y19>6TVU5Z)L>75H6%J5)595?94U%UI:I656H7%%===;
M>'%5(5"K);D82PQ5MF2:V36%T)__J+XT7:VV8A9-5K<>MTPF].QZ'!JR 4ML
ML9U-DHRQNG&E+&W*#!--L])^=IZ4V<7JYG*779FB34L&I>)!-5VIQGIPG%NN
M)N2E1.>0'QVUV*D5:E13?1K!N!"(]< !!!P=NDN?H#*M*V*U X%(8W8:PJC2
MNH.-&&](]S+%YYEK CABN7^&)]] 7ZI:7F$3,L9DA(<Q*:Z]X#7X8'?TK">P
M2U1N:)*-AEFL9<E=,L:?AB2&-V:\,='T(D)AFM<3NR,&!>]@'"D%HL>1Z8C@
M82.]JJ2^$GD'YDE4.JGE7QX#_9B&<EX<(JQD:>4H,52Q/:JHDH;%J52?1KJI
MH9HZ&NI=.G3;_:BB<,7&EGFL MA2TB<MI"7".'Z(K9&0-61S4=->CKETVF:.
MVJ^<?XX<-*"//MSFI"M[';8^*;S_T':GTJ>EN#_-&K1"T!##[WKK@5+>05H[
MCE/7BB/8WZJ)P0NQS#D-5"Y)]?:.4M0_7T0@O$&%?"_/B#F?)H'?[J@FX@LI
M-K-'(RUC(DBMSL3BXCK%6&V73])WI$M/V_^^Q?R9*'&\CW$GMB8-C'SL>A^^
M"#,P@U%H19!3V7Y*E38# LU4[*K>\Z14(>)E9T4@T4_JZ'6V[<6$8TDR4F'@
MDZ2% (V$TPM/E@"5$%8%R"N<PM1>!D>,0PEN+U31FUKZ-A6HQ(5P-QRBX.[2
M-J\DBE-:BQY,JG6RPH0H1/A94F'&UR-8'<\EI^NB%[\(QC"*<8QD+&/PKF43
M/]D$,]RJ_Q*=QB:0R:Q01X]K6&(XN*)2=4@Q]9J@R8P2)@U";'9B&]%'CD8\
M*<(+(B"C$<@FUZ<AN0QH_4/)2'ATQ?R!J2FS8QAV:(0XAITG0J8*"DY(>3"C
M#$:*2*$)*O$70$LJ:2'>^=)@].2[)X:I?O%Y(LG6A+,]_>Q..GF,"MOEP >M
M,$[8<I7A&%/+QM!'BII$T DI]A*6N:EE#XDC@*)6I?*I+(]CNEVGI!(J(V9E
MAX'#H3OA]DY1R9.=C:*G/)\%JJQP"6,6>N)U).:8G-FK8_%BR3!;-"PS*G2A
M#&VH0Q\*46-)9'62N9ZU6G>9EOP'8?.K6O'&=)3[+.D@EZ08\?^<25 JD9 \
M_P.*8C:$-(:-\&;_8I%#R)/%I*%200XY9>*")DXYV<=H<VKEGTIU2Y!%J2$
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M$Q08GDMQ>#A!1RW39S8)B/:*IM;!$!\: ZI1#RUZ$/*I&!(ZKA$1GS0Q##&
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MH[3*N=2)ERLI-/*::]I+Y,.1,LPVY&$(=,3 @U(+!RN*GA#'J5C K-C&;YS
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MLV<G%B/3]$PQQ$BG+D:\]O/HT^\#7V_ZI!B:U,N?3Q\['#5 X  !@G]__OH
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M<, 1WS[Z[;?,=)K@]^^^""=<'1KBB6'O@>8I#. D";J7K\0!ZJ?&/LL83%W
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MJ8S7ZN^=H&#GG3VVCX(Y4,^0ML[)^D3CE/^M#X5,%<YW+?T7E;Z4<+/B4F#
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M\D7LY2:B;^4"9F],VR=B3N@VTC6>UW?<S(W&5$87'PG(]"X5!U/(8#YMYCB
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M93,(89U(V'C<4EF@>K4G(ADP0X(D'$4F6\11&-7(_ I+HAQ.&DE%4(O*@IW
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MQ7?X#O2$F]'@'<JYQ5/M6,O88 B^E<]5%<-IQ?E@# &&!U %G^R\U*GT26^
MC-V8&A5]TZRY((%9BE1MQU&MHN@HRN:TR%Y]1PY6EBE)T\8]H07RV$CXU\7%
MA$D-DN84"M[T&JGUV!%B&L"Q!)<,%S[)T_;(UQL"1S2-R0B%$/]L-5@;N<2)
M39&EZ&$,S1[X4:, BJ%XQ4J%S<V_01GF*!,GF=/[H!,(:5Q*7%Q)@1X ZA->
M>%NV;=L"OL@]!A$.RDP6%B![583?-9/1/&!RR")0!J50>B"/K8U1UD8)XHQ(
M\,:%&1J+J0I/<5<V[871Y6$#51 LY1E8+4J!6).X<0IE#&,P<5B$9%5G7(8@
MHED>5HE>"=3ZZ0Y*B5&S#%H"M56B*-2M0"&>M5=(T>3ZY \ !4HNR4\0Q5C"
MR4=U-2+HD"2$=2/G"%HT1MJ2I$Q;5MVR#5?8P=<$;<OWM)_0A L/;J0A"9 4
M"M2/ :',$<A^X5&X.!^%2!A^! N3,=W_U,0::G!DAL3CQ:1>1@R9;\(D>;V0
MKH5-BKW6LA72<VP04@TE<S:G<V89'@4AL>"BG4S7<A'(TD!>+O70?S3DYIW&
M=%DB;;1,!TF6YR50@\34A(#5(,$'$Z50I\":,!F::4(72CDBCL5.7,!F..$&
M!*(-2<D<#%5<V=3A=1&;"5[7E[B&+DH-!*T&F;T?.^*:/Z(&T?PEEBR(HKP/
M>N[>E>C/":H4/;%B9)%7N=F3@PC16A7<UDW*0Y&6(!52ICT:_^W&K: H8>6E
M4Q(=]57DZI58H^'D"W)EY;4+*&:1)S(@D,5'QYR< &;.$P;F@KY-2/[%<UXI
MEF;I126*DHR@_UK9VSXH27 >C@^F()/4D$(Q''Y5W-B%5'[0F8K-#II8SW.U
MCS@5TJZQJ5%A8WBD6@W*H\=XH3;RB_W)F0I-T(=ZV)B9CRV5C#9Y(5_R9$,1
MIC+QAZ;98JG,V'2]':(()WB"&GU&QQ&%E\^Q861^BI@X&\><47O6*8>2QFZN
M1'2LX0'NSL<H9)^!#WR,D@(%4D3)%S)IC:5L!63"&@P-'6'&9H8)VCM"6*]4
MB9K8AKPPA(C<8]XM%'(*CK7]'EEB#5>VHI:&J[B.:_#0F:)TF?+DHM\0S1]:
MUZOXI=(-"*0A9O,@HV$9*+>257RT!.D!C:K9*I)%D:B\88&<S. -+/](^8Q]
M'=^QJBD9G@?$F,=(2F7IX1[5<0J&M=B$Y1+7K.A)S@\75BCX"&91K:<M=5B^
M2% /T63BK)C0U93&39C-&)]UK*M5#1U^F8DYB039\$^Q:$@VO=C-8">GX2R(
MBN@::=*,<EC-+48&L>ISR17\N>#_S2A.3HF'>=A$,* 6N0L8[2:LM-90*1$%
MLDMB< _LL.EAD2O;MJW;$LGBW8K?K<IW)*5,>E9MR1RTN)Z:Z%=;*%RV*$XC
M3B:=S"S[A6V14LY[PLF=@@X:!M@&9=,GH96?>&>.HJJM\M1^):.2H,RFX!ZB
M.LJZA%]\)@AY> IL'M;DN%6//0IEEJ[>P&%QHN#H_1VGO22'QG%D-J+@!>I:
MKYZEZ@8<)D79JPK*^AA6&F;A\\'-4B:L>\[J?? JR CL7< ("E(+R2 (DW&*
MG$3:R\C@#!I2=)F$AO+;QSV4:<E+#'ZO!,$G8,H/CX)O0DV8&KZM_=XO_C*%
M?(EI2%G_#?0H:.WZ*2L"U$O!IT35J_55XRLEBINH+5P6'Y&Z3/%FFJA<8G+T
MSS!ISECH65D96!D=*WID!9E:4@">X(-2K'9UF?U@$Z)89Z6<RLZX!&A"7\FN
MSZ%D)H&]*7>L4YQ&#EB*4W&D4=V 4J.T6*!8QRH*#K)4, -5Q^FZX.>PET@T
M*6<FU"EU%]GX2>A<T7*15^]VY5EF2'F^3/?N)R7>TT7.&%OA3>,J*HJQSI&N
M3B,!$J?%TWMH4CXRG@8'XTR":?[^,2 '<D[@*O[QKX+(A!A_)^DI;*!:5G-Q
ME0AKZRFNZF/P;-(DHQKA4IO>85=1TKK>*>9!JBT]U-'!$O/&_PYP\=-C=1KK
MN86!WJBZI B]^=^5/!7LJ$HJM9(=4]['V<X"M0WOIJ:^#!,1&B98'A6">1>R
MS.D9098%W;).EAZ@Q-2=OA2[R)1H51PFX>4P+2.TNI3?CI)_!51LA$O[17/1
MK"')=N81+A>U79PCLG(8XN'Q9@L_B6)$&)21"2P5>2L2$:XQ#5:_O2&)$9<@
M'S1"YV^7_LGA(,UE>$5T":+$7>)@6-O(,2W0"BE85@BUE(R]Y*8.8R/2$HZ=
MO$V?8$K^$-RL32=\)2/,EJ58<"<RQZ-AWDI5<0^^**HXSA9+A8F(*1^ZU!3W
MQL8I^=Z?GN)RN9!)%+0.@AA:\9ZL]/\,JYTD6>1T9-E/DZD:3QO7+2=F_$42
MC084.N$;)N^*&%LRGGJ&/P,+\$WC-/$<8E(6 3''..=H2[ANCL9A28B-*J%*
MS)$I8PK&2[JD)HR,OS +F8:=369QX]V<E0"8'R>T9$^VN,9MXTTDF/9=AX7A
M'#]IP]'?))'&16"*R=G02G&6#=Y%:&D=?.X5(%TP-X)S[9X%]++:N018C2S)
M8/$%.=X?2V<D7HZA;=[-W;DJ!--)XX(ONUI>9U%-^6@P+J6(Z@*0(&(R3<_&
M1U^;/7_G]EWNTUPMJ$7/:Z>12K%4I$R:^8I25(=5@WH<]"I0"27;Q8&>5 F(
MPB'AQ4 C&O+_MB'=HAIA"&3\D7BKU=VA7ZBIQ-S!BYM Z.#*GD!'+:]0M+!\
M*F57N(5?:702+J8Z"=WVGR!6<)4<"L^*-8!S\U5%1E3]K?Q<CPAU=!I"T/IN
M-A/CZ34W6HX(<0J[:F94G'I4E1E*HH.A\=9]!_"M9(<+X;,6J:6R,H->6U]S
M+)]HLM<$E-PT:8(@WS:Y<E-=W+!)E?#E8;))&<-%,U4[4-NQ6($=4J0FH7-U
M#/9\C%]JW135&0@78<AZ4*[ML$4[5Q/SB[YH7FYG:Y](".M2"S0JBE 3T#"4
MR-<:R %'+ZZZT]^5WON<<&S!Q(5GNJ;+(JZ2*2%FQ^/%TQSWRV78_XQQBFYB
MY=QQA2A75?"YD O:0?);HEJ=WY9R>.Y=XVJ3PZ?<[(^Z+'0A63-'.W$ <X9J
MSEY3=K;W*2'SC=WIP6^G6O1WB+3')6.JH@>LQE>JB#JV/]%L3%[%NIQ\<B6Y
M(%&/"Q:I#/-$)1N&-;= NBM8.R;_20YH=_C-G:[4?.RS?=IQ91T2*WL".RVE
MWZDXSYK9I?7JJ;9UA B)^ VD?FGUJM^:1 L=?Z.LLLRF9[S&)Y[(73:*\1'M
M2%;@^/EE+(MI$UQ\R))X+ZCUY<HI0;'I2:UP3ELN/U%M'JV!:"?>"" -/8;%
MB T#Q0[SOI1Y&XBRYB,*,J9$Q52$&BN%3O\84EL)L>YJ_G6D]E4;II)O?KQR
MK/@'IC[M,?FB=60.&=?U.O'4KN1;NF,+Y:ZLL=-:#M6IQ)-.\Z;+MU?@'TI\
M@TP]*\&\F@NZQST2 2F-$/L0X[ZKV<:-]G:L<X\*>V%$DF)Y"J6]>A'.L=SN
MWI>EQY%29&^\YW_^E<72"'KIN7*%3,1Z=*.;JZRA$[6R*[N803X'B:Z/>]4+
M=*4UFT>]JE ?KW@NY]\'=;2?77:?#!X':E?^/)=<:;;3K1M5BT:7$]FR8XYV
MZOFJD*++3F6*6X;P#F_LK_,R)N]Y"OYBR(YZ)F_.\(50SL6C^?04>:S_S.!W
MAIVPT;.3T(E%6JW_V( DMY+4(4 LH[=,GS)Z!J,-+&@0VL"#!P4R7*:,8L5Z
M!C$>W,>0XD2(T"A>O'A09,:(RB9.!(F29<J*(5MFI%APHD&"$Y-I&J9IX$J9
M+R^^%*I265";%5,.9*D,6LV7*P_"W#>5:E6K5[%FU;J5:U>O7\&&%3N6;%FS
M9]&F5;N6;5NW;^'&E6L5:%V+%5=>I!H3YL6:(RE&0XHRZDNG*I5&%.S2J&"(
M%$DV%"A0,CV0?B&[='JW)+V$)VU&G?A9V>?"'EGZ+5S1,LS3#CNFQH@Y]D;:
M15GJ<ZJ4*>O8HT\O)!TT:-/5@U."5%H2]5*,0D%.W C9HF3J+A\G79QXGK#K
MT+,S0S,ZN;3#B?56-L5X6#?'R$I;7\?=FSEAS:6?DD2J\.7CQ\4C^LNGDU!K
M[B*?5IK,/(K2ZP@VF&#:K"Z(/)MO*&46PFVZBC+D"[FE!).(.O2,\C VP!RS
MT#FD?$+O(=Q>C/$FZA:Z[ZC^B-$D)_ T>U OW$9JB# ($7IQ1/!*"FI&BN9J
MTLDGH8Q2RBFIK-+**['$4L42T>/,_R*J(M*OOXBB>^ZB&LTKB#__^I.ILMAN
ME-"IXFSRZ:""2O))* 9O XPZ#@L4TC#[$CM(O808'%)-IFH2TD6A+#.*MQOM
M:Z^F11W,]+G>8$Q-O**$?$A"R,J\D[%/_:3L/$C5>[$FRPI;C298*8,SME+W
M\TW7I&[T+"K1EFINU64$_8[36&42==)'E\+LL><"9"HJU2Y;S\S?S(M/J"1!
MQ:NXH)0US:D-!^M,-M:&Q8TR9<.4B3;N1A246V IK9!67\$+%CGU7(*05UCK
MU(^V3(B!,U2?R+T0M(X^+1>E!#D=L+!/LZS8XHLQSECCC3GN&&.CIB/1R^J4
MV>MA)H?<+_]:8+5=\566;(L)M"#!G:WA95G2KU\O12Z)M8;M"_K5 D&%34\V
M_Y/OWYT5)':I#1?4;35VA^R20$*OWG30$!6:S%)@V[T06M&6NRXZ/%LJ%#OG
M%/STWA,KVBC=%)\%.F@9&4;V//4<G,RXQ?A=L<NE1%4.OX-"E-3#28G]:#>M
M9=MH4DC)(W+G-N?$K</#O27\3VLWXY?O?!F"-[<])U)SZ%:97BK4B"27:2'>
MW/X-SLWB(V881+FKO*^BB8Z9;((85/:HD5*OFDF/F6_>^>>ACU[ZZ<,BTJY$
MN:0JQ9KK+-&Z%+5[$3!G64W:UM$$+_YEPATM>4_4%W00JN*/PM7_.?WDQC"F
M7_MUE;H'<_4:H@PE,7:ZWUT,99A0;4=!)GG?IIAUN 96B$ +J5&S()= 0_DO
M,\?ABW%ZPQMMB2IG%O+9PUP2*MDT)R.(TM5S8H0A A7N9072CW*V@Y'V>.=E
M#EE,><+&OFQ)R"AG*I*&4**ZU:P*,$S<570H2!WAN0L_@>%.:QXD$,$\:FWK
MNXZ,3,>P'B6O1/;JU(OR%Y2">>Y70-*31UJ%E]A,K74LTU?<J)='/>Z1CWWT
MXQ^UPBEN@<IG/ML+XU!XK1YZL25E6@E-D+B;LWT'4_"I5GC"=#DD,F=V@A31
M1;;H.0"]Z(>[>A'?4F0IP_VP6K&337R&_P@P'H4P:!MJ&@G7!['=-"UM-8F(
MDM+#PJM%9%&^!-(*@Z4Z5&;+),/+3*66(IR[0(5WZRD4_9"I,F0JI90E+.$5
M5]2KBOQ0([G"C $G]J_ <0J)AAK/H,1F'-! K&7H6=6D'A*B#^%.1< :C][^
M%T?5("8P*[K72=K8'7CUI* [.XT461(B(FZ*:.9BX) B,T=<L0N0'?7H1T$:
M4I&RQ4((>F"+P(2N&++D=80CEKE@LZ"%.3!KV&H<TT3(4B0]D'_G\J;6HB@F
MC,*(5\:,J3>O*=3!//0V^_3-<O241.@\3FUW"HT^5:C! ^J'0K4*8K\PA4V5
M+O4G#*HCGUXH+/_C>60S*<E0? :ZP=^5#EUM<HAUB*=3Q.FP<I@!S+,(PS?E
M\')8_FM7FL26J:,R\T%YZ91L)*4G)5FS78O*'X\ Z+X(U75UVSJ7J<(($55F
M<B:4.FQ+V\5/Y*&MH$W4GV&,I+6AH0DCK%S>2'&;6]WNEK?1*^(QN562Z1P2
M<#%Q;?( RR)X;BIF*21;D69Z)%@2])Q]ZPEF"!HW:_GU*/2JD'/*E"&T/?0H
M"+75,2-5GC^5\Z_Z Z7GT M9\+!RB0;5#+]X,RMCAO.=[<W?3=2&-BB"[I7-
M1$C*U/6=5;G.6D=%IO=LEZ' #:XRK1N;@K-36NJ4"34 %).$.O01BH;_\Y::
M,]CE1M= %OG)L:N:G40QPN$#$JM10 &:XNSIP*LB:[.^L12DH#78$AZWD1Q!
MC.\2E;.%510W9<JQ;81LN?\%\8%55L8:KUP1+&]9RUVF")>_[.4LAYG,8S8S
MF,\L9C2O6<UM+C.;W^SF-,>9SG.V,YSO+&<\[UG/?:XSG__LYSP'FM"#-C2@
M#RUH1"]:T8TN-**M'&GKO2^J>,Q?C 0U8+"U+W:=P>OD9,(KEX5&B]CBVMJ^
M,S\.;==""]OK?JP36,;VS:Q296@"T<=>3DFH@'):)Z;[5:88G]=597M(K&.H
MM\),)X8;"E)#VQ1MMHFF88L*7(CXYDS)V F=_Y7+$(TW%97VM3<I05R0X6IW
MZ3L^]<$RL6WE,HFVO0V-4/ICIAQ/-%@T=BJ"TJ%H5S]7.2.M2H7D$Y]F[R(M
M< _[R)X-Y?Q^C)&889=T(F8C34GXLWD-2G*X@@IHZ)AP&'W*F$5ETZ@DG7*5
MKYSE+7?YRV$><YG/G.8UM_G-<9YSG>^<YSWW>95_.Q\Z_8CHP-705 A<[L*$
MDH/G7>=;2TWC8V-T72=CM\BI_5O&["_)34[BXP[TK*8;=ZR4XN[8^:TNPPDL
MJS(;ZE%Y=2;RA YL@;V/O_OE0E"A3T!P8U?92+.HH-^EAP86NOJ>.=#1;9;<
M)$\PBYKS4"2#\X!TJ__,#^=)WK^2B>$*G;*&98R76RZL,:@KEZ!X-> #DSZB
ML?6+3WX\T1DNLMY#PR>M:3^J!=;%<$8$=_]<&L4+3;' Z<(]/O4Y.$D>^^1L
M"J[1GQ]]Z$]?^M6G_O6MGWWL;U_[W>?^][T??O"/7_SE)__YS9]^]*]?_>UG
M__O=_WR1'X@X*8]J/:CRW95:]R4YC"EYUJJ?H"5E]"EE9$J>A@>$GLE-:.J8
M-"6]Z.U24"UVQ&N71&X V<I8G.:I-,E& .998 RY4(XAZJ-QPDV'3A!3?&?_
M'LOJ@.Q#F.);5"3!=F:RH@P^V.G@!B>!TF;55HW<N*E3A&0%YVAEW.Y_U NF
MNS+JO.+J.WJ".V)M@F0HLWICP88LOOSDFS1EQKQN/=2C1!P0!7U&--Z*+Z:F
M"V4(P4B(:]ZD/C(#3=H*TS+NNY"0^!)%F(KE/6CIF80JDWHG9P1+/B@-W]C)
MI+K.$ N1$!%Q$16Q$0_1$1/Q$24Q$BF1$2?1$BL1$C%Q$S6Q$R_1$S/Q$T4Q
M%$F1$T?1%$L1%%%Q%56Q%4_1%5-Q%('.A*+*L;H/)/],YKV2(RB^#8!&IP#!
ML%9H\"<Z;,%<36OT+@'KQ/A42+LRC#KT:0Y[D.PB9+ &:X>L#3(DBNWZI\)>
M1-Y8RGB.;3.DQFMX#0/5;HS<+E;NKK'N:9/XIKU$:#-B9G9:BI;PZ3".*3D(
M+[Z@J-S81J<VY>FD(K!>8CJJ#I?>*"/LA)BLL/^ZPYM0HT0T25Q.*4@D)$$@
MIHF^L".4*+M4;(DR:^[D*-=HC:ZD;N'"T#+FS3>BA5'&A#=8Z(3N[@9)$B)+
M##Z,Z4!V\F'>*YI.H@"-Q/EP8WO@[RCC#RF5,BF9<BF=LBFA\BFE,BJI<BJM
MLBK;SZ0&9_H0D9VVA2JX9RC_]Z=4_-!F'"09"2HJMN/3H )B_FM(;DH-'^?S
M=I&L=(9J4"-$OHT8IVL!-PL@2>4<<:DD&6PP/V2('NA'T <PRC"VVFY5Z.8Y
MJF7)]D1,1$><@M'MJB7'XJ><9.5(/@<F08[='@67%NLA52:G;,=I!*;S?$>8
MW&=\W"O&7.LZ%N7>'$:Q8G,^[DK<.FQ^!DCMZDLDA 2*7*CWSLBG?BP+#ZX?
MD44U2NBP-A 'K7# ;K-.K,5PXNLX)$J%(*FLD"7C,$B5WBNYY*-!?BX]U7,]
MV;,]W?,]X3,^Y7,^U],0!RD,[2+[&L9DM(/L2(A>-A [A"7!N(-[UF?N/,S>
MY*,U_P2.//[+J@H#(PVF,!6+B<H$?"QD'F'H)PR.)*,1NL#(E_*I-WD*P(YQ
M-7Z(XA %NR[#@, ME%Q2:DBM?L[(*7;(&Y/%6/XD+U*,!FGG]>0Q7?Y+ET@%
M!L<)-S]NJ 3O0LPE!K,S"T?M?.R-G(H,*634DVP'MFR'R,CGA!+C2I%#))',
M#-$J-#U4NY1&*?1D"+V0:*S14";(1IBL@"0O"4.-3)40($T22F<JOPAKW-R(
M. 65D BU9U#E4 ?54!,540N5416U41<U4B%U4A^U4AWU4B754C,54RF54S6U
M4S<U5$%U5#^U5#WU5$755%,554F5556U55<U5F%U5N7O??_ ,&:NQRMUM62F
MHNJ>"D$.XP.=L$CAJ$B-]5WP0W&2C.)0S>N^*ZKBHT?@Q(B."C-LZ0S]AQT5
M3G_X#C^(@EZD128N:YQ<AD'AR8G&U6'&R$C6SJ#Z:6T&KD(H,H0RQ_.TKA"3
M0Q_S=#58#*CFTD2*Q<!,93MW<S4V,T,Q+R"?S;,\,F5([MC&IWV>D4V(2DPU
M%(Q@DAB1<%OQ0C6M-&Q4S#:)J;;F T%=Z#JU#MU^QUE&AT)(YZ>F,R10CP>5
M1D$1J<-F:4?%[4[-RL-\!\+0CCZ%=FB)MFB-]FB1-FF5=D\JS>C(Y80(E3Y6
MUFF13KZ4CK0RK%'N0TFJ2M0J["G_N.O9OK&\>..WN(6M8B0RI=2+)H4T^H4G
M>^(EM3!$92U=@"](XW58#P3($$NKPLJ)>H@T.@@DN<ZS6J,XYI$_T"=#C>[@
MIN:-;@AP=TAG.J4<Y:L -4DTF70&&26G#FXA.E(QK<=E9\+"7$<Z5^DY$@<-
M69);$ZE3%E?N>A!M,V=5$H:M?((T%%!:7V@O^X7>4*MN7'*60L]GT/9NYLBZ
M L2J]FM-O#40TRN4 )>OTBEN(>IW[K90KW)[L9)[O;=[P?=[Q3=\R7=\S;=\
MHZ]AT!.)L'1DYJ-IQ2/_3@+VWH=,7D5B%?1S)F9L:FQ&-6PUR50[$0S?O*>M
MDI62L!,S_UB+KG;PA9RPY%:D%WV0@VSD4+R07"$*,PJPEWY# ?MCG;01<Y*S
M=8GS)'-*,/FWRIR"8N1KAQR8L\*U"E?-@]Q(!TTL,A;VZQJ+-[KI'2N3(QXO
M:%3J36"C>46-D6:)8J=NJ,JHM)KCX\2-7V&$:QXK:P8NP08J68CGUH!/.J_I
M9,01B LG-.-(ZA0H5];%@+5XH:3-=45T-+T+=]IG YDVR=#3$.]8$O,X$O<8
MC^U8C_^8CP/9CR,&D M9D ^9D/<XD0.9D0_9D=>WCPUYD249D2EYD">YD2M9
MD349DRVYDR$9WRHYE#_YD3=9E#V9E#G9E*VL5@\/9<!P*^O/D/^J%FL(17>I
M+B!/!3)M&>'BYTC>D?G:%(M3\Y>T2S;Y5-C$R:7XZ\$^)3JND7H!4V@8*B&I
M=P"Y*HB1<-8ZR-U\Z.U*S28FMPH#1XK')(1GDR1-L"\8%=0\B':OZYC63NG^
M4D;!L$H'14Y:,%,F\IKAQIYZ)XI9;UX+BD9>\KFXZ9<;S">GL64QKXU>ZGW3
MY9[]\D#SZ70T"%J[*3I-0D^Z28)-YZ'!+3M0A0^MU/ $44:?L?"<"$9QEB(+
MR+6^ML9:LV?.]Z;1%Z=U.J=Y>J=]NJ>!&J=+.C$9EDLN:4O0$_^0+H(@I^P,
MI.WT5VO*:)=4B:("!UYUY5- USGNN7__M8ANEY&$]$W@$D6*E<I=.TC5.+I;
ML<6T5,IO=F:9B&*_I$TE*8688RBB89FCN4/"_&=OJPP!RTVEN^XIJI&%ZN6,
M9VTD3 ,\'"Q\.#HBA7"]8O@UI0;V^MDPZ4>OXZACH^ZY7D@V<;:\9.L$Q]IR
MBV;O1.1/]'0??W"A@V6Q9>,[%8X%D>:<89+(<INK.]AX=NB)/P<P?O&N BY?
M&C*,EC:YE7NYF;NYG?NYW].F0::D$B[H1&9D^),PUO(^I2IE[LM:8T+OU.ZN
M_:>:8LCQ?K*_6FAP80,ZC1391 G?2)B8(])<=+%U@Z9V<#:,,U9&[6:;JRE#
M';(U@]E_C6;$W)K5>_:*8NV66&,I9'UP,$))_KCGZ\!80,6:899+(%6B)EQI
MU<B(LA+D#X<E0\(.;CHKFDC-8UVKJ7S3F?SF5JR%OHZ'1[XF.!&/"RF7.>5(
MLU/$,51H0(Z%K&ZC+HUB.:T.@*CXJ) 3";TZA,L& &&LO;2I5G &>9[*(D=O
MB,KQP=-DRT>OR\&\:[R\:<2\S,\<S-/\P=<\S,?<S-_\R\M<SN/<1.?<SM^\
MS;F\SLF\SO4<SN^\S^_\S^E\T/D<S]'\T G=' ,=T=5<T2&]T<M1S _,L)V4
M9PI[*]W_U]+,+9QT.%,4,*RP]4A-T#\<#V?O T;#;89&K-+_N*>"5!#QFW8-
M\F>ZN9PXY4-'N]54UT26)N%N*O9R4\J@H]<OAPY)LDN8EW')QZ)_E7P<D='I
M.;8(V+,4)[^\;I?^KH7".+/JHVZ$4:G&EF$IKZ(-LR&%>$@*;AKS"H@?^.V6
M\8RE#7DZ<W#]\K7BDK"F; [;T0^!(RC_)\#IU3=>)W'+BTBKRWI7O+N2C+P"
M3I[>MZ<ZMSLF<Q!3&94?&>/75^,+VY,K;90Y?E=!WN/KV)$M?9%#_N,OGN2+
MW>13ON11GN5/OI%?ON5CGI1G/N-EON9S?N-W_N=QGN>%'NCS_\/VC Y") L_
MP] 6>74C.I+JP!3!9J_=<@QJ4^]E(.E^J1VN411LBHF]AR7;H+FHYI@A#\B6
M8SQ]9%,^4@0F( G3B%,\;X^-AG#IU#3MFBM'45N<;9VT8XP([]>M//+8KW9!
M:'CIC&NHT8I.V'@S1-M6KOK$IHV.$3I8&\4\)LP!L^TL/^)!J)@YL(A>V90?
MLY7JR4K& G?;_T*RB[(+]4]PR>9HO@>>/'=3A-)P/00@P27JH./NBW&EREX\
M"SK*'T8'0>@SAU$#EW2#%(0T$-/P>0GZI1^>:?WY 3#ZKW_Z5[SZL5\GM=_Z
MO3_[J7]&P7_\IS_\MY_\N]_\Q1_]R_\__<^?^[]__>&__>5?_.L__-V?_M^_
M_P%B&3V!RY0-'&B0(,*#!1DN))B08<2&"BD^E(BQXL2)%RU"S BRH+*1"$>*
M'#FR'DJ5+*&A5 :-I;)Z+E/.'%FSWKZ=*NG!%/CSY3)H!U/&7/G2($I]+WTV
MO>D4JK*"#94Q54EU:M&D^[3:)#HUK,^!-96B'!NV*E.286$Z+=C3(#2X*%U&
M]:H/(DJ1!.>B+=C5Y,B\:9-.S3E7+E:TA8%Z)0G4Y<FSD@OC]*E2+-628S?C
MG)DXH52;9B4J+7OVL$RLA-'>A;PU<4FF9('&+@C6:L322C'W%EA3(O"VOI%.
M9OS9*T+'Q/?__GY:>+%@UX=%$CYM=F0TN2+CTLXJ&"?%M=O1!LXN6NG)Y5'I
M15N>>N!WNX6WV[Y)EV;X[_1R1PU]ED8V^00@58EAQ19Q[]VW7F]A;9=45@B*
MY!J$-YE4$WA)E11@AV5QR.%@ZTV6'E$D@HA;AY E=5UZ*IJXX8@PJ>BBB#2N
MZ-:),GXHXTLMAE@BD"C.B&.-5O7XHI [T@CDCSI>]N2*/-YX))4EP=C4DD4V
MB22.6#*9XI8D.ADCE&5*"2:+7089I6A3%FGCC*:U!I9,(YWWDIV&Z8=49CL%
M5I5RS.%VG(5=J;0=@A.:IAV']UFFU%HSRL196Q<ZU16%64%4T'MF_TDH%G[*
MG)=5>YQ*=9Q4_:76W(#-7:65;12&)UI!M)'DEV0^\37648I&:I->GV:'**ZQ
MFBJI28Y.)>E1^2GC::#)=3B40H<)Y2!%H6*HK'JQME4M0O;M51:"EX5*V'B4
MF;M@49G9VNASP.UZV')^H==M8IYUMB*GL"YT(7B=#8ROK*'!9RZ"Q>E&5WRG
M3A?6K7^%1=]>:)F;%D*46LOC6U+11!U;0_4$8,8P5ANJ;R0[!59G^DI95,P)
MM4;A@F ."1N2C**(\T9B]KSSB$ +R[/.1 MM]-!*)\WTS4W__+2+00>XM--6
M0WVUU$=3'77167N-==A:5RTVV&-W#5%PFO]2C%-F-^GYMJ]]OA33GZBJ5ZZ#
MIFV5('8^K573H:FI)-E1:*7[=EVS#K5PPSC^?:[',KL5%+%RT4M3@VL-E3CG
MT(8E4W<'BC?QK!F*+*B9=)U$$7WTINI<9G>Y%ZI+;M=ZE^. W637,K>"OA1T
MOEN<.,915=72ZU(+%M>[V\KE8,6[#MR@PI:M:K'0$7[VEO+P L\;<@OFM>I]
MDI9*L:F&G>2Z@8*=+CB]J9D^\U(B.9O=J67]&ZJ!6;6,'\-5)T$DFQ:1!",0
M"Y7'.> "W@(A=I#</.9PX#G=ZB#UG2*Q#D"<&9&)[&(AA!#F@S::38IH1SLV
MD3"%HADA64IHG1/_E@="5R++"UDH0MR\L$HFE-,,O61#SN'05CKT',UL!$*#
MT/!^04SBBEQH1&U5*8DIK"'CA!A"(N:H)D><HA*_J,(;9G&*.^SB"+]8129>
MT8DM+"(7I7A&%"X12BL<(Q3?F)XX_C",6.S0'6&(1#3.<8MB]*,; 0F;04[O
M0A>J"6(,0YH[D<9N0>D/\CYGF9S$KBV_ M7M0*.IW%GJ-7&1GQ6Q%[!:B6I6
M%KI@7#R#P.Q,CU?XFAS+'/2IX^E&>7&QV:T469?=J&]6OK&/#5%BS'TE*F)
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K:\S&;>S&;PS'<2S'<TS'=6S'=XS'>:S'>\S'?>S'?PS(@2S(@QS( 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img42979713_6.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_6.gif
M1TE&.#EA)@*[ ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M=*:J[)#N+],C:1#X<*@L _DI$V;426V$-(R^*<^):%04G![FE^)@)SH>BI-
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M?E\8!S/7+JEZ@NJB4G'%AFXBWV] 3G&7,K.(4G"VHF1,SNC-:D2=, Y*)!$
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M3R:X[2Y+A!OS)=QBHWDX!1H*PK@"R[AL=#EE@!X 9Q_<< S!XI(J):^R1(L
MK_4>TR,9@^>.#3E^#$D10$FSD;H6PDFML9VF%#:QSB%B:4?52A_CTSEE(";E
MB"#L+2$?,$+"\%-^,T;J8=B6@7,H0=0F="@#2PRB@37+<"&84IK2)T,R$C*^
MZ%U$AME\Y4L?;S8\DWG L%!EX% %8A\((E#'(!IVJ+=B_^1-]R&JUDD)MXI5
MA8DL>&Q_$$<;,R78^'"BV,))RV(X\V])8W%5!")0_T]KGK$MP.(ZN@/O&$[]
M,'7$8H<[-NTIOE,QR/%33%0A?&0V E4]>^SB@%49'B>?UL)5(0OY[JL)XTZ8
M)A !?,P<R01(F23JUO(@1+55W\Y%9: P(;4@_#4TX90"%V(^3TO]B,I2-5)A
M&?9AI4-$$0,G$6P\,\&, %-@^R<-/JN=!#8":719#]95]P$'4$[WD,WJ3FT-
ME4=7=;-/(83Y]/$LD#4U$NFS5K0@:$=1#8(85)7WYK!*K3!+.@SPM @=T\]2
MM>@Q&$.58E4&/G4UF@<]255G.?]'5'5653GS(.CP3?$I'&>3ZBC(%"DP+35'
M0"OF!-=J3A4/!6443@"4)F8OZ8(".Z"5D6!O.LZEO&#/!*4,3/_QNV@3;DG6
M5.M1#@UP_BA4 OD&YO(%9A^$4QKGP-P6_^8O(J6*7L=K:!TE:1O6BIXM91Y#
M'A>#'GT5P8KQ76MU'UVU&8VM(!*@5J=1#9OK.>V5213R<1TO3L6P<D<R-FX7
M(M@QKOI*BZ85_3:P;IE-9(C1V%*.J<8V$(&W<!,U: X,\4P2RF85>@U"<P>%
M5_'%)&DQ!7>N=Y>EROP.&#UP;58&0^'**:CP7(R*4]^079/Q#Z.W+?:4W'00
M1W7T$KW_;09[=R""UT0@]T$H]O[RM6)#BJWBEB;^SE*>;7RLS-.T@^'4D7D9
M8Q,M+\AL4>KJ:"FI=T('5PP'&-Z^BWL0=ESVD%SZ,7'U$V7-C&5'3BNX)/:
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'>^UR!P0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img42979713_7.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_7.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MW7AB)K1\(!D:0CD1;#8E*!**;JAMYQ0-Y-5JA5=$40E<N*$0/V-N$\4"RF!
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M[=N\W=R\70^9P-O#/=W'30S+?=WOG-W;/0G#S=W4K=S'K=W,/=X^A=[5'=[
M_=L)X]S$G=S(+=?730S'/=J3(-QR[=W3+=N24-_B;=O=+=S&+>!HP-X'?MOT
MD :RG0D1SN#8/=_%_=O=G=]H(-L7?N'2?=NYS>'J;=OL#>#CC=O?G=YH\.'!
M/4,O/N+X;=T8[E,('N DWN+$0. &'MW$?=[F/>*CN=[NC>- KN+*W=[,3=SO
M'>3QK>2\'>+")-O#L S?S=\EWN"QS<YR3>7+0.":$-YMW130X-F9_Y':9Q$#
M_%/3@B'4!C$)SMC:E_':3^'.F6#G8G*7RD#7H[G1>^[GRE /T+!%5O'G?+[G
M@/3GB1[H@[[G];#G6[3H@.[GQ  -D$[76X3IB [IN97IE@[I.>/I?<[GD4[H
MT+ ,?9XSBC[JB5[JH_GID6[H^C#JCY[JF0[HT4 /MK[JF;[HRZ /O7[IH>[H
MAE[KQ)#KJ2[LA*[II*[J6V3LD^[LI'[1?4X/J$[LP9[LF?[HSV[HJH[MF[[M
M?5[KF_[GY,[LW,[HR:[MQ/[J]9#IOQ[LA"[MDK[H@I[ML;[KB+[MC5[HZQ[N
M "_MRZ#KL2[O -_I[0[PI([P>S[KE>X6J?]] &A0H.E2T!.?U:\2 Q._T >1
M"6,NYW;!VDL1VCC0SRNPF!5]%O1 $*AL$"V_#V*V+Q!-701ASS1_$&PV.IF!
M,VS&9F+6\PA1#Q.C#T _$"_?E$A_/"Q?\TLO$/10F03Q] )1#UQ73"NO]$;?
M$*,3\TF_$&*V\P0Q,0LQ\^?T\C X]4R/\\?S]6D/\UV_#_4\$'$O$$=?3#F?
M$#:_]7B?]2+6]G:]-X#?]J-S]4Z/]71O3%TOZ 611S,_%MLM!A-_VR)5>2TN
M]Y0O2TH-\@"L%X)N,*F=# 8AU[%]%A<-#09#]4__]$+O+)U/]/KPZT*?Z]'P
M^J^OURN?^GWFUT+KW_FF;_JS'W?UO/*U3RVMWV>S+_N*_^NP3_N,[_NU;Q*_
M7DS.<M&SK_SUO/O 7_I43RW1+_6JGUNP#_S+S_KB[_2Y;OQ4#_>*O_)UO?HP
M__3!?]'[@/JRG_JR[_IV??MY)/S13_L L4S?LGWTHAFLIR^A0(+[ZD';IV^?
MLHG["%+$^% C-(T'/1JD5S!:/8<<)2+DR#&:OH\%*U)D.+!B2(HD6X(4:5 F
M3)$D-3IL^7 ?1(HG1Z;4J!#IP8A)%[Z<69$DQ9 X08[<5S&KUJ@A35:,9I%E
MO; 4D0+%N7,H68<5!28,NU7N7+IU[?_>Q9M7[UZ^??EF(N97\&#"A0T?1IQ8
M\6+&C1T_AAQ9\F3*E0MGLIQ9<U8Q-^XJFP13(MF!HUUB51@6*T&L;1V:MK@/
MZ\BP)-NJ=)T0J,*L!&4V#-N0H&Z2O(&V-1CQ==:0)77K],E<ME#BHR':#BGP
MM4WBTR-J+T[6MO:0;&TBQ\JQ+4F=X+/:AA^\]_2QM6-C]QZ1=ENE#AO:-LZU
M_+:2*+>L1I)(/8)\L\VE!EE[#S;>9!*+J?D./$^W]ZYCJ;FBN+O.-=:Z:TLX
MZ?:;+JR06N,N*XIBFVT]B5YDJ+?49(OM./;H<RDWB,J;#S;=7FR.H.8V0S))
MND)3LDDGGX3_,DHIIZ2R2BLS>_%*+>52Y@#,[%HFDYJT I%'@DP22J$.5Q*(
MMM)<^JJ]L9HB:KH0F:*0)I?>9(NBHRHJ#2OQ:$MNS-;.A)$X^7 C#<)!9?.J
M48F$JT^B-UF#[L>5XE)O+8CLBRVEBD0-Z<T5P_MQ*+#@0HC.1%65\TRAJ/*T
M'I[,FG4^N-0DU,V6E&*KS3Y=?(_82/L[5522U/N3K>8V A0N25<2Z<8/3:UM
MS3=I/&FM0'/$J5K2$F)U):'>2C'0Y-A2]D\_;2KTP"WG'2P34)Q#RJ28H((*
MHWZ)Q177?)/:U]]__3787XX$WHC@;;7R]RH]18NIXM(L+ACB@Z%J_QBIBS^V
MF%^$-X;*8XQ!GE'CD4?>>.6657X9*I1C0GA;FT\6Z$5E'G;9Y=)TGOEG%WE^
M>6?M_!4ZYW\G(CKHDX%^"QIZC@94::9Q+I#>O;+4VDHT8FB0+GT TZ]:]^+E
MS;X1BT6-N]H@,O&U_>"UD:G9DIMON YM%+%89%5=3S\]92KUW.]@H]6EHEPZ
M%?'#EUMP-T6!BF[,G\1BM2G[#O5NO_;>J\T^]6Q[MZG26HPM-9_D.XY8'9<K
M_3Z6-%_]/A4A[?&_.A.E4+S>O^-[7+CG[!NU_^[#O2U!0_\]1^V$O7#('"ED
M\-7CFF-S4ET/'Z\_9]=B^\BNQ[=K$F*40?]###3.5U\,9311/S3XT0@MD_B5
ML9]^T-+'K/WS)TF?,I31/F40(WUH>-_]YE>_^^4O-  40__2][\)HD]][ N@
M)M(GOP9V4']ID$0$]W% "KIO@&A8WPG=9T QI*& 'F2@_B"(&1+N3PS$@(;_
M5%C  _)0##$$H@TS40\41I"(%[1@"@G(0@2R,(:2"-/](#B)$:IOB$7$H1A"
MJ(DD8E 2/GQB%&6XP2JB(1/+".'Z<EA!-(Q!B6E881O1$$40XD^*9)3C&=,H
M03$,HXL[-* ;$UA'!]H1A/N 8QK$- DK[J-]8DHC^^#HPSD.0X[*&$8+H>A
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MZ'S+)&U=X>?!9T>:BI+)\^G$':G2.3R<8T7K?HL<"PF>4(F^N2$VS,$1*R-
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M9%*/;EE/U8@/PKG.W:@\V(HRY8!"=[N19>&Z7F.XQ=N46705=7S_$\J\DDD
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MD.J$D49?I@/#--T00[$@,1PXB$'#L2+-L&4WMF8*D.EF #&9Q!Q06[7@RIM
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MRB*:,-]YE *:-!@ 9SJ+1L?*DC/NX$0G?IQHQ\0B":<2AC2]65PQ@5E!?>
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M3=:<AH$81U ,!U;T47>Y3W]0#J^,244PS<K0S%KD6#O5PQN4!@Y(PH+P5,X
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M:P,G_[W-XUZMFF[MHZ]\R'WX2"LK5JB%()A;1#7;4C"&K'?"-)J3+'Q\WE+
MP,C 4EY41Y+(#._>844X63OIP]38A,RT1(4_28(+1ETXS8S0Y"(J\3Z('@'#
MF%HPAI8D4H_13 W3MSA;6O@T*P$OH^/0@W0@CCV+01BXR(0Q!F74RGF( ='
M0)%9A'&8![YC1S0,PUET1DF^;W*X[][03,^L(G2(0?+%P!@0S5F,A7GDQ4!,
MHX 6AR;(&,O/1U5 PV^G&+(10S2<QU"4(._=G@!2;6"0<8922*AU<F9K%/0A
MK+RAVFZ-G.K4FTC9)Z!0L;M*H6[U\0P%''6"SI^KCK-9%+*G8CEP;5:S<:1T
MW=NS:X0/S_UW[3!&1$/,85\@JPE-] O-[=#\E!NG_M!NL5ITAKV#' K+BO1N
M.TM@T*SG6J<.U1EM\\YQA3!_9EOC4EL0_F 4QQ![1HP'\N%M/3W-\<L#*;MG
M 6=++ >Z")]N77ECKXY_B-1KSPH'16%MD1:B&Q>LE LB&TKCHC77=M9 ^2M'
MPDL&B<M:0Q:ZL7%\9$EB]4L,&R>]3.<. 48>MWWSA]:H_]N]^ ]<$%[R0;S-
MSC@J,0UW2]#WI=W-QJ3J?-<2]3X7&FQ!0D 'NS2&4GD:0. 0LV^?&!P$#1*,
M5@_:I ,Q;L1X0P_'#8,K,NW+%",&CA@9]S'<I^S&I)$XT!!$N8_8@1L>!T83
M8^!&/64Q'A[<2%#3#4TC.>(X8)*>&)<>,];3%ZUEQ ,XE.VSN"\:/4T0.Q+;
MIP_-PX] C\88&2 JM&5&(^+0M\\A1(%4ZVW-Y#4EL8@0M9(T*35EM!L!!HKQ
ML;7>1HXWM-(C2PRK6L(+H8TD6 ]RW*C+"&*.3)E>R(4A(W?^#"WN/GI5MV+^
MK&^9OKB8EX9<>CHN9=>AJ1(\W?]9]VJEK3WO XXY*FK82A=&>RQY;337H$NS
M9DU0MG/AS66+C(O:='*EN6DK1RY:*</MG:>3Y][:O'+J[^''ES^??GW[]8?=
MU[^??W___P&DCIXTHG)-O(76PDRXR9Q;9I+B0J*.,O"ZN^TZYWYS;:T"5>,L
M0M3TT42,J+[C#;/3II/N,]D4/.TZTR1;,#+/GMMNO-0FHTJ]Z!J<;I\T!K(-
M.!0C+"NN3)+BSLBE;,1P-@P7#$[!\ICT;,(,DY.-NL\^.X^@J!9\33?J,!,I
M*A>'A!*UT#YKK4O2E.O,R."X[&S"$R?#C;3-"(/+1^E$FC(TV[XC[<L(]^SN
M.O/X!)/_,O-FR_'$-A.<;,.M=%1H04?%6^O%M1[%K;8&(_PP-MC8N]!2-ZD,
MT-5788U55GV(.1.NWI;2L#1HB#%4F0(U^549RY3I;)FH8DB#H$Q6*)"83(JM
M3#AE(HM&&05-4R;8W'Y5[M>X> 7T2V*.Y36&G_1Y:Q]>H0VU2#!_#2G>D6K]
M=:T0M5H(E%I'NG:K:YM[=EYKB:%G6!=9\JG6T@"F3EM^)U,&VB*)T8J8A:B-
M[F$XZ1V66AB)JU>W?95QKU?BAA5NF*CB57 9DKEE69."O5NW5!3C8G(MG&&<
M#L0#*YP03#\K='FKS\*K[KD5V3-4,G@7+#-.''D3LU($8<3Z_U'/$&X-6T:Y
M7G W\=8M+[E[_9RP,]J(QA:U%1%<KU(89:W[56SMSEOOO>U[$#P0"67SN8VB
M$M$B8D1:6[E,Q/AII$D$FABNM\$UFZJE"ZKIU$Q=K <-34H;;S2UJ8(<#3'$
M0(/$IPU2_3L1!8+:4#QO$U/"&R2Q+G2@B5&=NHV \Y;!ZM"SD4'1-91,.?9R
MA1%,K(T5KC/2GGS.4-2(+ Y2F[?3DCP_VR0HLJ41MM.]"7$#5#D-E:N*[!61
M2WQ]KS7-63ONES]4,J=)QU%_R.@FI4A5"#HJ:A+#8&0B]D$*,\3IDV:X=S04
MI6IZW9L1EN(2/??PC8/TT4<FT'"Z$/\JJX/^T=8DDB2Z"#VJ1Z6)H LS1;1Z
MW* D&SG(A#3%&T?1S44;M).EQ =#5A'D.5<10R;2\!6\88I0.<I39CQ%IBA1
M3T)$5)"!H@@=3<7P*F#BTW66J#PR97%].7+:>WCSGNT\YSUNDE!LG&@S_>D0
M/@C+(F'XQ#$A?>A*U2J->BI8);IY;6X(3 ^%?%:Y2P4G1F'#E/JBQ*3Q229-
M0L,1]:S#(D^-+4+ &=-J@(-#\]6#/5A3#6$L!!Q;J5)1BGQ1&$L82Y#$DI:U
M-&&[#)293'&I>V^!1NILN!FRW00 21'#1X[YD^*-Z4-](M1-'/<=1<E&&0?(
MC_MX9+^I30+_#6E @T<XQ)(8''&<RG$(&C+AMQ_*,4M$[,YI"$<CYN1,(P>P
M#%!^4A[09*TTFLD0<-BX1\F()DP;M-798C2EJ]$Q-QYJ)=)0H[TX86@S]]H:
MGKICFX@^,$J9:E&$)GBIT:4M3^6)C(*T%ZGH1>F>N;Q,:A*DJ^4!"E0Z(ILG
MRZ12_TT(@&T34$.= Z5);2U*0P049^!7K3[9DI9B" !$9' #&81A:/X9T"Q'
M B2_4:=W:-#*?-(IB6%1]&8]HILE^VFS5&G-6T#"@>2B)YK.*:HX:\MH4-&$
M*(=.,#?[T,3I&N>HZ5P&5*1BF:7$1+_O8,Y-;%NIAW!J(#HJPZN%_Y5.A"R4
MHM\\)G%@K-*>VK,_,]&(D"ML)7,<N%G2]JEST_&G'DEEH>@,J6S0.6GRQ%2Y
M%NHRI&'*E/9P9;Q$=2Y1T.'2SCAKH*T]YXK]+&PG&]E ,WYG&8%:CMK<5[;F
M? =P/K-4E^87G)P9[45592K?L'I>]:ZW(2\-6I78)Z>OV&19,?CJ] HBAALH
M"QK[)<A4%A0-:&GB0=0C,)(^49HN[F-?H)C$3X@QB6$L;[[4@1-U1?J>MZP(
M#3=87 RNA3L)94D9M4*A,C:43DVTBR#?I,S*"!P5)/FKBRM"'9.4,[NB%5:(
M-F7CZCJ%VNEXR4>TY5C5R,8S'Q5(.QO\#O^)R.;: N;8-GUB&G/>6=Y--527
MLIV:D+9+-J>Q39Y,ONS9:O/ YP).4W,BH -C(R8$-39&N[F5 65;P"H',D:J
M;:+-5D>;&:UW;S=) QO[^I],X    R%(2\* EM(8Q2 '2"]+T/#@(()OK@'N
MK&=A%+_K?1H^8%+N$\E6'1S6U'Z1&B]+=75'14WM,SNL:7:Q9^&H(;=4.*[=
M=G6FD.^5"D'.S=)K<GE/H1+QC[<"8IF<N,-:EVTS3CO.'*%$HVF/B8U4I&/<
MV%:S1E89H;5CIEF'G*D!MHA47N+?HH9)M-5U:$: .ZG-!)W67],5E>Y+=DVG
M@\DT9C!M]XX:'N__Y^KUK2EP9]T@H?661HA//);U(!!,Q8LCK&D$Q&12AD'N
MC9F>*$,&QD3,&^S+/65XA(8=3^(Q+2T9U"$D(A'1KU#R<BYJ1Z>C.9T0LVQ%
M&AQ(XDOG@B8Q0$&DSMCPF&+ S#$] F)O?67E';&Y#" BXXY/YYO>$U]&H6B=
MPXZRMOBF)(.>$ZD5=2Y_W9E$#L0PAHP82J!LIQ$&R\A7FWG*0Z,B'165*^;@
MK*6BI;V2VLO.O(':U'FU;1(4S98KU3 7N6=+U8(2.>XU]7N%[B%S.#'/;C@6
MN^W#B?-E_8FH,"&:XK):QE=BM7))X. @XOOJ7#)239 <\ST2FT0:\E-M_WZ&
MG<]WXGO^5J1=/@[T0%6>4P7OK:'J]NC8.<9\X]NW93C)=)_4EE'\LF;35DG7
M2*;<$O@;F$OH[_*5J(S11%F]=]6@:6?9!4ZB9)<A9Q]WK7:W)-TSB56$Y_&@
MS4<(Y5Y,+Y0 IYTX9G5LY[*V!FL$2[N@[6FH@WT^:5=N1(N.;:D0ALG4Y$I6
M*SCX*KNJ!BX29:)N)4.H2U)JR]_TR?ST"C=:KV[,JP9Q4%:B0:Q*!552)%4P
M(YZ8 N:2 FW"0%EB("6$XP8>0EDDT")(Z2-F*",V@F%N "30(.5PH &T8BIN
M8I; A1B"I59$)C8ZPR">)R[VZS4^8AA<(BU21O\YKB(E,H$L;B(J$J(S%JPH
M<,!@(,):OJ*+7&@2;J!D0L5V%N^>^&A\P.W@QL1IH&R?P 1G9$L9Q@ 'MD4D
M^"2[GNRZH$?<S$->RJXL$@AH.J3^U"\D<BKY<(9/,"H4"^K.NL?8BF<33TTR
MULC3;@U2?&-&Y 3L.F2?<*,11Z=23JT>[$S=,&R%9N2C]FBQLB\'8>6;;A!
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MS50?+FYW?$N,UH(Q<NXEQJDST@ &\.8K9*(C.,)EA4,P"4(&4L(C*L+EPO_
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M-88\MJ+%/&@MM6<F+"PY*D\=)F0&@2WZ>Q>M\A=NC%(Q%["SB!)Z9T]/]D7
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MRCSHV-+H+;>(*H[&Z-Y*J[;5'GJII^$:9/^+/=AF'*ZFFPQT$"WZ<F).R,#
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M,S11Q9GV@XF (#B92Z7(9[M9&REY9J_N_,=\Y;$6">\(*$8*4$H)96ACE &
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MP!=S4V*BOJ(<36 DE=STIWJ:4,RY,V%L4^0+&I$#CS=B$]#;C\9AQ6TKP:H
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ME8 %EIM@L3=[$=T:AV2[[!Q17FR+T# '*$,BEFZ I)$(U=0S-XY<%#\"!(P
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M42MVG ME%'&\4NNTFYLYR*<1$_HTR*[4"+$0RD@Y6Y_(W5B-T*1PU1W!Q\%
MDB_MGD#J2B'"3&I41U0"U=A$&6<UT9BI6X,LSD3U%8ST3K28W:$Q3%U!6])L
MG?YD)&AX8F1&B3)(0@P<P TDCNQ1"5N067RXT1-AG%.>#Q+Z9?"YU831D'EE
MHU-&4OCA3K<\VB#*(!*!_PC*22+@39H.DDEP&)V'=%SKK.37V TR]F-(1902
M:<R\B4J](6%HV!=NT T23M,-;8DQK4X_7F$0R5AER%_ :4(FU-\[Q=/^*=QY
M;@^"Y<!_O43XG**/R04*;:?7M,EU= 7@#0^Y)-8)75?&^)D:2847EJ'Q+.'O
MA2#YS!%E:B13*$,HQL!DJM8+_B-0AMS:S=ES.==PY X0I2'%F QWR";5, RD
M!8R&# J>R-(5M9E:IH^C]1IJ9&<0;8GDX$V/,4=]M.'>Z$_VT2<YT@7%$%2L
MR!+]$%6-I QPH1V)Z$I1Q%+<=$TE"MH?JM*AS2'$R&B1"J-G5N/>!(B(7HIW
MM/]<=-W)S?PF-7U9JATD<<3<AVS.[N#>86%0:I#:X@AET,C,!_U3+/:F@FI&
M*?(IDQ"#&,1  -Q 9_J-/G0FN?05> @HB(T-M50(_IA%;( )V.!4V!S0X,%E
MG(F+-^V9^%!?#6H?TO$BM"3E2TI&R8F0G;)FM?%;5GW-<;*(Y^U+)35I5:1!
M_[G1C+P7FPHI<H77UJQC%GK9<(B6Z#64DK'C92 $>&K"&Q"</)HG/0[8IMC?
M2XA&^-S+YH"?>,5I9$3EE9 )A2P'!U':3L)(XUQH,]&5EW6(E["I69C+0DS4
MGW*&,K!6#*"!SDU",D03\ #2S @2:^2/G+)F%-64XUS_%*6BUY] 3'K!"9TM
MR@X&3@(!'C5!6DSZ!;/0Q:6<&OM$HU'6R-GPG7[8#8:D2RZ:+*4"D7O 3U>Q
MI7W,2-Y=&Z0L$1QJV"3IH+)DEK1(3NQDCE4U6K$T1]$)B;&,T0-^'(/*&;04
ME&/-QID B=G!B,3N(X0(E\1Z5+H,3,7AUUPIC=N\93(]FKUN1DR9K;I PS#@
M &:&DI\NR3)T9MFL#*05ERH5"!CVVBQE2%WHZ&WV1Z4V()A6FBV]67<L3@IQ
MEK10JN )2=+H(K19C'[,F1;^EM<-YX, EBJN*0REVC<%I4$$JODYF(= 9[Z8
MG1K)4E));E(%#73]4/'UBN^Y_UDQRFCL,<6-U(-,1,\D5 ]YGJ?^U5-*G JJ
M4(*JX-IMLIBC(N>52*-!,2E"<I]0M$@'[1U8(2=;9:5!A"#D3D?:6D8]I(';
MZEJ$SM?D/.JQ3E2.H$M234O%G<L.":4>V5"8\I80Q8I@$,ERT6VI0@[(;100
MW0UIA!!? >M%UE57NB%BVJ!0V4S.F UY *Q:G=0UFF$0,AUS *+&*%%L]*9.
ME5H+"=+_J*(T<=R%/&\P2>JT&)3,U-Z9H<Q^Y ?6-9<2/1L?-LNVY Y9L&F@
M3.=/B<\_H=*8:/#0OF%AM)@5>5[Y@B^$@B^3* \.&,"#KHLI*<,NZ4_9,HZ:
M&IJ/,)),R=@I\1@F>%CP' ;Q*K5-LHP-LW#QYVKAI2$BDB$7$CUP*YV(N-J-
MZM 2L#D5UCV>PL)QZGH4,7@*#LQ7AY!JK\[LXO28YB(4!4)(%[T/$WT-:B10
MC1#;Z;!OCF)&LZY*/!;<P7F*\*)GM<83JN@3JP#<^E"B\W)16;JQ6V+%R?P)
MD$+8N;B'Z^X26+5AS95JO/\],5-D OF28$GFG:.:6+/=QHR>7+T W<DYAR)R
MS2Q]3;4!Y1!I#N_UH<TZE%X!7ZHA<7D!2O$Y57D@%G 91_ND3C!I1-A=X\G!
M<!]5JJRV3*5>D@\.5H>=6<-DLE^(Q[VT6KB<7!BAK,RP1WDY, >Y[.P&33)[
M5Q%5WS6I$:4&$PRAQL5$RO/B3],Y2"T-)*1A&!#!W+E4REG$*$4GRB3'Y;<&
M<V4P<4L;"3&@P?E&"3UL)O<)E]Y(+)Q J@[6I2J*T6^%48NH#(E>D8\X$5R"
MTT$5(WC \>055VC!\T!N(#,>$XB8$+%\E>;JJ&IT$)'AI9I$C'Z^0:B8$Y<0
MCS#_YX"'9,BQ=,@>RPI#7])_D A9+"G>!N+V<15U*E/E!@K<9L5^P6/]A7)Y
MAHH]';8]X8#__5<F4((JDTS<2(55@]YE,>"3P:=>\-NA"<E:Y.U:Z47WBLDY
MMC1K'< I"80ZO30GJ8HP$0^WZ$V;9%<CQE$\ R=P_$XK6>R^O9)Q=1>UL,7)
M,!ZR=5E>M:PCAEI)UR1G;<T5UB[?9(ZH+D?I9?-%\Y8DTFA^$-$(;;>G_MC,
MA!K'YDF1III+8I8R;8DC77.O*=H6ZH>0SF*$C,VS")*X!5ITF:D3;C6\L;$L
MMA)2CZ"B-B!SGXBHTMDJCM32!!T!60Y;9O?^K+:]TA9,_Q=SE7B-_AS1">&>
M7A7X*EU-S)FL;?BC<-,,:!KL#D7ML*U.L9D(:QP3OL0&8S5@I2C9A'YW'\$-
M"O-LIW%I6VV0>NTF"T,#-Y+$)(#MT:U(?777U(68@ZEQ-D9MSVX0<)<&SC0-
MZ%4MTIVLZ=E'0IUJM%F&[RP#/+83/)ER*6N/IA0<]:2*3*RR:7$,J&W8.@>+
ME/G=@TA&M6$UBBR'+W<,&0=S/4AQ#+1M#!CZ#1#ZH*D6SQU7D,3N;3R5GWCH
M4!S59E.8<S2:L]'44_7*6DDC*L*-A)Q-&-$06#2:85EABR.KO9B<%14,1M/5
MBT%:8&34?:>%5#:IISHSI8.5&?_IL0 5\$+Y:JSFS;"_-?19L-DX5I_-DE6Q
M,257N4.VZ"_BG4D[BQH=(1FJ1PQ1[J5A1Y!BLE]H6>IA5'80$<N0'+$O&K$6
M"\TRUG-2N$(X<;QKAGA21B:$$NX>B3+<EN,8B%CD#KU@AVTL.6DXE5OU\(%P
M"%Q.'-^ 6JE+XOXPRA;#)*]S51'!\I40>/PZ[H82;=FFK.V\BHH NZG['A)C
M$YF$1#?2=,5<<B9 R=(N@^V%)O-]7R"MB;5GGU=#(9+29PXS(6QSW)X!QSX;
MRY++S67(WZI,#_7<W[22LDF(2L/9'S[RTQ5/G5DX5!!BV:. UZ3I]TI"4SA!
MACYK/4S_$\/T2 (YI0&TNH0+'O)Y_XY)WV2>4W;#\XH(6SNVO2@Q4MW"_PI
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MQY.PT-1<93J61A$'JS"/[S 7&JE$ZUE=;7KT*,M2BE4W-5-"*7!I:U'^TM8
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M:45-=8N8DI!2R%?ZT)>9#&1MENDE"692+P&CBY?N9+)C:L:11FJ:RA+$+.%
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M 9$!!"NF$#+%+*8_O,!$!YUW;Y)Z"\_S!)G:W0TN_TN7D?)&,[O9*2]OJ O
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MA1@<, (C, YHM9]-0C(\94I "E?HC%Q1 I]X]/!\&;Q4RO!5BSNQ;USLD5O
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M;PT8;1]E<-I"<9]LVB,]$*@D$1;NFQF9DEAI^QZ'2^2E]-$32^!OS-&AU.@
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MQ !TNH)]@Q$[.-,P7/<9)UA 7$%*9=853K=Y+M,CZE)FYA)QIF0F7=9%_A*
M-<A#G^4_<=%1ET%PS>8@HZA51?]SBM3H,H 4<:^C&@F5&8?H.L'S2))3(O<3
M2WU"3QU898LW:_>448DG+VSX.C-3)34D4VL&62ZX3<WX%?F8,> V/#+5%S4B
M(%*R44L5BXCC,>D%;F+"DC.A8I%#$1U7&RI23ZZH)\53<D^B>:P38"(4?'0U
M+^>A#&K5?)VQ00C !=;XC6>)EL74'/N@"0<@!M/D0;;"5SC2+W;4$)3 -LH
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MC22$.U:*>F9+?]=O3'AADV   5">RB&>V.%R#<9RQR0:Z-F_?>S'MG(# 0
M/L<< BP?FL P"9>BVL@?)18IZ=6(7)J3L$-+*@RAQIEC2?]UK*"Z?D2Z$/3@
M6TVQ9Y]U.T=14;2C52C")G%"E$0+J[=T.3PHI.JC<"OH,;KYLN<3:+ 4:#[R
MO.=S&1 H8SI5AC7X3S !7*S<(R5G.-*3.@#6S'R)P>+E+W-FE3R*.+,X;Z0W
MNE"I59FZ(YL"R3Q#2Y>S#W)JG<OF1Y1)ERL#%5@DBP1$EP)V8<2P5_>\5S 7
M'OAZ<\C''PCVQP$MT)RB*GNE"??,Q[:BGUOBN3R!69Y1*_/#>D@%LW_3;8<X
M$7"Q9M6B@14)/;35.(;64Y$"E/Y#@A@3L<BZ3RP\,D]\+D<+)19;SNH7((#"
M%CUVRQ>%P692FBJ%(6MV2,DZ$S;_[$D>JC+P6#_=)4NZUW"?(UV6U+WSD]3=
M2YRFTZ6JH6-0057/>",AJD;->A_FLGBW0[45M<OZ-L+1ABB(G).G$<8C&,IF
M 8\-U7KQ^D&&''-TRW+*(!O=P0)I8-<#+=B#O59\M9=E2B">P0)=DV\,9S%/
MQUCJHY"#M%/W];@%-7$CHUE#I%UYH7T'XR3+1J-$.#U%XGC+1A=!G5]?MY=Z
MAVVS--<%IYM%O#(Q.R4_UG]P6*)3LV(8.:,>U%0T4I)YTE$>^<3[TJ0</%#:
M>J :JG'9.:R\U2A1RMEG>),SPW"NAX+AYDJ76H[\XR[*0*3[R'DV:T9F=J1(
MNW^8MU4CUU3'<;5U<HK7#J&>%\;7_+%!!$O8^\W?Q*%\2$$,Y(B.%3(UCL,3
M;04:%7*9/OI)4$*$HNVAE?I#,:TS\#$R<U*ARXLLR6).;<1N<_;:" 2J ?<[
M 4<4H_JMT?DOJP1LM)B/G!1*87M%/H0A,-L1Y=-#T&HP$@*2!'3 \MBKM:2/
M\%*DS.UTD C/YS4_1W%UP$J@88P_UX.JY0>2-N)KC)L^QM-&.C@E;22JY_2M
M>0(2-XUE76KC_2>AVVO -D-2]&QAT1 &@TQ-"1T>+C??"^3/GT'G_<WG_WW>
M&] 0 ^B9"0%PY\9AV,#<JCO1?0@@8QK]<8X]>5YN7Y4L;EDQ(XG,C^<T4A_2
MRT#C.9':( (CLZY;PY_7.IQ9&QW5S#Y^7T[7BEI3YK&#D?-H?PPX)W&FTUK]
M.K3=JI[W.2O&U2V)L=%J)\X]+5K*&JO;.+6N>JJE2+WY<%R4P[?AH5]R,6+4
M=.RJQ& 6=AWY9]\:6?,%O5WT2)$";N9<=TH<L7?HQA:6"8$+#?2@#&+@0N;!
MSZ@V.&VSMW[.[_PN'6+@EF@PCF\9ANA8*X[V)[C$&:'!+YV*13Q%)19'7N8N
MI1(CD')W)PC;1(D(1*QN.UEQ1!(">XT)K&M&)O_#_DYW9T ;;&03?%^7<:/\
M=A1?+)1Y$:/<ZZ0'5%5TQ,R3XSJ* >.V=$JQ;51;^DJ !#B5Y:[$R+C0I2[H
M:[,73F@#]4B^C1\>:5$0;U4C-Z,'Q;HR93HB5<:358OEL]J=-3+[#D*%GC80
MA!N ^][6H=<9QM?)Q *"V^]YG_<X< /+P?<X$'VP9F-73_4?X8XY4'9)-C/K
MB/'!"(.65+NN;6@M(_FG';9#HCB3F3%MW262ODAC;R:Z6R8?+]=);96GY5[3
MJ2)<%)(Q?S7-2*%L]JCAU47*;!73BC2;1!2/PH[I:CBK3X23GK$[9/$@K&,.
MTWI.HF4F-=F%IT?I6SS_'RQ92 :3E'-WPS]V5$]0*)KD1GR8Y#IRK<WED!.E
M;NY@ I\;=W,>]1U7,\<VM*+W\:_W\J[^!K@KD_ )+,*N:W'.G@$0..I%TU</
MVKYE^O;1VP=MH$*&RQK6*Q@-H;YH]?91E'B0X<6)"I5MC,90Y+Z,^_:-=(B2
MH4.(&0FJ'+CQHL:2$S,J;#G2IKZ$&A$.36EPHDJ,0#=ZS.G08L*A#@^25(AR
M8T62* NJA(I28\V..#]"%3I2J<&:7YW:7.E5X4.C(U-NW6G4HD:I0FLRG$NQ
M;5J%*4GZ32DQY<NO&/EJQ&IXWUF5!X$JMAB1Z^/+$@LJE$B/(,6<5Z%N+OEY
M_V?;I40A/C:J&31<KHJ/5AT(V^W"SUY#MZ8IV'-9FB!',F[ZU:)*Y,F5+V?>
MW/ESZ,XS1:=>W?IU["K3Q "%/ T G]F=*YL47OQY].F53T(@0P8"'.;5SZ=?
MW_Y]_/GU[^??W_]_ )>3+T#J,M$$MX4NFRS!,=H;8[C*,F---9MF\HDCC((#
M22*-)!J*LZ&NRDDOC(222#.;S$K(M 2+*A&UL.9J*L'):G.)PP11NRLGK#[J
ML*)Z1K)L089J\DG(MA8$+:*W"")K)Q0]\PRIN%1:[""*;#0I+!"S/,C#@:2,
M#4$./RN1Q]$X3,I+KR+#R2^Y3.+HJK\$2\LBV91"4O\I#R]L2:8I.VPSQ-]<
MNBM!L(9BS##&'GJ2K1,5:HRTM%S"#+;)H)K2,Z4*@@DPP?I\K"L"]Q.J5%29
MNV&%&'"X(0 T\JLGDP%31;7!]V08PU9>>_7U5V"#%7;84I=11AEBCJTUU4F(
MH>G+)K/:9PSWQ'#S-A!YK*VEVI0Z="1PK6R(M04UG0A+BZ3Z<+2AY!)4T+.2
M2JFE)(FS,34/T:Q*+M30JDJF%HV::K>9/#1,S@V1\Y,MT[ R*K#!CK,LU!*;
MS'"QP[QBRB;$IKK(8!IS.^VW'?&RR;$L:S33-X!!"Q%)F.HM3-RG,"L4M21%
M6_.DR4[3B-.,/'KL,VCA'!3_KKQD<^W,1F5K=]00+\M),'Z'0BPD!&LB-KWI
MMOYOF4S$N$&,KO&#ICRO^2,&!P'<DZ'LM..6>VZZZ[;;:V)B,"" O0&(8=E2
M,R%&7> \Q4V,]W;MZTN0,,Y1:#S9/-5AHL1EM#=/270-4)KRM)"JHK!4:6'7
M#KJPK;%ZN\K$)OW-6O1E_(*KN-5D C'ST6/+23,/"^VL7J4^=?K*C0JW*\?>
M"3H4MX]J/*BHRFJVLKBVS/(+9='GK8G2S7!.*53<8KH)2#RG-DHC?K^RM*C+
MTH\6Q[I4 GA+SK8:%*K+Q1<UT+F89^VTX23(+#LB'U6R=#?HP V!=8L&VA:(
M'DWD_TH&.'#6 RUX00QF4(-R@T8,;B X8H BA,&:Q"<P![(*T2,'[DF# -N4
M.FTQ;B]MF9^3A!.2.9&K-'3!T%TZ]1K1*>HG(SJ+Z9[U$S 9JBH'.Q<0Z]2]
M$XUJ*S$+BU6, Y:8O 9/!GL+2/82N3^9B$JZ$<M3ML*2.XG&4M[ZF0VS$I[#
MH$F'4U)0<F*T&3 )S2<3TV(;$4.9K=1&9&O,H>S<R*D5_6A<9LD=R;J'I'3Y
MZTTI\4E.."46UC!.CE9Y"=3*U*F7W2\U)F.(]8ZSP=RADCK$F XK!6>@86CB
M(]4!''+HD899JK(YY&E/XCRD2V &4YC#)*;"8G @KPGN0]-X6=*(<,!"^8EK
M2M:[C(A*V2:_! I&G0M10BZ7%;YPS(K2:V;'%/6BJ0#G(I3$X<?$)Y33X AJ
MIWE1*F=H2>6M!DCU+!054:.B!.6+?FUAXIK$Y;*?&"50C2&7$%=4)-1![3:7
MPQ!NZN'-+BY&BI5[D]! DJ%SVFE<"+.D;G06M(3N9D$CTMB;M.)2B[ T*Y_R
M&%_XQ\,(\5 VVNS=N++$3CH)*3>0.<X755G+8*(!/&\ P '\MC<#(#,ZRA!;
M#,0 N%DA%97*&$/;VC:)8H95K&,E_ZO<8@#6K35P.CT:E%:4X;9,H(6C(%*7
M-H,#-%"]96.\R^BYLM8SU*WL9O:$&._")RH1V:0FNUGFIR)DQ$;)I)D_,E^7
M(K:]=;U%*1]2G;VD"-./B E'(W%,9VRX$]2FC(8/(]B+)'N2QHVK3$*!789,
M&TJ&B.F-O:EH -55IG5B;$O(<8U.AF:4SFT+>:2Q*0Z#IU!IH25C2>)2HOR9
M%J&M!:&<PE<TR^B_2WH,E6@EJ[&68I!EZ)8Z:1"#)C(!*^><3:L:C*#;<"#5
MLN97O_OE;WXR<0!:*:N"OU+F[+PDUV5,4 #(_"-O[">J<*&K:86)UM76>91*
M5=)'G45.7O]R5Y>*"?%/OS'<IW3"$QM%3X@V9&0 'P9.M^3SQ?UDG0^E>TG(
MT NUQ,.L4U ,VYZV*)S?.V!'$64FG50TBIU,RN^P1)HY$E=^.(Y*(:W"K?#U
M:XUM*DV1& >DWDP)16\*S+N.$DI(G62/LE4=1)'LTH$RZB0<$IV[3F+A\/@$
M1Z?2X(#[*^7J5&4?8EM6 ^>+P4FXISTY./2?'?UH2)-5&3$(0%,!P+<8B)=7
M)5P?B'ZR#V+TTEG2 Y.W<BN8$$'7*6TT(#JO]S@VG3>X1*N>3>@E5#J53HWR
MTXM5 GBSG>94IBO.D"(7TR781)$NVDS?A QCN#!E;4)>Q!&8DV?_.#F/SU\6
MV=-BB[2\+LT$S/5(C&3)2+F@+4EUQ;64]2J2E,%\5C<#=>F<H()&'3H*1"8A
MZ$8#9<14&\J D,,P2@>8ZM40ZBA=Z6.;Z.7-W#EMJ_Q%@[6,V>C(6+4Y]" /
MQA'(U?:TIX61)GG)32YI8GR"&,1(AB;\W"L#I929C*NO# Z$QYC0T9'^JQ&7
M.RDS65OMW"43W8LHAT1[JGAS6<D<971[/-P1JF9&2A(1E;RNZ6WEH?_+$7?9
M].P<:L9V3MRCN)>,F0OY\$EBO Q.B'+ -1D1104TG)UM-I,O;J92.SR@AWF-
M4D%IZGM07+$YD8+P1!U01O?J8LMN)WC[_YERMQ7%LII6ZZ1W%JS?W;MDO2R5
M8E4JD*QBP(%P B!ZY[ W!C*H%7DR@89? G-M$D3]R6U_>]SG'CN3&$:28>N7
M?63"/?&)FF-<^#^M53)!#Q^EBFM-R!@'\LM,_"W7.R]'F.R.M[8$_$+D?&]N
M4K-DQKV+9.:T6>1.$MN\?5XVH];Y5XNT-/ :FD/%1Q+NJHBYVCK36>S$)QJ1
M+IEK&9EQ.\/QD9BZF7#AMVBCE"V",10+H]&1*\#B$1M"# O\#:%9/X<A(# 1
M+%MK.^49+B<3(Y_!F0("KI98.L/1I=HC)C2(@0.( 1J40;]IM+!QE9%;#F.9
M!$U#)>%K&Q; @?_8TSTC/$(D!!9B0 /B0Y9@B;DA$HIIVH>:4P:CT;O-BJ),
MPJ2%HAZCD:OIP1C<>8B,*2Z'*9&-8:8QZ35=RQR\XS;NJZ;6B!8DN:0("2#C
M$[S4H"8UV2%Q A@W))[2J1+:LB@U69$N61#\X[* :YD@:C&M(),0@3)&NB8)
MB[L[01K&2*6LB!236I1,DL1"'*YG@3-L8C,$;)2W.Y3-LA[1(1QL0I=KLI\9
M*K.(^ZG-TD";&:D*>3<!S"4-\KA@G 0/F@0T2(-)H!7QF 0#>+GD<"!56H8T
M8(&02P,^2T)LS$9MW(_OD,'I0(,;(*%AB*34.HU]2(/ANQQW.8Y*+ W_-<*N
M@%LUA<F=7]+#C7*9T)"(.#F:&+,I#X0WGJ*-V'+'6<01'R,,*UH?XLBMK(D0
M.Y&QAQ0SO0/$1<PUY"C$ !J9HDJ-+%1$<S&G4[,F";&,D"F@U$DBUC*.!.$N
MGO*BNL*,$A0=;:H+R-(--UR=5>N9<@LNC5G)PYH> SHSM,B^H/Q'\Z%)03$C
M4#P9H:LN2XE#77+&L<J$'>2: %B6CM,EJFH;]R"O;?Q*L S+[*B'&T@#JFJE
MOP&6F"N2^B$,C4!'&6"TD*21M3LE.C*_HDND"%S*II,ZX/B=FT@GP2(:3$(?
MKKNBD  4S9NN4G.C2:('-B&QO["*:X,+0%*+_RT,L<62%/I+),*L2</$BI[Q
MG8U*$1$!#*F!MK&SQ;7 $3MT'42RK.N+F.6#R7I*/,;!/W;$&A<9R$4QNG%!
M(J/3B^R9DF\9GW6:.3Z[/H9$O]MP%U[\B.G;F9K!"A:!.##<H!?,/30(,!Q(
MR^901E2*H)"[+[$\3_1,3P%)2QR8CDDK0EN9A&3H2;<+BH.@%AFPE@1\N]B2
M$K4S,WI1P_J<GDS,L<G11^1@)Y>*KC_1NBV4C*#PH>!PQ:>!C&;JGE.,'B[T
M*TS:L^[+%U#\E$C1OBGJM;PS#0/[-#W3S7E4*,[A(5XLJ*6AH1#LQ DYC?;#
M(:&QD=CIHI=4$MBRJ%,*V3:LBZ?.,3=\LS6J:XF'(XTN$J*E-!3?B98:*A=Q
MX9::&8X744DYB1#+! FVF#C^(H\TD(0T2 ,T.+1)F,$#" .I'!UHS""XE $6
M& /X5$\\S?_3)(R&&)@.LMF'-P!/7Q&<? PVFT <!!B#^'%%+4I(,.RDX8!%
MS,LF,$(0%&NBT.A+T*B[XQN1F5B+>-O-+CL4WYBR<0DB1ID1)'FI<7E(N@@?
MO*L?H$/ [L&)^ID+1)0V#]FW4YVAG\.=-SR\)6.IF1B+UK&Q%W&WU<R(W[%.
MUDG,*@/*/)(Z$>DYY&Q67=,U]2&<F'$I(KD+?6N+@^ 6$Z.**N.\Y9$\DU'$
MO *_L9O45%.7H^(O39!!>Z5!C*.'.UT/822691 #!*!&&:A*/2U8@]4],8B!
M[4"#,= X8)D$9&(L'RJ)%1K8<*JF,3DU>'-']4%1V9BD;OG @OC_)!*1K!UI
MR7!:R@OIJ4K\*UR5C;70*.5JSDH9BJ#XO)/HB8!A4?PQ(#/:D9O(BJ4$+G4C
MK7]1GSDY3E'I%NGRB\VJ-2PRUVM22J!]#6S10H:4P(AB)@F%3IW<4JWH"@0U
MJ86*U]7BQ*W+PB-ZL. 0.S$DB\83)!<R,M(\KSD;TH:"C4AZVGVUH.TD)D++
M!!S0ATFX@;X]#_+X0032!!Q@@5S!KX.-7,DMN1BT5XM3R[7"HDUZ)@28!*1T
MNA0J"GD"FB%ID[1%D'L<&A[ZLBM4NR7BP)D+*!")(JL]N@XM4;U:K+P;C=GI
M-U8CLW[)*+SS*#EATH@:,1V5EB;1V!7)_SJ#M%4':]0<B@TMFAB=N=+:[=E=
M%4"^DC;E:93<M# ;&<VVW1>Z_#!SDL*"FTE,(APS$M<YR3L3#*^[L]6U \BC
M%(H?>SMT69V7BAE5>M.P$H,6(H9PW(<#Z+W[,#1$<QL$N*K)C6 )AC1C.99A
M:9;8HDU]*(9GD@&TPI'D.;.<02-2U3HH$Z/-^2XZ6R[^[):B8CY2U O-DQ3-
MDTCF<:.&H;HP1#X)\46D.*25 4648M$P,5FH 5DE&;J(Z%VAE3:#FLS3C!!$
MXKEJ6R;TZ[[4.J+A&AE1.D"N#2J'>YA[*6*UC;>C2Z+J,Z@_RL?."8K;G J[
MVCJ-@A*KL-;P(/]:),N+[V%(D=Q'K3G<!>I7#:JXE3B 9#%D_+@E8+0;D,N5
M79E@2(YD28L5Y$ # 0X<37B?!3DCM_'<3H*<;[/2)/*?AW@[-;L4ZL%"F[68
MUI4<([*M/5RXW'5A<0D1"?VVH$S..MJ3#X6,;2I'U:1%'<LBM-,AS/&+VGH=
M53/,%0S:'>HIE#FN-J&,+R;?U-@4#NU),50W[8JD\[(3T3&."+S(/($*:#FL
MF#C#T#'=-!/2F&HC!\V<<'[G=XHZCB42H$-)V8!#+ T.,R$5[:37M!2# YA!
M07X.\40@8L 5Q_U;27YHB'Z@>G!8E7 5$E(&+BX9BY@]FVL[[X4HWE7_%PU;
M1+I[FFKBE_X!/.GY-A>6862&%&GN"A.+$\(\DWI!WA)EB@&ML3,Z"FTYP1U3
MHD;B+"T$$WQC'\$,0*D1T'&Y'3$*GI6<6 RD+2ET59 1L^#HUL>"*?#UWR?C
MT"93FC:NIP]\-;;@T=R5MOP#NIUBLU+6FM00&I+9V:"S"T&I)OKY7NH-$:80
MK8MTP3'M&O*0A(,>CSBM&^$KSTN.:,9N[+F9M.Y CKPI[/K(A+6Z'"I[*_?H
MFI,(:C]4KC0CP]19#< ,%YV:PU=[)&QA1<$S#OB3C!5S"[9C6MB)PRJ*-^'Q
MO/2[C6[1YD,)T'[)#3>F+MI@"I6Y/JJ#-M4E_S?LNYZX53%O_0O*R+K?3+]T
M3I0.#)]7XXUR3 PM]-;S>5GH.D30?;+OD2(-O4@Z#CPZ:8GP.I].Y$Q+D5=\
MZR0Q>:Y35)FAL0QXDJ+F%5/](KW_8&"[J0=T["4[=6P%7_"ZF32X^2_*I@\,
MWNJEKB\*$KJ&?+"$V[HFOJ&E8[AT.\/\2=4H_CH%043,#+RFJ]Y0]#0QSDDE
MA6WEZUF.S:Y2=F\8&[$:!QU>2R4$75"RX$D'[:[MP>Y[@LWH<4"F%D#X;A/2
M"N/.+M[X/N+:>6F-Q+'+R3ZJCD3H]*SS$>L<RI0RXXE=?"WH\6ZGB104,DQU
M,JHG8=X$A2C68LA?NLS&#%KL88K!_[BE" <095@A@?5*!A]T0A<6@A8<]VJ5
M)XPK=Z8RX9N@FW.4-53(]PU7_U1GZ#K7!*W=.?3)'Q+QWP,==7NWI<8,<Y-?
M KQ5EZ9>IQZ3;*.SFG L3#HBV*@',;FU&V4NW6%;2%R^I.U229PEP[)97\^=
MJ5#-X]W$SE.31+'B>VE-'AYM?Q;)&_HB$DFRXWH1RU,[XEH_YD9.U'+2C<QT
M?!YF46&KBG3=FX5%(Y=7(!Q3#W(O8M"$<?2O/O>/^NHER"UT?N__=U11AN\T
M@!@  .)32V*8B8BJ'/:(RR>G=GQSMV4R*:8\XW92S&/KS=(JTA9I,\S#V[&+
M+1@7<WCDU)L5\XAZ5R5!LJ4[LG:+C<I4'B4]LRJZ+03,&7.3QZ"-5AYIJ1?A
M+DQW^2--':H X6+.*3T,ZNJ^0TL9T6L"WB^"J.HS&I"A8:6XFE6-(\]QYGH;
M2I^6*^R^V6W""I:@WG2ZC"8UE__32OXBZ*=R*D2^CZR<FT0+.3$ 9'^_>[S'
M#U?"<P+)A-Z#.%/=BCF%Q#@RS5*W84L4,K_"96U9HQ4&,=Y5^IP J"'5ER-C
M*.<N0O@3*4-9==Y&5:Z[67RRE%PJ^0_$_\GF U*7F917P]8A^HB.5\6S6V?:
M_+?)U,GYAF_NTBY1%#KF:U#4G9<)N9F-.9+D,)_:W-769O;RDYHNI46?J6D_
M9!^KY47T0]Z#Y*UD52(Q@OUHJ[X [B]EJ&!E$33[.&QBX2H)>N2\;W_W+ZL&
MDJJA-#+\3/ 98APZ<IVQ-Z2SKG2 V+>O7K1]T?350UAPV3Z% _=!>TBO8+1Z
M ADZM+B/WCZ&%O4MTQ>-H[Z.)DT>M @M(423"/<I@WF2H$B$*R-R%'BSH<R)
M-%76PUGQY4&&+A-6+(I0I$R9-F=6;*B18<2H/YDR)&DQ:DV//2^*I+FQ(<:@
M4D>.59BQ8=*'(/\%:C1K=2A2BR2+DAVH5"]'@AO1OJ59D"S1J26#(H:(U"1)
MHWX;&_S[,*;"QP8GO@SYL&!?L$A%^@2-\J/FQ!HG?GW[DB5-S1%#LHS:L:3
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MNW& )/2Y$R$F6Q^2>"2+"U0TQ&"<X;'II: QAE'*8 S#Y3?A"V]XZ4X"DS'
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M2),X_?P3T)*R-$T?99H#I<J'T$!.KT2-&S302"6=="%];I!RGYH(_-(R%A"
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M9A\F<3&5HT@F$>PZ1B?0PBE>1>'T,'[B<+O>\7HR)/5<+MJ@Q ?_>P/VF"\
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M;2,""EMC((A!^(BA3H9N^B3-/= 5)$[N)DXE1,6R@-U-;3I2W4ZN 213[F(
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M &K8V$PX(VU,L5;3PKW%#>;\''!LIM 3%<[WS"9NDTBTL\Z5?"ULAM(-/08
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94W_T^U[U6U_G1]WU"F-_[Q=?]DTF(   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img42979713_8.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_8.gif
M1TE&.#EAF0(% ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M,P&Q@9PJ#9)@%71_%0T<LXJ"IK.GNNY3W_D.\'LL9*-\["/?N#Z0O@?;[WV
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MU-:C'I)O>8BQGU_O/0N^WFC$P)YP)QX&":;)9A77U]=* Z*KC7)[XI@>H
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M%[(Y/U& D:I#D^(^+?0^0D27H<9_F4@AK5,@"D$[B[4AWB,VLG-%>VIZ]?-
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M. D-]2/*IU[VFDSHB7/C"8X%.Y(&$.XD$P@<' O$1[[$F:Y[9>,6QU2XDVB
M:D\NP9( QX #PQ5QB#W+@1B2N$0EXD!Y)E+01GPX)JOL8U<*@6!#;FB23$@M
M31:<HD7J@4&K8=$ 'H/(_3 R0-\A  <&[!W7GM@1],%D+OL@QF*\.*<T$ ,:
M(,DBL&0@PQAN;72#+&36YJ@A>+50-'W\XT0"H!!H3'(?!\#@9'"%*SF!!5&,
MTIQ&'NG'B;S!,)J0T<LBLDEEH&&//?F>V,+G-;#)<FQ.X<DGMBB32"VR3^\;
M2NYL2;B9\<&P:PJ$$05M!<$#/"0&"HE!0@# D-9L2@SF:XK9ZK1#'"K/ '0Q
M@$(R&(/A5;-CN[3(  6@.!88[H#A0X O(:*)GZ6AGO:TYR32H$]\WM-SGUP/
MJ008.M"A86L(1"=IG$<LBCFLB@3!%1H9(HE(&NB56X*32@*0*F4< )K*B(8*
MDI)0BF0"?(@SH.ZTADV*'!)L[4PI^5*B_\VPK*IDD MB,&<IN&*>-(%*DI]D
M2@:Q):U @P19AAAPX"$UE@2@;J*=33E64H>Q1B'P408.1CI0@F;MC2I%'#(K
MDH99%FX,+.@:6G7'4CK*$RFYVL<RZ,%62I&4(H&3I2UQ<%#0V94RRF3(,EH5
MC83(M26=-!"F4C>1QQ VKG/-5!I@D :WA$H, DE*17_RO;)F[7""(V36)O79
MSJ94;+)TBE\;QT6WQH2-!!0?#!,G5A,ME%HQ:2I)GOK%7MTPMQ7!JT^_EM<#
MMO:J[]R:.VEXRY/L%E!]?(-Q)?);X*IT:P:%K=:*H22)8J0UJ.S>)#3;F_%^
M*93>G01KI'L15_\&J)9;(^TP94#7B(P/GC(0P!OC2+@9S%2U'^GA0FQK$542
MA1C$1:E/NP;,'0'690MQL*+^JQ%B7-1**F1<4.LJP!FT$;]??>_O-I*&#H-/
M!DDTL=9,MUZAT(-Q*J/N7;.V3M+%-[2*5-* (;(,))T0PNPJ3'DQ2E]5]3B
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MU(B>*C7P)$ZM.8SVC EZ%(IU_,X<,,D48U.(>,N= ,&3J0W-<K$2>AF!NP%
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M8]Q<!Y5)@?RZ..X)QW*_4'P\U\B$7F!?/7%GB8-:*(8M22Y ^Y6(*C;&146
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MB $#&/X T#>V8-Z(8V?415O(#VM,YZO8=<1-_]"P'<@\EE9'[6W<&U]#QB$
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MP,7P:&?.)%>1%N,Y$9C[&4FL%:"(W6:#H*="$ DZFESW9$A,_-*;(D2",D4
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M),$P@L59ET*%*WD[JS)@]35:=1F: :-J%<)<&\+^+ ]/05B;)\)V-<%.O96
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,SWWWWG\/_D<! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img42979713_9.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_9.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M$Y)J(*1^0XSYY<!$9$E+J! @!@.")53%:M6T,BB64.6 !>51Q@)QT @^"82
M;U);U7+T.H\<CR1@0Q'U' *6R"$D>]M[F$$T]0;P36Q<C2,(\1#20X?TCR$
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M<A\#RJSLOIA\')D0 P:*;S<0 S& !@AQ<FEPF9'<RKY,O6[L'&E@RS>@2)D
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M@AY&SO^(9BR_C>9GZ5D?:<%-]AD&4"!@*N(6:M*QD**B)"8(0Q8(1#:('N[
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MW "ZQ,!%:0MV[HXZA>1]#BB-ID:+NA]PC%7PN:?4&$C6R=-+6(YOIH0%!D7
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MNM5OV>K3,OAI_#(1K1S>#1.7U )B5E#_+WD1 RC8C[N W208 "#1P\8N@R0
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M-5($-,T@MGGH-OA*K6_[A00>V5H+"8\EQ2WK8ELRKEQ'MWT&8%G9#UX/]XS
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M(A-H-SJ*9Y"KE427F8BK;H<_]GTL!&153C(U^4&;^)W->5#PBI8-=XM/M&6
M]5]^2<F0ZX/1BX.%]CM=I#C(T*+AE4H,^L.VZU_$_[*,)=E1]L'ZUK%OP5:Q
M6A<B)VDW8Y?GKA-=._I7^@L'_ZM+,4,3RD=[?B<&@LI<+(,I(C(YF0IY1RAW
M*5E]KSI)&Q.7(Y,R)7@$Q5/EINQ1#U,_S_E5\63GF,0(/P]J(1MJ-6&RGP*9
MK@^?S3BSIY>?UUB@U;AZW_B*9!$-[!DJ-*&.QTQ\T:Z%O%"%Q+!(7;AS5_=U
M+BA?\[HE_<:B<*NC<X6_5L!4;R":=6,GYG6!0[F<WQ0$)]J>X/>D$3A^??4
M&9D#P5E!&AJ1WP@YB2[+"&N1RZE(7C@VB<NK;S,@IQALQV 8=I>=F_<ZK5$>
M#5E%N *+>O(I3EIT794D:O_#;S080A.6<$"UHP<B)F+B*4 J,]+5K>&Z'FX
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M$<J+,G!0C$.A>^7@P8I2HA$#P&X-+ ,<]F:;JMXS7];$W\MJM$.3:C7O;:
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M;>GX5V(;_>Q'9TAX!\.6[\D!G@:383?K>*?(L>COQE*^0<G^/BX[ A]HT7^
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M:,20KKD#<GMQ)F4T\4L_L2KC;$&FVL/J0\=&1(^K$'<,";SNF 11/<K, D[
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M<4R8A=O.6CTT$_]-IG9TAKYLY<%1T5*)(6)!.8_@>]M-?<9S:S+99=_9<QM
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MGN#Z=7&REN3AMMFB)]B%9;;CWDQ$5G8V1O#19D61X+9[_\;\D(O:J)TC[#L
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M ^]-Q"3%LU.8PD1#4)'.(HUSFYQ6@[:X;<Y-4[,9H7:HL(_U+HD=2P,, %C
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MJT(D1FHV8?=<B[N**C2DELG-K:*1#QKPF2C^%<Z87+9ARVWEY"O2 QK(0!C
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MU+(KI8Y.H\XULCB:U)C'T ;$='8?$Z8/^64U"#ED-8%'I:YN&UA$;!/9!+"
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M,VO>S+DHW\Z@0XL>3;JT:<F(3ZM>S;JUZ]>PD::.3;NV[=NX<^LN^'FW[]_
B@PL?KI<R\>/(DRM?SKSH[.;0HTN?3KWZP][6LVM_&A  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img42979713_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (3!7<# 2(  A$! Q$!_\0
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MNZMXDOX[NY'F0K$W"#M_^H8KLKK7(/ WAFS&OWTEY<@>6K(N7G(]!],=:P_
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M-NB;N!^E6]<U&'4-8\-7=CXE^QVUP^4@",1=#<./Z<^M<YXQM+)?C%H"RV\
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MK7V"3^\M'V"3^\M',@*M%6OL$G]Y:/L$G]Y:.9 5:*M?8)/[RT?8)/[RT<R
MJT5:^P2?WEHHYD!H4445B,**** "BBB@ HHHH ***,C.,\T %%!('4XHH **
MSM3OY;.XT^.,*1<7 B?/88)X_*M&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  YQQUI/FXZ>]+10
M4444 %%%% !1110 4444 %%%% !44QN '\E8F.WY=[$9.>^!TQ4M% "#.T9Q
MG% SCG&:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM7Z6/_7W'_6M&L[5^EC_U
M]Q_UH T:*** "BBB@ HHHH **.^*0D#J: %HHJO/>Q6]S;V\F[?<$JF!Z#)H
M L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0B5!\H<XST[4Q:G3QR)-&LD3JZ,,JRG((^M.JCI.C6&AV9M--@$%OO+B,,2
M3UQD\?2KU(84444 %%%% &)KW_'YHW_7Z/\ T%JVZQ->_P"/S1O^OT?^@M6W
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!C^+/\ D4-8_P"O.7_T$U8T'_D7M-_Z]8__
M $$57\6?\BAK'_7G+_Z":L:#_P B]IO_ %ZQ_P#H(J_L?,74T****@84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:OTL?\ K[C_ *UH
MUG:OTL?^ON/^M &C1110 4444 %%%% !1110 5BZK_R'=$_ZZ2?^@5M5BZK_
M ,AW1/\ KI)_Z!0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !WHH[T4 <'J7AR;38FNK_
M ,?ZI:0%N&EDC51GL,BLB"R\/ZCJFG"Y^(DVI-#=1RPVSSQD/(#\HX'K6E\2
M)-/L]3\.ZA?PK?)%<.G]G>7YC3!A@LJ]RO!P:GL-7\/RW]LL'@S48)&D4),V
MC[ ASPQ;' 'K3).ZHHHI%!1110 4444 8FO?\?FC?]?H_P#06K;K$U[_ (_-
M&_Z_1_Z"U;= !1110 4444 %%%% !1110 4444 %%%% '+:1XU&K>()M(&BZ
ME;RP_P"MDFC 1.,C//?M74UR>A_\E!\4?[MM_P"@5UE7-)/02"BBBH&%%%%
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M1110 444CNL:,[L%51DDG  H 6BJMIJ5C?EA9WD%P5^]Y4@;'UQ5J@ HHHH
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M% &/XL_Y%#6/^O.7_P!!-6-!_P"1>TW_ *]8_P#T$57\6?\ (H:Q_P!><O\
MZ":L:#_R+VF_]>L?_H(J_L?,74T****@84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5G:OTL?^ON/^M:-9VK]+'_K[C_K0!HTC9VG;C=C
MC/K2T4 <->Z]JUE!+;^*_"_VJP+8^T6 ^T(1G@M&?F'UYJQI$7@'7XP=/L](
ME8]8C JR+]4(R/RKH]7U>ST/3GOK^3R[=&56;&<9./RKF[^U\#>*[2YU&5[&
M<6@)ENX'VR1 =RR\TQ'8(BQQJB*%10 J@8 'I3JXWP%?Z?=1WD>G>(+W4X$*
ME(;Y2)80?<@%E/8UV5(84444 %8NJ_\ (=T3_KI)_P"@5M5BZK_R'=$_ZZ2?
M^@4 ;5%!('6@$'I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WX,_X\=2_["5Q_P"A
M5TE<WX,_X\=2_P"PE<?^A5TE5/XF);!1114C"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSPA_J-6
M_P"PI<?^A5T=<YX0_P!1JW_84N/_ $*J7PL1T=%%%2,**** "BBB@ HHHH .
M]%'>H;J*2>TFBAG:"5T*I*H!*'L<'K0!R/C9+NVUC0M8L=+NM2GLY7#0Q("-
MC#!.3T8=JP?$FM:QKT^E(/!VL1V]I=K=2.44R93D*O/<]36ZS_$+2EVB+2=;
MC7@,&-O*1[CE:&U#X@Z@/+M]%TO2NQEN;HSG\ H'ZTR3H]$U2;5[%KB?3+O3
MG#E?)N@ Q''/!Z<_I6E6=HEGJ-EIXCU34?M]V6+-*(Q&HSV '85HTB@/2O%K
MJ.QGCOM0OUU"'QK]H9X88K=]N]21&H4#8RD8^8\\]:]IHP,YQS33$U<\^:^?
MPSXRDUC6XI8[;4M.A1YHHFD5)T^\A"@D=>*U/ ]O.[:UJ\MO)!'J=Z9H$E7:
MWE@!02#TSC-=:1GK11<+'.:Y]K_MG2=_D_9?M8V8SOSM/7MBNCK$U[_C\T;_
M *_1_P"@M6W2&%%%!.!S0 44@(/0@TM !39"ZQ.T:[G"DJI.,GTIU% ')>%_
M$^M:YJU]:7VAQ645FYBEE6Z$A$G!"XP.QZUUM<EX/_Y#?BO_ +"9_P#0%KK:
MNI;FT$@HHHJ!A1110!R>A_\ )0?%'^[;?^@5UE<GH?\ R4'Q1_NVW_H%=95S
MW^2_(2"BBBH&%%%% ')P?\E5O/\ L$Q?^C'KK*Y.#_DJMY_V"8O_ $8]=95S
MZ>@D%%%%0,**** .1U"&(_$_2"8D)-A.22HY.Y>:ZZN4O_\ DIVC_P#8/N/_
M $):ZNKGLO02"BBBH&%%%% '*>(O^1V\)_[]S_Z *ZNN4\1?\CMX3_W[G_T
M5U=7+9?UU$@HHHJ!A1110!ROC+_C\\-?]A:/_P! :NJKE?&7_'YX:_["T?\
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M=M',/&GB.42(")(]1VJV1U  Q31+'>%Y+G5/%MQJ1T>[TVW@L$LV^U1^69)
MV>!W '&:[BF0Q^3!'%O=]BA=[G+-@=2>YI](I!1110 5BZK_ ,AW1/\ KI)_
MZ!6U6+JO_(=T3_KI)_Z!0 _Q1:0WGAG4$G0LJP/(N&(PRJ2#Q[U#X.M8;7PC
MI@A4CS+=)7RQ)+,H)/-7=>_Y%W4_^O67_P!!-0>%?^12TC_KSB_]!%7?W!=3
M7HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCGA</%(H9&'0@]*=:"3YH[,47T)****Q*"BBB@ HHHH **** "BBB@ HHHH
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW?RJE&3V07*_Q!_Y%V#_ *_[;_T8*ZNO*?&GQ(\+:EI4-I9ZB9I5NX9#MA?
M57!)R1Z5Z+I6O:5KD FTR_@N5(S^[?)'U'45<H24%="3U-&BBBLAA1110!S7
MQ _Y$75?^N:_^AK706O_ !Z0_P#7-?Y5S_Q _P"1%U7_ *YK_P"AK706O_'I
M#_US7^56_@7K_D+J2UYA\5?'C:1;'P_I+EM4NAMD9.3$I[#_ &CVKH_'WC6W
M\':(TH*/J$P*VT)/4_WC["N'^%O@J?4+P^,/$ ::>5C);++G))_Y:'/Z5I2@
MDO:3V_,3?1'1_##P$OA?3?M]_&#JUTN7R,F%3_"/?UKT&BBLIS<W=E)6,?Q9
M_P BAK'_ %YR_P#H)JQH/_(O:;_UZQ_^@BJ_BS_D4-8_Z\Y?_035C0?^1>TW
M_KUC_P#013^Q\Q=3"^(GA1?%?A::"- ;V#,MLW?<.J_B.*Y;X,>*FN].E\.7
MSL+NRR80_4QYY7_@)KU:O"?B%I=SX$\=VGBO2D*6UQ)O<+TW_P :D>C"M:3Y
MXNF_D)Z:GNU%4M)U2VUG2K;4;-P\%Q&'4CW[5=KG:L49^MW-_::1/<:;!#/<
MQKN6.9RJD#KR/:J'A#6-3UW1$U'4;2WMA-\T*PR%LIZG/0UK:C_R#+O_ *XO
M_P"@FL;P)_R(VC_]>X_F:O3D%U.BHHHJ!A1110 457OXKJ:QFCLKA;>Y9<1R
MLF\(?7'>N;\!W>M:CI4M]J^H176^1DC1(!'LVL5/(ZYQ5*-U<#K****D HHH
MH **** "BBB@ K.U?I8_]?<?]:T:SM7Z6/\ U]Q_UH T:*** ,._\8^'=+O'
ML[[6+6WN$QNC=\$9K!\3?$'P]_PB^I_V?X@M?MGV9_)\N3YMV.,>]8?B#Q6-
M(&H+JWAX3:DEX%BG>P#Q/ 6&W#]SC/XUI'Q5X37/_%+7O'_4(_\ K4[$W.VT
M:1Y=#T^25BTCVT;,QZDE1DU>J.W=)+:*2-"B,@*J1@@$<#':I*104444 %8N
MJ_\ (=T3_KI)_P"@5M5BZK_R'=$_ZZ2?^@4 6M>_Y%W4_P#KUE_]!-0>%?\
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M8TM1_P"09=_]<7_]!-8W@3_D1M'_ .O<?S-;.H_\@R[_ .N+_P#H)K&\"?\
M(C:/_P!>X_F:R^Q\Q]3HJ***@84444 %<M\/?^143_KYG_\ 1C5U-<M\/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#015_8%U->BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5#]&%/W+_>'YUY"?@1;C_5^(;I?^V0_QII^!TZ_ZKQ5<K]83_P#%5')3_F_
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M,**** .5\9?\?GAK_L+1_P#H#5U5<KXR_P"/SPU_V%H__0&KJJN7PH04445
MPHHHH Y3X@_\B[!_U_VW_HP5U=<I\0?^1=@_Z_[;_P!&"NKJW\"^8NH4445
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M'H6MV'_H1ICI\9;[K(EL#_=\I?\ $T>P?5K[PYCV>@D#J:\5_P"$+^*EZ?\
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M_A49UOXP7W^JTH0@]Q"BX_[Z->U44>VBMHH+>9XTFD?&#4!B;4H[4'UE0?\
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MZ_KG_P!&M765R?P[_P"18D_Z_KG_ -&M7645/C8+8****@9R7@__ )#?BO\
M["9_] 6NMKDO!_\ R&_%?_83/_H"UUM74^(2"BBBH&%%%% ')Z'_ ,E!\4?[
MMM_Z!765R.A.I^(7B?#*<K;8Y_V*ZZKGO\E^0D%%%%0,**** .3@_P"2JWG_
M &"8O_1CUUE<G%X:UM/&CZZ=;A,+J(6M_LO/D@DA=V>N3UKK*N=M+"04445
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKE_!'_'MK/\ V%KC^8JU\+%U.HHHHJ!A6=J_2Q_Z^X_ZUHUG:OTL?^ON/^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N<\(?ZC5O^PI<?^A5T=<YX0_U&K?\ 84N/_0JI?"Q'1T445(PHHHH
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M:3QZW=6*VI$D:0QJP$@SA^1UP<5T<*-'!&CR&1E4 N1RQ]:?13<FU8 HHHI
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M!S?@S_CQU+_L)7'_ *%725S?@S_CQU+_ +"5Q_Z%7254_B8EL%%%%2,****
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M  .@%;%% &)KW_'YHW_7Z/\ T%JVZQ->_P"/S1O^OT?^@M6W0 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOI=O;Z+?:?I%G=)=S75]'Y;2%.55%Z\GO7HC,J*69@H]2<5"MY:NP5;F$L>
M X)-.XK$]%%%(84444 %%%% &)KW_'YHW_7Z/_06K;K$U[_C\T;_ *_1_P"@
MM6W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6=J_2Q_Z^X_ZUHUG:OTL?^ON/^M &C11
M10!@^,=)N=:\-7%K9A#<JR2Q(YPKLC!@I]CC%<UJGB7Q!K.CW&D0^#-0BO;J
M,PN]P5\B/<,%MV>0.M:6C7<UQ\2O$,-U<R V\$*VUL7^7RR"2X7USWJ_X[D2
M'P5JDS73VK10F2.5'VL''*X_' Q3$;&FVIL=*M+-GWM!"D1;UVJ!G]*M53TF
M:6XT>QGG&)I+>-W'^T5!/ZU<I#"BBB@ K%U7_D.Z)_UTD_\ 0*VJQ=5_Y#NB
M?]=)/_0* -JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH .]%'>B@#BO&FG)J_B'P[I^H+,^D
M322B9$8A6D"Y0,1VZUP%CI6AZ5JVF6%O8O\ \)-:ZP5:%E<[[?>2'],!"I!]
MJ]+\6:WJUEJ&E:3HL5K]LU!WQ-=D^7&$&3P.IJO9V7CP:C!+>7F@M"' E,=N
MX<IGD GO3)9V-%%%(H*YK5_&EKHL[_:M-U/[)$P6:]6W_<Q\XR23DCW -=+7
M&>++I_$,DGA'3&!DF"G4+C^&VASR/]]NP_&@3-O5_$EGI,=K^[N+R>[R;>WM
M4WR2@#)('   /4D4_0_$%GKT,S6ZS136[^7/;SIMDB;T8?X5@M&EC\3]-1V"
MV[:.T-MN/5E<%@/?;C\J?X;:.;QYXLGMV#0[K:-F7H9!'\P^HXIA<U=>_P"/
MS1O^OT?^@M6W7.ZY'<#5])=IU,!NP%CV8(.T\YS714AA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %9VK]+'_K[C_K6C6=J_2Q_Z^X_ZT :-%%% &!X@\(:=XAGANI9+FTO
MX 1%>6<OERH#VSW'UK(A^&]K+=13:SK6K:PD+!XX+N?,0(Z$J!R:UM(URYO_
M !1KNF2I&(;!HA$5')W+DYIWA+79]?TNXNKB..-X[N: !.A"-@'ZT]1:&\
M  , =J***0PHHHH *Q=5_P"0[HG_ %TD_P#0*VJQ=5_Y#NB?]=)/_0* -JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCEM;< 0JQ.8\# PV<CCWJUIFE6.C6:VFG6L=O ISL0=3ZGU/N:N44 8FO?\
M'YHW_7Z/_06K;K$U[_C\T;_K]'_H+5MT %%%% !1110 4444 %%%% !1110
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M110 5BZK_P AW1/^NDG_ *!6U6+JO_(=T3_KI)_Z!0!M4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !WHH[T4 <KXUM-':"UO]3UF71YK=F6"[AD"O\ ,,,HR#G(]JYVUOO
MU]9Z+X?TW70(K:\298@K%[B0$D;F([L<DUTNOZ--?>*_#U_]E2ZM+5I5F5\'
MRRR_*^#UP1^M<G'HVMVU_8Z-;Z(4-IJK74>JJRA!;LY8CUR0Q7%,EGJ=%%%(
MH**** "BBB@#$U[_ (_-&_Z_1_Z"U;=8FO?\?FC?]?H_]!:MN@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]17,;S6TL44
MS0R.A59% )0D=1FI>](>AQUH \RNF^PZG_9UU\4IHKS.#$T460?0G& ?K70V
M7A?7H+R">3QG?7$2.&:)H(]LB^F0.AKB-+O='M_#=[INM>&-4GU&YDF:YF_L
MYG+NS'!W=>.,5TOA/QK&NDZ1I5WI6M"\$4<#R/9/L#8 R6/;WJB4=_1114E!
M1110 4444 8FO?\ 'YHW_7Z/_06K;K$U[_C\T;_K]'_H+5MT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5G:OTL?^ON/^M:-9VK]+'_K[C_K0!HT444 %%%% !1110 44
M44 %8NJ_\AW1/^NDG_H%;58NJ_\ (=T3_KI)_P"@4 ;5%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 =Z*** "BBB@ HHHH **** "BBB@#$U[_C\T;_K]'_H+5MUB:]_Q^:-
M_P!?H_\ 06K;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.U?I8_]?<?]:T:SM7Z6/\
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MW]?_ .)H TZ*S-^M_P#/"P_[^O\ _$T;];_YX6'_ ']?_P")H TZ*S-^M_\
M/"P_[^O_ /$T;];_ .>%A_W]?_XF@#3HK$OK_6;"RENGMK-UC&2J2-D\X]*G
M676V0,(+'D9_UK__ !- &I169OUO_GA8?]_7_P#B:-^M_P#/"P_[^O\ _$T
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M"5H UZ*R/M^L?] 8?^!*T?;]8_Z P_\  E: ->BLC[?K'_0&'_@2M'V_6/\
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M?W$RN [*>J,<<J?2G6_A&UAU6*^FOM0NQ YDMX+F??'"Q!&5&,YP3U)KH**
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M/+C485!SVK:!!Z&C(SCO0%@HHHH *P/%F@WOB+3HK*UU%;2+S TZM$7$ZC^
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MZ^X_ZUHUG:OTL?\ K[C_ *T :-%%% !1110!6U&^CTS3;F^F5FBMXVD8(.2
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M'@;2$AGCD:*U19 C E#CH?2NGI#04444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5G:OTL?^ON/^M:-9VK D66 3_I<?\ 6@#1
MHHHH **** "BBB@ HHHH **** ,N\\-:%J%RUS>Z-87$[?>DEMT9C^)%/GT#
M1[JT@M+C2K*6V@_U4+P*R1_[H(P*T:* *6GZ1INDK(NG6%M:+(07$$2H&(Z9
MP.:NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4C*KJ590RD8((R"*6B@"E8:1INE[_ .S["UM?
M,.7\B)4W'WP*NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9U_H&CZI,)M0TJRNY0-H>>!
M7('IDBIH=*T^WL#80V-M'9D$&W2)0ASU^7&*MT4 5K'3K+3+?R+"T@M8<Y\N
M&,(N?H*LT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img42979713_11.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_11.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M<J0Y(:JDFJ)B8(\P&JDJ5+PH.:AEVY !78^FV]"-"A2(>0#?"L]M&=#G-WM
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M@O]$^?,7$?[L%\":Y ]'[WO2_];W)&6AA(#STY\#PY? _4'P@0V\7P%?!"X
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MA>*+W)$>4<*YXB,^C;"ZIC,GHQ..H/LEEU,ZIYN)4*J@UNJ?"J&PZ'JYPKA
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M"Z>7&!OQZ";=3,"EF ^9T[*T:[$$8RZ74 T5R(@UZB6M(BF8"<"E:C:.0B=
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MZF^_&::?)O8I/*UKD0Y"&OHX>;(+1FICUQK3EQYWM.?53E LHUY")M$8A_^
MY 85HZ"HA(4V[2DH4%C\C?$2R#<:IM)94.JELB;(/Y1]<I4&&=(5E_%*#"ZT
M>7S;TH\LF<$!/LIG*(I4.%GWSF!ZCD;M(AU)5N?1F+5D=0?U'08G.*/VG,MV
M0?17RWZ7EDZY\"P'D%Z_8-D@'"GJ)^=!S96V D&>7.VA#9.DU2JTS%_6=)=;
M1)>\R)4M4!+OE&!37J0>")=)+(>F8NMFZ!K'S(LY"J&=@Y<V*XH[$ZJL:9HZ
M$I%2F4%1TO);).T8:JS&KC[QY*8'6!7,.+9-D[!0B:Y[D$>1VCPM!>>3#^RD
M077YUG\2\'6%&^=*=">N@U!$D"^C&5C&%=>.+!7_GL4CIU;44JD+:;9$^%%M
MH?#3&+EE-F_IF>UCTX):TD*02Z7-EEZ?]-H[?0^WZ IN73VBT=3V-CM"#-(7
M3\85"])T?*'['S9]UZW8F:]E]N/ADZPW5&,FM:II&VG%?'5"H$+P0IBL$F2B
MQT(9F/%+:#E?[;J8K&^B";'3=-'A+!19IJJVE[ %;8&3-U-;*A>08$FPXQAR
MX,.V=; :#**SG#4[X*1K@*^LH_."N%V!8O>_>!4G2!5,R&_MU)XTM*W?I$F\
M%.80=1V:XS$5*R;$JNDJ:0!:#[D4QI-J#L2".K!; ^5?(GF/>"=BGAL'>*G^
MH8@G/W+P6>)IQ]45Q#QV_^P1- F6,(CZ$&DC;E[@IGQ .)HK31*N+)'PJN"J
M"HO)1DSLFAD(W POEH1NDXV:5(C,;(E!>C)X:));&=[,$I=RK3VJ;AV,7$A/
M6$I!I2R+&@@^K;PA1I$Z31A-M$/O3A: <WM7LMY+9:"1%+C#2^@\/QOG_"8V
MF.Y%VJT;QNK]T1AV>O;UM5C*WZXYM%LV5FX]OQPM!ZHNI*&\4(J0?2.>G*9N
M@2P+#X5*D#9)YI60\]O5'E3,EA;[:ZIV,T:N_#>?P;6<K9S+<(J#@]B C(9F
M%*1>'RGF[35/P^R5W3_S-^, KONY!&4@KG>8+?<^L->O_AZ)BCHB<^?5N7F;
M</_DH+THWVE8C9!U;E$3J5R"K+%+H=IDQ1X)\&^:FZ?>TPFH08?*/9,)=QV,
M)+;+O/*67.>O.O)BB!Q#LA@8!G'!-(C$W^GJQ7K7HW[+M/>X3!#C4;1/PZ36
MEY]IJ3"O:^)CDCI4JV*>K'H4SX.S<O*ZW3CNHHCAQU4OQ,]"T;I%VX!;LA,-
MHQ(W<&-K;Z+^'HXR;2*GU6Z85-NNW.W(G1BL*I8=<S92#S 5O_!2G&Y$.;GL
M2]M=$[RW_CSUKXLD4&$1;[.;G01Y%&3<MR%\:&N4.4L\#$@=+K1TP(R7AQ4F
M>VGA_7*WAY7A^[?[X.3^='CG'0T1>D9? IJ5DDH^\L'_HGP*Y7U3**?U YN/
MQH;Q%(Q4;/K!W8I'/B\6@]F'\IOR:?5;*I2O=BWO@D_K&",Y&^FVQ^S4(MR5
M(9$%VN.J$N&PB&I9DKW)7[M(E%9<77HMU.2DCR^5E?0)WT I#^VY#_O)QO!=
MT'4Q$1>E6[9EFC&MSO\Y4*IYGVE=&"Y%3H!US<F0(+F8T&K]W>-4$JP]ERM1
M#@)>R6GH%H14%6PEG@'R6^$\&N2$FOJ F>K<2J?\&9B5#A9MV):@E+$A$EW-
MH.^D&XEP&=4HR.$12\=='O4]D\XTDO=9GN,\" TYEQV]BY21G.UM'[9$8?L)
MV1S.X%5Y'Z;P6K&5VMD!'+S4_U&BZ-M,H5%'_5=$.948V9/G7%%%\>&(C0C5
M^9 =_A/QS1(!Z="50. #7I+=Q*'=2%-)4)(/P5F?P(D&"D_Y=9PH%<PJ/F&%
M\8HU"5OD0&$JL2*; 9P-RB)J*>*:(=KGP91,:0PW*6!-=0GVD5A;@92'3!VF
M>)S=--_WN-T-E864M!ZY>-Y<V5'5L0[QB%FH+.$>FMUW'1,(G8PF)0_:G5,"
M 1 O*A#6=(5Q&96J)5PG?F'8E=^,H4P[$DD#JMX.N6'%:)ZIW>.&2= WGF)[
M(,H1\=HT"=4:VIL8\19P[)9*<>,>6LM[]6 UE9\R^LPO'E$B9I_1G"!XO4K5
MF4^8\?](KLF<J'G@L&W0MD234^67NZ&.]2VCZ UB2EE3UD%<0 K8K<E913(=
MS<!%/L4=B969?=E0MGD*Q;$:;>6-V2BE"(%59.T@3#F5_Z5<(V$=7<V+Z$31
M(<4@PNF:^9&>TQB6TKD@]ER-LV AF"F3@Q#$<-1,.8).1I(3U 40$>DA>7W9
M7V))]?W/-A))7SYD-CG(/74;(Q*3M]#(8"X+,0)/7R)+'RW<WVG0&%9BOH2@
M,98>A*R@5+V)&($?MZ@C2C52M6F*-KW=/=J9FFQA*[G*T4&>ML49%.WEJ6U1
M(Y9B?I5-\FS6L(V60<&BB$UEJDU5SNE9_=T*]9U75U3F[!S_IF$^IF/>#E)U
M8GTE2U'!60.N(->%7-M%HQ9AEMFEF!HUW MM6B_""YSUU^PLVD.AT"U"R(?9
MGRS5$SZ6XI*D(;HT5-=I5%L!)#B6Y:_=$;:MR#.&7KJHB>=\H^U4EOG$4H<L
M5/>A&N%!%(](U#1B%\DM93DVSU&"I0M)V?,P4@GJI)&8VR@^7G(^"_D@F]:$
MV2+*(<.DF_Q,R%X2I6'!)>C!6LOT)8<"CZA9DTON$8$"#8%^4WFDV!PZ90[)
M%))(2"8LQ..@:+I%%="EAULF5\$IS#:Y8E3RET/9UH#)YW RV,ZE* _Y(D!I
ME"V):6YEDA?A9+G,35?F)[?YXT5A_YL_;2$D,B:/)MS3P20/<LTAXEQ2XHKN
MC),Y21\771>%Q19O\>:;>9]9B=L\+LNCO,]DF1<B'1DU30Z^*0X0.@R:%AMM
M-60P*DQRN2DIUH_YM=:AL%6-=F1%<E W#B)*1M(/T5ZL31])',TD#AFYF.A<
MB6%WY9<\YI]OPJ<I@@^0X6?KL!ZJ72?0C1YPH%?Y?$N7<A&>[B% WN81BN9"
M 9B9F2(\FF2-"8[F85>%T8H;)N!#N2K-Y5]+DI$":IR+;:5<XN:E&I/>,)%H
M"2Q142$UHD;)'4WBW%6NL9?#D),2)I01<IU 08Z#04[25<N.5LETC2FL*ERI
MY0LLK1M;"0;G9*FD9$C_0H*\:IX)+(MLX[HZC)Z1H P)&JKN3R2R(M4YY\Y>
MRVGDJZ>()\/I3LY&G/3Y;-(6[=(2"M&JR [*'$:08 ,RHX(^"FA=$/WD5SYI
MW:VI(3":HX).5KS68H:.65.-FOH<CI8B2X><1LF!HW+I#68R42')W68M62&.
M;4!!%K]%)!_A3MEPDQI*4)'B"HT]K3\>E,Y,;=.22-1:4^0F+KJM&:M659J%
M1<GA8$B6E"?&H6@-#5R:V.WAI-@^86\B;G2&%.0=I.V%B]F W3]5F_"0)JH-
M:3EE39&J;3KZ",#MS0(Q*]P5TQX=#Y/.*9'1Z]P.VLSM"8O-XM6*)$&E&OWI
M_Q#IPEW9.F%2F9:8)!W[F*(_(9ZO?HN5A=H(DB=W.22)^9NDJIDY227U1:<W
M^EI#L-^4*1^.SN5<[:Y:9E5%9@M%.6WE;LG33HCBNIGFL.K<5HU67JUD=42G
M&5'73&BV\%3XQF#_KJ%/OJN)X2):N2.-K0R90B&8XD<_->5(G? &3^S_PND^
MVB/[,)?;&1\K6J.3TAP3"6(&N>31>%M<+MWX"*R=?J)'4A;:*=2D;5[FO2CC
M;DEI866&NANRAM"^69\.A1O=IH>-253$3.1;*6 0898]8F8IPJNK3FOGE7 %
MZV$64E.$@5C$,G _ML]3_I ;%Z.HC(LMC27=B=GKC?_%$<<>D+::L*IOW0JE
M:)7HXTU3P.52'BM=>SG44J9.2L;H1_'7:@(<*D(A 55E^5T: O%P!Y&F8W3I
M+?4F\'SO<.(77$HIZ12@;7DPEJ EL?AI4D[9VW%+>;X;H? 3(7ZO6U&*:$IH
M@.(5-QJRR-HN>O;I@?)J@%KN-7XP_7YI\9X%PV%A5.73H^YE6%Q-2[!LO;6O
M&SERP\(J[MHG-9_/;KK<Q<JR0\:@#+[HD#;H++[-;SI,+->A.Q[NNTE4TW"S
MJLXJ;UDM--H--,D=4^YKA'QKDEV6/4$FVIC>&PMA'2I@G%0AHO%RD9K-K*EN
M9!D+!LFGW>*@J+0B:Z[(;E[_5Y#A69AD;@+/\NG$<3_[Y!'+E6SNT#QSV#,>
M)?A)E&S*$PZ!J8 2+^/25MNJK\$ 4.DT3I1NY [G[GO6:;L-&JGIV]IAC8'&
M7Z5N8/O5V5UEXK8RE:. =8VQ&XA-8@?#'MRT6I9%F!LG&V75<X5T5["@- 31
MW\JI%-1A4JPPH7;"9#ZG$K V=%&*[(QXJ@91C;J9S&+SEWLBJ?Q!+OH.ZQ3=
M2<R)R=+QV4W#3UYVV-92DY)P&\*&V!';TF8[KS\KK#.]HV)*4IT))$-4Z3[,
M-FW7MFW?-F[GMF[O-F_WMF__-G 'MW /-W$7MW$?-W(GMW(O-W,WMW,_-W1'
MMW1/AC=U5[=U7S=V9[=V;S=W=[=W?S=XA[=XCS=Y?_=PE#=ZI[=ZKS=[M[=[
MOS=\Q[=\SS=]U[=]WS=^Y[=^[W=^PPA__S> ![B #SB!%[B!'SB")[B"+SB#
M-WB"G[>#1[B$3SB%5[B%7SB&9[B&;SB'=_ATR[:'A[B(CSB)E[B)GSB*I[B*
MKSA^KZ,>B[\XC,>XC,\XC=>XC=\XCI>W?^<XC_>XC_\XD >YD \YD=<WA!<Y
MDB>YDB\YDS>YDS_YB8,XE$\YE5>YE5\YEF>YECLWRVZYEW\YF(>YF(\YF:=X
MIY4Y=HL! *QY#*"YF[\YG,>YG,]Y;;LXG3OW#0# ;$<# -S G?^Y=J_YFF<"
MH!>ZH1_Z@$LYHA,W,0  H<]V)@  ,2PZI2>W,@" &,SV)#AZI7>ZIW^Z>*/_
M0::#^F^K>6W3 Z:3NJKOMJG3=A@$P*K'NJS/NG$K.JW7]G78=I_W-BZU#ECT
M.K#_NK ?T;#[.K$?N[$G>[ C^[(#^T(Z.[3_^K-+>[0S>[ +.[9;^[1/^[43
M>[;[^J]'0^N(NS*0N[F/.[J7.RY! UA PQ&1^S*P>T&X>[K'>[N_^[K?NS+0
M.S34P[XO SW0NS[,N[_3N[)W.[A[N\(G/+@WO,,[O'6G.FVG 0 HPZU?/,9G
MO)UG_&S'0)O7=E#PMC)D0AI( AI,@B24_"2<?,I+PLJCO,JS?,S#O,O+?,W3
M_,NW?,[/O,[;_,[?/!JT_,D'?<D/O="O_-$3O<DC_WW1,_W2#_W+GWS30WW*
MH[S/7WW-9SW23\+,[SS.=[W-BP'JI3PCG+P8D+W9HWTCH $CE+S8LWT:E/W8
MQST:K+TDC(')KWW;L^S*M[W<GSW=VSW>UWW0CP$:$#X:#+[AW_WA#_XD<+W.
ME[S*2[[+4S[D3_[->SW7/WX:<+[G;S[75_>E/_IL#P.GWW82/;SJKS[KM[[K
MOS[LQ[[LSS[MU[[MWS[NY[[NS_X'^7KOM\[OI[[O@WOP%__N'S_R)[_R+S_S
M-[_S[SZ5VSK& P .V/8!A$%O$P/J98(F' ?W#T/W$\/WA__X>[\F@+_YH[_X
MGS_YLW_ZM[_ZE__ZQW\F//]^_=O_XT_"_>L__O,_0$S*-$D@P8$%$1X\B,G@
M)$D#'S:<Y(8@Q4EO"+Z1=#%C1XX?WV0:IBD3L4PE,VD:EG*D2)(F49K$(8-F
M39LW;<[$J?,FSYPX9?BL*11HT9LQQK",Z;+ER*8J23J-^O*D294G5XK$NE6K
MR'U?P885.Y9L664 ,H4]FU:LLC1HQ,2%*V9N7;EWZ>*UFY?O7K]Z\<85/)AP
M8<.'$2=6O!@Q7+N/[T*F.T8,CLJ7+6?&O%ES9\Z?/8<&/5JTZ+Z 3Z=^[)@N
M:S2N8>=]+3OV7]6H63/6O9MW;\:V@>NE+-@R\<'%XR*_;/PX8>7+DS.'CIRZ
M].K_RX/?UIX]>%GOW\&'%S^>?'GSY\/"1;^>?7OW[^''1Q_CAM@8,<0K<T-,
M?O_RRH911A-EE"$&E (%)-! ! <D)L$"#W00% <?'#"9 2LD$,,-%>P0P0\=
M)":9$)-!T,$ ^7MOF3$$D $!%V%\4<88:9S1QAIQO%''''G<\447Q_!/R"&_
M(@:ML(QD2RQZE,D$#0>7(3#**)694LHJKZ322BRUQ)+++,'\4L"32"+SI)3.
M+!--,]E<TTTUX4Q3SC;CI'-.-RD4<\L]O:0R$QE:!%0&%A @E 5!#2U4T409
M71111UMD]%%#)RVTTD,CA130,0CLT],N00V3SU#U_%14_U-+)75+F-Z\L\Y6
M[8P5UEE?K?5.8D8]E=1,</B1)E]AK G8884-EL9?C376UV6+1=9996\2 ]<K
M4]75VFI+)5+;;;D5+Q,QN@U7W'')]4X%_,(" -SPE)E$DW+]@U!$DP $)<!A
M[ 50DQ$OY%<E?4?$=YAY,REP7WI'&K%@A \N^-]_2[HPP(4_<1!B"$=2YCUE
MQ #6J(]!#EGDD8UZ48 T](%7Y;'64NO(LHA)0^.5Q\OS0P]QOEEGFWGN=&>?
M>^XTZ)SS#''F]S1QEMAD20YVZ:=M^A'J9I=V,0V:L6Y+:*"YWMIKHKL&^^N?
MQQ[ZYI3?(P;'8V=DV^FH;_*X;?]FGZ4;VKIC'".:K/GNV^^Q)EGW[\$)+_<&
M %R>)+\TABF\O&CFK;A)@R\L<&%[)YS<0'P=O)SSR5$TT<01"QPQ\P /GK!R
M T4<4. $7R<&[?:4&4/J'G'W,??==>\]V3&6<;Q;(Q4'*Q, 4B1+&4F.=IS
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MA[W8+6U)K,7S/K!2AYT1D15(D8?E?OS3K&&Z7:J& &)0G65:5OGY*%#BG_\
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MDS )3D(E5'(#*R 04-*\DQ"] 200 4,Z.Z07G4,ZI ,7S<0O5C(01IMM RI
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MYWA^B*J9VMDV80C.%KGZ1?06N>Q80'U8/@HH2?YEV\<9FB<B3^A!'RIXV<H
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MZEFFC*F4@,ZHT8\;(.H"X8^(V)J6WH>LJ0EZ2 ,(M",CF:YK]5M3OB$7TMC
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M>(8G+H5_JFNNT9:ERV>@DCG&,V6"WDP2912A.=&QTMHW8.!4/JE?POQ"O9\
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M(WP@DY@/22U&@WD3=PP1;LD4?.@>JE6'PJT7YS15NIG_8$'\S0_J%"8J'DX
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M!_ICLZ"%/Y95%*:B_RL/$]]3S!$:\YAJB&DST7!%N.7Q,8,!481TB%*TY2J
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MA]W#8R(P HNC :%% QUP RE0&68.G5B .\;/!%/B>(8IH0QB>5*NH;8.[W#
M %I%B7# N I%5KS.7/@KK@+E6:RBU:)KJ?A"CWKDNOJN_18(O^;NN,SO!&MC
MN1PO.\(G7E(MR4"$?MI,WE@)=I2.^P:'6:YP3Y#C0KK,*:10._ZJO SPRC3H
M,[0$M;"L/;3$P;BD\SY+'WHG#_>!'O1P'Z+A!I?!N !Q'P2Q$(UK,VZ0$/?A
M!CF0(P"Q=P@E&B11'^IA#_=!+ "Q9:YC$?=0$AFQ=Q81:C0A!DKP"4\1(_]Z
M#W^&S^6R#DQTBGJ ACXD(A,.8'IPT&F4[V^FS3?$3(T"*-82#W"TK7Y,:4&&
M<;?RI&)TITV\S\7R!Q6]HVG0T#8,"]M"KW%BZ<;:);\FQM3H":72)?1F+RI@
M20OE12GH2H,JS^0X9[S6$'-\[<IX#39D+AK' B^HD9GH[![[,2+R3&U(Z\E(
M0QXQ9_ANL5#$X  D81^N9R+JHWN<T&7J(3=XQ/3&[C<*2?I\L-0*3^3LJZFB
MB[[@AT :A^(.1!_%8V4DTA_70A/FXG_XR2]$CU=PY%P4Q)#49?8XYOX>#1O7
M!X)L#O!TB"D.*DP(D%):L3T*\O_,"Z]&B/-:<M#_CN_N.N.EI!(5R<WW^@RB
M."4.&8(%Q,]%]",BQ,  )D(AN\>GWF:%GLHW=H1U]&\RRHP+"</BA&N5+*Z,
MDD-0-LS6G)%F#DXLL7)$:"Q2'"[VDBUCR&EQ^D:X%'-OQJA(RB[(QHQ> ,QD
M>H?)) ?E4$L !T;R"C#SV/"O9$#4"!,COD[W?B?W4%/W !)JTH!+6/'_*H\@
M8% ^ @!2'%(BS))Z)B'&7$Q<\HW%[%(8UPRW[*O-K-!B($[>Q(:HNA''6$\S
M.TT&4E(JY0([ZV(9T$JR0A)9U S'>L3CV&=(DHV!R@J5](:ZS$B"0 $-.T,I
M1;/*VA'0INR2ZM ]HM(U_S.BQ:!N9;:S/X%)%:&&P1I,!KP2L'#J-(K/16(
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MT37Z6MA O:(S22! Y\[[TZ;#;6"7@YS"G-AE[/M*6&"Z&2('BF$,1J-2U*/
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M]J66)[;O9%5 82&\HT]7)14"H+"GN[S,^Q4"Z9PU%UNU@P K>"/+)8,!((.
M.H< 0+@O" "N P""9A.M@8.T9$VJ R#Q8A\,,1V?\HVA0G#M(V"88UK>)7;'
MQ*KEPQ ^"QC!J)OT4!:7N:W#A1TPP8'K.7=0>+HZ&6LTE:J\!%$<,T:=)7T!
M=SY<9E*B@[X>U6O;I":+Q')VN)"M!6=C*TD/B'F<!Q4Q\#O-^\(PW!5NBRS/
M8EQUAK!208H;$@,&.34?NP\XD+=H 8K;ZY\QJ)O@6Y&=RR'+4"#>!T'T=TM
MN+\ R#I>1T$?<5]@)Y@A648DE)N928S_9C4,PX"A7\.!!LR!L4H34*BM:TN:
MP<) B#5(KQB_UTB-WG=Q]]H2^A9./V5(2FJEWI5LGA=$9 N<"-B.0C/"+I04
MRAO#D/S"#SMH7(F)M>,XT8-T/$(EV)$)!I 9G%'$8+&G-3&#$^F]6K$,DG"X
MS0(-FH*^W!-D^Y>[L0E@$5IX[#-"^+9OH-:NNG1@<S,8_YNIUH*K[;D/IR=Z
MP ,L00*LS"J,C:6V,-5<%G2[YM,>V^1 GV"$Q79()(,?B"=2!*)O#J2XI5*+
MA^.U7,EL9?M4ZLA(5/E(P2NW,I"VD7S/D#S#QU(9^21#F*<4<VHCQ'  ?+L/
MGK%T!1T6RK=\_\:WB8!K?..+%<YUM,62N$#5.2E%/KLV*OSJQ07&F/:A:V6H
M=8$U3!L%:@8AF6*QP#(1=[BU#V41GZ\Q>ANZ8?0SH=OZK$3;?L7"?YR5;P=F
M+\XA7DSHQ?-Z,MM'JJBJOF8ROQQ-'$;:3KY;E6!Z0H=VPPGUI18K \F+SUX-
MP\\+L7=XR%V*L5R2!LR2"=PIRC5R@T[SG^8#4M@WB.RR/IH%I27AQ/2G;^J[
M.@22*>Q2<#IW?L?(K4X&/'/I71BJJ=N:K!F*TS!ATT,KEI.SQ(<Q4TYJ6J^H
M-QWY;Y.KO@6ZOG/CT^8C?OT70AM=3"^ASGXXG'D8%,2+U=([S_Z<$XM?^=6X
M?;KZ;"QO0+<7^R"87$]*H<-(.]A(&W$24TW7*'U$J=192CJ8*WZ9MF/XBHA^
M94B#%R;K$ATUF18Q2<"6$S'Z\$; RJ+NN:$Z/8PU@9P B4"6;1B4)1')!';U
M55)VQ75ODSH 2D'AUT#XRM'C?#JV1"G_^F96[:65_!A7J<A:K8!)T=6Y'>%$
M_SO)S4)Y$,BEEHQ<?N9$5M=Q1$4W_<4F(%<FET):UKC7=J-3^V5R6*9'F?81
M38@6&R9WS;JAF=!2N=&C'@JC7*/>5%A#P#/9R>A&%(TEE[.J1Y5@?N/B=(UQ
M YYOT"U@_J571"5^2L7:#X:._^R'9LN K"6Q0P&($C[F:*JF8L4X8[ 7!BL#
ME( #,D3<7^5\3C,\]\W9-6NOWTC7Y4.+<QQ:\*$I'CR2UP@=0FX3[I69,2FM
M ['> F$>)+IZ"?R9'5I#A8Z3<!PLJ2H^HG549V=K'UYVN[B4Y;1_'?0Y.<5-
M%V$;!-AF(BR\LQ5#5VVQP7D4"SZ]/?'(9)[KR4CAR?]B=)B(%'7'$RR  Q&[
M$YDQ+1)6O3>2,4O4[$OBUN\&'_("$IL6U 41$BW.Q=7G98U;.$EUI?I&*NUK
M@8$XC/]+(],:H@!L$_<S4X]>#S0JTS-QV*:+S/4>EM,<+!]BF'_NKHD7-WY#
M<)QNF%H[=CMK<JVC:Z8.4NTQC8-!A^EXX'1FPA$FMO+<<D&A8;J^\6*YVSU=
M;>8Q))01%,E5PU(1T#6B#+_'2IT1?"0+5\B-N&!"<?J6A/JQ430U7ER603"[
M[8]).)I6S5I,:^6A%2\)KHF6;IWR$OL8-I .$X^=TU)OICP=+/5@SN13F&72
MWQF7XH)D?7K\>/*;3-?5,CK_M>>K[K7M+"'LV)4F?,(I))PD[.7)R]X<?_<[
M%];A8G2]PIE!,1G3@A2904I'P0(-N20-%0,/=8%4!^>.,H@>Z<7BM=EG9X@<
ME6GGT66$-YMJ9SCB8W*"H5B1C<PUN@_&O2? 81Y,[R*07N-!3N^M]M[OE87!
MXC81%$' L?,'2C-UI+2?"HU+66I,NO!+V,$'EFQ\*-Q]^.7/YO9;+7.ZX\)X
M/_T>Z/'"HGM%<2),@3;C-ADF/Q2.[QUM)?N'(>=+T\2I*(9P(ZK!_]-WP_Z#
MI9I82F^A'M)8Q#=2U-TKC7J--:T 02^:LDG[#!Y$2"P3-('TEC6,)K">OF7Z
M)DZ,_Z;/(#V#T! BC/91Y$B2)4V>1)E2Y4J6)C6A4=92YDR$])1I4C8,E,YA
MRHA](@:*6#)-R8CE%)JSZ-&?3)42]:DLDT^@0(4:W8FT)\ZB2X<2XYJ3*C&F
M28/VI"DR$PL$,MJZA2M#[MRW<MO6K4MW;MR]=O?>]=N7KU_ @?VF29M8\6+&
MC1T_AAQ9\F3*E2U?QCQRDIC,DS7]=<LBVK*]B-/0+4A)L%M*G54>X.PZK;(T
MPV1#II=U&,ZS2\<"'6N4Z-:M6'4ZG:JIY]2S9I$>W1HU4]F>QZ\J'QM5<<B-
M!NOMXPCMHKZC)NM-5Z9,7_J(#R-&JR<^Y/?OW+U_M'A;___^D<0FQ>0/I?2&
MTJ2LIKX2*JBSI(JJ*^AV2FH8 H]"[\$%<9+P*>1N$JZY!Y=KRB?[$OM,+] *
M@RNOM]I*8+ 54XP+1;X 4W&PP I#8 R. N2Q1Q]_!#)((8?L,9/8B$QI$AEE
M$ ^P@B:)2XU]3J-1KDR$O.$&)$4B", M3QKPJA";RQ LHQ1D3ADT #@  !72
M^(J8&P  P( 5 +BAP3.E(L8-  *  0 TS RQ*Y^6,NJF[)KRR+&0])EOGYB6
M$>_*DS+1Q"%EZE&FH8H^U2@FC_+;)[XO3W4LF32\)#*:W7PBJD,(OP*J)["T
M@I4KIJRZ4"L,I3O*4 K'A H[LG@E99! M!C[K,8:;7Q6+[Q6<];$&V>$4;"V
M!$ ,56^_!3=<<<?]$O^-(\E5[<3O4E)C+Q;L:BU(8@*P]%0UZR5W'X6>"W9/
MG*:RSE:B,@$@*C14@&FJ&&*(*E@^<<5!A:E\$M,G@(/C*M9"M]J1IHE*/8@^
M2#F*2%*I!)S*)F@>4J8]BB0%N9[Y&MTGHWV6$8GD?+_51!)BOAS0N)L4S(E"
M/<=,3BR>%!6XT$2G R[-J=)T4*Q_80WQ.$4;^^S=)5\D+&QI00L[6FNGM5:N
M&6"L*X8T<-XY;KGGIKONG8V,^PT9!!A,$XKBJX?2P"EJ:(PJVRI(2#1BP!=)
M@G[>>4 .FQ+:5C&+Q?HY W!@R@"&E\XP:84 F$0A!,<4BNJB?5)0XYU&3,S_
MYIJ]*_E3>C)9]Z1)<.)4O/1@CBGX?2R*%&2[QR4&#;B1K <HWQ!5$+BN$O70
M**W/FA XHXG>]5BF*#>:N42K?O6K91?+Q,5LT\8VKVQ;/%$&^%'$\>SU3V2A
MV^/WY[]___]WS&;BEJZQP85O*V++_>8B $WP* 9L@F ,#G" %1P@ !-D4YN"
M1)#&B0L:X#/+4H2BF[ 0HSHE),;"&*1"WG"(-U^Y00QT0K'JD"E7U1%*5;XR
MN?+(!'8UV8C-WB.0DZ6$039IF4TXQ2F8O4PC%-'(\ ZB,P "21F28-60TF,K
MKUC%<M6AV(&P0K3IC%%Z/!E6K(P%% *-[WK).9#5_\22-*Z)K2\MFI;9%&A'
M]CUK!FB+'_UT5$5"%M*0AZR;&\XUKDQ\35NK8=M<.BB; RRLDA*,@><.  -,
M8G*#JXI;/0I$%%H1J&@C--^LQ%25A3&%DVWDC5%X!0 QY"J,U)M5&,42K#$!
MA68TX4Y]# (W)@)N4U-1R7EP8A-*040BG[K907 FLY+L*"0=0R1E7I+%(5WM
M.&<BI5&X@L;G*"TKL>S>+?OEL.+P)BL64IH+DY4@X' M@67KB_OHISY'5@ML
MAGG1DLBFOVP6U* '1>AM!+@S AHP?OC4)VL2JAAZH,$VD2LG=MS9%!PN"#K)
M(H@!:JD3"0( !@&(@2Q;I_\0 RR.32JX@0E'2,XV[DLY[U2*3["9EB@:)(H
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MXC5%XS5%XLF@9X0@*J*@6KB@6E"@!Q('Y)U@XM&'_JT HNPB4X"B,::%7*R
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MD@?]N(0\$H0[^@9CM _[:$L]UD\[[E8^GLI/,!>"%-?G) ^+\45FH!@!)0G
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M!AVVG'NNC(F3EIAP!,P,!2CX129X%L^%N"N5XZ!(D>R)B*TW2T^4^IY!B-C
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ME&0O85K*(\H)/[S+9\P0:( F#>YFIE8%!CY(#%*N,>)04&I#*B+B!HPO^=*
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M7CHII$ZD21'28<0JZL0(:;ZJ$TF^CGB')$N2Z@%'C!SI4=0,6.Z8TCJ+J)&
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M)7A4<AK6MH(DF#]JMU0[=US1%&^B-8*?9CRDT1.X=FU(126BAC [_]$QS":
M*W%L3L& ?P-*LH<ERM!*;H@AL90\5&-3?[%=\R-<P[%N8!58F8--X-:%TO=U
M@Z1V$X%JPL06@T=-FB4DSG>! (@TW,0TE=AAX)0;X=44R^43Q!![, ,;YG$V
M$2:*M((<Z)%$R.$IHX)$!\8>TT%$J#(9 P4WW!$=!W8>S1%0]O85\A$A,.<1
M.!=S731S#N(1JU=SSR*,QM@1Q'B,A2$A'/%A'#$&B@,H+2=SP (Y.S5%^2$
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M :ULY+*5$0AS+/);CO)4LYL=$$V<Y&<__2DM""822V!JTM0<:= $/N<  3B
M 1@: X::9X#.\=H_'<(6*]WG;,GS_]<I%_*\0V%E47;;1_,.U;3[^66DJ@2
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MJ0C&^M@P)XU429U42NV;2KU43(W4%MTB.>U43T4:UN3"[O"9&<#1BXBDED2
M'46RBP,\-B2>Q\(MT]O3D&LI3CI.2"&+$L*/=QF(LPP)@_RG>C0R4:/"3SU6
M9*4257L6@D(=&8BD4CW'H%C2MZ*3ORNRL8P.&C1!4IH>>:$D58.(*4.2FZM8
MU/83,M%YT9!(*FXDI&6X"G7M)X CJ62M5WL=_Y)0]1)L83+8K+YTC(CKRPYB
M>(/;W$V#Y4V+^S[ "[_XJ!2[Z0WLB8M]/ NXN578F)OC"3K<LB5C%0EY_--G
MT8?!Z-A^$K5VO5>435G?H-,KD4]72Z_U"@IP'0EHP('RX$__W*!R$<$!#4XN
MXXIF,A#)0@MQC9:B'8F?RM4_BU@A8]0:++%^>M<G+3+=X V5O5JLQ0T:Q9)R
ME%;Z7#B>6-7GP#L8V<T>39/?F=FC64.018FCVCB\$!@55%O)LU5I.5J1.$ZV
M.)!%!0L(+9B#$=!^4H;((-8'S%K$3=RF8%DK6<E1#<77#!.Z!8GU4,W9Y%3Q
MPJCIR!L3_$6@[;BA;/^O&OJE)EJ4TJ"/HLVAICD48M \@1C=TH S)7HIQZ,A
M&**P!\NA P.0V46S 5-%F<@P_CH>L>#<F."+MKV3>GC5\))"Q7U>Z&V)?*W1
M"LJ6,%3',1P/.!N2(06_Y%4)H^(R@P$TN9BL6>(A"UNB?8"V([+5>J$ET<.A
MIHFI"RNY7<*.6,+=FI,V.R,MFW,P.,/;)%L_$UHFL7 _OY7%7P4)I+-<#ZI'
M@@0O2XQ>"J[@D6#<*@'%H,D(5(4RW.E@,T%%X%4)'PH0'U(\A[!);&W3Z! =
MN\&*H!64Q$HIR*NS1$DV 68SW]U>VK4SG"HI1CFINJ4/TRK:F/HL^/6+BBWX
M"1=,5.OILIW:'I*]**7Z)ZE=8'ZBA!48 RRV8"^&WJV]$DI('0K:"1#.B(#E
MT7'!"1A"W6%"885XBLF5%N#TV0@%E$)-K*+MK 9SMIG(X?X5/1[BN53$+->B
MLUW:7?IHK3O;WN:AX=4$  C)X8_0V\-[X@1YD'@UB8_])WIH#2.;X"\>95(F
MIA&N1%25&E-,+UF;XQ16HYAXDT59*LL3Y#@6W/'*UN;8GCU9D+KHN%):T)"
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M:&+JD5B]&*H91*J7-B3V+C*357>3C]'YQE?%?C4I VH$ /44UN< T(Q59QH
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MHD$J;I,T_SHG):5E5F-I->8J0P(]XH@ )>G5D\D-!ZS0VK%)2F*;K,_*AI9
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M@QS@8 PXP($8?EQD(8L!R#E(<I")W.0QV 8X)YZRBJD\8O>(!+T7,8!>1(M
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MF9)TF5(PO=Q8K)<XY4UGK<#0X)MS 0#-= U5Q%]0G"&T"-'5[<@1<92O;88
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MII":+A5/0F0&<DA,"=U]$:+&'5NBL;]N[S[S,QB++1CW,QL#-$$;]!G-5+@
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M2M3)ES>?4%F:9.?9MW?_/N-BAB,A'J2W[_Z^92/I1:NG;[\ \8NF/WH"+#!
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M"%+F(3)YWD-C1&X4S95N_^2>2M*1+!^VSF%H@AC$R$1.=9I33;CNIL2XZ3!
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MHTJ=2K6JU:M8$Q)#0S2KUZ]@PXH=2[:LV;-HTZI=RQ;-QK291NXS^G9?IDD
M#$QJ*O!&3I O]^&<E,DD4)XB_U=H/.E4(( 5)A<#@+8/;]U]:.2R]:HLS<[-
MH$.+'DWZJ:9)74NK7LVZM6N">%\[--#8XL?:LM?6W(P3MVJ-:EDZ'DH09$&_
MQ 4:C4%0Y"2>,C,>'3Y3H$B2'YD/#! X=T=EDGQ['T^^O/F&RKB>7\^^?>;1
MNR?>N/P0)\J/*/.G!BNF>L$8*CD4%V5Q[2>1<1:]E]M'GS4$H%0(QI7;)/21
M]5& F&GF&(;6 8";7[A!<Q)T-'7WF$<(FD341V&T-Q%3#;HHXXPTJD4,7S7F
MJ.-:-ZP@FE$Q:I7</BOX!]%\",67%)(2%780@@UEXJ-@W3T4FT ,7M2C=Q\9
MJ!"4&%Q=N4\]FC$9471EN5'A6'C5EEUQ'+94Y3XCELA3G"!NB&* <56769 [
M%J2,)EX&:NBAB#:)6J*,-NJH0VAHMT^6!SYG4)=/:0C1) 9@]&!%9CXZD)A@
MA4J08A)A6O\6A6F9A,8DK^(UY'0#^65G02+Q)&E?R?5$T'(\3;G"G*(6:^RQ
M.D)##&7(-NLLEL1UB5)MLA)GE%&!80NEMD81->U ]HDG1H!BB"'KKL.A-.E+
M]TEWDJ4H>ED@0MKNA%^==BGV;GX[(4?<#=I]]):4!DE8F4[J0E=3#)9J=F]U
M]W:KK7$&3X(POG2^>X.1ZP8E[4G*W$L0<N76A9+%\.:7Y$E28C?4MP+)JJ]U
M*AEL%W$X#6PB8T^RC.IM+.>WD835_GM2R0J'E)]X7@%WUKWYO8O8?W-B/-S4
M!*GHV&4"#X2#AQ]Q_.S89)=M]MEH@S5O8?\&F)G'&T7:J4"94=;_[5QRO4DG
M=@$B*,;<!!GPE@$Q;*1JUO#*ZIBEN=Z\W[P&B8'N0)3Z".1*VOU=E\UTOG4#
M%W@'5>1 D4:N'< JD;G3IP98&VU\S'WT''X"B=A5X7T]2"GK'A:TMM8QQ.#C
M[E/ZM7J K7NL&>XTO06R75K?X#9Q?:[TG,VX<]I7/8)IEW><G0\7%-N4#_FI
MS5ON8_S6VU<&.%ENH?6GH'GIBNN<?J4FHJ16XTLKWA@:!DCFE[8"&O" "$P@
M BT6L^1(;DR:RA#W'-.8>9FI7!2$C:0^59R=^&I=OCE<_E8R$U4UKCGYV96I
M!B*X_]3E2K8"%X;&A;7"28\@"AK96X3'_Q.2B E3!J-A<S T"3Y522\",<"4
M]G:S\AF$@95)3@R9^!%FD8E[-OM(7]XBNX*43B!.BB)1'LA$@?Q,+G=3G?KH
MPZ3>'>2+T&M@5SC'L)AIQRA6Q-GD5A@6IYEE6 ?1&IW0-44P?K!#GSF)?^)B
M,@Y=J#B$(Y8")TG)2EKRDN9AW@U)F"&#C(YN48/69Y"HOD.V#B45,HIRD@.Y
M\G7EDTRTS_]JM28ZP>M70^H8Z0*CI#4J3&J&G%,,Q)8WA_U+4E>B(:5X B\F
M05&7E,(4\RJS1%KV!4/QN4WWI-,7T#5P7?SRI'^$N,F6S"0N$\24JN3RQ;@
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2N][%[O2]^_WO@ _\T342$  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img42979713_12.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_12.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M\]=>APWVV&*73?;99J>-]MIJM\VVJMI:^P[.=&.8'-U21ZUWWGSO[3?%F>
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MC\28M;)\H31_/%OW"Y, ;T!D :I8&:QC'<L!<(,M_*^NKWID-.\G)L"N#_
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M7N?TP#S9H>%[VLO]^I+X]>.;#HK8-]___Y>W[MN'TBN^:[N^_ILZ22C 4SO
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M(W3!F4/%,+1)HML\\(-&E/3+O_PU ;3&3/RTAQS )00UP[R^ZI/ Z\NWZ;O
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M,?#?1W0D^+$2W+>A"O6M_[M7S;X]?UG1TD]6M=?R=3]Q=&%EUUR6L3_^$;"
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MJ55TW,S@!CNE(6$F"QGJJ])5SF-L6\/8[.?Q;&RM4/'4)@O!4T=Q1_6E$F3
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MGE98&(WQEY0SUGCH%ZV22*BOJ5W(?6@,0B0A5L!&6J&!,A$.@.Q#*,E7$Z[
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M#D&C"( 8%%)-JDD D 0LB]2+X4&#]FE)#(B@2RH3BQ#2AY@1#4(QAM3T21"
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M5555F[4)<%)UP[098SXE VH I2DYZ+=EF[59K<#@0E23^9TQ".SZ%^RRSL#
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M1&V&8ELPFT22%NF.DC]:"&;_,!*GC4!(<K7CDD3F:*EH:@A%B8E:4LHGQJF
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M@<M]=%2T/!R QR;6L2,^%)>]@<H#@<N Z<K,_!NUH1ND,<O0C$,XU,J6K,J
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M,[, R(2M";IEZ+F_7(^,L"T8*;,;V"])"  S"X-,L(@R(\#_T]$$,X.4)%G
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M[-,&+,6PV\0XUWPT)T?"9U5(9&\LI-:^$'B)U-9V)W/=WGY*;=4.B*D9U[K
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M;+LL*8V%TF ; #&V*O#N+D5*%("#&"L\C;(!0,.B@C*)&P <@$(HJ4DT20J
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MJ2@S+ 8!RU6-T5:MK"(L7_F*)IK1C.ZP0; >?3D\_TVRU$@NG5E'(X<5#I.
M#D8>J!4]XQZ\B+QA]Y"P8=JPD'P>HHGQE&40 P>*ZQ+@NZ0219X$FE,2?+(J
M71.V;1)OT-0T4"!GR"JQS3&_8R1"V 9X8G2>2I\& *5$ BG@@.HG*/D:2OQ4
MSUHE*2," ?SMR5(26!TD425+KF^-S6[Q"FN8KR,O2KPR*.:%.'O,WM,Q :4G
MZMTJ,UFY+O;_$KYL>JKY[G9^B)5'3FSJ92+4MOVL_J1O+84EG<]N2[  8Y=C
M6L^ &8=-@O>_FDSP9C',Y08D"#3ZCTC49>-X0H+ZJ\5BX.(F+@WR3@+]R35(
M+(.FPT#PSH,40DM(RF ^[/_#U(]?2$8_R(PF0F.HO,7B)"%!,B$-V@,-#F@9
MT& ^+@9>3 BMF.9DW$H_Z.6^<F@B=M#EL(/MU.B^= ,^GJXKE(,R>.1"/ 2,
MGLR+7,1FL&AFA(9H9B;+C !H/"2KXD 3-J$P3*/,W*H)E8XLQ@>@FG 9S$R-
M-' "/2C$QDLC$D6OLN6G*$ELUFD?'$U1W"V  F>W&B\A[(9QWF+S)@*S<H)P
M("V3:D*6$.V12$/R.L)T'&//4,V0:.=PT$ E+DEM,(+7@"E11*RPZ"+\"*-Y
M1BW0FHO8B.\58^58KDLGQF]U<,V^RDVYOFU+X.VZDJLLIFN]! 4NYH@E_&<7
MV4+_WK"+F[#/5R!C^Z+E+G#QGI8!NK8O+8Z)V];M,>B)O*B/W5I(K#@.X\0
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MAFO>TE:O]&J>O'LSV(<M5L=NDPV<7#39&EHWXV)MY<O=H&>;=M$@J%C_:/K
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M]W9UBC*AG +AP&(*1EG%RH%(L'/^U6,;P-8!I6%#P2WC(,:W[:O,,%_JQZY
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M=UC;'*@JKP"  [MDNFB[NMVCN-1#6<(H!@,2<HI['$!)L:S;DTKT'-L!N/M
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M=WF 5J7*CDUA!,^@:[$H=4>^9%KDP@O(=T%"]\O=%8D;ISV?M!00BS>[H(V
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M+&3SBHVCWDVKEJ7:93G$E<QRMHXI,TM%H=+0J!(4*'NL65D5Q,:>X*4FXP-
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M/L!  +P!/<AR7&0R2JCR3+AR07*R)'XQ2/1*OA@ .1JC,FCR^;A)DEK*0P0
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MK<Z848IJ](H?+ @!V9D^489T=L,BZ4E1FE(E*D-W@5I& +F3'6BJCP7_@CK
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MT)1G0@;H\_K6Y^BJ6(^1(;8&^71&KM))R(DT,;![)]5B]WH!A1@B?OO? 2]
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M<\I7EW5AG]1*F15! C6"G.T@\!4S#];C;)"=4,=EX0E9:C8\W()K?:);*B,
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MYIMW_6@X:*'6/V2+:N:TU6]-]*6#FR<\""X<@A.;UG5]Z!GX^/V:Z9\?UX^
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MR]1;[,JA%WR5$=?"MS6O-YP 7*WMRL&+L:6$"' >_1=R6V\23,@QL(O?,5_
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MX<A LLJ-=! CYA(-"KK 7;.H7+V.05W"OOX5;/]A_5.&5H<Z3:1ZTY6<4QS
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M@+V>0C\*Q+_J>PPQ($'_68$E,A:%VJ%M0YOIFRSP2[CJ8+1N>HFRBT ^PA@
MH!&DDCUKXCAUFC:66 $X$L*V8;;H2)L]>XD8<#S0N1$Z YF4,1"C>\#G>*<V
M-#VH,Y#QRXZU^3<[NY$R:[?5&IF_>1[>2RAMNT!KZ<$<4[KFH#R6<)M3@[C5
M&J!]>$)JF:;#2;N:N3]+3*!=PD,:[$1/?(KMJS$=@QR%,9;G,(" X3, /!Q=
M>K>T4Z:9Z<#K "?06HDJ8B7/.3F6@(& 42>O(ZB+^L*8(RN-PHY2A D8@$1K
MPJK2>\"'FCKAXZ-YJ[*W4;U8M$'.>!;WJQ_:>X/ IH-&J J8&[E S@+ @@G$
M'4/%/:R.8MK#B[H8EX 9/N.][E.8ALK$"$0[7(Q  %#&3_Q'@$P*; Q(@BQ(
M@SQ(A$Q(A32*4%Q(AWQ(B(Q(B9S(41M(BKQ(C,Q(C=Q(CER<COQ(D Q)D1Q)
MDJP,BRQ)E$Q)E5Q)EOS(AFQ)F(Q)F9Q)FNZ\OI.L29S,29W<29Y\DY?L2: ,
M2J$<2J*\CILL2J1,2J5<2J9LBI]L2JB,2JF<2JJ$IZJ\2I@@AAA Q*JX 56D
M"JWDRL^)@7+$2K,\2^QX2K2,NS00IL@!0YVH,Y]HJ[)TG/)!G[O4(C2(@:.D
MB4S F$DH'QS:RQA0RYC0A!L0RT54PK5L3,<4EL<LR$F@F(;ZRZ.( <:<"6*X
M@6&(B<D4.KLT3)H((CNB&(%:!O0QJJ-0ABU0S"&Z =&,3-F<S8&AS7]$@RV8
M3!]R)4[DEZV,B;V,S2/Z3;Z+@<D<F[\\SOW!F<VLRYE@3>>T3>F<_\ZFZ$OJ
MA*' ;*NS"<S)H$O/#(/=?(K-1)/);"M1"X-)^,O8G,PY(LZ;P $BO$[YG,^B
M$$[ZW!<TN(%ZR$]W4Z>VQ$LT$0-?PDMDT00 /:N:,5!B($RZ$0.\/)O-[$R8
MV$MZ8 GU;)M)T$K!M,L/9-"OQ":<00,N4 :A^ARCNE"5,%"\U#J^9- 4S<L8
M0);Q#$SZ:ROT::@2O4\=W=$"X5&XR\YZN(&:X4Z^"X/G^,N1F<S"A"?,I#(Q
M@$U7JIG-),XG78DPX"QEN % =$^7T,TM@E*\J;-)X *O;)NS<5 $K1]"BP%H
M",N5D 1?^DO.&H;$Y G,9".*6:MI8L^Z0?\?/;73M2+/)?510BW4NC'44LO/
M]\'-GFA+-B++R*F9O5S,/N4L,=A2K9,!&<K1\03.&*C0(8J!:\M1RC'.TNR)
M3 #3=1K42"4W_0R@2_Q-Y;0F54Q5'VHK%GT.W#317(4GU70)%$548;U/ZQS6
M3,E.,W6<QDE54(4>*"72*.W3M8K5DQD&5B4W^^/2EO#24TU60 W5QX#64I4>
M(=VB)2W/5475)<75L>Q,[\13-E0G=H77+^R76356?)U.^\Q7.$$#&8B_R<P$
M(G54<_6A_*14/ V<<O55-$',D\&!N]R",&M.3VW651U56"Q3Z#G7O#1-/VLH
M$>T)-\U1Y4S58?' S@@%5[Z3 1,M);[<1%,-U7WE5YH=RF*M63=!5I60 ?2L
M&)UUU@H5UTN55E?"U)6P5@F-@3&;U%*54!Z[@?!4UN<@U7IP3^7DTYE86+X"
M4Z&BV'1=)RZ G)2=5U]-4IPAV\W$G, \F<F,3IQ]6ZJ<6;@U$T4-U1M8UBN-
MG#"3!'4BU<TL/RG]U;2Z :[J5-[$4[?=!TGX5 L5U;;)6#Z[T&!]-,]AVE75
M6N7,4E7<2Q\RW%7MSY9566%3IL6UV+D]]=VHO%G4!9*?Q1LNP!@'?8[%94.<
M(=5YS5&RS836-)CG2=5L5;HT@-HOG5I:L]I?15,[?=H;^5F*B=Q!7=M'E1OW
M3-NM11.TK=.(LM, #;/5[5ZFE%OOU9$@JA3?_=+R8=F5(-C'%4&-U5)Z3=%?
MG5+,S 3G\U6G=8G%)5_'Q1O(E=DYHY@;J%]@9=7/M*,8B#]E+26(I9AQ%-R_
M#- \95C1=5 _C1Q1"U\,#DK5S6"B#-(/U0RRY6 1WDGP'>&>)-7.L$P37F&<
MW& 6YLG-+.&F0.$7KN&5E&$;ILDS\@S/S6$?)DD7_F$A'F(B/D@<+F(D3F(E
M.EZX(%YB)WYB*&:>(XYB*JYB*X:3)KYB+=YB+N:1*>YB, YC,<Z.+!YC,SYC
0-.Z,+TYC-FYC-ZZ*@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img42979713_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $8 C<# 2(  A$! Q$!_\0
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M+>TM/.=+>!K?S/-5&*[G;((R0>!T'K38=5OKKQ1=64FIPV+03 164D )N(<
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MR)&8$@+C!) ]1C/>NQHIJO)6LEH)T8O=F?K-I)>::UO':6MVK$!X;EBJLOU
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M>&!;.4R[ 0"S(%W(H)'+ #FG>*-,?5]$>TCL;:]8R(XAN+AX%)5@00Z LI!
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M:PUS)#,LL<T;*1#*I?Y"K;SC"\8"KU.:W;"PMM+L(+&SC\JW@79&@.<"K-%
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MMW>3O&_'KMZXJ:G:P7N%%%%( HHHH A'_'W)_P!<U_FU9]: _P"/N3_KFO\
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M^1KL%^Z/I7-3_CS]%^IUU?\ =J?K+]!:***Z3D"BBB@#DF\%NWCX>)?[2DV
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M+;+L18I%E246@8'<N-OD_-ZYW<=.] '6T444 %9+?ZV7_KHW\ZUJR6_ULO\
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MR> ,_E[UI4441IQC)R6[!))W"BBBK&%%%% !4MM_KQ]#452VW^O'T- "R?\
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M **** "BBB@ HHHH **** "BBB@"$?\ 'W)_US7^;5GUH#_C[D_ZYK_-JSZ
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MI5L$>HJ]10!4O--M;ZP^Q31GR,  *<%<=,5)9V<-A:1VMNNV*,8 )R?6IZ*
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MT-/_ +/D_P"?G_R&*5+.6-MPN!D>L8_QH 9)_P >EM_N#^0J&IX[6:6U@S<
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MQEPJ"U.W(!'&"._4U7!O])BFU@PR3W$&H7,,B11,!(DN I"Y)QY@CYR<#<:
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M(+;3TQQ7H.JL6N/#XD):)KL%RR[26$,A7(['<!QZXH VV8*"6( '<TWSHO\
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MR  3Z @YK&TW7?$6G>#M(MVU76;?98W):;[#YTIOD*A+9@8R=N"3D\MTW<4
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MG@#TJ;5-'L[:U\62PZ9#'S$%:.W )0QIO P.1UR![T =X"& (((/<4%E! )
M)Z GK7+Z1\NJ7TV@6D?]F.D0V,6AB,N7WL@VG^'8#@8)[Y!K,+1S:L%N+.&Z
MU234F2:.ZMW9HX!)\C1-T51& V>A)]: .[# D@$$CJ,]*1W2-"[LJJ!DLQP
M*\WAMKZ)[G4Y+8)<7%G<W%LT$#+(S2R8"S'G=M#1[1QWXXJ:2VDTZ#4-(,,I
MM]+L)+6S9@2)?M! B4$]2-NSV_&@#T2BHX(S%;QQLVXHH4GUP*DH **** *N
MH?\ 'FWU'\Z*-0_X\V^H_G10!:HHHH **** "HXHS&&!.<L6_,U)10 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img42979713_14.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_14.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M9PIY-9PFD6<?'<>YD<6E$[PPKBN=0.IZTQH?E;5<-@R- 8=R;(IG6@$UF'/
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M-]]QWZU7W70KE(ZI]?_VB^]09C_L%LH6)8:,XE_[JSBUB37.&..+F?PX/\]
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MLV(Z4;]Z8K7_,F3O4:57-1^UTRQ+<F>!>*W1])QO%H,=N6L/FH9?ES3#6OK
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MW IU8T27/EUN);@Q(T&(914B-?MQ&<)]=N_BS:MW+]X;  !DTCOI;V"^>]$
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MPC*Y']&#&B*/SSBR:_5VQUD>60F5TD*FX^47(44,GP 3MF=2%A126T(,19N
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MS.-[:]T]UE\_'EX<]CW+T4QEW%LDGMM -MDLP^/?"]P;FKLX+B4$_HBF>BH
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M22^WX@>=;Q27BO(U+WR]_WQ%P?^3?HOK]%BM;WB %6QJQ\U^2(\C/O%.C](
M*XBF0TC-ZC"S?B,W",^4Z9:)  P#!U2F2)"3G*,C*[_6L3G IH;_Y(?U. !$
MA@V0D1SLL4\Y&B+W/9)7$(T $)OZ#I$^^1\BY6%S)/G$?TCR6<W\^Z)$#/B-
M 8^WGQ, R)K'#G&_V"&?D[W?#># ," 9FXC!E(V9EB&@0RC@];4:[>W#_!G
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MD)Q#S%U)\E<:.@0TT%]%&@!.U!U&Q!U%&,"FA%F!V.12X%JW0%^%"&)#8*"
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M4!S:\S7]/EI;-N=\+[V/9\..Z-FKK6KN9F6P>O/? _,SWB.) >  8O8DQH
MQ-X+ !SNRB0  Q>2GGK@EW]4)A-]&1RL;.SW0=OHIGW.>6F#0766VU:OV_#:
MI1M&D^%3Y_/\[VTC7?M^]T9_^/VMP!? O9A,2,HX0 RN-Y=, " &NP%%# R
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M:@=W.?;6+Q"W;P/6<1(K_L*"9R/B9VT% &8-0(X663*M+,*N<L7B_YJ6N\1
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MQ@P'SZR>8)JG/+>F93.FR]BKZGN@8]IS<QJ]_?JO"<+ANEN><CRQPW 5 0[
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M+@H'@ '_3,70XV@FKE9E4"ND:!-$10Z5&98]"7JBH;<1)E62!LH984(QV@4
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M&$UFD"'I@[?_'=TVO]6_O$!DF8SSXM8:UK]I?JA0AG0(E=RFF=\T\BX^Q22
MKU,S!1[62[9THFJK!KVL#C#$=HG@TA)LD>M(;"%(U%U?FLR@TP*JPE-^C'"\
M.J%E?O59I(3P:G$('(%ZY#+ZD[-2AP'&P[SS9@0:X2X_=-S1W1:XP^FG<^7X
M17#.=71>*U\,PU,D!_?)?;C4CG,K-]>=]?DZ8J'O?_YY&8I.=Y8P827DHJ>[
M1O\CVHGA 9JG#2H2L#!L)AS56]@N=)'PO+7(PNQ7/E?PRM5^]%LGLH]S,?S4
M_>&KSP2&6A&[!I_^U4Q6[W2:.AG$!0&M$+LGJVM2TTDQ-#[[U 3\B=RNR;XS
M38[<$A)5'!=MY/)5#FAY"6*IWMH09 'R<6N6E;?+URKP=B6"BI'S,?F33[XT
M#%0W$G=-!518NSVZ>X=I=E+SZ08 +AR!3$YF B%^68E_47:+0=[YSLIF)RI#
MG<^K[$!9RA%??I@C6XUY2]<=2B"_E]A<[A=[Q,(9;4W7P:;;I 79=$G^MG@?
MF7$6>;LY+ $]O7DQGT^?3"0J9!FGO=@Q*GLHVL\HZN__-]>9M'^4GFJ)!#HG
M;=T13/15KJ9C<7WG+"*]#9(9#GW$)6C@80S&G$\TU&V RI.[<N<3TQR&^-4X
M_="5IGFD::9(PLFD\(5 =:5 PM F9'U:M=DT[;M+]5M\]:F<U2:1&!M$((-Z
M=UF$LW.4ZYEEPYPDIQ1&(BA#W;%+3U2^I 01'][E8@?/<B!%):81(U/M%S(B
MBI66IH\H+Y2&$AT?D<_Q6_(KS""/,O2S!&_$(-LC/&]9-(]F,/*_W.6-77//
M+8+E[,D>I]P=SG3Y\Z&C(:M<"G5O$8&E$.W53Z^V- -4%GW"$/GB(BL %@Y&
M=;HW=?:S$K7%'E<U"6I6$:]F_TYN-3IP)"4WXX +\2&,!VN:97<*"&L&&%VN
M0V^<D8 X85L.@2BVU7:>)@;^Q74I&&NWMC(J\X(WD8-RD4'],1\7@V/LY3OV
MIQEBPW 7PBGCIWG\ 6YA!7K T79$P4T@ W#P9R82<84R.$'#-2GIP6./<6[^
MHQG4(S0D(G-H-7-X]VZ3<CDIDGM*<U-ZL2S^TG)I)2OVQ#(UPX00-V8LE";!
MI1@FYU3%U(<$]8?7(387-8C>AX845TO$QA*4N"/LH27M]S+9%&8MI3]AEB=9
M:!B%Y!XQ8D1H4&H4*&BZQ$8_)3W[=!VTTWG3%5+9]$Z71 Q3J#98TH1 TS ?
M@7B:4?\/"34<Z3%C,00L*=A6]T=4!>5V#S&,$A%$Q;AY'K4/T,!#M!-7EY$1
MN"0ZBL0D,B<Z?:89G)%Y(M$FSY1OI89 )Z42YX8PA#9]EU0LB)5-\LASJC<O
MVN$>\*$1=&99A 86S91)S0<<[L9M0)AC[A1N%^)A&O$AD^"05'9K93%A%<$2
M91<2?S61\S$D0A,NY?)2Q#5_;M%W^>)#6;AW!&D_#BE(2#@?P>4JQP%(F4!G
MHD<IC%A]PV98:N4?E_1QXX8Z(F< ,:)\FT5[Z#9E\R5U00F5M?.4DJA^SX64
MY<=, ! XHS-D;RAO!XA- O(;@])V'E:5[T=*/!25BD$_H>/_E-HS9S[7B@:1
M:UW13^'"/\=!)P<5?OW10+5%<OPS4R#Q=Q,B3V) ;Y.C@02T)_03 Y.08!<1
M(?_D>/14$[F6$1 G32_D0J3BEXB9:AL$-DGE0.93(Q'D>"WE*!AV0"$15]3T
M; -13UBU0GFT=B<B+_QS4YJ%:EP#,0>$B6X!1K\Q(Q11G'28A+]YD)*8->.T
M4YRG/W'Y4U18%EMF$*\)EW#"$^9X(0323OED5O6%/IC4>F(X.F/8FWD107AU
M<,'%;Q3!)/J2>Z93&%2"G.ZX-HN1GDFU'WN85AS1.U1I2B\4B'"H18A!-0:2
M8/YY,9!4E-_'/A)1H$RWGWK1.Y&#4FGXDD%%)F<1=%-1M0\K@%67\T(@VG+A
M632X\8.B87%"H3]+F:(Q*J,S2J,U:J,WBJ-.88BAH51#T:.(F*-!*J1#2J1%
M:J1'>AI4)!FWB3'EAJ3_3PJE42JE4TJE56JE5XJE6:JE6\JE7>JE7PJF82JF
M8TJF96JF9XJF::JF:\JF;>H8.VH4_P,9]!.<-D)W^V!>;JJG>\JG?>JGK_%.
M]Q%BG%D367,IX2$OK6D3BLI3:0*C;$-[*T02*(&; W1+?XJIF:JIF\JI^MF5
MA(9R-$0?+I$9FJB3(A$2BC4ASX1TD8,=F'@#\<AA&C()U:42T-6IN:JKN\JK
MO6H5R34V6&D<4<1V[!&".$%19C)1$<&D.\@3CU,EM4J76'.JOFJMUXJMV>JE
MM4H]]I$UPW:K%"DAYAB:-1%;Y(*5P])2?^(3X743.QJ#(.03%1&$&I&-$4&I
M1=JJKU(A!G5Z$_UJI)E0K?M*L#1*)X]%5!X!GIIQ$>OE4#VF#$"C$9=J)BIS
M$_9V0YBX1#J12@>3)^&7$PJ"$(:*.@KQJ/\%RQMYMBG#AAT8V1*5([!.NA:3
M "P .Q0 "YH^(;!_HV8+0S+$T+-?M!.71#TGJ;.#,[ HJ[34T5SOPR;:8GCH
M=9M=D:PKB*SIRC_=<XGFVF@X\6\Q$7\G:Q'F4XTQ1E^Y-GU+6QL9(GSMPA)"
M0PS^M2,8J2'YZCJR^A:J2!,V*Q1\JS-)VQ3*T+85TR.:I RXLR=B #'2FA0[
M*XUJ"[DTZH(-,6N3NFCD)78=H[(_-2@D"X86&RD&,KA.1(DB6J@?ZZ_E,Q^/
MV".90"W2VE"1FQN[:!&J$E$.5#$P@!TJ(P:J<KC]DB(WL(S!*CLYPIDR,2/$
M<%R<V1]OAB+\TRW_JHBA$M(?)"&GNT(2>BN]HE.T8-@V.QNS=?*/G=DF(31E
M<T6[N]@?/R5/VR,GU/,A=K)JR01/-Q6^$C226G2_\@9  KN^F,2/LBO M<$9
M_!5W=W6K$RF(_Q%C06@X1EM\<AFR;4LF-M&L.Y*Z_]E[\>HH+E.I UP;L<NU
M)Y(^<FN9X0,3 =0O836PA09 <442%+DKI086GW",#=&[(J@,NEL2-9M/;E([
MQ""X)S&+A2$&@#$),1QGJ4>X38*T+08=E$J[C^MI^&J9$YN^PP&POVNNU&*-
M.V&),V(B4;P1]NIH2?.-CMM_WVB1(.S&K"$VXR* <]5$Y(5^AJ)#$XNN_T8+
MIUYY$Z='E(4:MAG\5_-%,PS$EZ#[QJXQQ<PR7BHT>*BZ/5*B#"V%NVY[OF##
MQ7=;#[/8$.LY>1OF$2%!NRO@7R,U=]!@LS*<M2FW:7=[$)^AMW=[0!>BO.GS
M&;<,RR$*#5/UR5.4Q",HQ(4QQ(_;R.QC)]K($]^BPDZ\$F\UP\I5#X[+2(]K
MS32KP8NLS;%A.EZ6EA-!J@R;(H+A4S9[ _%WKE=KL6*2P[]DS6D%MS-AMT%T
M;F/YKZ@;2_\1$LSC2UG(N ?1$,V\S:\APC1!)K"C1KN[PCB"5;/L$<'9R/VZ
MP^GSR^9Z'9FQ(R?A$J[2'0[=+TB)!OEJLQR#D_\'$\,%,0EN\,SX%"BRU!V9
M8%1AH@PRS!\=F0F.NTM"'- +)HM)=5#$'+38P5/TL3HRG<06 0V.J[<PC<D'
M<1Q%-M!1?1H_<J"*2&V:@5Z"\3801E4JR+7A\79A.1 +FA W97E5S2^U7">=
M*4,[$B-E2$)20A$J<W^Y9K12'1K'S!$8+;3*$,ES"[PX8LEG9)&+-AQ<I4P'
M86$WO"OC=1Q#C-.^5KY ZZS2F!E]834/\1G5#,L@VR[7 ;ZK*]-V.X&H>MD_
ME=A<O+.;O! D031\K1-EA"^ZG-FCG*\-I<M,/<6Z[ ;'H<QX#=RD88)5X<!0
M,=Q(H1E5&]SH<D %@:N3C8T=FG!!T>.W,(-561-_#/E$/#S%$506NYAK8WLJ
M%81%?=&OVD,_&4$@$$,@W0&PU3S+F4T]D9<2M^RX1ZR.R%0F/[,^7)*^/-V+
MA)8=2*23=4DM=0EO3.TZE'-KQH1X;Y<2"DZS>2>VRVWAA]C&4&'&OYK!&*,2
M#'CA;ZS7J!%1(6[B?WK<4T$]55'244&GZI'=_R>^M*R=&M\HXS>.XSFNXSO.
MXSWNXS\.Y$$NY$-.Y$5NY$>.Y$FNY$O.Y$WNY$]>IAE.,"\-N##H+-6] G==
M%%+^'S83U#[+Y8P1V5G2X5!NYF<^&:,Y+!0WXA9<Y<_ZY>1"Y43QF+MLTF7#
M%!JZY1^<&)7,=EH>%#$ Z%?+6!XM8O#6UMOQQ$ XNFCNZ(_^&#=-PC7!!11'
MXU@1YLZLRT51W6&C(5F^%'IN+) 1XQ,1%:!^%*L%*-C,=EDG$<1J%&I\JND*
MZ;5NZ_J9>O81JR4;$?]3$.2C01N!S32;GQKT7E?E(&7R/[(H$VD;-Y#"U H>
M/L005Q,AN%H$L&@ &'C>[3JFXQ(&D$95?;?YV:V0,]\+)#NMO.*L9G7Y31 8
M12?:<>[&3N]<(A,%<>^[9#KBZA^;6,ETH@SPJT'?S7>:Y&<H@E'&J=_(I3I+
M-%?U(T0PTM4+,2EY QC-6Q."WA&P_1 >D^SOUCKC)$Q7X[\%0B=%Z.RWKO+_
M*W\7!<T1E3ZJZK%@H"T@,MS;=;<"%P]'4+P1I+TCRT [F5#J70PS<Q[S1_D0
MVK&S.&L?2Z]E)*'QP/';#PCB+JP,'JVA?%F_=C[+  L<7U\0)4W-AA(#Q"#M
MTC[% OO%3)=@RD$V2Z\2&0'#C\O%AGX0PVC0@*$08M_3U PH,2"2'_Y6)($I
M7N2WYB$EG-U.(ICW+B7O,Z&J5OQ-VH*[CGLS7G\PG\KRF\_Y:8&5NSYR,C/%
M?.M)"??K*F$UV[9R1;V.? @ ^K#)]'M#I)(0\FOTH<\T,HS?R[XKPV.]L%/;
MV%S&";K+%+G)$LU)P=,=$)=Z8^V&ZUD07Y_?UDAI_[P>\)R2&</H-48D<R6>
MT3#3$!G+U[3+Q?RV*V>4(M_S_7Z^^)1:_72I0MN(5=4,'%/,Z@>C';6M-1^#
MZD(+$/L$[B-V0^"D20)O$",F9N!"90;W97)(4:#%?9/0[+L!8. ^,9D^CB19
MTN1)E"E5KF39TN5+F#%ESJ19T^9-G#EU[N39T^=/H$&%#B5:U.C1?2M$FN2R
M=%\,D1'W*8LA,.1 CT^)'=R(T&JF>ED'8KSZ5-DDB2J605N!59G*&PFI3MS8
M\"/4J0:A><P*X*W%JU?]3G18UF(,97-+HEE*4>K7@X/%?A0;HZ#<JE;]EL4J
ML*] MOO0)"29*?/"BP :J__&.!* PWU[':+>EU7JX('0,A?T_'$2@*T'86<B
M;5KA5K$&I@)@_G:T2<0"E>^KEWF?FX19>6<D/5)9VX$:!4:?:GV@@>">WWY4
M_)RCLDP;QRO;;I&8?(Q>/4L4(Q_I?P #%'!  @LT\$ $$U1P008;=% @97 S
MZ0:G5GA+#(>(R<RXC SJ+SR1W+L*O8_B$PB-X#R:Q*$(Z5E&M8G,.PFO292S
MR,2!+ 1)HA@P5(^CPD)$[JT;"LL,1@/JJ6V]D<0X4J3!(OQ(,":QDLLC"C.:
M[CBT7.NM-@BKXG"D3 R*D$G]N"-FLH&V(\@@\K3ST+^IP)M+RBF=*O/$XLR4
M#,+_MCB+T:0DZSQOJ3_+.]$I96!#0R+AK)(O+I+(6[-*@;:;9"G$(E122L5,
MY!!'Q@;Z[K@'4U5U559;=?556&.5=59:3Q*#.>:RZXXC7#=E[H;,#  @H5N9
M\PQ7:,0C5:2PF!,3MK*BPU4&:!KM2$*4(@3@AK;L:FTBYIQ,;;W?7MNHU*O*
M_7"T<.<C"%=(12M6OC69VZK8S&Z-=Q\#BGVK7FYY?4TA7-_Z#$SJIBL6QAR=
M/0O7C""..%=M@:N8R!0SE6B%@NN9;KN.,&1N2^JR2I/C;9$+$]R"0<+5*;,2
M'JA9AN7DZJ-K9=QK,)1A>PA7+(%F5"+Q.-HJDY:WLZLV9=661JAB1#&M=6JJ
MJ[;Z:JRSUGIKKKNF6E"O#Z3-)?+ #ALGQ<Y6>VVVVW;[;;CCEGONDLRF6R@W
M6T*:.?#N?HD\OP,7?'#""S?\<,035WQQQAMW_''((Y=\<LHKM_QRS#/7?'/.
M_SOW_'/00Q=]=-)+-_UTU%-7?7766W?]==ACEWUVVFNW_7;<,<^;LJ&^%4I?
MEV4DD,T<I69I[ *1SWUYYIMW_OE9>X4..)RISU;X+U4".CV]?1Y*K*Q\)+-O
M[='&GM^5SC0:U>]74A[6W:&7?W[ZZ]<\DZB(5ZA(4V/ MJ3X92\ET<&32WP'
M%,6DS2: JXG^DF*\&:V'@4!QX$@F""L%VD^#&^1@!PMWJMKLRC( @,97"/BR
MR+R&/^U"F/;6XY>*2618]M*,N8XUL! RQS3&8@^N[B4QI@%G9S/4H7YZU9Y?
M>:9<(D'99(A(#&'U37HL$]?$)%(HJY"&>G,)FK'BDO^KCQ2$8P:C(7& B,*]
M#2N(!JD7^  0@[%]!PW-2>)RFN,R&K81)*2Y2I$&5BX9[JU,/ RB2 KB/X^T
M<1(5\V C'?E(2%8-D2>AD!BTR*\A+8<8>!*#040$)9989E!W04Y"]L2A'G%D
M*09("!S!1:Q=Z>@@_('3"Q5U2Q-QAC?Y:26+P$.\/\(H2TKQ3";4)P8;P<8K
M@)/*90B#,/)PP4\]E* MD6:5V:Q'ELOYDL<TQI&$7"HW:KS55D1I&_/LZ09,
M0H-\KB+-BRBSE6(B9T+6.9]CRH4_,(MD/_WY3X :2'TD@8B*'((8-X5D1=^\
M%AC%TD842H=O UF8P59FR7AOMO P;_'F,R%$LK$!@&;-Z:ABO(+%O."Q75O*
MR@1M0[1)["4\F_*91Q8V,#;Y)1.\$8-%U_=3P&VG8LW!B#*4 S2>22PK:01
M6W 31_#@*"1#]4@,([:>LO0Q.#<]: D[:A&DTD<B)JH/PP)Z5K2F_U6M.<%+
MI40"E164T"\))88;8#,7L%5P)#JB%(=0DY70M/,B&WFH0PH5*O]4YR[K88M,
M/Q*:+XF'F55Q3_&^Y-*5B6:1UL'.GA0%-@:&!$Z.S<H]W^.N;Y9L)$L[%;8^
MA#";4:::'YD.1ABC(0M&Q3K^V^.B3@L2?NH(LB;"5JA89)Y;07"MRV5N<P':
MTQ\1]&C;<M<62;@FA3AD$C+2*VW_Y9$]J2\K]#C *%>P$4KQZZUO,2YETM,E
MD#B$F/W+;*G:^J91GJ<SF/02?C/"1$018R]*$M<U::NDL?AH1;!I:7#BQ![K
MD&@L) 0)>G=U%0-'2:0XNQ*30$@6*%5)1]GBFX]Q(F3.]62"?/SZU(9FLZOZ
M^'(D[W-NC6U\8_M!38EW0=0JMU*QK>KP-"WK[D!$"<ZD_$IE^XB&"@BF&@:#
M,68(^];%!":1(5:EHQTU8JZVLS FVC)BYHFM>(:XE"5.9XXZG+*5EH.HU&#)
MP4QR4\6>=4:(95DS!DFC0YI5I/1T]#Z0:2.??P4G%CI+JP-9,XRB(^@H&^LQ
M2Q,66NJ(8TQG6M.;KO$!.?UI4(=:U*.NU:!)?6I4IUK5JV9UJUW]:EC'6M:S
MIG6M;7UK7.=:U[OF=:]]_6M@_P?[= $42G>)?: ,IN38PF9VLYW]O-^D1\(9
M\1E$&_VKH>ZJ)!DD<8)7@EV57!#"/RE+>F-2Y'&[!-W/9G>[W8TY *#!9]L4
M[$<K%9RPN/DDR_9V3HR]+YW8[27)1@F_O7.^=R=<X0MG7$,<RR\T^0R$LH60
M6*0D+%SYIR'7XA/+*(3"A6%S6UR&&-!0FRD?3D6:=]S;D=A<$"%7/(@V+5A9
M< 4;5K(YC?)AT[4RE/*-$S)GTKG5PKS'<*0G7>ET^U!;Z:UQ7.UV/05<TDE.
M#-R,N"$I)<QHAT[DH<S,!8IU Z6I*!PA:(BS2W%]B#;3KF'(/.1>2^DC:6*P
MD?-RT__LMXP4:"B\IK??BUBPX5_>8[/BI2=>\8OG6FRGO5![CV3:3D0P ,>J
M76+A9FGDJ4=;2M4;XO@&A8!K#4(E(J7DWM!>CU%ES,H%H\^72BP;O:Q2<<:D
MUD#D\EO_)N=)QGC@!U_XKV+JA@%7-(((3Y8%Q"[&I8Q+AU26MSBBC4S+,I?*
M<K+L73?:8_(]'J=6R4V9X,*=PB<2,6QUR71A<6_$5U7S'-FCW=_01K!X&_H.
M7__[YW^",*J0C;@O>=L[R0N. E*C?=N]T.L,3>&/C>",1-H2W*J-]:(X[%J3
MK8"OWC WOJN-+)E V',GD4@O8GHP##N8$_&9L/@N_[*( 7Q<BE::NG7K/QJL
M01NT"0J[B+9P/C-2,N$ACZ'B)Y)X#!-YCBEBLVOA#P/,EY&YLO6+L[-#)AXZ
M0HAA/9?YF91Y%[_XO(AB.S#9&=[*($2J"&1)*8\:PY,+F1M<0S9\;$,W?$,X
MC$,YG$,ZK$,[O$,\S$,]W$,^[$,__$- #$1!'$1"+$1#/$1$3+7[2D1&;$1'
M_)X[(HHW:A.AZ:&)P2&@ ;B(2B/V:IFG>+Y'#$51W,/_.[J?:!0),RJ!" L]
MJ0C8P(NR,0]BR)^2>8OM HF_J(JS6 [E&D5?_/_%->3 3Z2NJ@.3[^@(Y&"S
M8F$P;5,HV)C B>B;Z'A!C)H\X]&INY(0:!P/[@%&;_Q&&M26]7A!_L$-C]B+
MI<B2CL.ZDO +QRJ@=W2Q8GH@(Q-"XVB-#4M!2P1'?NS'_8L0@_!"WLA'C_B^
M%A(84!P+'M$M BR:UR,- V"2]QD,R*L-KAL[BO-'C=S(Q1,I+!I(6TJ;R1"X
M@>""3-2[4<(BWY$_Z\F1I:@W//$4#N-(FJS)=[,-FYJ45A*)WSB\>@P/@',-
MK@N+>L#("&%(?<Q(8*$FL[-%0W,-(;1)J9Q*7N-$@>B9..O)CK(C1TLY5AH+
M\[@!-!BJK6I%"[JY)@$DFH1XO:L$FH=!2[.B2KF<RSB<0;J\2[QT1$_+2[[L
>2[_\2\ ,%4S!'$S"+$S#/$S$3$S%7$S&%+6    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img42979713_15.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_15.gif
M1TE&.#EA[@3S ?<         ,P  9@  F0  S   _P K   K,P K9@ KF0 K
MS  K_P!5  !5,P!59@!5F0!5S !5_P"   " ,P" 9@" F0" S " _P"J  "J
M,P"J9@"JF0"JS "J_P#5  #5,P#59@#5F0#5S #5_P#_  #_,P#_9@#_F0#_
MS #__S,  #, ,S, 9C, F3, S#, _S,K #,K,S,K9C,KF3,KS#,K_S-5 #-5
M,S-59C-5F3-5S#-5_S.  #. ,S. 9C. F3. S#. _S.J #.J,S.J9C.JF3.J
MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MV#O32)SR8YSY0V955YVD<YW@,YZY69[<.9W>J9[AV)R?.)SO&9U3AYZH0Y_
MF1_929[Z>9S4.6S_:9^7** 8LI]LEIP&RI[B.8S$:6JI\2B!=$!M5:$:I4.R
M59<!55L'E53^9&+*E9<IM7[8U%7@AGMIR4_1YTU9Q:%\Y:%%M5ZM=W\ 14&:
M93^+4U6HE5 #E4__HULWY%>B]'R=]%8DZEA;>:+_LCE+*@I=<^FBW@>C]22C
M?Y58-:I9-[I0.7I=6RE3/ZI.436D?(4_1CI(2!HS2EI<39I3* JE%[6B@#6E
M4_6BH!2CV_5"B%5(D-.E-Z6CDQ6F(#6FC;159MI7ZT51(+I*;3I>;SI4<0HS
M44I>=@I36@JDA12F*3@0*A19M>58&KJFTS:B$V1<?;IYR_<_.7H_T=6C:)5^
M@56F+.1;:0ITPJ>H2OI#V"6J!V5_E"569%>GMK-6M2=:2H5F'=H[3_6GMA6H
MKFI=L)I0LDI%0EJKZW6KZ_E13S2BO(I:OFI@&EI ]S2LWB58!76LKY6LIZI=
MJ5IUJPJM O2J2U6M 72M_RN8K3A%J@/DK4O4JU(%K&E4KOYSKDYU?,=E8)@X
MH\28$Y\X&IN7$['$,</HL%P'L<R3$P49,N[T/@][&0HKL<A$L7(Z=0X4L1DS
MCQ2K9A;K$ZX1LC13D"73L3;A=A!;K"F[2"M;22V[63Z!6)!4-!U+,Q^;>3HQ
ML1E3LEZ'L:BCL2J;,2QK$Y_XLJWS/C+K,C1;=%GJ>/.T2SL[4'#'M$"[L5!+
MJ43;$\$1LC:!M.)DL8O$M$8J,\('BST[JS ;M#.+2CEALXW!M4ZKLV4+MM I
MMJX2M!RKMV?K$VE;M6L[LF7+K0.T/[298C]+3QJ#6@\D6$_'5/-EN1P#@3K1
M6?_%)JF5\RF7BWNA>RF;2U% Y[DQJUN92Y02R[JE:Z$KZW:.8SL^L4LZJDJ8
M*S^"-72<FSF>N[:PZ["/,KJQ1$&_Y',MJW6<2SJNBT E%[RS6Y!#*C/KE;I<
MN[N01T\>\[M2*[NO6Y K*C.@B[P*2TO(Q+S:B[K/6W316QG3B[G[8[W&B[VI
M<KJX"ZNC:TR]&[['.[Z;!TL:TX[4-1L)_%46<H @]:N?14$>91G>Q53I"EHZ
ME%&Y85PY=5"YY1MRI1K1-574"EP4Y%(4O%Y%M5"PU:WT!!O8]<#B*EP2K"H4
M7%L6O&*N!VZ[5"B:$ ,!< /PFWM5YURL2BG#,<*O)V/_J77" I7"FK7"N,I;
M_?K")0J=WW=;Y&K#+ J<X]<XLY7!M$0,F1  !R &SDO$J&/$#)S$UD7"3+S
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M,X(SP+Z$]2L3!<XLM%*&YIC"$!O5+2Q#$5^W?C.0- "N7BO92/"4D8:AX*!
MY<K$\40&$CXNA24'T6,AB4>0[PWN)54AQDO$$$B?T%%#/KG!Z8!C@)%<S"O
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MQF\\QW>\K?NZQX?_O,B//,E#NL27/,JGO,JO_)LC.\N_?*PK0P#$RF%<>*0
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MPX:3!CJ4.)%B18L7,6;4N)%C1X\?0884.9)D29,G4:94N9)E2Y<8T;R46?&
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MW),R>;TKNOHDE0"(=29O-&D2&;H,K[+TKW(ZJDAP<X!"A08P FWLTS01AC"
MRW3* !A&Z%HBNUYV5805R3#0<"$Q^-20I$4=.-I1P(KTR8P22:R)]NG:4_F5
M+B*:L!#^Q+!6IUA6M^FJ+4+<\0VB*?0@)MUC:$>T#.@6MU2//0DTHJK3- B7
MH]3_/5IW!N(<9=Q &=)@[/,>1EN,<!6WK/6NEU#$E+W:Y@#V[*KGWKLSNHEA
M81'!P0HR80L_*%8LN6V()N0%6N(":)WYC11O-S*KN*C@4O<UI8-U1HRXE*P\
M6H&!6UP12:APT[-[O&V)O(GA/5GW)9KP2G_LJ&*/@0( D]EI8MR!BI=ND;G[
M,"F!+;(F$Q7/O3*^65699V2)=8=8WL(-0[#AP:>\L4^(G020&[5@)3,)PIK1
M\I9UU;T(\B:/##D'(7;,5M,Y5\$K&BV8R?3ED#QY(ESCKDRZ#&<YV08-OCT
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M!*\AI.P@B'3$'F8(F6TO!41CQ#$-8I,?$0(:QJ ^UY,D+C1+F6)#6P(<RJ[
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M=4Y=(CZA5AB<)W((?\L<*D2YWTM">_<AIDH&(E)K.)[V5">BRI MBQN"IEG
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M-$PR'-"=:9,<$$-5?3&\=MYZ[[UM)A-#[7%#RD:41@R[IL%L8K<R1,E/+."
MZT7*+*,,,<JH+9+5>NYS5>3!=@TEV6/5E#C?#??L58ETY[5"BG4?I.J+IL].
M>^U03G+>0HLRE(9G$,TJ ^3 D;X3#OXA 'IIC<_6^5K+L%JIC!9G96>LM@O,
MR-EB1!9#FZ1MF!CJUX]/?L0'2-<H=GXS9#9$-6&.D'X(($5T84TJI'7'TU.'
M[GV]E_Z5F)D*6%.J4?F\U;;!@$-,!VR@ [^E"1C_%$53^ZN()@"PEX,<(  &
MX&  NK3!#OY-(4I32/,@8B>)A.8^ -Q')G(P!C'DH((C.6& <, Q&8SP.E;S
M3_ "AY:M)"]$_6(+@QZX+?$]3(E(;*(3K:2, %2%&#$ A4=B$)D;("0&2H2;
M0#(QK8BL;R&1HI'U8H2#78W,A)/ P1BH]I7%Q6\2.0*0AU*VJS&T,"LOJY0
MIS0)SSV13#K#6?T2$HUZ0*,>9QRD(Q^)F!M$IBX'4$&* '!)+U($+LK8'D("
M(#XT9% @DA1C[DS8,H<<\B#"HDI#TE"H I9.5Z(98G#<)3RU%*A4[5,+I2!9
MJ00.C(D)B6$.Q$!#8"ISL9DE2</VL+@Z+$(32Q;!@18/PD6%Q.!:!AG# 2)"
MB1WNXS16A C&]I@K0.42?^(4ROT.DH8<C0%^!^KD5,:03)'\D53[3(NRT,G,
M#Q%S8*L\2#1.LXQ&!G2A#*VA ?(I$4]JD)H:+&0F5/";3# B#9*81!C$:4.%
MU.,[<"S>3U:FD'ZB):2UV=A/($H=(.50!CG(!$!!TJAV6JD^ITP+P!I:I8*"
M)&YSR<Y *88?H"IUJ?\=@<8D;/81:R(DFA02""@/PAC:4$X97"6@0LI(DQR<
M5*BR41*N>L<6.0I$'\(20!J@*J)X(NHGFKEI1U3Z*-%]A1*4@"M3/411=QY
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M"!+U(8Q(1'V_)RQ:N=2''+$,5X%[0?*+,6B+,-&,ZC53,V0I"7(V&4,JI]A
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MAN-T5R<A1#WPY#Y(J9R.6)F"QI+ZZ=PT%O$\CC(Q$S,]TZ#:&:"Z"J.6CN-
M2PH2!$7H1Y]"ZGB]*7<X:J8R"1K<DT6@J8YZJI9U*F;$::E"2/P9Q#&!5R.H
M&5+(:JRN6:UF J)I J(AQ:W6&*+=JB;P:J+AJJ\. [#ZZJX6:[ B:Z\^1;(>
M:[,RZZ\J*[2JV; VJ[':JK5*Z[/R:JY>Z[0Z:[9&:[@*Z[AB:[EZ:[6:Z[1V
M*[&>Z[*F*[DBA;Q":[S_OFN]NBN[:BNRWFN[?BNW:BN]@NNZ BS!BJN]LBN\
MYFO!(BS#+FRT*NR_'NS#HNO"]FO 7JS!5FRM8JR^:FS$;BO'-NQ3>.8LX4D!
M,E,:2 (:I $:H$&TN2S*HD$!LNS*%F#+VFS+OBP:C('+OBS]^*RBNJS*SBS+
M[JP8Z.S*]JS+1AO-?DG1UFS1XNS,)BW/^FS3!BW4$NW-'FW5+NW/.JW01BW7
MYBS36BW3 JW+BNW6&FW9[NS78JW::JW-MBW5FBW<INW3TJPS^6P:,$+?HL'?
M&FW@#F[@ZJS+-H+/LJS@&JW@ZNS?'BXC'"X:)&[?,F[+.J[+0J[/2J[B5N[0
M_UXNX0[NYFKNY'[NX@)NYA)NY)JNXOIMZ@ZMYA9NY_KLZ;YN[*HNZ1JNY_;M
MWL8NSZ8J!QWJ0.Q3:[T1-.PJR2JOQB5:\C*K3NU3M-98L )KMY)LLCY%KNJ4
M))QK]>+J]5:OK6:OKTZOKWHOL *K,PEK^";:^))L]]8K^"IO\HH!][:O],*O
M]7XKR3IONN8J_:SO_"IONI9O]L;O_HIO_0)K_Y)O_GXO M^O_RY3480O [\O
M]1ZPM/+O!>\JTO*K +]O V.P_FJP^*HO_H[P Y=P!(OP R\>MH8O]HHO"IMO
M!LOP"7OO]$*P!1MP#9-P!R_$#@]P"QLP"<MPHD%O"=(O\&2Z1&VBB3XL@S+0
M0^'HZ11'\133QU&@ 3TLPQ0K0Q=+<12#,1<7#A>3<1A[<1>#\1=/,1F/<12C
M,1R;<>&H<1JWL1C?<1FKL1[;\1J_,1N',1_+L1_/,2"[<1[',1_3<2'_\1\G
M,AHO,B$'LB.;\2#WL3(,0WY(\1<K0Q5S\A3KZ15W<C[IJ9Y2\29'L2>+<BAO
MLBF/LBNK\BA;<2M_\BB?,BRCLBS7,BN#,BG;LBZG<B[W\BK[,B[/<BP/,RW?
MLB\?LS"/,C$O\RE+@L'1,A;_VX8B]L<%=8E+(!<QH$%ZI =R<4@WD?- E+-
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# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img42979713_16.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_16.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MD?(8$N\SB79?;T?TQ.&Y*\9Z9VOGM=0XU$/0>DH75''8?Y7_/')%>E?U,$%
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MM)]KTSE1V0X!#;.)FL5-+[*M([2=U+EMQ-\=%+O=S[9<$\\MV=B]$GE]$9F
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M.EX84<[GW,B7H,Z6.-[A29X1> X5+XW$KWX_EHX0T>T2C%S)E(W/.5WE'Z'
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M4#_:0,,S:(!61XC_L9EI5:LBHI(?AU25AH&D2FM=,\UIVE$UI(Q,(N][2L9
MUKZ4V.@SJWM?R33(,N310W6L@Y__IE0WO61B0/K[BW0^<L,8\K"'/J0+A0($
M'>(L)P P $GB$+*XVRUD;"F!7H=^5!:0$>0TR<A>]E)2,O1E3ACN@&!$SD<3
MJH"Q(R1R!R\VLSZ$E&]/:DSC#R7$Q)O4L$(+6M* [AC'/?*QCRN91( 0QJCB
M9&(8FA #PSC4F&4L#2-B%%,]-*,Q"_Z(4&K@!4&\,PSN(>1J8_$B)SFB#R#9
MQ(5-08J/9&6KA)#1@S#<TU;\V* !LH4Y:)@.('4BF.DL1X^R_"4P@]F0N7L5
M:#D).\ZS*((RC5EO:HV9%GN.AY'MT8,QPV!'VKAVFGE4K4=3+"-&.M,0Y8UE
MA!<9%S@SHH_QH<IR,E,7[?9QCCG*KI-P%.9Q9DB7C_C$( G2YU_VAL^!$O27
M2#Q(@F@IFX51!'KF^")2.G00-?Q@<A)AIT,L=[EL<JTKH\IB0E(ED%6^Y'T0
M(:<YT!/*BFPQ)BV*E59(.@R2Q@Y=4W.9,-RUE0X6]# *3<M'C+8/ /U4+[GK
M*5*3_^H_YAB&J403JBL1XCIE? HCI3&G0;9G3;%0;RN> ZG[V%23EC9D'B#S
M8CK;B!(GON1[+64;:4R#R7<R!*[JNZ=2=]D7YHAA.G6<(UWRE]?!$O9O"5J!
M&-# G'X>;D,4T4<ON,>VQ360(E11%5?"9CEF;FYS59P'/7@:$7I([D18;<AI
M/HE1B(ASK#89QCE2JI!:+<1RVQ-MKEYI$'2UK+!\ >A;ZFA#VNS,M\8]+L#N
M-2# _@5X%2F-5(-2)N,U=&O>H^2/:F6YY%74M5+C5DHAR%:7M#(S/MK1&B]2
MSY#*%KDT],NR K0"7P9FONZ]+WZ+E0DQX$ 2U#T.XIZK1O_X@$('T?2@5KQF
M76%L,YTG50-S._(NJWHRI?%$B*M,6"X+\O2T%4D&[5*9W[=$>";*\,QT#*<S
M^HZXQ2Z&D&Y*')BB640?IG3C/D!4V9,R<RNQ-<= 0FN>'%BT)1GFB#NZN%HV
M.KC&5_4.)KN"R=E>>"(F70@:=?MBFA1U)P&2,5[ZM>4QDYD_S.GR+IUC !E(
M+87MB,:G_EM;E-:(JYEK<D,A3!,;GR2U%B95:RN38-.T2WO[T-[S-(J>45VO
M0U?S;/4*%=(JGS2U8TJ(/F*+YS)3!+AL 9"GX7LD +&8TZ8^=5^""N:]3$(W
M,4@D2TG3#F)4E2%6TUH:R[9.#.ZBF<C>/0E*T</3\:Z$6]G4X*@<C;F.F8/9
MJ>(H);L:V[3%UF->Z^"E,Z)LC:6G-,1&]4A6_9(Z"HX8F<B$N%_4Z@0Y%MSN
M?O=;"@82 *C@F,:A\7-OW*''A =ZUL9D>O?!CG0_5\^9 9M*UME%(6>5E"+1
MGN6Z>;EG*]BZH]-<USB:P8W72KL:K5SL?-05NNY#8]OJ+;Q/0O"5W*Q": [L
M#E,N__.9MT1H.4,F A^;PF&4*4CK?/2JEJR^33]V#*&H"2]PNYC,$61[8OEV
M5A.-["AB+6V9Z^I8IMT+U0+%XQH]]*NV]]TZUY;2R:L1T6D>ZK34PP Q6(';
MY[UV@I6:YG:_>T8R8>YS\UWI"X6UE5-D$*!,PL#KC.WF KX0E+MD>&6RTX%+
MA7"7A'"NUDU&)*E6*\ZFK8)8IR+'/6ZHTE@W[1"9D^)5(A;3R_SE-=E( ?<1
M>^+6'>^VO[U"H"$X@YS;0<YM*/PJF 8@J$I5V+.(T%6R#&5HPI"@*/)*'%[2
MIP.9BI^GHD<S"%K+&=II#@NOV=($XIF@2VZXK\C*1Y()^__6XTC'$?/YXR__
M@V2H:B"IQT9.K.+B!+BAJB-]+WP*!JW41$"=2F0;E-&$L2E8YW3(]MT42I@#
M ;H$XZ%/;&R8V<W?/LS=3-20 00.2/ =WZ6?3!27!I[@W15,3@#  :A "^:$
MZ_4%OL4:NK##)+A&!5)$\JT$=/U:3)C5H&7@2$C?MJ2)ZY"/^:$@0W"@=P2
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MQB$T2HC>!:5O1,,A4@0^>B12^B$T, ( 1,T&PIU@'<3ZN5V[/80_2@T[N$,
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MRT,  3' 3Y(57K5TI5%L*)6TB"8B(WF<Y3X0PSQ\4=6DQ5A0Z7T!IU4!0&_
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MEDP&_U('<\18*J (/R(I:F -J\1'P,"I,!5BWH:L#A(5^XSUQBN%Z$:6,$N
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M3[U/8EM/A!RV7X1P2Y;Y<67[18#$1Z3P:P:N!C%P"9Q^NZ2 UZIX4+ K(0!
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M;_VP1-TA2F@?#L \O 4Q"OO;ATK$B2B55STBDIW=LX+9_3?<(V)O:"P,M-0
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MB+LG3>R)MLIES7*Y:Q!_&L1"PIT40?9)7?(2N"#(,H@!F(N@_;)K3 RN_U^
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MEAM!&<(;;M(W_S\T_##/S)_5IP).[[]XPB@TE8B([$]N0>GK*852Q06JWA$
MY?$),QU_8C-K_&!2S1.$6R00):/IGA%B_ZS\Q,L> =Y7%H!"M04XT-]6,RD
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M^&"$$U:X44P71E2PQ;9M"10 AJF*70N)=0L K[:DJ=V1%NO68XDH'%",%6+
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MGVH2I5HQOGF>M;"89<BS*Y.S%FVV06V(R^ W QPKV>$XR%J(: "MM8&>FS(
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(WSK7J1X0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img42979713_17.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_17.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M]F/4I*%TGABQZ>0%N!)VZ+DWAGWQV3<?>P>F,9^!#!J87X,()N@@?/QI<IV
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M*9,?OS=B"W59"?=Y'\9A>:1O!L%M<Y1L@75MWJ1!,/940(!S0!!<7R9UL^2
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MX4G\ C"<8B )R6?+ #GEZ29I(V_C]WD)I87Y$PRYBJ8#D0PK4*9/Q X"(+3
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MRK;;> I?C@F+_57-# J@%]F&PIB8%BG1O@4$U%9S7CE1;Q"6',50_SF%^W;
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MR/0TH,(\B=9(NQ+5(V;9NOW/J>;1=A  ['YL\3[I?9@'<$YF"Y@)%X\&78"
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MT3[L5Q$JW53\!RU*R+BYJ)4J&'!0C7\&JNHTX;!&4H=>1+OIR!AF$I& 2+^
M4-L$J;:2D. =C& %HY98$(+%D0*>).&T%3PJ*;01D_:T:Y\=QO 4U?C D(W
M'F&85A=@!W]]"U:4D;.:ID^^;)5ZXJ4^: 7:$73HP^Z9(Y;<")-*DNN,JXB&
MJ]-HR*R):!ZMEUXQI"_]F[,:W%R]1Y=4"C*^B &5;#91@HN!ET%X"=FJ+0-"
MD81N9M"!K45@%<3__)MT1!Q55BRT5"S2I=:$Z8>B2-X+G5TY=91M.EG\!,HZ
MX9&C44:J[I(2]=O,7@^EL4I<I0>NH.=XQLI.2B#$MLN],,CJ+.0"RLS5--.D
M6)>B?LHPRFW:M ;A[6?A61ODGB8,<0FF9")A"&Y")=//_M&*@ES5T*R"8LK9
M"<I-B".W%.&PX%TB<J.XH)2?S=E)5E! 55")AE)_G:*C^&LLG2JY,6&\-%F?
MZLA55EJY==7"0EK._AR2\4[9")H:@"#OI@WR5,I*"01*@ _R(HFJC!3QXI1-
MR2L4UF)HUJ6R/4TTN8LL!@8E$&&JR8F E9&PTIJ26<B@DB<<B:T"%M@._YD+
M]HJ>^\V 3R20G\IK1^5+\0&',P+B,*WI9S4(N"YBBF$2<DCI!HYG =-GV0@$
MR0XPP7"3240Q:41Q@Q5J_NC,VF4C:@[Q7-'1\U"KO$[7Q*U.^?TP7^*:ODG%
MQ6T5:;8Q9[G3UK(ML7E4Y2F73*2JE>''+5W%L1(<G]Q$G5F4''L/I&EF7?&P
MXFHMF48G*CWMA/ +RL4(2/B.$Y.0M0:O0*"D*XJ8.2'9"*-4N!59["3ASWD(
M%>6*H)Q2KM"N:.TI6'$'L!!EP^1KI3G&V?6A9KH+F"4)W&6-0$05$'[;#P>H
M+.9/"ZZ*Q!Y0#D87&P=5VEEO!+?L]@ EJCB&__^"$%EF:R5K2HVEP7Q.RFB8
M1']&3=A^8S$KV,KVY(+P31M%*7L.DXW"XM2-&-2ND[W=TBDF$< XS./V1<G0
M*H.TL#B16:U%:RKECM.Q650MX)D>!:PI4I^F$R%GC7'FCA@J2R [FT/73>-I
MTMZZQPJ.)'(&CTGX#@@)\#9K"AYZ(+4A8*4QQT/?T\6*UG8:6?/9H-,^AJ!D
M-"KGR[_U'S0)E'744ER,73I'2(RU$J5QT4NS+!C&S]EE]#Y<)\L4[<\ 1<34
MM,/@7, NFRJ510N?$@Z*[? FR,/\H;H6'&,@C+5^! JFM,#@)S8O<8DU-5TI
M,XGE794ZYIX*,3TA\MC_5AW&&LI-(,C.(L8]4TG\Y<!]58@*DQD3_BV?^HFK
M<<U:Y4LZT8>JEN-^9%0:KIS[N@Y(2I)YS?1'Q] 2;O32PJ^Y B):=-!1>!LP
M7NNWPC7!>%NHI"S"4,)N-@7=Q%6$$(=HBS6>*(VJB">], 7FKA=RJ^&;D3(3
M%MR76$>IH9Y=A MEA-K5"8Z[I9$L[B#+RLK^#(NPY&-7<"]Z>)G$]0V36&KL
M^-*"!9UQ_1DJ27-HP18LF7'>O:O:XN>BK90VV_9JU!AKDH9!:)=QLK'2HAM#
M!V1([I\B1K 6P2M\A52M&9R2B&,5/AV4.$\+^@62#='D_2,[38QZF;!'3L;M
M_Z'OO2V)\8J:9VH$((,4]OPTFH;/0967.U+6QT'03DYCI1E,?([(0 2X@+/&
MPI#@[>[S$G;Q;3)0>[?C^$9IU@'=[)@*5*+*T3V&2<GL38!-Y3RBO=KK+<48
MSPJ;I3H(DVW-,(68),&>Y_C(=>X;:G4%4] <:7:>8\":>.;H;K91&8H6Y*VE
M]VQL ]JIS1IBD27JRTUQRATYIW 3V< <MZ7!SFZ1?]K$[1P)I-1,B6=4NJ)E
MY$TIUCJ3/&DC823D)CD&]I*COHU4R#Q'+KHVIQVQK'Z6<1B&9B$<&O.7+CEW
MJ=.3?-]B+YNX<SGYAI[D)POTCDK'NZZ;>\_T]C59\/^,A+>^-:2GR-[Y#B93
MU;!I,7Z-Y[C:D8KI-U&E7\22^J>E>NT@$Y-6^(8,-7D#T%88VF0!ZL@\KHX'
M-WYC$HTK>D[<,^@!"U4,3U%0D9:W+T4/I$LFWLU1G!;_ZB$R(=XR(V99%)&"
MEQJ$LT 8>;9S!-5^4]T>1']24I@\$W%TD#!!]@M&9]YA$%J.7/24"0N6*8%8
M+&*L[GXED;V2(QE!($1@.4C_=8[.$Z9D3\Y?[ WR"0"BEI7<%;QQ4-50[OKU
MX*P<O&5%:T7#T;#FF0YBW/V8;?+JR0VJQ,E64Z@$\,>KR#)X:^&!1@*/-8[W
M9+DJ_2)M7K*Q\ZPSG[ERGO/_JM_.O'2X+BZP$#71/.\F>M:P"\BTNFR]T)XH
M$W=#X/$I>L>4B&IS#/K7'I00N:I-5^J1P9UOH!&#TMEPK&2L9^TD*4-)B^R^
M-/':JP7O] M-^HOLPNIX%K.)A6&EA2B7*YE%**+YW7?08\I*HH70_A< ;D54
M7WUDPR6-DU?P=S>>D%KHW1)V2&$7W_CE+4N$F/ L!O\B)]L.VT3:_D0.@>?<
M6<YB*4SPP'[L<P3=!H\<^E%E-5M1A;3]/ 4B%A] 1-LW<)] @OH(#ERF3!DQ
M9<OH#=07K1[">@;K,70(T6!!@O4&THO6D.'#A,H&0ML'<M]"APX14LK192:.
M+C-R_\P8(X/F#$W+5 [LF##:PF4.42;4QQ)ARZ,EEPT$:5'J/GT+29H4NG6B
M0H9C<-X$&S:'C)DSKKY\R#):TX(L,S(LQE!IP8@$C99D*[&@VX<O@:ZLZK;J
MOKLKFR9%*)!EPH.#AP[=%Y0@94ICQI#!O#ESYDE1'8<6/9IT:=.G4:=6;3J-
MYLPYU&PFDV:,)KP6!2[]6%<PP<-6AS:5O!OQ2L9OE6E*HTD-\TP_>R>DIXEZ
M<S7/-25E&?0H<^:3J&OZW3AY)DIPSE,G!D>&SADTX>-T#UX3L8]7K=8CIFD2
MG/Z4J-/.(X6(><XZ^I+*C:#D-#G/P?I48NFNC/AC;HR:W/\#:Z8-<VC0N^6R
MNV_!Y,[[+\#"%MR/DC0H:8ZZ"7=CD)(W2JS/H!M!NO$CRA*:BJ^I+G*KK<(J
M$HPJXPC;1Q/,:(MM#"?3R(&,)%>KTLHKL<S2L65HTXPVS&;;S+;0".OJQP$=
M:ZNQ918S4D*^)N/-*NJ6 Q"\YL +RB 2_5.NP3IM:PJD\JZCQ$#PX+#/*H*H
M Q!/_IK#; :;<L(0++#J?([-A):ATT-##56#&![W42:3YI:C#T1%R;.S0O#^
M2RJA1OL<XZ8-P[(IK!G H]&\/L5#,SE4&S2/1AL=4\91[,P[M;ZM!O(01%#1
M"S&_@X ,K3&/6 )-,K@2(G4X</?_ 05,SG+H##-%M6S7W7??58;)SK[LC Q9
M(Z*(R/R"6RE"%(OL3;BM+BJ,(HZ4+=3/0IT5#Z*%/ 4PU :/7:8>:.JISD,:
M^[R.NHL@HJX_6*LU[])<>P(+!YVN>]1BC),#<63TJDV#F(?I41:."FL$$,12
MHYF.V*%Y?D@D$IV=4<.;Q'BOTBY6?K+81SU^>!\5S5MXZN<R"MG/_Y;#<^=1
MZZ&GT^?N;!B\Y>R+ZLC*B+*(RD7!'5*H(ED2<** ^U*(22E;HZW+VN MW/##
M35-&,]<V@W(,;T4SL\?CXB9HN+<D:HRPNS ^6]IB'YP$P*B&5=5//PW5!!2S
MD9[X3DW,>@.0+M@5!C'L)7,:2W>G;TK5N9\>XCGI9A76Y.)EJ#[UU__, Z6>
MC$6./O7^_%2FGN[J/!:LIC>4 :R4?4J;8HDUH6A89S.=&$#;(':T6 _!FY&2
MAZ(IT#KA>_[);&@QDDHWKD#RKT4-"2YS>\RVB+./V#!.-F.@#240_Q=!"1IN
M20Y\TFMDDX;=Z$: AE'0HD3$%!\%*3K8DHK=5J*,^I6H9,TQ5GHF\9?4*<QU
MZ)%=I\+F+.:Q$#P4DMBQY%>A"XDE5V1AV;( 9)_JZ% 3-(M?GX+W*U UJ$\3
MRTZG_N,?FCDH:\L9"1?M!(>EY0YE8>'8ZT)E'H9$KT)^0L\+,P$QAK5,:_$3
MS[ JE$.QG2YHF;M62HB"P+T@$$TM"<E'AK(IOM'C,DW"C),Z X<)3I*25[J,
MNN85)@B",#3Z(DZ.*C*4@CEF6[B!%E%6@D70Z;!::Z/.,I9'Q1WR!PZG<HBK
MID@M.ZI!&9OXS[&JR+$TW&I2\+$4KWSEL__LP"Z,-7I=PW1&LO-TT3O]<<@.
M^P2K\34H.21#W1!W=18RYB"7+_3.,I5)QXG5*5'+2%MSINA*]+RA4\T4WJ-
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M6M8"8UXO),'JT]3Q*J0GT(HI Z\*0QH,K3*A*5%"VAP,6#[C*JYG/?;-!.'
M:*)"Z?2Q4';F(IXGO>"&UBBNR9",D CI&0,O/[KPHM3%)F\R_JS,OI81L,9
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ME).QQ@#J*I/)%RQ'-R98ZK2GP^5IP# G,<ULPC3 00[C]"%+U3")ME8R3)_
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MN-J:/5Q,-EPSU684QN14!>-MCN9&L6-S+5;Z R:</(VB"IE:MA<GV9R<1 R
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M#)R>)DA+#N1 &CR$BJHF@^:*<<"%)F1"<N#6),B KL+JC:I992C#KF[IL\8
M(PC8)$P+L*8!+7''S/WEX@375/*2G (8RZ%2G8 4.75,X4$=J_ 08WH3>>3
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M?BZO)O0M\F98I.%4X1%#Q\)'$0,K#N0GQ@HORS(B5M$##I-P# AHQZ:P0^!
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M6YH-69FE.VYI%W?_5[H/.8&K-65A-JLGE5DJC*3')U6LT2"[,(26LP\E^%Z
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M QF3 C9$3$8<169@ND5):T@U,?4]1I(OX382%085\S W+\=J#*15YXB40*5
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MNSF^RXDL);Y'I[&O^CAV-:UBK)+%.\+\=S0V+**?R*0GLFGV"<FLO(+18(4
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;-=(C1=(D5=(E9=(F==(GA=(HE=(I7:N    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img42979713_18.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_18.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MPV.(Y9 &,3&MBEBKKP(UB0R3J#0)9JY^B:E%8B"0:TB@'):1,F,\5BM!8^"
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ME$C?AB.[$H$)Y)-_A))AN$4=:)7C-8-&=Q#%IQ#9Q#^EUCT?4Y&UET()D@9
M5VELEX%.-RSA D?59A#UH'))$8MJ_V1]3L& ?,<HW6B0YD,,X01Q/%DMDR!=
MOT.5>*21E0)KH@%0R018@QDA(;4/A7B34U<0.LET1RE%$E5I09F"+VD0%>9P
MF.@8G:(HY/)STD,,L?4&)+917/1:\Q9LG0F6:--H?H5= R<0=&E@>..20JE*
M@1EEP7D0TH9F]N=&/Z-O'R1V$OAM>S<E%REI.TAOJ\*/3D<XNB2(G6*36">
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M-W#M0=X ,YQ2\I?T(DU:]Y&&T 28)?A\""01XEPM1A$B., /( T26IC,_]+
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MU0J0Q:1TS20I1+1Q%W=&"'@^A7>BQ6;NQ=68XSHVEDGH9&DNR+TDI6&(H$9
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MMFZLMW2LM7YLM3ID0Y8L]&A4N6(LLEH5&H!KMJAK,BGKQ1[DR1K7:Z100P5
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M^'O[M1=QS/-&/O/$A[4(^-^1/U[=F'N%W&;HKQ?:Y]<+31E\\DIZ[KD #@!
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MI4']CA7I[?TLPDF2D4*'TD#7D;_H 0<"H"MR8JD \B>G;QF"PCADH@T+0AD
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M*%*"+&_E..!IL!9@S?[!:M7>V4(ZOE*$T+?\[QXJZ[L,(O]"O] DI*4AR8+
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M*&K*P-# !F1H.2>WT9>.[N 6;1Q((V740TFQ=VR(Z3;AC%OS*A"K50V4(Z\
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G_=S3?=W;_=WC?=[K_=[S?=_[_=\#?N +_N 3?N$'&_[ALWQ    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img42979713_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_19.jpg
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M@% * 4 H"JJ4.%3&$TY\0LK)KR&<*+O@I1,X29,)IER2E![MAR/[,YINENK
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M:S@X>'CN["PO6B>6WLSKS".PS:*"HJ)-<6LB3""&?,A#GT+!X-X@M#()X?#
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M02"(":3#P*.2"$*Y8%4H(ZBHYP-/ Q#*8&DE,,8@V%(%<P@/9: 4 H!0"@%
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ML3)&L; ^-%QP+7SRPROF%G:V-[6[M <:,\2W1 E<MB<V:C@ID=-!D2=C)A6
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M5H\L@* QJ[X<\'8+[0E'\,4KSFPI[X=;>5XWH0SW)W.^\E@V\FI;[6.1)KX
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M8L:&CVHYJN8KV)C(CFJK;41R+G,.7]: XBW_ (;JU_IJ_P#_ )=K=/L:U?\
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M,I@XU?F5B'[437Y35ZK=NE/!RKO+<7F$8O5N#O#RNODC"]<R1F^JG!ZC"@%
M* L<X4O/28/1N0?R>JUN+ /ODT3\SI?U=,%7MV)O$UBY5JWZZE#6)5]CQP%
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M:GXX@7,,W;]D79+X-/.NVH#W]H7E:CN>03HJS^#58>0Z6YA,'R@:M$4K% *
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M<*7GI,'HW(/Y/5:W%@'WR:)^9TOZNF"KV[$WB:Q<JU;]=2AK$J^QXX"@% *
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MQ_59>'QZ7-Q?]18;_P" :?ES6GX5=]4D/NH]C>I'P!"^O4M]_+=@=1I:+@A
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M]J=_J@_.MP^?M]%_A^JO]#.AQ;P=(^A9Y$) C+<+=!KN],+GRA%8"4=553,
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MX@#WE-SH4B:I<2>$V^QE05"=R =<;I<XRULA+C@R;&$*-^[,+#LHTN.2)',
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M 7PS2N;)JK*)* !H)JFDG)>6"R#FA6(6;Z8>%2$3%/2K!DL!$ZG0"@% * Y
MISBP$*:&[ K@.*+??;V:!QX1^(LIA@BV9!!131X)U-MFN83_ -K6'PSB!8FX
MG(S<10EXNU5@BY")-02"JX:1P*XY@@MYQ>@N*'[QG*<U0T?=CNF+5:1H,^BP
M&QFIL]K2XNNO!O8FW"L-\F<: [E=2WFP9*.#FT0@U5APP[L"G*L>'<5QS"2+
M:JK:B+98MMRI^.#CSIHF%KEJNP(J*-22E:/FTWY\562#>116HM.HW'C?D!ZE
MT=>F@6)&0KK9QFQLE/M_$AEQRB,)NMD=YFBQ%3=.2J?"Q'L,*MO#]-^BWCL3
MZ. ES0P* 4 H!0"@% 5H;P>7#.Z*"^]SM<K+M?0AQ/OU=*D@M-_,]?I6M_<I
MU1??JZ5),NU]"$K:@3% * 4 H!0"@% * 4!Q#8B5W5"$5K4GM2(7G.8[8/H0
MJU'$:X9GI)56T>6":8MGF"W[$3(#L<J(5.?.X#8.J#;**9(F>N*Y$S(#"XPR
MB6\-A 1)NE39+-I0E1!QV%U7W:@]J1)%J^R;N%R-R <SI8TLR'$D@HZ *'9/
M(2,[B1=2*; E4=O+S?>K*2(UD+)G'6Q'9U2&5S)9<J+GT\2ZN)..TFY#&MB-
M#[B6GD>DR7)C>:FUT-@I[MF5Q-]PKK9CMMGU-51F2C&6VTV@"<*X*:N<4%EU
MNDNY)(>)O!/&>SW<F2,C^(#"K;P(GBTDCJ&!0"@% * KSX@2M+$=HT+S@PI]
M7H*8,;R2$ASNI (3-=#*#CJ3PBS127[(C=>":+@H-",9'R9"L]#20XV*IH,5
MJTEN,N\T$=) / C*<*6>+5UI=?:MF8C'&R1M)LL\"$VM1I&M6),6F\>;!3;]
MCH;=<$*;108EJ^*4C*3^UDDIY(LML9ZV)K:E(VL"@Y2D@_0_$N9R<CR5H^>"
M_'3P$K41++TOLX47AL6S.G'=;J12UN(8D9T),5-8+)!4LD\H845556W IF5Y
MVO!TKIT95<[V>KC/99J#C=[J63)M77UD[GX0T=,Y8 !%20)4F7$56TZ;0P*
M4!Q)PL>05&?8VD!,/Q:'&S98$B-UTIZQ'XRG+IAPN50:)IO"LJ1\5@ )L-/
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)67D7+C+;<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img42979713_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %T [H# 2(  A$! Q$!_\0
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MU_\ B:/^%9Z-_P _-[_WVO\ \37:44?6ZW\P?5Z7\IQ?_"L]&_Y^;W_OM?\
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MK_\ $UVE%'UNM_,'U>E_*<7_ ,*ST;_GYO?^^U_^)H_X5GHW_/S>_P#?:_\
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MIUKHJXYTY0?+)6-(SC-7BPHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH AN+2WNTVSPI(/\ :'2L:30)[-S-I5TT3?\ /-SP?\^];]%9SIQE
MJ]S:G7J4]$].W0P8=?DMI!!JMNT+_P#/11\I_P ^U;<4L<\8DB=70]&4Y%)-
M!%<1F.:-70]F&:PY=&N].D:?29CCJ8'.0?\ '_/-1^\AYK\?^":VHUMO=E^'
M_ .@HK(T_78;E_L]RIM[D'!1^ 3[?X5KUK&<9J\3"I2G3=I(****HS"BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[_F:5J4;>TI_"_P\BU1116IS!1110 4444 %%%% !1110 C,J*68A5 R23@
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M(<BXA'H&ZCZ=!^%"C[-I+9BE-UHMRW6OR_X!T=%%%;',%%%% !1110 4444
M%%%% !1110 4444 %<Y?6TNB7O\ :-FN;=SB:(=!_G]*Z.FNBR(R.H96&"#W
M%9U(<Z\S:C5]F]=4]UW&6]Q'=6Z3PMN1QD&I:YN%F\/:I]GD8FPG.48_P&ND
MHISYE9[K<*]+D=XZQ>P4445H8A1110 4444 %8GBC75T+26E3!NI?D@7KEO7
MZ#_"MIF5$+,0JJ,DGH!7#:4A\6^*Y=7F4G3K%MELIZ,PZ'^OY5O0@FW.>R_J
MQE5DTE&.[-?PCH+:3IYN;K+:A=?/,S<E<\[?\?>NCHHK.I-SDY2+A!0CRH**
M**@H**** "BBB@ HHHH *H1/'+K<Q#@M%"J@9Z98D_R6KSNJ(SL<*HR3[5GP
M0/'8Q3%81.NY]\G\ 8DG_/M5+83&3WQ$FR>:.S .-V0[?B<87\:(Y7LKR1KB
M5[B*:,&*58\GC.5^7ZY!QZTBW7E(D$$,TCR.#YDD>%DR?F/MQGMCI3[.*&WU
M&X@4%"OSPQY^4*<;BH_WLY]./6JZ$=2U!?6URQ6*52XZH>&'X'FH'MYH;F2:
MR>,ESF6!S@$^H(^Z?T/ZU9GM;>Y $\,<F.FY<X^E-A2TM<PPB*,_>*+@'ZFI
MNNA5NY4"1ZC;B\G60*H;8B.0<=^01G./ITJ>%H8[:%;.( 2KN0=..N3^=5[
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MC?PH,(@& OO4,NUM4MU.<K&[#GC^$?UH;NQ6LBW1114%A1110 4444 %%%%
M!1110 4444 %%%% !1102 "2< 4 8?B?4/LMC]G0_O)N#[+W_/I^=<35W5[T
MZAJ4LV?DSM3_ '1T_P ^]4JUP<.:]5]=%Z?\$ZL1^[BJ*Z:OU_X""BBBNXY
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M-F\YIO->TO(;C&UGMG5E<#IG/U/45KT5?.R>4QP+P2(9$E<N<()9%RA_O;5
M&/Q-:+V\/V7RGR(U&20Q!^N1S5>XE^R:DDTIQ!*@BWGHC9R,^F<XSZ@>M,U9
M[DVSQQ6<DJ_*Q9&7) 8$C&<]!3W:%M<AD26V$;J\GV2658WCF<L0">N3R.<#
M'O6H)HQ.+?.'V;PN.V<53N':\$8MS#/;S1$M%(, J>C9[?3'\JCL6-K<&"[$
MGG'Y87)+J5ZX#8]?7GI0U= M&6=2@CFLI&8?/&I>-P/F1@."/>H;6Y:]@0SR
MVZJ< B*7.X^AX&.>U3:@(9+8P27"0M)C8S$=0<C@]>1TJ"2*UDO1!=VELSR1
M;O,*#YVZ$#/X'_\ 526PWN)<6FFV@#,'A#' \EG&?P6@6T5S;!+17B42"3S)
M%.2P.1][D\TDT4EDNV&]N!&.?+\L2LH]N^/KFEM3+<\PZH98E/S?NE#_ $)[
M?E3UM>XNMK#I)+]/EEN;&$'^,@Y_(D?SI0UZ;J&-KB!XW4EO*3:V.QY)[TL5
MFHNK@W$22)D-')( 6 (Y7/H#_.JTTNFS3YO L?EY2$LK* .,D-TYQV/:A 7+
MEK:V5!-*J1YSL/)<_P S4L%W%<,5C$G S\T;*/U%5+>\TN!A%;RQ9)R3N_7)
MZTZXDLIY5S>ONQ@1PS$$_@O-*P[C[N_CMKF"-IHD4Y:3>><8XQ[YQ^1HMV6[
MO#=(28XU,2Y&,DD%C^@'YTD9F3]U;V1C3_GI*X_,C))/UJU!"L$00<\DL?4D
MY)_.AV2!7;)****@H**** "BBB@ HHHH **** "BBB@ HHHH *R?$5Y]DTIU
M4X>7Y!]._P"G\ZUJXGQ5=^?J0@4_+"N/Q/)_I^59U+M<JW>AT86*=3FEM'7[
MC#HHHKU8Q48J*V1A*3E)R>["BBBJ)"BBB@!\44D\JQQ(SNW15ZFGV]I-=72V
MT:XE)(PW&,4EL\\=U&UMN\X-\H7J3737&G7$ES%JEM'Y5WPSV[D<^N*SE/E8
M'*LI5BK#!!P1[UJ6>JDA+6^_>V^<!S]^+W!IVMV*P^7>11M&DY.Z-^J-WK(I
MZ30'1ZYNLY+"^BEW3@;3(.C@=S5U+VT32IM0A&=KF01G^"0C']<U0L[9=9T6
M&V641RVS\Y&?E-:0T2-=)>P$S89M^\CH?I6#Y4DF,PM(L_M5P]]=-MMX6\QW
MZ;FZXIVH>(+BZ+I;@0Q,>J_>8>YJYX@C:RTRUM( 1;@X8^I'3/ZFN;K6*4_>
M8AR2/&VY'96/=3@U(+RZ!)%S-D]?G-0TJJ68*H)8G  ')K2R "2Q)8DD]23F
MDI71HW*.I5E."",$4E, HHHH **** &31+/ \3?=<8KH_AYJ+2Z9/IDS?OK-
MS@'^Z3_CG\Q7/TS1[O\ LGQE:S$[8;O]U)Z9/'\]IIN//3E#YKY&-3W91G\G
M\SU6BBBO+-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL3Q'
MJ,L$$6GV7-]>'RX\?PCNW^?Z5,I**NRX0<Y***3_ /%2^(/+'S:9I[9;TEE]
M/<#_ #UJ7Q#;RV-S#K]FI,EN-MP@_P"6D7?\O\]*U]+TZ+2M.BM(>0@^9N[-
MW-6V574JP!4C!![BH5.\==V;.LE-<OPK3U77[R.VN(KNVCN(6W1R*&4^U2UR
M>BWL.C^(+G0#.'@+;[?G[A/)0_Y_G7654)<R,ZU/V<K='JO0Y;_D6?$']W3-
M0;\(I?\  _YZ5U-5-3T^'5-/EM)A\KC@XY4]C6;X;U":2*73;TXOK(['S_&O
M9O?_ /5ZU,?<ER]'L7/][#GZK?\ 1_HS=HHHK4YPHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** &R(LD;1N,JP((]16%H#M:75WI<AYC8LF>X_P X
M/XUOUS^LC[!K%EJ*\*Q\N3_/T)_*L:ONM3[?D=6&]]2I=UIZHZ"BBBMCE(KF
M=+6UFN)#A(D+M] ,UR?P_MWDLKW5IA^^O9R<^P/^)/Y5<\=WAM/"TZ*<-<,L
M0^AY/Z UJZ'9#3M#LK7',<2[O]X\G]2:Z5[M!O\ F?X(P?O54NR_,T****YC
M<**** "BBB@ HHHH **** "BBB@ HHHH **** (+RV2]LYK:3[LJ%3QG]*R?
M+O+%-Q$T$2_?:%Q*B^X1AD#V'2MVBJ4K:$N-S(L;C[#;+%,&FB&3'=0IN5U)
MSR%S@\_2I88WN@\L5_=@YX+1A5_ %>14S:9;;V>+S(&8Y8PN4!^H'%)_9<#_
M .N>>8?W9)6(_+I576XK/8JB.546:ZN(!Y@VS17 !4C/;G@X[<BB[6"VT]VA
MTZ&6V!#.K';Q_>'!Z=?Y5>CT^SA;=':0JWJ$&:A_LTQ*R6MRT4+9S"RAT /8
M \@>V<4<R"S(+/SFCECM4M[22*3#Q;2X/<$GCJ.<U=2&>52+MHBO]R,'!^N>
MM4+.S+*8C.\=[:?NO.7&73JN1T(Q^H-6&NKJR1VNX?.B49\Z <X]U)_EG\*'
MOH"VU)%TJQ1@RVZ\'(&20/PZ5<QQBJ?VV8X9;"=HR.""H/Y$TAO+AA^ZT^?/
M_31D4?S/\JEIO<=TBU)'$Z$2HC(.?F (%5K6*,R&>.)8X\8C"KC([M^-/$$D
MVTW17'7RD^[GW/>K-*]M!A1112&%%%% !1110 4444 %%%% !1110 4444 %
M%%% #9)%BB>1CA44L?H*\SN)FN+F29_O.Q8_C7<^(KC[/HTN#@R80?CU_3-<
M%3H1YJ_^%?F=2]S#M_S.WR6H4445Z1R!1110 4444 2V]Q+:3":!]D@R <9I
M&N)VF\XS2&3.=^XYJ.BE9 :T>O2M#Y-[!'>)G(W\$5)Y>D:D@9'&GS#@HW*M
M6+4D,,ES.D,2[I'. *EP2U6@'8Z+8V]G!(89TG=C\TB_RK3KGX'L_#D+I)*9
MKE\%D3M_A6JNI6YM;>X9MBSD*N>Q/8URS3;N,BUHVGV#%ZSB(N,;.I-<^#X?
M?Y2MW'_M$YQ4GB>><WJ6[C;"HW)C^+U-8=;4X>[N(UWT03QF73+E;I1U0_*X
MJ_H^CW%F9+J:-?/"$0QY!Y]37.12R02"2)V1QT(-;,MW9ZK%YL\[6=XB\D9V
MO3FI6MT ;)HKR2DW.I6RW<ARR,<\_6L>1#'*Z$@E21E3D'Z4T\G)Y)ZDT5HD
MUNP"BBBJ **** "L_6(RUEYJY#Q,'!':M"FR1B6)XVZ,"#50ERR3(J1YXN)Z
M/H]Z-1T>TO.\L2LW^]W_ %S5VN.^'-V9="FLW/S6LQ&/0'G^>ZNQKSZ\.2HX
MA2ES03"BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "N8T7]]XJU
M22_XOX_EA0]%B[%?T_/WKIZP?$=C,/*U>Q'^FV?) _Y:1]U/Z_K6=1;2[&]!
MJ[@]+Z7-ZLS7-5&DZ<TJC=/(?+@3NSGI5FPU"#4-/CO86'E.N3D_=]0?I6%I
MH/B#6WU>0'[%:DQVBGHS=W_S[>E$I:)1W84Z=FW/:._^0B^%R?#QB9_^)FS_
M &GS\\B7KU].WZUJ:%JG]JZ>'D&RYB/ESQG@JXZ\5J5S.JJV@ZRFLQ _9)R(
MKQ1V]'_S_6I<53LUMU+4W6O&6^Z_R.FKE]>_<>)-+FL>=1=MCH.C1=RWZ_Y%
M;]Y?P6-A)>RN/)1=V1_%Z ?6LCP[932O+K5\O^E7?W%/_+./L!_GT]Z=3WFH
MHFC[B=1[;>IT%%%%:G.%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5G:Y;?:=(G7&60;U_#_P"MFM&D(#*01D'@U,H\T6F73FX34ET*.C7/VK2;
M>0G+!=K?4<5?K \.$V\U]8-G]U)E?IT_H/SK?J:,N:"N:8F"A5DEM_GJ<7XR
M_P!.U_0M+_@>;S''MD#^0:NTKBSB^^*8SR+.VX]CC_[.NTKLKZ1A'RO]YQ4M
M92EY_D%%%%<YL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %"[_T:^@NQPCX@E^A/RG\#Q_P*KLL8EB>-NCJ5/XTVX@2YMY()!\DB
ME34.GSO-:@2_ZZ(F.7_>'?\ '@_C5;JXNHFF.9-,MB?O",*?J.#_ "JW5+3?
MD6YAZ>7.X ]B=P_]"J[2EN"V"BBBD,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#E_&$WRVT [Y<_R']:Y6MOQ5+YFK[,_ZM O]?ZUB5K@U?GEY
MV^XZ<1I"G#RO]["BBBNXY0HHHH **** "E568X52Q] ,TE6K'4)]/,AM]FZ0
M;=Q7)'TI._0".+S[:=)EB8/&<C<A(KI[*^NTLY;V_@AC5$S&VW:SGTQ31J5W
MIVF>??R>9<R_ZJ$@# ]3BN<N[ZYOI-]Q*6QT7H!]!65G/= 0,S22,[9+N<GW
M)K:U)&MO#]A;3 K,6+[3U Y_QINB0K!%<:G.@,<*GR]W=O:G:^TDT&GW#\EX
M<D@<9/--N\D@'6MW#K%NFGWQVSKQ#-ZGT/\ GFL^^TJZT_F9 8R<"13D'_"J
M:.T;JZ'#*00?>NJ?4WN-.%XD2SPXV7-N1]T^HH=X/38#E**V18:?J0_XETQA
MGZ^1,>#]#67<6T]K(8YXF1AZC@_0U:DGH!%1115 %%%% !1110 4444 6_ \
M_P!F\67]IT6>+>/J"#_4UZ/7E6ERFT\;Z9+G E_=GWSD?U%>JUSXQ>\I=U_P
M#&CIS1[/_@A1117(;A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<;?Z-J5O>S:=IH*Z=J+!G8#B#^\/8$?GTKK+6VBL[6*V@7;%&H514U%1&FHM
MM&U2M*HDG_PX5%<6\5W;26\RAHY%*L#W!J6BK,4[:HXRST74I[R+2K_+:78.
M71S_ ,MA_"/PY^G3TKL^E%%1""AL:U:KJ/4****LR"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,#_ (]?&'HMS%^N/_L:WZP-=S!J>FW0
MZ"3:WTR/\36_6-+24H^?YG5B/>A"?E;[CC/#7^D^-_$-UUV,(@?QQ_[)79UQ
MO@7$ESKDXY\R[//XL?ZUV5=V*_B6[)?D>?A_@OWO^84445SFP4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %57LLSO-%/+"TF-^S:
M0V/J#VX_ 5:HIIV"PR.)8E(7/)R23DDT^BBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!YYK;^9K5TW^WC\N/Z50J>^;?J%PWK(Q_4U!
M71@E^Y3[W_,Z<9_%MV27X(****ZSE"BBB@ HHHH *4$@@@X(.0:2B@"6YN9K
MN8S3R%Y#QDU%112 N7.H/<65O:!0D4(Y /WCZFMRRNX7\.Q+<KN@#>1(?[N>
MA_E7+T\2R"%H0["-CDIG@FHE!-6 GU"R:PNS"6#J1N1A_$IZ46-_-I\_F0D$
M'AT/1A[U=@N8=1L39W81)H8R89R<=/X36136JM("U?2VTMSYMI&\2D992>C>
MWM39[^ZNH8XIYFD2,Y7=U_.J]%59 %%%%, HHHH **** "BBB@"C>/Y&HZ9<
MYQY=PIS^(/\ 2O8*\:US(LD<=5D!_0U[%"_F01N.C*#^E98I>Y!^IC#2K+Y#
MZ***X3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH S]:&=./^^M>L::=VEVC>L*'_ ,=%>4:R<:<W^^O\Z]6TH8TBR'_3"/\
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MWL%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ P71+C/?:/\
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M6DCD+N)=2 W;YEX)S@43>)?'FG^)X/#ES:Z)=7FI0-/:7$7F)%;;3\^\$DN
M",8P22.G:K8>!M=M_ ?A329(81=Z=K:7MRHF&%B$KL2#W.&'%=7J.AWUS\2=
M$UN-$-E:65Q#*Q< AGV[<#OT- &/8>,=;@L?%]CJT5D^K^'X/.6:W5A%.K1E
MT.TG(/&",U-K'C/4;#X2V?BF**W-]-!:2,C*?+S*R!L#.?XCCFGQ^$KV?Q1X
MVGN0D=CK=I#;P2!LMQ$R,2.V":Y;4/#7C[4_A];>$6TS38([$01M<_:]QNTB
M=2NQ<?)]T$ECVP!S0!U/B#Q'XCB\>VWAG0K:P?[1IQNFGNRV(,2;2Q .6&,
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M;RT1&ATZ_:>X+. 0A0C@=^30!Q7C+Q;'K]]X3M5T/6[$KKUM)YM_9&%#C<,
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M,/QKMP_O-TW]I?CT//K:)3[?EU.THID,J3PQS1MNCD4,I'<'D4^N<W"BBB@
MHJMJ&H6FE6$]]?W"6]K I>260X"BN=C^(_AI]/NKY[NXA@M?+,QGM)8RJNVU
M6PRC*DGJ* .KHK.U77-.T6.T>^N!&+RX2U@PI8R2/]T "LMO'OAU=;_LD7DC
MW F%NSQV\C1)*3C8T@7:&SVS0!TM%< OQ1TY/B!>^'IRRVT,2+'(MK,7:<N5
M93A?N]/FZ>];^N>-M!\/7BV=_=O]J*>8T,$#S.B?WF" [1[F@#H**Q;CQ;H5
MKH=MK<NI0C3+ET2*Y!)0EC@9/;GKGICFLNW^)W@^X:Y4:RD?D1^:3-$\?F)G
M&Z/<!O&>!MSGM0!UU%8WA[Q5H_BB&>32KDR-;OLFBDC:.2,]MRL 1FN;USXG
M:?H7CNWT*XW"U^SN]S*+:5G208*A=H^8$$Y(!^HH [VBL+7/&.A^'DMO[1O&
M66Z7=!!'$\DL@]0B@MCWQ5G0O$6E>);$WFD7B7,*N4? *LC#JK*0"I]B* -2
MBL37O%NC^&VACU&XD$\X)B@@A>:1P.I"H"<#/6LO4OB%HT/@B]\1Z=="YCA5
MXT7RGXG"DA'4#<O.,YQB@#KZ*\ROOB]8P_#HZ[;+OU,0Q9@>UF$7G, 2N['0
M?-SG' YKJ;?QUH$WAU];>\:*RC<1.\D$B'S"!A54KN8\C& : .DHK T'QEHG
MB2YFM=/N9/M4*AY+>>!X9 IZ-M< D>XJK=?$;PK9ZL^FS:H/.CE$,CK"[11R
M$X"M(!M!SQ@F@#J:*X72=;>V\?\ CC^TM09--L(K.11-)^[@4Q,6(],XR:Z[
M2M4M=:TNWU&R9WM;A=\3/&R%E['# '!H N45Y5X0^).D:9HEQ%X@UB:2[74+
MD,2DDQAC$I"ERH.Q?3.*[O5?%NA:):V=WJ&I0P6UYDP3$DHX"%\Y'&,#\: -
MJBN2;XD^&%TZVO?M=PRW)<0PK9RM,^TX8^6%W8&1R1CFI+SQ3I>K^!]2U?2=
M=^R00QN'O5@+M;,O7=&PSD>A'>@#J:*YZ]\7:)X?L]-&L:NB-=6YDCGD0J)M
MJJ6; '!.X87WP*F\/>+=%\4?:1I5T9)+9@L\,D3121YZ95@#@]C0!MT5F:SX
MATKP]';RZM>1VL5Q+Y4<DG"[MI;D]!PIY-4-"\<>'O$=]+8Z;?%KJ-/,\F6%
MXF9/[ZAP-R^XH Z*BN2NOB7X4L[Y[6;4741R^3)<"WD,"/G&UI=NT'/'6J7B
MKXDV7AGQ;H^D2?-#<^8UW)Y$KF-=F4*;1ALGKC./:@#NJ*\ZUWQ?;:9\0= N
MKC4Y+?1KC2IIBC;@)&+)L^3&2W/ QFNM\/\ BC2/$]K-/I5UYH@?RYD=&C>)
MO1E8 B@#8HKD3\3O"(O_ +(=6&/,\G[1Y+^1OSC;YNW9G\:BU._NX_BUX?L8
M[F5;2;3KEY(0WR.P*X)'<B@#LZ*Y;5_B)X7T34);&]U%O/@P;@0P22B '_GH
MR*0OXU?U'Q;H>EZ5:ZE<:A&UK=D"V:$&5IR1D!%4$MQZ"@#:HKCX/BAX3GBE
MD74)E2"18IC):2H(F9@H#$KP<D5T&IZWI^CR6,=[/Y;WUPMM;J%+%Y#T''TZ
M]* -"BBB@ KSW6[7['JTZ 85CO7Z'FO0JYKQ;9[X(KM1RAV-]#T_7^=9SER-
M5.S_  ZG5A?>;I/[2M\^AR5%%%>L<FP4444P"BBB@ HQ110 48HHSB@ HQ1U
MHH GBNWBL[BV"J4GV[B>HP<\5!112L 48HHI@36MS)9W*SPX#KZC((Z$&K#:
MD5CD2WM+>W,B[7>,')'<#)X%4:*328!@4444P"BBB@ JE<P-J6J6&EIUFD!?
M'9?7\LG\*NU>\!V9O];O-7<?NX1Y4/U/_P!;_P!"JHRY$Y]OSZ&-;5*'?\NI
MZ$B+'&L:#"J  !V IU%%>4;A1110 4444 %%%% !1110 45S>I>//#VE:L^F
MW-Y(;B,J)O*MY)$@+=/,95(7/N:U--UO3]7GOX+*?S);"<V]RA4J4<<XYZCW
M'!H T**YJ7Q]X<ATM=1^WL\#W#VL0CA=WFD0X8(H&6QCJ!BLCQ7\3=/T?P2=
M>TPFXEDD\J".>WE4;@P#JXP"I )ZXY]: .\HK"MO&&AW/A^;7/MODZ= 2LLU
MQ$\04C'9@">HZ#FFZ'XTT+Q%>26=A=/]K1/,,$\#PN4SC<%< E?<4 ;]%<A>
M?$_PA8O*DVJY>&9X9EC@D<PE6VL7PIVKGC)X/;-3-\1?"BZO#I@U>)IIG6-)
M$5FA+L,A/, V;CD<9H ZFBL'QEXDB\*>%KW5G&Z2*-O)0HS*TFTE0VT9 )')
MX'O5?POXUTSQ%X=&I^>(?(MTDO#)&\4<3%<MAG RHYY&: .FHKE=+^(WA;5]
M2AL+346\ZX.+<RP21)/_ +C,H#?@:Z6YN8;.UEN;F58H(4+R2.<!5 R2?PH
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M<8PD[1*9%'LV,BF/HVER7<EV^FV;7,BE'F:!2[*1@@G&2,=J /,C>VND^-/
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M4445RG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&3ZD=_KUKI]K"KI5T?=?JC'V<J?\/;M_D=%17##6O$7A<B/6;8WUD#@747+
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M><]6^M6@ !@# %%.%-)\SU9G4KN2Y(JT>W^?<****U, HHHH **** "BBB@
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MZ:C_  JB=)P2/[0O^/\ IM_]:BBN^+;.1A_97_40O_\ O]_]:C^RO^HA?_\
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MX4446"[#^R8O^?BX_P"^Q_A1_9,7_/Q<?]]C_"BBBP78?V3%_P _%Q_WV/\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img42979713_21.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img42979713_21.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MRKL5-SND4F%PB?<=KI=[0(F8V_FS(6P4^N .)=S"! S Y6#"PJ# [/#$4*S
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MS0X6?1183<N-K,2VW-E.@4$'=-J1T;N7/+.: <(D2ZU$^ZE*G8_+H E]#02
M#01]30:ZG0-J\ .\K0,CBAU1JYR,+1+F?,#=S+^1O<?.'<"1/=&.;,OM4,-1
M,0_M0,4FG<*5_=%7 =L.8=K0@-JG[9[R7)$Z(-CI[=<Z,!#%  ?KK0-J(-]
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M%*I&&"$,8]JV%JE>D("9-)!H9*(1D5@>3* UI58)!)#SL6,NR[',DT1-/3D
MQ3>S#6WJ;((O]IQ@,:1B-#K_VHN)R525[:V[1=X LE[H3"1C$TE(E'35JS-=
MAEG2<&W-B)MY-&&11!EC-$91QH@?\96ZZNVTA'_'+Z_>-\]J*I<^A]QIR39Y
M539AW0XETXG9%C.[H[FTAZPQY0,!!:JD9]@*"OKFIDOX*'W]_W.B[[L>DC+7
MJ')EQW4L[QO"('=*1EY&3E6<Z+[=N*\,FQ>W%OVO(.JZU\6>W9J6,>L>V95(
M0AU-PPHF(EDONKR'HT$%<9WKQ+!40N ^=MT)AS@EYWO@;9VZ35C$/J:9#TM
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;+,B&K,B.+,F6K,F>+,JFK,JN+,NV;+H%!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>31
<FILENAME>alec-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:36:36.8799+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="alec-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="alec-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="alec-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidity" xlink:href="alec-20221231.xsd#Role_DisclosureTheCompanyAndLiquidity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="alec-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreements" xlink:href="alec-20221231.xsd#DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingencies" xlink:href="alec-20221231.xsd#Role_DisclosureCommitmentAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="alec-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="alec-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="alec-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="alec-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="alec-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="alec-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="alec-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="alec-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="alec-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="alec-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="alec-20221231.xsd#DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:href="alec-20221231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="alec-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="alec-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedClinicalSupplyCost" xlink:label="alec_AccruedClinicalSupplyCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationReceivable" xlink:label="alec_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="alec_AccruedClinicalSupplyCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="alec_CollaborationReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_20"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_23"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_23" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IssuanceCostOfPreferredStock" xlink:label="alec_IssuanceCostOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IssuanceCostsOfCommonStock" xlink:label="alec_IssuanceCostsOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostOfPreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostsOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInCollaborationReceivable" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AmortizationRightOfUseAsset" xlink:label="alec_AmortizationRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInCollaborationReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alec_AmortizationRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alec_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_GskMember" xlink:label="alec_GskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PhaseThreeLicenseMember" xlink:label="alec_PhaseThreeLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AlectorMember" xlink:label="alec_AlectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:label="alec_CollaborativeArrangementUpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_InnoventBiologicsMember" xlink:label="alec_InnoventBiologicsMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PercentageOfDevelopmentCost" xlink:label="alec_PercentageOfDevelopmentCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseInExpectedCostPercentage" xlink:label="alec_IncreaseInExpectedCostPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DevelopmentMilestone" xlink:label="alec_DevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SalesMilestone" xlink:label="alec_SalesMilestone"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_GskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborationAndLicenseAgreementEffectiveDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_PhaseThreeLicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AlectorMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementUpfrontPayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_InnoventBiologicsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_PercentageOfDevelopmentCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_IncreaseInExpectedCostPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_DevelopmentMilestone" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_SalesMilestone" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_LabEquipmentMember" xlink:label="alec_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_LabEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:label="alec_AccruedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:label="alec_AccruedPropertyAndEquipmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="alec_AccruedResearchAndDevelopmentCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="alec_AccruedPropertyAndEquipmentCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SouthSanFranciscoMember" xlink:label="alec_SouthSanFranciscoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AreaOfPropertyInLease" xlink:label="alec_AreaOfPropertyInLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_NewarkCaliforniaMember" xlink:label="alec_NewarkCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_LeaseExpirationYear" xlink:label="alec_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:label="alec_AreaOfPropertyInSubleaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:label="alec_SubleaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdditionalAreaOfPropertyInLease" xlink:label="alec_AdditionalAreaOfPropertyInLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_SouthSanFranciscoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_NewarkCaliforniaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LeaseExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInSubleaseAgreement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_SubleaseExpirationMonthAndYear" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaSubleaseExpirationMonthAndYear" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaOfPropertyInLease" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandTwentyTwoInducementPlanMember" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:label="alec_PercentageOfStockOwnedByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubsequentOfferingPeriod" xlink:label="alec_SubsequentOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandTwentyTwoInducementPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_PercentageOfStockOwnedByIndividual" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_SubsequentOfferingPeriod" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:label="alec_DomesticAndStateTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:label="alec_TaxCreditBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TaxReserve" xlink:label="alec_TaxReserve"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ReversalReservesOnUncertainTaxProvisions" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="alec_DomesticAndStateTaxAuthorityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxCreditBeginningExpirationYear" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxReserve" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_ReversalReservesOnUncertainTaxProvisions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdimabMember" xlink:label="alec_AdimabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FutureMilestonePaymentsOwed" xlink:label="alec_FutureMilestonePaymentsOwed"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_AdimabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alec_FutureMilestonePaymentsOwed" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_MilestonePaymentReceivable" xlink:label="alec_MilestonePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_MilestonePaymentReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>alec-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:36:34.4561+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alector.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:alec="http://alector.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alec-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2" id="DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidity" id="Role_DisclosureTheCompanyAndLiquidity">
        <link:definition>100080 - Disclosure - The Company and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreements" id="DisclosureCollaborationAgreements">
        <link:definition>100110 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100120 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingencies" id="Role_DisclosureCommitmentAndContingencies">
        <link:definition>100130 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100140 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100150 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100170 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100180 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100230 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100240 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100250 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100260 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100270 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" id="Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - The Company and Liquidity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100310 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100340 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
        <link:definition>100350 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" id="Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
        <link:definition>100370 - Disclosure - Leases - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" id="Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
        <link:definition>100380 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
        <link:definition>100390 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" id="DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>100400 - Disclosure - Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
        <link:definition>100420 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails">
        <link:definition>100430 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" id="DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails">
        <link:definition>100440 - Disclosure - Income Taxes - Schedule of Federal and State Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100450 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>100500 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alec_AccruedClinicalSupplyCost" name="AccruedClinicalSupplyCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_AccruedPropertyAndEquipmentCurrent" name="AccruedPropertyAndEquipmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_AdditionalAreaOfPropertyInLease" name="AdditionalAreaOfPropertyInLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="alec_AdditionalAreaSubleaseExpirationMonthAndYear" name="AdditionalAreaSubleaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_AmortizationRightOfUseAsset" name="AmortizationRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_AreaOfPropertyInLease" name="AreaOfPropertyInLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_AreaOfPropertyInSubleaseAgreement" name="AreaOfPropertyInSubleaseAgreement" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_CollaborationAndLicenseAgreementEffectiveDate" name="CollaborationAndLicenseAgreementEffectiveDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" name="CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" name="CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" name="CollaborativeArrangementMilestonePaymentsReceivablePerProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_CollaborativeArrangementUpfrontPayments" name="CollaborativeArrangementUpfrontPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_DevelopmentMilestone" name="DevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_FutureMilestonePaymentsOwed" name="FutureMilestonePaymentsOwed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" name="IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_IncreaseDecreaseInCollaborationReceivable" name="IncreaseDecreaseInCollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_IncreaseInExpectedCostPercentage" name="IncreaseInExpectedCostPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_IssuanceCostOfPreferredStock" name="IssuanceCostOfPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_IssuanceCostsOfCommonStock" name="IssuanceCostsOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_MilestonePaymentReceivable" name="MilestonePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_OperatingLossCarryforwardsBeginningExpirationYear" name="OperatingLossCarryforwardsBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_PercentageOfDevelopmentCost" name="PercentageOfDevelopmentCost" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_PercentageOfStockOwnedByIndividual" name="PercentageOfStockOwnedByIndividual" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" name="ProceedsFromPaymentsForIssuanceInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_ReversalReservesOnUncertainTaxProvisions" name="ReversalReservesOnUncertainTaxProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_SalesMilestone" name="SalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="alec_SubleaseExpirationMonthAndYear" name="SubleaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" name="SubleaseIncomeAndReimbursementOfVariableLeaseCost1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_SubsequentOfferingPeriod" name="SubsequentOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_TaxCreditBeginningExpirationYear" name="TaxCreditBeginningExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_TaxReserve" name="TaxReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" name="TemporaryStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AbbVieBiotechnologyLimitedMember" name="AbbVieBiotechnologyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AdimabMember" name="AdimabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_AlectorMember" name="AlectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CashEquivalentsAndMarketableSecuritiesMember" name="CashEquivalentsAndMarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_DomesticAndStateTaxAuthorityMember" name="DomesticAndStateTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_GskMember" name="GskMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_InnoventBiologicsMember" name="InnoventBiologicsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_NewarkCaliforniaMember" name="NewarkCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_OfficesAndLaboratoryFacilitiesMember" name="OfficesAndLaboratoryFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_PhaseThreeLicenseMember" name="PhaseThreeLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" name="RestrictedStockAwardsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_SouthSanFranciscoMember" name="SouthSanFranciscoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_TwoThousandFourteenAdimabAgreementMember" name="TwoThousandFourteenAdimabAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_TwoThousandTwentyTwoInducementPlanMember" name="TwoThousandTwentyTwoInducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="alec_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>33
<FILENAME>alec-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:36:40.8724+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="alec-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2" xlink:href="alec-20221231.xsd#DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="alec-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesComponentsOfLeaseExpenseDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="alec-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="alec_AccruedClinicalSupplyCost" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="alec_CollaborationReceivable" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedClinicalSupplyCost" xlink:label="alec_AccruedClinicalSupplyCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationReceivable" xlink:label="alec_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_AmortizationRightOfUseAsset" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInCollaborationReceivable" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="14" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AmortizationRightOfUseAsset" xlink:label="alec_AmortizationRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInCollaborationReceivable" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alec_AccruedResearchAndDevelopmentCosts" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="alec_AccruedPropertyAndEquipmentCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:label="alec_AccruedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:label="alec_AccruedPropertyAndEquipmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" order="3" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>alec-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:36:35.1799+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="alec-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:href="alec-20221231.xsd#Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" xlink:href="alec-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="alec-20221231.xsd#DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:href="alec-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:href="alec-20221231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="alec-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:href="alec-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="alec-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IssuanceCostOfPreferredStock" xlink:label="alec_IssuanceCostOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IssuanceCostsOfCommonStock" xlink:label="alec_IssuanceCostsOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostOfPreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alec_IssuanceCostsOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecuritiesGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_GskMember" xlink:label="alec_GskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PhaseThreeLicenseMember" xlink:label="alec_PhaseThreeLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AlectorMember" xlink:label="alec_AlectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:label="alec_CollaborativeArrangementUpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_InnoventBiologicsMember" xlink:label="alec_InnoventBiologicsMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PercentageOfDevelopmentCost" xlink:label="alec_PercentageOfDevelopmentCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseInExpectedCostPercentage" xlink:label="alec_IncreaseInExpectedCostPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DevelopmentMilestone" xlink:label="alec_DevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SalesMilestone" xlink:label="alec_SalesMilestone"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_GskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborationAndLicenseAgreementEffectiveDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_PhaseThreeLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AlectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementUpfrontPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_InnoventBiologicsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_PercentageOfDevelopmentCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_IncreaseInExpectedCostPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_DevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alec_SalesMilestone" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_LabEquipmentMember" xlink:label="alec_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SouthSanFranciscoMember" xlink:label="alec_SouthSanFranciscoMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AreaOfPropertyInLease" xlink:label="alec_AreaOfPropertyInLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_NewarkCaliforniaMember" xlink:label="alec_NewarkCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_LeaseExpirationYear" xlink:label="alec_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:label="alec_AreaOfPropertyInSubleaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:label="alec_SubleaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdditionalAreaOfPropertyInLease" xlink:label="alec_AdditionalAreaOfPropertyInLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_SouthSanFranciscoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="alec_NewarkCaliforniaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_LeaseExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AreaOfPropertyInSubleaseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_SubleaseExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaSubleaseExpirationMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="alec_AdditionalAreaOfPropertyInLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandTwentyTwoInducementPlanMember" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:label="alec_PercentageOfStockOwnedByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubsequentOfferingPeriod" xlink:label="alec_SubsequentOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandTwentyTwoInducementPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_PercentageOfStockOwnedByIndividual" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alec_SubsequentOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:label="alec_DomesticAndStateTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:label="alec_TaxCreditBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TaxReserve" xlink:label="alec_TaxReserve"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ReversalReservesOnUncertainTaxProvisions" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="alec_DomesticAndStateTaxAuthorityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxCreditBeginningExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_TaxReserve" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="alec_ReversalReservesOnUncertainTaxProvisions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdimabMember" xlink:label="alec_AdimabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FutureMilestonePaymentsOwed" xlink:label="alec_FutureMilestonePaymentsOwed"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alec_FollowOnPublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_AdimabMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alec_FutureMilestonePaymentsOwed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_MilestonePaymentReceivable" xlink:label="alec_MilestonePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="alec_MilestonePaymentReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="alec_AbbVieBiotechnologyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="alec_CollaborationRevenueMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>alec-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:36:40.7475+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IssuanceCostsOfCommonStock" xlink:label="alec_IssuanceCostsOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubleaseExpirationMonthAndYear" xlink:label="alec_SubleaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ReversalReservesOnUncertainTaxProvisions" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationRevenueMember" xlink:label="alec_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationReceivable" xlink:label="alec_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_InnoventBiologicsMember" xlink:label="alec_InnoventBiologicsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AreaOfPropertyInSubleaseAgreement" xlink:label="alec_AreaOfPropertyInSubleaseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdditionalAreaOfPropertyInLease" xlink:label="alec_AdditionalAreaOfPropertyInLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:label="us-gaap_TypeOfRevenueExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInCollaborationReceivable" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitPlansPolicy" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OfficesAndLaboratoryFacilitiesMember" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PhaseThreeLicenseMember" xlink:label="alec_PhaseThreeLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AreaOfPropertyInLease" xlink:label="alec_AreaOfPropertyInLease"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TaxCreditBeginningExpirationYear" xlink:label="alec_TaxCreditBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_LeaseExpirationYear" xlink:label="alec_LeaseExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AmortizationRightOfUseAsset" xlink:label="alec_AmortizationRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SummaryOfSignificantAccountingPoliciesTable" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedPropertyAndEquipmentCurrent" xlink:label="alec_AccruedPropertyAndEquipmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PercentageOfDevelopmentCost" xlink:label="alec_PercentageOfDevelopmentCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_MilestonePaymentReceivable" xlink:label="alec_MilestonePaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesGainLoss" xlink:label="us-gaap_MarketableSecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FollowOnPublicOfferingMember" xlink:label="alec_FollowOnPublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedClinicalSupplyCost" xlink:label="alec_AccruedClinicalSupplyCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseDecreaseInLeaseLiabilities" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandTwentyTwoInducementPlanMember" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_FutureMilestonePaymentsOwed" xlink:label="alec_FutureMilestonePaymentsOwed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DevelopmentMilestone" xlink:label="alec_DevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_LabEquipmentMember" xlink:label="alec_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IssuanceCostOfPreferredStock" xlink:label="alec_IssuanceCostOfPreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AdimabMember" xlink:label="alec_AdimabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AccruedResearchAndDevelopmentCosts" xlink:label="alec_AccruedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DeferredTaxAssetsLeaseLiabilities" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TwoThousandFourteenAdimabAgreementMember" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_NewarkCaliforniaMember" xlink:label="alec_NewarkCaliforniaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AbbVieBiotechnologyLimitedMember" xlink:label="alec_AbbVieBiotechnologyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubsequentOfferingPeriod" xlink:label="alec_SubsequentOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="us-gaap_IncomeTaxContingencyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_GskMember" xlink:label="alec_GskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseRenewalTerm" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_CollaborativeArrangementUpfrontPayments" xlink:label="alec_CollaborativeArrangementUpfrontPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_PercentageOfStockOwnedByIndividual" xlink:label="alec_PercentageOfStockOwnedByIndividual"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_AlectorMember" xlink:label="alec_AlectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_DomesticAndStateTaxAuthorityMember" xlink:label="alec_DomesticAndStateTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SouthSanFranciscoMember" xlink:label="alec_SouthSanFranciscoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_TaxReserve" xlink:label="alec_TaxReserve"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_IncreaseInExpectedCostPercentage" xlink:label="alec_IncreaseInExpectedCostPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="alec-20221231.xsd#alec_SalesMilestone" xlink:label="alec_SalesMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IssuanceCostsOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance cost of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IssuanceCostsOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IssuanceCostsOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Expiration Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal Reserves On Uncertain Tax Provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reversal Reserves On Uncertain Tax Provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ReversalReservesOnUncertainTaxProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of reserves on uncertain tax provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon follow-on public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from Collaboration partner</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Present value adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, long-term portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included In measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Automatic conversion provision of common stock reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value per Share, Unvested, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Innovent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innovent Biologics.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innovent Biologics [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_InnoventBiologicsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innovent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Committed Under 2019 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued employee compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of property in sublease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property In Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInSubleaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area under sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Company and Liquidity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of stock from employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional area of property in lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Area Of Property In Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional area of property in lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Federal and State Income Tax Provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Collaboration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease In collaboration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from collaboration partner</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInCollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivable from collaboration partner</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in computing net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 R&amp;D capitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Capitalized Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax Assets tax deferred expense capitalized research and development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefit Plans, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitPlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee 401 (K) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards And Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash equivalents and marketable securities, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, long-term portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offices and laboratory facilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offices And Laboratory Facilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OfficesAndLaboratoryFacilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offices and Laboratory Facilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income (loss) per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional area sublease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Area Sublease Expiration Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional area sublease expiration month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PhaseThreeLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Phase Three License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PhaseThreeLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Phase three license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PhaseThreeLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Phase 3 License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of property in lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Property In Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AreaOfPropertyInLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area under lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit beginning expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Beginning Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxCreditBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Beginning Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price per share from fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E convertible preferred stock, net of costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in accrued liabilities and accrued clinical supply costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and accrued clinical supply costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series E convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities, Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares used in computing net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments Receivable Per Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement milestone payments receivable per program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of investments were less than one year through two years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amount form letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LeaseExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization right of use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AmortizationRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued property and equipment current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Property And Equipment Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedPropertyAndEquipmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon follow-on public offering, net of issuance costs of $1,148 (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offerings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Development Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfDevelopmentCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Of Development Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Franchise Tax Board [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment award requisite service period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 200,000,000 shares authorized; 82,895,718 and 81,986,192 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_MilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_MilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_MilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit losses on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduced revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on-offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable securities, Fair Market Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical supply cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Supply Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedClinicalSupplyCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical supply costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options, term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of investments were less than one year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable (In years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Collaborators</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two Inducement Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandTwentyTwoInducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two inducement Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">accrued bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Payments Owed Under Company's Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future milestone payments owed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Milestone Payments Owed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_FutureMilestonePaymentsOwed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future milestone payments owed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements disclosure line items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases related to tax positions taken during the current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities Right-of-use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities due to related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S Government Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IssuanceCostOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance cost of preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IssuanceCostOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Cost Of Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IssuanceCostOfPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance cost of convertible preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value of units granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value per Share, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards And Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Stock Awards And Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards And Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Un-recognized compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, cliff vesting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdimabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adimab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AdimabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adimab</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decreases related to tax positions taken during the prior year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AccruedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from issuance of common stock upon public offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premiums and accretion of discounts on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from (payments for) issuance of common stock as part of an initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance deferred tax asset change in amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested or expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, cliff vesting percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cliff vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adimab Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Adimab Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TwoThousandFourteenAdimabAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Fourteen Adimab Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss from disposal of property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, additional milestone payments receivable per program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Milestone Payments Receivable Per Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration and License Agreement Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and License Agreement Effective Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeiture/Cancellation of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Convertible preferred stock, ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Convertible preferred stock, beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of instruments in loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized tax benefits, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized tax benefits, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Newark, California.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Newark California [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_NewarkCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards beginning expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Beginning Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward beginning expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AbbVie biotechnology, limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Abb Vie Biotechnology Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AbbVieBiotechnologyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AbbVie Biotechnology Limited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Sublease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sublease, existence of option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, milestone payments on option rights exercised per program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Milestone Payments On Option Rights Exercised Per Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive option rights exercised for each program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income (loss) per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subsequent offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubsequentOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward, deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_GskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GSK [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_GskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GSK [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_GskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GlaxoSmithKline plc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extend for an additional lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, upfront payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Upfront Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_CollaborativeArrangementUpfrontPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of stock owned by Individual.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Stock Owned By Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_PercentageOfStockOwnedByIndividual_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of stock owned by Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AlectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alector [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AlectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alector.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_AlectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alector</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SubleaseIncomeAndReimbursementOfVariableLeaseCost1.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income And Reimbursement Of Variable Lease Cost1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease income and reimbursement of variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income and reimbursement of variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Domestic and state tax authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic And State Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_DomesticAndStateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State Tax Authorities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Recognized Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating sublease, impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of option exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant, and equipment useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined matching contribution plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">South San Francisco.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SouthSanFranciscoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax reserve.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Reserve</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_TaxReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax reserve</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash equivalents and marketable securities, Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax benefit at federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseInExpectedCostPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in expected cost percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseInExpectedCostPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Expected Cost Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_IncreaseInExpectedCostPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase In Expected Cost Percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="alec_SalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Awards and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares authorized (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IssuanceCostsOfCommonStock" xlink:to="alec_IssuanceCostsOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubleaseExpirationMonthAndYear" xlink:to="alec_SubleaseExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ReversalReservesOnUncertainTaxProvisions" xlink:to="alec_ReversalReservesOnUncertainTaxProvisions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationRevenueMember" xlink:to="alec_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="alec_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationReceivable" xlink:to="alec_CollaborationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_InnoventBiologicsMember" xlink:to="alec_InnoventBiologicsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AreaOfPropertyInSubleaseAgreement" xlink:to="alec_AreaOfPropertyInSubleaseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdditionalAreaOfPropertyInLease" xlink:to="alec_AdditionalAreaOfPropertyInLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInCollaborationReceivable" xlink:to="alec_IncreaseDecreaseInCollaborationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CashEquivalentsAndMarketableSecuritiesMember" xlink:to="alec_CashEquivalentsAndMarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitPlansPolicy" xlink:to="us-gaap_PostemploymentBenefitPlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OfficesAndLaboratoryFacilitiesMember" xlink:to="alec_OfficesAndLaboratoryFacilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdditionalAreaSubleaseExpirationMonthAndYear" xlink:to="alec_AdditionalAreaSubleaseExpirationMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PhaseThreeLicenseMember" xlink:to="alec_PhaseThreeLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AreaOfPropertyInLease" xlink:to="alec_AreaOfPropertyInLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TaxCreditBeginningExpirationYear" xlink:to="alec_TaxCreditBeginningExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues" xlink:to="alec_TemporaryStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts" xlink:to="alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="alec_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram" xlink:to="alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue" xlink:to="alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LeaseExpirationYear" xlink:to="alec_LeaseExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AmortizationRightOfUseAsset" xlink:to="alec_AmortizationRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SummaryOfSignificantAccountingPoliciesTable" xlink:to="alec_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedPropertyAndEquipmentCurrent" xlink:to="alec_AccruedPropertyAndEquipmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfDevelopmentCost" xlink:to="alec_PercentageOfDevelopmentCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="alec_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_MilestonePaymentReceivable" xlink:to="alec_MilestonePaymentReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesGainLoss" xlink:to="us-gaap_MarketableSecuritiesGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_FollowOnPublicOfferingMember" xlink:to="alec_FollowOnPublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedClinicalSupplyCost" xlink:to="alec_AccruedClinicalSupplyCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseDecreaseInLeaseLiabilities" xlink:to="alec_IncreaseDecreaseInLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandTwentyTwoInducementPlanMember" xlink:to="alec_TwoThousandTwentyTwoInducementPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_FutureMilestonePaymentsOwed" xlink:to="alec_FutureMilestonePaymentsOwed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="alec_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems" xlink:to="alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="alec_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DevelopmentMilestone" xlink:to="alec_DevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_LabEquipmentMember" xlink:to="alec_LabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IssuanceCostOfPreferredStock" xlink:to="alec_IssuanceCostOfPreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember" xlink:to="alec_RestrictedStockAwardsAndRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AdimabMember" xlink:to="alec_AdimabMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AccruedResearchAndDevelopmentCosts" xlink:to="alec_AccruedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering" xlink:to="alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DeferredTaxAssetsLeaseLiabilities" xlink:to="alec_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage" xlink:to="alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TwoThousandFourteenAdimabAgreementMember" xlink:to="alec_TwoThousandFourteenAdimabAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram" xlink:to="alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborationAndLicenseAgreementEffectiveDate" xlink:to="alec_CollaborationAndLicenseAgreementEffectiveDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_NewarkCaliforniaMember" xlink:to="alec_NewarkCaliforniaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_OperatingLossCarryforwardsBeginningExpirationYear" xlink:to="alec_OperatingLossCarryforwardsBeginningExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AbbVieBiotechnologyLimitedMember" xlink:to="alec_AbbVieBiotechnologyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram" xlink:to="alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubsequentOfferingPeriod" xlink:to="alec_SubsequentOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_GskMember" xlink:to="alec_GskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseRenewalTerm" xlink:to="us-gaap_LessorOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_CollaborativeArrangementUpfrontPayments" xlink:to="alec_CollaborativeArrangementUpfrontPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_PercentageOfStockOwnedByIndividual" xlink:to="alec_PercentageOfStockOwnedByIndividual_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_AlectorMember" xlink:to="alec_AlectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1" xlink:to="alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_DomesticAndStateTaxAuthorityMember" xlink:to="alec_DomesticAndStateTaxAuthorityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SouthSanFranciscoMember" xlink:to="alec_SouthSanFranciscoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_TaxReserve" xlink:to="alec_TaxReserve_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_IncreaseInExpectedCostPercentage" xlink:to="alec_IncreaseInExpectedCostPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alec_SalesMilestone" xlink:to="alec_SalesMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294935536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALEC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2933343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 627.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">131 Oyster Point Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">231-5660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alector, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001653087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,027,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the registrant&#8217;s Definitive Proxy Statement relating to the registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s 2022 fiscal year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822302427744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 154,323<span></span>
</td>
<td class="nump">$ 329,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">558,528<span></span>
</td>
<td class="nump">406,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborationReceivable', window );">Receivable from Collaboration partner</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">7,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,997<span></span>
</td>
<td class="nump">7,071<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">726,435<span></span>
</td>
<td class="nump">749,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">25,521<span></span>
</td>
<td class="nump">27,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">27,811<span></span>
</td>
<td class="nump">30,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,409<span></span>
</td>
<td class="nump">5,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">787,648<span></span>
</td>
<td class="nump">814,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,189<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AccruedClinicalSupplyCost', window );">Accrued clinical supply costs</a></td>
<td class="nump">5,559<span></span>
</td>
<td class="nump">8,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">27,771<span></span>
</td>
<td class="nump">27,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">48,231<span></span>
</td>
<td class="nump">90,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">8,059<span></span>
</td>
<td class="nump">7,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">93,809<span></span>
</td>
<td class="nump">139,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, long-term portion</a></td>
<td class="nump">443,370<span></span>
</td>
<td class="nump">334,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term portion</a></td>
<td class="nump">35,268<span></span>
</td>
<td class="nump">39,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">573,206<span></span>
</td>
<td class="nump">513,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized; 82,895,718 and 81,986,192 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">798,696<span></span>
</td>
<td class="nump">748,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,575)<span></span>
</td>
<td class="num">(943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(579,687)<span></span>
</td>
<td class="num">(446,377)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">214,442<span></span>
</td>
<td class="nump">300,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 787,648<span></span>
</td>
<td class="nump">$ 814,658<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedClinicalSupplyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical supply cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedClinicalSupplyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822302428080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">82,895,718<span></span>
</td>
<td class="nump">82,895,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">81,986,192<span></span>
</td>
<td class="nump">81,986,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294795936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 133,617<span></span>
</td>
<td class="nump">$ 207,085<span></span>
</td>
<td class="nump">$ 21,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 210,418<span></span>
</td>
<td class="nump">$ 189,407<span></span>
</td>
<td class="nump">$ 156,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">61,033<span></span>
</td>
<td class="nump">55,038<span></span>
</td>
<td class="nump">59,403<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">271,451<span></span>
</td>
<td class="nump">244,445<span></span>
</td>
<td class="nump">216,272<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(137,834)<span></span>
</td>
<td class="num">(37,360)<span></span>
</td>
<td class="num">(195,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">7,778<span></span>
</td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">4,946<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Loss before income taxes</a></td>
<td class="num">(130,056)<span></span>
</td>
<td class="num">(36,329)<span></span>
</td>
<td class="num">(190,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(133,310)<span></span>
</td>
<td class="num">(36,329)<span></span>
</td>
<td class="num">(190,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(3,632)<span></span>
</td>
<td class="num">(1,557)<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (136,942)<span></span>
</td>
<td class="num">$ (37,886)<span></span>
</td>
<td class="num">$ (189,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.62)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share, basic</a></td>
<td class="nump">82,467,587<span></span>
</td>
<td class="nump">80,416,936<span></span>
</td>
<td class="nump">77,758,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share, diluted</a></td>
<td class="nump">82,467,587<span></span>
</td>
<td class="nump">80,416,936<span></span>
</td>
<td class="nump">77,758,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294507200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,052,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 194,743<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 414,414<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="num">$ (219,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on public offering, net of issuance costs of $1,148 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,602,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon follow-on public offering, net of issuance costs</a></td>
<td class="nump">224,511<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">224,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(190,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190,228)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,316,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">267,530<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">676,956<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="num">(410,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">28,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeiture of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">40,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(1,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (36,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,329)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">81,986,192<span></span>
</td>
<td class="nump">81,986,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 300,724<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">748,036<span></span>
</td>
<td class="num">(943)<span></span>
</td>
<td class="num">(446,377)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under employee stock purchase plan</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">46,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(3,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (133,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">81,986,192<span></span>
</td>
<td class="nump">82,895,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 214,442<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 798,696<span></span>
</td>
<td class="num">$ (4,575)<span></span>
</td>
<td class="num">$ (579,687)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297059728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IssuanceCostsOfCommonStock', window );">Issuance cost of common stock</a></td>
<td class="nump">$ 1,148<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IssuanceCostsOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance cost of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IssuanceCostsOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294534848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (133,310)<span></span>
</td>
<td class="num">$ (36,329)<span></span>
</td>
<td class="num">$ (190,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,714<span></span>
</td>
<td class="nump">6,329<span></span>
</td>
<td class="nump">5,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">46,146<span></span>
</td>
<td class="nump">40,785<span></span>
</td>
<td class="nump">30,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and accretion of discounts on marketable securities</a></td>
<td class="num">(1,163)<span></span>
</td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AmortizationRightOfUseAsset', window );">Amortization of right-of-use assets</a></td>
<td class="nump">2,758<span></span>
</td>
<td class="nump">1,986<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss on right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInCollaborationReceivable', window );">Receivable from collaboration partner</a></td>
<td class="nump">4,804<span></span>
</td>
<td class="num">(7,391)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,926)<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
<td class="num">(3,839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(2,957)<span></span>
</td>
<td class="num">(2,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(572)<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts', window );">Accrued liabilities and accrued clinical supply costs</a></td>
<td class="num">(2,655)<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
<td class="nump">12,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">66,383<span></span>
</td>
<td class="nump">292,915<span></span>
</td>
<td class="num">(21,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(4,274)<span></span>
</td>
<td class="num">(4,012)<span></span>
</td>
<td class="num">(2,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">601<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(20,329)<span></span>
</td>
<td class="nump">298,551<span></span>
</td>
<td class="num">(166,734)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(4,117)<span></span>
</td>
<td class="num">(3,247)<span></span>
</td>
<td class="num">(5,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(556,898)<span></span>
</td>
<td class="num">(343,402)<span></span>
</td>
<td class="num">(506,809)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,696<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">402,001<span></span>
</td>
<td class="nump">286,290<span></span>
</td>
<td class="nump">406,790<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(159,014)<span></span>
</td>
<td class="num">(49,663)<span></span>
</td>
<td class="num">(105,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon public offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">224,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of options to purchase common stock</a></td>
<td class="nump">3,059<span></span>
</td>
<td class="nump">28,530<span></span>
</td>
<td class="nump">6,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock from employee stock purchase plan</a></td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,514<span></span>
</td>
<td class="nump">30,295<span></span>
</td>
<td class="nump">232,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(174,829)<span></span>
</td>
<td class="nump">279,183<span></span>
</td>
<td class="num">(39,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">330,624<span></span>
</td>
<td class="nump">51,441<span></span>
</td>
<td class="nump">91,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">155,795<span></span>
</td>
<td class="nump">330,624<span></span>
</td>
<td class="nump">51,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AmortizationRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AmortizationRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in accrued liabilities and accrued clinical supply costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInCollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In collaboration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInCollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from (payments for) issuance of common stock as part of an initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297114912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Liquidity</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div id="notes_to_consolidated_financials" style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and Liquidity </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Follow-on Offering</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 30, 2020, the Company completed a follow-on offering through issuing and selling </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,602,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, including </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,252,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares sold pursuant to the underwriters&#8217; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">224.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting underwriting discounts and commissions and estimated offering costs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822382264416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of December 31, 2022 relates to a letter of credit established for a lease entered into in June 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.888%;"/>
          <td style="width:1.291%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.017000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.318%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.017000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.318%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.15%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154,323</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">329,152</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,969</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155,795</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">330,624</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,441</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> credit-related losses recognized for the periods presented.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#8217;s financial instruments approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_19d80ba0-b0e8-42a5-8784-39822104cb76;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize an impairment loss on its right-of-use assets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million impairment loss related to its decision to no longer utilize certain property through the end of the lease term.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company's common stock on the grant date, which equals the closing price of the Company's common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, the Company granted RSUs with market conditions to certain executives. The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for forfeitures as they occur for all awards.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee 401(k) Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;Code&#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020, the Company made matching contributions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296368752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements </span></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.882%;"/>
        <td style="width:0.826%;"/>
        <td style="width:9.942%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.294%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">506,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">501,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,352</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,346</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">655,010</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.882%;"/>
        <td style="width:0.826%;"/>
        <td style="width:9.942%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.294%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">218,451</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">218,451</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">407,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">950</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406,099</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">625,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">624,550</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the remaining contractual maturities of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">640.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of investments were less than one year and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of investment were after one year through two years. As of December 31, 2022, fifteen U.S. government treasury securities with an aggregate fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and an aggregate unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were in a loss position for more than twelve months. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is highly unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company did not sell any marketable securities for the years ended December 31, 2022 and 2020. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company sold marketable securities for the total proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for an immaterial realized gain based on the specific identification method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296250800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.       </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration Agreements</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 1, 2021, the Company entered into a Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK), pursuant to which the Company and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab (also referred to as AL001), and AL101 (GSK Agreement). The GSK Agreement was made effective on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 17, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the GSK Agreement, the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in August 2021 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million was received in January 2022. In addition, based on the development and commercialization plan for latozinemab and AL101, the Company may be eligible to receive up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the Company and GSK will equally share profits and losses from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">commercialization </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of latozinemab and AL101. Outside of the United States, the Company will be eligible for double-digit tiered royalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and GSK will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#8217;s disease and Parkinson&#8217;s disease and other non-orphan indications. The Company and GSK will share development costs </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% by GSK and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% by the Company, except that the Company will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the GSK Agreement is within the scope of ASC 808, Collaborative Arrangements, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of AL001 and AL101. Certain elements are required to be accounted for under ASC 606, Revenue From Contracts With Customers, where the counterparty is a customer for a good or service that is a distinct unit of account.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) license and know-how to AL001 FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which is currently in Phase 3 clinical development and (ii) the research and development activities, including license rights and know-how, relating to products in Phase 2 or earlier stages of development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at inception and as of December 31, 2022, included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All potential future milestones and other payments were considered constrained at the inception of the GSK Agreement and as of December 31, 2022, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The respective standalone value for each of the performance obligations was allocated to the transaction price. The estimated SSP of each performance obligation was determined using discounted cash flows from the expected commercialization of AL001 and AL101 and estimated research and development costs to be incurred by the Company in the initial Phase 2 clinical trials. The estimate of SSP for each performance obligation reflects management's assumptions, which may include forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. For the license for FTD-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">GRN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company determined that GSK could benefit from the license at the time the license was granted and therefore, the related performance obligation was satisfied at a point in time. For the product candidates in Phase 2 or earlier stages of development, the Company determined that GSK could not benefit from the licenses without the corresponding development services that the Company has committed to perform due the earlier stage of development for these licenses. Except where agreed to otherwise, the Company will perform research and development activities through the end of the initial Phase 2 clinical trials. Revenue will be recognized over time as the research and development activities are performed. The Company will measure progress based on actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development activities for products in Phase 3 clinical development were determined to be within the scope of ASC 808. Both parties will be active participants in the development, manufacturing, and commercialization of the product and are exposed to significant risks and rewards that are dependent on the commercial success of the products. The Company and GSK participate in profit and loss sharing for each program commensurate with each party's cost-sharing responsibilities during research and development. ASC 808 does not provide recognition and measurement guidance. As such, the Company determined that ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provision of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue under the GSK Agreement during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The deferred revenue related to the GSK Agreement was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">444.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">307.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of initial Phase 2 clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. For the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company recognized a reduction of research and development expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, under the GSK Agreement.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AbbVie</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">205.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in upfront payments, of which $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million were received by the Company in October 2017 and January 2018, respectively. The Company was to perform research and development services for the two programs through the end of Phase 2 clinical trials, which were each considered to be separate performance obligations. AbbVie decided to terminate one of the two collaboration programs, the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. AbbVie provided written notice to terminate the CD33 collaboration program on June 30, 2022. The Company will no longer continue development of this program and will not be eligible for any future milestones related to that program from AbbVie. The Company continues to develop the AL002 program under the AbbVie Agreement. AbbVie has the exclusive right to exercise an option under the AbbVie Agreement with the Company for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. If AbbVie exercises its option for the AL002 program, AbbVie would take over the development beginning with Phase 3 clinical trials, and the product candidates program costs will be split between the parties. The Company would also share in profits and losses upon commercialization of any products. However, following AbbVie&#8217;s exercise of its option for the AL002 program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. In February 2023, the Company and AbbVie amended the AbbVie agreement, which will result in the Company receiving a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payment for the dosing of the first patient in a long-term extension study. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in milestone payments related to the regulatory approval for up to three indications. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price at inception and as of December 31, 2022, included fixed consideration consisting of the upfront payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">205</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All potential future milestones and other payments were considered constrained at the inception of the AbbVie Agreement and as of December 31, 2022, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The deferred revenue related to the AbbVie Agreement was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, respectively. The deferred revenue is expected to be recognized over the research and development period of the programs through the AL002 program through the completion of Phase 2 clinical trials. For the year ended December 31, 2022, we recorded a net increase to collaboration revenue under the AbbVie Agreement due to changes in estimated costs to satisfy the performance obligations resulting from the termination of the AL003 program, partially offset by increases in total expected costs for the AL002 program.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innovent</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&#8217;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent would pay the Company up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in development milestones, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in sales milestones, and future royalties on sales and the Company would retain the rights to develop and commercialize AL008 outside of China. The Company determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement were not included in the transaction price, as all these amounts were</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fully </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">constrained as of December 31, 2022. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenue has been recognized and no payments have been received under the Innovent Agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296369568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Components </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.949%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.714%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.304%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.713%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,330</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab Equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,043</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold Improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,228</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,949</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,133</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,616</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,521</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,330</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.206%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.393%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.423%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,321</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,330</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,758</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,983</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">337</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">560</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,771</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,460</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296252800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leases </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, the Company signed a lease agreement to lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in office and laboratory space in South San Francisco which serves as the Company&#8217;s headquarters (the &#8220;Headquarters&#8221;). </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The lease expires in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2029</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with an option to renew for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The landlord paid for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company signed a lease agreement to lease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of office and laboratory space in Newark, California. The lease term ends on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 6, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with an option to extend for an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The landlord is obligated to pay for up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of tenant improvements.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The measurement of the lease liabilities for the leases excludes the options to extend the term of the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#8217;s leases consist of operating expenses for the spaces.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2019, the Company entered into an agreement to sublease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of the Headquarters (the &#8220;Sublease&#8221;), which was amended to approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,600</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet in December 2020. The Sublease expired in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The sublessee pays its proportionate share of operating expenses for the space.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Company entered into an agreement to sublease approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,132</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet of the Headquarters, which was amended in May 2022 to include an additional space of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,150</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">feet. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,132 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">square feet of space subleased expired in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the additional space will expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">November 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.102%;"/>
        <td style="width:0.722%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.773%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.597%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.613%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,638</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,589</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,785</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,255</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease income and reimbursement of variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,141</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,551</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,109</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,556</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the weighted-average remaining lease term for operating leases was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years and the weighted-average discount rate was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. Cash paid for amounts included in the measurement of lease liabilities for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are the lease payments owed under the Company&#8217;s operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.114%;"/>
        <td style="width:0.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.89%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,732</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,037</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,096</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,335</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Present value adjustment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,008</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296329568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation </span></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized stock-based compensation as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.888%;"/>
        <td style="width:1.291%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.017000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.017000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.15%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,542</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,146</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,785</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Determination of Fair Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.034%;"/>
        <td style="width:1.202%;"/>
        <td style="width:16.8%;"/>
        <td style="width:1.202%;"/>
        <td style="width:16.8%;"/>
        <td style="width:1.202%;"/>
        <td style="width:16.76%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend Rate&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan and 2022 Inducement Plan</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#8217;s employees, directors, and consultants. The Company&#8217;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or more of the outstanding shares, the exercise price of each share shall be at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value and the term of the award shall not exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The stock options generally vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period with one forty-eighth of the shares vesting each month or over a four-year period with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% vesting at the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> cliff and monthly thereafter. The RSUs generally vest over a period of three years with one-twelfth of the shares vesting quarterly. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, the Company added </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,099,309</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares to the shares reserved for issuance under the 2019 Equity Incentive Plan. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,463,901</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the automatic conversion provision of common stock under the 2019 Plan, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,587,550</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were available for issuance of future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, the Company adopted the 2022 Inducement Plan (Inducement Plan) and reserved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,630,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares for issuance under the Inducement Plan for the grant of equity-based awards to individuals who were not previously employees or non-employee directors of the Company. On September 22, 2022, the Company increased the number of shares available for issuance under the 2022 Inducement Plan to a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,300,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,401,483</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were available for issuance of future awards under the Inducement Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option activity is shown below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.134%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.927000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.309999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.862%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.442%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,654,998</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,264,059</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,223</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,879,764</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.55</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,644,070</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,996,366</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,239</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,628,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.28</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,713,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,776,201</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,276</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest as of December 31,<br/>&#160;&#160;&#160;2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,713,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020, respectively. The weighted-average grant-date fair value per share of options granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.42</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested stock options was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Activity</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity for the restricted stock awards and RSUs is shown below.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In May 2021 and January 2022, the Company issued RSUs with market conditions to certain executives, which are also included in the table below. The RSUs with market conditions are earned based on stock price performance and continued service by the employee. The RSUs with market conditions trigger vesting upon the company's stock price attaining a specified level over a specified period of time. The shares then vest quarterly over one year after attainment. The Company used a Monte Carlo simulation model to determine the fair value of the awards at the grant date. The Monte Carlo model uses the fair value inputs on the grant date to run simulations and take an average of possible outcomes. The total grant date fair value of the RSUs with market condition was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to be amortized over an estimated weighted average service period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years. Compensation expense related to awards with market-based conditions is recognized regardless of whether the market condition is ultimately satisfied if the related service has been provided.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.585%;"/>
        <td style="width:1.267%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.103%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.709%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.334999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value per<br/>Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards and restricted stock units as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,822,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.33</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">324,802</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,044</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.85</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,373,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,539,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.02</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">414,577</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">453,693</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.21</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units as of<br/>&#160;&#160;&#160;December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,044,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company expects to recognize over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 Employee Stock Purchase Plan (2019 ESPP) enables eligible employees of the Company to purchase shares of common stock at a discount. Each offering period is approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> long beginning on the first trading day on or after June 1 and December 1 each year. ESPP participants purchase shares of common stock at a price per share equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 1, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,397</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were added to the shares reserved for issuance under the 2019 ESPP pursuant to the annual automatic increase. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in unrecognized compensation expense related to the 2019 ESPP to be recognized over five months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296218160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal and state income tax provision for the year ended December 31, 2022, 2021 and 2020 are summarized as follows (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.115%;"/>
        <td style="width:1.963%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.235999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.974%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.248%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.974%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.491%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,209</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,045</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Income tax provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,254</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.61%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.988999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.988999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.022%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,627</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">344</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">398</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,570</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,010</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,733</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,347</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,003</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,421</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,254</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets and liabilities consist of (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.182%;"/>
        <td style="width:2.441%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.450999999999997%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.441%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.483999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,868</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,811</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,319</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,614</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,351</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,656</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,673</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,849</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,296</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 R&amp;D capitalization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,150</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,608</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,788</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,316</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,046</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,609</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,454</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,609</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company had federal and state net operating loss (NOL) carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of taxable income. State NOL carryforwards will begin to expire as early as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2030</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if not utilized, or have an indefinite life. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company also had federal and California tax credit carryforward of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The federal tax credits will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">while the California tax credits have no expiration date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.002%;"/>
        <td style="width:2.048%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.95%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decreases related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,939</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,199</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the unrecognized tax benefits for uncertain tax positions as of December 31, 2022, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended December 31, 2022. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company recorded an uncertain tax position of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. The income tax provision for the years ended December 31, 2022 and 2021, included a reversal of reserves on uncertain tax provisions of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company&#8217;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296250800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2014, the Company entered into a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its latozinemab and AL101 programs and is developing antibodies optimized by Adimab in its AL002 program (2014 Adimab Agreement). The 2014 Adimab Agreement also provided for the Company&#8217;s development of antibodies optimized by Adimab in its AL003 program. However, AbbVie decided to terminate the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. In August 2019, the Company signed a collaboration agreement with Adimab for research and development of additional antibodies (2019 Adimab Agreement). In December 2021, the Company signed another collaboration agreement with Adimab for antibody engineering research programs (2021 Adimab Agreement). The 2021 Adimab agreement expired at the end of the option period for the research program that was conducted under the agreement. The former Chief Executive Officer of Adimab through May 2022 is a Co-founder and Chairperson of the board of directors of Alector. For the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021, and 2020, Alector incurred expenses of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for milestone payments for progress of programs through clinical trials and other expenses. The Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> accrued liabilities due to Adimab as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021. Under the 2014 Adimab Agreement, the Company has made milestone payments and will owe low- to mid- single-digit royalty payments for commercial sales of the product candidate. Under the 2019 Adimab Agreements, the Company will owe certain milestone payments and low single-digit royalty payments for commercial sales of covered product candidates.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296209488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss Per Share</span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.897%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.309999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.309999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.584%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,044,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,373,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,713,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,644,070</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,654,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares committed under 2019 ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167,133</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,925,023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,088,350</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,928,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296363968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent Events</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, the Company and AbbVie amended the AbbVie agreement, which will result in the Company receiving a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payment for the dosing of the first patient in a long-term extension study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294696816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents, and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of December 31, 2022 relates to a letter of credit established for a lease entered into in June 2018.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.888%;"/>
          <td style="width:1.291%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.017000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.318%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.017000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.318%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.15%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154,323</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">329,152</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,969</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155,795</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">330,624</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,441</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Marketable Securities</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All marketable securities have been classified as &#8220;available-for-sale&#8221; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#8217; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#8217;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#8217;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> credit-related losses recognized for the periods presented.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#8217;s financial instruments approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_19d80ba0-b0e8-42a5-8784-39822104cb76;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize an impairment loss on its right-of-use assets. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company recognized a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million impairment loss related to its decision to no longer utilize certain property through the end of the lease term.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company's common stock on the grant date, which equals the closing price of the Company's common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2021, the Company granted RSUs with market conditions to certain executives. The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for forfeitures as they occur for all awards.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; equity that are the result of transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitPlansPolicy', window );">Employee 401 (K) Plan</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee 401(k) Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;Code&#8221;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#8217;s contributions to the plan are discretionary. For the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021, and 2020, the Company made matching contributions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates in one segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296282688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:56.888%;"/>
          <td style="width:1.291%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.017000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.318%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.017000000000001%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.318%;"/>
          <td style="width:1.0%;"/>
          <td style="width:11.15%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154,323</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">329,152</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,969</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,472</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents, and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155,795</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">330,624</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,441</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296369568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.882%;"/>
        <td style="width:0.826%;"/>
        <td style="width:9.942%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.294%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,848</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">506,372</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,569</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">501,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,352</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,346</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">655,010</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.882%;"/>
        <td style="width:0.826%;"/>
        <td style="width:9.942%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.445%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.294%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.256%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Market<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">218,451</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">218,451</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">407,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">950</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">406,099</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash equivalents and marketable<br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">625,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">624,550</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296261024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.949%;"/>
        <td style="width:1.32%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.714%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.304%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.713%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,310</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,330</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab Equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,043</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold Improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,228</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,949</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,133</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,616</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,521</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,330</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.206%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.393%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.423%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,321</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,330</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued employee compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,758</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,664</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,983</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">337</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">560</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">372</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,771</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,460</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296271264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of lease expense were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.102%;"/>
        <td style="width:0.722%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.773%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.597%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.613%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,638</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,589</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,785</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,255</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sublease income and reimbursement of variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,141</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,551</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,109</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,556</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Lease Payments Owed Under Company's Operating Leases</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following are the lease payments owed under the Company&#8217;s operating leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.114%;"/>
        <td style="width:0.996%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.89%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,732</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,037</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,681</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,096</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,335</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Present value adjustment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,008</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,327</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297851536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Recognized Stock-Based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized stock-based compensation as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.888%;"/>
        <td style="width:1.291%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.017000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.017000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.318%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.15%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,895</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,542</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46,146</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,785</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated grant-date fair value of all the Company&#8217;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.034%;"/>
        <td style="width:1.202%;"/>
        <td style="width:16.8%;"/>
        <td style="width:1.202%;"/>
        <td style="width:16.8%;"/>
        <td style="width:1.202%;"/>
        <td style="width:16.76%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options to Purchase Common Stock</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option activity is shown below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.134%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.927000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.309999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.862%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.081%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.442%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,654,998</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,264,059</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.53</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,223</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,879,764</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.55</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,644,070</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.41</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,996,366</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.11</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,239</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,628,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.28</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,713,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,776,201</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.75</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,276</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest as of December 31,<br/>&#160;&#160;&#160;2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,713,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,583</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Awards and Restricted Stock Units</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity for the restricted stock awards and RSUs is shown below.</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.585%;"/>
        <td style="width:1.267%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.103%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.709%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.334999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Grant<br/>Date Fair<br/>Value per<br/>Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock awards and restricted stock units as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.95</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,822,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.33</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">324,802</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310,044</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.85</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,373,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,539,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.02</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">414,577</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">453,693</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.21</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units as of<br/>&#160;&#160;&#160;December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,044,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.68</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294713536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Federal and State Income Tax Provision</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal and state income tax provision for the year ended December 31, 2022, 2021 and 2020 are summarized as follows (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.115%;"/>
        <td style="width:1.963%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.235999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.974%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.248%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.974%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.491%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,209</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,045</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Income tax provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,254</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the federal statutory rate to the Company&#8217;s effective tax rate is as follows for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.61%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.988999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.988999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.464%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.022%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefit at federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,627</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,948</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">344</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">398</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,570</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,184</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,010</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Uncertain tax positions</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,733</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,347</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,003</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,368</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,421</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,800</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,280</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income tax provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,254</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant components of the Company&#8217;s deferred tax assets and liabilities consist of (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.182%;"/>
        <td style="width:2.441%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.450999999999997%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.441%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.483999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,963</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63,868</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued bonus</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,811</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,319</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,614</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,351</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,656</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67,673</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,849</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,055</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,296</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 R&amp;D capitalization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,150</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,608</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,788</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,316</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122,046</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,609</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,454</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,609</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,742</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.002%;"/>
        <td style="width:2.048%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.95%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,592</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decreases related to tax positions taken during the<br/>&#160;&#160;&#160;prior year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,939</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increases related to tax positions taken during the<br/>&#160;&#160;&#160;current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,199</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,138</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822296182304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.897%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.309999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.309999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.3%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.584%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,044,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,373,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186,425</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,713,272</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,644,070</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,654,998</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares committed under 2019 ESPP</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167,133</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70,406</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,677</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,925,023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,088,350</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,928,100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294719984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Liquidity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,602,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="nump">1,252,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember', window );">Follow-on-offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offerings</a></td>
<td class="nump">9,602,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 224.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements disclosure line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alec_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294888848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesGainLoss', window );">Credit losses on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss on right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution plan, maximum annual contributions per employee, percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined matching contribution plan</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822301282576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 154,323<span></span>
</td>
<td class="nump">$ 329,152<span></span>
</td>
<td class="nump">$ 49,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 155,795<span></span>
</td>
<td class="nump">$ 330,624<span></span>
</td>
<td class="nump">$ 51,441<span></span>
</td>
<td class="nump">$ 91,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294956144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">$ 74,848<span></span>
</td>
<td class="nump">$ 218,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">74,848<span></span>
</td>
<td class="nump">218,451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S Government Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">506,372<span></span>
</td>
<td class="nump">407,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(4,569)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">501,810<span></span>
</td>
<td class="nump">406,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">44,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">44,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">29,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">29,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cash equivalents and marketable securities, Amortized Cost</a></td>
<td class="nump">655,010<span></span>
</td>
<td class="nump">625,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Gains</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash equivalents and marketable securities, Unrealized Losses</a></td>
<td class="num">(4,587)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Cash equivalents and marketable securities, Fair Market Value</a></td>
<td class="nump">$ 650,436<span></span>
</td>
<td class="nump">$ 624,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=alec_CashEquivalentsAndMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=alec_CashEquivalentsAndMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294458160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Remaining contractual maturities of investments were less than one year</a></td>
<td class="nump">$ 640,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue', window );">Remaining contractual maturities of investments were less than one year through two years</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 10,696<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair value of instruments in loss position</a></td>
<td class="nump">133,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822293753360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,900<span></span>
</td>
<td class="nump">$ 307,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,418<span></span>
</td>
<td class="nump">189,407<span></span>
</td>
<td class="nump">$ 156,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_GskMember', window );">GlaxoSmithKline plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborationAndLicenseAgreementEffectiveDate', window );">Effective date of agreement</a></td>
<td class="text">Aug. 17,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementUpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfDevelopmentCost', window );">Percentage Of Development Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,900<span></span>
</td>
<td class="nump">192,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_GskMember', window );">GlaxoSmithKline plc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram', window );">Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AlectorMember', window );">Alector</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfDevelopmentCost', window );">Percentage Of Development Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementUpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="nump">$ 205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,700<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">$ 21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,700<span></span>
</td>
<td class="nump">$ 117,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram', window );">Exclusive option rights exercised for each program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember', window );">AbbVie Biotechnology Limited | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram', window );">Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=alec_InnoventBiologicsMember', window );">Innovent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DevelopmentMilestone', window );">Development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SalesMilestone', window );">Sales milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborationAndLicenseAgreementEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreement Effective Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborationAndLicenseAgreementEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, additional milestone payments receivable per program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, milestone payments on option rights exercised per program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement milestone payments receivable per program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_CollaborativeArrangementUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, upfront payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_CollaborativeArrangementUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_GskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_GskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_AlectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_AlectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_InnoventBiologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_InnoventBiologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297542384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 48,133<span></span>
</td>
<td class="nump">$ 44,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(22,612)<span></span>
</td>
<td class="num">(17,286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">25,521<span></span>
</td>
<td class="nump">27,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,430<span></span>
</td>
<td class="nump">2,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17,165<span></span>
</td>
<td class="nump">14,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 26,228<span></span>
</td>
<td class="nump">$ 25,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294887632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">$ 12,321<span></span>
</td>
<td class="nump">$ 13,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation</a></td>
<td class="nump">12,758<span></span>
</td>
<td class="nump">11,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">1,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AccruedPropertyAndEquipmentCurrent', window );">Accrued property and equipment</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 27,771<span></span>
</td>
<td class="nump">$ 27,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued property and equipment current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822293992448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Amount form letter of credit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease expires in 2029 with an option to renew for a period of ten years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included In measurement of lease liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AreaOfPropertyInLease', window );">Area under lease | ft&#178;</a></td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AreaOfPropertyInSubleaseAgreement', window );">Area under sublease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SubleaseExpirationMonthAndYear', window );">Sublease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-12<span></span>
</td>
<td class="text">2021-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AdditionalAreaSubleaseExpirationMonthAndYear', window );">Additional area sublease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend', window );">Operating sublease, existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_AdditionalAreaOfPropertyInLease', window );">Additional area of property in lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember', window );">Offices and Laboratory Facilities | South San Francisco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of property | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  06,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseRenewalTerm', window );">Extend for an additional lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AdditionalAreaOfPropertyInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional area of property in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AdditionalAreaOfPropertyInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AdditionalAreaSubleaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional area sublease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AdditionalAreaSubleaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AreaOfPropertyInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of property in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AreaOfPropertyInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_AreaOfPropertyInSubleaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of property in sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_AreaOfPropertyInSubleaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubleaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubleaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether sublessee has option to extend operating sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alec_OfficesAndLaboratoryFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alec_SouthSanFranciscoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alec_SouthSanFranciscoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=alec_NewarkCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=alec_NewarkCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822295586800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 6,638<span></span>
</td>
<td class="nump">$ 6,204<span></span>
</td>
<td class="nump">$ 5,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">2,785<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
<td class="nump">2,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1', window );">Sublease income and reimbursement of variable lease cost</a></td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(2,141)<span></span>
</td>
<td class="num">(2,288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 7,551<span></span>
</td>
<td class="nump">$ 7,109<span></span>
</td>
<td class="nump">$ 5,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>SubleaseIncomeAndReimbursementOfVariableLeaseCost1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822301454672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 8,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">8,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">9,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">9,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">9,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">56,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(13,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 43,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822301296704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 46,146<span></span>
</td>
<td class="nump">$ 40,785<span></span>
</td>
<td class="nump">$ 30,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">24,895<span></span>
</td>
<td class="nump">21,443<span></span>
</td>
<td class="nump">14,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 21,251<span></span>
</td>
<td class="nump">$ 19,342<span></span>
</td>
<td class="nump">$ 15,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822290571664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Share-based Payment Arrangement, Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294349728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards And Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue', window );">Grant date fair value of units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based payment award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Un-recognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Automatic conversion provision of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,463,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,099,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_PercentageOfStockOwnedByIndividual', window );">Percentage of stock owned by Individual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price per share from fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage', window );">Cliff vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod', window );">Cliff vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,587,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.42<span></span>
</td>
<td class="nump">$ 14.70<span></span>
</td>
<td class="nump">$ 10.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Automatic conversion provision of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_SubsequentOfferingPeriod', window );">Subsequent offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Un-recognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alec_TwoThousandTwentyTwoInducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Automatic conversion provision of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,401,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_PercentageOfStockOwnedByIndividual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stock owned by Individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_PercentageOfStockOwnedByIndividual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, cliff vesting percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, cliff vesting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_SubsequentOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsequent offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_SubsequentOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandTwentyTwoInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandTwentyTwoInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294644048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Options to Purchase Common Stock (Details) - 2019 Equity Incentive Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, beginning balance</a></td>
<td class="nump">11,644,070<span></span>
</td>
<td class="nump">12,654,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">4,996,366<span></span>
</td>
<td class="nump">3,264,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(298,239)<span></span>
</td>
<td class="num">(2,395,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="num">(2,628,925)<span></span>
</td>
<td class="num">(1,879,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, ending balance</a></td>
<td class="nump">13,713,272<span></span>
</td>
<td class="nump">11,644,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">6,776,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">13,713,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, beginning balance</a></td>
<td class="nump">$ 16.41<span></span>
</td>
<td class="nump">$ 13.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">12.11<span></span>
</td>
<td class="nump">21.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">10.26<span></span>
</td>
<td class="nump">11.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">18.28<span></span>
</td>
<td class="nump">14.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding, ending balance</a></td>
<td class="nump">14.62<span></span>
</td>
<td class="nump">$ 16.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">14.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 14.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable (In years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested or expected to vest</a></td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alec_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294441456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details) - Restricted Stock Awards And Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, beginning balance</a></td>
<td class="nump">1,373,874<span></span>
</td>
<td class="nump">186,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted</a></td>
<td class="nump">2,539,014<span></span>
</td>
<td class="nump">1,822,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested</a></td>
<td class="num">(414,577)<span></span>
</td>
<td class="num">(324,802)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited</a></td>
<td class="num">(453,693)<span></span>
</td>
<td class="num">(310,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, ending balance</a></td>
<td class="nump">3,044,618<span></span>
</td>
<td class="nump">1,373,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance</a></td>
<td class="nump">$ 18.35<span></span>
</td>
<td class="nump">$ 6.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Granted</a></td>
<td class="nump">10.02<span></span>
</td>
<td class="nump">17.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Vested</a></td>
<td class="nump">18.63<span></span>
</td>
<td class="nump">10.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Forfeited</a></td>
<td class="nump">16.21<span></span>
</td>
<td class="nump">13.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value per Share, Unvested, ending balance</a></td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 18.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alec_RestrictedStockAwardsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297429904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Federal and State Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 3,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294475472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at federal statutory rate</a></td>
<td class="num">$ (27,205)<span></span>
</td>
<td class="num">$ (7,627)<span></span>
</td>
<td class="num">$ (39,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="num">(16,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(20,184)<span></span>
</td>
<td class="num">(9,389)<span></span>
</td>
<td class="num">(8,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain tax positions</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">4,919<span></span>
</td>
<td class="num">(2,368)<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">38,421<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">62,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 3,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822301478176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 20,963<span></span>
</td>
<td class="nump">$ 63,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued bonus</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">26,319<span></span>
</td>
<td class="nump">19,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">13,351<span></span>
</td>
<td class="nump">9,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">67,673<span></span>
</td>
<td class="nump">27,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">10,055<span></span>
</td>
<td class="nump">11,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Section 174 R&amp;D capitalization</a></td>
<td class="nump">35,150<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">175,925<span></span>
</td>
<td class="nump">134,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(164,316)<span></span>
</td>
<td class="num">(122,046)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">11,609<span></span>
</td>
<td class="nump">12,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(5,155)<span></span>
</td>
<td class="num">(5,488)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(6,454)<span></span>
</td>
<td class="num">(7,254)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(11,609)<span></span>
</td>
<td class="num">(12,742)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Assets tax deferred expense capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities Right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822302127872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance deferred tax asset change in amount</a></td>
<td class="nump">$ 42,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Uncertain tax provision</a></td>
<td class="nump">8,199,000<span></span>
</td>
<td class="nump">$ 2,406,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_ReversalReservesOnUncertainTaxProvisions', window );">Reversal of reserves on uncertain tax provisions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">40,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_TaxCreditBeginningExpirationYear', window );">Tax Credit Beginning Expiration Year</a></td>
<td class="text">2036 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Tax Authority | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Operating loss carry forward, deductions</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward, net</a></td>
<td class="nump">$ 203,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_OperatingLossCarryforwardsBeginningExpirationYear', window );">Operating loss carry forward beginning expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_OperatingLossCarryforwardsBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_OperatingLossCarryforwardsBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_ReversalReservesOnUncertainTaxProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reversal Reserves On Uncertain Tax Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_ReversalReservesOnUncertainTaxProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_TaxCreditBeginningExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit beginning expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_TaxCreditBeginningExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297877056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, beginning balance</a></td>
<td class="nump">$ 6,939<span></span>
</td>
<td class="nump">$ 4,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to tax positions taken during the prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions taken during the current year</a></td>
<td class="nump">8,199<span></span>
</td>
<td class="nump">2,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits, ending balance</a></td>
<td class="nump">$ 15,138<span></span>
</td>
<td class="nump">$ 6,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294550208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_AdimabMember', window );">Adimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued liabilities due to related parties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_TwoThousandFourteenAdimabAgreementMember', window );">Two Thousand Fourteen Adimab Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction expenses</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_AdimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_AdimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_TwoThousandFourteenAdimabAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alec_TwoThousandFourteenAdimabAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822294283264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">16,925,023<span></span>
</td>
<td class="nump">13,088,350<span></span>
</td>
<td class="nump">12,928,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards And Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">3,044,618<span></span>
</td>
<td class="nump">1,373,874<span></span>
</td>
<td class="nump">186,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">13,713,272<span></span>
</td>
<td class="nump">11,644,070<span></span>
</td>
<td class="nump">12,654,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares Committed Under 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares</a></td>
<td class="nump">167,133<span></span>
</td>
<td class="nump">70,406<span></span>
</td>
<td class="nump">86,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139822297444048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | AbbVie Biotechnology Limited</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_alec_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">$ 17.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alec_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alec_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alec_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=alec_AbbVieBiotechnologyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>alec-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:alec="http://alector.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="alec-20221231.xsd" xlink:type="simple"/>
    <context id="C_5c63d7ae-a408-4aaa-b856-64a3f876dcd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ea97f9ff-6baa-434e-8a41-03175d03a38c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_6eb70da4-a1bc-45a1-8da8-c9552a0a4ac6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0120a0fc-9112-4e54-9638-49d731099e2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_67cf0962-6249-477f-8bc4-dab96a763b98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_338e36e2-ef61-4f44-861b-3a1b978b8228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a90b3f2f-9462-46f0-84ce-63965231a711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_dd06c0e7-b9e9-48e2-9fd2-99b651c4b5a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_e759e0c4-57cc-4d3e-90d2-e3c5076206fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b2c6f352-9d45-4576-a18a-112160c86b51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_59b9e1be-3875-4c2c-8688-02e607d91e6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_180fddf9-2bc6-4a44-a946-c3ac0b3b7336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59545206-883a-4aa3-a49c-906caa840899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_816d6294-b950-41ec-954c-c41ce41aab6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_69eaec9d-be8a-46cd-b047-8697f5e418ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0994610a-2693-49ff-a322-fa66e5902607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eebe0049-dfc6-425d-8d39-93f33680d12f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-30</endDate>
        </period>
    </context>
    <context id="C_ed1f3bb7-c84d-4b92-a5a6-e2a94d7ac051">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-22</startDate>
            <endDate>2022-09-22</endDate>
        </period>
    </context>
    <context id="C_319ea842-0000-481f-8857-4a411838770a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="C_43db021b-c8f9-4318-82fe-8c0ec28ec33c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9d16d809-66ff-4090-8fd8-8bb44fd13bcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9cf5d0c4-ca22-4be2-aa95-e9fd5130a84b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2057c28e-bb01-4164-b42a-733be6be9aad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2c3e6d3b-2fe3-4f9b-923c-d40ea56722bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6e29ec8b-8d03-49b6-84f6-bb02efd765fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_51b97a6f-177d-4792-ade6-51b7eab823e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cee82e6c-ce42-4848-8ad7-b247c43c8a26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9f82b000-4be4-479f-8d5a-48258e77ae0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_80e23df0-dda9-41ff-b7a3-932c8bf26d7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4670a0e4-4053-442e-b19c-76a0ef8da1fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b6f138ff-488b-4b84-a7d2-f77486a49d63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b3e5c54-3f8c-4714-8434-7829b44103ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_57f29121-2ac0-4227-aa7c-e698d47d2373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_16a6dfb4-c570-4d0c-aebd-ef6ff61c25e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5506b44b-1aea-4b19-b486-8910d5fdf80a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e26edbee-11a6-44f2-9f0f-58d3b932feaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7a436588-46b7-4c39-90f1-b29291faef62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d339045c-e830-4398-bf09-392c72a9d130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_591622e9-478f-40d8-a4c4-83e7718adf29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_51a99dc6-2893-4e9d-b0b0-79417c0a1aeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4a365a03-f3eb-4107-9a82-26a3d4345ee8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bc7bd397-63c7-41cc-afa7-7230b2cab7ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:InnoventBiologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9836c7b3-8244-4a0a-9397-0627ae5caac7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_14db55be-444b-484b-9308-f5fa77d06c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dad2a26c-287b-4267-9f7c-8a34fc96b55a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0e9e000a-a972-4453-815c-7beddee684a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bb53d62d-50b1-4820-8847-5ea059efb08f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_595ae80d-557b-47e1-8c82-0647e75f5492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_48a91691-46db-40c9-a5b2-794422b8838e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bee6f6bf-d1c4-42f9-9ab2-0d5a9c70a44d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_7bdf40b1-3e1d-4b1d-ac05-25a671e15c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="C_d0630ba0-e9e8-4702-89d0-bdba73bdd2e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0bbd6899-6eb8-4d93-b39f-c6d7afda1a04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d7eda464-9214-4fe2-80f7-6b4a12c2cf10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1eae11ed-31bf-4dfc-a698-681b39d46f70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d2cef38d-be1d-484a-a61c-5428186c190e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_2dccbdd1-17e9-485c-a5ee-03938c7e22f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cf8d8382-eb79-4d5a-aace-511cc534b48b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_92d78956-76c2-4167-b848-5449236c361e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1c68a962-b28e-4960-a9ae-21e424ed19e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1f8633fe-5aaf-447e-ae50-bc7154a4d0d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-30</endDate>
        </period>
    </context>
    <context id="C_4b7ae830-6548-4c51-9858-5fd1f867e8f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e30431e6-e3b0-4a96-9bef-19773862a1a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a84f0779-d476-4feb-8427-952120804b66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dc0ce554-adea-4930-b36c-ddea841a6c0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alec:RestrictedStockAwardsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d0060090-89cf-486b-ac52-984818190a96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a935fdcb-ad72-4392-9a72-8a721afa0563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1daf4bd9-70b1-46fd-8ea2-c3707e3a6d0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1389774a-b29c-48d6-a55f-f4bbb7532913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_52877e94-eb03-44b8-a6be-a533ea71c990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_79a8adcb-cfbf-4eba-bbda-4e86d5eee09c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f5a26f10-025e-4a2e-83ca-fad8cfb00b35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2d982249-1d80-47dc-833c-6f8db5de8881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a3b39a72-f9d5-452e-8491-11e893261ed3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_235ab5c2-cb0b-4693-a7d8-c6af3cd3645b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_23fa1cec-8bf2-4e74-94f9-7b74111d38b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b2eed340-5921-424b-b2bd-6f6e1a65315d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5ede9fc7-3539-445c-b590-2e32ccf2dc14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_45035b09-08b3-4500-b7a8-9c651c96035b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7aceb927-85b2-403a-82fd-27292ccc4303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8df03805-8723-4874-a2a2-8c93c5cbd3d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_68921c7f-cea1-46f8-9606-82bf1ee5887d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_b8e32b37-b52b-4be3-bbcc-061f59815156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3bca2306-c6f8-41f3-9a71-4b209e479578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_98dece0f-6865-495b-b2f4-10ffd8b3e0d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e86e0f59-9472-4a49-b595-48701d364860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3b2caf5-7252-4732-8fff-6572963b403e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">alec:CashEquivalentsAndMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1ae3112e-641f-46ac-8cd7-601ed0a853e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a249850f-9ff5-4ed1-8915-381e8e7d8c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_6f4164fc-b4c1-41ca-8455-663b93759519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e21ea263-2f4e-4a53-bf66-2c7077518b36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c0a599ce-bcb4-4bd2-baef-99bf600a266e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1066ab24-de91-4fc8-b8ef-54102a1ace80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a63e3081-f730-456e-b5ed-d6fc2de87931">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AlectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2e8bb82e-dade-4bfe-bc72-3759b7ed3710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_43d96e6b-e335-4918-832b-938ca6e7af68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fe4d91c0-ce81-47c8-ba8d-75ea9ef9fb79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f138f916-581b-4f02-aadd-4cd12427fc86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_76299c65-2f3a-4aa2-953a-8368c1d95f6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c9cdc029-237a-491e-84f0-8ce387ab9c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1909874-9ac4-4faa-a605-aeb9628d2105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:SouthSanFranciscoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_33d99e34-332b-4171-90ad-9a300bdceb05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_739d8fa6-0e40-445b-8283-8871a7bb5917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandTwentyTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25d652af-cdb3-4c04-9508-c4f3acbb1dcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_493c7746-435c-403e-8f86-4bcdeada8dd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_558fd0f4-ad61-4047-b762-e6960a1f35eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2b22c619-0e67-4a8a-9893-c4a93f9df158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_176df7af-82ab-480c-bae0-7332bb4be390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a0aa7056-f119-4199-97e6-cbcd61a7b3fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:AdimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9fea33d6-9da1-41c4-92b1-404be25d8a1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alec:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-30</instant>
        </period>
    </context>
    <context id="C_f312b892-d20e-4878-bd76-21a8ad92aaba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dfad70cc-a2ab-437f-929e-a3eb95fd5c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:GskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="C_0aed28b8-d995-4247-8f88-dd02919d008c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">alec:NewarkCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alec:OfficesAndLaboratoryFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_873e87e5-56d0-4394-ba3e-604f72c1fb04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alec:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-06</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="C_bbc12a08-d369-441d-a256-6c6e5a6edbac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_57a31f45-5c3e-4095-acf4-1177aeb8b664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_30408e35-6b1a-4011-ac8f-7e1456941ba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4f49c42b-493f-47f8-9739-cb8ff352f950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_07adf335-3612-4d8b-8411-b0ca428a8c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">alec:AbbVieBiotechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7d5342d6-08d3-4f1d-a440-effc09b14ff7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_73e80b90-789c-418b-a25b-f51ca32e11ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dcbe690f-5774-4129-bd39-6000b70e20db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ffc3dde4-e230-4e99-96ea-1e5e5dfbddfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_edb4f89e-28d7-4da4-8c65-2ab76be71025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alec:TwoThousandFourteenAdimabAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_abf92419-83da-405a-8247-30fd4646394a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001653087</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_a3866d38-7523-46db-8d9f-8bcd3b2d27ed">http://alector.com/20221231#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_b7cff7a8-112c-4256-b606-e164953835e3">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      id="F_98ac5068-7936-4fc0-9429-483bd823749b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      id="F_9570da83-0995-4ddf-8004-16aa50d300a5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_5efed98b-6248-4e22-97cd-ede4e5c8887a">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      id="F_06d00587-146f-4b77-9cfb-7f1be4902705">http://alector.com/20221231#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      id="F_88011f76-3c2e-41e3-bb75-b765e6c07793">http://alector.com/20221231#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d7eda464-9214-4fe2-80f7-6b4a12c2cf10"
      id="F_19d80ba0-b0e8-42a5-8784-39822104cb76">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:EntityCentralIndexKey
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_cc21cf17-7429-486a-b806-104d61bd189e">0001653087</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_0e7814e4-5073-4e99-b6fd-985c393ee224">false</dei:AmendmentFlag>
    <us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend
      contextRef="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9"
      id="F_494536dc-8307-42a5-8e8b-fe55a7199628">true</us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend>
    <dei:DocumentType
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_bac464e5-91bc-42a4-b71a-f24347a6f1ab">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f6112d78-e83b-4397-9810-4cd8a71ffd34">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_400c5e9a-a747-4ba4-a177-0e5e1f9c0bb0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_b5f461f3-4da5-45a6-96fa-81624f08ffc2">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_93483845-578a-47e3-a092-9752294ce3d5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_d62b6e77-78aa-4edc-97f3-ec97f38817c2">001-38792</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_46fc0ac1-8912-4ce3-ae39-9912bb703c97">Alector, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_e971bbff-3f10-43a3-8ab8-adab29f4465a">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f2c92e05-a750-44b0-90e4-dac3838f2df2">001-38792</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_d4892758-22c6-4606-95ab-a55e06041f91">82-2933343</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_ff1a4942-5b29-49ae-8bc2-6e2006c02600">131 Oyster Point Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_cd830c8a-0824-48ae-8ad9-0273f148620d">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_e43addef-5226-4a76-8b32-bdcfbcf0072f">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_5eb0382d-4144-4111-82ae-44acdea6f43d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f96374f5-e4f2-4b55-89b7-83cf0f8b371c">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_6f96e951-acc7-4ab1-bc74-11b17baeae2f">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f1d6bbd9-5701-4737-99ff-4a4d54ec8218">231-5660</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_04bb1806-e8a9-4ee7-a4ce-70a0e7434e5d">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_0c2b1fdc-ccd4-4699-b5c4-fd3da1769b7f">ALEC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_62b8f5c2-f461-4f0a-9f1c-e0f5c634d812">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_079840f3-0086-4e41-ad98-df83d491c956">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_00d17e73-e65d-4094-809b-114396915cca">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_016dda0c-00ff-467a-bbb7-4af27ebeb60b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_fc121107-769c-484d-a606-3dcddf701c78">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_114402d8-2d5f-4c3c-81a8-8bc5f1a34b8e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_1ef09cfb-494d-40cb-a350-8cb3f5034acb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_6a028717-c0f0-4545-ae49-912de26912d9">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_2a1b660d-0112-459a-bf01-67d7996358e9">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_5601c700-a945-41a3-9271-81007280be13">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_595ae80d-557b-47e1-8c82-0647e75f5492"
      decimals="-5"
      id="F_5f484f64-8f2d-4c86-a953-f306b08eb39c"
      unitRef="U_USD">627100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_7bdf40b1-3e1d-4b1d-ac05-25a671e15c71"
      decimals="INF"
      id="F_13d006c8-ac36-46d7-90cf-1b9bd3d20eaa"
      unitRef="U_shares">83027910</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_3d79079b-e6c1-4bce-adaf-189dc094234a">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s Definitive Proxy Statement relating to the registrant&#x2019;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s 2022 fiscal year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_ef82858a-f802-45fc-942a-3271e92e9b76">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_49d14a54-a1ea-4f89-99c4-c45d5022c20f">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_d5efff96-f60b-4c49-987e-174aa79f3a46">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_a0b855de-1ffb-4e4d-a91b-c833843f29b3"
      unitRef="U_USD">154323000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_d29cf376-bfb3-42b0-9973-0c365b69fec3"
      unitRef="U_USD">329152000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_6697372c-71ec-4789-9067-0c968a7207ff"
      unitRef="U_USD">558528000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_eb850478-b1e6-4bec-bcba-ffad8ea93b13"
      unitRef="U_USD">406099000</us-gaap:MarketableSecuritiesCurrent>
    <alec:CollaborationReceivable
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_9abe9769-b588-478e-9d8a-3b461311250e"
      unitRef="U_USD">2587000</alec:CollaborationReceivable>
    <alec:CollaborationReceivable
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_a454f0b1-e957-4606-a865-4b6cd70906bb"
      unitRef="U_USD">7391000</alec:CollaborationReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_4589cc93-62dc-43a6-bafb-fb57d9e73b7b"
      unitRef="U_USD">10997000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_32029490-21c2-42bb-8907-35ab5ad721dc"
      unitRef="U_USD">7071000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_c5fa82d5-fe8c-437a-8d9e-42f960f1d672"
      unitRef="U_USD">726435000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_a55122c0-e715-46f2-b875-10cda4c1a00b"
      unitRef="U_USD">749713000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_317fbbf4-bc5f-4387-9315-016dbc99dcae"
      unitRef="U_USD">25521000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_0deba312-4171-4032-8d58-b2d0b6762533"
      unitRef="U_USD">27330000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_0c902e55-6f42-4787-a055-26f8335f9633"
      unitRef="U_USD">27811000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_d4e54f0a-d840-44c1-8dab-176ef525ce91"
      unitRef="U_USD">30569000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_d4875854-ec84-44d9-91f4-b3a0ccfb1906"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_f97c547d-df5f-451b-9e91-ba29441e43e6"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_95637662-777e-42a7-bd79-6875a3d982cd"
      unitRef="U_USD">6409000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_40ac6994-bb85-4a3d-b5f3-267008a9ed2c"
      unitRef="U_USD">5574000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_e8109e9a-f6f0-4bfe-a16b-a4a047c015df"
      unitRef="U_USD">787648000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_4b32936d-77bf-4fb9-82bb-d0d62b22d935"
      unitRef="U_USD">814658000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_819caf4b-24eb-4d20-8b54-a30852ceb965"
      unitRef="U_USD">4189000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_23cfedf5-4571-4991-8da2-4fb3e87b3b85"
      unitRef="U_USD">4749000</us-gaap:AccountsPayableCurrent>
    <alec:AccruedClinicalSupplyCost
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_3650a029-d140-41b1-b030-41dd9871c965"
      unitRef="U_USD">5559000</alec:AccruedClinicalSupplyCost>
    <alec:AccruedClinicalSupplyCost
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_d25911a2-5d9c-48f0-9a56-ea37fb58dc0c"
      unitRef="U_USD">8748000</alec:AccruedClinicalSupplyCost>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_ff1ae905-3cea-46c4-9fe1-0d3ea79eefd1"
      unitRef="U_USD">27771000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_203079bd-2029-48be-92ac-4cbd5d32bf9e"
      unitRef="U_USD">27460000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_7f60b933-2f0e-4dd3-b0b8-ca6fe66bc0f6"
      unitRef="U_USD">48231000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_9d325bd8-45bb-44d4-8c59-0da2ae5025ab"
      unitRef="U_USD">90803000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_2e092bf1-9643-4cc4-befd-caacb83e3218"
      unitRef="U_USD">8059000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_e7a20f63-8237-4e3e-b406-50177c277393"
      unitRef="U_USD">7795000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_37ca2f7f-4e07-495f-8e3c-586a5b9b17ed"
      unitRef="U_USD">93809000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_e14cba99-a885-4812-99c5-1c4913c57ec4"
      unitRef="U_USD">139555000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_24126d02-cd2b-4a48-ba68-27d45569be85"
      unitRef="U_USD">443370000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_68609b3b-a5a6-4166-b1e6-aab30e8e252e"
      unitRef="U_USD">334415000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_47907588-0e75-430c-987c-7090fea6358d"
      unitRef="U_USD">35268000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_db5eab8d-9f1e-46c9-bd91-d7ba1bd4acda"
      unitRef="U_USD">39806000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_82b421ed-cb15-4342-9e20-ee2c3234620f"
      unitRef="U_USD">759000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_e1fa6adf-a9a3-4161-8956-56b45fb73a9b"
      unitRef="U_USD">158000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_745596e2-13f8-49e5-93bc-b004c6e5ba47"
      unitRef="U_USD">573206000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_be86ede3-fa5c-49df-ae1e-240d77ec9a30"
      unitRef="U_USD">513934000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="4"
      id="F_54a293b3-7489-41d0-99ca-97dcb1a2ab9f"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="4"
      id="F_3f6a27e8-923a-4b89-9159-1bc9b8f98875"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="0"
      id="F_ac50ca2b-04dc-4b88-9e24-bc2cef05fa54"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="0"
      id="F_882f6b93-5f1b-4f4d-a053-acbcb5ce3523"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="0"
      id="F_bf5e3602-14d9-4d1e-bfef-3935abb56447"
      unitRef="U_shares">82895718</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="0"
      id="F_c577f4fb-b456-44f9-a5f1-7ba684e52edc"
      unitRef="U_shares">82895718</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="0"
      id="F_2a9144a1-336e-4719-a8e7-a038a1817a6b"
      unitRef="U_shares">81986192</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="0"
      id="F_3779249d-8bef-42ba-a16e-11b17f82d990"
      unitRef="U_shares">81986192</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_6c0dc0c4-4e15-45ee-98fe-2b1a092089ef"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_07ca0083-8d8d-40d8-b40c-664b3fab3da7"
      unitRef="U_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_9d868411-0747-4882-a92e-26d177ae1946"
      unitRef="U_USD">798696000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_8e18e319-0865-43fd-8d28-92459b796244"
      unitRef="U_USD">748036000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_61b566e7-4018-4364-a841-f5ce8f66e11f"
      unitRef="U_USD">-4575000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_2a0ba543-43d7-4b79-bae7-5784dbe6707f"
      unitRef="U_USD">-943000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_2419cdfc-5b64-4bdc-8559-7cf3adc0385e"
      unitRef="U_USD">-579687000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_bcebf795-4726-4c81-9d91-a0df001c926e"
      unitRef="U_USD">-446377000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_3e401b39-c94d-4e23-9ef3-439717894588"
      unitRef="U_USD">214442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_e31edbbc-79ae-4510-9e0f-b7bc0898cef5"
      unitRef="U_USD">300724000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_726c690c-5dfa-4018-8154-403afb713636"
      unitRef="U_USD">787648000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_f7577054-2aa4-4ff8-a728-fef003f00160"
      unitRef="U_USD">814658000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_9124d315-377a-4e0a-9e8d-7bc6462f9deb"
      unitRef="U_USD">133617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_6cdf0bbf-9031-48d7-a9fe-0bda3ca64fea"
      unitRef="U_USD">207085000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_f3090757-59b1-43f9-b2e1-d9dd81f497b1"
      unitRef="U_USD">21098000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_023bfd3b-9aa8-4e18-863f-7d33376a5759"
      unitRef="U_USD">210418000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_36001254-55f4-40e3-9f4f-3106eb6b3eae"
      unitRef="U_USD">189407000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_317407be-7580-4505-8506-2c900574b69d"
      unitRef="U_USD">156869000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_5426a2bf-2a6e-4c46-bdda-f09dea183062"
      unitRef="U_USD">61033000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_af920b35-e431-4bf6-8491-ddfe4854045e"
      unitRef="U_USD">55038000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_a1665bf8-77e2-4ad3-bdd1-c3461ceb878f"
      unitRef="U_USD">59403000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_e718aadc-54b4-4302-a7c3-07461958578b"
      unitRef="U_USD">271451000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_7ed100f9-907b-4d15-a86c-9f66bb585f05"
      unitRef="U_USD">244445000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_ed001acd-50ae-4114-8945-83f8f02514c3"
      unitRef="U_USD">216272000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_b22e48eb-f811-48d0-a161-a71e80e08d42"
      unitRef="U_USD">-137834000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_a85b84e7-9fc4-4f53-8c9a-e09c01d93b7e"
      unitRef="U_USD">-37360000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_85d0f97a-6a4d-43c9-baa9-62d37aa20bfe"
      unitRef="U_USD">-195174000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_8cd9cb6e-84ab-493f-bf7d-70804a9dcb79"
      unitRef="U_USD">7778000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_727efc33-5ac9-4f9e-ba85-58e59de7b31c"
      unitRef="U_USD">1031000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_9f0e0f2d-1670-4416-860c-e8a027f77848"
      unitRef="U_USD">4946000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_0bc2ea86-4bba-466c-81b5-08e35fd04395"
      unitRef="U_USD">-130056000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_d969e68f-bbae-47ab-b98c-22536a13451c"
      unitRef="U_USD">-36329000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_06aa0568-eeef-4807-836a-848cba5dc3dc"
      unitRef="U_USD">-190228000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_5e6c1c50-7974-44fb-89f6-158b0914a460"
      unitRef="U_USD">3254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_5a02b272-3115-4bf0-b004-15bc0d4837db"
      unitRef="U_USD">-133310000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_bff49685-aabe-4ac9-b76d-db3851a1462c"
      unitRef="U_USD">-36329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_af5f00a0-afe2-4703-b3c3-ce1a1f295795"
      unitRef="U_USD">-190228000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_a2c0baf0-3734-44e4-b7eb-b0035d9ca6c3"
      unitRef="U_USD">-3632000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_ca3ef75b-4b40-4816-ae9e-3fc9999b0575"
      unitRef="U_USD">-1557000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_5ab53735-679e-4300-bc57-3d3a5a61415b"
      unitRef="U_USD">472000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_691eb6c5-cbab-4357-b75a-559fcf0eb7cd"
      unitRef="U_USD">-136942000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_2e79f814-70e5-4f11-890e-0e0f89464ded"
      unitRef="U_USD">-37886000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_0a49a3f0-aa18-4463-bd22-cc149aada2c8"
      unitRef="U_USD">-189756000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="2"
      id="F_d873c8f9-d49c-482a-9578-ac396d44476d"
      unitRef="U_USDollarShare">-1.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="2"
      id="F_1c749ecc-b7fd-4616-8aea-e1f5350ac60a"
      unitRef="U_USDollarShare">-1.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="2"
      id="F_daa5aee5-84ff-4468-b88e-eab0974c2d9c"
      unitRef="U_USDollarShare">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="2"
      id="F_a3493b84-8c0e-432b-a710-a3f5009af262"
      unitRef="U_USDollarShare">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="2"
      id="F_99db0574-dea7-4cfb-9600-d18931030523"
      unitRef="U_USDollarShare">-2.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="2"
      id="F_032f5f62-7b02-4c37-ab44-edf379e24ba8"
      unitRef="U_USDollarShare">-2.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="0"
      id="F_d6b71838-4482-4bbe-bf8b-e1a0dc81954b"
      unitRef="U_shares">82467587</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="0"
      id="F_681f72b8-43fc-4250-8fcf-150578f2684b"
      unitRef="U_shares">82467587</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="0"
      id="F_d83a4ede-79ae-454d-a308-00c9932d01de"
      unitRef="U_shares">80416936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="0"
      id="F_32635583-9595-4660-8d5d-1a8094040afe"
      unitRef="U_shares">80416936</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="0"
      id="F_2f08418c-5e9e-4a5f-a993-71ac5320ba8f"
      unitRef="U_shares">77758806</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="0"
      id="F_c4fd5749-6959-42d9-bc80-4cf8295f8888"
      unitRef="U_shares">77758806</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e"
      decimals="INF"
      id="F_2e2e6d4a-80a1-4d13-94c3-eb60fc32a8da"
      unitRef="U_shares">69052873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e"
      decimals="-3"
      id="F_457727d0-7cd2-49f1-a72a-14e3063d1b74"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ae3112e-641f-46ac-8cd7-601ed0a853e0"
      decimals="-3"
      id="F_aae3d6b7-5a9a-4d09-be6a-c52056c3f85c"
      unitRef="U_USD">414414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d0060090-89cf-486b-ac52-984818190a96"
      decimals="-3"
      id="F_5159ece8-6c85-465e-87b0-bb61b4df7aaa"
      unitRef="U_USD">142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e30431e6-e3b0-4a96-9bef-19773862a1a7"
      decimals="-3"
      id="F_dcf7743f-846e-48b9-a7df-8eb1c1098bc0"
      unitRef="U_USD">-219820000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_52877e94-eb03-44b8-a6be-a533ea71c990"
      decimals="-3"
      id="F_82e7e39c-dd40-44a8-a8cb-391e980f2176"
      unitRef="U_USD">194743000</us-gaap:StockholdersEquity>
    <alec:IssuanceCostsOfCommonStock
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_cb2f192a-0271-41d4-96a7-b51dcde41f0e"
      unitRef="U_USD">1148000</alec:IssuanceCostsOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724"
      decimals="INF"
      id="F_cc2f2a20-a6b6-4b25-9ead-5dbc22a354bc"
      unitRef="U_shares">9602500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724"
      decimals="-3"
      id="F_4a49f922-6cfd-427b-9323-4ce349e84c84"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0994610a-2693-49ff-a322-fa66e5902607"
      decimals="-3"
      id="F_8d716e52-d342-404f-b2ba-0269d1f69234"
      unitRef="U_USD">224510000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_1e7b2206-f6d2-43ae-869f-ed593b40ac54"
      unitRef="U_USD">224511000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724"
      decimals="INF"
      id="F_b880c4f0-e345-4480-9cf4-f53c04742d47"
      unitRef="U_shares">655772</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0994610a-2693-49ff-a322-fa66e5902607"
      decimals="-3"
      id="F_121ad564-23a0-42ab-91ff-3f827cdc362e"
      unitRef="U_USD">6331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_b9dbb91e-fe2a-4adc-9eec-e349ed341040"
      unitRef="U_USD">6331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724"
      decimals="INF"
      id="F_eb79aaa3-82df-41a0-ad1a-589638302730"
      unitRef="U_shares">86870</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0994610a-2693-49ff-a322-fa66e5902607"
      decimals="-3"
      id="F_e5e29720-9954-4a65-bdd0-e0bd4fbde3f1"
      unitRef="U_USD">1179000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_4694710d-1a88-4da7-a98e-49e9d77cde32"
      unitRef="U_USD">1179000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_3608d00d-4b80-4ebb-a06f-7e9864fa2724"
      decimals="INF"
      id="F_e46efd88-0aa8-46f9-a397-0d4ba79ce16f"
      unitRef="U_shares">81754</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0994610a-2693-49ff-a322-fa66e5902607"
      decimals="-3"
      id="F_fe5e9978-5cd3-443b-88bc-5e4927f2df74"
      unitRef="U_USD">30522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_f00562ae-1a92-44a2-a3b7-4866c2cb6451"
      unitRef="U_USD">30522000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_23fa1cec-8bf2-4e74-94f9-7b74111d38b2"
      decimals="-3"
      id="F_0ebb765c-9ed0-466e-9c61-d4de11709c2d"
      unitRef="U_USD">472000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_b2a3c1d1-0bc5-427d-9e33-f8f45c6e5638"
      unitRef="U_USD">472000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_80e23df0-dda9-41ff-b7a3-932c8bf26d7a"
      decimals="-3"
      id="F_75579dce-fcfc-496e-9896-efffb66f5863"
      unitRef="U_USD">-190228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_d9f1e4aa-966d-46fc-a8a8-de08ce18c08f"
      unitRef="U_USD">-190228000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_98dece0f-6865-495b-b2f4-10ffd8b3e0d8"
      decimals="INF"
      id="F_3fea63e4-821a-4263-9efd-fa45474e2421"
      unitRef="U_shares">79316261</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_98dece0f-6865-495b-b2f4-10ffd8b3e0d8"
      decimals="-3"
      id="F_1cc7b087-e77a-4cf5-8218-e0b52e37c2ad"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7d5342d6-08d3-4f1d-a440-effc09b14ff7"
      decimals="-3"
      id="F_4a9db2ce-a632-45f8-a063-9b944311c688"
      unitRef="U_USD">676956000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7a436588-46b7-4c39-90f1-b29291faef62"
      decimals="-3"
      id="F_8ddc80cf-76ba-432f-8f33-4819bfa3410f"
      unitRef="U_USD">614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b2eed340-5921-424b-b2bd-6f6e1a65315d"
      decimals="-3"
      id="F_6b87b223-d2b7-4cbb-bfbc-c277d1cce03e"
      unitRef="U_USD">-410048000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_b86c39d8-93b2-465a-8104-bbad4b3d85c4"
      unitRef="U_USD">267530000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664"
      decimals="INF"
      id="F_64920d3c-22ca-4a05-bac3-8025443bf39e"
      unitRef="U_shares">2395223</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66"
      decimals="-3"
      id="F_56f36e41-cddd-422d-bf41-1332b0d0d6da"
      unitRef="U_USD">28530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_4cc75d69-98c2-4d6d-b016-487f4bfef627"
      unitRef="U_USD">28530000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664"
      decimals="INF"
      id="F_5290fb3e-8983-403f-836a-18dd3dc70913"
      unitRef="U_shares">156420</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664"
      decimals="INF"
      id="F_599fab06-127b-4355-8c8d-0adbe0e713b9"
      unitRef="U_shares">136331</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66"
      decimals="-3"
      id="F_12790951-efd1-45dd-a6cd-629eefb01815"
      unitRef="U_USD">1765000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_de4c3ee7-790f-43a1-8207-146c3980e48a"
      unitRef="U_USD">1765000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="C_57a31f45-5c3e-4095-acf4-1177aeb8b664"
      decimals="INF"
      id="F_7e5ffe08-e6c8-4655-9b9c-71e8a26e498f"
      unitRef="U_shares">18043</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_83036f5b-1343-49e7-a9d5-ec10a4f20b66"
      decimals="-3"
      id="F_eaa61ae7-3cd7-4c35-9a09-0f38d95ceed7"
      unitRef="U_USD">40785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_42eaa775-e7c7-4343-aed8-c42b70a8bdbb"
      unitRef="U_USD">40785000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4a365a03-f3eb-4107-9a82-26a3d4345ee8"
      decimals="-3"
      id="F_3b43f485-247e-455d-a771-d12bfe41cb9f"
      unitRef="U_USD">-1557000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_ca9b254e-fe08-4ffb-8b05-f37dbb78b85a"
      unitRef="U_USD">-1557000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_1daf4bd9-70b1-46fd-8ea2-c3707e3a6d0f"
      decimals="-3"
      id="F_4d8b5461-cc70-43ba-a2d3-9515787258ad"
      unitRef="U_USD">-36329000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_ea8a9b81-5e06-451c-aa8f-fa39f9a8619a"
      unitRef="U_USD">-36329000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2c3e6d3b-2fe3-4f9b-923c-d40ea56722bc"
      decimals="INF"
      id="F_10d78e87-8528-43b1-8303-27a04bd2119c"
      unitRef="U_shares">81986192</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2c3e6d3b-2fe3-4f9b-923c-d40ea56722bc"
      decimals="-3"
      id="F_50dd6c67-9b6c-4dba-ad12-3d3cb0fa86ca"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_14db55be-444b-484b-9308-f5fa77d06c64"
      decimals="-3"
      id="F_2e9b2d52-380a-47a3-ba70-9ea2918be759"
      unitRef="U_USD">748036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dcbe690f-5774-4129-bd39-6000b70e20db"
      decimals="-3"
      id="F_07bfcf1f-8b76-4aa2-9117-755bba5794f4"
      unitRef="U_USD">-943000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0120a0fc-9112-4e54-9638-49d731099e2d"
      decimals="-3"
      id="F_c5d5c04c-a839-42a6-9b00-6cca5830b8bf"
      unitRef="U_USD">-446377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_baa01c1f-96ba-4e56-8fd7-0f7db974db91"
      unitRef="U_USD">300724000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5506b44b-1aea-4b19-b486-8910d5fdf80a"
      decimals="INF"
      id="F_6017e044-a767-44e8-ba48-a8d23c733dd8"
      unitRef="U_shares">298238</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a935fdcb-ad72-4392-9a72-8a721afa0563"
      decimals="-3"
      id="F_33e492c0-f116-4342-a82e-eb8cf3df3228"
      unitRef="U_USD">3059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_b417b927-23fc-4b49-9a92-db56e4270ace"
      unitRef="U_USD">3059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_5506b44b-1aea-4b19-b486-8910d5fdf80a"
      decimals="INF"
      id="F_e019e6e1-9800-4bd4-91a4-eb74210d6ed7"
      unitRef="U_shares">414578</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_5506b44b-1aea-4b19-b486-8910d5fdf80a"
      decimals="INF"
      id="F_ac8fd1c0-aaa2-4e1e-b244-f8d2b9e0b9bb"
      unitRef="U_shares">196710</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a935fdcb-ad72-4392-9a72-8a721afa0563"
      decimals="-3"
      id="F_7a223c40-776d-478a-ab13-e1c8a31a5c56"
      unitRef="U_USD">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_d85f7e45-7119-4ec8-94c6-dd4f6f6be6bf"
      unitRef="U_USD">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a935fdcb-ad72-4392-9a72-8a721afa0563"
      decimals="-3"
      id="F_c1a99ada-89f3-4f6d-86bc-81bbc3da1895"
      unitRef="U_USD">46146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_4241f4ea-29d3-45ce-82b7-0d571175f729"
      unitRef="U_USD">46146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_43db021b-c8f9-4318-82fe-8c0ec28ec33c"
      decimals="-3"
      id="F_827856df-6651-4842-84a1-f89bd81f1fd0"
      unitRef="U_USD">-3632000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_50783cc1-7679-4a47-916e-fc079b4f65ee"
      unitRef="U_USD">-3632000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_176df7af-82ab-480c-bae0-7332bb4be390"
      decimals="-3"
      id="F_ad7183a6-eed8-4d80-afa3-5ddcd6d93968"
      unitRef="U_USD">-133310000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_e0aa6595-9f88-48d0-ae49-9865458fda58"
      unitRef="U_USD">-133310000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5c63d7ae-a408-4aaa-b856-64a3f876dcd4"
      decimals="INF"
      id="F_9683d49a-d8a4-4e8f-a477-09a6f03c1030"
      unitRef="U_shares">82895718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5c63d7ae-a408-4aaa-b856-64a3f876dcd4"
      decimals="-3"
      id="F_dfea04cd-7c19-40fc-ae85-df76d49dc7ff"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_180fddf9-2bc6-4a44-a946-c3ac0b3b7336"
      decimals="-3"
      id="F_9ea9bcf2-748b-4422-bcb2-fa8ff14066b1"
      unitRef="U_USD">798696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9f82b000-4be4-479f-8d5a-48258e77ae0c"
      decimals="-3"
      id="F_170beeb0-7e18-49aa-a1c0-0d90527f0a15"
      unitRef="U_USD">-4575000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_33d99e34-332b-4171-90ad-9a300bdceb05"
      decimals="-3"
      id="F_82071a3d-b23a-4f6c-b982-4940e142463f"
      unitRef="U_USD">-579687000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_ebd401dc-dc06-4df3-8b20-82de8585c08e"
      unitRef="U_USD">214442000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_67c0cf48-4cef-464d-b84b-fcf04a74f464"
      unitRef="U_USD">-133310000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_63f2bb31-b402-403f-8a55-8ded04f98478"
      unitRef="U_USD">-36329000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_9fd4eee3-be9b-40a6-abad-8ea13a647bdd"
      unitRef="U_USD">-190228000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_ba00a58b-1f35-4f19-83e3-98ef0b5db7c0"
      unitRef="U_USD">5714000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_cd05a873-ea66-4d58-ad0b-83b1ffb1b1b2"
      unitRef="U_USD">6329000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_a665437a-2381-473f-9e17-713a9e007ff5"
      unitRef="U_USD">5870000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_f9dd7617-c1eb-409c-ba62-dbb6c8d164ec"
      unitRef="U_USD">46146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_2149bc04-5bc8-46e7-a957-2a9ff9c796f5"
      unitRef="U_USD">40785000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_c12e5b35-66ae-4d88-a676-e981fbf1b9d9"
      unitRef="U_USD">30522000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_dd042337-f555-43cc-9a6a-5fe0176a69ac"
      unitRef="U_USD">1163000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_c8b49d8a-422b-4968-9591-3c2f2688bfc7"
      unitRef="U_USD">-2099000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_e4721f4d-ee25-4737-81f4-a8febb58ce5a"
      unitRef="U_USD">-584000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <alec:AmortizationRightOfUseAsset
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_301042a6-a635-452a-92c0-ec88c27803f1"
      unitRef="U_USD">2758000</alec:AmortizationRightOfUseAsset>
    <alec:AmortizationRightOfUseAsset
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_3662129e-e715-411d-b85c-dafe64130d95"
      unitRef="U_USD">1986000</alec:AmortizationRightOfUseAsset>
    <alec:AmortizationRightOfUseAsset
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_7c11a9c8-211b-4d82-ae48-67dfaba9015b"
      unitRef="U_USD">1395000</alec:AmortizationRightOfUseAsset>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_3994cf39-6e2b-4f81-853d-b583ae7f7d9d"
      unitRef="U_USD">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_8bf731c6-ece6-4c91-bf4a-ac79a8d35580"
      unitRef="U_USD">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_3c001b33-2408-42a5-ae91-5c54cf4e1cd8"
      unitRef="U_USD">238000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_c661ab2f-3a66-4480-b8dd-29cd19127a8a"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_8811b57e-e886-4d98-849c-97bbe0e07b06"
      unitRef="U_USD">-0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_e84755fa-f894-4a20-bd50-584ffb43cdd3"
      unitRef="U_USD">-107000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <alec:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_2687a601-ed46-4bc5-a746-15e5da1a11d1"
      unitRef="U_USD">-4804000</alec:IncreaseDecreaseInCollaborationReceivable>
    <alec:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_abdf6569-2dd5-4023-a1b2-a605fc12c442"
      unitRef="U_USD">7391000</alec:IncreaseDecreaseInCollaborationReceivable>
    <alec:IncreaseDecreaseInCollaborationReceivable
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_fe312059-2d9c-4eac-8cab-e5406f9762ee"
      unitRef="U_USD">0</alec:IncreaseDecreaseInCollaborationReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_73bbc66c-ba65-4108-9de7-b9e1e1e6ae7b"
      unitRef="U_USD">3926000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_e917a66e-3eea-40b2-8d59-d03db9ecdbcc"
      unitRef="U_USD">-1132000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_73f18ec8-025a-48e7-8727-e6a8d271d42a"
      unitRef="U_USD">3839000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_f76d3d48-f08e-485e-8db5-39c26f345015"
      unitRef="U_USD">835000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_16ebacd0-449f-4214-8724-fad4d23f0815"
      unitRef="U_USD">2957000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_7a01def6-1707-4998-bce7-f481161e9cb5"
      unitRef="U_USD">2498000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_7fbc1125-06cb-484e-915b-4ceeb99b2791"
      unitRef="U_USD">-572000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_8684225b-efc0-4e0f-b555-63243cf96e4c"
      unitRef="U_USD">1917000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_1b0301d2-fe75-49ad-9bb4-f78acb593df6"
      unitRef="U_USD">2409000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_75472904-e13e-471c-88f4-86440dbfe643"
      unitRef="U_USD">-2655000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
    <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_c244747f-e07f-4473-a5d0-1d30b4e85ad4"
      unitRef="U_USD">2391000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
    <alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_eed87b91-8fc3-40e1-874d-c7c523d07635"
      unitRef="U_USD">12232000</alec:IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_61352ca9-44ba-4ad7-9beb-2f6fc0dafd2e"
      unitRef="U_USD">66383000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_8b6144c5-8f19-473c-855e-e53ffe58519c"
      unitRef="U_USD">292915000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_3fed7faa-4bb0-4796-8a41-187ef3cceea7"
      unitRef="U_USD">-21098000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <alec:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_bc632c34-a361-4861-9f82-f6bcbe889bb6"
      unitRef="U_USD">-4274000</alec:IncreaseDecreaseInLeaseLiabilities>
    <alec:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_c2f779fb-6be6-4f13-961b-5ff43873e41e"
      unitRef="U_USD">-4012000</alec:IncreaseDecreaseInLeaseLiabilities>
    <alec:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_78ca8a46-29a9-46a5-9261-2fbd0fafae9c"
      unitRef="U_USD">-2407000</alec:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_afd46c96-eb35-41f7-a60b-e3a6e06d4eec"
      unitRef="U_USD">601000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_2c13c2d1-fc4b-4127-9511-9547e7bc1426"
      unitRef="U_USD">-314000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_ba142384-7196-4ee2-b22f-a93d436c16d2"
      unitRef="U_USD">-21000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_3fce8191-a3b3-48b5-9bb3-f2efee921021"
      unitRef="U_USD">-20329000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_6ab0f384-b516-4b8a-a046-c473d1d1e9d8"
      unitRef="U_USD">298551000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_f182e07c-c8eb-4083-a498-cb29c9bf96f6"
      unitRef="U_USD">-166734000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_9d12f410-1208-44aa-b59e-07926a3356a1"
      unitRef="U_USD">4117000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_a448ec2b-f35e-467f-9af5-4d93957a3ba0"
      unitRef="U_USD">3247000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_d769418e-c3c4-484a-952f-8d023d9f5b04"
      unitRef="U_USD">5032000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_19ea10dc-16bb-4021-a62b-791931e31b29"
      unitRef="U_USD">556898000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_db8709b5-4df5-4c06-b7c3-b0c315572c92"
      unitRef="U_USD">343402000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_6122f8e8-23cc-4991-b4c6-05ace496694b"
      unitRef="U_USD">506809000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_cb165776-7384-4935-aca7-33540c34434b"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_25dece49-a150-48e7-9b3d-c5c3c211bc45"
      unitRef="U_USD">10696000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_2ffc12f6-d615-4386-8fb6-3b2052db41dc"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_ebd2ddaa-70c8-4e20-8761-965b8d6c1e03"
      unitRef="U_USD">402001000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_710831d6-012b-458b-bf1b-4db04e7c04df"
      unitRef="U_USD">286290000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_18657b42-5bd4-417e-92bb-288df498dd2c"
      unitRef="U_USD">406790000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_6568069f-a7d2-4c0e-a65f-5d95ecf82e5a"
      unitRef="U_USD">-159014000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_12b8c1b7-486f-42e2-b518-b9362da25073"
      unitRef="U_USD">-49663000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_230df080-a3a9-4fec-9a90-085c0874c52d"
      unitRef="U_USD">-105051000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_d51e59c8-e46b-484d-9089-6a20cf6ee878"
      unitRef="U_USD">0</alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering>
    <alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_15775f6b-6701-4583-944e-75922ae78a06"
      unitRef="U_USD">0</alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering>
    <alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_9f3c8ab6-26df-4af0-ad29-eee417385ca7"
      unitRef="U_USD">-224603000</alec:ProceedsFromPaymentsForIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_ae5879ab-21de-4f49-8fb2-785043d14fd9"
      unitRef="U_USD">3059000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_99d4a5c2-5dae-462e-9ab0-3c7e97f37afc"
      unitRef="U_USD">28530000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_4a543bd0-c12e-4d51-8fb3-c5ec024260b7"
      unitRef="U_USD">6331000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_52450061-b80f-498c-ac22-7e091cfd310b"
      unitRef="U_USD">1455000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_09c7cd2d-2071-40bb-9c3c-596067cf5f09"
      unitRef="U_USD">1765000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_bad1202b-6b23-45f3-b3f2-1394bacda434"
      unitRef="U_USD">1179000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_77ed2f21-fe14-4b7e-b950-aa4540c89779"
      unitRef="U_USD">4514000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_2261cb4c-4846-45f4-84cf-594888b6656a"
      unitRef="U_USD">30295000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_afa8d53e-59b0-4417-8919-da2601399517"
      unitRef="U_USD">232113000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_ba0b15f6-79be-4cb0-9063-c22e33d8d94c"
      unitRef="U_USD">-174829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_926de501-03f4-4c17-aa61-5b17c65cfa3b"
      unitRef="U_USD">279183000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_fce16d47-81c9-481c-9622-18444408ba51"
      unitRef="U_USD">-39672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_c22b7b28-edf0-4f26-979b-8116db0dafa9"
      unitRef="U_USD">330624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_cfd5817b-9618-42d1-aed8-e8740a5d533f"
      unitRef="U_USD">51441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_52877e94-eb03-44b8-a6be-a533ea71c990"
      decimals="-3"
      id="F_38accf55-3ef5-4570-b5b2-56b6b2075b4b"
      unitRef="U_USD">91113000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_f63dd2b8-acee-4743-bace-70b57b34218a"
      unitRef="U_USD">155795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_d6578687-eb56-4ddc-a339-ea708b08df94"
      unitRef="U_USD">330624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_41312248-fa94-4439-af62-43ad973cbb66"
      unitRef="U_USD">51441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_4530f519-671f-4ffd-b375-96a6c5833b81"
      unitRef="U_USD">493000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_269712f9-1a6a-4430-9c0b-b0e834f041aa"
      unitRef="U_USD">705000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_e4871f6e-2acc-4c1b-ac82-e6d49674b758"
      unitRef="U_USD">428000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_cee28058-a75b-477a-ab43-14cde552e037">&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;1.&lt;/span&gt;&lt;div id="notes_to_consolidated_financials" style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company and Liquidity &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Alector, Inc. (Alector or the Company) is a Delaware corporation headquartered in South San Francisco, California. Alector is a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Follow-on Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 30, 2020, the Company completed a follow-on offering through issuing and selling &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,602,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,252,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares sold pursuant to the underwriters&#x2019; full exercise of their option to purchase additional shares, resulting in aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;224.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions and estimated offering costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1f8633fe-5aaf-447e-ae50-bc7154a4d0d6"
      decimals="INF"
      id="F_698546cb-76c4-4d91-8b85-fbaf1ba6568b"
      unitRef="U_shares">9602500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_9fea33d6-9da1-41c4-92b1-404be25d8a1d"
      decimals="INF"
      id="F_4f9533fc-4fd5-4651-bc8c-fc29edcedf73"
      unitRef="U_USDollarShare">25.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_eebe0049-dfc6-425d-8d39-93f33680d12f"
      decimals="INF"
      id="F_625c7e65-8f94-4d16-81e6-0566af2a6683"
      unitRef="U_shares">1252500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_1f8633fe-5aaf-447e-ae50-bc7154a4d0d6"
      decimals="-5"
      id="F_eaa4eeb0-212c-4cee-8c7e-af1d9e6f03bc"
      unitRef="U_USD">224500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_d1bcd315-bd1b-45f5-af0e-09e4594e15f0">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash as of December 31, 2022 relates to a letter of credit established for a lease entered into in June 2018.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.888%;"/&gt;
          &lt;td style="width:1.291%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.017000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.318%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.017000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.318%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.15%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;154,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;329,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;330,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#x2019; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; credit-related losses recognized for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#x2019;s financial instruments approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_19d80ba0-b0e8-42a5-8784-39822104cb76;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize an impairment loss on its right-of-use assets. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2020, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company recognized a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million impairment loss related to its decision to no longer utilize certain property through the end of the lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company's common stock on the grant date, which equals the closing price of the Company's common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2021, the Company granted RSUs with market conditions to certain executives. The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur for all awards.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are the result of transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee 401(k) Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;Code&#x201d;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#x2019;s contributions to the plan are discretionary. For the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021, and 2020, the Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company operates in one segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_e012bcb4-6147-435a-8de1-515be9f90b4d">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (GAAP) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;as defined by the Financial Accounting Standards Board (FASB). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_c4d516e4-6375-4f64-8efa-16c2a1e87254">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_ebb2b064-3d49-481d-a1f2-542d3c9aa75e">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f59a3dd2-863d-4be0-b66e-488ac0417412">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash as of December 31, 2022 relates to a letter of credit established for a lease entered into in June 2018.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.888%;"/&gt;
          &lt;td style="width:1.291%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.017000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.318%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.017000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.318%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.15%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;154,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;329,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;330,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_07fa97c0-51b5-40f0-a71a-297050cdb93d">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:56.888%;"/&gt;
          &lt;td style="width:1.291%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.017000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.318%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.017000000000001%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.318%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:11.15%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;154,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;329,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;330,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_bfc1ef78-32ac-43c6-a19e-e15587f4c822"
      unitRef="U_USD">154323000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_c35698e9-dbb1-48dc-8fb8-27e61bb78a64"
      unitRef="U_USD">329152000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_1387a433-1b2c-432a-8861-2760470e6248"
      unitRef="U_USD">49969000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_ffdceb9c-b79b-4410-9fc5-178f14152889"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_56901086-7416-47ae-bd84-1a36752f1ba4"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_a584ce28-0e6c-40d5-8e6d-bfbd480aa792"
      unitRef="U_USD">1472000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_d0fb1f16-f0dc-47b2-9523-1878f1dc77b7"
      unitRef="U_USD">155795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_5377d2fd-2c60-49d8-927d-62c1971123a4"
      unitRef="U_USD">330624000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_a86d56b6-9f87-46e7-9673-b3b8bacdcfed"
      unitRef="U_USD">51441000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_841fe1b4-35f6-4e00-ab04-663ce2cbddbb">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;All marketable securities have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value, based upon quoted market prices. The Company considers its available-for-sale portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may be one year or more beyond the current balance sheet date. For available-for-sale debt securities, unrealized gains, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of stockholders&#x2019; equity until realized. The Company assesses available-for-sale debt securities on a quarterly basis to see if any unrealized loss is due to credit-related factors. Factors considered in determining whether an impairment is credit-related include the extent to which the investment&#x2019;s fair value is less than its cost basis, declines in published credit ratings, changes in interest rates, and any other adverse factors related to the security. If it is determined that a credit-related impairment exists, the Company will measure the credit loss based on a discounted cash flows model. Credit-related impairments on available-for-sale debt securities are recognized as an allowance for credit losses with a corresponding adjustment to other income, net in the Company&#x2019;s consolidated statement of operations. The unrealized loss position that is not credit-related is recorded, net of any related tax effects, in other comprehensive income until realized. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; credit-related losses recognized for the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management invests in money market funds, U.S. treasury securities, corporate bonds, and commercial paper. The Company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesGainLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-6"
      id="F_02b72bb6-aef6-489c-8888-942f903fa197"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesGainLoss>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_ca7d7dc8-fe11-4275-a3a5-09da5e9c1586">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, marketable securities, receivable from collaboration partner, current and noncurrent prepaid expenses, accounts payable, and accrued liabilities. The Company&#x2019;s financial instruments approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_0ef4b93f-ec50-42df-a1d9-002a8d3ac56c">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_19d80ba0-b0e8-42a5-8784-39822104cb76;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_7aceb927-85b2-403a-82fd-27292ccc4303"
      id="F_a450bf5c-c9b8-4be3-839d-bbe8a9539f65">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_d79ea052-c9b1-4e2d-9460-9c73249e9176">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines whether an arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet as right-of-use assets and lease liabilities. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company excludes balance sheet recognition of operating leases having a term of 12 months or less (short-term leases) and does not separate lease components and non-lease components for its long-term leases.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_da1bd203-d7d3-4f22-8b20-be9e29874ea3">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds its fair value. For the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize an impairment loss on its right-of-use assets. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2020, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company recognized a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million impairment loss related to its decision to no longer utilize certain property through the end of the lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-6"
      id="F_36e458e3-387d-4d89-bb53-40c2018ca972"
      unitRef="U_USD">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-6"
      id="F_1a47d64c-a071-4929-9a35-aa468f1201d7"
      unitRef="U_USD">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-5"
      id="F_d5c01deb-3d63-4692-b5a3-c6482fcf3d47"
      unitRef="U_USD">200000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_1da655aa-5c92-4a9d-9c4f-8337f271dcbf">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes revenue when control of promised goods or services is transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies the performance obligation. If it is determined that multiple performance obligations exist, the transaction price is allocated at the inception of the agreement to all identified performance obligations based on the relative standalone selling price (SSP). The relative SSP for each deliverable is estimated using external sourced evidence if it is available. If external sourced evidence is not available, we use our best estimate of the SSP for the deliverable.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes collaboration revenue at a point in time if control of the promised good or service has been transferred to the customer. The Company recognizes collaboration revenue over time by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. The Company re-evaluates the estimate of expected costs to satisfy the performance obligation each reporting period.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_5743359f-5619-41b6-9d29-6faaf1d116df">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf. In addition, research and development costs include the reimbursable costs incurred for the collaboration agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers. The Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further, the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f81fe624-85b2-474c-8d65-b85c29261287">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation is measured on the grant date based on the fair value of the awards. The fair value of options to purchase common stock is measured using the Black-Scholes option-pricing model. Stock-based compensation associated with restricted stock units (RSUs) is based on the fair value of the Company's common stock on the grant date, which equals the closing price of the Company's common stock on the grant date. The Company recognizes expense over the vesting period of the awards. Expense for options and RSUs that vest based only on a service condition is recognized on a straight-line basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2021, the Company granted RSUs with market conditions to certain executives. The fair value of RSUs with market conditions is estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the stock price on grant date, risk-free interest rate, dividend yield, expected stock volatility, and estimated period to achieve the market condition. The expense is recognized based on continued employment of the participants, regardless of achievement of the market condition. Expense related to the RSUs with market conditions is recognized using the accelerated attribution method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for forfeitures as they occur for all awards.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_8803af79-426e-449d-b87f-8e625bba5d4f">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; equity that are the result of transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_1c20dc0c-300f-4d78-999a-4f26e521f3b9">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statement and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;recorded cumulative net losses in prior periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PostemploymentBenefitPlansPolicy
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_e7abe557-cb8f-4ba4-96c5-cfeb901b7fe3">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee 401(k) Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has a qualified contributory savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;Code&#x201d;) covering substantially all U.S. employees of Alector. The 401(k) plan is designed to provide tax-deferred retirement benefits in accordance with the provisions of Section 401(k) of the Code. Eligible employees may defer up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#x2019;s contributions to the plan are discretionary. For the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021, and 2020, the Company made matching contributions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PostemploymentBenefitPlansPolicy>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="2"
      id="F_8283c786-6957-4083-8e99-05addfa851a2"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-5"
      id="F_011a027f-ee19-48df-a6d5-8302771c9882"
      unitRef="U_USD">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-5"
      id="F_6f1e3abb-76f1-4768-897a-f221247820bd"
      unitRef="U_USD">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-5"
      id="F_231eff40-f628-4172-a150-3ad87a8ebe4b"
      unitRef="U_USD">700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_54f820b7-9ed1-4647-9b82-d1d982cccfb9">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company operates in one segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_a6199b44-8cad-4184-8173-0e5ac1cecdcf">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;3.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.882%;"/&gt;
        &lt;td style="width:0.826%;"/&gt;
        &lt;td style="width:9.942%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.294%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;506,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;501,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;655,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.882%;"/&gt;
        &lt;td style="width:0.826%;"/&gt;
        &lt;td style="width:9.942%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.294%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;218,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;218,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;407,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;406,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;625,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;624,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models for which all significant inputs are observable. The Company classifies marketable securities available to fund current operations as current assets. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the remaining contractual maturities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;640.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of investments were less than one year and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of investment were after one year through two years. As of December 31, 2022, fifteen U.S. government treasury securities with an aggregate fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and an aggregate unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were in a loss position for more than twelve months. The Company does not intend to sell the investments that are currently in an unrealized loss position, and it is highly unlikely that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company did not sell any marketable securities for the years ended December 31, 2022 and 2020. For the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company sold marketable securities for the total proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for an immaterial realized gain based on the specific identification method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_aad6988f-9b48-4007-955b-6dba5739adb5">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.882%;"/&gt;
        &lt;td style="width:0.826%;"/&gt;
        &lt;td style="width:9.942%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.294%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;506,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;501,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;655,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.882%;"/&gt;
        &lt;td style="width:0.826%;"/&gt;
        &lt;td style="width:9.942%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.445%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.294%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.256%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Market&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;218,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;218,451&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;407,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;406,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash equivalents and marketable&lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;625,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;624,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913"
      decimals="-3"
      id="F_5fff132b-437c-487b-95b3-4b17f74ca7c2"
      unitRef="U_USD">74848000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913"
      decimals="-3"
      id="F_361d2a99-4604-48e5-bb48-10d6dfdfbfa3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913"
      decimals="-3"
      id="F_ab5a9da5-7658-4f05-afd7-01f5ea37c211"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1389774a-b29c-48d6-a55f-f4bbb7532913"
      decimals="-3"
      id="F_be6f3a7f-db87-49e9-8864-e1e9958e6f20"
      unitRef="U_USD">74848000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a84f0779-d476-4feb-8427-952120804b66"
      decimals="-3"
      id="F_b197c5a3-7339-4af1-963c-d69023887022"
      unitRef="U_USD">506372000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a84f0779-d476-4feb-8427-952120804b66"
      decimals="-3"
      id="F_c326d355-5f7d-4dbc-ba5f-1f27fbc05841"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a84f0779-d476-4feb-8427-952120804b66"
      decimals="-3"
      id="F_153ba4e0-e188-4107-8443-f98ef36fcc49"
      unitRef="U_USD">4569000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a84f0779-d476-4feb-8427-952120804b66"
      decimals="-3"
      id="F_73488795-f773-484a-82f7-142594440800"
      unitRef="U_USD">501810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c"
      decimals="-3"
      id="F_dd83477c-7ed7-49cd-a55c-07592f272e6c"
      unitRef="U_USD">44438000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c"
      decimals="-3"
      id="F_5ca2da23-8c32-4d3c-bf6e-b41a632563bb"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c"
      decimals="-3"
      id="F_75c50874-27fb-4efb-8379-f1d39ccba00b"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9be7a4e1-ad65-4413-b922-5dcc88d0c47c"
      decimals="-3"
      id="F_6474fe35-21e9-4c70-9bbb-edbc67cf8b15"
      unitRef="U_USD">44432000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e"
      decimals="-3"
      id="F_9eba3b70-5d75-4cb1-976f-e2cbd54ddb8f"
      unitRef="U_USD">29352000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e"
      decimals="-3"
      id="F_31730c6f-3bb8-4e1f-b5d2-874bf30a9b0d"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e"
      decimals="-3"
      id="F_efb826cd-1418-49d2-99b0-bb6131affec8"
      unitRef="U_USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5c63491e-bbd2-4a44-9ce7-1a744e8f162e"
      decimals="-3"
      id="F_8872382e-a954-4b6f-9c16-73225d6fd821"
      unitRef="U_USD">29346000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e"
      decimals="-3"
      id="F_8a395f8c-65af-4bb5-803e-8e03ff8c378c"
      unitRef="U_USD">655010000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e"
      decimals="-3"
      id="F_7ed68213-427d-4a39-940b-202299e7feb3"
      unitRef="U_USD">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e"
      decimals="-3"
      id="F_dfa77273-c3a2-40bb-9219-1586965b90ea"
      unitRef="U_USD">4587000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e3b2caf5-7252-4732-8fff-6572963b403e"
      decimals="-3"
      id="F_61eed76d-b2ac-4dbf-b29f-6391e835a84e"
      unitRef="U_USD">650436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba"
      decimals="-3"
      id="F_0b4103b9-bf51-49ed-a40b-cba8a89accbb"
      unitRef="U_USD">218451000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba"
      decimals="-3"
      id="F_fe90378e-3d31-43b5-8511-0241a05e30a2"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba"
      decimals="-3"
      id="F_a7ffed52-2d19-4158-87ad-dd6e79632157"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f312b892-d20e-4878-bd76-21a8ad92aaba"
      decimals="-3"
      id="F_a2b41df4-6eb7-4e94-8f7d-38dabacc72fb"
      unitRef="U_USD">218451000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4"
      decimals="-3"
      id="F_eab55c2a-70fb-4ad7-bbaf-63f450717557"
      unitRef="U_USD">407041000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4"
      decimals="-3"
      id="F_4541ca52-b56f-4f11-b20c-eb46caf7c92b"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4"
      decimals="-3"
      id="F_325d631e-5f49-4e88-8909-b39380f12346"
      unitRef="U_USD">950000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_51b97a6f-177d-4792-ade6-51b7eab823e4"
      decimals="-3"
      id="F_a4be830c-44ef-43ab-ac60-5c0aee92a595"
      unitRef="U_USD">406099000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1"
      decimals="-3"
      id="F_6ceaf543-e78a-4b96-8d35-2d6e312f8e26"
      unitRef="U_USD">625492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1"
      decimals="-3"
      id="F_12e702ef-60b5-4cb9-95d2-6507516599e1"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1"
      decimals="-3"
      id="F_254ae394-08ec-4052-b9bd-a93de13f3993"
      unitRef="U_USD">950000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1c68a962-b28e-4960-a9ae-21e424ed19e1"
      decimals="-3"
      id="F_be63ca89-6d89-4094-a0af-f5ec25c02983"
      unitRef="U_USD">624550000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-5"
      id="F_22f59799-ed2c-4070-b88a-4012f40f2a03"
      unitRef="U_USD">640800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <alec:AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-5"
      id="F_f5ff3209-4fdd-4a30-bfb4-56a14c6e5639"
      unitRef="U_USD">9600000</alec:AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_5ede9fc7-3539-445c-b590-2e32ccf2dc14"
      decimals="-5"
      id="F_d02b5fa0-6194-467a-9cc3-e4c674785411"
      unitRef="U_USD">133200000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_5ede9fc7-3539-445c-b590-2e32ccf2dc14"
      decimals="-5"
      id="F_eda69cdb-338f-4490-bbed-cce63f47ee64"
      unitRef="U_USD">3100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-5"
      id="F_e07346db-c703-47fa-b316-8c4a365a7aec"
      unitRef="U_USD">10700000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_fae57147-5df3-435e-81b3-fb50baf2a666">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.       &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;GSK&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 1, 2021, the Company entered into a Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK), pursuant to which the Company and GSK collaborate on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab (also referred to as AL001), and AL101 (GSK Agreement). The GSK Agreement was made effective on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 17, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the GSK Agreement, the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in upfront payments, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was received in August 2021 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million was received in January 2022. In addition, based on the development and commercialization plan for latozinemab and AL101, the Company may be eligible to receive up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in clinical development, regulatory, and commercial launch-related milestone payments. In the United States, the Company and GSK will equally share profits and losses from&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;commercialization &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of latozinemab and AL101. Outside of the United States, the Company will be eligible for double-digit tiered royalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company and GSK will jointly develop latozinemab and AL101, with GSK conducting Phase 3 clinical trials for Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease and other non-orphan indications. The Company and GSK will share development costs &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% by GSK and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% by the Company, except that the Company will solely bear the development costs of the initial Phase 2 clinical trials under the development plan, and the parties will share manufacturing development costs equally.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that the GSK Agreement is within the scope of ASC 808, Collaborative Arrangements, as both parties are active participants in the activities and are exposed to significant risks and rewards dependent on the success of the commercialization of AL001 and AL101. Certain elements are required to be accounted for under ASC 606, Revenue From Contracts With Customers, where the counterparty is a customer for a good or service that is a distinct unit of account.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) license and know-how to AL001 FTD-&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;GRN&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which is currently in Phase 3 clinical development and (ii) the research and development activities, including license rights and know-how, relating to products in Phase 2 or earlier stages of development.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price at inception and as of December 31, 2022, included fixed consideration consisting of the upfront payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. All potential future milestones and other payments were considered constrained at the inception of the GSK Agreement and as of December 31, 2022, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The respective standalone value for each of the performance obligations was allocated to the transaction price. The estimated SSP of each performance obligation was determined using discounted cash flows from the expected commercialization of AL001 and AL101 and estimated research and development costs to be incurred by the Company in the initial Phase 2 clinical trials. The estimate of SSP for each performance obligation reflects management's assumptions, which may include forecasted revenues, development timelines, discount rates, and probabilities of technical and regulatory success. For the license for FTD-&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;GRN&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company determined that GSK could benefit from the license at the time the license was granted and therefore, the related performance obligation was satisfied at a point in time. For the product candidates in Phase 2 or earlier stages of development, the Company determined that GSK could not benefit from the licenses without the corresponding development services that the Company has committed to perform due the earlier stage of development for these licenses. Except where agreed to otherwise, the Company will perform research and development activities through the end of the initial Phase 2 clinical trials. Revenue will be recognized over time as the research and development activities are performed. The Company will measure progress based on actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligations.&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The research and development activities for products in Phase 3 clinical development were determined to be within the scope of ASC 808. Both parties will be active participants in the development, manufacturing, and commercialization of the product and are exposed to significant risks and rewards that are dependent on the commercial success of the products. The Company and GSK participate in profit and loss sharing for each program commensurate with each party's cost-sharing responsibilities during research and development. ASC 808 does not provide recognition and measurement guidance. As such, the Company determined that ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provision of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration revenue under the GSK Agreement during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;192.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The deferred revenue related to the GSK Agreement was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;444.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;307.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of initial Phase 2 clinical trials.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs associated with co-development activities performed under the agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. For the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, the Company recognized a reduction of research and development expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, under the GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;AbbVie&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company entered into an agreement in October 2017 with AbbVie Biotechnology, Ltd. (AbbVie) to co-develop antibodies to two program targets in preclinical development (AbbVie Agreement). Under the terms of the AbbVie Agreement, AbbVie made $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;205.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in upfront payments, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million were received by the Company in October 2017 and January 2018, respectively. The Company was to perform research and development services for the two programs through the end of Phase 2 clinical trials, which were each considered to be separate performance obligations. AbbVie decided to terminate one of the two collaboration programs, the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. AbbVie provided written notice to terminate the CD33 collaboration program on June 30, 2022. The Company will no longer continue development of this program and will not be eligible for any future milestones related to that program from AbbVie. The Company continues to develop the AL002 program under the AbbVie Agreement. AbbVie has the exclusive right to exercise an option under the AbbVie Agreement with the Company for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. If AbbVie exercises its option for the AL002 program, AbbVie would take over the development beginning with Phase 3 clinical trials, and the product candidates program costs will be split between the parties. The Company would also share in profits and losses upon commercialization of any products. However, following AbbVie&#x2019;s exercise of its option for the AL002 program, the Company may opt out of sharing in development costs and profits or losses for that program and instead receive tiered royalties. In February 2023, the Company and AbbVie amended the AbbVie agreement, which will result in the Company receiving a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million milestone payment for the dosing of the first patient in a long-term extension study. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in milestone payments related to the regulatory approval for up to three indications. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price at inception and as of December 31, 2022, included fixed consideration consisting of the upfront payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;205&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. All potential future milestones and other payments were considered constrained at the inception of the AbbVie Agreement and as of December 31, 2022, since the Company could not conclude it was probable that a significant reversal in the amount of revenue recognized would not occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration revenue under the AbbVie Agreement during the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021, and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The deferred revenue related to the AbbVie Agreement was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;117.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, respectively. The deferred revenue is expected to be recognized over the research and development period of the programs through the AL002 program through the completion of Phase 2 clinical trials. For the year ended December 31, 2022, we recorded a net increase to collaboration revenue under the AbbVie Agreement due to changes in estimated costs to satisfy the performance obligations resulting from the termination of the AL003 program, partially offset by increases in total expected costs for the AL002 program.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Innovent&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company entered into an agreement in March 2020 with Innovent Biologics (Innovent) to license, develop, and commercialize AL008 in China (Innovent Agreement). AL008 is the Company&#x2019;s novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumors to evade the innate immune system. Under the terms of the Innovent Agreement, Innovent would pay the Company up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in development milestones, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in sales milestones, and future royalties on sales and the Company would retain the rights to develop and commercialize AL008 outside of China. The Company determined there is one performance obligation for the delivery of the license and will recognize revenue when it is probable that there will not be significant reversal of cumulative revenue. Development and sales milestones under the Innovent Agreement were not included in the transaction price, as all these amounts were&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;fully &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;constrained as of December 31, 2022. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; revenue has been recognized and no payments have been received under the Innovent Agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <alec:CollaborationAndLicenseAgreementEffectiveDate
      contextRef="C_dfad70cc-a2ab-437f-929e-a3eb95fd5c88"
      id="F_fd1aac3f-1263-4154-a114-4825738a63c3">2021-08-17</alec:CollaborationAndLicenseAgreementEffectiveDate>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_d339045c-e830-4398-bf09-392c72a9d130"
      decimals="-6"
      id="F_a5690e85-6119-4413-8192-bea980e46161"
      unitRef="U_USD">700000000</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_dfad70cc-a2ab-437f-929e-a3eb95fd5c88"
      decimals="-6"
      id="F_7b336d79-21f1-48f8-be70-ca68e617c886"
      unitRef="U_USD">500000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_b2c6f352-9d45-4576-a18a-112160c86b51"
      decimals="-6"
      id="F_d839e9eb-c765-4362-b7a3-160ab891c9d6"
      unitRef="U_USD">200000000</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram
      contextRef="C_f5a26f10-025e-4a2e-83ca-fad8cfb00b35"
      decimals="-8"
      id="F_a1622419-ebc0-4e94-a923-9d5d11f89c9a"
      unitRef="U_USD">1500000000</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram>
    <alec:PercentageOfDevelopmentCost
      contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4"
      decimals="2"
      id="F_35921857-412b-48b7-b477-407f6fc94425"
      unitRef="U_pure">0.60</alec:PercentageOfDevelopmentCost>
    <alec:PercentageOfDevelopmentCost
      contextRef="C_a63e3081-f730-456e-b5ed-d6fc2de87931"
      decimals="2"
      id="F_b23a3e78-205d-4c31-9a61-31f6ba10dfa4"
      unitRef="U_pure">0.40</alec:PercentageOfDevelopmentCost>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4"
      decimals="-6"
      id="F_a93377a4-b7e2-4056-a077-b0cfbf3cfb55"
      unitRef="U_USD">700000000</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4"
      decimals="-5"
      id="F_7d76200d-78dc-4f63-9b75-31ee54b766b3"
      unitRef="U_USD">62900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_76299c65-2f3a-4aa2-953a-8368c1d95f6b"
      decimals="-5"
      id="F_7f4cbba1-b978-48c3-9afa-9110ab1278e2"
      unitRef="U_USD">192100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-5"
      id="F_5a90f735-d147-4c54-b0b8-7981b5c5a12d"
      unitRef="U_USD">444900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-5"
      id="F_296c2957-879b-491a-a0dd-d45f8591a4f0"
      unitRef="U_USD">307900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1bb2f1ac-be94-45d3-842e-fdca9f440db4"
      decimals="-5"
      id="F_25d4d1a0-f610-4e04-be78-7dc4069ac70b"
      unitRef="U_USD">14700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_76299c65-2f3a-4aa2-953a-8368c1d95f6b"
      decimals="-5"
      id="F_97a9afb6-0244-4fbd-bfd7-9ab27392cbd3"
      unitRef="U_USD">8800000</us-gaap:ResearchAndDevelopmentExpense>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_a3b39a72-f9d5-452e-8491-11e893261ed3"
      decimals="-5"
      id="F_a7876ee1-e37a-49ec-ab59-ba912f6a9442"
      unitRef="U_USD">205000000.0</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_a3b39a72-f9d5-452e-8491-11e893261ed3"
      decimals="-5"
      id="F_85a11d26-f59a-4976-b3cd-9ee1e077d167"
      unitRef="U_USD">5000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_bee6f6bf-d1c4-42f9-9ab2-0d5a9c70a44d"
      decimals="-5"
      id="F_d7913f05-4410-4944-a6eb-d94814fe4de8"
      unitRef="U_USD">200000000.0</us-gaap:ProceedsFromCollaborators>
    <alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram
      contextRef="C_a3b39a72-f9d5-452e-8491-11e893261ed3"
      decimals="-5"
      id="F_8b248729-54c0-4534-b42c-7048224b38d9"
      unitRef="U_USD">250000000.0</alec:CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram>
    <alec:CollaborativeArrangementMilestonePaymentsReceivablePerProgram
      contextRef="C_c0a599ce-bcb4-4bd2-baef-99bf600a266e"
      decimals="-5"
      id="F_0e5ed3f1-83a5-4828-8946-ddf729064889"
      unitRef="U_USD">17800000</alec:CollaborativeArrangementMilestonePaymentsReceivablePerProgram>
    <alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram
      contextRef="C_ea97f9ff-6baa-434e-8a41-03175d03a38c"
      decimals="-5"
      id="F_256b28e4-b127-43a5-b293-d12a981cfe72"
      unitRef="U_USD">225000000.0</alec:CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram>
    <alec:CollaborativeArrangementUpfrontPayments
      contextRef="C_591622e9-478f-40d8-a4c4-83e7718adf29"
      decimals="-6"
      id="F_9a1b1aa4-f5ab-41a2-9f21-48432ad8fe63"
      unitRef="U_USD">205000000</alec:CollaborativeArrangementUpfrontPayments>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_591622e9-478f-40d8-a4c4-83e7718adf29"
      decimals="-5"
      id="F_fc2bc8bd-45ca-47a0-a83a-fb06a58ac0d4"
      unitRef="U_USD">70700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_07adf335-3612-4d8b-8411-b0ca428a8c48"
      decimals="-5"
      id="F_0c319fa2-76b5-4511-bd2e-4835f8d82d5e"
      unitRef="U_USD">14900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0e9e000a-a972-4453-815c-7beddee684a4"
      decimals="-5"
      id="F_23974d13-3a39-485c-9524-b86a63c882fb"
      unitRef="U_USD">21100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_57f29121-2ac0-4227-aa7c-e698d47d2373"
      decimals="-5"
      id="F_5fb1675c-30f1-4d9a-85f8-7455878d41cc"
      unitRef="U_USD">46700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_bbc12a08-d369-441d-a256-6c6e5a6edbac"
      decimals="-5"
      id="F_322e3fbe-7164-4c87-9f29-196086c1cc71"
      unitRef="U_USD">117400000</us-gaap:ContractWithCustomerLiability>
    <alec:DevelopmentMilestone
      contextRef="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6"
      decimals="-5"
      id="F_25781380-4434-40e3-90d7-628654ec4884"
      unitRef="U_USD">11500000</alec:DevelopmentMilestone>
    <alec:SalesMilestone
      contextRef="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6"
      decimals="-5"
      id="F_06dfe578-8f09-4f24-b362-e74c32481657"
      unitRef="U_USD">112500000</alec:SalesMilestone>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_1f26cdc8-1fd5-4488-a6f0-e8ff9cf532c6"
      decimals="-3"
      id="F_1e42260d-3e3f-44bd-aba8-0dbcdb44ebb1"
      unitRef="U_USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_afd0f89e-ec44-400b-8b13-6cc2b86ef408">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;5.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance Sheet Components &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.949%;"/&gt;
        &lt;td style="width:1.32%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.304%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold Improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.206%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.393%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.423%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_95cf66a2-00b3-457f-9b29-74e37be1bfc8">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.949%;"/&gt;
        &lt;td style="width:1.32%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.714%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.304%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.713%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab Equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold Improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_59b9e1be-3875-4c2c-8688-02e607d91e6c"
      decimals="-3"
      id="F_7055793c-8bb6-4205-b53c-4f2d76f0136b"
      unitRef="U_USD">2310000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_51a99dc6-2893-4e9d-b0b0-79417c0a1aeb"
      decimals="-3"
      id="F_1e69416d-d057-4015-8189-d56b77f4a328"
      unitRef="U_USD">2294000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cee82e6c-ce42-4848-8ad7-b247c43c8a26"
      decimals="-3"
      id="F_0d57b30e-7d4b-4012-ab0b-3592be4e29af"
      unitRef="U_USD">2430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bc7bd397-63c7-41cc-afa7-7230b2cab7ed"
      decimals="-3"
      id="F_e800322b-fe9c-4740-b47e-db71d76c2a10"
      unitRef="U_USD">2330000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dad2a26c-287b-4267-9f7c-8a34fc96b55a"
      decimals="-3"
      id="F_7bd2714a-d706-49ad-8c60-4c16c16836c6"
      unitRef="U_USD">17165000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4b7ae830-6548-4c51-9858-5fd1f867e8f7"
      decimals="-3"
      id="F_49374286-8b54-4466-9ebf-f28bd6783fc6"
      unitRef="U_USD">14043000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d0630ba0-e9e8-4702-89d0-bdba73bdd2e4"
      decimals="-3"
      id="F_69067060-5cfb-4b2e-b692-f0fd1bc29dc4"
      unitRef="U_USD">26228000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_92d78956-76c2-4167-b848-5449236c361e"
      decimals="-3"
      id="F_17a7e8f9-9091-4804-975f-8bf7abc4a82c"
      unitRef="U_USD">25949000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_3e106a37-33db-40ff-905f-64bc4cec2c4f"
      unitRef="U_USD">48133000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_149efd90-dfc2-4d55-bf01-a47c542d4bdc"
      unitRef="U_USD">44616000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_9850ec9b-0547-4aa6-a7f4-230ee757f14a"
      unitRef="U_USD">22612000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_b2704d81-899b-42e1-80ae-980f5abc4e03"
      unitRef="U_USD">17286000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_df035bb4-d8e4-4c1c-8592-82e494b690d3"
      unitRef="U_USD">25521000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_9f0a3c42-cff5-470e-8499-180a0fed75f0"
      unitRef="U_USD">27330000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_2bba8ac1-b782-4f93-b8ec-df1cd16e4a7c">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.206%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.393%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.423%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued employee compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,983&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;337&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <alec:AccruedResearchAndDevelopmentCosts
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_5ee2aa0d-7f31-4e7a-84b8-35d9f7b39eff"
      unitRef="U_USD">12321000</alec:AccruedResearchAndDevelopmentCosts>
    <alec:AccruedResearchAndDevelopmentCosts
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_c8c07ef9-f224-439a-81a6-8bae20fdf9f9"
      unitRef="U_USD">13330000</alec:AccruedResearchAndDevelopmentCosts>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_0dedc888-8d09-4a34-a3ca-05e4058430e1"
      unitRef="U_USD">12758000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_adf80a7a-8adf-4970-8e1e-612fba3416f8"
      unitRef="U_USD">11664000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_8e0060f6-4f41-4ab4-9923-7082dfa09afb"
      unitRef="U_USD">1983000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_4a4fa02e-9b4d-481c-a319-d723d10108bb"
      unitRef="U_USD">1588000</us-gaap:AccruedProfessionalFeesCurrent>
    <alec:AccruedPropertyAndEquipmentCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_ed8468d7-b35b-4062-b18b-d08283f686e6"
      unitRef="U_USD">337000</alec:AccruedPropertyAndEquipmentCurrent>
    <alec:AccruedPropertyAndEquipmentCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_eab3662b-ef7c-49a2-b28f-c94940add6cd"
      unitRef="U_USD">560000</alec:AccruedPropertyAndEquipmentCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_020a0cff-9d8e-4526-8203-592ef2c1f9fa"
      unitRef="U_USD">372000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_c15636dd-27d3-4fc1-bf52-030cdec5b15b"
      unitRef="U_USD">318000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_37f9ff3c-4710-45fd-b3f2-88d77716b51c"
      unitRef="U_USD">27771000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_789dc442-70a7-4869-9bef-c55b76c86613"
      unitRef="U_USD">27460000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_8a071638-95d6-42ce-aca1-efe19e6d1898">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;6.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2018, the Company signed a lease agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet in office and laboratory space in South San Francisco which serves as the Company&#x2019;s headquarters (the &#x201c;Headquarters&#x201d;). &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The lease expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; with an option to renew for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The landlord paid for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of tenant improvements. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company signed a lease agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of office and laboratory space in Newark, California. The lease term ends on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 6, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; with an option to extend for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The landlord is obligated to pay for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of tenant improvements.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The measurement of the lease liabilities for the leases excludes the options to extend the term of the lease as such extensions are not reasonably certain to occur. Variable lease costs for all of the Company&#x2019;s leases consist of operating expenses for the spaces.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2019, the Company entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of the Headquarters (the &#x201c;Sublease&#x201d;), which was amended to approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,600&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet in December 2020. The Sublease expired in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The sublessee pays its proportionate share of operating expenses for the space.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the Company entered into an agreement to sublease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,132&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet of the Headquarters, which was amended in May 2022 to include an additional space of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,150&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;feet. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,132 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;square feet of space subleased expired in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and the additional space will expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;November 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.102%;"/&gt;
        &lt;td style="width:0.722%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.773%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.597%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sublease income and reimbursement of variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the weighted-average remaining lease term for operating leases was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years and the weighted-average discount rate was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. Cash paid for amounts included in the measurement of lease liabilities for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021, and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, was included in net cash used in operating activities in our consolidated statements of cash flows.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following are the lease payments owed under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.114%;"/&gt;
        &lt;td style="width:0.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <alec:AreaOfPropertyInLease
      contextRef="C_a249850f-9ff5-4ed1-8915-381e8e7d8c32"
      decimals="0"
      id="F_5db62e06-58ee-4694-90ce-a8f863ee025a"
      unitRef="U_sqft">105000</alec:AreaOfPropertyInLease>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_47b49882-644d-4f50-b032-eff58ec74db9">The lease expires in 2029 with an option to renew for a period of ten years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <alec:LeaseExpirationYear
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_8a3776f2-ce6a-4d6a-96d8-e4dbb71c0b44">2029</alec:LeaseExpirationYear>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      id="F_8b1b6155-1641-49aa-9b81-45d9f99e7097">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-5"
      id="F_5aeb2508-718d-4963-b91e-e7bafba22a65"
      unitRef="U_USD">15700000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-5"
      id="F_9d3c87af-6ac3-4659-ac8d-43aa9fda0d63"
      unitRef="U_USD">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_69eaec9d-be8a-46cd-b047-8697f5e418ff"
      id="F_77665e18-b526-4c52-b400-ff433df03366">In October 2020, the Company signed a lease agreement to lease approximately 18,700 square feet of office and laboratory space in Newark, California. The lease term ends on February 6, 2028 with an option to extend for an additional five years. The landlord is obligated to pay for up to $0.4 million of tenant improvements.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_68921c7f-cea1-46f8-9606-82bf1ee5887d"
      decimals="0"
      id="F_bdc03bef-319d-47e8-802b-93a06bd187aa"
      unitRef="U_sqft">18700</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0aed28b8-d995-4247-8f88-dd02919d008c"
      id="F_207d8686-10cf-44e9-a74a-b23f76d254d5">2028-02-06</us-gaap:LeaseExpirationDate1>
    <us-gaap:LessorOperatingLeaseRenewalTerm
      contextRef="C_68921c7f-cea1-46f8-9606-82bf1ee5887d"
      id="F_88d29fc3-99d8-4923-86a6-31470ca126e2">P5Y</us-gaap:LessorOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="C_0aed28b8-d995-4247-8f88-dd02919d008c"
      decimals="-5"
      id="F_44b67a50-4a0e-445a-bd5c-492b5203da32"
      unitRef="U_USD">400000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <alec:AreaOfPropertyInSubleaseAgreement
      contextRef="C_6eb70da4-a1bc-45a1-8da8-c9552a0a4ac6"
      decimals="0"
      id="F_bf4f192f-65f8-48a9-a53b-7c633f4bdcff"
      unitRef="U_sqft">25000</alec:AreaOfPropertyInSubleaseAgreement>
    <alec:AreaOfPropertyInLease
      contextRef="C_6f4164fc-b4c1-41ca-8455-663b93759519"
      decimals="0"
      id="F_383c269c-6156-437a-b4a1-d8711c6a7af8"
      unitRef="U_sqft">23600</alec:AreaOfPropertyInLease>
    <alec:SubleaseExpirationMonthAndYear
      contextRef="C_3bca2306-c6f8-41f3-9a71-4b209e479578"
      id="F_3109d8ca-6c66-47aa-8894-656cf52bdc47">2021-11</alec:SubleaseExpirationMonthAndYear>
    <alec:AreaOfPropertyInSubleaseAgreement
      contextRef="C_a90b3f2f-9462-46f0-84ce-63965231a711"
      decimals="0"
      id="F_7b91ff0c-c229-4c06-87b7-792a03d08e72"
      unitRef="U_sqft">7132</alec:AreaOfPropertyInSubleaseAgreement>
    <alec:AdditionalAreaOfPropertyInLease
      contextRef="C_b1909874-9ac4-4faa-a605-aeb9628d2105"
      decimals="0"
      id="F_936f8caf-7073-4489-9371-07dcfd8c0eba"
      unitRef="U_sqft">13150</alec:AdditionalAreaOfPropertyInLease>
    <alec:SubleaseExpirationMonthAndYear
      contextRef="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9"
      id="F_58bfbbfe-c406-4f99-b80a-86b013a56fa6">2022-12</alec:SubleaseExpirationMonthAndYear>
    <alec:AdditionalAreaSubleaseExpirationMonthAndYear
      contextRef="C_90a05fc9-2fdd-4bb1-8a9c-3a2e42b08da9"
      id="F_d0c3aded-b09b-4b04-a20f-95ec910b9508">2023-11</alec:AdditionalAreaSubleaseExpirationMonthAndYear>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_252f2c92-fc22-4133-b186-15a6c3692558">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.102%;"/&gt;
        &lt;td style="width:0.722%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.773%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.597%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sublease income and reimbursement of variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,551&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_cca9d451-c5c9-44a7-bb57-05b6e74da968"
      unitRef="U_USD">6638000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_e5842bd1-d5da-4db2-aab2-efba91938cb6"
      unitRef="U_USD">6204000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_04d67e0c-df75-46f0-9bde-7f2ee801ef45"
      unitRef="U_USD">5589000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_f93e8881-fcd8-4ee3-8c0b-35f47fe0e899"
      unitRef="U_USD">2785000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_c61de42e-44f9-4ef3-a0e8-8e6fafb4fb60"
      unitRef="U_USD">3046000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_edc59773-6bcf-40b7-82a2-605062316940"
      unitRef="U_USD">2255000</us-gaap:VariableLeaseCost>
    <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_5a410081-0a80-45d4-a998-722fa2795927"
      unitRef="U_USD">1872000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
    <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_c3f449e0-13bf-4220-9fe4-748688a79d74"
      unitRef="U_USD">2141000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
    <alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_821cc1b8-42eb-4fb8-afea-dd8c492c3c64"
      unitRef="U_USD">2288000</alec:SubleaseIncomeAndReimbursementOfVariableLeaseCost1>
    <us-gaap:LeaseCost
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_3ffbdb26-48ca-4a68-bd08-95855fc9efb8"
      unitRef="U_USD">7551000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_eaf21c23-7652-4a70-b684-fd72fb279c76"
      unitRef="U_USD">7109000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_24a1548a-16ca-44ed-b239-07d8b8178c54"
      unitRef="U_USD">5556000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      id="F_8c815f2e-ff1f-4e90-8528-560ebf90a875">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="3"
      id="F_f3b24d31-d2ec-451f-b672-699a3adb4196"
      unitRef="U_pure">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-5"
      id="F_88cf206b-9d7a-4067-ab5b-6c0ffdea477e"
      unitRef="U_USD">8200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-5"
      id="F_5bb8395b-d3a5-403d-aedd-40f502352b3e"
      unitRef="U_USD">7900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-5"
      id="F_075e85d3-77ac-4347-a602-c08c195b6f45"
      unitRef="U_USD">6900000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_cdcc6352-5c06-42ec-8402-b7169aa75adc">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following are the lease payments owed under the Company&#x2019;s operating leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.114%;"/&gt;
        &lt;td style="width:0.996%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.89%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_37230356-c3f0-46a8-9497-dfd193c7fa14"
      unitRef="U_USD">8436000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_bc16753c-a1c1-4471-8167-92aa8fafbaad"
      unitRef="U_USD">8732000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_5fa7c0a2-9e1f-46f2-b346-91b751a0427f"
      unitRef="U_USD">9037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_61e596c3-e407-4636-9f1a-626f5d34b06d"
      unitRef="U_USD">9353000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_cf32c108-bb3b-424c-b2fe-2c4e481d4f60"
      unitRef="U_USD">9681000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_b3d6d428-d156-44f1-8c97-c745523043c5"
      unitRef="U_USD">11096000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_f08f0029-e6dc-4997-85bd-d1da994d4bc8"
      unitRef="U_USD">56335000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_bfd3d66f-f01d-4aa8-9111-b3dbdf44f4f0"
      unitRef="U_USD">13008000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_a1799339-3cfb-4e78-a78f-b217ac4088ba"
      unitRef="U_USD">43327000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_195e5664-78e3-4bf8-b6aa-13bd12f20a2c">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;7.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based Compensation &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized stock-based compensation as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.888%;"/&gt;
        &lt;td style="width:1.291%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.017000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.017000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.15%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Determination of Fair Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated grant-date fair value of all the Company&#x2019;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.034%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:16.8%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:16.8%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:16.76%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of each stock option was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The expected term represents the period that stock-based awards are expected to be outstanding. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has limited information on the volatility of stock options as the shares were not actively traded on any public markets prior to February 7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#x2019;s business over a period equivalent to the expected term of the stock-based awards. In 2020, the Company began giving weight to in its own historical volatility in the determination of expected volatility.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.08%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Rate&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock underlying its stock options in the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Equity Incentive Plan and 2022 Inducement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 6, 2019, the Company adopted the 2019 Equity Incentive Plan (2019 Plan) under which the Board may issue incentive stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#x2019;s employees, directors, and consultants. The Company&#x2019;s 2017 Stock Option and Grant Plan (2017 Plan) was terminated; however, shares subject to awards granted under it will continue to be governed by the 2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% or more of the outstanding shares, the exercise price of each share shall be at least &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair market value and the term of the award shall not exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The stock options generally vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period with one forty-eighth of the shares vesting each month or over a four-year period with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% vesting at the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; cliff and monthly thereafter. The RSUs generally vest over a period of three years with one-twelfth of the shares vesting quarterly. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 1, 2022, the Company added &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,099,309&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares to the shares reserved for issuance under the 2019 Equity Incentive Plan. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,463,901&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the automatic conversion provision of common stock under the 2019 Plan, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,587,550&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were available for issuance of future awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 1, 2022, the Company adopted the 2022 Inducement Plan (Inducement Plan) and reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,630,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares for issuance under the Inducement Plan for the grant of equity-based awards to individuals who were not previously employees or non-employee directors of the Company. On September 22, 2022, the Company increased the number of shares available for issuance under the 2022 Inducement Plan to a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,300,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,401,483&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were available for issuance of future awards under the Inducement Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Option activity is shown below:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.134%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.927000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.309999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.862%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.442%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,654,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,264,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,879,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,996,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,628,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,776,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest as of December 31,&lt;br/&gt;&#160;&#160;&#160;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock for stock options that were in-the-money. The aggregate intrinsic value of options exercised was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021, and 2020, respectively. The weighted-average grant-date fair value per share of options granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.42&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.14&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, total unrecognized stock-based compensation related to unvested stock options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which the Company expects to recognize over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Activity for the restricted stock awards and RSUs is shown below.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; In May 2021 and January 2022, the Company issued RSUs with market conditions to certain executives, which are also included in the table below. The RSUs with market conditions are earned based on stock price performance and continued service by the employee. The RSUs with market conditions trigger vesting upon the company's stock price attaining a specified level over a specified period of time. The shares then vest quarterly over one year after attainment. The Company used a Monte Carlo simulation model to determine the fair value of the awards at the grant date. The Monte Carlo model uses the fair value inputs on the grant date to run simulations and take an average of possible outcomes. The total grant date fair value of the RSUs with market condition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to be amortized over an estimated weighted average service period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years. Compensation expense related to awards with market-based conditions is recognized regardless of whether the market condition is ultimately satisfied if the related service has been provided.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.585%;"/&gt;
        &lt;td style="width:1.267%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.709%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.334999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards and restricted stock units as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,822,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;324,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,539,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;414,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;453,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock units as of&lt;br/&gt;&#160;&#160;&#160;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, total unrecognized stock-based compensation related to unvested restricted common stock issued to employees was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which the Company expects to recognize over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2019 Employee Stock Purchase Plan (2019 ESPP) enables eligible employees of the Company to purchase shares of common stock at a discount. Each offering period is approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; long beginning on the first trading day on or after June 1 and December 1 each year. ESPP participants purchase shares of common stock at a price per share equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lesser of (1) the fair market value per share of the common stock on the first trading day of the offering period or (2) the fair market value of the common stock on the purchase date. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On January 1, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;591,397&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were added to the shares reserved for issuance under the 2019 ESPP pursuant to the annual automatic increase. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in unrecognized compensation expense related to the 2019 ESPP to be recognized over five months.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_b1ee039c-3e70-466f-a34e-73c914974868">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized stock-based compensation as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.888%;"/&gt;
        &lt;td style="width:1.291%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.017000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.017000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.318%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.15%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46,146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4f49c42b-493f-47f8-9739-cb8ff352f950"
      decimals="-3"
      id="F_0652d4df-9d51-4629-873b-c99ab3826579"
      unitRef="U_USD">24895000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2b22c619-0e67-4a8a-9893-c4a93f9df158"
      decimals="-3"
      id="F_bd46bb9a-a7db-4c84-b290-f8bad7dab4bc"
      unitRef="U_USD">21443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e21ea263-2f4e-4a53-bf66-2c7077518b36"
      decimals="-3"
      id="F_a66e0526-94a6-4fa4-8485-966349f1ff5f"
      unitRef="U_USD">14980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_48a91691-46db-40c9-a5b2-794422b8838e"
      decimals="-3"
      id="F_21f786c2-09a2-4677-8233-e13f603e64a1"
      unitRef="U_USD">21251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9cf5d0c4-ca22-4be2-aa95-e9fd5130a84b"
      decimals="-3"
      id="F_822f61f1-8aec-43e6-a85e-4f0106a5be81"
      unitRef="U_USD">19342000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_558fd0f4-ad61-4047-b762-e6960a1f35eb"
      decimals="-3"
      id="F_f89fc1e9-fd70-40af-8fff-942cfc098b4a"
      unitRef="U_USD">15542000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_00c3e5b7-f057-4bbe-acbb-32012628ac6b"
      unitRef="U_USD">46146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_daec6c10-5632-45fc-82e0-015e23594c2e"
      unitRef="U_USD">40785000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_7c968b69-0905-4a4e-beed-4406ffde3597"
      unitRef="U_USD">30522000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_bbf278c5-9fbf-4834-b2b9-552e1e2b4237">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated grant-date fair value of all the Company&#x2019;s options to purchase common stock was calculated using the Black-Scholes option pricing model, based on the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.034%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:16.8%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:16.8%;"/&gt;
        &lt;td style="width:1.202%;"/&gt;
        &lt;td style="width:16.76%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1eae11ed-31bf-4dfc-a698-681b39d46f70"
      id="F_8f97540d-2142-4004-a6d0-a4213e0ad0aa">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763"
      id="F_0bd0f7b2-8cea-407a-9443-c4a03bec4c61">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_30408e35-6b1a-4011-ac8f-7e1456941ba0"
      id="F_4de86e97-ab01-4166-a4bf-a50ed662c517">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7"
      id="F_e9ffcaf3-eb32-43c4-8f66-ddc1c8005b10">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f138f916-581b-4f02-aadd-4cd12427fc86"
      id="F_e46834a8-f78b-4011-95f9-195bd8ece2de">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6"
      id="F_13436713-cacf-43f9-a7d1-f6ce35633c72">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_1eae11ed-31bf-4dfc-a698-681b39d46f70"
      decimals="2"
      id="F_d3bb1579-4830-47a6-a527-6e99c8d2649d"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763"
      decimals="2"
      id="F_439dcfeb-b211-4682-8102-53570ab10677"
      unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_30408e35-6b1a-4011-ac8f-7e1456941ba0"
      decimals="2"
      id="F_5ca5c176-46e8-4781-948c-9cc612160681"
      unitRef="U_pure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7"
      decimals="2"
      id="F_ef4c04de-f354-40ea-af8e-ccaeb2142362"
      unitRef="U_pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f138f916-581b-4f02-aadd-4cd12427fc86"
      decimals="2"
      id="F_dc1b4c62-b7ab-47f4-ae63-9b20ec3ff4cc"
      unitRef="U_pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6"
      decimals="2"
      id="F_99f0d22c-6101-47dc-bd8e-b968efb49f16"
      unitRef="U_pure">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_1eae11ed-31bf-4dfc-a698-681b39d46f70"
      decimals="3"
      id="F_e29dd424-e56c-42a2-ad90-1d94cf89c7c0"
      unitRef="U_pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f8f34b34-fe41-4a4c-8e02-daaf28c6c763"
      decimals="3"
      id="F_5d637236-007c-4f2e-b571-86ccbf4436af"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_30408e35-6b1a-4011-ac8f-7e1456941ba0"
      decimals="3"
      id="F_2445fdaf-7fd5-4832-a50d-3197a1eb9ff3"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ccf7d22e-ae2a-480f-8aed-1a1fe86945a7"
      decimals="3"
      id="F_8fa63f91-e97b-4329-9a8d-105922a945fe"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f138f916-581b-4f02-aadd-4cd12427fc86"
      decimals="3"
      id="F_0206935b-411e-45be-82a8-45ddc892c627"
      unitRef="U_pure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_8bf00bd0-2f6f-49bc-9cb5-8b025f1823f6"
      decimals="3"
      id="F_baaf0fb5-b855-4213-b403-4dcb46c0ea12"
      unitRef="U_pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_235ab5c2-cb0b-4693-a7d8-c6af3cd3645b"
      decimals="2"
      id="F_e420fc67-aa4e-4c31-a8d9-2ba4c506b383"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_abf92419-83da-405a-8247-30fd4646394a"
      decimals="2"
      id="F_6b56790b-a5d1-492c-a633-933f49fbd37f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_25d652af-cdb3-4c04-9508-c4f3acbb1dcc"
      decimals="2"
      id="F_9be491ce-b45d-4174-b845-bf2886b4f0e1"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <alec:PercentageOfStockOwnedByIndividual
      contextRef="C_319ea842-0000-481f-8857-4a411838770a"
      decimals="2"
      id="F_64be59b8-2924-44bc-87f3-6d89f121298b"
      unitRef="U_pure">0.10</alec:PercentageOfStockOwnedByIndividual>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_319ea842-0000-481f-8857-4a411838770a"
      decimals="2"
      id="F_5c0ae263-2576-480b-b547-eecd657f7311"
      unitRef="U_pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_319ea842-0000-481f-8857-4a411838770a"
      id="F_217d4dd4-71fe-4a59-986d-b9ce7ba7e874">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_873e87e5-56d0-4394-ba3e-604f72c1fb04"
      id="F_32a5ef2c-f174-4c33-a1c7-6a2b0f0bf2e6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_319ea842-0000-481f-8857-4a411838770a"
      id="F_9d4b2141-3cd6-487c-adf2-426fda1582c4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage
      contextRef="C_319ea842-0000-481f-8857-4a411838770a"
      decimals="2"
      id="F_da9b36e1-c2ee-4e5e-bd70-561082696edb"
      unitRef="U_pure">0.25</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage>
    <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod
      contextRef="C_319ea842-0000-481f-8857-4a411838770a"
      id="F_de2e4e80-14aa-4348-bee3-42be43bc5983">P1Y</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_dd06c0e7-b9e9-48e2-9fd2-99b651c4b5a3"
      decimals="0"
      id="F_91767744-9793-4d18-ad7c-4449888286a7"
      unitRef="U_shares">4099309</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="0"
      id="F_3ff1c73a-3a82-4521-9bfb-f318f82d9a1e"
      unitRef="U_shares">20463901</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="0"
      id="F_5e8df67e-5865-4473-85ae-12c15e78a70b"
      unitRef="U_shares">5587550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b6f138ff-488b-4b84-a7d2-f77486a49d63"
      decimals="0"
      id="F_10996163-e7ca-4046-aee0-94e4d2d5d7b2"
      unitRef="U_shares">1630000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_ed1f3bb7-c84d-4b92-a5a6-e2a94d7ac051"
      decimals="0"
      id="F_566b77f5-e69f-4b60-883b-b22f28de587e"
      unitRef="U_shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_739d8fa6-0e40-445b-8283-8871a7bb5917"
      decimals="0"
      id="F_f2019476-ba1e-46d9-98ee-c23cc3f7a43b"
      unitRef="U_shares">1401483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_f53df731-9012-4cd7-80a1-9ee774422e5a">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Option activity is shown below:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.134%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.927000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.309999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.862%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.442%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,654,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,264,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,879,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,996,366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,628,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,776,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest as of December 31,&lt;br/&gt;&#160;&#160;&#160;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff"
      decimals="0"
      id="F_e3ac7af7-80ec-4d12-8c15-103c191e0b49"
      unitRef="U_shares">12654998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff"
      decimals="2"
      id="F_20fbe5d7-a237-4df4-af65-bd4b0aa99a0a"
      unitRef="U_USDollarShare">13.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="0"
      id="F_e71215c0-982a-4d85-ab87-cee5a20d8b82"
      unitRef="U_shares">3264059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="2"
      id="F_a5308a91-57a1-44e7-9f42-60c87156fe10"
      unitRef="U_USDollarShare">21.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="0"
      id="F_24256b07-80af-428f-8d97-ce8be6e8f139"
      unitRef="U_shares">2395223</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="2"
      id="F_337402eb-ca62-47f7-976b-cd0332917c62"
      unitRef="U_USDollarShare">11.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="0"
      id="F_9d6db0ca-626d-40cd-8cb5-d55acde50a02"
      unitRef="U_shares">1879764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="2"
      id="F_349836db-dd0c-46b2-995c-411a4cfc1f1a"
      unitRef="U_USDollarShare">14.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b"
      decimals="0"
      id="F_54419dcb-1f7f-4c34-badb-1987517b170d"
      unitRef="U_shares">11644070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b"
      decimals="2"
      id="F_a5942fcb-b054-4208-a262-eb2bedff8cab"
      unitRef="U_USDollarShare">16.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="0"
      id="F_2e83649e-5d6f-4a69-a9af-8703233cd990"
      unitRef="U_shares">4996366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="2"
      id="F_6fef8182-7a8b-4197-84b4-c894c6d8d34d"
      unitRef="U_USDollarShare">12.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="0"
      id="F_4cdb9194-5861-4691-ab19-9493a86737f9"
      unitRef="U_shares">298239</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="2"
      id="F_820c6b8c-9b9d-446f-800d-1ceb46d60693"
      unitRef="U_USDollarShare">10.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="0"
      id="F_89c5a5d8-517f-4fa2-9ac7-d8d9301cbe15"
      unitRef="U_shares">2628925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="2"
      id="F_5c66e94a-414e-497c-bd7a-cc7e30295928"
      unitRef="U_USDollarShare">18.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="0"
      id="F_6a3849ba-3a26-4b51-8c5c-7113cfbe0ffa"
      unitRef="U_shares">13713272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="2"
      id="F_36ee61a6-6f9c-4af2-8685-3727b1d87aa8"
      unitRef="U_USDollarShare">14.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      id="F_3979ef9f-1816-4566-a4e5-705ad5ad0882">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="-3"
      id="F_d976191c-6716-402d-a6f5-45a174a8b09e"
      unitRef="U_USD">1583000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="0"
      id="F_272f3dee-16fb-437f-83db-76f608c84c66"
      unitRef="U_shares">6776201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="2"
      id="F_9adea0cb-3725-4141-8da6-cbc695eaf1f6"
      unitRef="U_USDollarShare">14.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      id="F_54f1b99f-bd89-4e0d-9a7b-63b9bd336ce8">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="-3"
      id="F_b69c8faa-e909-471d-9bcc-f3769d40427c"
      unitRef="U_USD">1276000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="0"
      id="F_c14e7293-55ff-4a64-815d-c5f84e3c4eab"
      unitRef="U_shares">13713272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="2"
      id="F_18b1896d-b9c8-43f4-a2f7-0e7fc0a426fb"
      unitRef="U_USDollarShare">14.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      id="F_94b5df01-a318-4802-8a23-e6b60d1323f5">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="-3"
      id="F_c64d49fd-e59b-4623-8897-9543ebd7abcf"
      unitRef="U_USD">1583000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="-5"
      id="F_eefa7a0c-63dd-42de-a3b1-b4c26ddbedd4"
      unitRef="U_USD">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b"
      decimals="-5"
      id="F_1b26a879-3181-4618-bdd4-6823719144d7"
      unitRef="U_USD">37100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff"
      decimals="-5"
      id="F_8b7d0e6a-2eab-4f2c-a31a-9681a073d206"
      unitRef="U_USD">11100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      decimals="INF"
      id="F_766e19fe-2d50-4ac7-8acd-72227946a4c1"
      unitRef="U_USDollarShare">8.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_053ac8c7-c0c9-482b-ae70-6822a65edfd8"
      decimals="INF"
      id="F_7b6e4245-184a-47fa-881b-dd218a4828f3"
      unitRef="U_USDollarShare">14.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e759e0c4-57cc-4d3e-90d2-e3c5076206fd"
      decimals="2"
      id="F_cecff5c5-b37b-4ee2-8ea1-e661eb13b9e6"
      unitRef="U_USDollarShare">10.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_816d6294-b950-41ec-954c-c41ce41aab6b"
      decimals="-5"
      id="F_2adf5b26-25d4-433c-a985-b7ce9d9d0f32"
      unitRef="U_USD">64400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2d982249-1d80-47dc-833c-6f8db5de8881"
      id="F_47e5f63b-fb7b-446a-9808-f4735133ef73">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_38df48a3-9919-4464-a5bb-d719c8dc3acf">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Activity for the restricted stock awards and RSUs is shown below.&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.585%;"/&gt;
        &lt;td style="width:1.267%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.709%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.334999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock awards and restricted stock units as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,822,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;324,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,539,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;414,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;453,693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested restricted stock units as of&lt;br/&gt;&#160;&#160;&#160;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue
      contextRef="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf"
      decimals="-5"
      id="F_aff8a1b2-2d5c-43f9-8f00-efb37bb5104a"
      unitRef="U_USD">6600000</alec:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf"
      id="F_4d6a880f-10fb-43c4-bf08-f159b6da1d02">P2Y1M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_338e36e2-ef61-4f44-861b-3a1b978b8228"
      decimals="0"
      id="F_341d6709-e160-4d28-81b8-2e5b848a2ffe"
      unitRef="U_shares">186425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_338e36e2-ef61-4f44-861b-3a1b978b8228"
      decimals="2"
      id="F_a60deb84-1d11-4584-ac4b-3cb6a8ff35b9"
      unitRef="U_USDollarShare">6.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"
      decimals="0"
      id="F_7eee7aeb-878a-42cb-be52-8a9d24df8c77"
      unitRef="U_shares">1822295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"
      decimals="2"
      id="F_b8fb8ec9-0f05-4502-9784-fe61bf56839d"
      unitRef="U_USDollarShare">17.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"
      decimals="0"
      id="F_c2d02e6e-50a1-4091-8f86-19f656837b97"
      unitRef="U_shares">324802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"
      decimals="2"
      id="F_efdfae21-4134-49e0-b3ec-53a63be9cc3a"
      unitRef="U_USDollarShare">10.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"
      decimals="0"
      id="F_3960887d-7d55-4584-88c5-9ddb41bd4b96"
      unitRef="U_shares">310044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_6f4cb42b-a164-4af9-8e07-55f54520f6c2"
      decimals="2"
      id="F_70fc51d1-ce08-4df8-81d6-bc204b8938c6"
      unitRef="U_USDollarShare">13.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_dc0ce554-adea-4930-b36c-ddea841a6c0d"
      decimals="0"
      id="F_9a56e332-a0eb-4877-8291-903340ea5fa6"
      unitRef="U_shares">1373874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_dc0ce554-adea-4930-b36c-ddea841a6c0d"
      decimals="2"
      id="F_cfb02e2a-5750-4f1f-979d-0a8eca08661b"
      unitRef="U_USDollarShare">18.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"
      decimals="0"
      id="F_7e89d3c0-9540-4e3c-ba90-8b61c7d43697"
      unitRef="U_shares">2539014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"
      decimals="2"
      id="F_2acc8fdb-44fe-43e1-a926-90d667643ca8"
      unitRef="U_USDollarShare">10.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"
      decimals="0"
      id="F_09957d0f-9810-4b39-a895-53ec06fa1557"
      unitRef="U_shares">414577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"
      decimals="2"
      id="F_1e075dbd-4673-4c86-984a-cec3a4786435"
      unitRef="U_USDollarShare">18.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"
      decimals="0"
      id="F_bdec96e5-e3c2-4b39-b857-0f4eb29291cd"
      unitRef="U_shares">453693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_9c34c6d9-b77c-4731-8005-1d4591ff61d6"
      decimals="2"
      id="F_1733ad58-72c1-4ead-9e65-5d74b525cd3b"
      unitRef="U_USDollarShare">16.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_bb53d62d-50b1-4820-8847-5ea059efb08f"
      decimals="0"
      id="F_9f2d7daa-ff31-4de1-8a33-75b97b4509e0"
      unitRef="U_shares">3044618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_bb53d62d-50b1-4820-8847-5ea059efb08f"
      decimals="2"
      id="F_a9e9fb71-09ac-4927-9784-27e98739598d"
      unitRef="U_USDollarShare">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_4670a0e4-4053-442e-b19c-76a0ef8da1fc"
      decimals="-5"
      id="F_5cebe2d2-71d4-407e-af85-51856dc84f87"
      unitRef="U_USD">30200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf"
      id="F_78e70fd7-5edd-492e-9b75-b5d6fe9860d1">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <alec:SubsequentOfferingPeriod
      contextRef="C_6e29ec8b-8d03-49b6-84f6-bb02efd765fe"
      id="F_2b3b3a41-7c66-4797-8009-1e2446c8c213">P6M</alec:SubsequentOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="C_6e29ec8b-8d03-49b6-84f6-bb02efd765fe"
      decimals="2"
      id="F_c0787a54-5d1b-444f-856e-00d528f9e61b"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_493c7746-435c-403e-8f86-4bcdeada8dd8"
      decimals="0"
      id="F_eb7cbfbf-d520-4df7-a580-39291150a3a4"
      unitRef="U_shares">591397</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_6b3e5c54-3f8c-4714-8434-7829b44103ee"
      decimals="-5"
      id="F_2a512444-dd86-46f4-8120-52ab212592c6"
      unitRef="U_USD">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_56f9330f-4fbf-465c-88d0-87fcea5cc2a7">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;8.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The federal and state income tax provision for the year ended December 31, 2022, 2021 and 2020 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.115%;"/&gt;
        &lt;td style="width:1.963%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.235999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.974%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.248%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.974%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.491%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.61%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.988999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.988999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.022%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant components of the Company&#x2019;s deferred tax assets and liabilities consist of (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.182%;"/&gt;
        &lt;td style="width:2.441%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.450999999999997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.441%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.483999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance for deferred tax assets increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company had federal and state net operating loss (NOL) carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. Federal NOL carryforwards have an indefinite life and deductions cannot exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of taxable income. State NOL carryforwards will begin to expire as early as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, if not utilized, or have an indefinite life. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company also had federal and California tax credit carryforward of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The federal tax credits will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2036 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;while the California tax credits have no expiration date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#x2019;s ability to utilize NOL carryforwards may be limited as the result of such an &#x201c;ownership change.&#x201d; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section 382 at this time.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.002%;"/&gt;
        &lt;td style="width:2.048%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.95%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Decreases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If the unrecognized tax benefits for uncertain tax positions as of December 31, 2022, is recognized, there will be no impact to the effective tax rate as the tax benefit would increase the net deferred tax assets, which is currently offset with a full valuation allowance. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended December 31, 2022. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. During the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, the Company recorded an uncertain tax position of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. The income tax provision for the years ended December 31, 2022 and 2021, included a reversal of reserves on uncertain tax provisions of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company&#x2019;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_d1da5c35-6676-4994-b039-6b0a8ad0d357">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The federal and state income tax provision for the year ended December 31, 2022, 2021 and 2020 are summarized as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.115%;"/&gt;
        &lt;td style="width:1.963%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.235999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.974%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.248%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.974%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.491%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_e06e28d9-a533-4e22-82c8-4a96a788843f"
      unitRef="U_USD">2209000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_062754d2-9dfd-4552-aec7-19211a4526ac"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_439f54ed-4299-48d3-88d8-4bc0c212cc4d"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_d2b48f6e-d22e-462b-9fcf-d6e4126f26d3"
      unitRef="U_USD">1045000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_662d3bdf-ce17-45f3-a085-7c4abdb22a37"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_14e44b5b-9786-4ed7-a1ee-504d2ba97d72"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_4c351c5b-0aff-42c1-bfaf-0666ee891993"
      unitRef="U_USD">3254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_94995899-37fb-4bd1-9eb1-f3baef10762f"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_0cbe893b-d83e-42d5-b53a-8dee48b8451c"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_77784388-8cc9-473e-b177-bca76332ca81">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the federal statutory rate to the Company&#x2019;s effective tax rate is as follows for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.61%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.988999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.988999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.464%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.022%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax benefit at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,184&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,010&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Uncertain tax positions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,800&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_71c95db7-c382-4887-8597-859a8093aecc"
      unitRef="U_USD">-27205000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_d5dac097-7d31-4e66-b66b-b06892505f97"
      unitRef="U_USD">-7627000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_36677caa-e2e0-4854-bcdc-ee18bed8f76f"
      unitRef="U_USD">-39948000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_5de1f6ed-da47-497c-9a81-6d5f4131357f"
      unitRef="U_USD">-344000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_f1f496e3-ef5c-4dc8-82d3-b983da8e864f"
      unitRef="U_USD">-398000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_a40df87b-2be0-422d-8255-85aec5dcb19e"
      unitRef="U_USD">-16570000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_06c17099-78ba-435b-b064-18d6240cdd64"
      unitRef="U_USD">20184000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_a3c0d116-037b-4aea-96f8-9f0eadade874"
      unitRef="U_USD">9389000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_30fe3b92-c71f-4c15-a9d7-cf2252a885d6"
      unitRef="U_USD">8010000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_902c5828-5f7a-4b69-b4d7-ad75ce44d71b"
      unitRef="U_USD">7733000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_67c1b751-7c36-40b1-ae3f-0ad95b5c10ec"
      unitRef="U_USD">2347000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_c27a6cc0-49db-44f0-86a0-ea51d1d8c9b0"
      unitRef="U_USD">2003000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_cf3a9e34-9333-4dd7-be8c-f0d90853587b"
      unitRef="U_USD">4919000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_594bc4aa-266d-4d16-aa37-5213f0aaf15e"
      unitRef="U_USD">-2368000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_8a769d2d-8089-44f4-b793-f9b5328f3b54"
      unitRef="U_USD">353000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_5e98e769-1cf7-445a-ad5f-57bf81e4987d"
      unitRef="U_USD">38421000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_ba598f64-2758-49e9-bacd-a764635b1980"
      unitRef="U_USD">16800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_d4835f91-67a4-402e-8393-8ce09579dc51"
      unitRef="U_USD">62280000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_e5574620-9f00-485b-b4fe-7264a9204434"
      unitRef="U_USD">-86000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_4fd5ea7c-8c02-4cc9-bb2a-566998d4ab6a"
      unitRef="U_USD">-161000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_10efe741-650c-462f-a8cb-84c1a524ee0a"
      unitRef="U_USD">-108000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_d422b4e1-be77-45ad-8092-2fa0ab33b3af"
      unitRef="U_USD">3254000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_5dab44a2-cde7-4fc7-87b8-4f70fda64578"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="-3"
      id="F_7f89bd48-d896-428b-b1fe-38b3fa1243c4"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_3920b2f5-3962-4f16-aef0-47bbbb8a68be">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant components of the Company&#x2019;s deferred tax assets and liabilities consist of (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.182%;"/&gt;
        &lt;td style="width:2.441%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.450999999999997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.441%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.483999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;63,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued bonus&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,351&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 R&amp;amp;D capitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;122,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_f39076aa-aaa0-4bcf-9b9e-2704109ce9a2"
      unitRef="U_USD">20963000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_1168ee43-f1e0-4de5-a2e1-9a89f8e0175c"
      unitRef="U_USD">63868000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_1bc5bea6-d0db-41f0-a283-c924729ec60f"
      unitRef="U_USD">806000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_e928825c-08d7-4c97-b4f8-10076ebabc1a"
      unitRef="U_USD">1811000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_00e54b88-788d-4ba4-833a-bb67513609a2"
      unitRef="U_USD">26319000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_7b0e5f49-8bde-4450-b363-7012728e6653"
      unitRef="U_USD">19614000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_3e3839aa-cc13-433b-8a90-8c704a9fa007"
      unitRef="U_USD">13351000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_6940c21c-1f24-4c39-8430-37c55ab4c2fe"
      unitRef="U_USD">9656000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_5cf33964-7404-4814-b614-d33c7760f22c"
      unitRef="U_USD">67673000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_cc6177f3-76fa-48f1-b0a3-289a48b5aba8"
      unitRef="U_USD">27849000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <alec:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_030bb2b5-06fb-4b97-90d4-09251211349b"
      unitRef="U_USD">10055000</alec:DeferredTaxAssetsLeaseLiabilities>
    <alec:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_e1a86321-1f31-4ead-99df-e7e70f90fb6f"
      unitRef="U_USD">11296000</alec:DeferredTaxAssetsLeaseLiabilities>
    <alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_15fa6b4f-8b51-437b-8771-7987fcfc7b01"
      unitRef="U_USD">35150000</alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_23a5d470-cc8b-4f53-8800-2c1fd9840591"
      unitRef="U_USD">0</alec:DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_05dbe2e1-41e6-49a1-b62e-2c22ebebb09f"
      unitRef="U_USD">1608000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_2bafb95d-496f-452c-9271-282952421321"
      unitRef="U_USD">694000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_6cf6c7b9-d6f8-43c9-8487-b7c8f2526664"
      unitRef="U_USD">175925000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_cabf4766-04ad-4a9e-bd39-38f2ab5b1ea3"
      unitRef="U_USD">134788000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_7b606d0e-4205-41b0-805a-fa3df707cd23"
      unitRef="U_USD">164316000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_ba691e31-d382-4d81-90e8-c5b03efabf3d"
      unitRef="U_USD">122046000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_46ec38bb-6d61-4d93-b3f7-4a8e80b45296"
      unitRef="U_USD">11609000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_c575c4a3-513f-4b0c-b322-f5eac8e4ddff"
      unitRef="U_USD">12742000</us-gaap:DeferredTaxAssetsNet>
    <alec:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_d2a289eb-fc36-4c9a-beaa-7b84d7549b51"
      unitRef="U_USD">5155000</alec:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <alec:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_719122c7-b680-41f3-9522-7057ce7f081f"
      unitRef="U_USD">5488000</alec:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <alec:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_bf579b96-55cc-46df-950e-712fc77bfb04"
      unitRef="U_USD">6454000</alec:DeferredTaxLiabilitiesRightOfUseAssets>
    <alec:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_96f42371-0914-4c0b-a73b-4afa74a0a1d8"
      unitRef="U_USD">7254000</alec:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_7dd64c52-7827-484e-9972-5481d5a7c669"
      unitRef="U_USD">11609000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_0c1cec5b-9c70-40b8-8f84-e0a28fc0f675"
      unitRef="U_USD">12742000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_12e1f047-f7b1-4401-8c2c-21f83bef6461"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_0f7f4e75-6f2d-4252-ac1e-9c2ef3ab8394"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-5"
      id="F_b2c10c56-c806-4f81-8550-b7bcc2f713de"
      unitRef="U_USD">42300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_8df03805-8723-4874-a2a2-8c93c5cbd3d5"
      decimals="-5"
      id="F_607bb9e4-3d9e-4bdd-b9d3-3c1c4f8cc6aa"
      unitRef="U_USD">40300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_79a8adcb-cfbf-4eba-bbda-4e86d5eee09c"
      decimals="-5"
      id="F_cbd6bc38-f714-4665-86a2-098d28dbbd04"
      unitRef="U_USD">203500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="C_2dccbdd1-17e9-485c-a5ee-03938c7e22f4"
      decimals="2"
      id="F_db8ddbc0-1992-46fb-b360-0ce8b8017716"
      unitRef="U_pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <alec:OperatingLossCarryforwardsBeginningExpirationYear
      contextRef="C_fe4d91c0-ce81-47c8-ba8d-75ea9ef9fb79"
      id="F_dfb1a02a-98a2-4be6-b227-e276f3d81a57">2030</alec:OperatingLossCarryforwardsBeginningExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_8df03805-8723-4874-a2a2-8c93c5cbd3d5"
      decimals="-5"
      id="F_23a0e581-2125-4dcd-97a9-f99bb085e169"
      unitRef="U_USD">28400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c9cdc029-237a-491e-84f0-8ce387ab9c94"
      decimals="-5"
      id="F_e0e96491-b0ba-411a-86a3-c42c1651d5ba"
      unitRef="U_USD">11600000</us-gaap:TaxCreditCarryforwardAmount>
    <alec:TaxCreditBeginningExpirationYear
      contextRef="C_9836c7b3-8244-4a0a-9397-0627ae5caac7"
      id="F_ace9f30a-7d4c-4e64-9525-6756fb847c77">2036</alec:TaxCreditBeginningExpirationYear>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_c90e7831-c157-4c5d-939f-af7d469dec47">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.002%;"/&gt;
        &lt;td style="width:2.048%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.95%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Decreases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Increases related to tax positions taken during the&lt;br/&gt;&#160;&#160;&#160;current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,199&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2057c28e-bb01-4164-b42a-733be6be9aad"
      decimals="-3"
      id="F_1febd091-ab9c-427c-b08d-b4b9399e734a"
      unitRef="U_USD">4592000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_cd31a57a-9904-4916-96fd-759d866bbc31"
      unitRef="U_USD">59000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-3"
      id="F_06067c11-6010-4c55-b4a4-4b5f0d4eb235"
      unitRef="U_USD">2406000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_3ae26f02-3f33-4c97-8e3c-23556a8384c1"
      decimals="-3"
      id="F_b844b693-049d-489c-83c7-da87e867efaa"
      unitRef="U_USD">6939000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-3"
      id="F_3952cafb-79fd-4dc0-ac5b-425bb5d7463e"
      unitRef="U_USD">8199000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_59545206-883a-4aa3-a49c-906caa840899"
      decimals="-3"
      id="F_46e82a15-6511-4ccd-9f4a-91a8ac47e2de"
      unitRef="U_USD">15138000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="-5"
      id="F_e67b05c9-5efc-40a6-9b6f-e8275c97428b"
      unitRef="U_USD">8200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-5"
      id="F_1e824884-f823-439e-ba4d-e5469d53f065"
      unitRef="U_USD">2400000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <alec:ReversalReservesOnUncertainTaxProvisions
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="0"
      id="F_40aa4436-0ac0-4337-b422-c366c8f02946"
      unitRef="U_USD">0</alec:ReversalReservesOnUncertainTaxProvisions>
    <alec:ReversalReservesOnUncertainTaxProvisions
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="-5"
      id="F_0cb911d0-a100-40b7-a51f-b3e11c9a0e6f"
      unitRef="U_USD">100000</alec:ReversalReservesOnUncertainTaxProvisions>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_0d8e5958-7286-4883-a974-a0799a279930">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;9.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Related Party Transactions &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In 2014, the Company entered into a collaboration agreement with Adimab, LLC (Adimab) under which the Company is developing antibodies discovered by Adimab in its latozinemab and AL101 programs and is developing antibodies optimized by Adimab in its AL002 program (2014 Adimab Agreement). The 2014 Adimab Agreement also provided for the Company&#x2019;s development of antibodies optimized by Adimab in its AL003 program. However, AbbVie decided to terminate the CD33 collaboration program, after AbbVie and Alector collaboratively reviewed next steps for AL003, the asset being developed under that program, and concluded that further development of AL003 was not warranted. In August 2019, the Company signed a collaboration agreement with Adimab for research and development of additional antibodies (2019 Adimab Agreement). In December 2021, the Company signed another collaboration agreement with Adimab for antibody engineering research programs (2021 Adimab Agreement). The 2021 Adimab agreement expired at the end of the option period for the research program that was conducted under the agreement. The former Chief Executive Officer of Adimab through May 2022 is a Co-founder and Chairperson of the board of directors of Alector. For the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021, and 2020, Alector incurred expenses of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for milestone payments for progress of programs through clinical trials and other expenses. The Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; accrued liabilities due to Adimab as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021. Under the 2014 Adimab Agreement, the Company has made milestone payments and will owe low- to mid- single-digit royalty payments for commercial sales of the product candidate. Under the 2019 Adimab Agreements, the Company will owe certain milestone payments and low single-digit royalty payments for commercial sales of covered product candidates.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_e86e0f59-9472-4a49-b595-48701d364860"
      decimals="-5"
      id="F_494e25c1-362e-4ee6-b090-5732675c6ee9"
      unitRef="U_USD">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0bbd6899-6eb8-4d93-b39f-c6d7afda1a04"
      decimals="-5"
      id="F_12d8093a-fd92-4350-8ccc-a91d5ce4dd90"
      unitRef="U_USD">1000000.0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_edb4f89e-28d7-4da4-8c65-2ab76be71025"
      decimals="-6"
      id="F_61f4a9cd-7e75-4728-9c73-cd022bea4cf7"
      unitRef="U_USD">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_e26edbee-11a6-44f2-9f0f-58d3b932feaf"
      decimals="INF"
      id="F_afee6412-7720-49e6-b5e6-442dbf5d53c5"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_a0aa7056-f119-4199-97e6-cbcd61a7b3fc"
      decimals="INF"
      id="F_d8feff1a-7b95-4af5-84d3-ed5dffa5a282"
      unitRef="U_USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_277702b9-dd85-42f3-a12a-8625a6a3e226">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;10.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.897%;"/&gt;
        &lt;td style="width:1.3%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.309999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.3%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.309999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.3%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.584%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,654,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares committed under 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,925,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,088,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,928,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_69e65dbd-a850-4fae-bac2-e8a1a500774b">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.897%;"/&gt;
        &lt;td style="width:1.3%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.309999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.3%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.309999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.3%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.584%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,044,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,373,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;186,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,713,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,644,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,654,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares committed under 2019 ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,925,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,088,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,928,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_67cf0962-6249-477f-8bc4-dab96a763b98"
      decimals="INF"
      id="F_9c35cf09-d544-438a-84fa-659f85119627"
      unitRef="U_shares">3044618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ffc3dde4-e230-4e99-96ea-1e5e5dfbddfe"
      decimals="INF"
      id="F_78726509-8a92-464b-ad9f-32caa0af826d"
      unitRef="U_shares">1373874</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2e8bb82e-dade-4bfe-bc72-3759b7ed3710"
      decimals="INF"
      id="F_b5c1a10d-dac5-4771-b5e6-f8b1b7ab6638"
      unitRef="U_shares">186425</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cf8d8382-eb79-4d5a-aace-511cc534b48b"
      decimals="INF"
      id="F_17dd26e4-455a-4c85-ad83-7e7924d4b435"
      unitRef="U_shares">13713272</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b8e32b37-b52b-4be3-bbcc-061f59815156"
      decimals="INF"
      id="F_207033e4-6dee-4d82-b967-d655881c6c7d"
      unitRef="U_shares">11644070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_43d96e6b-e335-4918-832b-938ca6e7af68"
      decimals="INF"
      id="F_6cee33ac-0562-4a54-b4e7-796518992287"
      unitRef="U_shares">12654998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9d16d809-66ff-4090-8fd8-8bb44fd13bcf"
      decimals="INF"
      id="F_f5900f29-3023-49e3-8302-85f1e2cd9249"
      unitRef="U_shares">167133</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_16a6dfb4-c570-4d0c-aebd-ef6ff61c25e1"
      decimals="INF"
      id="F_9e82c3e8-83d6-43b8-9695-6b51abd9be5f"
      unitRef="U_shares">70406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1066ab24-de91-4fc8-b8ef-54102a1ace80"
      decimals="INF"
      id="F_68651e79-eebb-46a3-a3f2-19dc78036945"
      unitRef="U_shares">86677</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      decimals="INF"
      id="F_e3ae58d6-adec-45bd-a85a-a1ad081cba5b"
      unitRef="U_shares">16925023</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1a5850d9-b406-4dd9-81ad-2220ce9e110a"
      decimals="INF"
      id="F_6bddfa7c-e85a-41b6-a2da-26953af85888"
      unitRef="U_shares">13088350</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_45035b09-08b3-4500-b7a8-9c651c96035b"
      decimals="INF"
      id="F_cf8d7cdc-1db0-492c-ada6-c722becaca5f"
      unitRef="U_shares">12928100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_73e80b90-789c-418b-a25b-f51ca32e11ef"
      id="F_c87372ba-e601-4a43-b41e-0d89015e925b">&lt;div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;11.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2023, the Company and AbbVie amended the AbbVie agreement, which will result in the Company receiving a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million milestone payment for the dosing of the first patient in a long-term extension study.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <alec:MilestonePaymentReceivable
      contextRef="C_d2cef38d-be1d-484a-a61c-5428186c190e"
      decimals="-5"
      id="F_6fe92fe2-7006-45a2-a1cb-c8f20914b3b7"
      unitRef="U_USD">17800000</alec:MilestonePaymentReceivable>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M)EC6FE-A.1*KP+K:P;JRGMZ3P EE,S1>91.>FO#8ZWOW'R,3(&O5J8 <B54
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MJ)%M#<SW*R'TZXT]8-__0V7Y'U!+ P04    " !F@EQ6? $*K(\"   O!P
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M4->C'1I$YL)?=_E#9-2W QOGB5J>:)2GVC)7I<@/3+"S8BQ1K_4/U E"Q^W
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M@/6BK&^#Z@<E-M7]R$(H)?+J:\)9S$LM@-]70JC#@VZ@O9.;_0=02P,$%
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M[3DFVP"*&$#5*#$@!F5(9",&QD"@& ,V>C6:,9A:XBCV0Z3>&=I[/-D(4,8
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M@^3:*FQK-\=@O(.[KQ#I:/@ PY\A_P!02P,$%     @ 9H)<5CX5QA8L"
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M4]8 8;E.+F;GEXM@'PW^4+AWS]XA*-E9>Q\6GXIUD@5"J%'Z@"#X[Q&O4.L
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M   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULI5QK;]M(EOV>7T%X'NL
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M*(8S=G B'>1<;M6G3D_;*&?@0U"DU.OUQP)JDGSFSE%^%[)/\BE-3<4-'VN
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MV?Q\N&=:$\S^FIW/86VVJA@!CC9.2J523"DLS\7A=W!-*H]=--C$YL,V(%@
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M9ZC)$6RHR[RB"HLW\ @RWH9'3^_N/ND46ER,CUCO3<Y#%13ZG*39?I 5"ER
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MU.HQ(A-Y7<ZOVH&7W%7T]@"WP'AN253I.IDD&/HH+1K%GA4_,$!!<GEZP?5
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MNTZ?DTX!H59VQ56-GD\:9^!-H=;$S,7Y>?:W?L3/A"<&N:DL9:VIZX[?GWU
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MUP:WZF@!OE\V31M^H0WBGT-Z^[]02P,$%     @ 9H)<5M1#".1P!0  #0T
M !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULO5=+;]M&$+[[5PR4('
M52(I2I8=VX"=-&B !@CRZJ'H846.Q(5)+K.[E*+^^GZSE&DYD9WDTHN]G)WY
MYCVS.M\8>^,*9D]?J[)V%X/"^^9L/'99P95R(]-PC9NEL97R^+2KL6LLJSP(
M5>4XB:+9N%*Z'ER>!]H[>WEN6E_JFM]9<FU5*;N]YM)L+@;QX);P7J\*+X3Q
MY7FC5OR!_:?FG<77N$?)=<6UTZ8FR\N+P55\=IT*?V#XK'GC]LXDGBR,N9&/
M-_G%(!*#N.3,"X+"OS6_Y+(4()CQ98<YZ%6*X/[Y%OUU\!V^+)3CEZ;\2^>^
MN!C,!Y3S4K6E?V\V?_#.GZG@9:9TX2]M.MY).J"L==Y4.V%84.FZ^Z^^[N*P
M)S"/'A!(=@))L+M3%*Q\I;RZ/+=F0U:X@2:'X&J0AG&ZEJ1\\!:W&G+^\K72
MECZKLF5ZR\JUEA%Q[\[''N#",LYV0-<=4/( 4)S06U/[PM'O=<[Y?8 QK.I-
M2VY-NTX>17S%V8@F\9"2*$D>P9OTKDX"WN3'KK[2+BN->.OH[ZN%\Q;5\<\A
MISO(]#"D=,R9:U3&%P.TA&.[YL'ELR?Q+'KQB,%I;W#Z&/JOY.91H,-F3D;T
M@ +Z6# M38F&U?6*O%J4B%/7MOI?)H_KEZ9J5+U]]F2>Q"<O'"UUK>I,JY*4
M<PR,J@/,27E:BIYUT".-B&;.6FL%&PVE'2VV5/*:I?9]H>N@8$^FT&R5S8KM
MV1%J@JL%V[XNCO9\N*J,]3 PIT\U!E3Y[3&POE7VAOW1\1M18UJGZMP]/T+I
M\A9])7>T;$&C/X-%,3VEDW0X3^<X!&^3%_=.W>71I]&'$:W,FFTM,21O@_];
M<N*K]IKO$*?1;#@Y2>B$CBD=3F>G]!RT>#B/HR/$M6(; MFH!HYV0@FEZ3"=
MS'$XICGXPV<"=ML8JSS3PMP9G5!R.IQ,(03N. *[?*>SHX_& SA3KB#^TFJ$
M-^0;,=CY+JF&4[/I=!A!\"G%$_P)9LY/@"-7$33/OLM$_']D(HGGPW0:/Y"*
MW>TOY2*-3H91&B.FQW0ZE5"ER$YT>OKSL4JFP_0TP6D>0M6A"!U!P_GC@6ZY
M3=.>0<IR5^XYM2ZT7:%M_ENCK-]28W4F-&=:F[$;!=">B'[6H%+KM827=)UC
M<8B_'M8JFP=@%;9@97(NT:[&TJ;064&J+,GI5:V7.E,(EJZ;UG?FF(5 BYNC
M?2\H*]'CX(?*O4CL^[)6N@Q$;T(.2?I=4H''A V&@,GUU&YDC.C*D5G2=SU.
MPS 1,)WPR!"/,RP:F=@M$H3%?*L6L@A[&HWFV)1E*>Z"I.LU.]\-M@W#+0PS
M!T"%VYIIR\J&I#ZET]'LL& GIY8>1O4ROK"F717D-R80'K9_B.D(6:[I9RI3
M9B ,(K5:65Y):^^/SV7HR<DHZ2T5V^^QMW=]AAVW"\MD%/<2P1LM@SC<-\;I
M4!M2%&A<[H+C-URN&019ZO<+(#>PLS92+)ZA'EG&.ZL,6=H/-W!\J*1=HLMM
M4%M_9^*M"</@C0:PP]1?%1!HL<UN&(< MK=Z$"BH7$A=H#UETSQDQH*7XA6V
MCD1^*P$!"V*J^C&5&>>[933<]46EM@(.G;L*VWX3 YV'$ 2-0CC<"A)3L2=4
M"+$\C0X4N'B-0X25O,?_ 'N\ZX=;2YPI\Q]H]V&6-=9DS/FN(N)H=-*7A# B
M+QHK'D4NVZ=/T I-%QZ^N2QO07,-9S(N2.>(;Q@<W6QAS/%\1(>>/N.])RH6
MW"H\Q#$!3%O[[K7:4_NW_E7WQ+UC[WXH8&^L- 9(R4N(PHOI@&SW^.X^O&G"
M@W=A/)[/X5C@]PI;8<#]TAA_^R$*^E] E_\!4$L#!!0    ( &:"7%:D&3Q#
M% \  ,8O   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;-5:77/;-A;]
M*QAOMDUF9%F2G3A-D\PX3M.F33>9N&D?=O8!(B$)&Y)@ =*R\^OWW L0!/5E
M9W9V9_<ED27PXGZ>>R[ YVMC/[N54HVX*8O*O3A:-4W][.3$92M52C<VM:KP
MR\+84C;XTRY/7&V5S/FALCB9329/3DJIJZ.7S_F[#_;E<],VA:[4!RM<6Y;2
MWKY2A5F_.)H>=5]\U,M50U^<O'Q>RZ6Z4LVG^H/%7R=12JY+53EM*F'5XL71
MQ?39JS-:SPM^UVKMDL^"+)D;\YG^>)N_.)J00JI064,2)/Z[5I>J*$@0U/@S
MR#R*6]*#Z>=.^ANV';;,I5.7IOA#Y\WJQ='3(Y&KA6R+YJ-9_Z2"/8])7F8*
MQ_^*=5@[.1)9ZQI3AH>A0:DK_[^\"7ZXSP.S\,",]?8;L9:O92-?/K=F+2RM
MAC3ZP*;RTU!.5Q24J\;B5XWGFI>PII!S8R7[Z&)IE8++&_?\I(%T6G.2!4FO
MO*39'DG3F?C55,W*B1^J7.5# 2=0*^HVZW1[-3LH\;7*QN)T.A*SR6QV0-YI
MM/64Y9WND??>+F6EO["I(W%I*F<*G7O+996+#U8YV.Z_, OQ1E>RRK0LQ!6^
M]'X1?[^8N\8BF?ZQRT5>@;/="E"!/7.US-2+HYKVLM?JZ.4W?YD^F7Q_P+RS
M:-[9(>E?%<K#DL[&8I\P\>/5+^)])7YNBUOA0X-_FY7"$V4MJUN!5<JJ7.BJ
M,4)N""(WO],9BEKU0I'RS4K\6,@;(_Y ?6:F5.+3+UA8ZD;E(TAQ[=SI7 ,V
M*#"\] H_KGXAU45=9.(A%'LT$G5K72LA$YNO5SI;#72C[<F +"JE!+2B)<O"
MS!'I7%T#J&I6BU9#EU)92H*0.+1_;<W2RJK%YL? EVO\4"U%:2J3%::"%"B@
MYR;7RHW@AZQH<UI0R,9\@;ZEG(N'LG"&4$U9<A:YRHF+=Y/)%$;0QA?OII,I
M6]4[ZM%8_ 95!]^)-1XL9:Z$6BP48QR9=-$N 1YB>NY#),;B$ZK2LJF(3^G(
MCF93V#"25F4*XG+Q0)Q/)D"?HB 'Z$JT]<*BUD4M;SDK1B3-N_N!>)RL)>6B
M&!W58I7(R@?XN'_US_ QA9SJ?RS>(GWR7/OJ)23.N]C=';2ZD)5 "QO$(+IY
M:'8I;\4<[BST4L\+1;$)2L%NCE2O"&+]0$S'C\6\=TZ&M-#9,)=&$+%L:7-[
M.]K0$3JU5;8ZM@J_PRAX0P'W*:^#>]EV4O%3107AX<B-=J;V&HH(]6<K"Q2H
M6TFK*%T7&J5+2PKCG'("X2MWY_9.!XW%^[9! :HN:PXHP@JD_B.WYZ;%Q^,<
M7Z$T-0.$-;>RP&?GLWJG(?\T@!$8$ERY+WP>0+BPJ[S-N!P_K) BXK0/1V-A
MJ6-U+HHO*P5N8;_YR]/9]/Q[)W+M%*WG/B#M9XWF4.W\U<!8*RI3'1M;KR2%
M/(=\\M\A2WPHTDS-C$-0GDS$7\7\EA?2 V?A[\2E(Z%N,E7#<2O9;/L:74P5
ME++2;E6#WR,$#7YH*-^\9V9;GFDC0J0BJ'1\RM(OM;04LM2F$E6Z0$-L+;E]
M>_>0C$/?(% $BP1]G5%#6-..HZI]XKL,-)3LN+BZ%$\G3T=I7T%A7EC@\5(%
M, *,S!&FJ"QIZ>F?_RK3T &:!>'\D_8K82:M5C>U<1Z7G5Y6>@$_02FKW6>_
MR*JUM#DR0X$>YZ1PP"+79IERT><[:XQQ/JVN2V4;$&C43.BRI(.%XW1H#G/2
M,C-M155'&>QC1=YX,GDR$A_A]:I5X@W5-9@-,Q0G_J"ZN&06J2P<LT;JJJ 7
MR;+DCEORM0QD$T))O!1+8Y#KH.]@*6C8/DR\$,6  LL:Z(!BACE!LV& <T5M
M!J6:1#@^62O+\T0%P68.H/#E,[2*<L3A"<+YQ3/Q4#\21: .Y+K/E5D?KT"1
MX![OT#>_O3X6/W[\FQB%7@1ULQ;]E2$$[MV"A,W&\5!C$]*4V)FT$$'?#E;%
M7!ET]J"7I1G #=0CY"\\08"B@&+")]=K,R,G8Z\"H"A<@T&(<R?9T_L5$:V<
M]*-,;2DB%(^*<*$C5I*?!&M6Y1S".N;<*4J9HV]4[OT*1_M\#%XF!4/.;G9W
M^GY  <8 T$+4IL&O!"B+%L6O^L;E$J",0M:4>MW600L8Q1D2\J,W9Q<Y.6RC
MHX<'X(BD+'( =1/!1FA/EQ"%N>363IDIAR4.QUL'HSIP*"FW:5,;:@QDP&#]
M%^B]CEN8#)GF(X7<J0,10SRK7!;4RZ]ET?I>J"3R*ABXKQ!(2X"FR9@1('&:
M72G@]X//=<GKKJX^D&#>8+=D%IR49NL8L[7KL"63;B46&-4#1Z!] 8:P1^TA
MPQM@QI]ZE?86DN\-'MH0NI9I\+#O=2&XHV\-O4 JD1^BI_<X M2;3@:(.U?2
M=XYOX7/GVI)3T'4@0G0P%! )5?"0-XRS <M2JZ"#HI&$O@Y.%=9S)'* 3SQ=
M^&9#.:"RE;?%-Y6.(W9M9"S>&-^2.X@ANQ*@:PY KB=$E*%S52E0P#ZD$4A]
MX9':@^\I36C$(4M#ZX?#8/THP*.GJ@>2S.&C6VA?W!)@H:FI5[Q5;U7 0Z0=
M2%1.COH:9+RO^52@^US@:89IF] 6+94O6.0FEPE]T&V3,"C+E:&;4*O!*R)O
MO5,'-FR8P/'$(M<K-!8_>+KGN[4D_&.Y#*AK4-$=A+O;\QZ-"P];TR[]9*P(
MJ.]%#\>19'0,/P%"<TW,D;)(NOLV4"8Y06^5#]D#;U&"<[=^?H$/P*GBT$=L
M$XIY#(GH 1=1"E$PP&MZW"3E *;XL\%#"9H%!/*I>GL(D".RWVD4Q7.[R^_A
M'-P3T[QE.#S >\?B54ILNT@<(+>#<AE0]<TY-,'TM#2_FA+[ILJ&;7#C9.;=
MH,F=QW8/4-&NAK(TS+-QG.4QA,JUAWP^GPD#;H4<H@=Y1O0_$^G]UG$"''</
M^[)W.J)SWG;?[XSYN L)9ENL)HC!MM<T(X>ZB+PLY#%'?-D"YBIJW1>.G+ Z
MC&&TQ_GIA A^HL;K-*9,%6KL#4I =O(!!3C'$H7)"96>E%22F5H<3A('L/8N
M20#9$:]A4#S<#::WR/$(I"SLU^6\M2[,,HRX%,:N:_BR1%5$3.WS.)UQR# :
MKS/+PW<GG =\K^;>@J0B)RP=)6R,1M#A:63'Z/K!=T@X0PK0#[<T75,VY]OD
MDW?W!Z$4C ?BR6S\73S4\L=<T^]FXVGWW:96OW&=AJ/ GF:FWMIQZ/= G)V=
M;6UT.CE/O]M-EZ/&>_;&X!1ATF/2%M8?@D. J#9Y4MM4C<.^0QA=J"Z.=[:>
M2\9JL#.3:?8*5W-FCO>@<&PK26QE/TA8U<]$NKH[C3HPS>*= 1YT_:4 3 !.
M^ZQRX3C*GZ FE4"K?,\)QSV!@BJ>:N0PLPD:XO8]7[IG&FZ<XG:1DU]7/7[N
MFYZ-SS=R[.GXZ>Y4'NTK)<#=?/Z[5@,D&=X45$F X.[W66/(NMED>NX=&B2\
MTH99LP'$8<-W#:C#0__;(TK6/BF28WBNHK6)G:&1=JE\DZSAH%V].<@<G+[O
M.4/?7#GJON%S>3KC?CS^BO/S9&T\(T^^8](0C\FW1Z:!YTA ?XP^?;H+>B+I
MDBZEKWO3(\)VX*ZI9W>RRSUEW4U8;!!WYN1XP,..4VC6U-7V\K+@Z5QE.@]H
MR1W47^W$5D<J9@/P[Q0.U?+Z]'3W M"D14.G4GXC'G2I;&%[EIY!%E1JUUJM
MH46E;N"F1M7AN!DC\JG?!Q"F:!A)QHL$I&23[,KD;-!G%ZWE,Y4T&&$"/^7H
M$0L!"?.#6_1-X"4 34LS2D7+^$@O]=5A)Q!_^+F%.XF+^.N8+;I>&="Q:JG(
M+R@\ZB,;BH+6NBB1[ O/-5OW!21T^U1IT!)[7WF&X8W=.F5F13BO.U3@BH7+
M9O'Y'K0V*SGZ<!7F&G6#@#@BVWS61W+5#7%:/I5$%V"O[1?HH2RM6#(7)?XX
M*?&Q>+OHGNRD ZNHT7CY7>$-S(BHXT^E&OE9];TZC<1<+75540:R,GLN2I(S
M_^TAO6?8U,\Z^N9J<&=\:-9*5>EUP4:VL'Y\ >IO$"*G']Q1M36?3NX83TA(
M/S'\9-9T9C>"5XK"K,DN[XAX?1,C1%3C3B]NW@5BM:#S >K*@2M#X>VSK'#
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M-N>9K5+-X! D^_K$\<^MZ(J<9Y[^?N9K#D%#"^&CMNX4O2.0:3$R'8WME"D
MOXUB%@LFO[?1'#]8[SJ6W=F;J2U6""1LNO<<^2O'VI<!86Z4@#F2#LDR)QYV
MW_'\&([AX[W.]C&IU^HI2;]<P?A>P&!8#(M<BC21DM#Z^)[8;9A'N_*^?'UV
M?GSU]N.'8UG4*TF]=;66].)0 %/A6F ^=:7P$TV]X"EA'FQ+8SFHZIH&4 ^9
MS/)U61*+=[?@'^7>>7;;G%'_G0<RP/4 07UGI+(>/TY[;5I@/>XS_$QGPZ5
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MJ\IV,Q"4LO+__*'E86O#-'QF0]QNB!UN[\BA?,,MO[K0:L4TK88U&KA0W6Z
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M0T2%TCFKN<S=ZB,6I8,)RJXHR)+?PT&8+,'3O2//#(CQ3%55VV><>]NAV\T
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M3L9O*3_<B6D X3E8@B.WI#\+#B672EL>, Q[MIXL:C;;<:,,-O,BDN?G'.\
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MF&GF31NG^W'.[+2CJ34N&_I,H/$.9*\UE=-QXP.</CSK?P%02P,$%     @
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MKJ$;C1F2*4H_!-L;&(?+@P?;MA:#ZA*PRFR";XAPI_Y(AO,H^74\\I,W_!N
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MW2_L&M\1\R"MM9'%(9@8%*)LOOS;(0]' 4GX3@ [!##'N]G(L;SAAL\F2NY
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MS^&<PY$],]Y*]:@3 $.>4B[TQ$F,R2Y=5X<)I%2?R0P$/HFE2JG!J5J[.E-
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MESTM(XJ+03%1?&-/O@57^ARUP[6^2X$P +V_Y%P]3\QA6MW.1O\ 4$L#!!0
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ML"@B//T]<(-7A.=UMHEDG[<;>VG!,&6M#%WS&.B_I5H+6VG5BWUGR%K9=YI
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M1M$"+1K$27LH>J#EL46$$A62LN.W+TDIJA<Z\*$76Y3F__7-#!<-UXP_B0)
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M\_*=@.47D:V*M[\]94)D2?%QR6C(N-I!_C[/,K']H@K8O9GQ]A]02P,$%
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M09@%>G[)N7KIF"NBO^'3WU!+ P04    " !F@EQ6P2Y.EUD#   ;#@  &0
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MT=^_*TKT54(F_K'-3S'^R#Z^=K![L2,QS!UE40+X 9SPYY_PQ/O%INV09-%
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MS9^D).0I>Q%->/X+-J6L8X%HQ05-2V6)((VSXHI?RT!L*4#_@ (J%5!3H7U
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MR_;:>[C3:E>W]VR2 :)-;&H;N/[[VDX()"1<]\H+Q/;,^/MFQC/VY,#%F]P
M*/2MR)F<.ANEMO>>)Y,-%%2Z? M,KZRX**C20['VY%8 3:U2D7O$]R.OH!ES
M9A,[]R1F$[Y3><;@22"Y*PHJ_GF G!^F#G:.$\_9>J/,A#>;;.D:7D!]V3X)
M/?)J*VE6 ),99TC :NK,\?T"AT;!2KQF<)!GW\A067+^9@8?TZGC&T200Z*,
M":K_]K" /#>6-(Z_*Z-.O:=1//\^6O]@R6LR2RIAP?.O6:HV4R=V4 HKNLO5
M,S_\!16AH;&7\%S:7W2H9'T')3NI>%$I:P1%QLI_^JURQ)D"CGH42*5 V@IA
MCT)0*026:(G,TGJDBLXF@A^0,-+:FOFPOK':FDW&3!A?E-"KF=93LQ?%D[>!
M<42*%KS0V2&I]>\ O92117R%GD$JD25*"UD%-#]0D4I$67JY]H5E2J)?'T'1
M+)>_:4M]ZO-^]0'Z&7E(;J@ .?&49FKP>DG%ZJ%D17I888(^<:8V$OW!4DB;
M!CSMHMI/Y.BG!W+5XB,D+@KP'2(^(1V %O]='5^!$]1A"ZR]H"]LO8XI]<)N
M/5,4[N66)C!U]*F7(/;@S'[Y"4?^[UVD;F2L03&L*8;7K,\^[XHE")-])=D[
MG1E[G2R0WJ$EK#/&,K;61SBG+($N3Y3F(VO>5+/]# >C(!Z%$V]_3K)#+HY"
M,JS%&O"'-?SA.^'_*2A3[60LH0XO()!A,/9Q&^JE'(X)(>,>K%&--7HGUE?K
MZ"ZHT06$08C#X6C4@MHA%Y P]DDWU%$-=?1.J+J:KR#K03OJ0#L,HG'00MLA
M%V#?#\-NM'&--O[A' :6?B>!XPM0@484X;@%_E*NG>@-\.,:_/AJC?EJ6R"D
M [H'H5LZ6IL$'J14 5K13* ]S7>=P,>WK$$W,M9P ?9/[=&_&L&C$]"\<H(]
MQ>C1..&#<<*K<0+:ZBC;$+^[2E7[CQMGV@V&K1AWB$5NW[G'9]T?WYC>E2I6
M[87Q.1??/3OR%9<NN9$;!#ULR(D-N3&;_CI7;=4$&;M1NW)TROGG 6R2.75X
M?+6[_@"9JY6PVJV),W+-;:3)ITLN<.,^/J=VCJ_W\_]SDKY?*ZO-&\<(NU&[
M5':)Q9?!\LXNU 6(M7UG2)3P'5/EG;&>K=\R<WN#;\T_F#>.O:B?S)0/I$]4
MZ.H@40XK;=)W1[JWB_+-40X4W]IK^Y(K_0BPGQO]3@-A!/3ZBG-U')@-ZI??
M[%]02P,$%     @ 9H)<5G<Y";6J @  _ <  !D   !X;"]W;W)K<VAE971S
M+W-H965T-#,N>&ULK55=;YLP%/TK%JNF5MK*9^B6$:0FK%H?*D5-NSV[<!.L
M@LULDV3_?K8A-!\$]:$OX(]SCL^]AGNC#>.O(@>0:%L65$RL7,IJ;-LBS:'$
MXII50-7.DO$22S7E*UM4''!F2&5A>XX3VB4FU(HCLS;G<<1J61 *<XY$79:8
M_YM"P383R[5V"X]DE4N]8,=1A5>P /E<S;F:V9U*1DJ@@C"*."PGUJT[3D*-
M-X#?!#9B;XQT)"^,O>K)?3:Q'&T("DBE5L#JM889%(464C;^MII6=Z0F[H]W
MZG<F=A7+"Q8P8\4?DLE\8GVS4 9+7!?RD6U^01O/2.NEK!#FB38MUK%06@O)
MRI:L')2$-F^\;?.P1W##,P2O)7C'A. ,P6\)_GL)04L(3&::4$P>$BQQ''&V
M05RCE9H>F&0:M@J?4'WM"\G5+E$\&=_3E)6 GO 6!/J*%NJSRNH"$%NB.\B
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M8:[:,W -4/M+QN1NH@_H&G[\'U!+ P04    " !F@EQ6GH6=]KT#   [#
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M?"8O[)7MUK,R^P(1"+T3W\QE.\Y[%[,MM#KKBLC E\CG'+6M&+2$5H^!7\;
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M+AV4PAR75-WSU1>H_70-7\*IM+]H5<=Z#DI*J7A>@[6"G+#JB9_K/&P _.@
M(*@!P2Z@<P 0UH#0&JV465L3K' \$'R%A(G6;&9@<V/1V@UAYBM.E=!OB<:I
M^(8E/ ?T@)]!HG,TU562EA00GZ-')B#A"T9^06H"T @8S(F2Z'0""A,J/VC$
MXW2"3D\^H!-$&'K(>"DQ2^7 55J<V<)-:B&C2DAP0(@?H%O.5";1)Y9"NDW@
M:E>-M6!M;10<99Q <H%"_PP%7A"T"!K_/=P_(B=L,AU:OO#53*,)D0GELA2
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M^[T3"FV:EF\,I^O09KEVU+1A6]&41.,=Z'ZIZ<FTA@_0S=WL-U!+ P04
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 9H)<5JD%>BD4!   DB$   \
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M:]2[OJ?>*9_:F*X]/VM\_CVISN=[X_7QE^7/27Q?U!>< _S]77P#4$L#!!0
M   ( &:"7%: A/B=P $    >   3    6T-O;G1E;G1?5'EP97-=+GAM;,W9
MR6[",!0%T%]!V5;$>( . C9MMRV+_H";/" BB2W;4/C[.F&06M&HB$J]FT2)
M[7=?;.EL,G[;6?*];576?I(L0[ /C/EL297VJ;%4QY&Y<94.\=$MF-792B^(
MB<%@Q#)3!ZI#/S0UDNGXB>9Z78;>\S:^]H6I)XFCTB>]Q_W$)FN2:&O+(M,A
MCK--G7]+Z1\2TKBRG>.7A?4W<4+"SB8T(S\''-:];LBY(J?>3+OPHJLXBVU+
MYL.N))]VESC3HYG/BXQRDZVKN"3UUI'._9(H5&6Z+WK3G1SB#M/^RJ_.;\MT
M!<:9,V>LCR?FZ/*XXY$TJ_LV%B(7BNY//"7&TE=_'S6GG5/^R^RXO1_&K=KS
M\*R]7;_'7\_X5/_"/@1('Q*D#P72QQ"DCQ%('[<@?=R!]'$/T@<?H#2"(BI'
M(96CF,I14.4HJG(45CF*JQP%5HXBJT"15:#(*E!D%2BR"A19!8JL D56@2*K
M0)%5H,@J4625*+)*%%DEBJP215:)(JM$D56BR"I19)4HLBH4616*K I%5H4B
MJT*15:'(JE!D52BR*A19%8JLP_^4]=V8U5__DVSN::6+^IC/VA^_TT]02P$"
M% ,4    " !F@EQ6!T%-8H$   "Q    $               @ $     9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( &:"7%8K7196[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &:"
M7%:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 9H)<5ED [W)S"   PC0  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &:"
M7%;$'IYF+@8  %P9   8              " @;80  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !F@EQ6? $*K(\"   O!P  &
M        @($:%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 9H)<5M*'4IT!!0  GQ,  !@              ("!WQD  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &:"7%9*!Y=R_0<  'L^   8
M              " @18?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !F@EQ6,JFBZ10"   E!   &               @(%))P  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 9H)<5CX5QA8L"
M0B8  !@              ("!DRD  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( &:"7%;N4(I]M ,  ,8'   8              " @?4Q
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !F@EQ6Q6GX
M:S@8   :20  &               @('?-0  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 9H)<5M1#".1P!0  #0T  !D
M ("!34X  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !F
M@EQ6I!D\0Q0/  #&+P  &0              @('T4P  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &:"7%9#'F9_?0,  -D'   9
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M970Q-BYX;6Q02P$"% ,4    " !F@EQ6%7<"VB0#  "$!@  &0
M    @($+C   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M &:"7%;B65#&>@(  )$%   9              " @6:/  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 9H)<5IMI49=;&0  B5$  !D
M             ("!%Y(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !F@EQ6,2R J0D#  #'!@  &0              @(&IJP  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &:"7%8T!0;ZD0,
M #D(   9              " @>FN  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 9H)<5LN;%BF6 P  3 @  !D              ("!
ML;(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !F@EQ6
MTS1=]74#  #'!P  &0              @(%^M@  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( &:"7%9M#^1$DP4  $H.   9
M      " @2JZ  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 9H)<5DS9Y%W!!0  :@\  !D              ("!]+\  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !F@EQ6IG*YJ3@#  "W!@
M&0              @('LQ0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( &:"7%;%GSJ\M0,  -T.   9              " @5O)  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 9H)<5KSI]_G>
M P  UQ$  !D              ("!1\T  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !F@EQ6G#&$4>P"  "I"0  &0
M@(%<T0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &:"
M7%;WAA0$-P4  "X@   9              " @7_4  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 9H)<5HL^W4BQ P  GPX  !D
M         ("![=D  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !F@EQ6M9&,RG0)  #L<0  &0              @('5W0  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( &:"7%96/*H5M0,  %81
M   9              " @8#G  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 9H)<5D,3\/GL @  >0@  !D              ("!;.L
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !F@EQ6%B'+
M_N (  "E40  &0              @(&/[@  >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( &:"7%;P&["F^ (  /((   9
M  " @:;W  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M9H)<5JBV.P_8 @  [0<  !D              ("!U?H  'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !F@EQ6P2Y.EUD#   ;#@  &0
M            @('D_0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( &:"7%:0&1:$U ,  " 2   9              " @70! 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 9H)<5GY'\DE>"0
MAUH  !D              ("!?P4! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !F@EQ6-R#%N!<%  ",%@  &0              @($4
M#P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &:"7%9^
MT%U&R ,   4.   9              " @6(4 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 9H)<5G<Y";6J @  _ <  !D
M     ("!81@! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &:"7%8H&^^%  ,  'T+   9              "
M@4TK 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ 9H)<
M5O*'(1?8 P  ]A$  !D              ("!A"X! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !F@EQ61$5A6V$"  "#!0  &0
M        @(&3,@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( &:"7%8?=>^1/0,  .X3   -              "  2LU 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ 9H)<5I>*NQS     $P(   L
M ( !DS@! %]R96QS+RYR96QS4$L! A0#%     @ 9H)<5JD%>BD4!   DB$
M  \              ( !?#D! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M &:"7%8X@V\FQ $   T>   :              "  ;T] 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &:"7%: A/B=P $    >   3
M              "  ;D_ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Z
- #H S0\  *I! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>144</ContextCount>
  <ElementCount>314</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100080 - Disclosure - The Company and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidity</Role>
      <ShortName>The Company and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - The Company and Liquidity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails</Role>
      <ShortName>The Company and Liquidity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Leases - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Leases - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Income Taxes - Schedule of Federal and State Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Federal and State Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alec-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:LesseeOperatingSubleaseExistenceOfOptionToExtend, us-gaap:PropertyPlantAndEquipmentUsefulLife -  alec-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="alec-20221231.htm">alec-20221231.htm</File>
    <File>alec-20221231.xsd</File>
    <File>alec-20221231_cal.xml</File>
    <File>alec-20221231_def.xml</File>
    <File>alec-20221231_lab.xml</File>
    <File>alec-20221231_pre.xml</File>
    <File>alec-ex10_11.htm</File>
    <File>alec-ex10_18.htm</File>
    <File>alec-ex23_1.htm</File>
    <File>alec-ex31_1.htm</File>
    <File>alec-ex31_2.htm</File>
    <File>alec-ex32_1.htm</File>
    <File>alec-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img42979713_0.gif</File>
    <File>img42979713_1.gif</File>
    <File>img42979713_10.jpg</File>
    <File>img42979713_11.gif</File>
    <File>img42979713_12.gif</File>
    <File>img42979713_13.jpg</File>
    <File>img42979713_14.gif</File>
    <File>img42979713_15.gif</File>
    <File>img42979713_16.gif</File>
    <File>img42979713_17.gif</File>
    <File>img42979713_18.gif</File>
    <File>img42979713_19.jpg</File>
    <File>img42979713_2.gif</File>
    <File>img42979713_20.jpg</File>
    <File>img42979713_21.gif</File>
    <File>img42979713_3.gif</File>
    <File>img42979713_4.gif</File>
    <File>img42979713_5.gif</File>
    <File>img42979713_6.gif</File>
    <File>img42979713_7.gif</File>
    <File>img42979713_8.gif</File>
    <File>img42979713_9.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="602">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alec-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 602,
    "http://xbrl.sec.gov/dei/2022": 39
   },
   "contextCount": 144,
   "dts": {
    "calculationLink": {
     "local": [
      "alec-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "alec-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "alec-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alec-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alec-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "alec-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 483,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 11
   },
   "keyCustom": 39,
   "keyStandard": 275,
   "memberCustom": 16,
   "memberStandard": 26,
   "nsprefix": "alec",
   "nsuri": "http://alector.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Collaboration Agreements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_3608d00d-4b80-4ebb-a06f-7e9864fa2724",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - The Company and Liquidity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
     "shortName": "The Company and Liquidity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_eebe0049-dfc6-425d-8d39-93f33680d12f",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_2057c28e-bb01-4164-b42a-733be6be9aad",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_1389774a-b29c-48d6-a55f-f4bbb7532913",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_1389774a-b29c-48d6-a55f-f4bbb7532913",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Collaboration Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "alec:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "alec:AccruedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForProceedsFromTenantAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Leases - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForProceedsFromTenantAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Leases - Components of Lease Expense (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail",
     "shortName": "Leases - Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail",
     "shortName": "Leases - Schedule of Lease Payments Owed Under Company's Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails",
     "shortName": "Stock-based Compensation - Summary of Recognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_235ab5c2-cb0b-4693-a7d8-c6af3cd3645b",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "shortName": "Stock-based Compensation - Summary of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_235ab5c2-cb0b-4693-a7d8-c6af3cd3645b",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_e8757c43-9ac4-4718-b83d-6fd4e5baddbf",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_28c7a53f-bb0c-4150-8427-88dac7a0ee4b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
     "shortName": "Stock-based Compensation - Summary of Options to Purchase Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_91adb916-1de2-4b5b-aaea-cd88d5ee5fff",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_dc0ce554-adea-4930-b36c-ddea841a6c0d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Summary of Restricted Stock Awards and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_338e36e2-ef61-4f44-861b-3a1b978b8228",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Income Taxes - Schedule of Federal and State Income Tax Provision (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails",
     "shortName": "Income Taxes - Schedule of Federal and State Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_59545206-883a-4aa3-a49c-906caa840899",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_3ae26f02-3f33-4c97-8e3c-23556a8384c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_2057c28e-bb01-4164-b42a-733be6be9aad",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_e26edbee-11a6-44f2-9f0f-58d3b932feaf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_e26edbee-11a6-44f2-9f0f-58d3b932feaf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_446a98cc-5ad3-41d6-9b65-62a3811f3c9e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_d2cef38d-be1d-484a-a61c-5428186c190e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "alec:MilestonePaymentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Subsequent Events - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_d2cef38d-be1d-484a-a61c-5428186c190e",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "alec:MilestonePaymentReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_45035b09-08b3-4500-b7a8-9c651c96035b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "alec:IssuanceCostsOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_45035b09-08b3-4500-b7a8-9c651c96035b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "alec:IssuanceCostsOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - The Company and Liquidity",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidity",
     "shortName": "The Company and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "alec-20221231.htm",
      "contextRef": "C_73e80b90-789c-418b-a25b-f51ca32e11ef",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "alec_AbbVieBiotechnologyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie biotechnology, limited.",
        "label": "Abb Vie Biotechnology Limited [Member]",
        "terseLabel": "AbbVie Biotechnology Limited"
       }
      }
     },
     "localname": "AbbVieBiotechnologyLimitedMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_AccruedClinicalSupplyCost": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical supply cost.",
        "label": "Accrued Clinical Supply Cost",
        "terseLabel": "Accrued clinical supply costs"
       }
      }
     },
     "localname": "AccruedClinicalSupplyCost",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_AccruedPropertyAndEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued property and equipment current.",
        "label": "Accrued Property And Equipment Current",
        "terseLabel": "Accrued property and equipment"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentCurrent",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_AccruedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs.",
        "label": "Accrued Research And Development Costs",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCosts",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_AdditionalAreaOfPropertyInLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area of property in lease.",
        "label": "Additional Area Of Property In Lease",
        "terseLabel": "Additional area of property in lease"
       }
      }
     },
     "localname": "AdditionalAreaOfPropertyInLease",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "alec_AdditionalAreaSubleaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional area sublease expiration month and year.",
        "label": "Additional Area Sublease Expiration Month And Year",
        "terseLabel": "Additional area sublease expiration month and year"
       }
      }
     },
     "localname": "AdditionalAreaSubleaseExpirationMonthAndYear",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "alec_AdimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adimab [Member]",
        "terseLabel": "Adimab"
       }
      }
     },
     "localname": "AdimabMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_AlectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alector.",
        "label": "Alector [Member]",
        "terseLabel": "Alector"
       }
      }
     },
     "localname": "AlectorMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_AmortizationRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization right of use asset.",
        "label": "Amortization Right Of Use Asset",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "AmortizationRightOfUseAsset",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_AreaOfPropertyInLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of property in lease.",
        "label": "Area Of Property In Lease",
        "terseLabel": "Area under lease"
       }
      }
     },
     "localname": "AreaOfPropertyInLease",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "alec_AreaOfPropertyInSubleaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of property in sublease agreement.",
        "label": "Area Of Property In Sublease Agreement",
        "terseLabel": "Area under sublease"
       }
      }
     },
     "localname": "AreaOfPropertyInSubleaseAgreement",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "alec_AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value.",
        "label": "Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value",
        "terseLabel": "Remaining contractual maturities of investments were less than one year through two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_CashEquivalentsAndMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Member]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_CollaborationAndLicenseAgreementEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreement Effective Date",
        "label": "Collaboration and License Agreement Effective Date",
        "terseLabel": "Effective date of agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementEffectiveDate",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "alec_CollaborationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration receivable.",
        "label": "Collaboration Receivable",
        "terseLabel": "Receivable from Collaboration partner"
       }
      }
     },
     "localname": "CollaborationReceivable",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, additional milestone payments receivable per program.",
        "label": "Collaborative Arrangement Additional Milestone Payments Receivable Per Program",
        "terseLabel": "Additional milestone payments per program related to initiation of certain clinical studies and regulatory approval"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalMilestonePaymentsReceivablePerProgram",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, milestone payments on option rights exercised per program.",
        "label": "Collaborative Arrangement Milestone Payments On Option Rights Exercised Per Program",
        "terseLabel": "Exclusive option rights exercised for each program"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentsOnOptionRightsExercisedPerProgram",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_CollaborativeArrangementMilestonePaymentsReceivablePerProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement milestone payments receivable per program.",
        "label": "Collaborative Arrangement Milestone Payments Receivable Per Program",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentsReceivablePerProgram",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_CollaborativeArrangementUpfrontPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, upfront payments.",
        "label": "Collaborative Arrangement Upfront Payments",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayments",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax Assets tax deferred expense capitalized research and development costs.",
        "label": "Deferred Tax Assets Tax Deferred Expense Capitalized Research and Development Costs",
        "terseLabel": "Section 174 R&amp;D capitalization"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation and amortization.",
        "label": "Deferred Tax Liabilities Depreciation And Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities Right-of-use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_DevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone.",
        "label": "Development Milestone",
        "terseLabel": "Development milestone"
       }
      }
     },
     "localname": "DevelopmentMilestone",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_DomesticAndStateTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic and state tax authority",
        "label": "Domestic And State Tax Authority [Member]",
        "terseLabel": "Federal and State Tax Authorities"
       }
      }
     },
     "localname": "DomesticAndStateTaxAuthorityMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow On Public Offering [Member]",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on-offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_FutureMilestonePaymentsOwed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future milestone payments owed.",
        "label": "Future Milestone Payments Owed",
        "terseLabel": "Future milestone payments owed"
       }
      }
     },
     "localname": "FutureMilestonePaymentsOwed",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_GskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK [Member]",
        "label": "GSK [Member]",
        "terseLabel": "GlaxoSmithKline plc"
       }
      }
     },
     "localname": "GskMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in accrued liabilities and accrued clinical supply costs.",
        "label": "Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs",
        "terseLabel": "Accrued liabilities and accrued clinical supply costs"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_IncreaseDecreaseInCollaborationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease In collaboration receivable.",
        "label": "Increase Decrease In Collaboration Receivable",
        "negatedLabel": "Receivable from collaboration partner",
        "terseLabel": "Receivable from collaboration partner"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollaborationReceivable",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_IncreaseInExpectedCostPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Expected Cost Percentage.",
        "label": "Increase In Expected Cost Percentage",
        "terseLabel": "Increase in expected cost percentage"
       }
      }
     },
     "localname": "IncreaseInExpectedCostPercentage",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alec_InnoventBiologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovent Biologics.",
        "label": "Innovent Biologics [Member]",
        "terseLabel": "Innovent",
        "verboseLabel": "Innovent"
       }
      }
     },
     "localname": "InnoventBiologicsMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_IssuanceCostOfPreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance cost of preferred stock.",
        "label": "Issuance Cost Of Preferred Stock",
        "terseLabel": "Issuance cost of convertible preferred Stock"
       }
      }
     },
     "localname": "IssuanceCostOfPreferredStock",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_IssuanceCostsOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance cost of common stock.",
        "label": "Issuance Costs Of Common Stock",
        "terseLabel": "Issuance cost of common stock"
       }
      }
     },
     "localname": "IssuanceCostsOfCommonStock",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_LeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease expiration year.",
        "label": "Lease Expiration Year",
        "terseLabel": "Lease expiration year"
       }
      }
     },
     "localname": "LeaseExpirationYear",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "alec_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Receivable",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_NewarkCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newark, California.",
        "label": "Newark California [Member]",
        "terseLabel": "South San Francisco"
       }
      }
     },
     "localname": "NewarkCaliforniaMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_OfficesAndLaboratoryFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offices and laboratory facilities.",
        "label": "Offices And Laboratory Facilities [Member]",
        "terseLabel": "Offices and Laboratory Facilities"
       }
      }
     },
     "localname": "OfficesAndLaboratoryFacilitiesMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_OperatingLossCarryforwardsBeginningExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards beginning expiration year.",
        "label": "Operating Loss Carryforwards Beginning Expiration Year",
        "terseLabel": "Operating loss carry forward beginning expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeginningExpirationYear",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure line items.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alec_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements disclosure table.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alec_PercentageOfDevelopmentCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development cost.",
        "label": "Percentage of Development Cost",
        "terseLabel": "Percentage Of Development Cost"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCost",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "alec_PercentageOfStockOwnedByIndividual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of stock owned by Individual.",
        "label": "Percentage Of Stock Owned By Individual",
        "terseLabel": "Percentage of stock owned by Individual"
       }
      }
     },
     "localname": "PercentageOfStockOwnedByIndividual",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alec_PhaseThreeLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase three license.",
        "label": "Phase Three License [Member]",
        "terseLabel": "Phase 3 License"
       }
      }
     },
     "localname": "PhaseThreeLicenseMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_ProceedsFromPaymentsForIssuanceInitialPublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from (payments for) issuance of common stock as part of an initial public offering.",
        "label": "Proceeds From Payments For Issuance Initial Public Offering",
        "negatedLabel": "Proceeds from issuance of common stock upon public offerings, net of issuance costs",
        "terseLabel": "Amortization of premiums and accretion of discounts on marketable securities"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForIssuanceInitialPublicOffering",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_RestrictedStockAwardsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Awards And Restricted Stock Units [Member]",
        "label": "Restricted Stock Awards And Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Awards And Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_ReversalReservesOnUncertainTaxProvisions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal Reserves On Uncertain Tax Provisions",
        "label": "Reversal Reserves On Uncertain Tax Provisions",
        "terseLabel": "Reversal of reserves on uncertain tax provisions"
       }
      }
     },
     "localname": "ReversalReservesOnUncertainTaxProvisions",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_SalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone.",
        "label": "Sales Milestone",
        "terseLabel": "Sales milestone"
       }
      }
     },
     "localname": "SalesMilestone",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, cliff vesting percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Percentage",
        "terseLabel": "Cliff vesting percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPercentage",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, cliff vesting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Cliff Vesting Period",
        "terseLabel": "Cliff vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCliffVestingPeriod",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alec_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Fair Value",
        "terseLabel": "Grant date fair value of units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_SouthSanFranciscoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South San Francisco.",
        "label": "South San Francisco [Member]",
        "terseLabel": "South San Francisco"
       }
      }
     },
     "localname": "SouthSanFranciscoMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_SubleaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease expiration month and year.",
        "label": "Sublease Expiration Month And Year",
        "terseLabel": "Sublease expiration month and year"
       }
      }
     },
     "localname": "SubleaseExpirationMonthAndYear",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "alec_SubleaseIncomeAndReimbursementOfVariableLeaseCost1": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SubleaseIncomeAndReimbursementOfVariableLeaseCost1.",
        "label": "Sublease Income And Reimbursement Of Variable Lease Cost1",
        "negatedLabel": "Sublease income and reimbursement of variable lease cost",
        "terseLabel": "Sublease income and reimbursement of variable lease cost"
       }
      }
     },
     "localname": "SubleaseIncomeAndReimbursementOfVariableLeaseCost1",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_SubsequentOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsequent offering period.",
        "label": "Subsequent Offering Period",
        "terseLabel": "Subsequent offering period"
       }
      }
     },
     "localname": "SubsequentOfferingPeriod",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "alec_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alec_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "alec_TaxCreditBeginningExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit beginning expiration year.",
        "label": "Tax Credit Beginning Expiration Year",
        "terseLabel": "Tax Credit Beginning Expiration Year"
       }
      }
     },
     "localname": "TaxCreditBeginningExpirationYear",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "alec_TaxReserve": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax reserve.",
        "label": "Tax Reserve",
        "terseLabel": "Tax reserve"
       }
      }
     },
     "localname": "TaxReserve",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "alec_TemporaryStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary stock issued during period shares new issues.",
        "label": "Temporary Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of Series E convertible preferred stock, net of costs (in shares)"
       }
      }
     },
     "localname": "TemporaryStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "alec_TwoThousandFourteenAdimabAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adimab Agreement",
        "label": "Two Thousand Fourteen Adimab Agreement [Member]",
        "terseLabel": "Two Thousand Fourteen Adimab Agreement"
       }
      }
     },
     "localname": "TwoThousandFourteenAdimabAgreementMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "alec_TwoThousandTwentyTwoInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two inducement Plan.",
        "label": "Two Thousand Twenty Two Inducement Plan [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoInducementPlanMember",
     "nsuri": "http://alector.com/20221231",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r242",
      "r247",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r278",
      "r404",
      "r428",
      "r449",
      "r450",
      "r464",
      "r471",
      "r481",
      "r520",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r278",
      "r404",
      "r428",
      "r449",
      "r450",
      "r464",
      "r471",
      "r481",
      "r520",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r212",
      "r406",
      "r466",
      "r479",
      "r515",
      "r516",
      "r522",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r212",
      "r406",
      "r466",
      "r479",
      "r515",
      "r516",
      "r522",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r269",
      "r278",
      "r305",
      "r306",
      "r307",
      "r403",
      "r404",
      "r428",
      "r449",
      "r450",
      "r464",
      "r471",
      "r481",
      "r514",
      "r520",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r230",
      "r269",
      "r278",
      "r305",
      "r306",
      "r307",
      "r403",
      "r404",
      "r428",
      "r449",
      "r450",
      "r464",
      "r471",
      "r481",
      "r514",
      "r520",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r242",
      "r247",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r480",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r435",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r480",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r512",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r478"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and accretion of discounts on marketable securities",
        "terseLabel": "Amortization of premiums and accretion of discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails",
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r60",
      "r129"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r135",
      "r424",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r24",
      "r94",
      "r390",
      "r429",
      "r430",
      "r499",
      "r500",
      "r501",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r478"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r508",
      "r509",
      "r510",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r78",
      "r79",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r107",
      "r115",
      "r131",
      "r154",
      "r197",
      "r206",
      "r210",
      "r219",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r350",
      "r354",
      "r366",
      "r478",
      "r518",
      "r519",
      "r569"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r125",
      "r136",
      "r154",
      "r219",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r350",
      "r354",
      "r366",
      "r478",
      "r518",
      "r519",
      "r569"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Cash equivalents and marketable securities, Fair Market Value",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Cash equivalents and marketable securities, Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Cash equivalents and marketable securities, Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r216",
      "r221"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cash equivalents and marketable securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r56",
      "r217",
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Remaining contractual maturities of investments were less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California Tax Authority"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r127",
      "r452"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r42",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r41",
      "r46"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r102"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r154",
      "r175",
      "r176",
      "r178",
      "r180",
      "r187",
      "r188",
      "r219",
      "r231",
      "r234",
      "r235",
      "r236",
      "r240",
      "r241",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r366",
      "r451",
      "r493",
      "r504",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r110",
      "r120"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r225",
      "r226",
      "r437",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureCommitmentAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Automatic conversion provision of common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r508",
      "r509",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r478"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 82,895,718 and 81,986,192 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r141",
      "r143",
      "r148",
      "r419",
      "r425"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r113",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r253",
      "r254",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Reduced revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r253",
      "r254",
      "r265"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r253",
      "r254",
      "r265"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r4",
      "r5",
      "r66",
      "r67",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Conversion of convertible preferred stock to common stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r506",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r506",
      "r556",
      "r557"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r218",
      "r222",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair value of instruments in loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r218",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r108",
      "r114",
      "r329"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r88",
      "r555"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r88",
      "r555"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r88",
      "r555"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r87",
      "r88",
      "r555"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r88",
      "r555"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r88",
      "r555"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued bonus",
        "totalLabel": "accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined matching contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan, maximum annual contributions per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r39",
      "r58"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r282",
      "r310",
      "r311",
      "r313",
      "r317",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r12",
      "r233",
      "r234",
      "r235",
      "r239",
      "r240",
      "r241",
      "r394",
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Accrued liabilities due to related parties",
        "totalLabel": "Due to Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r149",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r175",
      "r178",
      "r179",
      "r180",
      "r184",
      "r357",
      "r358",
      "r420",
      "r426",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Basic net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r149",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r178",
      "r179",
      "r180",
      "r184",
      "r357",
      "r358",
      "r420",
      "r426",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Diluted net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "auth_ref": [
      "r551",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "terseLabel": "Operating loss carry forward, deductions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Un-recognized compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares Committed Under 2019 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option",
        "verboseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r123",
      "r145",
      "r146",
      "r147",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r186",
      "r220",
      "r252",
      "r314",
      "r315",
      "r316",
      "r336",
      "r337",
      "r356",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r390",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r359",
      "r360",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r96",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r243",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r360",
      "r400",
      "r401",
      "r402",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r243",
      "r270",
      "r275",
      "r360",
      "r400",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r243",
      "r270",
      "r275",
      "r360",
      "r401",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r243",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r400",
      "r401",
      "r402",
      "r462",
      "r463",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss from disposal of property and equipment, net",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense",
        "verboseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r57",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r155",
      "r340"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r156",
      "r323",
      "r327",
      "r334",
      "r338",
      "r341",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r157",
      "r171",
      "r172",
      "r196",
      "r321",
      "r339",
      "r342",
      "r427"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfFederalAndStateIncomeTaxProvisionDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r319",
      "r320",
      "r327",
      "r328",
      "r333",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax benefit at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r405",
      "r502"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r387",
      "r477"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Lease Payments Owed Under Company's Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingSubleaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether sublessee has option to extend operating sublease.",
        "label": "Lessee, Operating Sublease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating sublease, existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LessorOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Renewal Term",
        "terseLabel": "Extend for an additional lease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r154",
      "r219",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r351",
      "r354",
      "r355",
      "r366",
      "r459",
      "r518",
      "r569",
      "r570"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r109",
      "r118",
      "r478",
      "r505",
      "r513",
      "r561"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r126",
      "r154",
      "r219",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r351",
      "r354",
      "r355",
      "r366",
      "r478",
      "r518",
      "r569",
      "r570"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Gain (Loss)",
        "terseLabel": "Credit losses on marketable securities",
        "totalLabel": "Marketable Securities, Gain (Loss), Total"
       }
      }
     },
     "localname": "MarketableSecuritiesGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r40",
      "r111",
      "r121",
      "r124",
      "r139",
      "r142",
      "r147",
      "r154",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r177",
      "r197",
      "r205",
      "r209",
      "r211",
      "r219",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r358",
      "r366",
      "r460",
      "r518"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r197",
      "r205",
      "r209",
      "r211",
      "r460"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r381",
      "r477"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment loss on right-of-use assets",
        "verboseLabel": "Operating sublease, impairment charges"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanysOperatingLeasesDetail2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "verboseLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfLeasePaymentsOwedUnderCompanySOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, long-term portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r376",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included In measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r374"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r386",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r385",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carry forward, net",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "The Company and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r140",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitPlansPolicy": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans.",
        "label": "Postemployment Benefit Plans, Policy [Policy Text Block]",
        "terseLabel": "Employee 401 (K) Plan"
       }
      }
     },
     "localname": "PostemploymentBenefitPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r30",
      "r53",
      "r150"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r77"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of options to purchase common stock"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r124",
      "r139",
      "r142",
      "r151",
      "r154",
      "r163",
      "r171",
      "r172",
      "r197",
      "r205",
      "r209",
      "r211",
      "r219",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r349",
      "r352",
      "r353",
      "r358",
      "r366",
      "r421",
      "r460",
      "r475",
      "r476",
      "r501",
      "r518"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r59",
      "r128"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r61",
      "r119",
      "r423",
      "r478"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant, and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r276",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transaction expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r276",
      "r393",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r80",
      "r122",
      "r577"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r436",
      "r494",
      "r503"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Amount form letter of credit"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail",
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards And Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r68",
      "r117",
      "r432",
      "r434",
      "r478"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r123",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r220",
      "r314",
      "r315",
      "r316",
      "r336",
      "r337",
      "r356",
      "r429",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r194",
      "r195",
      "r204",
      "r207",
      "r208",
      "r212",
      "r213",
      "r215",
      "r263",
      "r264",
      "r406"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r267",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Federal and State Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Recognized Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r46",
      "r106",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r279",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Options to Purchase Common Stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Awards and Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r474",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [
      "r495",
      "r496",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E preferred stock.",
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Share-based payment award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of common stock, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested, ending balance",
        "periodStartLabel": "Number of Shares, Unvested, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value per Share, Unvested, ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value per Share, Unvested, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value per Share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfRecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Outstanding, ending balance",
        "periodStartLabel": "Number of Options, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding, ending balance",
        "periodStartLabel": "Weighted average exercise price, Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of option exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested or expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockAwardsAndRestrictedStockUnitsDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfSharebasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable (In years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest (In years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of exercise price per share from fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r382",
      "r477"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r47",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State Tax Authority"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r154",
      "r175",
      "r176",
      "r178",
      "r180",
      "r187",
      "r188",
      "r219",
      "r231",
      "r234",
      "r235",
      "r236",
      "r240",
      "r241",
      "r245",
      "r246",
      "r248",
      "r249",
      "r251",
      "r366",
      "r451",
      "r493",
      "r504",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r65",
      "r123",
      "r145",
      "r146",
      "r147",
      "r160",
      "r161",
      "r162",
      "r164",
      "r170",
      "r172",
      "r186",
      "r220",
      "r252",
      "r314",
      "r315",
      "r316",
      "r336",
      "r337",
      "r356",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r390",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r186",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r65",
      "r66",
      "r68",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon follow-on public offering, net of issuance costs of $1,148 (in shares)",
        "verboseLabel": "Public offerings"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Forfeiture of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r65",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfOptionsToPurchaseCommonStockDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r20",
      "r65",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon follow-on public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r5",
      "r6",
      "r65",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedLabel": "Forfeiture/Cancellation of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r65",
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r52",
      "r478",
      "r505",
      "r513",
      "r561"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r373",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r373",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r373",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r373",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r231",
      "r234",
      "r235",
      "r236",
      "r240",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Convertible preferred stock, ending balance",
        "periodStartLabel": "Convertible preferred stock, beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Convertible preferred stock, ending balance (in shares)",
        "periodStartLabel": "Convertible preferred stock, beginning balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureTheCompanyAndLiquidityAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of Series E convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Type of Revenue [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r457",
      "r468",
      "r470",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S Government Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r318",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits, ending balance",
        "periodStartLabel": "Unrecognized tax benefits, beginning balance",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decreases related to tax positions taken during the prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to tax positions taken during the current year",
        "verboseLabel": "Uncertain tax provision"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "terseLabel": "Uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r189",
      "r190",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance deferred tax asset change in amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r383",
      "r477"
     ],
     "calculation": {
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r174",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Shares used in computing net loss per share, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r173",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Shares used in computing net loss per share, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://alector.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r489": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r491": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0000950170-23-005111-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005111-xbrl.zip
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M1CB( ,GZPI,DL8$XTN.!'86N':K>PJ4>$6=)S.R[&U9[?8:5N3Q47@!R)?P
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M$^J#'Q][,@)7G@IP03:,5(_I8_0 R@0.31+!0^+&B6ZPB054S"91XCL1MRF
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MO3#FCD@"%?9NZ_C),WF>)O>")UQPVTT A4;8],O!4DYEDYA++XXH2WC2VTC
M54V\(-H\###/A]01VU%:X0V_%B"?F[*5QYS$3C"3.:%XO):B>+J"'1 J61*Z
ML7 =N[<YS4-H_X9#]8(U,8@'L#J1GD\\!-.^$SDDL:D ?O%LFPDN67\9I(_%
M<&N4W<A+1*QH2&SIVU@,QTCLQAZ)X\BA$6-!XO2NXNIN250G%_"T&7QQF(LI
MUR1\\ 2J=3:C"$08N%01+K#JB=N@7@,[)MP'R,(9<P3O;3^A%XXN_<3C4>2'
MQ/<"CF58 %E4#'\R+B05X$?V-UWTCHF)74I^F99\1*N'3T^\Y$#>Z[ ^0/L\
MYA'A>,*K'X-9HC*R21B[+@T#*=3&D^C16[T\C7\0!+$2ML*FP*$#PN9'A(%[
M1V28A#9UE!?(WKER&W1@[]-H4)>Y+@^=!%!)&(%_'E.2Q(D'QH\FGDJ$<H+>
MBF?OTSN>J'@J"H6* ,_$+F58VL\QO<,F$?H$#*OJ'KXYY,;[ #V(IU*;TL@.
M0J(<D$_?21*21#(D',!-B"Z#IWJ+2[\[L=]D\6]*S46B) 57.R2)H#K%$L^I
M9=HH,@G^1$R=WA8R]^58FZ52I:63:NY#&>4Y+HL3EPC7EE@#$Q,FHI"X#C:-
M35Q*V8/W3?I1R@P-G3>K1F.=ASDH*B*;<VQ1 3;;BQ0HE$02ZDF6!$H$/.X=
M#.O#-DE,G.@N9OG2I?<QRS:5PHU93$2"578NN$&QBN%/8;N)DPC;CGMKEC<I
M!O_P32PN9]??L?GFY8X7]ZIW9C*BOG30IP9F\AV/L 1 9" X2+RPN1_UEIG6
M8:[<1S17F 8L2YYBD1C0Z*59JS5&S./(DW$D Q*$PL;#;'SP,#U)0MM7D<L=
MQ>S>[A0_5$SO3CKOAU)-[JG9,+8##FQX!\UV^=)[M>5DW'$I6%WAA=C[T1&
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M$T&Y%WNQ<H5Z!B&IM3+V74-2SY;E!VVUL:3;<&TE_#AQHR F>$@(\4,[)$E
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MZ;VD?&1Q/+GLUA2S)V.V@:DVA*E*JGW"X]D87C/PT\!/]_2"F_8@6D?)%DX
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MML/-]S?=YQ_:619<( G^\O,K]]5 L(%@ \$&@KU@@CWW<.H >:[;&U^Q93:
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M>-P:2#LKCS"B;-<>=]8+ZPO ;^OP\'!^ ESSR*/YEOX!K)3EV.1WC+7J!YI
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MB7'3R0B0+QA%JH762"^*9T4SN4@N&*2P-QPQ2.%363E\; M'@?6^RMHJ)FC
MICDZ@YB7<LU^!4!'2?FHO?E:/#J(66](/HC94QF[3G!%?INT(9>54H7QE]4[
M?7A;X\I9DV(R;0Y_&@2L-\0>!.S)[)C)N]0IGG@V?-T@0A@*!CGGN8Q@SW"C
MG$F."5_TG*89%HL,,M0;>@XR],01#Q"1Y9SF3IA?@1G+SXPIZJ1#+YPP'>?4
MFQ-F!P"L627E5ZN"KW"70DC3BL'D-[=)DT4YP;QT44[/NE=LW80_\:=S6J8%
M.'<M^!S$N#<L-8AQ#[!FP?0YH28-+=7)J:L*&H;-]@T@[B!03R%0\ANFKH!A
M:\1F[HAUQ*BS)W[-!MXB8>R?TS*M,(E]\-QZ1>E!NI[*7+75&2A268H%75CK
MN)RCHC<'<F.;+F5RWI*FJ9I:CT46MKPA!QNOOF-5X2"[O>&C07:?=@]/.X-7
M0*<6I:(&3Q"#FC++I*D)A2\Q*6QFZ5XB2\XCT%'FNLP*971N>K%X+:^;XJP+
ML*)#X*:/+#&(X5,%;G*IRP@ML)FRNWD <E85>2ZSFY(\#9C5(JO#,?.;MBS9
M1&VR&<+:#*>#@DG;$*NN?("7MGDR^NN\:G(_\_.T+')$Q8.0]H9A!B%]LHHD
MSJ=EI[!HD0VZZ)R!D=-<UZ#/^QV<2\#&6P!2)VFM.RK\.04IU[ZF0;@=>6]Z
M:L"#4",,Q4B]X8!!ZIX*H7;:S'0[ABPPYZ* XKS ^(XVCTU:=%47_"L UI0/
M-;6]H>L@2T]EP=+Q! %CD_#%"T!W%##>M+)>[WW^^^%[XB1O+$QND>.4=V6L
ME+RMAL_AM;AK1[7]*HR<M7V?KL6)/]9U[O[];1ZO[=Q#MY$>NA^NH_OAH.T'
M;?]2M'VG$#O-E=GZ>H<Z?$!"/:'3(!M/EVV(_0M2F7?<^39:S6EEFDGJ#^BN
MG]-,-GT.U;0)Q"TW>^RX_LVMQMO77X)[;T(!"\]_^W]\#U :6@'>G;K_D-:(
MGDL+-8MHNL+=T/XOPRJ';-8"63XM==O*3@9<D[9M6N29O['!VQ+NW=* &J@%
M$EAJ[Q.6@8^PE,(PB+S4,K6&MXA%ZZ>FE9[.;*5:;5]Z_.).W$9MNJVN[,VZ
MU0X70[_UHJSQYF5H6]J=36D)R%Z:$N>&QSN.-VX*=;(EV@:F-SP9AD&_PO+"
M&M-YW31NUIK/BQ9[.A16HFCJ'JLZPMTI@;Z^_2FMJNEX8D@C9,7+E+4-_.!I
MAFA6G=89?-MV%#R"IUD'ID_JO*N@[AZ45=+L4"UW -RV?I6F.^HMJYCF(]WY
M%.;;F8D>?=/.=6D"NFTE3,_P"Z<Y4H%)J^F4:#J@_CG%)I JQ7(Y[&UI^DUJ
M@I4-\]Y.X:I]9KL]UU 7 Y1-*]KFL]%@:<FG8W@ C!<7066F7T436;GA3<C$
MS2R:IJYZ$@6&3PW!EGK+6KJ)9=,RMMM$ME-UVTC?@JPW]=3=_\;EI,8)-QI7
MMXZEDTF6<MQQ!)F_V$*I$X4>)^Z!(HTF4P97P(NG$\.?)49OTTJ:_K5WZ1J)
MI$]!,H&#=+(0C($V\]3[+O <])\!CJ$\-1FR73)LS7M77L"+AX:V+]6*'>;S
M;8&EWJ+:8,S;R\X-QY(*:YN>+K7VUN)KC K>HIJ4MDF:&W60-Z7OF3S'%M*-
MZEK1H!IUG+&MTPG<U6'EQ9X^2M.TNEG?&]T-ZPR7=RR@WL'L/A0_&2FB59'K
MI\/K4Y/JHZ]>#&[KZNVF5F3>JA7;2>>XRYG)6F[-=U6[]FJA6QDN"-4;LTT5
MEYQ;;(TQFI0F>"[%5CDCB@#\'&T ZIV9K@7;:O4(,$"AX)59M@A9HU&<+]I\
M\3OCOX8 '2,SMR=F-F@>\ JP57B_-#-!>L!0X7)M+S3EZDL/'I3-,XEQ#;'6
M>ZZJ.\1:AY-FGOI(EB^[1R?684]$VS"8E8J?7V'<[M0Y;5W335_F0YB.Y8!W
M-UUE_C9N.H8HZS/E3W_JT*W<'6Z*R_"@:_GY7):(,5_6DJX)")C[<9@[&+5-
M^?7+#,[".-4G25AITX5:1\,NEZK+\:2XD*9T(1V/ISE [5F%R@9+(=#AS^6T
M+(0\DWD3NNL4&;7EL+W#Y'=?J76A])?&BS?$M=&OHU:GM@70J,728C*B\&JN
MVR_K"/%X@I&F"?I_4N?V:@XLB&:YK,!CN2CXA<"X2YV;=34I=@1J:VYJ0+JU
M/@<!?/<K_+IM'5YZ;-,SJ&HY7LPJ!?ZI86[MQ!=%W1XRI:SQ-*M3\,2Q/F"$
M#UAJ]"!*<*5+'4)8O!4#^R5F.H.$%*6 W[>M9F4:05QN&V%JT4UR-0=Z S+$
M#!CC^W9?6Z4X&IK+8EJ!A\S04]:GJL'C1I)F]6C6SFH^I>:\"#V@;>MX.IGW
M#<20 NXN8=!VL:Y;^H?E\\ITP7Q:<2!&.<-09(V^OR5UI*/"*(IN)W.N@^\4
MWE50[!E<PF596NC>H"L*I\Z!]?&CCGR.IL!D%JZ@:>$]WYIH8RZZGV@ZU@W9
M](S@$^OTWZ\E'S4LUS;I.,?#=48P#+FT'X ="/1^+IY>MXA];LTC)LV)3'B<
MEWZ&8]N7U:-A(0Q\E%*NG!U6;?X+7C*FS'I-LZK ^)8L2T-F8+3=#[;MO-G2
M_[HF+K+[P;&=]C"TN0@M-4/6\2@Y+V?K*G=3;;8H*UL^ZB.=Z#EK3C294L!!
M;9!)P"I,RA0XJ6Z;*IMHT);I:]?R2W<5X='P%<;=FVTI<YI(/LV:6O"3H_V/
M[OR,$;-Q@:4W\PX.>NNRG.;@G0)%0=.=C2S7=H.YM!B6FE_>3NS68TV:N9I>
MTDO;IHM!XQVXRMW.U8L;L"00A!GH^%M&OQ4PH"S3O5S^^-WZ8,)TJ)ZJ*:M2
MD=)2LZ"^]!A^'/VN7S_)N/7ZM^/?WQCB,O;W5%J_IH5FU4;%?:C%MO7:_/9F
M>S!'Z\7NGW/K/S&@Z&PA8SE:Q+7GK3=I].;=WA(#(*$^I!SWR*W=,Y!MS>J:
M+8"0FIJ+[]\8A=W>+]L ]5D&FBF[<D3/U<;E1C&V0D-T:%6SZ;C("Y[I;'O<
M5&.%T/MPBUS'KG:9:XYMZP]@D<8JFC/&3&1[:=1Z$5 #I+CG]=<(E!NL<Z;!
M8FY-)ZHLL/,7G371ZOF^WU^#SJ47>N>J>4BSWV6J:?^<4JUQX3Y<<SV\O[JW
MW*K2LJHOW>J">BW.S![5G )-WS]]!-'"BAIH<*G$5D^DP*/A@#I(CK&.9UNO
M#T[>H][-_C62P%6EV9=(WLT;O( \X@5?:/DUS:LBOW)!LZ4[GA5U6>@VH'CX
M'+ZDXIDL"XS\O][]</RF=]!X ,*/LYX?.O(Y!FN5::[L6LC77WX[^O0&C<A7
M.5OT>=")< 9K4#S#M:D3F$,X(PD-3K+@05\U^)JCU$L ^%QV06AW5*EN(K$$
MBPJ#I2V0#VW<X+<2>!U1J@ EJD>/!Q3JRI_K7M-@XR:M+P!Z@.C#HT/S:2(+
M'.:U_2LT"D"-[:RZ?G^*9;W &7_@CN @78-T(1\W^5#H$4F3]8#]%+1MH:TQ
MGJ3G!>:Z?1FA@O=,>X4MZ_#3P='G3R?$VYK[DXM2G27/D@J=!P*\C6DRIF58
M8Y>JV7@"RTU1(D%V+&%P.5V2=Q05$-.F81G:(/)8P=Q'#ZN 9MNPN5TWDS=S
M7P3>#DY!TT-<YF<8UM#4[W:ZFH*OCCZ4:5P\3@4!'..9M"6 +).B6K1!EJ9[
M9!.@ ^]ZJH\D!_ZHZL9_H]D,H83I?V#R&;#D&3#+&=Z*1VYG4IS)!8J2F3 *
M&%,*C'_>N.>MJV=XO)&&.?M?ZCMB9J8D!@?GQWJ >GZ+9V#/?>J%?(AIN<@$
MF,=V<&J+\T+,*068JX")B?,31A9#,&_6#9]+D&7T!/$$[EQT&B/I[H!2"F2E
M;>LP-UZK=;F5RK+[W00$U%2?^KTXD \3Z33BO@+%K0SM(JXY_]I&4 RG@37,
MSTRBI,PYN(I4D\(,6;<4--UB6%KH1M?E<E>7UJ8OVV+02:"Z9&[.<J^+3)KA
MP4#:L,YYD6%@"&--^$!4,]W37-!G-:K-H5OM)V9PJOG+O=Q:9EW.YI .M4B'
MFCN9>)(S.IJB.9L#NUUV"*ZY'VE6Y&>%CF\ GQ/P(V5V#;D6ILI%>L]IKP5U
M,":]FMMU,]GNT!"=X&[<5X+F9UE:C4Q"\.*D4*,-%G%./@*W%N.U EZ3:D76
MZ*^EF$"]Y!F+HFH3D=%9 !\6-W?F.LK$KQOG=TE?@:K&L!=&.N?*7K-<]V4X
METN:JXG'@;Z&/]#30:8%^1^A,:O&U+P%W N&.>"I;BN035-AO=X[/M!QE48#
M5Z@65^E!"[-< '/QD10Z'%H6634'<:U!TM:V'?FV];Z9XSR+#0QL4<$J9%NF
M_&@\UC:FS=F&AYYEJ?;G.XNE\^(UV3#9MC$,\Y@.1HQK6 [,E(=AC:JE,1CC
MV$2!V\(B\[85\S'C&*/'TZP'VJG%"L)B&5=,I3!V?+QIG\)'Z"J^_J0^O,$,
M_+%)_-4L)E>,<-OZ.RSK6(*FX=;'HT.PF&=G0#V\)RLNFE.&,/<7+ICJL^IS
M79,PCVT9WY3J<(AIX[+@#Z(G+\5":777@%KMI$>IWLO@[>SA7P0:YFBQ$M@X
MG6 ][P(Z_-9XP6@,#\&33(TG^OJW_4\'A^Z;>1=[P XH*&!T]R[Q-:;E S(P
M.8LFS(T/WGM_].]_<2+_':PUH*=/NWM[\)(/[\GQKU8%MV-J]S1OD%97$A9D
MQG638BEF;9QG8!$VL_SX;TNKH*>CAVU=XH%F%09?]^6BBH]Z5P,CHI>P1:<I
M2_<(,-FQ,P947[(.()]+ %)K=&IMF)F].X382XI21>Z&S>]:"6NC?R\DFO"\
MJ <&F4W3S&R"M@4-IL9HP/7]GMOUN/XA<,52]/%9<T(CX)MF?ZZ;SI(,/RO8
M-M1GW'U!O:$^X^GJ,P;GP2QI%_0;E-%NB^D81AO!H):0&=7A)9T&^$VWC,QF
M5N#_35^>YU.,<& XLXF@=/W9U>[\)2]^[IOL?OB S@?\7&$FXG2LX_B+0M+5
M_O3U,:;NI"X*8KSI4DJBB@R_YZ4>,(*K;H(:PSS"R6@&,\#L2C3>38@%L\*N
MC4SIO@4F %/JQK48<LC:@!&LX^)UIF?NY?SIQ<; ;P>[7_3V$C:N-I$YS&Y,
MA;SBV)EB[WD%[$M  QLVOVOM:L/^BTX/!9!Z1#/59#EY0V3GA2IG5'O'<E)+
MW3UDOG64FDBFSLEM]X)P6W.V(HJS^^'X2A2G1=-M=&#;^H_B E-YMI;::^OF
M6^=%=H[."3XG PT&3LA$ZE'PK#"M:< 3,6]?/C%4YJ#;,Q-5_X<)8&-ZGJ[J
MGJ=CR'.:34U&H]G#5LN=65;/Z"$%XBH^'02B-P*ADUBWNGKR2J;W?*\;MY3F
M%09;F&JPM)NF]_7EBBW]K7GG"=QC6O">R?^9+BSWDONM-SO*I6-R%[FX-R22
MZNWW:]-(MZV/T[9]DTG: *A0&N0%<&K*3;*&_#9ID=9B$T@O@,Z1KZJ"&WVA
M%4 +>(3)4]*%*?.:DWL,%3%:GF(&!(ZR.8ZQ>9,>3#,VT]<*=^V6,BUPMTNV
M1W7@+DVS4U<MSO36[UBQ@X[PJ$S'G1!W)]OA<N)*+:OV4-9F%W5K:0MURVH*
MD;!!3E-KTGXC9CGP,&]VW0"H-6TOYGNO&,C)I-E--1T+87;G,C?E.+K5!^/3
M18%.NT>K\\U-<<?*E([M^8_MBJ[(16GX<@)K,1EA'4[3,ZO9>\,#%9HB!YV;
MEC>;>^VS$4 WT25-BLM@NM9-/\S4NN/6ZGU1)[+0^R8I;FX0#,[1J49(@T5&
MZGRUFNJ6[IHL+Z#N"[.T@D-!Q-HWDSZ!W],"CLO[2<N;2"T%"5)P3M\&.K3B
MI[&!YI%E<4=UMF"\%9[;:NV!C+R\O:T=.QP!$1*3P9#S8+[@3S5I=<OB;!RT
M98%&:5)IUN7"RM3!M7VMNIA$;UY?4??M&;*[[XVF?+\$>]KN7&T-G/%S\45-
M^1,^%<'^EE'2IA&?V;$V20IP_VZ5PG\OS^?UE]_?@(BGXJQ-;<4V7YG97L:6
M86V&Z^J\H44^W>[[09K67,X.9DA7[ZW *6V1Z4F9GIV9^M8CB2W?0#?O&X-N
MLCD_SH#S4DR&R8#_7>NU+IM[8_HY-<$$G=O9%'32UAB9\CJ3<M@>C2/SD>8_
M8'J=N4+U8TW68>,,-.FL"Y#>A0=Z,BL+:V] #JNKZ$Q)V^#<OE#9.,QO0&E-
MT>MEA-A%:49^FD3K1>DK"%JA"/S?6')@];0:M[@(-PZP @L,PSD>UFTJ=;7*
M7P6X8'S_"?@**S=7>-Z'G_[^^?=]@F6YF/ KBC$&/[?:F"8VZ;Q&W6H+HPMZ
MN_U5S9-U)S583..B:"!U*=[JAL%RKI,6I49_7RN!6JCSXJ)CAK#QG?Z4=S%:
MZ"\_O5FZ-@FUG74+I;%D&1[)I2G^UA7';?_6COOSY?.^)?VW<OGA6PL@H8W6
M%EI/78&G&[XQT#D7E\G@;76* =OL+<0/9K$:Y"!T9$+C@@R&3K#4<7&HG_7Z
MP\G^F[9?\GQ*J\FE!W @6=D9P87LENMB5ITP/7KG7W4J*0V!L32]::#9^*>F
MOM'DO?_5B;;C>?7C&(%(C?"\*;%<Y"P659-I=W41=!#>@IDU@&O05NN-/(QG
MV@@?R<S(_]BD]>^R)KE3EW2\WCTZW'W3\7 +!H\]7_2;O2)(UV,R0&,6/DX;
M8TRY5*DN=*C:W$OTD3'IDE;%F<2$7PG:DJ*3.0*M6:4"005HT E\;COC@E!B
M[P*N[]1/GU<65*/B(E\"%7H0EZ*'^@2Q*XG%3>_&A0;Z?Q;&OY-E#"(/<%MJ
M1ZY.":@IC[GO"&W6=E'(K*7N#M*Y!1XLR(">",<( <BFCGATZJWT:2]%3I"^
MH/8[P4YJ@1L!@KGHSHP/(F5#XN8&A.Q@$.9=A74#8'1-::9?+K^!GJOT'L_5
M_!RM%!;J#^A4U#,,H)H^QN>I\6M-+U%TI4\*D/\Z/4.$V'1;OA2^P3%J'62,
M%2U3A&AS]2M%JR8,W.LZX]<HXI8Y;U6%!]JK:((GZ/&-L-2ENO=*+BW;J&C:
M>.=D5(R+?\W.\-96!393P%"$S&03>EATND@Q"J&GBR8QA;&@Y "&2$T3%&V@
M,0HR3U.?=[K0?9,KW)<\FX*,Z/8?^K6:NQ:/, G7-&]0QP(OFRZJ9G72JG'$
MIO-Z>WPJ;20/5.%AOO!6WZ-7_7'QAKUB#$P .,1Z??C^X]Z;UHS 4VGCUVG3
MJ[NQ3G,8M[9 VCEO,_CI5]GH$I@A]A7(A;',@V58=TS:]OVY-S>68P9X4 \H
MSY&8/@%P",H1]38SK[-VK=<;MGMY]]W9C\?^[H9-[H9,3,Q6^">V/L90>8:=
M;HQ.N %J;]CD7R1E3;%U(XUC'>ZL=+DFIE: WJ1YU4JRMA Z*J/W)K1'1&O4
MQ7(>I:EDUN9Y8,1FO!2Q66K.T)STL&31VSP8["4V#\LL1W.T9]MIMZWO6UQ\
MGC9N\?:5+6,3P346@,OFT!?T'$#5$]-3JW7!N_ZI[R\%(FOCEEW:+-(+L;3S
M=LOVT:)ROB@G !ZZ =1MZ]>V?KEQAJTOOU\M<$,C9XX]D AE34LTW(IN(E(:
MJ+3=H5J:S)O!4%VP2\#U16:>QUX[/;+0-']Z3[ *>=:96[-UWJ5!TVIL"6\M
M#;4)*C^O"->0X7GW!?6'#,\'R_ <$.J=%_6D33-<;E'8A)&,7<(F$K2<Y_V
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M;S7A4Q/]G-]R84[:FSMLRXU394NNW-H;I3G=:D[GVD47'1NRZ;M+J3<L;N_
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M(#7B%E\:Z 2IYU8NQ?&]</I($\LZB/VH$X\*V%G"#]TN@O[<[][I8!6,:>2
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MK:*)VPTAK(*RO%N;6D,PLY/DR!VIG1I_7O8&'2)L33D+[:!+A2WS[F #2 G
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MH<K<'&SLA7G&.ZT:I+)12K U'P3I'$*T/HN">\#'?(Z65"=H(P"EG;6Q6;$
M$ C8B_+_MZI;5]V>5"A4#Z%NS%AJ?^"G*)=(FC?LY)0,7ULCC%_O9[@%KK,?
M_5JY;B$;8))KO4,<-";$)\+9V]JSP"Y %RUCF6@O3!]P9KTUC+;76I()@2O,
MA$%M,R#Q3-EM4N(Q<ZZ_6"X=)%V:-:(SQ3J\$B B!D*SG*=53<O&B\\+$P#K
M^K"=]PM$=X^P]+<.0G^7+GG_1.\Z='KW '8^%+U\3M'+L?0AET9['#/BP!H:
M*&6""F\Y--9]&JW)?0=?]Y=\__WWWC1)+8+[];L(G"OTQK1X8!+H;^^\*ZK*
MCC94E1WU5)4].3H)^%X/GU^_JNPZ]7,G=^6,?0'(U=KA41 4T,9U\2>)X44\
M'D5G/Q\>'-I^ @<'1^LM.L.F/<[%4'H=T$I==2)=V:F5_E,NH/7-YSPXZZ^V
M1&"3W[:'>UB'>\ "N05]/F"!OAZ]]&#F>C,WJ*]72_<>&;I#5.2S-H/P1X8^
ML>I%T."&/;\]B(CYQ1A?^^['][^0=F-R2V5F+3K4%KT$K=K/M2Z+#K$LAR5>
M?7@I&I-9+GI+'YD9BVD779U1E,0E.FU?(K:RU!(:O!&#5.8TIN6P ZJ+F>$W
MP&[@9+9Q]4OM*=HF]NC8RG,H)B  #)'43"J\Z;VV!BC>0NX!_)&9!'PTI@05
M198NBVE3)2DG6D9:5(2&MZNEL/..5U$R3[/)'%"G">?:TW@4 <)'D\R*BNXR
MRS0SRTII>9C5IC/^V &:B^5J?0;*T<,73LIBR8V%E)GX].!;?NQ3^J_M/,4,
M=';UM&./H,; "F#7HU/BB.^N)558Z>?TO"7V1LDT'S3/IZ<(SI:\PJ0Q:0I%
M:0KNM"L5:A6MHNG4 %NVX:J9S5!8RIO ;=;5.B">)PP;4'9WNXPKEI@38-32
M7$MP\7WS'CG8?.5Q\]MIEWFIMAF2B_@C3J L:ZNELN,X%D)41N6Y@V(CE/?+
M]KP%2?_DGDKZG_KE&B.&.O6,3&J._ DCA4@P(MAJ@4#615.FKH L6,&:',]P
M0LRS+&)C9ZNJ *%P0*K(HY@8"> FG (JFV4=-%'SW;OF=&M1U7&5=FI7M/1D
M40"#M%ZJK\);SJ#)I&9E&B6KNA#>8/SK(X>-M5?X,A/(DJWO(='3I@4.6KQY
M$:2XW#;Y(Q?5._I=)[]I5$V96T9B2R^&H%-309@E']TW@N2Q-3!8&S,)F[F%
M7&9";!\PE76*0T"P!A[,4K)?(_]HKI5]\)'PO^TO71&'.MX0ASKN8S<Z>AZP
M&QU]1AQJ"/1^3J#W9(L,"@6.-7;:1RH\;%LDT*3A?##G$F_N3'U]5^L>.=T#
M3]-?:N[S]OV'P^A%P<S*E9RDG\7$4 W]/;E*N[7CKS^[(=QPPT8H^V5LF'"M
M;]=#$X98WW>&N[M"F-;HETL7BCUF!?:L%%)7LF;,$K\_+TH@(?/H$>_+QT(O
MNXA_9ZJ<F?C;K3"%&EAVPRZSN%(D4<!5+IL<Y-]1A3>$KRQDES/<B(Q=&J#1
M8#__WN23@A^* F[,M<F:Q=Z/139+@2N*23\H<U#J'V3?.$YSL<YH(Y2QL\AY
MS'IY,."@-Q"JD9=,%I+"8@?81!L)E[ILHI:DELR;Y>+D*^!*7=MVO&=])':P
M@?[T7B\/=6V,^KBQQ&J8DZHT9@\LG4Q:SWO#TD/1GLT 1RG3V/5X%N>;<3,<
MM G0/#1&_5QAQ7H['(%NR-B)#X^_<Q!$LI[>9W.Q1U0,!IL'=IZ))@7,.?*9
M;/2'JQ(G=&=EM%1PG0^H^TB-D2*P@]UGLY6M>DM(*E>DHF<['E>VQI)'9<F/
MK+1T$=)JC5J[X$(:')5Q5B0<,9*)273-T1[9KF7<Q ;UGE(N0W(NGHH<<_60
M#@:)X>GALH3&[G@%'G(HI42.#H?M81ZVWY3Z78.]V)^7',R@8Y#T\?Q9NF7A
MS,&^'860 (4","H@[!7B)'Y'J?LXD?28 E*PZK3A8.I%"<54384""7KF1" %
M8!3K/')K2L(G5=:F-FI#&SB.58,KUU,0!H49\L ^;AB .2L;,;<<'VD>S,[B
M.!>I\(['X=GL#_$_HH?MW3&T^?5M>9KF'9O;IID\EBU6F:2P.J5GH^D!Z=UB
M(#'*0 %@+N(,DG_+?G;;ZV\D+5(/V-'T'B/I62J0#5S36ZWR_/'\WW3)O5(5
M T+F^@MZ>#! 9(8.[%][%WH29<X&D<Q#KQE4ZP FV"]Q*^F\R\EAQW,&AU1+
M'XLLB\=%&;3C@*BKC#BHE;+.U6D-$(#MQ?D]RI_(LY6?3[X[E[(HL@#.LBSE
MK+A]U+YMTCE8KS>Z%W[N,SPY_D-J<N*L-:DK@3$J7YB9<?%E?]T_Q\XHA![W
M):X[F]#+4BYQX\JS5R_/'MNDO>>A5O-N%!87O4)AVH<2V<'6R_KN=;8@[Q#8
M=ARM^9%U/!/.IE.X@KJ1V6)$<^I-,ZJ:L0=PZ/PK[0<%8Y=F(3XB&I R4SCK
M]E0()V)Q(LD4)57/M3IVT-:(F'+39TZ.UMHE.YF'([ ,N3)>,FP0)^3C D**
M8-3F$]G+%3,':=>^A8DM$3B>@:&"$!R>O0P9-LQ*\4:_T%]I+-__S//)% 7,
MG4=1[*3M%N.%D;<5S*;!GK2;$__5(XCY]Y5!GS^&KXPP1+-D.$V6+E+X[-S@
M=5%Q'W!O=,7<]I3+NJ9!^72S-$(4O+)!";LL_+%U,8)UX(^-:9/)5WS4[[;A
M2X^X?Y!</I40I%VX.1KIE-9U6'\-?S=>U0I<&A)%C2_B- L*N:K&U6L)'4@=
M8*;TF6Y7TJ(;77+T3ZS6=W:XAPH(VEPM3;^A^!+,\I*&9V=J)OO1#Q?<6-VA
M S!E3$$W1?MX@S:RD2!JKS<J7W_M^-KG)BP&4QQDW7*RW?#LRAX_;$3?5G+#
MJ6D4;X1786NP/:V]<Z%_1IM.@X]GP?0WN3\-+*YD7$(;(&.3#<^_"4Y":Y?S
M.^SGDF/OQQ\<@;&9%MK VGQ:IKX/\H:=Q#N</M';#>+(384^.'I.X_QR-6XM
M?&.\B^GPE+71S@J->^=(H2 . D:KD9):X"[;5H0I\&5_D]!-JU;T81HGV.&6
MNBQ$MG$<[=.2OJ#^45\GD]=..KI3V3^#1D)O:;>7)=@WY<V31TV^H".Q,!,6
M!C@6^ZY@3:5]_Y"E"0)ZY]7RQ<&6(PQ!TU)D.]L[3>Y*']P1HUTR\L0\EJC<
M+IW$-ZV3)^HE1F,+9G8GU<%Q"/_!>S?6_@-+.7_A;&9HR=@C_*$CKH9,[1W9
M.U\,&'Z-&&:L@%LR"J7-5XX475XD&4<;@U8T B ,(+$=.&(8K;7QS2$DN3MS
MVWC\K$FV[YP;#NE=I#'"CR79-3D4&I3Z$BH/W<FG3<769FA,^7:NXY7/76%/
MV"RSSUY;<O2%PVHKR4<K-\5VM=8MS.-LNH=>WU8-;<U71<JH1]-1+CI5ZIP2
M[Q&F+=NO6BW !LYDYXC2:S(A;C6WY+B[Q9_?KP39$&SZRW+A[84IK8%XDSKY
MBT]DT,HW#%DE.<+ZUK8V<OT6E.H-,882SD>0R9'4I_60V9[/"^_A!GW/W..9
M*P8-'K28B'[1,&BKJIVCP-2<89LGTN5,NDPK_,25Z63D% @MBS2,4+XX\E>Z
MT2GRD+BW L\NG_'UI"XJ"&?R,_9L9SF5JZVT*!#[3<:\,V-#3C2Y)AY#C_8/
M6 +0C(*Q1VN@XOQ3:NH6=4]&[VTL"91]D'B"X\PL*J&$*+5Y1(LY3]%'M"*Z
MB-,8*E"6@W[KDF?_<&DQ4I5*),4:2= ?L>"G^"DNS$&/D^ 1Z8_# UU:SH&(
M&PY:M4#E5/(E[4\:5<BYG^&$_4IIV,$K[V-*]O*F$DXBVB'T(N[QI]#GDU.,
MX$F[!@O?%Z ^G4LL7^[TV7[T$] K([L@J/]*)VP5P-.'X[DGXW"[+*[X2\;*
M,8OOK9=L*[MGG5])X!W.*R/OXGQ;OC+=, #:Y+JF.HTGNMKW2S5_"8E[127$
MR89*B).>2HBCDU-?"7'X_-E0"7$[E1"G^]&;]Z\9QE72WURKRL62I6#,(%PK
MG>Y3%<-@@5Q[/<\RC99SJ2X)[&51((3(DK.J;9I++JJUQT(9<TSZ0F7K,I;"
MV7BBN4_.!3"AK 8?-9$P$QA6''W,B\O,3*!>QJX$.Q5*/ 5!!6H<VNB27ID;
MP5]Z12UPE\2(@HP5O\G%@32'4UKC@P-6<?*OI2F6OC/OKSGG:<YKUW?"WGAX
M*-?KA3\T=% ,C8+N0(DC&0TE>Y+W2HD,J);/0+4<#JB6 =7RM7>AX\XE>90*
MG5V((_V.2XPYP&L9LCRTW-?DL!A_"F''CZ'?6)R[P[*W"!64/B/V&'I)5PZ!
MW5V:VY6!7=H3J+%!<//T6W%$OV4/D'2NZDGKR5\KC;<#/LCI!A_DM*\:^_EA
M4(W]Y'#P06['!WER%2L-BY.0C ;D,P%I\%9"%DO_YVZV=W' @.EFVIS#0<"?
MI=8].=6/#A]'[^=IGD<_C:(/,6VK//IE%+U)7L1DT9I5=#Z*_MV4.1G49$^_
M&=&S<?+GY 6>[;?8PQBB%':TU:J-3342G/G;1]H9N"*HATXETCG7$.(:- &(
MSIK9=]')\:-GC__UY.1P[\GIT7[T\NWK?Y'XV3\\.'SRS]_W2:=5^W3QX?[A
MX?[!(7FQ[]Z\?OFOZ/CTX/CYX<GS_>C1T>/HI1!Z_$CK0HYL]**8Y>#8+\I)
M] -J&NEUAT^^>_*OX^.#O>.3@R_UH6_U3/W?XY)DU+V8RO7-P<&9O_:BOLX'
M,VRWYG:E&8:LAVU![<M5+<%1F)1V]AHDM,=M^:0Y%\ MEB:OD-"P.6PV[Z%3
MN;3:OD8*O4, 4:>N2 NQI6S5J4\=7<&5[)S]9O(YI/"-EL7"*>!4?1$@0T+=
M[<$AXU68VT]I8KVY?5]:5)L*_DF(V6=>0P6DI/(FE)8C*4*KPHQ66G=NB0#1
M((0FZGH<#"=FI^9VM>."CR8IL&2.UA.3D#4/'5_19UW8L(I\MD<63P_'98=O
MC'-O(; E;D'Z[U>ZZ*O39CW9X*@]Z7'4CD^/ D?MV<D-.FJW$E2[<Y:8.FI/
MR5%SJ@1Q@,1!P[ORMFIK#L=J(MI!F+,8C5ZUX%U=$LVM0K]]IO>C,_H%S30N
M X7G1PF00U85%GNLD3!!\=^GQ-80H_^,&/W1$*/_BN3L?WLCWBGA^AE80"M,
MWRD.^X6GR7@9U)B\RY19ZX4%]'PH8>^_YV@7R]N7=--N";<!2;@+5:T 9S5E
M*9B^L>&"':88FFB0-"O&0,&E%P5 (>_F"*\>1S7O+\M\'M=[3$#-*,0 ^BPE
MH.DR;E6BWC$GXR$Z4*,HCQ>T!5[_\NK]VU\^[!U;]&,^*="XDORE2=&0Z;0W
M)HE#/RTS&NJXX$>@\(NQI=@B?G/1);D0VN6X(FJ6G$EZ=C!LBMV:VT8Q;%.[
MW&LA96+YI$3^E_'$GU(Z](:A- &P-*U]2*<%HAE!F9&Y/U+(C)32-O"BF5G[
M/) C#-E5&=.1*;21QN'&E'@4UZ>W(F)DX>L>#5UW1 "X2>84?LNE,1\9G=Q]
M _L+])I9>J'UI.C@*F7AKO^4O)7#6:X4A#D9Z6*3[V7QV&2@4$3?6Q3^O_WY
MA\<L:U?<U.J_F]QPVF,4E-4'D_6D NY0RMV,Q)(SY>GC9'ST >@MK4K5&&SN
M6GZ%B =9M LF?$.9>%UDIM00WL@RP-%W3#B@%RXGTTV%RS0O),XB_.GXS,^?
MR(+:(76&K<_G<=NUPF48L&/)$[&S+&EKE>BN.UD6J5382,NN7J542>%XC")T
M*3EFK%=W"MC'KBTK-PGC+A/23MT6$+UX^9X,W:<GW]'N:>C$G+UX0>+JYY=[
MY]_K4F+LEM@=$+.&K3/WY'2QC--R(5#NO(50%[SYB(:Z*$I:C]^;R4R>%E*[
MM\CUI?*;2W"#U>\T16,7O+4DLHGERPMS%);3C=&N*YU)!Q,)^L:S5N<=XJJB
M2/PL!1[.\GP&Q#3K]Z"L.F[J.:J$==B+=+)'VULUR;(IET7E2K%0YL\NOJ6Z
M3QH,%>*FJK5W6YRM0,4M:@3]VIEGU2P,3+99 !/4C31-3391RM 8FX==_::R
ML6_L4H$DZC;R&]2MC%T^FMG47*(M;1!8_"?7NTN5>5C[;VO-9:8,:L]7/#5.
MCPHA&S<"IELF@#3V'&UG8$F5-JW<Z0C]4)3SUJWRU)@)=,G]BCH.QOSGY/&0
M_^9>B)KT,=JMNDM6P=N,6U3GLX)I1;QB$H%QY';@4><0[ =_\40:HE-,!4!9
M6LV5&&+*I36<]/'ZA#E,YF610Y^W.7 Z@EGH1ARH8$)R0M,O4O "G<<:667\
M)!16 >2WU7B;CAF=1&@4ZQ3S:H@16E^:C'17IVISL$EW9VY79WI8_EJ(HG[0
M!5TWK]:M,-E#(-<QJB'"_7=IX>2R?9DKQE,EL#)HYUK18-Q,7*J(7>* ]_K%
M^2NN:)*<4H5B*I!0=U.,*#O:H\V7S TWS!)2?4>4U 2D*:YJ[X9DZ4U&@GN3
M.$\W)'&>]O8^>1(D<0Z.;C")\\ "C5=D<9ZU4S.ZCRNWCV]H"^]6U/&VS9*[
ML\5NWRX):5_%^W#=ZWJ[+M N8S/&NE$3J\KW I;U95G4)LU;)<#:PX#4_".S
M/]L?12\^G+\<13^?O7EW^'@4]O1Z].+P__W^L18!HS'7+$M1DQP]^O'5V;O'
M+;<'_K&(^U^F/[./Y3VK(S702S4FO.656GN,.ZF)?U,Y^",JF0UXJCHVBY^!
M]?M:P]9F8OSK<-BCH \1>J1)9["ZM-"<R[B<:+>V]$_5'R4->B'%5944 O2H
MS%#+M.IRX7BQJ\PKV'/<=T<GW:<4V9 O'!+7O8GKXR%Q_371Q+=N.3_;8#D_
MZ[.<#VZM5O[NF#5?PG)^WK:<O::TJI:>[#5ZIZUHH/C)5H!E_;7B#E\XC?\%
MHPZWZRJXF$.8=5FS#7LCLG=0Q40H&))(-EMX$<:_M+V )]$OT7]%)R<M6Q#L
MJ1R8L[=4,;8_F:NHQHGKZ'MK1>+FPT-+4-W*:M#%QWSQ$VN4UIN#,'C.\PV/
MP?E[=,*/.CRZYK,.#WH?=E>TQO,-6N-YK]8X"+3&LX/K:XTO/-,[8#'<N/GT
MU3J2?PDU2@_=H$=M(6<5_<CMQ5^EXS+-,F0MSY)T0GKRG80!K-^N\03Q>"O;
MH'Q3E('1P(/6W<F9;=&Z =Y@J^:E1S6SF:DTU>J+F;AFU4=/=B=4<84XIU?^
MOISUR'/[AY9 /WEZ.@CT0:!_#8%^N(]8Z6:Y"^Q(&'3T]AB:87A5L&>S>8.0
MWLF9W8"0WAFBD'N2;_E01-S 8R*.&LW/Y8[70!!1,::'781P09<;]S /U:7H
MH=T*\=-_@7GB'($9JLAW;&[7.YH.<?;C#[^\>GW$!*WH;MXL&/Z0J/AM')/Z
M$AC=O *0ITK MLJ;@O]JDGF>_M$8VZ(8FT(?ZYOU@ 4O())R^+TVR-+A*R/@
M*^MVMFDJ36[N%=!MR'5\1J[C9,AU#$1Z7WL7EF;*N?/QRHM )\T8S^TMX%$;
M@^@8T$/1-F(6M4E!0@X/B+B@1B1D*D530 C'2<*P_8)1^RDJM'(//QALJ9O]
MQK^RV@.L:6'("DI C<S(%*'"[U"'';8(4]2BLH3)9:P%,-/XHG#-\[)NU,L,
MW"([-K>KLC_1LE@R$T'0$^]R7F2.)H3[JM%MA2/13E I\,G"EBO;BF"M?*IG
M.]F^ V!**+6KILDS%!1(R0AW2$#1D[:$[-KLSLZSIONPW79J;IMF<G=BE(<;
M<D[V#^VDT^E!"/+]#$K-(4:Y&W;LG8M-V1CET7YT@58'7"*CB8*HRERCW0TB
M5OK"B&CWS1"^MB(?XI1?!,(QV-4WLNQ]$&JVJX60B2'BIJ=H*XA#;2O(K>@>
MB4)MO2R5\F?'E?+2=@!Z+[Q2YWB,WA=K"6Y//Z$715'""^-[7K#"Z!I\X,XH
M@X9<W$B=N:C&Q2>:5BDW\[@MW3#-'^;D6@/W3:ERKOZN:K8>&:$-4=;;GXH\
MUI-GWV*C'P:1.53;A=#O!U=(>ON6T=$FR^BHUS(Z#BRCPYWGL!N,HKNL"*U1
M=+RUQ%$K)>/03')">KT%WF#][,;,_J;UTXHIV'B"SQ=)M<]]8<5_SPPRI-29
M\80#/&] !BR'X;U9BFW_1F(WEL_#%J"Y/-7_BA?+[SBB&U_$:<9(AV51U7ON
MBD7X!.5 .GJHNG<PC)UAO"Q3,OO:I O5Z(K"=.74IMW#9 H"O08[SM13GW8J
M%P]C/=V/\O\Z/7C<6\=[Y7N[SQS3)B]=>3IWP]97')X\_M):88@VW@35?,V-
MZRZYQT= Q).M0K9=1]ONFCTI]"M4'4[T7<Y-WBHF718%E(\GY@KQ8EH<(VP@
M7&"[-(F@!Z:DM(K+/4A/FF7$Y$4=$J0R9/G@$MQ[)5L'W,!GX 9.!]S @!OX
MVKM0-:6RJU9;V6<D7@19VU:[(]?!?5(V,]\5W6@3B\D%Z6[P)[!Q2>8$N)/V
MLG21"A2^_??20&E[$.#FJK5=7,^[$_XYW@3>/^X#[S\/$V,G _O-K84\3K;1
MWW@$>]7E(1T@Z3LYLZN#'1BZA4=H@5@9Y^@KO872Z'K8JN'L_=5M]LXUISI3
MVQW_E-8<T@@2V9"0"!]=17:+4^KZLQWB)C>?4"PG .(5DA*+F'0)ONN6%I2.
M2W)<%C'N1D/X'EA7-P[.J4I'.6W^:%+U8\&HB_8,L=_"G@%;[3VZK!C7L84'
M^N8SC/ZZB!W7'TU"/=VD9U!,P>O"MG$>OA-3A5:JFG%E+,C+R[]']SH(\^)Y
M44Z?'MVQ^6V:S6,;D>^A:.VP$W?94VEO,]_QIV6L???\#B$)X^2JI4EN:C*'
M'IS9/TA0)T'?H-N[4L^W2(2#C2-\PEV:ZJ/^+2CQW@Z$(8[TA#HQY=H)#()I
M]^:W43"-HG&39ISUTO(M&VKEG@ =U,K]_:SW)^B_[Z%0"K@*6AM\%O9*ZR/8
MAO$(I?L.-K]?![QSACM,UW30;6<H9AFU'*-Q-#%9S'RGG6J&DV^%?SMOF!AM
MT@M-"Y-"&^N-G?HY^_EGZ!=?LSI8+S<=LSS9!%D[Z8.L/6W%+)\.,<O;BEF>
M#C"MG9/'.PO5\F*R3<Q\UQ64SFLO>IMWP56  TB+*(2"6HKHGH*L!B# 9P !
MG@Q @/O!VMUOM)QN,EI.KR)+/CKX#):TP6CY/*/ER?Z5)(^OSM[]!0K'^V_#
M?#%T]:UNA($4[&MIO._1BLJ>LXGX ''>9*A<E8/%Z0(-Q+J< /JT+<!>;J+G
MG('@3H7P**9E3+^DC?GHCEF3.^L^W'HB">%V)EX,FNA(1'ZL,C9.DF9ADYX*
MX/YP]CYZ^<O9WCB5EI/:=B<Z.8X>?7CY;N_D^/%^],,G9J6)9^19SMSM\F?N
MA,;ETHG)(,%1=5DT-&7I)!5SL,>UKL%%M%-CC O@WVIMN*XUZ>;$;M@3B+NP
M#7''G9O?1F^'^S__?#ZH@!M/\*$?%3)[:9[6<J#B3<ED;;UE(_[]C:&7\YB&
MG!0?4T[DB1*QOYRL<AIS4O5UC#8%SB^?9OK2W#0:K<17-)X[MHL?["FUM@*7
M6] (UG NDBYRPGJ!(CK>#''2U-J45=O =@0YRC:TGD0U3M=8H3T;C8'40Z33
M<2/1IL3]W.T;S=\%Y,QT'4;T5L):(IZ1-JIJJY^6I&MHA6?2?CW#ZEGE9RZ*
MC#NY8Y=F]*0JB9>&L^-)5E06MBUM1-L("]_07)IETRA^//\WZ]^D*4OZ/?><
M=Z=,VED#^:/U_S9EUCD[UY6,5SNGSQZ88+S^47U+.^<BI:?0\M-ZWZLXX: Q
MK[V>./2P/W$B8RY]RV>C:!K7("MQ:92+#88HXQ%9I-!S1L+%5M2%XA&]C^59
MXJHE<SDF="<]P-C:-4@'NN+2Q!]S>N&(9&J59(Y9< 1"WSA;,9TD<\V9/QH6
M+^@<.8.JIP&EBV6<ED(1-S93$/>VGBX6-V=646"7EMI5/DXSH,*B'^)D'JU,
M7-+K<3,3'IZ.#@X.K#;7Z?RZ?[[/4DY)+JW5CL54FCO/4G)\*$^PN8WN,[*4
MI2\_@)L?BWV_'[UQGBK^1K<Y/8./T++_<=\=4[H/UJC QQOQEQ^;+#47BJJ-
M&[!)A]__O$GF0;@BB7/G20(*V_%CO2/*00UV0UN[WWF?WO%L[=/GI]^J+J!7
M,7"8-V?^40:X;DB<M5).)P=[('.$[4/.+:\3 ]WU2&CQOUQ1@3$(C6W:+XMK
MLLO'C5+[#'MZY^9W#4/YA;/[!.I-WW)A)JWZ!O[H13XU953DN)#M9O#2-621
MD+5(!R,W] ;M]WL9PJN6\AQLEZ:<R9MR8R9F,M2NW.J./?OY\.#0D;]^" %O
M/7QA+Q7WA"_X+B[)>:Z*?.W/MU;9LOX1A\J6'98?OTG,5IU":615&12:P 3E
M:A/2?I-T F)@FTKA=H52(46V$&]/].^8-_1:TGQ)L1B3J4D[=%'D!7FR.7<G
MK=-Q 3\6+BT3\=7@O"2S[/SM^P^'-AQ+XHB65_00]S"O39^+7J4T\Y@+<@(/
M5GSA]GSD]-3V=1$S;6Z*#;2"O!6L@+CJ.V23[8?,&A*#:_<P3]6[(EN1'[.<
M!^4'E>Q\*-Q2[#9FWQ;+TWQ:6M"<;G 2[GS.YO&%"8-1=>')4!@5GU8?<7&X
MX__J?ATI(8K-XX4ERGX<+1X@\*ZTHE^JIJJ@#([]SQ09((G2#<?B@1X+R1%T
MRW]2H&W215#[$S ^=1,'M;9;O'[68+26,I!M/DX+Y4[C&]DYHB>#(;7 KJ6?
M:60E;?N\:"HZKK2QJV:<T''.C?PFGM!,TXJ&SS!(Z)G^VF[WQRT9<G4?E[06
MR[E!LL)5C\:<U"BK5.:.(X8^'HPSM,\&GX>61?"1[!)XU=K_@SV^8-RL,J5M
M.*[S<67V)X-"4P;'<WTIOH&/B+C5DG&TUJ2]@!R$:JU@./@>QK%^2;2.T>$Z
M >8@F9BEX6,9T:;,-4#&I".717O(]TH&#>C,ST!G/AW0F0--T]?>A8_>O'QL
M9>HH.GK:HS7@29D481R3,M. R,KC@V@Q^^?'6?3Z?\"PA"@Z].6E,1^KZ-$?
M)Y>/64'$)$MKJ9GEOXN8_O_R_SH\_-]1X1^&IW7UVJ/S%X_UV9";]M%'ZX^N
MP/$4//OX?X,7O32F=QYO7F+02L.W27%M(J52-CXH0'F.S!4ZX/R%CLXJ'TGS
MDMY]0?\/963+6.A37Z0R26^ B.'AGAY: :-@D,*HREP*JJNA>_Q]3KW0V'14
M_(Q]C+<],J\N Y.@K=,"C3>RE<USVIFT#\0MYL=T^FMV=HBL$T[&4C(JG<OX
MV]-%-%*^"(D//X>N8J_]@_VHA0: ]'S,W<HX3]YV8-8K))X<?(MO?71 _WUT
MM/]D#S\=[]%*3N@3C@LX&K;2HJWLVP]ZAOL/]Y]MO%._D5#UO_NW>#\O87Q-
MT\SXJ:U]>T$K=I>B:I9++A!D*H-6(AWPLXT1!4134G$!74CAI0YF9V!(5X'>
MGVP"O3_I [T?!95ZA\^/;Q#T?F<4R!?!O#^U4M3'Z3<:S3T:IA\D??@9(.D!
M!W)#.)"-@?Q=<U2&6/U7 XQLCNLQCN3*F+9$()NJ$7[E.H9#CR+>;!7@)DF+
MEM&34X9C"*)N)AKQLBC)8JKD I1 DG==VS8WBZ*J$4=8H,R>,^H<E)26-R/D
MS&FM7?A"38"G/FW-N6C1U.&C: P8JG A;C@HP2),4M#JD^;F"8'^?C&F-:6W
MP@@EZ2B<I"0UJS#C#\K2.$\XZ"^ODJ2_P#PXODEFW\)Q%>2SAENP,@X'V!*%
M%2Z*8A)5L"1 ;5Y4O'R+@KZ!7J" %RF?S;&P9*U,]Y*XU.#KV,QCLE#1U2>M
MJL;(4&,._X016V=3H.P"]HY0:2.,A;[8&.>DC"\EGB9;3^(O19*:>K4?_5C&
M$]X'HVA<3/#G:9,G/L5+HZ]'C'K@<%LAV 4:32;P>HG +0T:TD[;) NT<!=Q
MN1)04KU:<O@N2Z<<YC8)^1G)*K"Y?+M:^A\?) DRY;(#AVCQ Q5WO\UAI%N4
M3&5!LW#AXLS0:;U"'/@]V'/1F59]8,/Z5[!\3&V46JGI\7\>E/9D_S2BF66X
M\8P>"7YZE*;0W20S<<3([C,(%4^G(GGX"%Z1D^$7YPV$%4X!':??Z: 8K5UA
M&4@V&:3S>$6C>W*P?X4@Y-.9?H*TTB,<"&6 D"P6+D_QFO.:YV]#SM-T6L_W
M-MPI&9X"(^_.>F>\F7MR!()6 YSXJY$?YWR%H+H-[;&D!D&6Q3C:S6"QF85@
M/R?QBA9VC_[CQ#RC3;=L(@[3<%>&H _#N"GI&UI&+O$HH+Q(;5:U6="N3!)N
M5S>S.++M9T_.IRWL@JM<<>*!GZD'L:=/W16G28@Y2?.(U+!62/^>7VML-S;1
M-\='A]%83OG('<#+8J^>IR@:IH?2UB!7GD[:N"AS/I9X]!L&7 7K\8$C9<MX
M)217F(JL6B0Z'VW6]\CQ7D3>!J"S13K3R"+PY,."EO6I^RG;F58;CG=IVJ+%
M9Y*+0,1]<[C/+J (.?X*IP>#-_@%O<$O@-L:C*&=W"\;$24;01OB^WDYTELH
M8(TG^$#P+>B""[1R$#&ER)0X94PHZQ3KU*&BP,JR'U@,JF1QD!'G_!5C#JU[
M#XKEX#S^R)JF3&?IA!/T<#A1:2"^T84VEF<MY;TWEG67<8:;$<:WA08='\DY
M9J"B95!9D21-N>^;K8Z-M'95?]+R(HN_-X$3//.VI0. OS0.CR-H[4_PF@0J
MC;?(TT;RME)AWEZ"QA$K"O:, MF]!2D6O64![M;.>IYPN(N25\V8I2R3@4?)
M27D[_?TMC[Y7$F-(=']&HOO9D.@>$MU?>Q=J_ ?X*<C*JAMH%/N?W4MXM8C_
MQ?1[_.J:(:.QJ2^!2ZPY[\RE+AJ[Y+W-;RAR9:JW G;P5&_V,W_@6$E:<=,H
M-4P6!2GT%?N"+CL%=^8J "I_L*6O6O$]Q+DL:I':,B7[5!NX67#9B__&T6MF
M(LC"[%@5^1WI"O\ 3M_K&U;9S((B&B33BDFQC#4CCW\ND&N.9P62^]B+F&Z#
M[%N!")6]P9DA&0P?<=O)G%F+0]LXJL9B;"TGUCG-&Z/NJ<1F!64;EOC(2SKO
M@*?*Y9R*F5P(?:%$BP7C;Y \  30SI/V+&K/QK#V)%T8E[1<)1=#SIS5-IRB
MF\[P=*,G/7OR%6;D\@W6XB299Z.2UN(LRFQ"+S%KI:[;S-!V9>'S RZ@#>*<
MZY6W6SP38ZMZUTL>#_>/>L*HMNG)]49K@R[\AJ.#XX.>\-,5"\@^$9>K,&-T
MB6B:($_U!QN06G].JPC8RI<1)UA 4V%(V0%6[$(_>"P.+FZC4SKB;$<G[J21
MIF].CVST"8D?F6!_1"<#$%A+9UI/XX&W\3+?/#MPCQ6B;._.M1_+0>;CI_<K
M]7*/@E.WBBU!$ZP/[W]X<[2;7;"&B-,7LNAX"W!PJ2Y).".53O\UG$E?(BYD
MN=K$^*IL$1/;/L@;N/90:9YS^>!BT>2V0)Z3T283&P7> 5D=:4(;+O.!>JY\
MV-?-V+J@C^MM"3)!?HU6/S/7VR*=*>92-4)%RRJ#^KU!8*5]N2V$'@4XJN6<
M[+MD5</AZ)9(\4WT /@JI19BOY?DQ824&%+LFK.8T^C^7,T0(9,)N<*P$?"X
MODR,ALJD<HX=D:LOEBE2_ AS*>YPG=;(ZD-UITX.%#>:MSPJWI;T9^<E];A5
MI$B%S^\B+E/IO\T5)[;K^F6A(V+Z [M1'(JWMT!M2\Z&QTW.&P,Y]Z-?BEK*
MTR=%FS,RMOA,>ODJ>/5GOBY(:#'\H:FWYL%:F:?.IZ,]/T_'7"_/4)64*^L[
MOJ:;GW5+Q1CRFPCX9MP@E3XPN!=&X"-APXKNCBJ:6O"D;C3[T0]T :?&.4I9
M-;.9J:Q[%$<@IF) N*8 ?6ND .?AAQ44);JU%O8 1J3XFK_EW.0%TFV.^VKS
M>MXOFV+0)Y\3(< >2 JN*\#QJ,FWG;DV7> [4<DE6XWVXC:, ]*2A\><O@U$
MTS0M:?N93S$*VEAH2*)6JKZE>Q"]L5APFUWP&B$%C-@%.^W8__BPZ13D&"4$
MN9>#+IN.H49IK70P3ORHUK(2"$VS]T08#,=A. Z]YA5H;[FFTEE76;I,)^HM
MILM";:R@<F!9!+^/?H@>T6]^>*S;'!M6!IZM5!^W;2E?F5XM'$J MSCSP]"C
M?)+K8ZX%YRV%N;7\? LO20C0B$NCMABK<ZYKH6/+#YO&"8Q+'LX#.3:#9_K7
MJ7$.#HX^EQIGM_S9 4__M<XF AUK)#>H^*,]-1+/EREMT$YNI$9)G B8&Y"&
MC>PVR$OA)1,7V)N8C SETL;4757\R-7[<]?<:5.Q!RG;FD?0]GG)^9Z!><YV
M<%[0Z#.%KAH=HO7/[T5/A[O&0[=I'AJBE?R0*DNN:17)55\AN0*KEV:7Q>.B
M#'J'GXW'_Y.:_>@5X@@%!Q^FF([4B$IIU\;;:."JC(TXA75:HR1,7IY\]SV8
MELD-E)]/OCMGYI<9* 0SVI9P-L-!R&63W>OE<\<WT.'S <UQ:VB.72BP?;JI
MP/9I3X'MT=,37V![?'23K3"_RG??41#/ Z.DO*K:^-E^],8D<[*(JH50[5LR
M@\+EC+R!U$,@R';-S?EN0S[I#BDP00BU&Q3D!7XPU57>?O3ADI,W-&0D'20W
M+ZQ6L%QH&4R9,=+(D21W(+T!?YUCQ]5TR:N79V+!&!L\IUN9F\_N[GBQRHH4
MP.,Z1EW,'XWB<Y9%S2CCS-.4*8&N!?0F&?<X=PVK+X0D0R=B"SPT4Q C#MJJ
MY!=\ <IG#7WXA*8&6PQ]*-@8Y-Q#H2F%6=;4,5+])8PS]0R*4HIJP<=7-C-%
M< 0<FW.3+84+I;14\T+WA62=XH$D1\(I&4P!F)+:+, D7:Y:C,&3@CYIS0AO
MY+3FI,PZY-=,R&5KFD;L-TT$:QU;D 1^MZQ6-%EI^E(:+6K%94F9CKGD=+I'
MYJS)' Y,3%B;<5%JFK*W_B@PIEURIU.N%\]26]/+Q4E"Q&^!YW#;>( N(3AQ
M>/'[%9D:Y-NUU_.]%)@S9-!IO$ID4RL\NEW6.>2_E%A.BT31A-$X*Y*/3%*S
MRH']P]XS.6GCA(LT,Q.7[(VAQTM:N69IP.NE%3*K$)@BR?98DL'WC)O(A9C#
M2/%(&]SPHY57@+S*+%XL[+F@;5\:M'W -1=QE30@Y)VL*IM>'$4+>@TI:;J7
M?JVA"[E9^?[HORP?ZN)3FJ2H2S_+N)@$E  BP2L3+B>G:D+YI:R^OS? :?D\
MD&/OV9[995W!F76F_%&P5^WD9?AJUB!5$4UIEJCCE_<';*CM2DG5 X,X>)CB
MP/$DM(Y<:#P$9Z_=K*4TRDT6+>>KBJV*8*MV#1N;3UEO:1$["HI K><Y)^W3
M>M5^J8<;6U4]LIP959)R2A3'&%1I2_!]<6P2L2;A#OT4+=.DYEXNO[FQR 4&
M15UQPK5AWO1AJ&>6?A0BY#^:%,;A9,):-"13"V<>=EWA^O-NZT8;*\U<9YE[
M=?R&/-%?+JYU_ND+:ZCO)+AQ2 9]1:J%_X[S!AX-^EB.VHTLUSI(<Z^\:X#&
M4D=AU%]H"E0,F6V38B%9IDG1C#.S-Z9=2C\I528/4YC:1L)S3+?,) <%.;DG
ML<7.""_C=AI*R-XZF/"C)Z=1JV^V>,(\9) 4UMH^Z/D! R<K\C*+L= &,244
MX :7W%U0&Q3J]7$>DD<_.6F_1#5/D<\*2//7O_S/VW__L&<'SMT5>>H"&.+:
M%PN5]#K@[-W;'R)S\D_3?OA(/#AV!]$X4=9X6=*,Z=O2:BSIG;4-6G66#$I)
M>#[7:W(0#&CJ-$O_M 3D3I:X:N/W8G"?-QP?^[[X1"OVZ,7+]WOGWS^6@00O
M8I"%?9M3>-.L297^>A'/N,5P6G!!3JEF*D<4*G%PI=2@R">8G U"K)&@]W5.
M=4M1M<QQ(57'-U!@J1&E;_(8FW)&>OZ".2UDY8YM0TYV[(,3=#P*\%C!]_%?
MQWUUZ6_)/!R6CU"""94P$])>^OG##]TOUB:&9[/#;D-+9][=6 &YN>Y *=/^
M@P9=2Y&\C%P*PXKE'C.)RORY#M%'C4"J2Q>U;SUY:/;&D)^S"WIT,.3G[G1^
M[I[8,6?O7Y\%P>Z0(1K2<TWE;FC0#?/FY7[$3X-W^>;]:Y+E.11O97'E"(F2
MW+N(JX)T!33*Q"PXK#0WBZ)*)PBH(C1*_ZZ5VY'4MP^RZUBK3?UM>! = +ZP
M=W3)M!-3@H':FV3_\+:8^)RFD68@I/L,<R&2V41VV_'XZ+L]&]]7%(_59EBO
M*]9I)#$CGHAT4^0 51P&]-FS+O(]?#?R@?>CGXI+J&ZTS*J U+3$;[HB>Z7)
MV.C4&T!6PJVFA;M2.4>@)"549CZ1151)%4T8TG;+%1A*,P7JL\H/R-#)WBI(
MCTU 6$5N=)TR&Q?PF-6:EXTQLGEL*X-!'ND--<.:FSN)Y=U^(AM,-KLYKUAL
M %QLJ8H&!N=D!W/T[N^M9&O9YH7":/.]H&;'(G5T"@A0FLQH]Q1?G9W"\N#I
MVG(0G)Q%D2-/PQ9[TJ&DER +4BMD^:?5G(8S(PN02<PU,8;=Y1^AG.M@#_7]
MOTNA&4?.BE<GK=2LDO@SHWSIJ;&>/!)QKU^^>3'R-&8Q5E8<!6P+$CI-SEZ(
M)<B/I;9G$7^T1BQW>J,A3+3Z9)#D-^V1PJN4=O"N00\7-0M-=QSAT$("/LK_
MZ_3)8_ZP/8*\A_A;>R8C&Z]@PYX6/&HC6T[\BO8I.UXPS/G\MDUR2QO>R?#)
MY;XQ#Q?^(;E&"D1H&,*PN9QHO)IKX"H:,AHN2.SF4<7_?:SNP27B[B9>! X2
MGQ</F;29B#C3>"<Z*["$=GJQ60+RYNNWH>,2\>)X!)I?,/E,SYOX4F513/?H
M?PN'A]C0^>G[6-,W[&X$G:K65+/[JFN/L;HF<--(A=(]'?^0#VHG<A'LE[';
M+[:.3WU1NQ<";I8K:!8#)38.)\B2 E!#1S%H&T?2"7([4UW&<#Z]JV>++2,^
MUPLG,K%:V'\YFJ(P[% .2<8>X[J7Y^:OZRA"C^,C"SK>@5?WXNW_O'ZY=_B<
M'D^[E3:2#*&:IU-'F<@KBW5?BQ\XJZ&_>9E"B[L-],+F96N[;;1ENVTF=.,X
M4\^QQ[/Z3"2K_'9&A%\%EGNV"2SWK <L=_(\Z$9Q=/CD^F"Y+SO5.^"(?1VO
M=&<3$%<!YIZS1.@5;%VU.#'>Z:D42M>N$U;]M7?X'K=[H0\:19_XLO@[@+Q1
M&ME1,B*!^N73_GT!VT/+5UH!RMJ^)J,U]Y''*3Q76W3&WT$[<8F/RDI,O%%!
M2Y7<O4J 05PSFK* #5_#?SP^Z1.ZC_Z3'D%N%UVU_%]9_1U-]13ZYL,>&BF.
MHO_\S_4+#@[]%8^']NI?*#?X+K!17M(FV!5M>$\<&I$]KN35T7JPD]&4TUA\
M4V^^][0$!R\<4F5K(@\6=3TO76N*)5BTZ5"O,A<D.J>32F+@S,<S/JQ*A"I,
M].\TAT1\=+[Z^)@<:FD55X#;#09_$K,M&-30, ;PTG1,.51D\239<ETO"O/N
M"'L]KH.Y+DQ#[@^-I]HC<9]HJU4FUP68@U=KQ,TUY#-A$;AP-Z!IP#K%W)QL
M+6BSO2!76U%[]"RS;<B;N6GS]KJD_>@5LB&F!.!#S5R8SG#'I&N+^)C2QF[1
ME%CS5PFJV=A)A*8*PG\\EN #M_A5- >F(3L!U A/1N+I[JTRG:S ,L!]N %N
MX0QF=VDF\8*,;4^V)T0C@AZUKPE7@K^FY;JI;'-&?"GY, B 6E(#KFBV)"KJ
M=7%-H7S/(5WT8--%AT.ZZ)YY*3>TS=;/R-\YM]$#6;4;7;1=6K.K(B'/]W]?
MSOHB(?J'=MG@L],P$G*398,/S+VXPO,_.M"X>K4YUHUTG7#/5;9;#SHVF"F0
M\)]M@-T3U_W1?\(=UB!\Z!"W/.(!+'NS+!AOSD_.NH#8+^ST/KGC3N_UXPU8
M['MR6CEQO"@4#LEH!.\VMWR@C%PN3LY=CQ4M>A\X3@XU>\=6[6%NB0P5:T(B
MUG&T>[CRKMW,D7W^5I \8#KE[73G5.##W!["-2<-::4[KR2SP5/_^43#(8-P
MNHE!V,81N_M14?7MF&,;,M J\K8=(_S%%ZEF;O>CMY)<.3GIH3U >"L,8G(K
M9%/&2>TY] 99M[N3N]9F5GQ4*\9+EUZ8<OC*=V)RU_K*&I,/R(_UDW*F]YSD
M%<LT[2 LR*V%X59S2+]R.019T7L2!&X!IS1.?G(R\M!-KM^Q^0LM(A> 7QP*
MF.W%2&VF"I!_LB9V?6,"D%*J#7/>_5OW<X!7<N BTL*IUA0QY,9CB1P6,;9"
M>=F45<.@Q0B??J]9BK.Q%&=#*JB%SQR8Q%]>(ODQ687"4Y(&H11VE.T!T+0U
M5/KS-,W,0^M9>JM^XADT;0'4T \+4(P 1"Z\_J]!%5*049]([NA=NF3TZFZ5
M5MYN:N/.Y'B_<'*]LS=V:TM<?QI#M>W-'CJK)E !2=9\+,!B:$A/$;_,XIKS
MQTC[<XXUT%DC1X@M@!Z3<;?5M+W=6F0$K#/5.*]"8I5V>Y)Q*E*,2S0%=^U@
MOS)4?J6R&C#/E!):==^NC$O\7@5V2O5*O&3+05]HV^N^<6X%K0%-WD,$NFE^
MC,'U<%"+1#JBJ%GI266YMPA*&935I3U7UZ6<JRE:5+3K'5OL@B_B!"GUF LO
MF -W5>.?O_Q;+ASYAN3T;Z5XX/FT>\F3Z\66BZM\M3PS:K>$? \)"A?*40\%
M3=S4A0[3-CNNG!F2<8GLS.XMU'"6=>KC!WVKT3))? ES9T7F)ODHA<1V(ZE%
MTRI1MK_3SV_KAL]?OW_GG-K0?<#?TADIVLY?1]H&WGT?-]61%M* >R=;Z3H-
ML(('"RLX&F %=[H*]8IT[]'!AG2O_4,;^'[RU*=[#YDR]J;2O7?&D/DBV=[#
M?;JSVXT+$EWDL<:!9JX+:[\6#FP5]$ZK8W'8?42).R9G\9(4F7:;U<['S8+4
M0Q#>#%2T5 M:TV+PB&_534#*__F(8\%O8-58;?YU4ZOWU8G0U4Y= RC8>.'1
M"DSQM:!\)0"-Y]IE(?Q:CE?5)1S"X+U0+AJM#O2'F8W17M,^(KM]B1P5V^HX
MJ]P2SO$YQE%2I@P0B6;9"@C?P+P$))?TM QE@DJ$RCV]63K6T7 R8FPB.Y)B
MMT9QDDZ06EGVS@<AQK)LEO7:] 6M@G9S])JI*5W\;<UGTG:,><1&J:0XT"<N
MK+UW1+'<2S"Q,.,@"MDII=9ZYO[*05C+)IG+;Q4 SN1XN:P$/PV 8M\&N<2>
MK"S>^OD#,Y+OC-#X"B+[F8ALN&4T6=*;@\"^-8']3 7NQMXY(GVJX&N(<'N&
M>M4F!C_7.@4](AR(U9"/K8D'>FH\*]"[1T)$+UZ>/-T+OK"5J]R/A^2,]<U9
M'"+[^V<<E!/09IC$8>ET("1=FAH--0/#BYD4Q)Q;%]C1HVK>U%S$'OVO_^OX
MY+M)D?\#I!$US4_E+O^>.[ME-E2&NF",]%42S1 '<2^OVAUP6?FA';AP@*_L
M=*M CP@'BMB.? ?GL;]?]00K=,WLRP+:".%50P"CU?UWL3)<-Z$!H4MOV<H>
M0!_;,8T M?U@B[O Q1P<HS'-0 :#%HL<1Z(C)+$SIP0<B\=T:A#*<S6.DM57
M*AC^X'XJ]$E0X+Q>J/*LJQ!1H-0"%M#O@D6PK5>#4AWMG"I!2@[NM $./EC)
MS^$OAZ ;2#J6)DD9\;D2"HY*!\4<>G8+=[?<ILTL6T79W.T'_,!?82]HS.!O
METVDM[/.9/^3ZT4Q@HA$I\DER38KC?$U^*_SO+C0&ONC@Z.#D3*-R,YP?[TL
MFFP2I/@FDA MDU0JF/0+T.>:IWD\TAEHKDGO+@U_T)!#N_L@.9NJX6T?3N/8
MG,4*V ^&A> NJ.K'SN8(&C,YNAK1#4IT*%R*<JQI-86R5C+[_%JZA,1$KCP!
M[E66..;JX=LW!N,D/W"1UMSJ@+.C/C.,]4+0UC4$6R$4.B]*MH-&6NHORYBZ
M-2$)D1CA!"[&6%7,FJ24N4!$EIL'I+%VYPZ;2'%YJQW5OGLP"/=8\@#%U3BN
M0*'G2!K,-;B?10\F$2^7F9I]++:"U"Y$9%'6=KH\?Q&8.H-?]\\?F.4V>-N;
MRKR+!<EJV48?++'TD&&\(YOE"S1W;#=:80M*TU'0;4DM[?3RWVTJ3;EO27^)
M*H<&8KX9_HFS1RG+M"Q,[74[JI1F45P$Q.6)5+!RCX5]OU&=3>!9YUS[]) S
M?L1$\=,TBQ="6E:&_1R@_O>J5=XDF6&6'4D;=<=$AH3(_[Y!:05P4C;DG7MP
M(_)@:;4$P,>R%M.D_]GW"$L"3YIA)@TG7 DW9^%(X_B%IU64M.X\*(E68XX-
M+DT@-J4U9+DRE^,%_HLF;!J S"\MF*66'R?5,R9/Q)CQ*IL^7@8R>J"UP).3
M!+*CTHZ&G'%LA1NX\D;6!Q;#R"JA:8,B:^5R@]5#7SS@7>/'K<2$XMPL/T^9
MDIAPBFR3)JN5-F+]C0]-PPT)/)? .QX2>$._OZ^<UMK4XO7'\W_OEGDUA$R_
M"F'.!:(+YG*W]L)@:G_-UAE-%O3-Z,207K1:3\.8^IFC2H:LQ59,B>3+2!#C
MB$;0O4K4*,DU^JL%Y=GG&4L?)%TIKA=C$5!6WI#)M<>1#^F1MA:0YC"*QW(A
MR/)GFIM%/);@RL^'!X="&(:1^:F,34)FJ3=H.2?5S-"@[/#IB%?IIG@6[XZ^
MNN4M^*MC.::=MW XR-:'X:V)$#:SN7WS]." _!32;Q);:I9DBW.^=<5^U@C/
MD/WWS6EP*6JYW$-2]V7Q57E;?'.TY>*@/\91AR>7QJ9!<?)H9JD&QO7FWJ8J
MWQSNGT9C/P/G0P2G8!3$!T>=(T$[FIRON2/)ID&;JD8JW:X!#Y&#;GF**\[K
MF)&>XDF6M>OC9?YH)'HWA[_'U1?:S!,=R"P]7N]IW'"LWC8U/"O[(3L#N#3R
MWG"U$&?5[CD3^A7)CY2%4%FLX@Q#O5].U:"?/J?S<'N[_@YD!4CK-2W1NP='
M3B>%S.JVZTV;.?.J!L;\U'=Q^3'-JR+O_[,$F9#([*O0>AEHMJ2HZLH= #YS
MD^C)P;?(96*X>-J)_-B@1^@G9.TD5F4/3E5DB,:,3;R>G)#'NSRG%H3U,O)7
M ;U\^ CD!48.TMQ:>Q$1].V::8R&@=VTB[Q=!<IP9!_HD;VFWJ'M;\^R8JR<
M*KB^LM&#WE119N*)S9JNWX^GKA]-9YI>??-MRH?M^M*9SI 7<O3_^GKQY6BV
MT05OP7XI2-(@.Z[CP&GGZHMISR'G64W57+B&M9#V; H8U[%%]^V-5WL6Z#>.
MJU0,&(ZSHSF+MQOR@EZ5SP29RY>W,K\;5B,L('+"[068)W,M%[+F6M?TP"AS
M4T=5G)FJ?QZ(^],.DAX.(B3=VG#07]9FG[\E5AJ&;II+Y-MTL_.'SPZB2;RJ
M_H$D-SE; !YCE#5M/^GF'HY]4M  D W/C4UA+%&N0W_J= RPEJ&S:@<)O:L2
M^@L'57X$-CU'K+!W2]Q!'<2N?=**7:15-.-Y2L>(6+0/S=$8%G,0&X!KF.C1
M?Y^_T(Z/]"\^L.1<Q=SA)W3BJF;L;F(D1<'8)A.4=4$(_"Y IS* NNY'Y\T8
MO\==64J/4(6DD"+?P*7C!:=RE!6$ ?D_<]\NF$$*X\X"M+CK#_/OI S&&#.W
M167RJJG6[#S(+G\K*9HBNU (4U4!VZLTS:8B0]*A0/RPZ;%I@7RK21IM,C8E
M&5;Z\D9Y$1L$>?!@4,/(,T6,P5_.&,XGU'IIM6QJ(R-J)/7GEW":2N=KF>$>
MS9BQ,8+M$0B2?'5.$&,(@WDZ"#]9WQ^T!5NZ84_<1>GW4GPS&U/;$%(3M,34
M(<*L-0P9$!PNXQ?(=GL7.X)D&Z,:67HJ<C.$\[?-VG:@=4)/L6V&!.@9^J.M
M:X>3.IQ4=2QKP]VI&FD!CX+P^W-FWU[FI";GZ9*Y$,*I+G6J$0CTM+D;W9B;
M /FT?L)@[W!!8\;1,G$Y?+<O]K'D5<"%%OQJ\E#L+>QP<2]2WPJ:%:J6]S#[
M&HVL8D6ON:%%S*@=VZE0 ,BHKX]KB<L'Y?7R*^N\P730N!8B7S"7;'1 VWLY
MPZ'/!1LYX35WM!)_9<3L;]JA60&V]K;];6^R;T#\;0HQ;"PDN?5P6&$J,[F1
M]1Y;)8[C0CN?JU5&/B6:FS>UA.K98<2'E!R'W"G7V'E*5&_*F3J+3$NR.%U8
MX)MSAOT'$/FK/1&LN>98$"Q<3CI^B';H%>UVVE5K8OT[6DRT@#1++K8COIP7
M"XT!R-A]<UQP1$WPLU5TG<_ DW=F=#RN3/B)92F]YSWHF$''2+X!YA($PP<-
MT:! \[ZHF+-:XT)P?"?7LA$9K8:HEO/P-"@%/&TQD? DRE[;(:VN1(@0"$.A
M #EC*XU90N\ [FGVHS/G5$/QX&; =\UU'MQ5A+&KA(B MQ,+=_U.52H2F!6A
MPQ*.;%N('I*%28,P(,=+@]G+M/F9] F&[EY? +DF74)W"[ T@-<&\-H 7OO:
M"NUU'KU-ZD(X6X'/ZN+7)%&R][(#+7N[9'W10;")G%'#FTMC5]&L$&Y7%#0H
M3JUR8JH=7PZ> =^+?8Z]S<63 ;N"=(N#;]>79@SRAVV:&HF*,MO:_3)?AYJ#
MSZ@Y.!EJ#NXT:=@]$<4>Q*DBL W=M,75^D>:JHTJ&VX+*FFD:R.!&<[A6K_B
MFO/7/_[\PXOHV 4L1(ZW$*7=D6DTBI6%(*6Z0%+<^<W1P>F^AX4J3C3XC6M-
M#(0 1QB  *BLVJCJ(OGH6"V[T V)TZ#83TE*;7"*[K8,XPPP40R7DNB@L%#X
MAR873#7@.)1"EDYPE7,7JA9Y9MGD7#K>A8-M)2)G-,9_@PA#V-%U+<'ES7SB
MZA5BI;WC+#H14]94@G!2M+\4/_F5&9<677L\LJAQNUL6Z+,]";]A'.PNP9D+
MA .5>;9=ML <A*3IF\.G^\_<%UM#R_I/(:3DNF$DI+2DN:BS&3/T9(_]93K"
M8%?@&L1FLJ)I3.WHZ"O2=F465.RAI=NS3.G >U8G[V$M%G[RS=%IL+FZKG'3
MCY7N/7-K*%OD<N(R[P<D'QV=AI#J=4!Q9+'&^AU#\H(E]@'H[FB.\O1ZCA!E
M"V7TJ@!'!I97ANOWF*Z07;8M2]6!*5F(4H=APD.4 @R.T"((4,<N=MQ&^S [
MEN!\!+^CH=CNR/]1^;$"\Y-?\8WU\P@CQGA="-A <$OP^40:1JZB<4T4]@L"
M3-G>T3KE@23HEZRYJ2^+\B.+3]N0&50Q<5EK>D).9\I<N\K1JT%A,F'S63WG
MQ6.&M:*<Q;D^N1+699PD*24>@^(C3N;*[RQBL.1>"S6-JQ^*LHNJ[\%Y=5\\
M0>^/FIRS?G_G#EI-5C(PQ,A.\RJ=$>(!22'4J61[Z&2G98OGRAI6I"G$&@I^
M07[R!,AW*]AB4G:??'Q3PKY=.<UB<^G2/LP70VOW$1) [A N@;8!LPX\5[(P
M-KXJ)_U"SAK6-4K-M+8 X8#(."E!Q9!/-DC/4"]/XS03RIN>M0[BX>$Z20!X
MC8(R5-P"?, _'4OAVIC_JGG *"FK/_ Z0)6O82$'ZL.Q*.Y';Q%4U:?1>]GF
MZ]IH<30CU9CW3=GN5A1-P:STKV50<EP5@APC25^4LA!; R#TFU)TH65<YS>*
MYAHJ" 8-,.!3=QV?NNYY#!#5 :(ZR+\!HOK7(*J]D8PP%G0KV-2UR.!V>&KW
M\N&@#@=U0*A> Z&Z'H'_NR!5KRVOQF,ZO&>L@"00."L>DP/T?BB;@*\;'O:[
MI?M7V0/[ ESU'?\Y#!KVN'[6OP^=WP S.@KEH)VLC,S[\8RS"E[#]\M[]KOW
M;IG;:@V\:M&X<W1K6P?O;A:.CA#0WN20I X>O$6R=N+?G1D ,MR+O.U^W.TS
M5ZSHY^%DU^,RVR"R/;DG6=]K@V0')3,HF0&BNL'G=&4%P2TV.#AJD^IP)*J=
M%%%F;2=>UF&G/<>W!6D=.;[9()+6E@Z;A=QH'1#+' HD3<R%C-D'%SM9N/8[
M2B,MRXNHJ3:(SDW VKX97AM;NW;S *_=.6CJV20%%42;T,U]L1WCWA[PM5\3
M7QN)R7K\'6"5)]'VG1,]"B]ROW[\T*R V\>Z8IW[,:[7^DS="_VGVH\\?*OW
M"HG",'R)8RRL?J:T?*[!!KLF<M?//[^('LF_'Z_==,VTD5*[C%SLQF7ZA-F<
MVTR+9T&^S0+YI("*W45OU**_5Y;S@([]#'3LZ8"._7J,W(/HEB6U 63I2R59
MGL8W.E?OA%$8H0P3(2>7JVA59&,_M==ZFTPOG;NO\8W;K/SL>0T:&AVM/W8(
M1.SJ/A[2\G\[Q-V4O64]>BZZ*7IGE?B\-K<5J6I%$9/+FY&!0R[Y)3.SX0;N
MJW5AJ?*"="]G]'L>R?%D\N31#C%>%-SU2R]RY?D"=C5+1I[C!\XW\RTYK0%B
MB05"K?Y.M/\:Z?/$3^^ INK^T=R9Q+T2&4CT 2")RIB/-(AQ6K=Q<HN8)E8.
M8FT0:_<VV_XN(.;?XN4%V30T0^K' !42^HS':8:TNSIU(7H3;:YLH-!5B+1"
M@B&U"MDY2Y>);PG?X4@.1W+(JS,A3IER89*K-7.*N95!+RYS?]*"L+NDSQGD
M)QGZJHO1ZWTM$@]HF#OSG7D3U#Z3-6*J;8,UKC>N\!55OIN=E!3A,LUZLT!
MC0TT>PSX^$CSMJV4A^;#TP4$BH)\D&)G&>93[/[[P\*II5D=FLW;'G2:HI45
M\3C&A!P>WRS/X\K1>S 8O;QNG_:@IOCA)X7Y]@ ^/B$[IDS'^"#D>%V..F$R
MEK5<%QG(Q9A)HGUMI*;(?<V5=GOM7WAZ ;+>@"8"#Q"*<\34XK)<<>44Q+>N
M+8?0QB0[5+AO &[8!?E.JQ29E9YYL3OK[Y",'@NO/7K)]I->Q."*=IV);:8^
M2\=E7++Q%HR:R_R$WICS^[!0$\YAN87AC2[  GM( @YK'S;D8U#C74+XSUG&
MII06B;SV-8BY;VB=KL*H^$>U@ LC!RD9*2A!7'@#Y9JLX1J$#?IR#17G#BNM
M/-8,FP0=E<LT<2H<&S=0X<$0[#*/@D]EW#.US+0#YN!57%]V=FDJTWZY0#^F
M-<-\0/+B*R*V'!]TVVSC809$Q& >K%>(O;UG%6(?-EGKKJ:>/>W>>GII$^YS
M*.OJM$7LU:#AO12T]H4A47/?$RSL)EL$KJ$A3SK;-NK9*D'CXNF)6@2A^=/6
M_"TK@L=AP1V5^:,!5*)R(+>P\Y>-/#B$EZZ$*X4:V8K?/;11H8>.(#]%UK$]
MI&+/HGX=5:,W)<360N,B!PSSBR+QC3;\9,31DI%@"Q<Q!M&@L0$M4(:.55/#
M%H7\2':.M%*'MN5_=B9IRYNY1%G;TQ;YVE6VW\.\6<1Y2#HS8K-AOLI8V$L!
M71K/\J+"CPVW*Q#A[98"@MMM,]>;)@[LL-#\BC>88-X$NE&K088A9 #X]*U1
MMXPJ#KSS1Z!W3--R82;M*!_MDU*0XZS=/IJ54W>6$U78)[M5BBX:I^72[L$*
M*P*N4"U/4<.\A4+>4]FZDX)-'JV09%.%OVNPNO19^Q87;,YJHIYECKE(JV8#
M"%*_1.&I:=B,RTD-[ ^VENW\@)/B^FZ#>5N]/0'^:;0&@%HT69TN,R\.,+DY
MC8(>7'4$S2./X?("Y(H5?:R'*<[(J9FLA!C4C6D_^G6IALX&"WV]]%%>.^JQ
MJ5#DWS+:Z%07]363V6'=HSNSLK']<%K;G[^WC$8$I_-" J-LTA&7L/_'>I*L
MIUB9+KU"93N,JWD%MH>"?T.W9F04H@.ZWRJ5VKAU6F//RZ%-OOL>PZ?-(#^?
M?-?OHLM?)]\-EMI@J6$^KU+DBQ 79/Z2>V.E_688#M.CV&R89MU?++JY)J:V
MCI.D*">>_=)SO<C!]W'8U@G>*-0ES9Q5A8C*98$AXP/T,+PL3>F@I$SE8OE-
M6D8'.6-[+-W3R1Y$6(;21S1MM"0J[GGMWE3KS"K0< 6YX*5HT8[MLA_]5%P"
MT,HUI1;VI(UIP7] ]F\5RX*R+1P45*I"#G5MR9:5?[<M52'#(;;,0=S J2?_
M%PM*7YQXSXQ.U\X+!"3@0*/IDF_^I%XP%"#GZV@<J"#UC:)\?RF6U#QW7J#!
MJQUDY?W'^2OVQ2:#VUCT#=FI+HUT#^0^]N>;8WSKD$ ^JJ[\70W3D12<@;)J
M06.<VQHN^ $T8LMN%@2 6_U_6YGF=6A]O['=4T$PZ@OB!2)_W<*V#G+7A)22
M@@Y:WU0A"-]A\(6YY;DTG;.J*Y@R%^+Q Z1O T,5M,DC6O.)U QIW\9F6I1]
MC#2;P:7"C25>61"]) ]07BHT;6$$UGT,J;WPW%H>;!I/Z+.8<#';@4BG)Z9E
MD_J^J>T<Y)8(C/A(E:U6K"]--H6VR/,43 O@LVLQR75T8=!CH:V2O/'=L0\V
M-4P4=I4FK\L5?JW_M'T4/X3N<#L)86-(3 V'>@[>R.I_5DUYP9[^]EVY*U4:
M]P>U^F1 K7X]U.H#*Q?Z_.H0Z_%#3URG-N3YYMJ0W2@VNOX2/#B3]XL4M3Q?
M+VJ)<]%$NG/:+EF\5M/2L\4Z-2WK5WQ63<M.E+%$6X#D;#E!::\,F9;8AY+4
M@:.\CA9MMB_-_7)!KY3XSV_C--[0<MWH:MTH\_FM& WW0$T.J/@O@XJ?Q@G0
M*PQFPV^;7*FFP4P=EY,TQ,E?(? D,:78''9M(#J;>@[</>-CF(,\G!OP\T()
M3NN8HSL'>TSCJHXYO@K8VW2*>*^G(RB:$AEKITAXJK%SJ?\^Y'Y$H_!_L03@
M-=TQ8&D'^?2@X.U]!M\ ;Q^.Y"X>R0'>?N_A[2\<R7DOPU< )/I,1+N'S3!K
M6PL>C^@W2\0; KTK",H!\0)?=1OW6<=[+XW_D$WU732W6=[E7P75E\;Q?5JK
M2D',+JUL 5S;H=_T-7A]I7V,+D>8=+C*<1;(47T5'?_Z-/2+,-\31T.P1RSP
MW:^% W,IM'$M_^4KNT=M8&5K%="?#MGSJ2G+H;!A .P/@/W!X!D ^S<*V.\)
M,MQ]P'ZUAM?OV%D.AN"UT-_'XO=JCH>-S+\GR.9!'PSZ8( %WSXLN,]3L0@\
M0(.OTY!P:D2T]?@J/<8@GW<G;52^6/C=*FR9:,Q?@"@SZJD7HGP56HG!6D4-
M[\(U>;T4"0V_4'I?66%IX<ZW"G,>A. @!!\\WK<O7'_+>-\G'<3K#4-^>QR
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M'_FJ'"ZAT",LFJCSI/'BX)+&(J>P\ 3V% -A-I3:#Y9+:[9$<VK7?+.V#O#
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MP>_UW%C>=6N!#)KY+7I3 0H@!Z1JES090NRL^=UU"6/+Q2/12M7B=QZ5603
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M%W=M1]5 X?4J59IRD/ /W&Z#SJD8KIAC. 0S$E9$<,F<RWC%\60";LIRG$S
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M8O9[[=MVHP>EF/,^9S$.4]F'W>!%CN[QS=92X =\[;*LO&QI(#/I#ED=N<S
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M^^[$[JNN2GB[_&98D&208\Q';F-44Z3L<%#S/+N3JFW=#1R89G16W8R>-Y4
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MCO"?[0B_\57H(O/"PI-#_(4LG\]L+U\.7-<7]*=F72ZR,]K!Y"6\@#L1X!3
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M4SN8:1O>CH#DTV8PCG&- =Y_:6')VNSG 3?R./M["=%@T:R:Q7M5>5]#8N@
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MRM'6)[JR[;2ZRH^QO&^V*A3YUFZ9!,ODVGPRE4*L\4="P.!6E]S*$K!;,;G
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M_A@2A,,^W)3&OS&O>-I6UT/VP[([#&%DU>#.YZ6&,G.20>)&:01(>H3:M.1
MH'Q4T)SWZ(AT^01ZO"EK8MJ'UX=*OI* ]<HVTI'T1-+HELAS!<V%T<,R.45E
M\T^[\Z:LE&EW7D_E+C H(P_=8:\&%140EO _1LE*KFCR3G1]0\.KSWS[_@2N
M_81HF';OA0BX,/O"3LY?F(%5N>E,RM#W^TB6DFZ:17PGG;V(FV.*%$_AVHL2
MVCD&VQD=ZZBI.>!D%Z#,Y&!_ <MX,AW7@MK$?-,\2?J+=6+EQP4@9SXI]M>F
MM33M-=UCVDLW^+U.>^DZ]E+MSAN0^0E;UT73\D$H$BJEH"*2IKJ9]MM)LMHC
M:A*9-!:-"5XR9+&D=#1MM9ORVJ>M=AU;+57[&$:/B?3'AT+/4%^/<6T]IBH?
M"N#S9!O3)]BKS=FCK1GFQ'J),D16*I+ZCH.2W@Q?3YWI3Z>0F;;_C5F*T_:_
MWG34,!1E'&,((('UNRK I;6Z\FU\O]0L-OIVRR9"P%TLS$)K-6.U^Y9+P60"
M7 )Q98Q-PNA43!OTQBR6:8->\P;UNY$VTGK>MYWT"%[!D"N*Q/FNF9@[;] [
MG?;1]>XC\0ZA1.\VVZ X/;Z#\LYG8;>MR[?:X3Z)FMRLMSOMJ&M&%$A"AEE8
M@/9SBU5- SX/6!W=<J;X.&V?F_,JI^US'=M'%)3Y0/(TG!(L#>@WA7KS"N&@
M ;V827I.>^S&O.]ICUT/RVW(9P3V/_[9O0=.+60(A0LPZ"9[WC_I;!_C^VLQ
M^D0 'MJR+,^^;2E00V]EZ_!/7/Y=W5P>K9K+J3G^1JV/:4]>(^L?[[U5+(PK
M]1^VTJ>Q_^$<!;X42I66"? 0_=_41_^97NS/38:@>780F;^];*X(M5<4:\^=
MJ[G,6]; &A]G9_/Y/TN'%O.R4.RQ_ZO CI_?OS]P@%AK,5_3HD*SG+\"5M@9
MS'C*6T[C [+JHG27=/F:WHGR-B.K=O;#R<G]&=\'>(ZM,@3I4]'GQ35CW%6\
MJZC/X5A@.ECZV[)OV:4;3 =?/KNDQZZ;+?TO'#=YZ,#Z54GWJ'G\1=5T\NBO
M5U K/QT@.$,ZD*[^X,'^/&<P^47&A;"2.ZQ?_X/'O&TJUX8VJGR;'V??.NWY
M%XAWW:\=K<B..['%50WMW((8Z[IF43)(G MYQ: 3G)\%*?Y>,'5;-.^ZHEP(
M-].V7(M>6):O423P:\7KM'-E_W)%*X0NP]P+<[J<7BCTB,$Q7KL<AF395Z%E
M#%?5CC'ZT?L%PT[=<IG1)UJA7M"W,$O%XH4,(:C%S]VN4:YN[YXG- MT17UH
MI9XJ4+;$XW[W_ Q#\7416S6EAUEP&QYFR+70WLV\/&$91R90?%D/M,SH/CJ$
M:F<$[WG:2GZ%K8P$4U0X.E0"F$)GNDGC#(QN&&(TAKMBV#C0M/Q@@V5NKK^_
MZX^S%_1^,#QMA5XW[57YN/+J-F]98>'1\9KH6;"JTI9#,%T,5VM:"!_6OO$4
MX<[[NXKCMOJ\40SGIBHYL:C\EL=_2)/JQ#AQF R S4'ME#5'< B61L(0*2[I
M]*C9UQ?Y& '(#Q>NC['W.4L/+DZQ_7FVS,M*N5-U)-L5K=O: 5F1PTL1@A>Q
M91BT&&1-2 >D$V]<$ ]4$"QELR.,Y7TGM"NT@P%\6I=D6<FP] O9Z_&$%,K6
M Z2KL_ (B8D.Z*E(Y#JQ;GPI&^]/8$HR_+[,P!&.M62[\0'.S6&+'-).):PA
M_K.1(Y7YCCPC47K TM(.IZNQVN+W,TMP@[Y0QQM%SB=F]Q#?\U*)0627N\*R
M(V',F[:D=T7S$)CZ/0$(!JML3 DQ$GDYFR7%#MN8DI/4'0.2X.O5*NQAE%$/
M9>3D,^*3?JF-Z!/7Q^_E^OC;Q/4Q<7U<]RJ$9?O^[3^.L^>Q'>%0%3PJJK.#
M._#[E^KXFQ+YDOR:GB[D-"Y#0J8H.QCU)&OZW<_/9Q27_[IR] BMCRPZ_UGZ
MVP]OY;1XG8,=KVOJD0\IQ(RB;E0=$3/#'=23Z?#!I#1[WGVD1VG"E_(D8H@!
MJ??=_#,?B.VO\A#+$!-U_6(U.M\8@ 8;LW&5PV$L\@<Z:3?A.)F<LH^>SS->
MS<_))5G/:2'>/YUER"6K*U2P S83-PQK^X)<G=H7)J0N+UV&T>>AR_WE,9W7
M3U"9K,B%.<Z^]5FC)#\02">A\, WG+N*<RR<D!"WKNS$:'SJ,&8AQ]/U2]J'
M)6Y)>V'9:[Z%5OZ_A*/3^'?>JZ,I>"A$0H[NO^88G7W+57.950VPY@/W\[>.
M$Q=%(NJ"PCZ?C0IC-".C$##DWO*NZ]<;/^)\R_TH<V[4%+>28L&^98=6/66)
M_SP#9[R9MT?D$M,?T-;9-4TM6<DZ30G)TPYR6RP!SL]=MHM^W3$@*BUL1=;G
MW/(^)[3/,WX"21?VJ0_/C*% [0_2,!78F;KMZ%!M]DHG -?W 3Y?3E)%:WK8
MG5QA^*1(M<4,9O)\2=J.=E+;R#E@;]+F99=HI."E[DVO339QJF^Q:C@CUVB-
M488)]JNBVH6O;1#"#!YULN!?J07_OFKFM+[$NG1:T**EP8$LUG)+M@^Q[$6#
MW59YPF"02_N,_4@DNLX7;>/HMPWH6(KFLJ98F0P.Y$/6@=[%[]/";F9M.2?C
MP EBCTD)%PL,,E>1OYR[9M/0X-A51!H^+9CCBV_ZKBMSU"(N\DZ3:[^\:R&E
M-X/3!9?T_[+WMDUN6U>V\%]AW2\WKJ(4OR0SF4G5K>K(]HQF[-AE>Y)Z/H+D
M(8DQ"#  T2WFUS][K;W/&P!2+5MR4Q*J4G&KFP0.#LY^WWLMWED4.,".!\H+
MES"V!NLP@UO&.:8(4:S<#F43NM+.1NU0>CSG=(MSO\]OVD+4LOI[E:BLQ5;>
M[]D5[1BJ3I6&*B5+5V0+[+RF[U!G0/%)M]+2V=/I#3+P*NR.7-SP>-(R4; "
MU%_-*;='OF1"Q89<85/;*&6:<6R@MT/"439Z&QO._>5++55EIJXGCE"!Z@T>
M1TQ<V2V]PEXE^2'H[4S[6P(3J HH2ZU_9O)1G/H J0WU?)%HRBINH>PPF:E-
MH==3/QP^>'"PY0*KM"@5[]]Z)9[;\I@E?<#KMNV!:VX>TJH7,PE,B(;X"GUM
M'HVX(!O783MR;&WX)ZT6MPO##$^NLO0YZX)PX_[T>Z1OA!O)TBAZ;?-P8FB!
MJKD!/Z@IY)'D.(^%*=BWIC:)^5#AO&=K]"9E? 6+/]'AMLKBR!OR.N%*&I7U
MN5KTW*F$9&W<ZI3Y]_B**%C1Z_ORJ 17XJS[<YG"Y8=08%-6_0G2PY+UWL^$
MJQWJ,K<<^D>MC6CM4E:T,:T0",Y;MY4[TA]4A&>%[8]">*8"8JL71+?(9$67
MAO2)/%8H*JEJ\0IRZ;5@7P_&V(>4LGSR-F1;=/%$1$\(8W69_J'6HKUJ0*II
M#<AJY[B0B/?)IW,2XZ2TU&BCV<)$KTUA, M1=$FQ-'G->&EXBI290'/U\A&Q
M3:H+H3,*?G53 GI&'&5:D*F#HVZT/S99JAR+.6$3=EA?I454O4.8[Y](IQ_W
MA4C$VO7J:MCT<+1"-/(PSNAUDX,@H9V$=3U?AKU=X]J(G>NXK5E?WT+0(;^%
M-Q=,DC=!7.&4F9%?[]#5X>F NVA[0]AG]CHY'S"J'Y;ZG6O;OYA-(;A^F6,:
MP_W@7VVGVR^N92)UFIZ:HAXJBX)  %[D(X@]F5)$EO\YNI-G=ICJ\OA6G%KX
MT$$F587PIM1>2BEJSQ2[N$Q.-@W%Y%RZBBYZ0"F8:,5 UXJH7SIRF6,VD6@E
MV\E&MG2<BF'8[MN#*F>M.N:U:2\-B2UV2'J#OJ?\6=2+!/\;R^P2RGJNG+\G
M8OT;\5482!1Z6QE2?O;IIQ(!'OK:&:^G&.EVY\#V]-/>B$\N23"ZQ?XIGOJA
M6"W93/BY2O7=-Y]]^MF2101D!2::,9.L8B0OLK_G0=>Q/+)!',L9JY;ZZOJL
M?1(-CK&E$TOZ+SPN<M2HV\O#[J$7)E27NG1!$R@(]$B&30%V>8N7CUC)9:1M
MOV]+E5Y;3=23VV:-T/CU7X%J"DZ9KY%YW!)F4(_%:8\JL.EL](*:'IKB*FD6
MQ[[M/$K^YIZ-:-Y=CH6L^-A0]E75K-E3VRQ<L=YK7F/8O^F=LS,T'WM1]6@A
MK^FZDZ$+NI\OD01<;.JK,RTL_PR0,K&>8 H7#W%HY&:.?N8Z]CX..T+E7:Y_
MEJ6%SE"Y<[-])O]#>ZX[GJS+]>^\>DTOG'VP/N9/GI#/%S!R+CPB5ZZAQ;CX
MF3Y@* /@[R?+EAT<4O$H0JRI&JKBZ$$>G76MG).K?%C^X6Q)'KV?_]D\.#I2
MSC?.7JC9MTES]!"6R0LEB^;IX5Q&2:OE>WW!GO3+0F8-CMD%*0')><]*..;W
M32M@-&V*<+%0Q*#42]8@[VO74A6;NXU0?1I31WEK^E,'G3GN2I!O!&'4!,;!
M791*_0)2''+_'GGX?SHE2E'S9GZTZBXS%\QF<C0E.K2-+MQTK*CSCJND5FIK
MGQHWE6QY3&^0E[D9'X#@R2$J-#+FGG]0*F)N,'N#!K-_FQO,Y@:SISZ%L6B1
M^IH/A8>L5DK3Z:A<":.8T8,E*[J0*JM<$3@H)B9-#*TEF0OQ-_!IU4V)C'2R
MIN(!M@2UT)4[D5TU+=H\7WS-,E"!08&EV*$::=>331QH[L["J&0X+)WQ^E,P
M@-'%E->AN,!:D+$LI'QDIT-@^$RXU50X,IQ1"9:"=WP>O]SUJT-YPB7E,+W\
MZY?1J7RQ1W7)98Z!\@U8L2H9F2N[4,XTM',8N(3*H'+WL.6^D.5AWS"ZI$OC
M!OM5/0\71N<0;:)C2E;<='CE&NF(E<2S)M^G&X*'$,^@,OO.B*?!F=,"FL<T
MM\?E\W>=0C\J/-WS'Y\O?BSE>!<M!NQTY-LND!CD.&,1PM?E(AL?=%,P['2U
M.FTLRI)B:OYQ!",M"FH-:#MD*=(ZB>2O@!@Z>)ZCA'U76VOP/#&#/3BMFG4_
M(-5?UNNF;1TG//PC\,GDC8L4>D_C/E!2<S*.=?2X'Z,)KE!TG99<65Q+$6U)
MQ&9[OBJ;099>M*F$R>V97'.)/L!AO]8[2L=0NPEL:Y1U.1R]"^S+KRFFZ@3R
M1$%5CFK'*6/\+;J>DQG&B\K'[Y=/)MHN#ZK#@VHY&@%VC997Y!B:;ZN9B/2+
M-G=@-:VI=Z)_NYY;"+G/BNG,<""YNS[)F3Y9."'L:=(YQ*S_2=,02RU*7:N\
M7&J#G:P134,]M\VYJ- 6DT,^HX_/)1D%V;V'>&8X;<P,R4F\(DRVXO#Y]K5[
MIC1BW2I+F.BP^J)KJL>H97U4=?BQ%0HZ%N/_;MW*4GQ^P1K61&1X3%K+T&!(
M5-X6VR Q@:OGJ?+O7_.&3+#)FX)\E"1!/*NP]-2-OKO93Y!IQL_?U-IBY&N;
MLMC5#:*> 0FX=JM,38[YJ4K8-[2"0-CR @,#K)CH\G<(HW:FTWDVHDFR)2?U
M3WV#ODT/J7K'QE"G#1PE,',Z-\]<OD57[@=.?/^0,X!]Z6/;I1\AB+GE%U.N
M"8[_]W9R7@0QOZT2R;N-4=^;T. W+C?]<*G)2_7@L,#OC2J]4N2KZ$A!*9Y5
MR8;^*_G$WA7W9>6I87E1TT6QBOC(FJEJ0BNL@- .-J.#\:#3\!B&2N:;Y9J(
M'';P;*CYNJYOBY#,OCHQ[V=;.(&8*,JTH23%/P^8ZV8!TT'DE8./@<TXDSAH
M-41?GNN7[XO OOOZI1U[MEKZ@QW/_D""#G:&+6(<GN'8JE_665PQ,<FKGE@^
M8!R_:,/LE+?IA(.ON9XY\+[N6W<!TXLTUHD">ER]SWY/PBT-6"JKO"$ES(H9
M!-5'I1;+P\5+0@SH+.LV,JT$0<TTUJ ](R-JL 4OIQ@8,I)N*P/6EWD>W-6&
MD4'TLY%U,$[1]XT\#?/]>9/W5MSWYF&FWIZAV69HMEO>\__S_RYX'#[U.DTM
MFGH]'J2H&;$*SU"D-_.>9]EZDG'[B59%"!92VS9##NG1X:!]\U"'Y!N"'P0I
MK&$'VFV?^5K+GS% U+)('5K$6?U&,@2.1%^S._%L^1*]1JE0:'&,9=,XG>\Y
M.,#C3V9CUFW)+.LLSC=SM&9Q?BI3Z=%&FU9MI(\;DN*ER2-J(>YB_UNS0AY9
M6Y<K^/X>(O5^YB>[G7<^R]E3R-F%!(+O1_,BEPS21+0(>JD8LR7FYL6@/W:;
M8J1KX5Y)\-HQN<:RS2R"-W,<9A&\<1%<N53BLKZ(@!IK0/G1@YT63#;=S))X
MHZ=BEL2GDL04Z.)"2$E,'X?4+&54P1%TT&=47?/@Y8/+:/\W<)+07,&\KI^"
MB]EB-"_-GNKM'919.&\IP>-[1(NC2M#6: 3TTSH1ER"<_:-'B8M]7=MF@"LX
MA>;,>G&*Y((^G 0Z>I;+FSDCLUP^A5P"CV-J3)RETFZJ5IK"%T54H$ UKRSS
M VY[BC>JLZ7A/F3%$C/:R5#3%(O ,LQJC2A*9^:HFSI5LR3?H(55:<&@0R<B
MNM6AYUCKD(#4VF<->N@ ZAEV@6, W_K?&;,^0\QZ-N9L#Q9FU9 WHX^:I]8>
M_WK_^.D\M?;.IM;F7K=';^K+,/&BC5HV;-( DC=U#4C&PF[H8B6JQGJT4H?=
M-Z>%8!VM9#8*8L!1EGO^!8,LR7!0.OZ4#@JM%8 W:33+9MF4(,T:.7RWEJ<5
MBVQBRE.F S(@2O.?G*1=TV&$'O ?OX*Z38G5=&\B3=J ?FV&0/A(!?3O+J_W
MA#;N04\H@;@S>/X,OGP*I\KZ7''I(T[KR>8=_, 61??0&,_<Y29MZZP&_MVH
M4SOIR=29QL %QP$<!8&;HH4;#F<&5.Q[)NGT/HPQ+@&PO(:+[=NFN]+_GG8
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M*?$Z3B\AT</L7+W#M$T]-!<J#J+/D]IR#*9BVG2/E-.A*$,21*VB"%A9<4+
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M;IDVZ[.Q!X2K^M=?D]L:(R@ES<GA*FB:=FUM;*^=+'IML88(A$O;G894S7)
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M+ ZIQ 29B!C:DMB4>G?:RV%6E_;5,I2I:X+\RGX$$?9 B#S-P^YB>+Z7</^
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M$W;H!/ ":_ UM%[_1H]-UWDF<[E?.N#*,?Z 2J/0WJH^#2$'WX<54OC@Y&$
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M!"FM.D<4_]DQOIE#-@OVDV"RA>&(V.^Y<8>F9KW/)?4[FN,WL\8ZLW"M5PR
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M+WC3MRA\!#X/@;W1&[C/38**/:(5?P.H[@EH=G&1']?>7>SE0[O(/^[.'2G
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MX#B499-.*047 +6>Z :[\B"?(=PN+R$J#SMZN)VKX#S8"<L)7<YSMD96T/H
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MV*:Q(X<_H\2FBPEWD;'1@*:BP[O)BRP*3N.X'B>6XO5&)ZKF;H>@!(V0 F0
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M'1F$S_ SC7\UQ$V^6Z^<_]E/[09(/)Y4B[V@DXL1<(N9_C#-] ])A\J4(>
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MHZ1H5<6OK[RNB]Z$O'BO4_)B]JM@6?Z1)>AJNBHIVP)AN!@4#GV.#D(;& M
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M;0J3'B';Z?><1,M8%E&>C-&L&ZMKV?LJW[C/2K[W43<J: QTP[ _,D?RD\Q
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M4HH\D+#K<?!61G(^EGDP&H3!L#\<A@%"H8@<_E:JX,7)R=>]/^@%'^&))(N
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M$V!V/305*]@$,\&Y6,*)H[2UXK-P+QBODI_0E\!>-I771*FO8K8,B@J6:UZ
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M7QA2@>03_-]$)B7EL'-QP5+GPE,B/Z)RL%3KB-G,IQ D\9^_@WV<?SH3G_[
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M"?M?5VPR@"E1AWLC1P[:?,B1U5CAJ\^X(D>.@R/;<UMU^"1R(X(K@BN"Z[C
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M:G(0E "CDP"<$6:%)<!H8.UI(@_&$@U<.B]=U(S&T$>6S%U) #TENK=X$"J
ML020;DZN88<,(#$,(-U^8KQ=KMV\GU@1[NS5H4<PP%[Y@./.WO!P\GIA%V1V
MAD4).9DVMJ,=F&A3D7C9*I)I5)KU$=LY@(1C:BJXQ$T]Q)P*AQS)M@8KC&+
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M^'>;5(#[5Y2$LRRS8J ]8>5)N0;GA8 4,]<V,>%=+TD/=ZLH&2I*9+L[R8/
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M^H=;Q?]>76X$\^TYOU2JJ6!X0 LA"4,JR,SH!ABIKS%2C_XT$G]"6D%:03=
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MLB?44'GH@JPW+OAZ*:9 IUI)7/,A*B$Y(SFC&^":#]=\Z$](*V.P"[I!I6Z
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M7 3K."$^AJ+EY%V++ZGM5!F-\NNA(#O*+Y1?Z*25.RG*+]QI.]#Y,Q\%H3%
M#$2!B)F#\8R 83$9:60@YDK[&FFED*Q<;DRK=9SCX(0-1;RHX)P1Q%A[1SMM
MC(JI$'6VHADJ$MXY19T>'BM_MRV+NA]O&H\_UW><AQUTE.YQ,*Z7-7>"?+<[
M([5]?WN;3V;K\@SAQF%^>Y0F+H3E<7FP3[/%^\EBN2Z?ZU;EUP4:RV7O5VX^
M.7&K]629)^NCU*06!;NSHVZ=XB3/%FX19N6B9EU^<5P^MWE\W0)Y& ,RJ6/*
MU7><#OWO^P>54G9I1(_.3@F?N/=I2[+@<GG<)V[^A_O4_/1H\A><B ]N(OJB
M$ \VI$^O@^<[> K=EAWHZR%^??[L[:LW]_0D_=IC.GDQ!HN\?#8*:_0G7@YZ
MF_T(%=47)';+Z'UA^.Y<#KX+KCEZE^?+/YJA0^>S?>G[6_>$HYCTK9E:@?^L
M6&KR2VNIA^0%#TT8?/URZ(<7B[+H6VX:MXC-CY<&NXM2G#[L?N]9MUDO3\,^
M[;.4A>43\E-W.<S=I^5F7;[F8XH_;;^2DLY"NS>489F[DR8]:5)9=A8/.QW\
M+GRY_>Q'EVOL?)@U,S^;S]:?GIR^_YI2.]NOD^JQYO;/K;6N"XGM[NFQ4.R+
MUY O74$>6Z:^_V,>"\U'=C-?\T47KSA42^;OW@[ #;@Z:QW6%4ZNR IES-M7
M_OJ(DD=W:Y);E)^LTJ7N@-I[G1#_E]QJ\KR,6;Q0NZP./\6:OP?=3D*^'*3Y
MD"^KL<(97S*DRP=!E_64]$1N1'!%<$5P'1>XTCI\$L$5P17!%<%U7.!*ZO!)
M!->[CNKL-@.K;C%Q1REJU6Z]WIA8T&Z\=RD2D[Q:'D^6)VGEUFU&;IO)_V&V
MGJ7F21VG7RHS=4U=)KZ>;GNV2?WGC&HR$YH&38-(ADB&[H*F&8=I$,D0R=!=
MT#051QOZ"B\]D&C#@8\BODSKR7S9-'7$"BNS9R7.=]=-@BNS0M^5:/HUVVU+
MT1PNEZY2)AL@.'ZAP-_MOFR XW!]J1RE PE9&! A91!*E!ELA(<<,A%.BUQ^
MU4>K]M>K9;F=A]6G'2'X#DKVH7A!\?*P/0?%"XJ7!RI>>&;><PI>$ :"\ S&
M20DFIDA$MD9H<Z6CEI-&DFC;][2U <M/AKH(C#$2DBWBA;B[$B]<33FSJ%V&
MCL"H75"[U&J%NCT'M0MJEX>I76R.(J7$P2?KBW9Q"IPO.L0D1[E30OL8+VL7
M(0F7GE@@QG,H_R+@M3-@@Y(T6-6^>F>!%TNFC/76?!PAN"KQ@HG)(]TJ?!K_
MN6G6726WR7HY6:7R4IC-TV2QVT-L?]O^W)9YFVR:%">SQ7D"\W_ZU>0O.[&U
M_R?F-0]'"V,.3>V)&IA#@Z9!)$,D0W=!TXS(-(ADB&3H+FB:P>0U[X_Q[I/Z
MBU_LUUBF>^.-(8UOG!@_I_*M8>:ZX*I;Q(D[7I:1_W_=+^K87T#FP[#P9UK2
M#7C !\]AN"&UVY#RCA GC0>:N021J?W_V7O[YL9M9%_X__LI6'//WB>I$KP$
M")# 9'>K)I-D;\Y)=J8RFW/J_K6%5YL;6=22DF>\G_YI@)0L6;+'\5 V)".[
MF7ADB@2[T=V_?@7BA2V0X-;EBAE5Z7R,2N!-=?UF9MYL*.M13L]DDPK3E)9*
M^B="DB?#&P,73H+@R?">BN'5)F>25P6RLO05J8PC:7(%UE=AYQ2&_Y$QJE@/
M;7A3,6O2/[&2/!G>&+AP$@1/AO=4#"^86T:+2B)2<(QH53@$EK-"%2ZDL'E>
M.<?&*,$\O,?+J]0!&Z7^.5@=94I-'(/>^;!H]&](25]&J9O+N9UU7Y*52/GX
M."##[^5#TI$ILYXPVJ,PFA/&5"6 ,HVM;Y,1&M1I29!1JM3<X)):/496XL.%
M;.VW7E&_W=#3H\ S6DXP+<?"9TGW'+?NB8SDR>C&P(63('@RNJ=B= FF0NF<
M(J8T1[2T%9*"58A(X9S0E2AW R./R4@<TNCFDXJS9'23[HF0Y,GHQL"%DR!X
M,KJG8G0U)I:I@J&RE!8,*.=(EE6)K.#8*8>5,&*,;,0!C6Z13Y@_:SD9W?AT
M3VJ2>-&9B,VD8]:X#-9P62\ON[YA0NO6KGYCZD[#JRVZ#/X.Q/G-+J2:6KB_
M7K9AQ$,<B?;()/IX,%W*\$9.\*/'=$>H'].PLONPJ3$Y)451(<<80[30&@E9
M2L2<S7%5RE+(4;(P;U:&:--<O7/?K4S2FYEY/QBN'V=7=AAD- IVQ1-<%JF(
MYB#@YPGW;QK%FL!)K%PX"8(?/3A)1GT5<.**"L,EHH0H1$7)D6 "HT(31TK.
ME=/5&%F>0QOUATPK)9-<I-Z4I*-B)'DRSC%PX20(GHSSJ1AG2RN"'37(6L)\
M;TH%AM91)+FS2C&N+9-C9(-B,,Z,IWD-46JHU+V2<D8;.:.@L5'CT+*SF>PZ
MNWAL*BB5]\2!+U**/7*")T!W?&IS/Z K<IQ3XD]Y*?UX+48D$D3GR&K.-:EX
M7CC\)2D4@%_Z]:;&_L6_ZSOW:V??>%4]2I*$3"HVVI$O2?D<M_*)C.3)ZL;
MA9,@>+*Z)V-URY)@(BRR%0:KB[$_WIYI9*2S)<5%;L07=;(\B=7%$\%3_VA2
M/C&2/%G=&+AP$@1/5O=4K&ZE,99"<T0P5KZ5A2!I*4=E99Q44N38)R(>G[QX
M(JM;B-1 &J7R2;TL+SHO\>/E7-:M3T3V)Y:"WADO-9%J3>) #RF3&SG!$UP[
M/LUY1Y!$"*I=(5!I?2&HXQAQ5@#[&2^DK5QEQ,Y1](_I[GBW.D7Z)RL[>Z/%
M?]_A])N0[=^V;8SL+OS6_T1R3+])A21)_41(\F1W8^#"21 \V=U3L;M<N:K
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M08IACI0H2F( \^353DG18Q*(SP6.J)B499&P4<)&"1LE;)2P4<)&"1LE;/3
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M%X:Y;5'T8ET^,)?GMC<Q2#IXW==R^E%>=]^\ROYX;+KOL!;"$\/45V-9IC5
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MC#K$BZ)RI,)&*S<&MOC%.RY+^T/;7+Z%F_DM]#_UXN+ML@-?S[8IEO'<3O_
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M /KH-L\A,)MW@)U,9K[)8@!XL=BG(UJ'/>SG\45SW.^__YHOW-Q@_Y6;"V_
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M7Q5=4Z<?C=B=4[&6!6%6;_3N2>-YG5U P).MW]8V6 YE? A2!2[;%'W5BV4
MH^%ZOLIVB.,.;^JM;=$SD++S:1FU\X" MW141P!%A"K$,],Z:AB8Y=0:37R*
M:L?U&JU1R:2$I+,6SN$ CRPG"#.B1,#,,NV?==3.5V$C^AJ<5N,]W%O?K!?8
MZ.S1E'=^RAV)<C_.R_8(X+U;.K%GO9WK/K,BWS;[[+:]TO'R=>)0WDHK1@_
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M9GG.7/T![O#=9.;_^::*P)67>0_,EQ$>?&,9=G9%&->7$WOU-DWBESU1A7^
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MJ;$ZZ[,*3%4X>AI;&C<*;;&"7-NF:Q.% =MU/ 4]EPW8!?R=K^OAV_&BLG-
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M?JP70)>5$_ QWC\]4J_$^0=:_P[G'US=SO\YJKZWDS&LV71LSZIK?P_(V L
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MG$()"X6X<Q%9[QQB%!,JJ;9>NF.,O'A&7,KEB'#9V]RE,E6K-PJM@(O^T**
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M2OD>F<OSC_D],PA8VDE^BO&\Y?KNG5JILOM610X4.7"K'+BNXSQ!:;#2U>?
MIY/QQ3B_\'C:(N[,/+.6[ZY[?&8^VL0 (!1:?JVS.5!7GR/(B.D,=&^CKD%%
M T_F2>1PI7RCRZ6#50<]//]G!*%S";PYSZ+DI^CF2SN_JM2H@D4V-X3)Q@-L
MBI0TGUTT=S\?PT/-LV7;/=WZA#$\%#RSSR\ZSU@:!$*<KYZC^7J:C_D\7IR/
MP<S*@&,:EO5B?M4\0QTW#LH"$!:P!C-FOA:!&Y>&+S804+M?S+NZ<EGPQ1J>
M! 1895<R*8,7@%<9JG1G;DO/0S*K/JM^GE9Y@.%H"W&Y^!%VY$<PLT VMILH
M7[A[K=GGZ>8Z;2SIN*7R"LIUI$_[EK^(RR(N#U7QHIRN4JWR5:ILYI^@R)SG
M-]VM5\YF2LNBG<S\^]GO($#FT=9+$&M-5D+EE_-/^;PJI@2<50',:A@OGP_\
M]G&>S1>0OE7V<\!]EY=PL>T+@6SMI!4(T<5RWDHX>WDYGWW)ADX6N2!7@,'W
MB93"OH5];T4[ZS2:$^7>-3>$U8L"WV9N6^&83424<<RE'0?X,*_"#.XXSDZ%
MQ=B/+S/+7MJKK&GSX:O+U9G]L[8%5' QFW9H!%8ISB?-P?FW;0#5:5]@>P ;
ML<$1:0F<'4^(61_BB=OC,NPIN]X84_W4S)I!9?4C8$> ;C]/<\0D.\9^G=AI
M8PL#+J3P?5CZQM'5_/ D!'IMXO00/7Z97ILOLC5?MG&Y#<#KL?52W$*\;YO?
M\L<_M!*C\XGDT[Z; >X'C0]@O:Z7&4.L3MT2)B,05=-Z <  8/[5S=\R6 'P
MGQ^E^67WFR8J T>V?V14$?VXM0?F>2GA)[!=&OL0'F!U=-YUFU]WMN A:RA>
M7$YF5S'"F6$,-X!'[2Z2;:OE9 $BMFX-P)USX3^J^KUYNE]:)W0^[S\:X+1>
M1-4M8C855R9-#.^J\]GG" ;8:/6 G5LY/VCGX6H0&"Q&N_P@[3^/)Y/&LS2>
M+F-G\'W,5MR&PWM]Q[/J]_;"69+/&P,5%$<F6+,L;KEH5$I#05BQY3S_D&\_
MJN"X_-/U$XWV/]+6_5IKVX;0VJ*MA\R.)XT.Z=ZQTR[KK;5^QKM>?OM.C4LP
MF[_S",_MSQNDZZZ:!X>73''<^@2W-WZS>G92-\NV?U&V;K9ZQ$QZU^QX0,4;
M>V26C>>L6<>+!0!PV)_917A-B7WGG'>*W2X7YV#Z MO!&Z^C%OF/S^>SB[4V
MAENL7!GYX3.YVV5IWVRZO'#PO-D+TAS5?ILO-EH[(N.7./?C.F;OAH]@JR?X
M*7L5,D;(R!PL\14(6#M@,S8H11RWI2%Q%X5Q&E%#.>+<>:158D@&;1*AA!KM
M=FJRB8E6<XHP_ ]Q31+26JC<2(,0S;12>)V&9"?1O_T5* </83_&7U(C97[Y
M#(S^W=7/:^(=IY$;.=TV^IF#+@#+KKQ7&Q&"+9[9YI+K &,^)/_;,A](G0E8
MOHO"&[>W/L<V4LD0%;G_N<8..<$5BM$'*512C.RV/O\*WGCT\+1?.YWQ:Z;U
M+^G[QCAJ&*SCN".QU4GS5<M/35"^]9]WL?F5WMGT&3<JO6.C#"SB%Q]!3S[C
M0#]*5. A<*1(BK"KA$%&RX"<\5$YJZ)6_$7WY(_K&.&OC3M^[_R^G$H'ZGGX
M1DK*MD*>1EB?]@3+L^H];/D9\,!\C>GV ML6:U872U NY[;)++FID];*9\NA
MNLN G<=WVXV;N;*];LN8F0OA"L_/B(Q:$1/U*.5T0>X90Y9XA:2E#B?L$HV[
M7705 _Z, @D9@!&9X<A9%I'$/"GJ27*8%T9\T :%_[P./OQP?L,YL9&WE1,X
M5L'09V0%$W@>>T$0 UP$^D5Y9$.BB%.9@B5"4W\\G?20]-GFG_]NLUM:9M@_
M5O9DN"'-EG.4V>&TN6$5\6_B=K-IX^U?7*'FWN?K.'_K=U@E-S7F$,#D?,!\
MQ2SK]=JZ8C&.;ANL8(UC,A+D:00@&D5$+B@,JHU@3:61,3S><?!@CO]^,D[I
MFN,[[\-QS"%ZPFW;5ES2A="?48F$2"./&B/"K05LQ#5R,3)0(BYRYKPPN[7)
M+[:?3AY.@3!]#?K#9[(V-D6C$2:-OWL>;0+;HH5:O_W^]T,(:S,%-B>N-/!S
MK8O0XG.<I(-J"$R?^2)'K\_V,MD %_.7:?5?=MJ$Z\BH"9?>#->%)[+0!KA8
M!^K0B))*<8Z,,KF/$M$ I'-7:\Z-UIIJ:7=ZC(6 <Z\EA9R)><9TI,BD /\8
M)P7QW F[T\MZPU'XO;W,<?$V>O5;%TOZ:3;_J<F5^+F+)VTISG8G;^I+?'M+
MZA$V9L3PR8Y]OA&9K6^+5MYPENP-69^,2'C?) G_$'ULPGNLDPLG\G;;XNW<
MAFN2%REWBY1C*1&OF$7,:HJXH 09EQQ*C.BD:3"6[#2]U40&2;._S A >B1Z
M9 3WR'/B(R?6.KG3A>9YI1S%(R[9R."3G86Y$FRK6,AR,<OU##G=?PJ(J&[*
M@N:S3^.Z2W3?3=;;]A*/\D%M,DYAF-OBD%&')%5$0DL!8$ QI(6-B%!/1%3:
M*KQC:C^$81YL'?VM2=_X);7\]7Z5+ ,,UJ00/8JOQ$AH-1+B9$.06S4^UXE&
M6Z@!^*1-7EU5J@PRAQ7H%[_XR3+$%ZNQW]\(8X"[AE"^L;1M7X,_G:\;<%[:
MC[%M7H(:8_:MG7RV5_6[-]4?!]7?X*D;Q.S=DB6#][D\ IL)O+OIU=6W-[[X
M0^.J*2C[/J"!@-$MB60H*I][A7&);(P8&1YYH$$$Y7:Z,SO9="Q/B&OM$'>:
MYUZ/%"6EN):6F[ [%^MY438920;+CD\>#1QP&MSDD'Q8_KY-CLC9?HU#8;O!
M0%.LNLJTK'-B[G5!,;SCI_%L6>?ZME4">9LV/46K+Z[S?E?8O^/@LPI8_/<(
M3-S8]YF_=[E\//6YRJ[C\YN9OH<0SZ:YL$<RY/1J^&>1TWY3$02W6@]2.J62
M0%$:X&PG,=*:.>0H352'"/!ZQ]R.@23FG$)>\P#GF#RIR4H4\TR:H*S'@AS=
M>G@?PCB?LI(@[]O4\O^-X5$B@XT8?@TBXZQJW6TG\E:GZS4LTNH6:96R=X@K
M"1HLCUF1(>>WQH@\9=ZSI"QG.[X.Q4S(D[00CAPCSH5#FFH&8DX1JYP3AAQO
M(M93^CK(B&/X?WVRHU4>XNLXC'Z&Z04!(+:'ZQ_4R.] *D42+.3B!&0PH7G8
MD$(:6_@SQAQ=I#0*N\M#46-G,%+:>,0)X']+@9&2(-XRF@=(IQT>\N<Q+">Q
M8X8=;FI+?=HLQ?>Y<0T@TP^9X!_@OM]-X,<W5:R]O<RNB/DROGF59<Y/;81W
M]9S=^C=]_\YSTYJF.>#;0;+0@!Q83]N@<]7/=-'6INZR3@[2O'.S.4C0YB''
MTX]O\;OF<#2Q5[/E F[Q)89W[>V,S(O8'0_;8&(OZ_BVCKD3TR*NUJ>I66XO
M_6;?])\< 7)-7Z.WJVL<F '4WE60,\+X-WEI#W5L;@\$BFARC^-(?HN[CR)G
MABI\_;_C7?JX#ZK/&#:;_^OI<YHS+6E/GPW$ 6B^!U[NCC%7NN'Q%YER]<@Q
MDOJ9 BQW2$E]DFW@O[(E__%I\0!]]=R4@'7/OS8IU\]*E4['K9=.7"ZJ>C89
MAVH;]_2=LYZA\<Y1]\3?5O[?/[EY]<<.G=;]X=8[]L7F[8!" ]@@/6/X(GK[
M0HDB>E^9Z/V_S2UB:"7O^[;I=_O'CUV%=OM7TTZB^C7.VS\;YTY_F+I(Z"*A
MBX0N$OIU2>C?XH4=3\?3C^V?W\_64QG:+_)<C?ZP=9'11487&5UD] G*Z/<?
M/\[C1[OHY/+/((?'TWKLVS^;(7W]8=TBAY^,^TM,X&1(651JKRCQ8BJU<$Q_
M.:;0IK^T*=*L2+/",84VIT&;(LV*-#M]-\:W/W?]<O_0'\[K.XU[QHM%*O:%
M$D4JGI!47)S/EK6=AB(9AR@9[W#+=E4A7^67Q6I$.09:TL?1$M;_WH1[INJ5
M(=8S;0P^LGO["^)'\.VQ:/V56K,GQ4I/W6WG:6DQG0V'$B>SZ/=77->:XZ4(
MT=2M'9L2 Q2A^ROO([->V91KA://S8<ITIX(1##SQ)"('3<WJX8-L<$9(A$)
MD2+NA$/61HM\T#J(&$5*NU7##ZV\[VH%-A1 6TSPN))[.I*"CXS1!VONB^AZ
M[:+KJS#WLW4M?(W:_&(<PB3VC24>H .>4=S_:P]XJJ-;@0.#@0,4)Q=%4,A2
MI@ .)(YLD@*YP!VVUAB+=YJ(O# <6*5/=XG3JZ*6IIQE"R3\_?<?<E^">7/A
M]0P@O#T"Z,^$G1G9/U303Q%X,GJG6/3/XPE_=89FWTA5R%/(4Z1:D6J%;0IY
M!AJ9VXZR;JYW=[7C!>LVFZJ1C;4?G./AI:W-_VBGQO<GMEYTWS/2HCBZ^Y?:
MU7\M5IQRJQB=(I0(CY'1U"(>M$#6:85\C,)2'+33.T,]L&#6:P\'89\'A%*'
M;%0824VIE2*&%/2QG7*-D*]_GK:CDO]C/JOK1_;PIY*/L#@\0K3(KE<INWJV
M[$5Y]X42)[/H17F?BO*V@F%M#4%"68(XCPJ9Q"F2V&M%A$R1X&=1WO57:>_C
M1M5N':%+SL3AT1=%P+U* =>S9>^;AN]#Z4E/%4_?2%7(4\A3I%J1:H5M"GD&
M&G#;CI^6@-L0C-&5P?:8D%M)-^F/2"VU)0-8],'KL0$*NF_+8-W;\ODY%=+A
M9A1H0ISJA'0P.72H7911)\)VROL>Y'W,0S]_KNME##\LY^/IQ]:+V([+W9P(
MNM9+CXH,TA$S@"_I4?V&IRQB^UVK])B>&P6D#%=?#HF#3F;1!P]2BG+OE#MC
MBF,:'?)64L154L@H"7\&S!@U1'GY/'E!=X465TK_!:*+>=PO*2BAR+@>+WO?
ME'PI?!F"H[= @T*>(M6*5"ML4\@SY.AB*><;GCWZTVR>XK@4] U'^SUCRNQ]
M9Q3VC&(G0YSCCY#LJ5X<H. LT<K;')HFR."PMTA2&1#'/B#MG4!!".M#%-CB
M7A0Z=NIO.;_V:#ZN'>E(*S-2DO>V#.*K1XKV3+B?;ORSP*CA:NH2&^@?/.H_
M["EP817_Y$8S0 PH!.P1EXXB8P1\(L1RGSQ)9*=9Z8O$/_?@A6>,@/(S(7H+
M+(J4*VJ^?VJ^5"(-P1E=P$$A3Y%J1:H5MBGD&7($M(P:[).M>?>H0=*?Y(6>
MD;M'?%I2>4]CT0>ONXJ[KG/7"<Z)"=XADE1"W#..G WPI]%*$.6(PN&FNXYJ
MKZQ@"3F777Q$8*0Y54CKD.<6XABYZ_FH03*2G(^PPJ4*H8BN'B][T=U]H<3)
M+'K1W:>BNZTPG";0W0X+CCC%&EDJ*8J.NAA2TMZZGNGN9XRPR3->:@R+<.OS
MLO=-NY=JG"$X.PLF*.0I4JU(M<(VA3Q#CK"5&L/A&:)E9."P=%])&AW\H@]>
MBQ5_W:KO9]1,<A.1"#(A;J5!UMB$M,*,,N:#,3M3AV@PFE)N$ D:(ZZ"1QH.
M13+IX$2(6FO2]Y&!?&2,'#$I2\)[D5T]7O:BO/M"B9-9]**\3T5YRQ23)IHB
M9;5#G!B%-'<<>6VXET$'QG<399Y">?=U9""A9^2H ;<BX(8OX'JV['W3\*7X
M8PB^SX(+"GF*5"M2K;!-(<^0 VYE9.#PC-$R,G!HVJ]DD0Y^T0>OQP8HZ$H3
MSMN\C]P'9XCA2&A)$)>&(.N(088;9K543*6=D8$/\CX^\\A HT>4F9*F_V3X
MY1EW;AD86"!*WREQ,HL^>(A25'NGVC7%7CKMD7$F(,YE0AKC@(B/CLL@L32L
M%X'%EQP8B,_H4;.'BHP;OHSKV;+W3<F7LI<AN'D+-"CD*5*M2+7"-H4\0XXM
MEF*^X=FC96#@T+3?,R;,EH&!O<ZE*0,#2ZSRQ=?A@$/3>&%%T$B0W%(T68J,
M]0H%'0S#Q+M(1!_*'(\],)"._G_VOK:Y;2-+]_O]%2C?R6Y2Q=;T&QK=]NQ4
M.8ZS-UN9.&4[LS6?4OUJ84(1'(*4K?GU]S1 4J1(RK)-20VZ4[L>202!QGE]
M^IS3YP@J1XJF.]<G#PQ,-?^98=1P/77.#:0'C]*'/1DNK#J06R&\XAIQPCWB
MJK+(N$HC:RO/,%6EHC*)_.?C#@R49U0F"RRRE<MN/CTWG\\A#2$8G<%!9D^V
M:MFJ9;7)[!ER!C0/#$QIK_GQ@8$TG>*%Q-B=D)X^="GO=H2<GM$8(G?-PHQ]
MSGNFH"IW9U#Z_C"' %>]U3237!F-F*8"<5,2)&UI444(L\%X'(*^&0*41#A!
M%4=&E1AQXBU2);?(<F(])UH;D?H00C:JX/]I19,]V?!1;4L^9?BUV,4]9'@L
M-EQ;VZ\=5%S4SHU]:BJ1=A;]3PGHU))O&4$,!D$PX;T@6B 1E$5<!XJDD"5B
M%:T,<;+2>B>)^,@(X@%SA_Q,)(@QTK2.)^.2,F!(F3LYG9ZT2IRHOU^[3]B^
MPA_LRGNJ2OF@ B+@$Q$OA4":^Q)5N-0._@]+28]6@F,^[CW-)WO/U_Y"UQ/X
M^PM89/1P"SU^ZV<7VXX1M=X^=8O9E=>SX8>XY1E>Z\X65Q_?M6<[EH@=RZX]
M%=>>)MK-L8 <"SBU6(!3E2"* !2I(IK!U"$M0@FX1I.*:VFP\HG% GX"T%)/
MVMK^78\7.[O_]9Z?;>[Y$;M]TS\J)<N;_I21P;T?P\]%*$DT[]8Q77;\(I1<
M=ID.1KS'8YJY""6Y4LM<A'*"L)%6-##G/2(B&,19%9!DSJ!*!(&EE=P*D0)L
MW' J1RA"$:.J$B.*TYW<EVM0AF(6<]PI04R1YH;K=.-.Q]*I''<:&H!0VGF-
MK8E%)V4\S4Z0=%H@:ZQ0I=>!A"0 Q-]]&Q-G$_?RP]1;^/%M$_^T@2L>M#2E
M2K!?3II&\V0\5<81*7,GIW235HD3A0$'2E-*'HA1*B#CI$+<8X>4K@P2S"CC
M&!/6'Z\[S!>4IGRR4SU4L4).N&*ENH^*E6S>3LJ\98^?BL=/$P3GR$&.')Q:
MY, (9670&GF% >14!$".L18%5@GE..:TLD>+''P!R-E ,]L5*^1()2NT.NJ4
MKU.V@R=3LI+[IJ1DH/I]3*$GKO#+G4PQ;XI+^/.>$I:_F%GQYZ7(;/Z;VZN<
M3&5+;J^2]$8LMU?)\/)C\-(2[BNJ&"K+$!#7@B-)2GBK,DCNF>5>FX034[GK
M2JYX2=1<YKA5@E@CS?W:Z<:M\DFKKQ58$&F(5 +XK:Q$G 6.- T5PKX*%FM.
M11@(L,C-6)(TFB?CJ3*.2)D[.26<M$J<* PX4/&BN"E=P 1I1L"I2DR1U)0A
M+XS CC#*PO'&)QZ_XN73>[2<<L5+[M&2S5OV^.EQ9T@@.$<.<N3@U"('5G#'
M57#(E\H@+@#?2*FJ& I@/HY_-#8,(W+P_-V[F7^GYS[W</D:D<-F00S\'$NC
M]D ]5U\>)M8WZ94@T/LEX)H2RZ7')3[E9R5CWSQ[?.(,T,B^/?>%7AFBHEY9
MHN(RFJ*B;@M07KL8ZZZTIRWF<+FK0_ S/[&^,'[^WOM)]V>_C'P6TQCZC/4^
M\:] "S\;7\5A2NV\L7\436\>NSJA>$'0]6SYM.57HKW5DZO_^+\?*";J&2RA
MN;AH)LOO@]&[<:?YN9X7[V%%1>3MN4=PL;\Z*VY_-7C8Z@:KE;OB/;SB&I9D
M][O'_7H?=*6Q18(YASAU'FEF"#+<4N&<\<[QA-WO1AWJI[I?L>5^R]O=[]GA
M0/W #48!-QC#^XRRHMR>X3)4:%DIQ(@D@%.)1 9T PE)6444X=Q5.\$X:2M=
MLH", 0WC!+1%<EH!P'4:/L'>\Q-3%%:='>X?<S*:$GU=UI;;M$6:RF$O-*)>
MPZXN4!N#V!HI(8G&%7,4[W1 4$0[HXA Q'D:9W\9I+77R#K0E]+[,H1P6MI"
MR.EK2P?P(@R,87S 9H ?77$B[WBPA^/ WZM[&=+;.?@)CXJ9;Z-^U)=^O$3B
M[Y<I':3[G$[Q#G1NCES$YAM[@"E0IRO,W 3HW:49GM_!CE9">**"1]1%J VH
M 4EM':HHI97B0G-+CI8"_ ([^M^1H^U/DU_A'1MW(]W7??@#",:/(!=[K>=F
M(<VU]?SIEQ]CWHR?+/;.F/LCTF^$YY27B$BN09*#!NA,#'*.$JFYI#*PF]*/
M2Z8MX&YDL54(K@$4X2L<<3K5HO0N.#D<Z8]=D?#IBG\&TA]-CW@;0FE+9%@%
M0-H#,I9>$^2%(-X09I3? =*^*I7'EJ.RLK#M=,PCA1U%GMD25P*@=W )J\!G
M5%+B,\)/5TN^)@3],>CY_/;FZ0,GQZB8-W,]!N68>=N\F\ 37!\=1UWQ50R=
MKY43*-/'\><-?.&R/ZZ['4K/ /NCO9ZU"Z6A M'2<<0C3M9*@KFMK%=..1S8
MSL"SSXE_O[R8CILK[]_XV65M_7YS^TNS9&-G6=NW418V/W_1M/-?FOD_/*QD
M)1YO(L.71O@H00G!ST[6EEZ'\& E]GPS/;4\Y-Y&;5HK7]&  RLT_&%9L+B[
M[9UV#B\:I?O0LP.5H;SR91#,H& B*H!](%(22Q1XQ4K"F _5#C#^G&WAO4EM
M#Q-^;&;+/\7K3KGZDYY5Q4?*/P?^AATX.=OW,BFNMKB7(H0]U1*)5B&89NR^
MF+C]]^,BG]:@\[4]2.[78!] UB- Z?Q5\3P"NGI^=2]L$"D6%1T:N"I=X%(S
MI!11T9)SI$MCD*N(LM)9IG?+WRKF)38*HTK&$>=$&J1I"<Z@)%8SZ@GQNXD2
M>^[=8NQ?A?W5_M<<ZACT?.)N_.4W,-+MBFUO8V;D+:SH^S%\]*3P@#.FL9YI
MME@.5*LG"W (\[N^XN]D^#9^19SU?FUV+?4]+->=@^SV-J_?_-;&<ISVO'D_
M*8P?-^_/3MM!%#]-BK_IJVY_UY'@?_1DH6=7RVW?)A2KVQ:DIZ?1^WI^7H"^
M_N'G4;!<O2P2:@KK9W- 9;'<QR[B_K!=P;J8;@"HVQ3UQ(X7<;M<]S5-757>
MDMI=%N.V1\2[@%.;P-?[S=>Z9JFOB +DU^&56#@5WV<M]I$0$2X5YJJOI%JB
MJ(\_$L3EW3M G!%/1;2YF#;]PFU/F?]LMU:@Y_,E+-5%W"37H8:GCSULE5?(
M]?K/UT!U#NSKU]*WS(A/F/2-G?X%')G' J_^^\VDCSH4.LSC[;KGQ=!/__45
MOQ:1.KKX6^1U\4+/QDW1UA>QRBQNM"X:!^L!ACD/-P'Q\ <*Q5;J,>]^ZY)$
M1<PG]0_;O'M_2WAL>_-6]62Z !"_)-OU/3I8OYALK&M9LJ;_B-PK5G >EC)M
MVK:.<M(LYD!WW_;/[W?F&W?<?8'#K,T[\8_NQ'4(4A-#8ZK+QB/D"LF ,?(A
MACY-23#7.Y%.6965Y>!:M.6Q7:)$1C('>QK'?6FT<V;M"6$C;#\_S/GR7PLP
M[3]-P*(OXA_;5\#PV=MS/=D; #T8Z/R\+?G9X6:(0_<*JS(!T$\#FGC1S.9=
MU*NW7V#=P1)>=&&NU=9[K:LK,_LX6W GM)0X((*[(6$@?R;$+3@IE1%.$X=W
M D>?(JY?')CO_GGM06Y;8/%R!]]+YVGOM,F)XZA^IUULBD,7O)JT?C,DO/2F
M&^YH'4->XPT H!N!YECG-'-CWW8Q]O?G/IJXSK'MN#/XXF+<*R9@A;B(M@,9
M=5@BWWX9*PT]!^]G8F'Y=-9<U@#(AADH 'GR'SI$^6AG./8?T1R@&!-:;I"V
M/S?SE_-U&]DI&/C^1!+JL.=3/7ZOK]IG3XH_#^K\S'T?0-HKDJD$4%;KA86Z
M^O*X#GFYV](;"/*N@8;5(:U^-[B'9GHQ;U:]]R)K88?U%#_K+D=C?07[ F#,
M!^^>]4Q2(A)T>;V-J>QIZY^V?JIG8 57M.J.@?:W?K*O<?(E^&E3CP%E/EW=
MXT#[Y/ZI0IR5LOPFDN/0V;_^0G)&176GZ_!=KF)G!+/CW>ZLPNJ8BV.,JXW_
M/O/6'^EN+3NY?91Y[%_8-4"FT31 )M4SX)'FIQ^?%Y_AH1Z:$T#W^&E7TO.@
M7-GNI8K/8BO5MAG7[G [XR0UZP'204>5B;Y3+^PH^A;QW6:U34=9/R(6NPUV
M4Y>/Q/0]6]Y4.)$M[U=F>5=5N+WA7=;B]K]TT>K^QUB76\1X=?_KWU?'=C;,
M=3H*GJWU@_0OR0-]3K UR&^K&N';ZA)V/HOIJW;/P)^N.CN!CE]I-B]\[+!@
M;B/Y%;>1S"WO4C&Y^RL=&"=.5%@A#R*$N*,226(DHKXTDDM-0_ W4\>,2<^$
MI\@'01 /G",IB$%,$Z,J:22EQSO6^-%BAW7)]S'&\$@QXC$9E%ISNVS/LD//
M#CTY3N0FN!D1G!HBT ([#[X?$4? NY?PD[8<O+LU0LL06&G40!#! Q_]%F<J
M0X>DH<,]Q)6V@XJ;E%W>[7BAILVR$+)!Y<'YP,<V?/_=]WQ*)Y2<<T4/QHEL
M)--+E69TF*"1/- &RWM?:6^0K*1&G%J#C"_C,"CE*'=!VFJG]:P(W!H>FU\1
MP1'7\32-QU4<_%SRDN(@+'TX=+A]..;+PD4C +8C>ES4EPW:\ U:]N=9_+]B
M\<_^?##^W,A@I+<*X8!+Q$M,D:HD1\$+8D(I)%-N2/[\H;O]56?LJ+.0LOD;
M0,QG.S"78SY#,']]=_UT,B*)Z6;.*:;"B9,A^N!!X@"MW+>YK<MM#:RIP]0+
MCTJL">)8$22#%(BH("+4K8Q*/'C5>[&C!*\8Y2.)#\\SR&9Y0*4>WZ5CUQ/C
M6P8VJ7#B9(@^>&"3 <%JXFAP07L*6( P<.[*8V28MZAD6C#CE;5LI\];RH#@
MX6==L%SQE+3YRQ5/24#!QS9_/S:SX.M<\Y1SI)]](CZ;TT=1D\]H6) HZAR@
MV<SAM%O/#BJ!I:P<JEQ9]B<%I+0E4LX93HSC1NW,@TL+/:_=XG$B:@38Q0\/
M+$K<TN\VK$C,Y)]N""Y#JZ%Z[[P#30\RI0^%,H18E9/C8$OB"+(>2Q3KQY$D
M3B!C*>9&*B;M,"#$ I#"0T??V)G,E>=)V[[<Q^K$XVJ'^UC=UJN*I).L2DP$
M<K8V%4Z<#-$S6!R>6=T/%I4NA6>,(HV]05Q6%9)4$:0P8QQ[70:] Q:=Q=:7
M)4?:>8VX8C'#*RQR\*OD1 N+W4![58U8Q4:R.FJ\*5NTX5NTQ,B>77HJG#@9
MHF>7?BHNW0:#J:<:E56)$0\D(%4IA["6WFHLA2!F("[]H:,_,M=>)6[Y<NU5
MCA$-N=M4!H@Y2#Y,HF> .#PS>:C?E%2.68Q4R0$@>F:1T0HC:02QE>-,[![9
M4Y9Q*YQ"IJHLXA4C2&)<(N)XJ4@(@C@QR'Y3=%0R-<(DW1*C;-"R1\\>/1U.
MG S1LT<_%8].M;4R.(,X#QYQY@G2B@JDL!.B$IQ9+8?DT1_^S-UQ#^UG\S>
MN$_N.#4\\Y<[3IT02,S1\0$0?? @<8!6+A^1NPWL8J7*RN& E"08<<,4TE*5
MJ&3>8A$T*<O$PU='[#C%"1^55963EE_[<;<,;(;K8X>D02=#],$#FPP(EH"
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M%28 @S;2=]L6$OY@?+'Q]2[G$.I+O]R!GFTE[F]N0V-6_O\4Q5_@?_>HX&Y
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M"@9QXPA2WA 4F-$^$%P)NG,"^G,R:$<%$P,JILY0(AGW]169MXQ#,@[).&0
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ME7U@:::8G1UN8GPBXCR"G40[A4TF;$7'5V?%CTN+#S;]ADD_U]T6MXB@(=1
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MY75GR$!&,E8X[@'&\RC^G0Z 9;/7#(G:4Z^88C>9$M9,F:V84H JK6S,OQ8
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M&DW(T1W_-1$[W!?ND(TH?&V853"K  /  #  #  #P "^-GQM^-H[Z6L?[)_
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MRJ"J7QK]R)O\^C^_-(;I*/CU_P%02P,$%     @ 9H)<5GMJE5A]$   LK(
M !$   !A;&5C+3(P,C(Q,C,Q+GAS9.U=6W/;MA)^/[\"1R]-YT26+TG:>.)T
M?(D[FG%BCZ7D]#QU(!*2,*$ %2!EJ[_^+ !>Q0LHB4FH*3O35B86NUA\BP6P
M6(+O?GM>>&A%A*2<7?1.CHY[B#"'NY3-+GJ?1_W+T?5PV/OM_;_>_;O?1S>W
MPT_H$WE"EXY/5^2&2L?C,A $O1A]_!G]<?5XAT;.G"PPNN%.L"#,1WTT]_WE
M^6#P]/1TY$XID]P+?! GCQR^&*!^/V1^+0A6S]$-]@DZ/ST^/>L?G_9/?QV?
MO#X_>W-^]NKHU>LW)_\Y/CX_/DY5X\NUH+.YCUXX/R-5"V0S1CQOC6XIP\RA
MV$.C2.A+-&3.$;KT//2H:DGT2"01*^(>&9[/TCV71@<?BQGQ/^$%D4OLD(M>
MJ GVB.-SH=L/ D]/3L].>@C[OJ"3P">W7"QNR!0'GG_1"]A? ?;HE!(7NM8C
MJD\R!*EBP(+)<]<7?7^])#*6IWKN>2*\(RYF R@>J&(E^;A_?-(_/8EJ$A8L
M3N-:<0U%."#//F&23CS25V1$Z+Z6_5,%N:DNA1]7GF(YT97AH=8Q(E*Z6SK"
M$$(_9A1X.@L;<WPR^./CG3&3B-BC[&NQND!_-E#%$RQ)1![(_@SC9;ZU84&F
MQ2ZAV3Z1Q#F:\=4 "C*$JM#UB_KO^/7 %*9):46#P<I]L+RXP<\Y!</N.'G[
M]NU E_;>_PLA;7UTL>3"1\8([[BCD:H0IO[J1Q+[ZE'_Y+1_=G($S'J(Y<RW
MHKF#_1H1X;13(V*0=VU$!)*2_KI,;B&JM23*O,CJ<56C"9:!6;M=A7:M?O35
MC\J&Y$;#=D(+A]Z >+Z,GE0VH7CD[H9'@6?4?\M:-ECD5W?LBLAGFFZ O^IU
M0>QJ$[&8,>YK6>I1]'"YI&S*S1-XI@;.>31Z'LD4:7]RCH4CN$>JO<Y@*?B2
M")\2F?:RFL%<D.E%3_GX?N3<__3PY A<6D22$Y =TJIX %6(=Y<T+ZKK4U]5
MOE/%$FD7&)4 #!<]"7WNA=[@N^NY%&1;/:&*A,E=HU6N[D.*JFU*NV2ZK=)0
MA3):K?)-3-,VA1WL;:LP5'$"SP+R=4)46V7%?0SE2/WX_#BL7&0-?/S,&5^L
M3:,>X3]_1BONZ/^7S/W H$'K(3@+L="MZ2$*J[+ZY%$3HT8F<+\_.5;_P/(^
MM=*/?V+F(L,-I=B]&VPRV6 ?2.+>L_?Z]^9P"BN')!45-Q"J72]KRH75PH<1
M5 T#. )E]?[@FJM-$G7A3_<*>VIE-IH3XLL4?#6(+>"=*/!B-DCMI!).*&2%
M#*\.N3+DDCWP'0%?(-6^Q@T\<C_5?S_@M>I=>?]$W,_,)>*:+Y:8K>7]4J_T
MV,Q4NR$^IMZI ;AAGA8[.-6#.-G*]Y&IKJPC%(SXU#Q$D6RDA",M'87B?X*'
M40,B%B],&V!?WEG0GF/_ 0LHGA.?@I);.8)L38LUG&WA%="+#.N?.XS+,"X$
M*7XH[Z?AR(%2F(?5@!)DKK:%*W+'9>CW]V5B0?Y5)?*)'.4,$DEZJL_(0DI8
M9PH[F\+(Y\[7.?? M<H/?P6PAJH)?T%%"^2OMX \S?TG9/AW*#>(<H&#WYN+
M!?\W>^+?30"-V<,UEO-;CS_5]?4)O07C7[; 6#%%FFN'9/5>.UXNC^<D7/_"
MG'M'85BXL<>N1VK![]?<\ASX1&MN/?O&K#K0:H(V"A8++-;@/^F,T2GX+N9?
M.@X/F-J\/,#H<"B1A2#6K&H!]6T.U)"O]K0)9Y2P1A'O#N6:*-]B*KY@+R ?
M83,*?VLW5PAJ,64UAB?'.0P5&Z3YH#2C#C![\.2:>QZ><+.IN)P)DD;+3F:!
MZB0'58812CAU6-4<7.D(@YJ,."L=726D%LSR8:E,\ $EG#K,:F(&7;:@?ACL
MAV6@FE8(*YWJ*L@MV)T5C+>(5Q@P2''K\*N)GPFJ%F(5%EEP>542ZNT0J+MP
M5)O@*^@R'5XC3.9.U6RD%H1>YQ>&BD]?G3.:.%O$J<.L)F9#!K1DC)]+ADZZ
MW(+.FQPZIC+2M3M$:B+R2#P5?'C PE^/!0:#=G0LN1">4F(+5K_DL HY(<T*
MI7EUR-5$[A/Q573_@8C1' M2"-@FC06G?'P#&.@S! 0LD.;1X6/?08V"B21_
M!:#YAU71UBE7;L&E*$01<4"&10=+H_&F!N).->-/I_G81?WX$WH1_>KB_<T:
MP!A/O+W@#QE8P,]'0[8!W\CHH-\K"EF!=!6]!=A\R*0D(MFAV$RXJP+&R@H6
M'//AD[+05P?D;C&4"N R!!:@RN(I'2S-!%:J)L2J"A;8Z@=9.B#WB+94H)>G
MLD!6'7GI8-IS(U\!53&E!:Y\\"6_J>] :R;7Y-)U=?.PEWK5PN1=%R.Z QL+
MW%ODJ$!9(BG]<DB4*][90\.[RJWMHP&V%GO9)_VE,Z"&PH5U0$[>/'DD#F<.
M]:A6V.0?JG]5(N@*),-F!+S)(Y&^H(X/JS(HRQC9CQ%=;8AG>\7!LN_'9%L9
M95.^-#F5J::^U/XP::TAZ&RWD;A*;%KQS1^74A)?AC3NI1]7NV> 6" $0 K;
M""JK/.*WDF6QSGR@KBR>D[';Y-83TZ"(U$783W, *\4H;AC2+>L,L1E#W'K2
MW9Z+Q7CJ!P.["?4;9C#:#6$_%A8K*,K$*LY\[,S@6T>+XPGCP=Q2H+9?:F&P
M5/T/^^,J][ ?1XN1Y,.8I?'FS$03236O^T=R7^J]?F<T#1L-K$!%0&"_CB>P
MR%177.QA+^7,+*:2#YW6,Y50($I)[$QDQ\.+BOF@XD2CJI8%]'SP-;XAH'K*
MZ)#=#MED](17/7QX5D<1Q JNI:(%WWRT-L8W-9[C.R!"WAW(NX%<\S:/4>%M
M'A4VL!]?BXGD([S-7Q+2V=%>AZ7QY*XB43-&_U8O#!<15L9^FV%ML::"^&_9
M 6QF%9&(#RM<%9S8=JN*+:+ JA<GI7#K<SI=' [IRR<L#/3W2T4I53C!;%>E
M#!;F65G8]UO*JC:X5P5QWEH&IQL54H7-0KI=+PT#%#;M)8H;AU*MZXRQ(=^V
M_1G6]FPL)E20-5EN0ETDY?M,=>'P&_.'0#AS(%/O&4*YJK7'-%>'K<5<\N'7
M>AXG%(U\CB+AR$@//4YG0\W-;\DIG";4GCU[EJB??P9%=IS5=I%@L:Q\2+?N
MXBD^<C269!JS>1QIRG2#.EO;QM92.6W)5NR6P.8'>X"XOFDGIGD0?$5E^5'
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MD,"E35PB*=7#<K%_,:9G .H!L)]!<!=@\!'A&O1-M;^B^#ZCL)FP.GF6<I&
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M(P^S:D9"88:GA!1HEP_Q,.Y^O0+"N$ 9@5QV^KM$<YS9QS*&?Y#0=<R00"N
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M"E2MMZ=4ROM*\(S'(3NR=PS$SC1@*"#2\:"U/ALQ(O:_12 V<8FY'^BB: I
M5XNAQXA?&86PQC1G/^^RBI+(S&<="G4J4=$^:"9[?4G[KEZ?Z3' O,E"KS6]
MVH^"[))O9;PU$QZUBZ5TD+8V_E]Z1K0U@EL;H-]XK0CMYM:^7]-L@M0;Z:U-
M&F@,Q,X?8&T<?N,EH,K38&V0?+-)(N^KL";2=H9\4!"\.X=$FP?B!-1)50-!
MV*V."T8Y9!X,5<G955M-Z^6@/.S/-X4O4A>!-FE+!]-.DLK,[A5@AY/I/$>C
M^ K/^HK*7)'7(7,H3(.[^-''[A14:?:@(#^&5UA^C-ZM)$=?7(O<"A'$S35H
M0#-[PA554= N<I6'^]D>%WT?/U+L88=L<M)2,)'YY96)T@GH8<XC7W06OILC
M#-@5\P'HO4S=S2_Q7W"TR%=I)B&D6^UI0C_@B W[3>#A-?9BQ]\1PJA:X-5#
M> 7:,&=AMFFA)\8N,4GT7^Y2+170A3=GOZXN-]1)T;L8[SB"F!=H^!P^+,*8
M.H%W'<8D0BA(A=_DB: D>(PO):7KZ@A\C]%#F)->&-',0, 1CH(*ZC3XF*7"
M?L$^HE$8H"R5EDZ?4?G*V=KB%H8,RAZ2JV_=:W0:-=23+I'@+7T0W5E]Q,="
M0Y$8=E2A5,1(\P-??F%4'5",1T,4/Z(:#M-#JX8>7BFU!FJ/AH6]0$(V&@I&
MO>#G&QQV@KYX:!T$I[)JP-'G8>O0.N+,LY43Y>.FF1BTN'*TA6-"8C)5[C1F
M8E:O/@G/]-L)TGA^&8]&E8+1%1P6AZL.(5A1S9XJ;_X8! JR^ZW(>F(F$/UO
M(P+=U<R(1<5SI=ZB928,_<T4P<YC9H!GO] TB'<U)A[I*XI8K.H=(LF-B'L<
M+K$?L\#FY&=Z]>+Z,?2:Q*4YOANG2D16#'FE9O0%+DU H?&VI",WAD' )?+#
MY2J.,O*O',*",'>$'PB&\INIJIK7&@AU)!=R$5)*.M%Q99CO4)KM?L)(B8J"
M.LAE=RN#0@-HW9$L+SLA27R_64TM'4\6'S=?SC?5#8@>0.ZP1V, K+UCK;;:
M<%C1>7%9DC3%=,F\V! %#7'+&S,>TBM%>#F2FK:UQ#05WN\2RMOJLCIN&UNN
M_'"#4$)&>JFUD'!^>=W$RY-=1; =$0:JM=GJ2 0UZJ"AMM1Z&P%?X2O<A5*G
M9QG*O]R3?=WK7H7WT&JW=^/!%'G^#4/3^, !.<]ZG?Y46*P52]I0YNOE4Y>;
M@"+%;F#8BF_%XNA]9F+0P@*JTCJD<*Z)Q:*93IR.9J! B3<3!X-FH6 ?,=.]
MT\<<DIT]^MP6>X\%<U.BWV(8P:LU<\T9ECE=(J_.H< MKBFO+4>+T,Q?5=0
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M,_KW C8[=HSF#VPH=D8Q/:;I56F\WI4NX-/P!;2.'HJ NG2"B5QN*+ 1/]V
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M">)IN4A[K1=2XC/;>F*2WMSYW_'I0O,VPDY<XJVY/:6,K.N8K,LF"W"$[3S
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MB!KCV&0TG'!<EG -.1$\#..-()=H,#+(8P]$"% 9P4T_C&$C/4=R[1)=$2(
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M24]@9$0"Y*,Y/FI<RZRKY_VS8,:3O[4,=7#;\LZ*VW&ZESL2LJWJ=I3&Y="
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M8H()JIAB.$N^/DL;G*6UF"6/SY)OS-)&@_U4-7$.FZAY*=0M@_!X"%^$47%
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M4;X=[X5R);+^BO46>L37S;[<^@O86V+'+Z-]*:.]!#PFR9I\0P$GY](;*8P
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MF4*DH:T"?\(T.Y@+"3>2P%=:(D EJ?2.0BMO]KVL_"^\:&+4E]*(0&'X^Z%
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M[LL"GY$[W,]A,LW"1V-&4S6CD"H> 7@)^Q8^^S"9!9\_4M:K>XH;!Q"NI38
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MPCD"L G.D]-\*86<[A0N';,UQT=(=RZGV>:H7Z\%U56AB .:OL**8=MDV6,
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M?E 4IJ6KHG-H*@=23=17$9W 4K>]CF5&$V1.E&B2 _LZI0(8!/OJ8BH8(']
MVWI!_TC$JAHDUW&9W :4R>VQ250)B?21S$&LI"8[A*EHRQ2Q(7C6[L!NN&;"
M"R-.V";-R0M'[@BM<1V(UYP$LV$ROKA)HX1\$AYM_BN-HK_$R6M\SU9-$M,
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MFO-"1B4$R*PO-]=]2FLG\/H>H?35 ]559Z[%5L9H(#;VD]'H&F/P9R?@P;$
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M!891A,N\.C[65#A9YA*L0GQ#Z*V=TA,<NR=R]DE:SCZ96U6<LP\@/@<_.CL
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M8IW-E.>/H4?N=#G1!M_I8#K:J,W5)0[B302)NY<6/,5/53=F#C8T,[95SI&
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MNY9$^JT>HR;-R!:G;'3T;W%DZ;-J<0J9>/U;&2GBK%H6*_:86N6XJ0C 5 1
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MZGQEU0 T7?8G-.71Y"D@RZ,_:C&EZC\M01I<^*%_%N/-:H6&\/:GWRX0ARV
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M_9@5VEWFLLD9RO9P\A2LI2D1.XS!388-F0FCQ^ENR^WZOJ,4TQN"4ROJ& P
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M$G.#=9VQ +U,87VB6+8\C<Z=45__D4O3^V3LHK &&A6/>@G-8L)#$WL1-_6
M&M,::>377[</6[U^TW9WVF]FSXO'[[DV/)I6B'Q>0WP6?!@KF:<AS5M(Y:FQ
MSW9;-?>SU[M3UM[KW0_A!.T0GB]%^&B8#F]C[G,#!%#[>*VA75-5H\D_+!JS
MA2S!(3#:?$7;W]^'.9Z/O9!4JH2)NU)YH*6<(^U7/ 6>1G8@PV4*,=/@(Z:
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MKD&O"   I5$   \   !A;&5C+65X,S%?,2YH=&WM7&UOVS@2_KZ_@M=%]Q+
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M[F9B_*3#F;"YI-,HE?QA@[/_6UA4.^O<B]6MH\9UO4OKX(G,1C&U7 K%-T[
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MDK:(6\+AYH*"9Q)H"#&'#66+6!?NZ;ZWB:SH7)IC329]OHY)XEFUQY,C#SX
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M90&8Y]@;>//$L2=$SAK-$,I_0Z;SK);3T\;[=YU'0O"/6;5]%!!93MBZU<_
M?[88RX76$JH[ 4_68]@ [R/_6<<3FSEAC.$Z)-?E0@L+<*XSN+S4"L-XZLV$
MV4([G/6_4Z[8PPWB P [(A]Y; I\/K9]42/M9KNS[.%-P*JPL'$![.(,DW7,
M_.@9!25[,9T_F-I^]#25P"OC@;GCSG)P$#[ LA=SN(><?&)/5M^<V[0LJABF
MXNUJ1JL9?<F,9H(QR?=B1JO->%^PMW<_#+#VFOKG4>-#H]IS*X:N<%_-Z '/
M:+7G[LM,[=V>>S42/"6#!YX4^$ JN0D/J1Q2:?=5_7OT.3QZ3^6ZDX^_%=K
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M9)?F<]2PYX ^%C(B_-G OX@!+V+J*29BF#,5@@HI].)X1CA<4[UY .PYQS#
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M3<O=!"-<;?D3,J5Y43!(H*AT")^399IM_KL-_8;OZ:MN(WLS^&]02P,$%
M  @ 9H)<5O)B=3RN80$ NF$! !$   !I;6<T,CDW.3<Q,U\P+F=I9D1V9504
M;!?MT$.G-$@W" S=W0U#=PR-= H./73'T!U#2(,H2.?0#8)T"2@""JCO7+][
M?]SS[ZRSUK//V7L_:VUU334)28<?Z"GHOP#_KT    0 @ , 2   !> % 'A!
M %X(@!<.X$4">%$ ,   !@' $  8#@ C 6 4  H 0$$ * 0 A0.@2  4!4
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M,NKR+>#8O*^#(3/Q31F0G&7;!]S_]FXB470\,A 2-\:E0BQEUD-:A[=6'E@
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M>UY@O;W@U9P=ESN;0G0A<.;.>J^^>U8_1U6;<DTH8$K>_<>"S])TMD<[#A@
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M]Y!1AB#W1I/@S)A8Q&S%S7&'YVQDA5\*/VHU5K"-ZQ4=,5\XTX[K7$R_9^H
MWE*SU_P8UT=CO?9+S[LY]!?.4X,-4B)&52^(544,5:E<1 SW%&X)U2]B<G+[
MZ"*?2=7HRO'C>ZD]D[_5N)E$P%B()QN(]?A_X8JF_>2H7M&2.J%80%L\Q+\?
M4KC^_96?J]%+_Q/.;0E?6CIMBCZY^5W<#S.T7]O-GY ?63*9,<]^"U<G*8SI
M?5#[A"5N[3?)L-&@$<%STU=2$7&K>I$PJLGMDF\,F:R,2]9#L3-SLV1/71$L
M/P@T?S:!?.IXEE[Y^([>Y.O6C#!H7<&4[C>1U4M@,>7L*#4DQ9RK_5"@:0G
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MSN11GY'*";^,B*/9,U_R++GXCWZD8+E2^DJ;KNT,?O$1Z%>-\[22[4PF'*>
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MK:C<!-]R2I!ZFRA_U49MW35L7M;R"G&LYC#O!IH14URQQ59N[FM/-G+*_,?
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MH/2$!B1O>R<!LD?6V]AP@O:#,']<O3QOU]0M_.ZX*Z(,M96]P::SR/=USB^
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MU*?6ML!_7Z2=T>'/M!,?,FBKE>Q#2!G76ANK+$I(:]#!!R&,4,()*:SPK\!
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M'FX13X4QW)T]13(,J2!*+?Q)BW>>-4<C!A*=4D&DTNIDR+54#WH&@IU!7HE
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MS))7.HFZP8+ 9AZ1' _RI$//>\8)N,.56:'<\RRSV6R9R,T;SN[VU.T!:C;
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MC@*EHY-H2"9TW6N*H,&CF<#O>O<AWY'Z6AG!CL&40ZH,_ Y6US&0\DCS.P8
MM#27@4V#,J , %1I(M@DU02 =9V)<!] $RI2&X(K-!B=-NXLNR*+I-::P0<"
M9WI),MU3VE/![1BDXX>$?DZ>)US:"N[F.*%\8(G#E*U%TK.$%,_)>7X#L*36
MS"<ZHU9S\WW<%RO4U 67CUFU6]H!U7"WX'KE=R,\,OAY!M<UMSE<1GH#7@/
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M1U*P0FKJE',%-)(B7=&C<BY$OZXCA?-$ 2"DLB[Y1@H'("/<OJY$;!#YK!,
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M@R"'5\2X4MJP-08!_4^.<Z0C1LXT-W+9;3DAT6,=OZ6_OX%D3O?J#FERHCA
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M2!08$:UC&)$[B)2J8DS1SHYJYA/0]C"TU 59EDBI>US& "0E]>1-*= SR/O
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MS1L2#30->[LS9\XRGA.*;=I<(R D('DA\CB8Q-7+-AJ#0+V=;6S3E[ZA,/,
MW<44H:&GO\*,"5*B40P\SX>3$:62K2<6H;2\<- 6P@QG8GS,MY?1/64_[^?T
MDL3_P[R61<'X$(KW,IC9%IC. ^*>O7$4%\UPG'N#7LM8DGGQ6B>$-5H-9^63
M+'3,9QX_.1=.G!Z=FP'Z7/,84>><<)*N3N:+7U_&L$"-(/4R@P(.:M8$M[<=
M>I-H(A-\;E641*,3.%-)W7F."B8O92D*<3PS$FJ[+-7^PMP1RT#H8U7>A&'$
MON ,,"K@.V'^$ACL!VV?P+>MK V?%L4K'HN,M]A9%OO)@DF$$N!\^;7&,./1
MYU_ST-!?N8(SDN2HA^\ZDS[3/X20FY,XB=-#NCAC) T),P1 ,SNX U" .MBS
M ]DSL^^J$TA!E)@ '=\S+]X9"1 *,(<!!:R;I,BA-5%[_[[F.[RV6[\71(OL
M*;OS*"V\"Q$B(B(@"H9;T4$0\;3(&3B\0 .VDR7/2+S"4[[#6PNO* B"<8E]
M.1RZ:B/*>SDR0#8#W$)?0\&QRCF>LPV.6(93^#S-(Y>7R+)C,PFLF"3ZB09B
MR*LTD#H)U$"I4S,X0$"4&" 4U(26:K&M,QRZD)ATDRB%^2!!;!7V<0GC<D$D
M?$$L,C_-8#ODF#-:R@]@XL%8P;X@&AX60[[),;FO:)U-,;RWB\2PN*RWB"Q7
M8[W(6Q0V>@U9A W*"T,NO,7JPKDOI!LSS(@S\3F/NT4L2T"6, D.:RL1I"1C
M&@-NJ\"I>[INTT"4F(X.[*_0*/^;L-DGY:(4#V*8B*I$=>FS @$062,=%S1%
M4RS%DBFTA="0W\E$U#(B7=(EYH$VH:"?\4G"&(PUT8JU4IS$J *6)Z*MEE(&
MV1@GA'R-R\-%AF2R>I@;CBB7LI*R4 !&7!0@8IP7:"A&T#F(O(E#&7@Z;<,V
M/%0S4!A)D3B%Z,@]3<B;7;$1=0F-#D&/22F^AZK)#DR*A,"H<82^J!*+R"H=
MH1RTGL01!,@>T1FFAD*/3 S"8- +'00Q7%JQ#_2S]%DUMGL^Y^,X?BQ*?4P+
MVV*]_E(&+#E(+%S(ADS+W_B)D1@.M\PYM_S%D2@)YF(.<ODYG7.GW3 )4_ Y
M(-G"7\S_LJ,+"<2!G$O4.NT9J*C;MJ>KP#JTNK6*B)IT#$S1(,?1B3T)G9?8
M+HAJBNWZQHI;1,I9M!AD0B7DRB94Q;$(CY[ZI-]YRI@J#.RCF1>IS9]A'H38
M"DKZ&%C#$7X<(Y]4E?0K1QD,,L+RR!V916VA/#50*;5\SMTP(!24F_Y#D[OL
MO^#@/.J<3G*)RXBHRXKPPLYCI^'X)(WPB(I\#BVD.7<1S.M0P*-K#_.@+??(
M*PG<A#+3A-@KLY&$NN%8J]#KRQ2<DJOTND6927'S3&)XJ ^""H9 (Z72QY*"
MOJP4SL4KO,H(*@W12WTYB*8T#-N4RB&BRM&@DD/QI-)@OD?T_PQ6=$)T+$X-
M4ZA%\179$"?Y@0TUZ,X#@DX>M8C<RT[_L\YUDIM=]#\C%8[^(Q<!6E+MBDN0
M2!>8)-**'+8X&(Y>; B.Z,LXR;]EL(-XL1.ZC 8VC* YLXZ.D@$<P#8)Y+;^
M',D\Q#F/Z$O ":#\@HSY=(F:P(O"3#F70*SZT!P_?;.%HD\"24(5)4Y6G$$9
M7-0-"XT"/ BH?)'%F$H@-(PCBDI;8Q6]M+%4=(M#7516;!VVN*RV,\Z9C#-Z
MJ#^SA+D<];EU"L8>C=4-:5+]$=+I!$8"FLM?M,[IA,LA-=+]*1?.ZTZZ65+]
MT1]B72>_U!];O#F?P]7,&T.C0SV/T/\3!-6)_&"S'\!/-,-#V,M 9[P#8@P<
M:%"8W!PL_HB@TMHF:'@4=\D<AHF*/LI62%3"WB3.Z/.*WQ1(] D-=PK!87 1
M@3TM9!A8=B#8@V4,@66B@53!T""0PINW46V^H7PA444A]&&I!-FJA,22NQRV
MX"@V67W..ZI5+%M/BJ"3,UFG[N2\($U/8(U9_UM9O^P\ ;I2A>"(B/Q+H5//
MP'D)E( D9#0O5EF/-!" -:4O9Z2Z;HW&N@DDDRA#..T@)UHH1LJ//,53K1V*
M>"T&S2&(IS##<;Q8HPS.3BTI)]R44&T): E-J^2-^&LQS6221SR_KU05&30?
M'0&L-DR-77O_+H1,UN$0")_;!/4<6;54!MD+CAU-#I6%2RGE/([HFR?[U;G)
MKO&4R,.M#;_T2Z'#2#6,CJ&H5O"8$9=(NH0(J,:<0&B4.I2$4V5023 U(((0
MMZR#'.R O .M"H]PB@X2,,3R0ZS Q^:R4/0[0E1<PA@$"^?LR TAI@<=2-$<
MWKE##6VZW2@Z&E)E/^1MBWU-B^5"-H.TOUU3R')9V5^%!N$ "<2]1?ZS V9%
M63"ALLD%4I=UR_0DPY^C67/9'Q1DW_,T%X' V:^2UH](PWEI'+%1']9SNC.[
MP#+#3PPLLY((7;:*ADR(HSUA%31"I$ !M95HB@55K ^R&]O5G@9PVCY5B;6R
M&-NMS-?IHRT-08X-\R0:3@W'0:_F(:9-19\9=J+\*,K?7,46[M3+2-3-6!T&
MQM:7H#R$M#\G0=_.%59A!>#VS;P PL_&91ORVE7M)-*/[;S]J5_R;-;:&D\S
MCJ? U$C#>0B9R,QHF21$<@P6D '^3+,(OL#9\U+OVLAEZ$OUI1.L"YL*VA=T
M,Z0=FJI3[2") M3BDQ)I08C_N%>T2-3I&34FM! T>%ZS^QSYG=ZM6ZG;K3B>
MZB+5I P+==&O-)\"04J"= ^RQ,+GBI_+6UF0W=D@+8DK_[:YA4% =)*.,YE<
M[=3%F+6#B;0(FD43 C8G 1),<KT.HBJDOMT*X%-=#$2S#,0V-[4#B)!:08J(
M.74S3SY7^LQAK3WD%90*22EA$ZR([8T^Y#4\%;TL?ZQ$U C+>UZI<^'@6D.*
M]D .>"/G26K$559>[3V_&!Y$T"$&CKV2&\4_A4#/P576_JWB9=[E.L*Y*OUD
M-0Z.GXO(]!126&T(].T;\PRK\<*3][03CRC,+_/7JOP3,8A /.[6;\-F^E*#
MD$D))_.N.9D*;G%4/+T@"UHN!K:7R<%)AD$L29&4 E.4H5#%GL1DS)AJ5#1.
MY/0D]8@9.RT2Z!%$_IBK)\G9JO_E(1N#BWT]V^AK42#+#!TALHM:SLJS/&2>
MFYHM%Y!>WXO&Z/LYD^VB.5T<-ENFXF.^.<KM&R5;8V>N5M! 7>8*2\79AZ:;
MK\>$8#C(@1R@ ?@BKVD$''&N("I\*QE5(X19CZR3%T@QP7AMF#=,7:H&2@O]
M7GN3(02YH)B&WE<4(:@6#?"<%@L*'? B!E)U1,M@:PQU/-[Y0^>ZT9B#:(NH
M7V5>7_PE*Y_EZZ]:-HZFKL$F7+RT67,Q$__59>I27/@L+\GDR!R.DE.5R968
M!!F:P K4MJ:=/3C0@1P8 \S6@>&(VI"0TP&+O$J\06>2DD2$LZS0B4E9ZA(<
M84<A"(O_2PBE@@NOI.0+E:4TP M+#+5Z\1*1'=2@$YT&TLW(4Q3Z@5A65N5[
M3>7#.P 'R)ZQ1H]EF+\V@BY:QHV[#M9?'<^1Z&'KQI]Q"871JUE3P*X!AEE>
M?0Z&V-7SI:Z^$<R5) Y=1MT%YA"S21"!HL.:=D90P.PQ< 3,UH3.C@Z(0$&8
M=,6P<=@.8>#04!RO2^VFH \!>G.[R8],P $6?^USG)Y6CNA2+E#;S6'5:*Q:
M4Y?+>=L+@I[\V*8(/6(5C[&IS@$"8Y]ZN$+HXECGO@WU'>R)YM]=M-(V_@U(
M,B".Z$ZT[/$D]U(#! EF_;G.<U4 $$#OOYL=((6@XIQ#*^V*AD RO9;_CO*5
M0V<5W-IZ<>#8JT/8 P+,SH$9((.'F-I C@BFT-.S&\0H'&JY$AH^^5/.T1QO
M_%,?,K<-^8&ZK5#C;ADTP.>X12"OEMX=H:T1JAS]4',X"VMG!\\ZMUOC'6('
M8/%,<%0^>0\KY%BM"IGBH!,Q%F-7]=\J]O3S)@^D"_61:/@BE=PT-O6ZN<7
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M!JMW=<1*I$RY\PWZ9$)V=;-=H4PD;C,]]K*?O4\D$V_/C#8SYT8BNT4C:,U
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MW3PRWS[>[+Y2^J%9$5XV3/[>H &!>P%_E9.C:QDSW*-FI,UK]$@?,XW:(F7
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M8F(TZDDI/\.[?&4074P^OT-JQC!8"J=CW&?W= +9^H8W84Q ,"ON\H>5>,Q
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M1Q$21P52#8A!&<K35D.J'ORH(H4PCS2%/0Z)411O_RGL[)"TIS-HKRMDTU?
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M;H1YS=M6U2"]-O:NFC!4TW")!RAQ4L:N:PW_K3J5$13S%/)P/#R/XNBSGK8
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M=)<4=9!(,E8Q,B>3=5>7+K93/ZQC%@[F+F;%.FBH8;2E6W663WYQ%P6T3M!
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MTT.GI5I.V8W]AD2 8Q]+ FF[-3K^5H77LIC:8BX5]WJX!WM2F"S]419+1",
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MDZIJ.6VNHER499_^(AN><I;?!HW$I'@>J&-O:4PCVAHF1+O_DCHW=FE.Z)E
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MTDZH%HB)$'U@D%+,$G')R$-1S=&DAY-]FW4MHEYH#I\8E<5\3D5"I%Z 1Z%
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MHDVF(@9><'&03&SZ)%RT5:FZZHE^6<&TCEQYB:^>67?%*CGI&1O]V<P\KJ7
M;H&!V2LB95&" NF=0D\Z233$7PZF1#$64 <-,0]?!-3.AU5>13-R&EAV:41X
M)91JZ9=:JZFQJT0 G\)&7Q>/%AI6TDOTIX%^"U!8&U8<#D]0PGH2A/\(78&H
MU!@$JB8%#GS$&-1D&/P\&[/$4D^X+WV*8?5"!1 PZ[?=L2!>I#N/&RC0H&*
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M.7'@PD5&++(&5A6,PRUR;3R*7>\BAQX3Z?PD@,&N]FAU/KVPD**3H8R.NOR
MX)H'@O_SJ2;Q8]-TUK"!N) )F]9FA=ZB"TQX7TNM&$N,08H?SIKFU#[.K59X
MUDI$G]O:Z=4A>+8(:FOGA'N4=(-7%*NP<HC)36-C1>.8S[JL1XM#5W!/NO\-
M6*? #/)4!G JTUVY;!#UE4J&"<(9QH\.T9FQS)>(>DU*=YXQ>5O##*1L]:.I
M42?C6?:4]^H@QW?L*)6L=Z5[Q82]=U10 IG[3?TL=F7-CTBE<1@&]6+G5-J0
M\?WN ]O^S]C<#=>>34NCST".(7[_Z[_J+^*4JVU%RZ]D5$(L(? J5"X?Y"F%
M<[('6V[ABF-KS=>M6IG:<*EPKZ4/DU7_>S#E\2,FS$\FTUG_']/I)$S)@(HA
MNY-L9BJ>+3"C 8H'WRQAY',D*DJ-CJC,U/J=\57,;K=>#PHH;VRRGCRE0(?X
M!@F[=/F%%[6<BLO37(1KPQ@_VDA!(AE2+WLK'TO"+B9)<#O8LK1>#D0.4,).
M2<AN!=M) R96!!WXY2F]IAA-#&B3+#V(TSR9_K>]C]AK5PVKS-(RJ%!S-:C
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M:B8I'#D*;S(["TG$HYVKF4<LT,H4_KKH109E92/P2<KV+&*3ERQ#)AIQ"5)
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MGAOQQ(/R5.^YI!(5(_3\ LPOH%_M3C0U:T+I9<?2%FSFW:CR#4L9HCY\(&*
MN\&*FE-/H]@T4DUQV<,\ZG9HHZ35U4)Z9N,N5V$;8:BRV//5V5\V7_[=3'%3
M(O$CHT<*+><U]2$RP[??'N-XQ;W__JRZL6KTHVB6HO#NO/#CFRNAZK)T\+)"
M.85\\.TG%'!&<5KTT]2_U3 FY@'/=FK2*CFQ"4=<6Y.(-)$&. "-(8Q 3@S$
M4$!S*>,XP8(@\:Y3&^4-JAZ@F 0<--$='?&(,^1SF7&PY+J4@)[&73![B/1H
MQY+0A,=-$1F;R] $K_*IZ2$8DEP U7 _(QYQ)W"A4..JTI3^[>\J?2-0W1@W
M.,*YCXE(U.)ZW$>7G%!1/IKH"U_VXI=M=6=6$NG<<Z@2(M%PASHU&8^,4C,\
M OKJ'9HYCA@V6, TI6EL,,2),K"TA3$8C2I&(TPCZ,@%H(7H)K-J'KJ0YAVP
M41)-'FEC'!7)$F4$L"!YJO_?%DF9.&74+6(\J0O$>J(@ARTL0*'*HGO($A>M
ME!*7ZZ&8_G "L2=^,H#?@HG)8(81Z6GD,&\:3$0J<CA??:07C1B#&!K1B#.R
M)"P#448UQ4#-1CRE=MBD59F>6<P2$8.;WM2:?+@Y!D8T H*^8M6'QA62Q9CD
M<,R3G@*?8ZVMP4L\\IF(7DK%-GSE$J&*,Y\3?^+$N/CDE5(Q%"JG0BA]%&@L
M"=5H4AXWL)P\ZJ$8T03E- 08DX[!36D3Z-<0\Y$%:=)('D%G-*MY"QP=Z43U
MJ*DCHOG(<6*RC4>S%DPI,B>*6-,1MZ!$(VB2N>HL-9J.@*=@$C,H-)+HC94D
MVXC_QJ5 <PTGCO;$)GD 6*^2;A2M%SOE?B#'$T -R"Y 6514F *X\4F%EWXJ
M"WYFF=:T*@P_._%83<K:MO20S3"<J\Y$4!>KGS;F=R99JB,FX8M&J.>J&-GF
M4B=QV<--3VH#.>9/Y^2U?<S4FHWH13T)8YW.4M::?819G$#RS$[>*&JT*>;1
M-"=)>>VCDR'KRZF(VU>_'K<]_%&B7#TV2IM0,52F<*C",DHHLC#*N,C%Y11W
M0H_]Y&<99"RKJ?)%V]*N)#SI?8Y*0'M C*"VFI/PR$U]=]3.6G:J*5N@;FUR
M,O02K[.7;80CC*)&D.R#I]:\Q52-5M_#24>0<L*.U^#T_Y$>/N:V\D22./-B
MT+V,#(#=T^Z(W6.?_60W89%JJT\DU955\L\JFD@?@WPI%A+[=7TKO@E#/T(O
MEY05)GORH V)<TD"EN_(-]*'92=!6:5J32[;O$5GFYS;)$W$;-:1SF>S(QZ9
M)CB:V^+P:) J8-GR%B=XR>I^&5NF@5YK0M #[I&D69[)F>?&>6Y/W5AY%#[+
M&"D4_2XH3J%<_A %Q>RY;E,(I^=<^E+'-UEB30!3D+[DX#RH AN::A/6?Y)K
MSA_$7(!C"QVMI:Z:4NT%PHP,29U-$J?0'' UB0%)29Y6M=7LQ0!M2!WJ%56L
MP/X5J*W5'1I"3Q_@?)<R@V9GDO_)Y,R.EG:@G>C1HP3**TGA"H76]Y]E%!H_
MR1L<5@(EE)M.VW[0[8DO)^07#9550^IAXTGH_9$J)6J&8_:G:)1!#&+X8DPF
M$FU8_#V,#2I6:^9BC&@R6>_'+H,8!H\G1:HD'W_[@AC@%';UTN5JZ?2P3%BE
M)'$D&2*\A-'#9"2NB-'=<IXHH]P.XRB/M3V_[[(5NH -Z;[( K&/+4;<+K\8
M7;$R8X94]".P(>[279(#YZ2OP-<I9UZH?J:RY82_Z3-JQ<EVMEO7TU4AE[.%
M7;VY!<KP7"R)6O4T_KQLOGV9D%GXY?22H9?DP-U"U[LJH1MIGM2'?G$%RXLK
M1!>*<CO_E1A+T+:+(I9E0./Q5MH[GQ0F>+?RQR9"!*#*7P+!J$7XP")'5WW+
M"397F\O8_:TZP@5^.12A_D0X$K?+W#YRJV?DPJ].UR0SB\TYH<S"*Y%.RXX6
M%&D.=WLE=>[DA2X^F<]\/V7W"8'\YK$H.O3$BG/(0\B29.8[B.@[3^+'"DA2
M/)5U@X=;$-=\]=F!AUJ_]3::NEP]*S*%5NZ[57V:/X1/P;PJ&G*KR$XB[%+F
MDHCO[:A".NC)I:KNULX.C0R#$G;CPP"H<KX/ ]7'4YX(*,['\L*'<:2(K2B$
M0!S&Z#(0W;AK^K+M(X")9(;+I&0#;1909;RC^ SC;$:.X:AB_W9$@X8"$%VR
M@^M,@OCN259 @Q[J@1[>1%5:"EXJ(E&D3YR\#/^\PYD.#(86)*@F0HCNY-FX
M!P4Q$*0>Y01Q@JW\#BG^8P,+Q(FZR"[@)PR_+RZ\:/KJQB;$B(Q +"8FH5="
MA#!,3C&@$#LRAZO4#LZFSDINZ+'TS]3&C![HH1V&H1V$H1W,81B$X1R$01(E
M41D>\2:@L".P;&O.;9/D++%"@OA\R[PBZ4BNL-E R:#4H SC<,1*\/F^(L?:
MHMMRKN_.,/%HT>5 RMH@:GPR[]G\X@?\0MZLI%R( P%/[4_FZ\C*Z7=.T0!M
MSZDDR9]&3A^4(1+9@1=X01C,@1?(<?\<S>$<QU$=([$=9*/^6JI=(,NHW*[_
M,&GLI%%GK&,;@4LCU@8]*.?9TF#Y@)'$4*DNT(*M6.XL0*HK#,4-21"5JHL@
MIZW;@(+;;@(@RR@F+L/4SBM62DY9;FI$;FT(-2?8RBY.LD-LJ"XT]$$2>P$<
M,]$<VH$7V $F;](F,9$7:/(<RA$3A>$1_Y#>UF7_XF4H3VV^K!%S'*Z><(J?
MB$>80*DOHFTB]8Q J M@:*XM;)%_?!'GF$(3!K(J-\J)9C%A%N4]WLW=M.<E
M1.RED(QLBNG6SNT!=\],TJ@B9# E$P->Z&$8P!$= Q,F=[(F?9(<V2$P"Y,F
M 7,GAZ$[5@H:SIS2G 8NK$;$+.K1,>YOC5[%3LSC)>XE0Q3_<BQOK.^&\2M>
M;#Z$ C\*;8E>:0Y+$!02;31)Z7%D,R\PK]V"R<.<P\!,I+5"HL&8B7BZ+N$L
MR G!SNP&Q6N\<1C(D29Y<AR;LR9[P1*KLSEQ<C"?LS#/81C8B]YFI1[,QB2)
MTH=,Q->N;B7J"YN:4ISJSK T4MYF4]K>!^E <#\.9-%ZL=H*SR#E$[D(!!=O
M4:3^\0M73GFPT?;B2)Z@PSJ6:2)FY_:$S;WDA#P90A)]LB?!$1QI$AUE4B=M
M,C";<QP)<T,+DQVZL_CDLJ5,(H[X4CZR Y*LBDQ ,=8JX]E(BKB*R#^EC8KN
M,RW&YP-IB=NHR\4VQF"<R#9WU'M\_RE)M8D%!_3NB&M[.B]%6Q%M?*B-GBD_
M'I"?^/*?(JM,$D,Z2S0F/[0Z=[)#U=%#>W(QJ5,G.9074!0QXFY-U*QYOH-=
M!"XX*2[M(H,B^$)#WI,O@DY)CXL^!10L<(Y/&-+Z/(5_)NKQ"A6A'/(K=DG\
M&((2Q*M>_"('(&CA_D2HFI)%J\YSS"ZT<M"T4(33Z$%-%1--I],F2S0P,U$F
M!Q,P171-Q_%$54( (6R]@C#6$-#DY&S&DLF#H@$6M\<OQ%)2<\E0NF(M((U9
MTZ*6G$*ZZ/,ME(N*X+!9M<A2F_0L!><CU"!0B0O$_*)[:(OV6NH9>^N>8,5*
M10(D"-&]\/_RG^BA'+.3%V025K=3':OS7P>35J/S,*E35GE!,;AJ5(_3)EH2
MSO9)M ;*)(+*O91!B*0T2OD"7+OU?KPML-0BQZ;N0+JR46',\.J38SNV;LSR
M)J@K/V+FQSPS@$RF,N4%82(L1'*H8:_4C^)2--SA7YM30P?6''"R'*^S3-=T
M:%T51 D6$Z/FW.JU5"V"UT*O^)9R'K/)8CUS\_#$-%,VK9XU2,_"4B^5\HQ4
M0&I,Q7!N8\&63P#G*M+"VZ+G/ I+(\'03#CN_>J2;%#G_;8PU+"L_]:UUX!K
M1!=S7W_2.0LS33.41(\V1 NV3*US<8&2R-R+*@S(]HSI_N2U3VO_HDXF,)C6
M4C3=-I?J0\585B=:LVW1@E$CRE.Z")5,UWL*YF/3HBR#@HR2C[A"3/]B)3H,
M\6A&B^3RKQ!' PCMTB\!UG'3='$Y5$T_]"8[M%]GTD0-$U<=$UYI4&OVE!\Y
M[))&9/@8L#LZ4V:)I%Q+EW9+26S5]RA*<%K=P]M\<8KFD"D"97WGQI6^%BRJ
MM:W Q&UB D\HH2(B;'Q9D3NR:F%KRV?#9O^D$V IES"AUWK/04.G,S Y5$0C
M>'J1%GO?#]G$[NWZ$CU1L4]]Q04M,)C<-W^UZ,3$E2U@3/' J$<[2L5^L87W
MY;O6 Z3J9'MV8TK-U85";E:$=56&##B]_V]O"V,X6-0'T9%#M5-6QU&*"9-H
M%5=Q]34F-51?:34[F)*2DE<S=8;^JC0Y9>I4RK4@R(A#<ABMW) IV.-DXX9P
M!HT-)VH.G4)DW?A!9I<]_N-!V?);>-<\FHI.V9/WNE>.S--ZUBG43"(2G7=$
M(WB#W_1ZS:%I,]1-SQ1Q._EZV^&_7H;+IJ/WJ'!9'.S^0D: 9Y:/-XJB8I,]
M F9L_\46 P>/=[B5-24N<'@KZ^(A@ G(O/ E+C,*;\0D[4D:&T[RDJP9Q>F7
MR9&3T50Z-=@2,:(=W($B,'$8!J(=>-4<C&8297*:RU&"NYD;-S<NG4>=6XI.
M%TB(<!2 3(J%<__9?D9P$U27[W Y8RCF4<SM^EZ)VSB0GFG,#O%3*.YY&0"R
M;@NTCU#OM_*"V>81;/ BPV*O>3RB'6+51#=9:+-S(,!Q'R9Q(,91M'AA(.9A
MFW.D5B>W.3=X,(WBV(H*)4[GH<78B76P]C9"=&%B9(;KL 8ZEYQOEM,"/Q"5
MEGL4^VY9Y_88J&,X;L$/*Y3.;? N4'WW!IW05'$D[HRJ1??K3"HL1_S5<:%7
MG'E57RO"G/6A)@?"I$.:B\G4,&VU'$'Y!K\8J[=C0?O)@4?O5];RW0*2#.:Y
MJ14'-N/7)\J6?_5E?^?7*K3B9"G*L <;*'P)G_MWI "U7CQL#"C!0CH[A_T6
M*_@NB7!31KT:$3$04XL)TWG+L<%L]7"H<YL3(QRCN!Q+M$W986!KL";63O5L
M]EP22#3J+IB9#F__)7N+6G.HU8(H#C)N($U"ZO<,W9#\C%O1;K=/ZH[INI9D
MNL9&2.24G=!!20N;!% Y\74Q-=FVCQ8PHZ9H09JMP?%P:E)RK?APL1<=:53W
M9%!.LO3]1"-Y'O!B"\JL7"*QJ1M\"GL^<"ZRY^.B'.84 .U(^&:7S]!06M?
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MWD.B!R%$DM_>_.]]<>?=//.<,S.?[\SSG*.IK2$MXU!.'$UX _A_!@4 X
M&@#  @!X  0 @$ !$#@ @@9 L  ('@ # &!0  P.@*$!,"P A@<@ 0 D%("$
M Y!H !(+0.(!&    P5@X  ,&H#! C!X  X P$$!.#@ AP;@L  <_M_= #P4
M@(<#\&@ '@O _W/^Y89" 7 H  T%8/_%H!  % *%0N!0"!H*P4(A>"@, (5!
MH3 X%(:&PK!0&!Z*!$"14"@2#D6BH4@L%(F'8@!0#!2*@4,Q:"@&"\7@H3@
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M3XU_2/[5]2_X;Q0@ #P$BH? \1 T'H+%0_!X&  /@^)A<#P,C8=A\3 \'@G
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M=F#5TLLHA[/3S8C0CAY50J.]7R_#]KV.Q^R]T!LS.6B"?O%/"8YLOG[[GN$
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MC2W3L.&-5X_F*MTL'$Y?6W3YN2F(75B*@[]0D7T>$AG+CA?GC[K.ST,Q-60
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M;N!JELK:(UU5V<*^CEQ3RVI@?SD$"32>PS *8 2.JM4H*@$<%>AJC!]+#KE
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M+<,W6L;M:!WUN3#%;/F! '=DTJ=?NAW^>!.I8"IF ?A''';ZJK*6CVIC&9.
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ML,CY-!Q!J%A:<%0G/#1FOE(B6M#@#720)O^*()[KZ[   PW20!(FF&70A"6
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MP.A#8@/1A&+DLYA&F&:(+PN88$I#*KTH3#57BTS%$*(,'[QA'W_)TV.0J$/
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MIS)5F* AM91H\L)9_HBC1A*Q])"(TD.>VR"-FEO G,*8 O0\T_,F<VL]"JQ
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M"'ZFKREA6NWGH46NDC7*^56J#7X\#Q9F]]C N*(2QCUHIW[JP1K(1BM3F05
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MVBLK/J$K#FVA\FSM61J<,:0TREFA&8?E"64CVE5_ %+R<6@3G9Y,J="RX ?
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MU-OV;%&F[!9*Z_0\NP09\J; OJ[XTK&W504-_^TS/NRWX 4%2L;<R=!=NL5
M)W(0>P\3VHDJO?%O+M?$BAA5RU53*]7&2%CD7JE]7F162_9DEPEJ.A[5!% Z
M+IB.CDP99MYP LLAO2+W^&U+$U!=UZU*"]%=(BH,0QVQM5P](X5W'NJC7J;
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ME!3%:KKE\'8L(1(R>ELIB,LX@M7EX2O5&$[B(_M]WIZ]"AAI4.,FC1O>U8:
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M!0T>1)@PX3=WX-IE:^<P6\-V#!U:?!CQ(46%'0V* :#,XTB2)4V>1)E2Y3X
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MNM;5KG?%:UY/LM8 AE5"T##HS=R4!H79Z7Q2NY//U)(6^&5B+82J2V2;YA=
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MUA6L?A5=T/+>=4D1HQDVC]*%*T.2;+@([WF.)/+=!+IN^W:/&,GK!J/VLK.
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MA4$,@.S9TP 1!Y%\3*=V2LS0%O?Q$@<9+)9_*1 UGZ230\7L;-?,)LL<F4C
MC; C$.0CW03&)66L:FC_8\">\(9A%W,EB6RG N4_ 1I0@0Z4H 5=S):BH0PE
MJ6B(RF@)*I62$PJ-*HOP(0D<U0>4([(LE5\S"9G&(A:504E,.UE+,8DY0WTD
MDW)Z6LB?(G*0\233C0O1CS"B9J6!R0=1TF%@X;!4'XF.KB>9 N9>[/8EV&#H
M01OZ25:^Y,Y4RN:;,O/7[UJ%/:T2(XADRZ-!P1I6L8Z5K&5='G#N(ZMDI,:(
MO7GJ2,/92 [%$RB$%*:"M D5)]:5?1S!I0K)H 9><NF<>N4=13M"CV$T@A<(
M":-%#A*G6]Q"&(V34^+N&(R4L(,X4F(E-DO5Q-&\9'/J_(EH&-0F:(QO-QU;
M_Z)T7/M-$K8R9C(3B55@\ZZW';(Y5EQ.BKJ*&K*9E;C%->YQD9O<S31%$\4S
MD4/5%+B51%!P!6**;K[8,A$BM2.VM!W=-!%)2=Z.J3[D*?CH08E>E*P7"TE(
M,FV:#%XT0E*W^ Y!!()9CNQ/NC&KSTM(2S>AS(-UGY67$_4!09<H8TYLJ>V7
M?J9="%$H;MZ;AW=UI].=EN2*(=VJBS"L7!&/F,0E-K%!&V127#6I+*6%:E3$
MB3:X=92P6Z0K^787MZ_F\:_]2@XOH_A*W<J/)TWY#^I*)XSOQ&D]O$#9+>@[
MC'4@8R'$#,DPH$0P-FU7BSWQK#X.1K,-5L4V52'SA?_S 1*7A"2!#"8F?OHZ
M(6'^1)OQRJM'+KQ;'+.DME L8G(B&9:ZI.;$A3;TH1&=Z.D]1S0G>A4T2O5-
M,<W-HO5Y\:6@8UJ=8N4Y7])N%5?%MW5EFL+K7$E-&M&+_A!C'NI(1IP6P@O4
MH0X7O9"'&Q&WDXU\[Y3OQ*9*=>>2@=FLEKL9!D4]/4(P'X[!<]+?/-K19GJT
MAIA]E5F"1F*AJDAUKJ[CHC5O(]Y5$5K1Y3;WN=&=[ASUYE#H:BN7P%W8AS90
M3(PDCAQ+VI<^[[AEN!R:OP;[6>_]1) 6S>9_:MV?813D(8M5+X D@9 $ZI<C
M[&B-:#Y8U'1F"&8ZJ<Y>-NC_$>?L&CX;M-M*5)+2D"".'<B(]H5CYB5$;N@H
MM_4US@*&\B*"Z*IDT(2Z@1YTH0^=Z(7QLBK5\KIRROQ!5.VR/P_EV2V"+'>)
M<5^'R2#UPJY,KA%JT&U\,0D 24K)\J"',!J!BTE V1?L,,A(.#L@J50THMC\
MKL@3:^;F//50(.%KU>V^0&BP8TZ%%XG(6!N4K&1SAD75E-*'8S,5_NZK1;?\
MY3&?>1$/=70I;Y*K-&7=P<W[>ZK+)N@T6E&==VGOD5>3A?8&:+#T,K'P[M!4
M)MI=7]R"$K>PR1OWP?M> ,@7"4R&2O11\+Y *'"S<62B/JYMX<0D:N[DV G9
M"15R)0:^3;4\W# 01RCPKT5="II3<V!7SJTO_B?(X;FJ0JQY^<^?_O7_YZ1=
M@]-0R%,EWZPLT =_S7,4Y?H T. (HR>((2SX)CFB*SZ>(DS>JJJ*J/<F8>UZ
M(1G8JQ%2#<-DHYIPPIH<C_T41& X373N+*-&B!XL#B>TR=("AZX^1;KVX>/V
M0A\.9^)$9[0(2V/N:C>D*X4ZK&CL;PB)L B-\'DNR#K8:AD0"I&60C1$RSA*
MI2E"R)N6+\>^B]((R_VN"BR:*%,VREYR(ML\PAUZSQ?4ZS_"SC\BK5YP(^1Z
MRHX0!F8(I_( #)54$!DTB[-V#3A$YP%WJH-\PD%,8A[>,/6*8R3\3G>VI&/J
M9I6(XT.6(Y<2[P@M\1(Q,1-QQ+^<@S9(PRU&_\;ITF<'QPG'J'"OZJBVX)"W
M[LU>L&1+EB&2)O%@&&00\6YC"BS3BLAT2F88;&+W@(UCM!#_>H,.6\DW7LF+
M1DC#=@."!((>C _/@@'+J"('>:?Y^*AP[D=!_ D:7^E3&$B$<N;YQD22^,:?
M-#$=U7$=V3$QCD(O4,*(W&W+@H)^6*+.5N*K2O'K>@U#["J/JF2)@")HA&8L
MZ-&U#"Z.+DH<EZ$7<&$8;N'GJ$2.< M*J(V0PO$Y6$NJE*]3MN(E..N "*P@
M^.CLUD$>"F4&LZT=^JB<^JQ0SD>0X,PDN*W U@8I* 4108J>VK$G??(G@;(C
MW&*(#"8MW,(LSF*5F/\JQIKJ0")/-U0Q7VKP@IX#SO["NR8QDHC!2%2)L/K1
M(\*N)GIAPTP/?,(Q]++/462N$*>JX)C-&T7"&0GEU3!"&%Y-9/;AV&""Y!2/
M#*V#FU)O?&P.Y61'^?RH-@3I*R+);QHA*!WS,2&3"(^'+LC&1/:C=L GQ?J+
MHUBI\G!1 F]1H[3.8]YQ\E;EYR[DZW@'?Q DW[)"&4I'[%+&5$Q"SFHO1J1$
M*6(D#,WK.K*MJ';S*A)('A+G[! H(MJ!.%<*)?5!._9!'C@"LYRN*-ZD<++M
M]3Q"J@SI$!-I\4C"+?=A$OD&#B*S/,WS/(..J_A)N%R%W#;FB[*/<[JIJO#_
M95Y^LP=9)GWB)?YH#RC^JB #;B=,@MJRY/@\Y:YLH_?4<%'HI2I?:Z]*[QC+
MZ0\] J-\@B4-:% $PNV"@5 *PD/UPQNW8R1J9X-6"3"QKRND2I9XD-?2IJH4
MD&C@!SUIM$9MM,3&1BYNA43X"M-T\Q@I1>8$$OM*K5+*;SJ8DNNP[]]6)>"F
M"&PZPA##9R_H(39-I_,T!)M>@\_\+#4/DTI;(J>2J$H&#R.083N(,T[H!"8N
MPB#TXTSW(7':H5TLQ#9MYW"$C'9\<WU6!PJA9*/8;TL(,D;MZ48-]5 1-:SF
MHJN,QRC7HO7NCLL::'7HTVYF#'SBYN04A:D,I1Q#VRTL]*HIOHR1#&9>OJGN
MHB$LU:X2[]'@((PK/),J=+%P?"HE#H9.@F&E0")QXN09%0<9V"&!)$X@GNTY
M%65\U.]11V8V;&Y9F:J;\$8&E4(!?V<K$_5:L35;,VEX5"0UF##TG"]/9T8A
M_1)]=F;&'*0I9FA+^LR[6J;/8D\Y6O(L%Z4>GL'.5(8J2B=2>H',I$13[[0#
M-2I1XDE=2=0XF&H1ZP$91 *!]F$=5LI.V)0>D&&E@M6]5HHCP(]$/TLC?8+,
MH,3F5//V=!&M4,E=<.-#5.6J1D1;7?9E8?_6>;B*+H+(+EX%=A;(!TF*PD;Q
MJUIFBF;.G[9L%/\LER(I_HI,KW(0.&1I0,+N9"XP^W:#T7 V_4P59;^+P*@'
M&;",(_3'L?++O>1$&=*T5U_-^$(G5T=**A 60O+,71*LU_ZTFY2T=NIN3%9E
M$CTS9OFV;_W61VBE6\LF/CZ&*<_&2_!E;@+L7DXBGL:'37!'0-XU7E(HU,C
M6M^0:&&"!F-0<A-K7V_!%U)R=^QT4?QK2EMKNZCC/C?E;EM.'M9B(*B,(>8A
M3O0!6 NB.7/U($*B('!"&8(U0JS-MC+-&VNO0S[E8*KPO+#1*PI2:/XV>J5W
M>F]D16[E-&Y6>+?_"_\.9E3H-7$%$&:8,4+'%S]1D,.(YC2]\GB%3:[ \10[
M8M4F@1)@;MJ(*4GM9L?F-EXL32H[S3<I5CP2)Z:@C<H>JZ80PH ++XS@]-LZ
M-K&BAL$.!7Z!MM+2YSV @UKY)N"HMX,]^(,=8R[T:<54 Y!PYBJ4@D Q2#6A
M=*H0%_U:*;0\XDCG#/#VX7<BB9<^S2J JDA]JC95[71\X7 4$<Q<8K5<P@;U
MPH>NC\C>:3JST&17HN76023.=""PPYD(0CP0 LP$ CK9--?RU:)^J''OR!GI
M3'LKQ43Q[PX-L'+]QE]0$X3IN([MV"]D18::I!;7Y'.*8^JB S-+BQN__V<5
M4Q1Y)]5=WN-@PBLKA? 5?0)!I,XYY-.B2.<6Q+*())4IDOA1;4R*L:][A,-U
M]$=.=4(_F$R+A2$?#L(@@D%8@W4DY(3-X*,J:^QV% 6#?]1\$)DBO_,VWD<L
MYOB.B;F8Z3A)\.GSMDS]I(A 8JQEFJA4;E+(Z- J\3./6K@!3RVDED.0"HQ5
M-2=M#J1DB*$7 J3:#K"I@F.I=F=NJ()A]>?X]D%_S$X8V(B+N5A.$ (8#D<@
M$&=.UD$EXZZ(,N=N+)5Y-0@=):U^>D.T]H%,L(X_C7FB*=IEE<9<2N263R\^
M5#@?CTIJ$P5A58]3X<66W>19$ZM.^89:K=7KPO_G\(QJ@DDB#>GK.J2(AFG/
M$;%0?NS1X&J74%[BU5Z9'1+L8A,8@0G"J*,-U\[4@/:!J(4A/YYAPW"YSX8-
M7#'-91C(\0IKB?9F956EHL5ZK&%VJV %?:*$BS*S4T^H2M"1Z4S%[HY"H0/O
M)((P+'CIE/IKP6Q03$CK-<*N'C"9<'Q-D%!B)@N)U,2W?@RK<Q G3>FD\+AC
M'XZ:(L1(; 5B(0QBI31K.Q*H</@2K^1(0DH-2@6V%>>'?>H#&AP!J\@@$\@Z
MMF7[4&_%7-3"\<X&XYX8/W-+R(BCG!Q)=KSGYK#4-ZA.D]%FD5;BKP@54RC2
M)19LHRWR*0F'CG;GK;JTCNMX^52O25.S@SAE2A@6YR(B DYFEW8[=!W KXKC
M5#_T <M6ZK;X.!^1-+77!V1C;#80J[>N*H=G^[\!O#RUZO,>^(A*4;JS[!L1
MYBFB=;\5"5+KVA;K,1&]PG+[IA'/!]F<HIA.RI;"<#2L\>XTY#V\LU[FI66R
M8GPH]HZ 5>(,R"#$=B+:(8R (4Z(4[.53#N$(1X*11XL%A +ZV<2K^Z.;D!A
MN*O5.E0,2Q*Q:F\#_,FA__P2E48MK)N0"1D^;_%\G-E>U(]"*)+=DM9MK,3(
M57?G_DV8#TNX-TQ\WW*U9D87M1.ADE9R/65 N3I-Z.6?@349YM* V"& N8,[
M6 I7'X<]+EMVUX'\MD.!)G6TDP*;$_E_3S:58@*B5Y8,)#K*-7W3Y2\N@@@M
MW&*&[^:W6?&N @PJ+^APPT<& ;G@8F1ORZPSN5E5?BX713"[>\J(K?R.KJL&
M.20S28)3O!,=D8*8"D(/>U7)\+G&,6(]VFAV%^;5SEB!P#@J^BC8U2<G:8F-
M8>D#)?RTE&,L.)C3R;W<,X\RVU,>N=RE*96QFS:#KFG[W*71-NS_0#;TG++I
M.O^$$LY<+#!D5&&89G3;UW<J7N8-MY^#AN\\@[94N/&2Y6YJI2#"V?U'G_&+
MT+F84%8N:G9S=< -#G^CUQ>%379"'[F1;<0KDH;9W%F^Y8/N:;R5X_TX'/73
M.J8S2 WLW=59:A&)Q(\ #T#POY&^*>2K9]$5%PADB+Q=_M7 A(J58D2<6R<W
M/*O$H=0XPD^ 3Y(A].?0YP%WN=B59?Q.JF.E<MR-K)K8DZ*"ST;2M<@O3S=>
M5\7)73[NY=[$&#7I]$S8U]9<.5-N'-%0,J4JRN_>?;LK7O!!*G&>K C-MXX3
MO\NJ.:[4&$BW#U3)74E1^DPA@YQPH&TXY:3EQ(B\,6(\VB,>[O^9(F3*LA_+
MO6Q*Y'AB&Q&3Z5O)V\V)SS:N16\I\?L%[@]C$@ @TZ\& ,* ,6X@!GA$#(HD
M2'@? ,3 +Y1_+X;_,)Y_[J4_>F2H+4BC:A%I&ROJYMOY:M7'KN#WC<%QI)R#
M-&7&-%?6P'AG%*'8<]4XTTI<2;'P12MTAL_.+HE3(+0#5R$BF0 BF,!UN];1
M0Q9L';"!"8/M:L@.V3J!\H0%T[=OGSYE\]@ERU@OH\9H(D-FU!<2H\A])D5&
M:[DR&KV5)I=EA!92V9B=9':.T51/F;)]-E<:/8HTXPT 29LZ?0HU*E1B #)-
MO6$5*0 Q4KMZ-;KUJUBG8FX\10-@DK+_K$F554T:]FO<L72;9HHQM*[>O7S[
M^OT+.+#@P80+&SZ,.+%>4,0T$1.J;!D]DB)Q[B-ILAYFD$0SDE1YTG/&HBRC
MJ509DK++DRU58E9M]"7HE99A:[2IJ><8-3R)A;:)\7/+>BA%JH3&<O7HX**)
M&ZVIT7C&F:99(E^ICW)UT1F%S=/(3J/WB>LL3@S&#B+Y8,+8+5RGZ_S$>?J"
MS1.F3N"\^QCG)?,XTU$F!7A9<<^!EEU*K%T&4W+7':7)&+KQ1L9CD4&F3%!U
MK6"68HAE H!O3X$HHE%NL>4A4FZAD2)8,3P%0(<CAJCB6UZ=V&)38@"05XX^
M_@ADD$(.2621_T82V9A0RT0V65(A/9C<9S0Q.!I(IR7'V66A8>F<EE5:*5*3
MPR%%FG3<[4/,&&E,^%.66'HVVSZ6&861<PT2R!Q+L]79W)3&9;;@F\0)HP\]
MR<RCGS[F-11,?@NEQY \C)('*3V(IB<,/9*B9U$[<1:8&IVK:99G@V]>V5E)
M?(K$VVX^J7'AA4O&:NI3T*0E5HQ'BH367B3ZN-1*5/6XZSXX0K5C4K]ZM2QA
MP18+;;323DMMM=9>ZU1C%E[HTDRD&M4DGYA!&9V7I9WYDIMQAF02:+9->1UE
MP FZ'$RMZJ9F:UJNND^3,247:K=A)N-MEO(J1Z!JJ%%V'4Q2GN3?I?^(CH=,
M>L#(U]!$%9U'#J,,":.Q/HJF5]YW,?%;;F> @M9NNL7%&V5+Y&ZG$[X]41+4
M,A82,^NLW$9%%8I1N34)M#>\J%>O/L: =$:3\"AMLTX=G9327EE-&-/8;LUU
MUUY_#7;8^VBB#-FSUNJ92;9MQID^-@UHKIT(PG9PN>D2M3">E,'D;FRU4B)A
M&A)*V.-P>Y>T8)P!]ETHP<91MKBIR#G'=I;93<=9-.T0"S(R[<BC#*3SM,,H
MI)PB.I%W(%^<L4#L6!31?/X9"-.<W\*)>'1TY[[EJIIQ.39/:^ZDB;'&YBQ4
M,4I")AE4DO"XXUP911\7 -9;CS0Q2VWU-%F7UP\#0!H9/:],]%QELH+U(L8
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MZFH4XW\3(9T3 8X)>GB?)%N,%;P@N%L^<S0JT6/+NY\^2ZW:,0S 1A776[U
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M'?8^-!!$I%OZ[IM$HN?4@!7GA39_8U[B>?WQ$*_$^#?51 0(  #V$2QH\ 8
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M8)+IAI-27.US4T^ BG&E,F*L(%">%=U$%&F#&G235%EZ92@ DW[J:$&2$@I
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M5A[IVSS 1GC P20(AQ$00S0<6R@D XP89&O@#"PYY#3!AD-&H\FPQS[\U3Z
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M<( \WE5!E[[B$0.3;^#3BQC9.TS.Y*%*%=W_"9AHSWWPK02*8$D%.+K>)?.
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M3SSF/UB"65PHAW1B&!(#&N9A9A B<CBH60IB'D3) M*M_2H'([XH(E(/#HS
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M1BK^18GF!2H>LQUD46#H05D:8ESVLK(LHBXF+XS2PEE^L4KP0B_&0 W:$K7
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M)/:ZA2$"0Q/S9!.'X11!H4ZE(FB%#T9B4?ATH71@!QE>!RHB\6&<*#5O1Q_
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M!8I>IG;_^"%=>=W5UI*NSMCDJ[*Z^EHFL]YZFF8 *(EKK[[^"A@:1.*&QH#
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M@<;" FGXS71R0-;<Y&V:Z:F/3\\LXXY]D#X<U0U*2]O BV7%C=#9E>.;KQ]
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M&J.VLY//:ZDK&&C%8]O-=D^83E 5[J5HXF,L:[)I':M\&[>+U!),*=U"(UD
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M+ ..-U3@2!:B6PY+ _LM"CV)<1& E;PT**_H7C?/$\Y[3/>*<0_PG>5]T<L
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M4UP<H/ID!5 P>G(RNO)NQ6ME0N\7,'!18$+X9'N;H\K+&-?L8_)H"IP]^;8
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MH,(U(TG4-U-FM_L)WP*A3&F@UG$W\WO#,\KF=$EU35T"B0@<[2T#/IY(]PC
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MR\$ )A7.;<9X:VO]P\'EO_H_$=^2R E+ P\:-8 .%"B!Z'18[,MZ@U!G&2B
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M$?\/=/T5&TT+(II7/&$99\? 4P $ C$1V2Y\B8WU>#^X[:^YJ8' L@@""9M
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M6=MDS#\^&8NU(H-MD'X\?-))?J8&M]UT&[R%EZ:T;I%/'0>$(QJ/YL-.C\?
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MWCX$BF\[,$;@,PA;->\JICSOMRKE"727+)C5U+9,IAIYNS6=H:NKEXY\U^<
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MLBLLTA. &XV,O^J,\$?IU^&U(HU?]](Y5?PC31X0=/X1.$S#+2HZ_?\EV'Z
MOPS,Z4%"/H[+$0P%Q-J%$LQN;P$VK*-/'4!T%LI:O48>EJP<4JO;CTE:4(U;
M2#>;"F2FC3<<5?]E"L!NEG\7E!+(AM+;E\<5-MG8?=9FC$&"K_FV/VU;-V,]
M!8>:Q6[Q(FY1^-TSK@?,+0/G03MU=MD*!<[Z;M;.[L<'=(X^O =JFO@- 44Z
MK>>OQWBT/ZHG$[I= )6'Z'VVUC*V]E-I;*[72-'HAN(9DC]8E; E8@*A6XM<
M>,!U*(7);EY^41QE*Y]:HI-<S0*M^,?S$J64,<C/N^K_*HO^WLJB04E71B2O
MO>24!3EAS>$*RN=2;KUBYJ"@L;%IJ7%6209_=]"WM"$N;&9![:FM.9PC<B9M
M$>_EB?L!!^V+HO/JT.#R&2N/YY(CY9A2#^H^1W=99D_4DAA]#'9(T9_(*ANY
MM&78PG1*M1R<XO!B#72KRE^-1'V6K: "N;5Y"+5/%#\/&]TST&L"WGLL<B!U
M%]\5*_GH59UUAVM[["*YH/:.GL0$>]+]J0E8^5?2Y0/BGEA; Z,M].]RM#PF
MXX^XR-GXYK:)H6]TG@_WQ(M\.(L'96U#KFJFM:;;[##?1C[$RMDC; \$5J0$
MN+Z,"=KXBLU4Q-9).]"IRV0T$8XJ3%:Z\ F_OX.*I0*J&+.R_0VO&*.HZ\#N
MNZ<%9CSLEQ5.JZ#NU//V*.#*2XP9OUF596&F->OTS'\&G/0#4"ENC\?7QOVY
MDZ6 Z\QH$"R"WA++JE&*PW\9U-3V]DV&)++%/BFI*N*R?<=8"MSV&?7\(\K-
MW+K8.9ZK?X*U?M*^4\GH -%< "2@;NXU/\I:QV5KE+\^9Q(S^L+Z8B6JAWIV
M*6>HYB5S]9<IN,HBI/GUHYX:<'2!66SCRK=FA@7+MG7GWA]ZV$JZC8YDET:2
MQ\TN>R0^-MQRH3A>K'%ERM.Z-74R?Z>/D,,UU] ."(PY#=-J'9K!#\,(1'3?
M: R.:G_*IZY*]CUT:)((C*8C_=@@:5A%7%TH%<A[N=Z ![Q4 .5($OEC9\9,
M+5DB$1] T9"!2"'U%917.:UZ+YO=2,$+9'[\[Y_4!0QS,-(A>TIJ&_,':$MZ
M<\<(LXNE?D9*RJ$(/LD9!0I-3%I65D)HPUOP)72/7@,XSM7BG_\M5PU3^S8,
MG?*G,+1/<\,^DR7UT2KQM3>SQV]#W<"&>G*N?V\#D_]AK3N" (L"CD8)J@-;
M()D\8+E,(#VQ?"3)Z/2CSN E$K3DHVY+UT2F!06L]1K@SI4H*&9_/DBO?SDP
MQ7'' 6KKH+<: "+D&PM+E38'VN%D#KG,6>I]Q2.F1YB.3\O367^'5C7,_A9"
MKN#'7]M:D9BI8]:RBY%B,J)"OP57Q>(H#C6KWN5ZMG+)@X60[5ECDGX"#(J[
MC4<=[N\J!N':]CIK0<:MN$3&R($]%F1<&"YG5= ,G57.-/0)7BRT$*+V%PM=
M\6T=UW"R=X'R<$342[2CR0.04@E+_SOUF?Q#]!<1T^;Z!8(58#$(-T#ZG'<V
MCON;QH<G>@:DTIQZ4EPY69&>7GC%KQKN&OBS TT^.1>K1IN*-"MLR]J@?0&]
M8TF1K=Q=&:FI*(9M P!3OET1@<VY5)F+51[\+W>O>OTJV$X\4S]7#2N9<F>+
M;-]_&D,1BM HH")FGJ/37JHC3O;L[0N,P@YZ3[ZHV<S\FM<#NI:.43KL$_2^
M9%R'RJAH*^IY<->EK$+0[>5@$+;$-:;)0\;/W)@>* "+L1]KBB 5/3PQ@]-3
M+S^WW-^1?![>,J*N_LLO**) _GOA3!O^F^!,]06%*,G,JL>+&*!1O3> %S$3
M$7Q=H7FAKJ!MW7<^#@N.>R@?H7QA 4<Z61_9<D=H'2CDG;&#$5(<]"1#:4?2
MQC@I=5X./1C)*8N1VTO3JR4Q/%KSP*V0,U_\8K]X?.?5KGZ:+44H8;:EXGOD
MJZ7#;)GIS9_$\N^J$OZ/MQ[]XYWO3$XSY/U5X5N_;MSZ%2J]3DS[?3,:OV=+
MN47W@2SM]D*Y)^/GE$DQ.11*TP89E6(H+!_1/#6I5BG&#9;TV#<U=[_T0B+1
MV9'H"^Y1H#N6 -]?+!'V6%VS-HQSZB01S375E-35!+1\7J0I:9=JES$GH01C
M6,@>8K)8%!:R;1O= -2P9,@\ (UY&T5Q0(;D:'-KEN^1)/C<MLH$B%:CM+XN
MV2E"7QR6'A'JK1]K>[3&#!=B,BP7%N;>HR5 X44^B#^L6;6MHT7IRW+RL,Z=
ML]S7IY%)L]I KIJ_5RV/P]O9E/V^.YEL3,5@]ZHH/=R%RH(VO<_Q,3U>2FXN
M2)K.]JY%:4$>*%(V5R LLOQM+_>XY##-\%;&_G:J7FYU_S>W^)Z1^4 !\0S9
MTON=^U*DS?MS#QVDS+;_4W*9+1O"^HBL<[","6$\_R+(@P#!=Z$?&^KO^_4&
M8#6K7[ACRF('73$9"4D%06",V5,V6S]9*__HGM']_HN,5,$[U0-CYY.G.\@V
M*MY"T5%ISO9S(M8^MB"7QTG0JJI/5=.N$3M64>K&W!;_I=C:73^MJJ\>/91#
M'%:,D@]3=,$:?SPO74',3Y#\?O6PL'9;Z*#QY%QMI:@A;ZX)Y$*9.19[@.Z$
MMF2?B'AG4Z>8*&P/3>JCC"W/9&JUJ?<\=_NT/\J242=IYTF;21CVVCO"\<.$
MVK,CF;.<3TU P96F:)KPL%B?@601SB[^\[^W1O ?[7;S;R?U/Q=K5&3\19 '
M4$-NG:\;0 B(9>9A<VRLJQNS+OLH?DEG !&@FG(7QYI0@!2B@-%U T _SF\;
MH=Q[C^'14?%6B$6.60%;/\1&,DP>/2[HF;)D#L7!NKX&8</[^Z'<U0-U:B8Y
M%,PSW?0%^'EK\N1><OC]EM[<0;.\,(F("+%8FT*1#:N709-TH6,$OM 7N6DX
M#A&AS[XK#_T=+BKK9B44"N/JS?)IC)+U$QQ&5&4B$>0?%N W<<E>4Z_D&1*E
MKUR[CWV']J67U_@7*R7Y<\U_:@/_NVC6^^F=HY^"Z]KZ>>!YDJQ!VT-!L4VY
M( UKF2F2N@&35VS^@&6\Q%<?$F8D.VKJ8VUMT^<LS\63AO1Z01[4,4,$*VK$
MQ0^_N-(]38]YA2$HW28&C2EJ4O^&W^&)Y"W'']1ZJ"1.Z_N_]<0Q/.V0KAZK
MX[*S?G5WNH"^E"Z1Y?-CPYR))<)>JV2&/=2RC&G+NZ<<BD''&QR87YH,[@NV
MH$#-P_G&8D*<N#I:B^^V@!QHN'?%*L?:K@U8O65\C_I=&Y:J\:E1K**XAF'E
MBG%TT=36:!1%PA18*GBEV; $2N:AWA0W48P7.N-67BE#$#7!!Y8VG&ZDJR3Q
M,LXS'1?BHL(0W;\=9H7]BWSC?SG]'/)D:8^WM[JFW=U)R67MSY2C3S>5H-46
MJ19I==S410F-3EO7KHPSLC6^ >Q&:6^B:!-I\&^?1%(/(V"$>Q0,76I!-L:T
M_:(SUTJUK\H4G5K'3<_LWI,*X&073$XZ[UH]EG%Q22VG;?S88;/PU3P<_;ML
MC"-\,>][5T,,VF-J6+\?0WA4+NAEB:Q'H5<][DOT49&"C5Q#XZ2+W3E[6)'.
MDK*&II^81MB%_6 4^\)S-BU[J;)3HY?2YID=UA>U'[IV]H';VRKND9Y/I2@
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MI9%%?WB,>#P1U8@(=]C(ENM)=,3J<:HJ)K P/1RHVL^\])8-5XL)971WOWT
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M@<,@< P$CH? "1 < (*#0' P" X#P>$A. )D%@"9A4!F89!9#&06#YDE0 @
M" $"(< @! R$@(<0_NOCO[$A,  ,!L#  /C_VH*! 3 P! :&P< 8&!@/ Q-@
MQ@"8,01F#(,98V#&>)@Q 08'P. 0&!P&@V-@<#P,3H#A # <!(:#P7 8& X/
MPQ%@LP#8+ 0V"X/-8F"S>-@L 48 P @0& $&(V!@!#R,\!\$_R$.P0!@&  &
M \#_AP@&#," (1@P# /&8,!X#)B ,09@C"$88QC&&(,QQF.,"1@X  .'8. P
M#!R#@>,Q< (&!\#@(!@<#(/#8'!X#(Z F05@9B&861AF%H.9Q6-F"1@" $.
M8 @P# &#(> QA/_0_X]L"!X PP,P> #^/S+P8  >#,&#87@P!@_&X\$$O#$
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M=S8Y]9]X^BVWK9(\&NR28/ *VVM;N;?WH9>Y\_3M5OHWVK5?[125GM$T?S8
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M<^4.L5 *2U>*8+-!L#7GR#0G6C3?,[))B9:1T:^J)7#CV/V:T\@^:1\:,08
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M? ;TKNO5;R$';;#389)<ETH]-[@UZ5*%1E"72LWVO S]0M6M@?>IC[I>0,A
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M9& ='[_=0D03#4&TIH%B=T3VG]TZJ=X?O5L:SH_FBR,KG!OF_,A79_0M<+?
MAJW#K24HJ)2P[F4_!^(V$?.THLRC7#-I*N,=R/2(];Y=3%ZK/'UN%)=-3RVY
M?C*"WISPH.N3V=P_L7):,Q[A:(X(S1_D6TTG4,KN**F,.QFCY8N*BW\O DLE
M:WU=:TJ"6@]*QYTOK4H=TW-:I"RA%C=VK5VMUB>2)C2$MWA5L>/30L31BAY
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M(?7N>8SH7SLX' B8SP\:K?_5K$6[I5^OVU<PEY;M4BI>Y;KID"1G5&:?51[
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MQJ!(1V-P_^7Y_)L[["(JW$3&3M=6K'?.O>XE%CF\.Q"[$CC[^-UKD]E20_B
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M#X+K$0HG-T2G+;CZ]:#NE8=)DA+SQG^/F&^NMX5DR)3;MET0+Y2608#3E)X
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M]6R5J1L'.LI-2(AOZ'B,>!^BH:W"XG!F!@#012S ';#3(+[+B(U7_PJIA _
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M.+"@8'%7W9C@@,OUIY6.7P''G()Q.4ADD48VB,:01[8%F&,%B6$7_T.9Q
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MNFU2.M,9)ABR&6*@!W?ZPWT -K=+1/M#,/.I.'O_NC3;^IAEBT,96)52-$)
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M>(8G+H5_JFNNT9:ERV>@DCG&,V6"WDP2912A.=&QTMHW8.!4/JE?POQ"O9\
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M(WP@DY@/22U&@WD3=PP1;LD4?.@>JE6'PJT7YS15NIG_8$'\S0_J%"8J'DX
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M!_ICLZ"%/Y95%*:B_RL/$]]3S!$:\YAJB&DST7!%N.7Q,8,!481TB%*TY2J
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MA]W#8R(P HNC :%% QUP RE0&68.G5B .\;/!%/B>(8IH0QB>5*NH;8.[W#
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M1;/*VA'0INR2ZM ]HM(U_S.BQ:!N9;:S/X%)%:&&P1I,!KP2L'#J-(K/16(
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MT37Z6MA O:(S22! Y\[[TZ;#;6"7@YS"G-AE[/M*6&"Z&2('BF$,1J-2U*/
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M]J66)[;O9%5 82&\HT]7)14"H+"GN[S,^Q4"Z9PU%UNU@P K>"/+)8,!((.
M.H< 0+@O" "N P""9A.M@8.T9$VJ R#Q8A\,,1V?\HVA0G#M(V"88UK>)7;'
MQ*KEPQ ^"QC!J)OT4!:7N:W#A1TPP8'K.7=0>+HZ&6LTE:J\!%$<,T:=)7T!
M=SY<9E*B@[X>U6O;I":+Q')VN)"M!6=C*TD/B'F<!Q4Q\#O-^\(PW!5NBRS/
M8EQUAK!208H;$@,&.34?NP\XD+=H 8K;ZY\QJ)O@6Y&=RR'+4"#>!T'T=TM
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M3&D2&640#["")HE+C7U.HU&N3(2\X08D12((P"U/&O"J$)O+$"RC%&1.&30
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M[/5/9*';X_?GOW___W?,9N*6KK'!A6\K8LO]YB( 3? H!FR"8 P.<( 5'"
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M.MS5OW[VIZ3 # 6;7M\R!LON(P?J>S"0&![I WSRHOE:!JQ+N;,:P%N)CJD
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MJKLKZK>6&F65](R3J?S"* ^6XU8>[,;UJMYQD[OD)@]4EQE;<3)/HM5%=(T
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MHOUD8"MNHB3&XE% XTO8WP?^XE6R1 B&8FY:92U&U'$2!RT>Q>2Y)!I%WG!
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M8@BN@-/!1+;F* A/X%4J0SO[9@@R[N%H!7T3LZ"#H*8,/'%&HOVLA5$0@Z*
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M)6!2<3L"X?ZGA4DBPIKC:-?WAX&X/5YOQ&2G8IQ$E6*RX#X(P4C74B EU6Y
M0^QP7'DJ427X#U?P:9_G ?]B/=;W7Z^L=WY&_GS, "N$YYP#@ _F5_+*>,NG
MC.;V1BA2;GDFSL@G2NTL>=.3W=2'W#)6>"GT\K*U].0SIJ;#>[45AN,W(JP#
MHAJ+D<8@:R<IB"FYDD.L?26']NHF+?(')6KE?O*454H&#@\ 4\6Q1ITI#916
M]713C"3"45.P/X M@55/*,3)9Y8G+;388 \QH5S08);F>MA+6TRD!_FX6AZ/
ML);7@RV256^1OX+W@C$2G_]$^(I+K']2S/9,$R,^+N$<ZCT/+":DU9+)N9S1
M5R(.%'/-Y9!Q3SOVH8/N-%Q9Q0V+K(5LPCQ6A1[20(:T4.G2RBWUHX>2JQYH
M.>,RL8H41* ;<*C0&&'E<H"'L(,_4B(3\\X>,H[9:YA1F$BX9F[5Z%G()C#I
MTH\(2W=](PRS="CYT[%<F$QM%DM!XGPSRIQINJ8!E"9B3[6Z!&C".2VXL21\
M.$X"@#PZ@W4L%)4;\I>K4H YQ>=X3MNLCT&F-G:M#0VE,RO'2Y+;0V6N.$#2
M:R^E=S 5@F<RN&+AC/)(.@<E.DG=J7M,L12'65G82H65\7O]Q\] ^31+;^!
MSB,8HO6<A4.V!!MD"'NP#;NP$?NP%=NF&=OB_RY7<CK.).I/@.K4*8(V)>"
M56+ 'QT"%$S'?U.FBM]147ME5&B,ATY;EN=5?<&X1JY(RW39UR X/4"A$;IZ
M/GPF<-<'\:#FGX0$/!EO>/_*+]U,;Z=TGMBM/!_2+JV99ALW\Z@P&;^YKZ7;
M,?-'J8DCJ$$'K[F[N^.FL<%;TU[O3W[G#?RG/HQDA->*.DBS([1[0TIY(M!@
M!4#[=50Y-YEZ@-VR@&$[4M77EL6)G)8GO-))J\%C&+![8?UH2))%1 3K>XHW
MP"!/W!2/K>&'(\&E@L>G6L)F(OLL,R_";:(C7?::U )M&?D:F[OCKV=Z.*+[
MQ6GRQ<-[QCWL6HN8(_]," 'TK>-(8L5@QET_19_Y.0N!ZK;GPW;P0V9F!6@*
M&N-FM_]>NYP&T#[6%CQ",6$21+?IJB[IZ"+=J$CJ6*#T#(\8HF&96Z,/C[F1
MN_'6RDIG$M#J>J&HV]_XNN!4_")DFN&*P[OYG,]I_,]-ZV<;IV7590Q>20T\
MUY4F =%?Z97P%R<QQ<A/BFGU3E0.<'EV)_N:_.*Z"HO\3Y<9=29,^BE (<'9
M5FN0)7WBZ^\DVK^PI8S*/(VL!6_#9I[B)Q>C)5I>1"_M3(69]5FE\#$_K\3)
MM'#/I5X VS=@?-EC_+$ _=E1ZK$;AS$#S:[?DPVE42HW?8)J2-+1P\MTCD+_
MY.*X@.:]!?3MQ.G:J*X!<\5"#M;*'[I7>B=PY7B#C]<CV\I]Z(S,S6U7B62/
M<_U:EGF#N>?.[LV:Y6:Z!RZ<A?6;53PC# VZJ<1\J_RF][R=-2^O#0[:.7Z8
M!+U 43)+LN1=MKTFEK(Q<$ ,4G[E57[Y8.B^ ]C;"22\J&ZJ*]= ^@]68'N_
M>[GGK=PZ7[":"2NBJP ,0/._]Z[.3#M1O6^%>[^*"4;"7%L":G[&1T?<G,Z#
M7>--O-@Q/C-9&L(B=SC>.RA-C.')'B,Z_NP]:8B=LU>HO=J?>Z*:N$[T(N4@
M=-58J.YAX  ,X.6'O/7\^8:P$FW9?6: S+_W)!T[+!,76%;_P,M4%KHXBO,F
M0 %(@5DB?_!$-%%\Y,NL^PGG.Q^.G 9JF,:@Y&P6D03"6?UN 8D]3XS4%KYF
MQ[[A#1?KA3)TCC'9=^-N,'[W'ZSST/[W)>CC%R?47EKD>]R]+04:V"/6Q@WT
M*9U3U@-18UZX#M83Q2NJR:GDC^]%T^,L=$\KUA[L$?KK1NAV#,O=;X*7-C0B
M$%SFTV,9MJ5$Z)WTOT=;X*QA5[W!09J>FO>L 6*8,H&:DA$S".J@)F(#00DD
M:#"3LGT4*UJ\B/%B)AD(.,KXV+'CQY$>28H<>1)D290L4ZI,&;)DS),B:<I(
MHR^C3HR9=NZ,V5+F2J >;=J4X3.I*-*E3/<I(P:MJ=2I&6, H(HUJ]:M6AER
M_0HV;-), (B)70I C,^>.B?_J3T+5RDEDQXUU9NXK!ZT>LOV+MNW;-D,DB!9
MP(F+./%796B&*7X,.>G B9'#UML73=]?>M'H*:O'MG+&&U?%3@(0>G':Q)D$
M/E4&N_,RS?JBU>N\[W93 )-BQ$A*3!)ET51A$_O$<%C"I\B?$DNH7*$R3=,%
M'GP.\7KUI\LE2DR>T*%#YPD+$GO.\'LRZM&71Q_.59/*^2^'VJ]9E.[1^BZ)
MLB2\TG]C_)55:DP1)@!)+)2T8$@+CI1@82>Q@!]:OQ&'D1B\8=@4:1Q^6!E9
M%TH%0(DF H &,2>NB.(^IYT8@QCP+96)AB7&, E\5ITHHT5DE:51BQFM8$!%
MRI3X_Y:1 (RH%#0O+HF&11K.Z.-.-8(H5B8)=O2@#-$P-<E,(QF(99E<*3.)
M66:NB=5K;"KU96W[T$/11)_!1B:&5FT50Y%O8I4)0[#=Z9E3N>5$469-H7&5
M 4GJI D:!/Z9D2;6L3<>=N-9-YU!#R6$G'O35=?=9-\IA-U #%$GD77B/=1I
M>LD=QQ Q$H6E"87T^1=@KR[1MRN ]1%&E)CX 25 &EOEF928^?T7%'Y!$8;6
M#50Q2B56C#*[YIZ45FLFMCZN-E6)-X@1P[D2W7 #%Z0!<&ZZ9C$J1B:3H+$C
MMQ<1LV.Z_5:D(HYH]+:DE.9>=)J:^Z(&L(GPJ6@M4RO >__OQ%%2I,F&.G&+
MQJ/?,B6??F-,D@;))I><QG!C$,L1)1^_[!.:^L+,YJ@T4X0H19<!IL]MG'TV
M,V0:;G7#"C<KE0EU@BJSS&=[:<;SSA9]J=.1/?DFF7!'&S?>=ZPF-VI!EG*7
M:JWK8:>=>@LQAYY!9#L$'JV3+920W+0FM)[;N++<GU!&Z><WM,8"#I.PO:J4
M!IU934(5@(4?ZSA=A%M(5<)'@S7TY1<57*;E7Y&[4^86G0;?D4!*AB1\F8Q(
MUL44E:CPC@!(O8^'&4VII%5,'LGD6J#O4Z+4!I26$>,;>ZSY16D\"ZQ*FAB)
M _,?!0W9 0'$<, ! &1O0  '&&#_/?C7?ZM,RLF3[Q7-MNF\3U3[0,V99\M0
M[[OI%PYS8I EKEZ:BJZK&!H5F6@?/S(1X\BB, &6R'568U2)LG4DXS$*>#?B
M2J &!1MZ0&,9G*E'SKZTL\OD+$,76D'$=D(,-&2+4O08C]+R%K=6O49L;K.4
M>+1#'?,H0R*8LLYZ=D@KA$3G.N&!U7N^TY#SC"<L&_$/K^XS+98-ZU?0 EQ^
MBO6L9"V+*ENRCQ2O."W_+ @MR%.*N,Z7%6^A\7<?.B-7X)44VXWN=!4ABY]V
M8KJ9;<LBI!D.Q1A6$0 8+2.<HXB*)C&\X:BHC,6C8^T ,!S<981;;D%CI:QX
MQ4GL;!DK_PM03-2P)A@<H$^^*>4HL>>; XB2?)*@GR4A,YGD(>HV'IR-+>GA
MRHWMKXZ E"19C+>C.FG,*8 D"ULJ63LFD84RQA3F6TSW%CE:Y$@7>]%$H,'&
MJ63";8+BH"VA-A'%C;!J@$P7'G>8!H6]CT![:5]NW$>9=D9%+W6BB#S?6<_V
M76:>\+0(-(AAGO?<C5.VVN%K@J@TZ<C0;G83FW96Q<T?!LH@=X,H0 V:GM?\
M!6H<W:A'UPE21,FG<"B9 199-A@P-N]O0)E)2@\G.0 -J"*9V6<^^5FEJ41.
MI3 E:;0H-\E^L46!)E*3DTR$HX:M2$V> R"_4J<1H5HD+<IX5_^/%&B\.DJU
M(AYZ4E8Q<M0;/86-I#'+GFP4 [,H8T>/FB#_J$H1V1W,D.]*BSJI:M6)8#6J
M-QHJB_0Z3!>9J%XZ*:1.I$D1TF'$*NK$"&F^JA-)OHYXAR1+DNH!1XP<Z5'4
M#%CNF-(ZBZB1@(#DR4[<P,CSA<F3A!D#32<1K)1 ]I5K0E-C:?LA-UV.:N^C
MR"UGLT,+_FZX;QEN_X8)0(J8L"K*/-WO%(O9)"7W(A&DB!M%!ZBE*<,S=C(4
M3;];$=K%]839K)-;Q*#".=ER3K:!7WLW\U[VUE*^[IUO!^OK7CH=%&]C2PZK
M1G6>];CJ.J$B!D& 2"KK-">C8H/("U?_A=&!F">( '7;!3L:TH]B6#-Z 4V#
MO(A2GE+Q;U7\XK# R%*/J$4S=%HO9]1+7PX2D"K.\E6THOA$<&%D8C>X%^R<
M,@G2U&L2\[1*C_%%+C3=BV"4.2/O*$::$^Y#0RMP0R-V.=D5X(@T,4+1BQ3&
M8Q_347>\<>!L*<(%BN%K(B6R"&9+PV7>V(@L/;:*ZTZC(3$@DESV6M(DTD21
M'_WY77X4Y):7I*&!_5BY:OXQFH1LKZA4-ZYJGEAA4TMIC+BQ(HPZLR';K!10
M4R31G&:8J)O)D\ FE[&?CE@*ESRP@;'ES6S14&H6N;&=(!.W^YA+3#N2@TGE
MZJ0J$<#S>%VS_S3D$MEG@09UT/B7V_0,,_+S=%.6J:34F!.SKGND,!G(L$E?
M1 QW)*V=2DO,GE@MVX0TGF)'33Q *6U0LOF,H<+)OG&92(5C[IT_=YBCH_VS
M:S/\8=L48G#HA,T@",$A-^'VJEC%2E:@<O@+Y_V=YMP*+".5HK.>&+C]/&MP
M)"[Q1Q( TV1-JG*-(]:#$* K&<2\2S.'T$AT%1*@7L0 "CO2"3UGW=^Q>IJ9
M%:R:!!B:H5MVJL1#4D7R)<P3\EQ))]10#.#Y0$+Z6T-9_25%N%QJT(G:FD\O
M;=%SD_5 %]WIE :DSRLR]:A7!.C[\)_:'\4L !C@SP,+N,$P0O?$"O\I(XQB
M(-__G+LE#^]1N+.UX&^[CSTJ*4HJ\M/;2<LB4:\57B6:K6%S.DE,:^X-./](
MA&8P'$U$2'(Q'Q.S:^OWUV-(4"^;C<YRXD%[7D89+.[,LE.=P,Q;2]S[\-9T
MZQYN=#^]N6;!=L/4C=S "M/=LZN(9*ER00P6JKM3ZZU/GK0B2: PO3>K!T'
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MA]OD))("?G+D.1PC\>$;(_IFWMSY<^C1I9LT6Q"-S>DB-1G/R!WYSN%JIA^
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M0L5]7NAMB7RMT0K*EC!4QS$<#S@;DB$%O^15":/B,H,!-+F8K%GB(0M;HGV
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MOMK&YR(,IZ"J8HE54-.>G3K$&EN0^_)*I;QKEJ60\T<IEJ73!%)..2=;N/\
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MH3%H#MH,\&R2;A)=9:[Z$2!C!9T"TNG>ZS/22E'Z[2;NXN?J#J;$C@(GI,,
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MR?5$T'(\3;G"G*(6:^RQ.D)##&7(-NLLEL1UB5)MLA)GE%&!80NEMD81->U
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M_;,TTR'$J@BQSZA0XI]A%N24JU37>=WHQJQ51\+&?(SM8AI%0N<LC%0B3GQ
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M@57=JA>]=?UFI(5UPVYZD77C8>F!==-I*[U-\^6(A4V+=VTN4 :?GI@_J9Y
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MW#;A:Z!]^"7?^K9*$@&D8#*I<"/)^R[)ER39GROYC8%=!<!.[U253#*1'#[
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M#+9%Y+1.I%L_]IZ6VLUQF^4<B$1\Y>-("6XP-O:%A-W>')/*5[804RA=,6P
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MPP D!1(C!C$D\0K'VX8QZ:"<5$ CC25="JFD(1<)(JZY&R?JRJ(;9(@AAAO
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M(5>'>9RAN9Q-\9RI.9W?1)W)&9W_JY==>7/MA%=]%3"<.6OFQ'%AE9@_:-8
MHR_J(M8,#+L(N*#WA(@Y*26^E0*I CF^LKCJ(8M*M"-R""@DY-AB<\.$8ADZ
M)UX42;'T80Q*E+2BHQXPT%^-T"!F(@T(\H\,,AHR_X$1/D9!/&883D-(PF ,
M0(:G!&+'OD]<A.ZXXOCYMB6X,/8>NZ6+&6J^U(S+-N]6K$_[?+/0+ S2JDS@
M+HZ,VJBUS*56B@.1EJ]M3J46S;@'R;3F#,[B7)(]).JA)&<AB^J!N?IHGR,B
MEZ.96L,+UXR@H9:$IBW^T.)+2(W4)&9HTB3=QH(Z]R\\HZ*3,]F2T[-0US9N
M@X #@L ($-4(S#,.--NQ-;L\_Y8]_T(3(.(X+FDX9C5J4MO \ 2L5E59097K
M!@Q/;@FKYF2:E5*VY3-5355559NU"7!2=<.T&6,^)0-J *4I.>BW99NU6:W
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MY)%%,OUT4F(MJ71B3S:I=%.$&CFTXD@CL=@AA#@E]%!$%K$$$HD9L;3A/ID
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M$R@@T$$+C9V!6B%X78+&&?_T&VYS-L1829/"&/#$5G/&$Z,?C7G9JC,J1*E
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M0HQU5@B%U8*##>&0AGF6%Z/%4L,;U/#=ON!%+.TU%U@NH!9R70 NXZ+O$8#
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M<UR=(EQX5B+75&*F)7(U4E@ST2@^9R,C1V1WLR66-7)2MS65]%H*-TR8$X)
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M(ER"6K-H63T!.4?!:2FE#-<%A!T9 T!H%)9F3L>23AN97<G0A+X"+8.!7IH
M+\\2+?,$DP)!#&@0AF'X=9F0!I, !^+%4GM!>>VEAK_V7HTG%W H>62!AO?E
M%^U"&)L7:8FH;/L0>HV1"7[X$*/7&,DB)0L&>PV6B+[BB9"H8(=1'N=&4>$F
MB1 D'6I)+['H&1?6,#7D0[EW5'F)EM,1EQM3-$AUE].A5)@HF'YI''T9F(#I
MA(+(A\0 #?2P08[_81#^J R!>!".60].X1CZ,"_U@&",Z9B021'$<!V5*8B6
M:94:H0S_\AB?"3"N&8C7H9F4N3@'H0DGT9JSR8=729J.85&:V9N7>1##(!W
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ML,K0L(R*L/3JKK/:J_*JJ2;+J1H)8F@0 T@QA%$Q+T8HB(XQ+[;G8/ S,<H
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M*O0"R\"1RK5W&Z[!4\2\?(&::!6&:4@Q"3& DEQ,+!X4O,LQI(\[$&GY+&E
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M-0&Z*5X*289!3)(.U!9810=9F7@#K?!(EDQ\!@V:( LQ:A6OHNZM)),!7D>
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M,BW%>0. T64  -2+5F]J49Q78T:# 8!85F)7;R@4 R 34K5HRBZ-ILQH5J@
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MB(1-FBHCD>Y$E\Y%G[0BWA2="$UC;V8"87$-A"@6HZ 9DT:$/F22S_]L:>Q
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M2N8.X:5$VT[EBD+ @+(N \TP!1"%6U,LAOJ\R/BDX4O,U/7M% P4Q4P)8E&
MVWR1"@YL!WD<6WC_9%5P:4B7=5F+)/5BS<20(5G&B3(S*6\U]P13/\2Q;&/8
MF;*(L,UO(8C'*NF?D*EE&4TT0(C>\ AA'9Q#A*\D_!^:_@@M[Q8%3R#//0A<
MVPXSST0T5*:-7=(E\QRA!AVD=58OZVD+HA8!^V_F7$[/ZFF;PDG*R4LHW,&0
M.O"/9*]6OZ\Y280R4?5G.XATNE>2/.1S-(=9>NI]^A Y31LCEO Q!5"Z*.B^
MK"TABIOI9;%M0]MJ X@5<QOLF2[QL47F,=]L<,:O/>A-FJ6%386IA<QJ$]S
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M/(A;96#]YA%#"$[JUY%#O,$T2L*.ZUPT!OEI&/.AW,%31&.'Y\0"\HA'T ,
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M28K>_)+$V;E%E3F=RK>HRIF6QK*FGVFJ6D')K;L@$J^0&^7O'J@MN#4&>O_
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M72=J'>XKP"-UOO;S=ZB[#_5KM3QHPX W( B#F?8RJHBW DM[&^L+ /X[M6(
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MKUC90NF47<07QC$O,$6)P%@&#46(J0&81VD\Y[ )8 E8Z(#8K<5;]&C.JP2
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M=AD"Q0"IUU>I,;A/)@09P!1!V$%)T),Q1?^YW$'0*'3:END=A-M#6^ZF%9G
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M&$3/V6F%//&;3/H$0R7^:HB.*J)1T+?$G%000[^;&?AVAKWDE8IXS]/(3.
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M;]E$P@C8<4/1 UF;"$ &2[9)]FYL$V6P0 :U(_*$C220F5@5 :=I2'XM>,S
MNE&J^C3QKGK[9I2U3\YUMO.(O7.HZHA'$Z0T'W<E).,&'4BI18-9DF6 YIH
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M'<+U;I)45@XDMHVS"L+U=DY $0)!2W.!U.,+E6DA)I0@-%2C+-130I35-I1
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M@HDF)DP^Y^*O>@FF,D>/;18!X !\9@UMIGM=N=LR-GP==RZIBVB9]686U3*
M[[ZM]-^;EZ:F.N^YSW\>+7KD/-8K.%.NBR=;M8"Z(FE6<%_;9T\X"0:NB*JI
M6G)@S[AY40RB6L9B$QHL.A8OKV]FL+2%S/6(,?C22AGCV2A#=1^1#=)*;!-:
MZ"[(R,I)35]:I!;UOD2Z$63;0RZ\NOT'="O!._&EF3?C'P_YR%,E&IE8/+VW
MS!AQSGQT:(DG9PX[<33A1=&9ZCR,!:/H<()>W?LD:.K+XOGV'I;P%C;D6;;%
MMT^5>C"T3TOJVQ+[71GO]'<A/6'P\IC=EP5'4FNQN>3#,O3G.T5;TJ^^]:]?
M$9_?>K-%]MSFA4C@K(W&U,,7_:G%[Y8>:W[(6TZ,N1D;.>*3'_E@/7\1VW]\
M^1M>@/=O#/;_&_]_8.%X 4B !6AORI!8]L8LZZ52W0-.IW=T[#9_W?=]]-=_
MKS5QO+-&+)5E,[<H;5,/A#-<+^9]W-=2RM<UIH9Y!<9^AA=Z]5<6SF> 3Q%]
M,P@1]V6#.:B# *9B]U9TA]=>)1@9X->!6P-;A>>!_">$AM$IHA%ZL>6$;'03
M?31^10B%FJ5N1KA^R<<8,)ATD;*#4F%Y8>@C3D:&9XB&IU4/VG1Y,%B%$1B%
M!(:!)2B'8A6%#8B'>^4X',B',%<6-X9)60:$?2AZ2;B"@DB!FP5S21B#:=@4
M-3B#Q("#CDB)E7A*D A@VV>!_>9OA7B'1%:%%HA_71A6%ZAEGE2*_W>( *#W
M>I_$@6^XB5^X?LJR?Z#H@JIHB4DQAF>H#&:8B[\(C#=4>>X6 W[8&#)'BW;(
MB$9(A("A?+$8A,R"?GXH@?.G6?AWA1XF?HSHC)WXB<O2;X\A@Y6(B06H"0D8
MC.FHCL!3#ZL%:[V7BJ\HBLH85N#(A1[X@N&(=!XVAXF(:HG8?>NVA-BHC4"(
MAUQ(BI\30%AF=.N(.NHX@ XID1/I.O[U:@< BT^8C)EGC?W'D>ZE@BTX8/NX
MA)S(;IQ'?L^XD?B(?MSHAO7(CUBXC0*GCN5(@#Q'D3FIDZ:C"?S$:@(FDR0I
MD@+Y6@89C2Q8B_DHDT9VBO*(A5^HCP-IB@]0B8K@&)1O@8PMF(T(@&3_O[B+
M9!B1.RF68WDMM!9E*?B41EF+)VB-1<F,11E^BLB,'=F-U:A2(_E]5[@98U5_
M ;E_<+F6;%ES#FF3 8B39(F8B0DFQ%"8,_6#GXB*'SE\6PB!,.F7' F9*#F2
MT!A^TFB+@HF(M^B1!0F*=<B":-F/QN.07QF&8:F8KPF;KF&6 (:6IKB10=B1
MN1F/<8B;UUA^ 7>(MMF4I7E\U:B9OSF$I]B)1N>%2H@WXTB)C8E]U!>;U6F=
MJ*%#))=?0&F,@,& O$F4XV>73.F-S$9[W3B:BNB*G)B2;4ESE6F'HPF2M\F2
MOAES&+B:Z]B+U\F?_;ES_,69@YB*(6F2_RB(_."Y&..%EYZXFS,YBY&R+79S
M)G8"/<J)A(M(G,O(7EKXDDH(G8XHG=<GB?Y)HB4J%2'Z0]P)FD*(%N"TE7D(
MAW;)GH&CE(:1C5X&8HSC*A-*$;%'"=6B46\1; @R86C!1\[9F3-I?I3)D/IH
MCW(I.<'(FCNXGR9JI5=J9</IHO3'G.;GI:-XE9)I)NAVE%ZZ*SD $GKU$'I6
M6(M#)[KX7/6023DJ>.MDGP':I,GHE,09< S:%Q^:ABA:?:Z&I85JJ/REHD08
MGPOZI'U:AS):?VJ 8PU*BVI12F/V=F>1,9-*;4E11W]%.GJ%IH:$FD$YGWOZ
MI$;WG6:2E>*I&/_Y"9&^>*BS2JLS=9)YF(4KVH5=ZJITR(]DRJ5FZE G=G!K
MPP)\\B5OVB(?MP]_\G9VLE@-TIR6&:R\R:L@F8)\N:MR :AH**C21YVU*J[C
MNDU?)96+:J-5::')&9)N"5;;@G>N<C>B!BM]<B8EXT7YXQ8?04GM]'&))$6!
M=%*DHSXGQIPL&9P#6I^AF)?AB:VPFHZN2:X32[$)U$TK:9\WNI3>B(+MJE*2
MNDDP\3;(*A<DFQ</X6S?U2=W]44F@5ES]480MP]NQ2=SFC[NL38$"I.0"8VX
MZI&7N8]GTJV\J)^36+%'B[2G8ZX;:G^D")@HJ9DK>)SU=W 1(X4)U2O_ 5EC
M<[$^U@.R>,1M=W)0;)%8<MIB,3F9<KF)^>>&0$N/5^D8$"NELIJT=6NWW#*'
ME9FJ[AF8K]BQWWA[OB8#(X=CU!.SA[.M[(H0;_.RRDH1%=6FAM0@.+ M@T)S
M\PFW"XI\JPJ>W?> &SFT9/BMSW>8=VNZIWLM0*FANMFH &FMZ<: 6FL67VL6
M9.1')-@@ZV2:0L9A+@:V=U=*E"07A+<^30<2E;JVCRJ4[EFC[=FA;M&5N3BE
M.EBEJ&N]UXLE>>I- *>GBCJ!H<FA*\49*15BDN0\ KL/=].;@3&J^Z 6C4L^
MT&"\!$%F;N$>F#(0)?41.<N>&+IKJ;FVC!J>6\&J%J$;AJ-[6B["0#' P#&@
M72[2P X<%?:%O15LP:ZAB9C;;]P[&0N9A6ZYGO2(GF2AH&2A4%)$J,A&K7DQ
MB1MF6"9,3FWA'^:UASGZM&G+I[YYC_/7JDS;E^3_$['WAC!* B,?D0DWP%:3
M$# T6'F?X#LJ<L%1+,5:060>K(KL:HC,NZ1W>HMK)5%H<3ADDU%TFIER4;44
M04\IP18&I4<D)J<#I5=MU!>0HL%]NK-]V[G)"9B#J9_V)@8+0<0PX4P@D1\3
MG F'G F3@(Y3S,B-K!2JBYD_+)]ZO+-YFZ$P^+7":V@P#!)BH+#&T\+DLPR5
MM&QJ4;R/8WL$ 0JYRI0:>80!;,E.VYY6'*7 .+U1AL1*<0,8(C/1ZQ3$<,:.
M+,S"C)$:";6?B<SLBA?,=YK)2<?(AX-Z9:2"DK:[2Q@*>KM)<5=Q [#4$PTS
MX!Z*8L?]VX<)&Y>-2LF,_VC 5'IS@2P4"9,\WN(MO.P4U3O,]SS,O8>0XMNS
M=[G'&'JAAPBREU-2:1$_:W/.6'Q9D\ILBL46_J$,15I[%/&B"&#%_OMO#BN@
MIY99O J&ZWC+4);+-[$NC[C+I&2T^*S2UEN,!UNFM:FV:O&Y3BH:SSRM>,$D
M;+<:9-867\+30VG'"%#"(A<J$>-/G[(^D.NXBU7'?VF%'8JJ^;=KK,S'-=G.
MZ)@?7:7$\P4*4+S27VW!D(S'DAG)K7O3&*VNO%><+<O46^S*H1=\E1'7PK<U
MKS>< %RM[<K!B[&EA AP'OT7<EMO$DS(,;"+WS%?P S6BVW!Z@JX<<FP!IK#
MRES+?T[)%X:;>PBJL\N9D)M]QR79H([QU\];IN#[@NM,O3<'S[W\E6BPQ$Z1
M#"G-V+--K@)FFNEZE-BJV4JYSSE,P*+A/F]CIK%\=";HJJ7*I'DQT[!(T\A[
MVY :&O^"36^$O1KN#!%,\R3?(=L5$<RT[=WDZKHRL*5JN=N>6)\WC+##S6(D
M:(*GRK:]^I+EW+_LF="EAIQ//:#VB=HYB,"BM2[R[$S>,L0/<]U(DA]#G'/$
MX-7?S>#D^E4)W=G_QE(VK;:;69X^O-'MECZQMY>4FJ1IZ=([C+S4.L)W>9#W
M/9YPX<N5&-(SV# -#N,3>[&EC==:.=_PG=>]VJ7HJ:& S=PZ7,8B[MG'_-(<
M?>.;V1EHN]\VV-^0=\@Q#N6U&D3N6CS<>YOJ>8RRS(??::K-O*&Y-K5 [KR=
M#=G7>M\!G&X=W=X*C>:O"M(@3;=1+N?7J=MF+=\^+.06G=?_1S?>'FU@?@OD
MSTW54+C#':[1;8&,+OV9KWC1P>D_2^[B13OGDVZEV_?A+?G9Z8V;/-Z,DAR^
MO]VT5\S%6M[IN W5NFKF.0Z?H<@9TBV]:(#(B*S(B7S(LV[KM8[KM*[KM[[K
MN<[KO^[KP=[KPP[LQ"[LQ8[LQZ[LQL[LR=[LR^[LT0[MT_[LU2[MUI[KV*[M
MU\[MU-[MV^[MX0[NX_[MY2[NYD[NYZ[N3VZKOKKG03O)1![)H!Z9]2ZL'7O;
M1A["FIW1>%K-&^L6S"?BO;V)D&Z 3>[DDZ#("D_K:;#PM/[P$0_Q$R_Q%4_Q
M%V_Q&8_Q&Z_Q'<_Q'^_Q&N_P($_R5"%?\B=O\BF/\BNO\@L_"6G \C'?\C)/
M\S-O\RL_\C>O\S7/\SOO\SV?"0[?XKICZ29.YG><Q76>J]YK](ING*3M] =Z
MR?,^1,P\[_]+R>DZPLJ[E_^N/I'L;GWZ, D(+V5@?WTU1?:QI@P3X9,P!>C5
MZJZI#L*?_+KVK<QW+\OTCN(C_M1A?N)1FY:KWML$7T0&7X!I;WV(_V2*_V3U
MP/A,]OBJYG59]8/_G)OYCNA4C[%'WYM6*:!_CNG"V=PQ"M3N#=K-B\.B#^9N
M)*64[OJO_V0<.-YIG?K&3/LLZMA[K,%)K[FD6=G(>>>92Y_*DNA3[]AD8>5E
MSJV$"?O-[_ST5?3[K/R(7N+K"^I<&+N=/X\-B\Q3G:VW+^_4R.I'#G.?6_V4
M#>_=Z/7/S_[MKTH82?7'K.<<2ID\ZQ?9?YR"WK;..]I-"A (9 P4.%!&08,&
M$2;_5'B0H4"("2,RE.@0XHR"$3521)C1(L&/%3LZ_+BPY,  ^U2N9-G2Y4N8
M,67.I%G3YDV<.76J5+;3YT^@084.)5K4Z%&D294N9=K4Z5.H4:5.I5K5ZM6=
M DXV'&F2ZT.P'$$FG'%RXT20(T4V_)J69->Q<2NR=6O6+=JZ8N%NI$B7+E^2
M?1>6#>DWL%O"7+$N9JR46&/(D25/IES9\F7,F35OYMRYZ@'!AP42]H@7[<2S
M:_$>UCLWKXP$;0TO5&NZ,%S#N5_;]6LR-6W1H>\&!IP7;6S@:%-Z9EZU9W/H
MT:5/IU[=^G7LV;4+75&\+O"PND-[?9TZ_&K4:\N_'2_<&#?QPKSC<R0-WRMN
MX[?[RAT^&^Q[&0[8;O] G!XC\$ $$U1P008;=/#!I^[3+[_2[)/OJ^3XVRI#
M\%A[3ZW^^L///X_$PC D"=63"ST3?PM1MM,\#&PY" ]\KD8<<]1Q1QY[]/%'
MH@+8RC4 -60M+(&0^X_((\<B+\8-9=RM21"C+!*PU9"T$+^)RHHQ2^%.A#&X
M#X&TSD STU1S33;;=//-J\B;$$7VZ#2/2BGC,F\O+4T<4TPL9>,/RB*'JU+.
M0K]L[2)%R1IT2=EHA'.S&R>U]%),,]5TTP>%O+/*)H,S"*/>YDL/U##K R_0
M*_<S*38-&UV1PA:_(M4V5#ETE43]1I02 4XM0S/8YI0!  UB%XL!@&212@/_
M@$J;%8H8 #*1=BD ;NA,3OAHA7).,&-,C$]6U4,44G+;XM,U)T/=<M;<; OQ
M7$+G8Y?,$"6]%JMH]_T) ( #3LK8251:MM\> P8@AI@$=LE8 ,1 Z@:&<U2X
MXI:6A?8EAXV29.,:%;;V)30 'KDE,0!&&"A0JG50$X!;@AA@B5^"&&.68 8@
M#:0B[JR[(4'EMLZ_EI273D<_%%0U]@#DUNG67C24Z*)+O$M5(T\U=;^I*XQ5
M+W\9&S;LG8RM>9^8CZIG9Y5N !G( $8V%N>59AY[GY2S12H,?1O,!(""9=*8
MYY;^3MNH2=YNT%AM]TG\9);RIGL?NX^B%O($ Z8;O^2_SV:)6I5=<MOGHTC?
M[%P]W[H5Z0F]^_/=W9XL+#%\WZT0."7O?9'4]G3+LD/OZ.WZ7JAQ-:AOLJ5:
M.?F:C$56I;\Q%XK@2]WNUVR]6XHX^Y^,)=S@R1DTO>$8W'8IAO*9#8K[?4JN
M!\*463)@A9=23CG:Q.\/*OZZ75YPV7W<@'XQ,=_#MN<YRATP*(D;UO@RXZF/
M>&EI7#L4UR[4K2,I;6I,HUIX/.@[.^%I76,R7@4A-1 E%2IJO:*@J(#%_[RJ
MW V&-5G;V8PEO: 82Q*72MDR7+(V-.AO)7]#6_APHD.6X$!]#TH<-&@2@P ,
MPW\J608 AJ%$H:"/)8E;WH$,@#,NNJ1D9FN) <3P-QGBA'\JN=R#Q&  F0B1
M)00KX$H2IP\'ZB1Z+,GC9607'Q=UJ3871!>3;C?!I2F-+ZM;UYU R"(.@K!6
M(TP/"8?T*!E@S7@HF2%5NMA)FQUKB ! D^$.ET":12Y@-@2<2M:X,U..36%I
M)% ,8!!*,5!O)>5#&PY8HK%3HF]FA -FZ,+ L( ]3R5*#%UVM$B3+Z*M<2KY
MV#X N)*2!0Q-)4,;P"J6S8!9JXD:PYDI<3B=%?],<Q]_Z]?]ZK@/:BGC63?2
M&<"4"3-BY$U]]4SE#1-WRIDAD#K/A,D:<U:M/:[D6%549C<[AC8TQ%(E"DO;
ML4!'RE\^%"L0!).[4H3!N3BR7?GQT]3&9:$6OBI,1A,3!W\7PD,6;:5"FRE*
M[16O@X!2*K34J4N@83KNB>%L:=/E#0QTS2(JE'"OS)X0R;C.*28H93C\J<1B
M $>5T , FDBJ2E0@H+:!;'30FV(K5S+6?<!L9/Q3AA&E4SY]+K$E*F"8' \@
ML3H*\7$J^6=/JKJ2=&XQ='^%ZG/D:IUW)E25RFBC*^'(0++*C700(^82#0JZ
MP%VSJ%R]CD%=PK[^%6S_8?U3AE:'.DVD>M.5G%,<P!HGQ )F0J"?"5" 6("
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MMU&]6+1!SG@6]ZL?VGN#P*:#1J@*F!NY0,X"P(()Q!U#Q3VLCF+:PXNZ&)>
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M8BJN8BN&DR:^8BW>8B[FD2GN8C .8S'.CBP>8S,^8S3NC"].8S9N8S>NBH
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MW#*C(<'S+J4A#J&8@#\B@6NS/F^IY_C=@4F:/AL?]20H<J!@SL/W$%6@2_.
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M=Q;,,(/LB[\0( \GI(_C$^$P2MV849, G'7!>55-08,*SDQ.FRI)QL^@ Q^
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MKZTC!5,/S\X>.U+1O^*-M!])R[C9>DV$N;6IW^S*=_$CR+:-AX3TAM*3RN1
MK_V]W??FB+3J9$&-8[CY+G<W5BEKN^Y.ZJ]ZA**\ZQ%*0L+IM3.>F@^ ->:5
MHT^.'<^*_?SY'D3'*-A<,IYN@ZUN@RGS0#AG=!KBTACK,#ZWUWQHOJH6E\ML
MGY?"TF74'+@E+%^TX>0XEY<-Z5CX:9OB K_>%!^IT^SPW]$!1#TSYSN\;'K2
M\HA_I\XU=XY#QE9>=EDF#@',K^KK#?&))6T"ZOD^Y0#P,[5V^O-2[G:C\O@]
MB^*-:GN33VSBCMKG_&KP94PX3>%/J1SI1%F#-.38M+8\%OB#X,-6_%T?DS"
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M^3'^@/Z?@4$@& B$ (%0(!  X@*!N, @+AB("P'B0H&X ! 4!(*"05 8"(H
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M, "% 5 $ $4!4  (!0&A8" 4!H0B@% 4$ H 2!" ! -(&(!$ $@4@ 0 - A
M@P$T#$ C #0*0/^OV']"^X_M_R#_;^[_6_S_&],=UA,0Z"^(^W_._^X$" \
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MN,4?4_=LS #3C7F?=L29BY.;\<'0A&\+2?YO)\R@90FJ@,F8<R]/QNY5)9*
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M'/I"B1]4*2>>,^*ET[(9$E\%++[V^NK[B^S>2X?3UOVQL??+0!B<8I'=>7+
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M*F*( 5(!P#PC-G6J)AD7U]H;7[&DB[[UM>]]\9M?_>Z7O_WU[W\!'& !#SC
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M/E515'89M1],RB $HTDXU>2B2R:Y9"1_%['$5%"T_;A5D$E*A%=-OT'GDEU
MIJA25OKM*-5/!>W'%$E5ND5C0WB=)5>-4=D89987/>E5C_M=!1T]&"$78 PW
MM'>#GUP$2B@QFV4B1J"9&.I<<I@UZMPRH.T%J7($H79:1Y5R=I$IKF4:RI@+
M=0G-IJ8VJM1N+/W(%S'&L42,JJ?.2FNMMMY:F402 840AM$X.$E.^S V$88=
MA:E8WT4!HK0LE YJ4J- FCRXCX.9G.B1@H_E5)!&U94GT'AHM"D4 #@@I&
MP@+P8333!MM1#.Y=9MU6TY87)$'G"428H<H"X*57&@7%[5D<[?D2P4Z2A&=T
M"JFEW5!MJIA62"5=>>13ND*G(TDPJ@3CG7'M&MV.4R[)EK IFZBRKD :Y!&>
M25:4)YM$<13P2%^U:%%9LH654,@^NG357&[2G-=3:S7D4<!;_R&W6&-23ST<
MKK,^:K5H!&T2:M:<1:-1IJEYO1E&GX(*&YZTD7VK/O6HJHR>Q+DZ=]5,LHUW
MWGKOK5E2&I<T'K@*WE 2?G'MN\P*!^P4C1@"1G,>3(X3T_!<WA6$1KU0W9MT
M0OXAF"V)%GN$7T'B2L1N=^L)!$ 8 CF>%XE*UL-N3"H<0);CVJ4\UUII^HTF
MQV#[F.)2PKOTLEM-NPDVS*,:Y5:+-*)\LT-<(KDQ1=JCU*7+7/8._,4D(\T1
MDWXKZ9:,/4VW,?#:&8VNCS%&KSV.(%VE$;F_ZQ6^6G_KMY"VB,]O_$..XYBC
MC$FX@5%\$TPFW-! Q!0$-!$,C$U&(O^V"I(F)*?A&F@D):F66&\I&MQ,;_:A
M#[!532A54\8P[/:J$LIPAC0\%4:F8KYJ 0!>^P@ ?6C#+OXL:R\&@ %&)F>3
M )WE6<8KU;30@!#_:(* TB)/CDKDD>K JUSEX4A;V(4N*^XD!@;HR+M@8CC(
M38TQ.-B)=M0(DP.HX"RZ8U/1SG>DE8B%?T[)'O3>LK[16<DM.G/*\F)$LZ:,
M1&=BVAU<Q$*6Z>002A0K&=*.DI$\5L5,+*OD_(RRD#7M"(MRRJ&2]&*Q@NEG
M*]*9'Y&*ID?S75$HWJ/+Q0SR,J(0D)(H@@[4"H,;_[10:IF@X64R4\.+4'"&
MTW$-I6J8FX7_G$)2GY*40FKRD!*JZB'9I$=+=E,/5U7-59J"ICG/B4Y+>80V
M/(H&?';GN I=!#\\09SBUMFXQQFK(YG31$P<)[7OY#-9/AH<M^8RDNJ CHLY
MJ8[4"!>-P!TI=0*Y'4N>!: 5[$5Z+VF("MQS$8LNI([*NZ1'@A0_\!'O*+V#
M4I"DM+&EJ:QGTWO8 /TWD#(-[RDCJ0O+$F:RC37,ELO;';;85#^('.QA\XL+
MB[H'G8, Y892=5G/D.(_G^AQE1T-7UV6"C2=[&<A8LK1_RZVEI/%A%7'"5!N
M;K""OCAN41BB(=9DF!+0V"V"*51F*%I3SG1&2B%G^R!J:&D]A,AJ_U.]J9HW
M-171N$F(G'QYIF OB]G,?BU).YG6&@' H(Y05"!#W(<!0OLZ^B1Q0WZS%K^L
M8T8 0#$:GPNK&DNY#"WJQXJ_VB$:VZ6@<\&$, @9C]2NL]H^.B^. -O+ 8P8
MD3IF*WJ^NV%:#'G6]L$R7T#AZEJNLI^7JBPDJ<32C%(Z5+P8C6%JXA@5?4<D
M.&URG1Z[RU.>!%^M]+%'4:423QW2R\Z-<*=(69X 4:0G'_&D:#);:?%6N:6N
MI EDR_WE6V_0%WKNHSI[U>!=-3C!P.YM3=1$C64U:\,QG0V$L-%*-E6CE&PJ
M1;(#>94RZ(;"I*!XQSSN,6+<>Z9E. Y:,?_9!V'\N8S:D01Q,0@ 7 S$$9(F
M6;6T*X_JX-7/ @X( &E0D5$4NA")8@<&;BD=0TEB )!F3D(=D0B8[;N6-<$
MI,L0*7L>UTN\H-1_!L,(GKHW%_4*:W<V.\MZE_?'I$XU)T&F;XGHU[%H:5F^
MN\+?61*<V +3C+/8DPL5"Z;EY9Z5HW V=$X]'3SO7=>G:$512^&2$[5AR<\H
M"[*<R(*<#]=&#''M#WV(\^L9ZIIO _E@!$.<*1_G39J%97'"MK(VOZ2*.#;&
M<7&J%A7(*'O;W.XV>)D'  -H-;>\Q8\0-X00&)01+R2=EG#A\Z!H' #="I)M
M1QPT#/[4Q''@8AW_@G0;1C&D%EK+F/>'RB7<CL@QME,K9D=\"*4D9Z)@O0)
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M3#,!XD^.1!@(<A(BHA C&2WY,^*X@AD#W*QAB\>3DAP'@W<"/7@PY$W4]L?
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MUX'F)9^YB+%4$^ 7)_LP6\L6*IU=.65'6S/KFHBTW2)#D:#RE=;F#'T7&XW
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MG&M$QV!ZU;\NX482[,">ZL!JV:RP+7?47 YQQYH=X&;B9QGVV51@YLBJVWY
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M=]0==V":1C=2]SK/,E!EH!%)SE'O>+SI[B-9"!@$42B25<WM>MG;7B_6[T8
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MMXJ!=< 55K!%.8LZV8%6Z+*\+3*/KCS?B7)WWE-F*!_WIK4;3U!C.N8L5Z=
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MIUR/ !3 HAYH=Q+$UGJ<9/0T=G$ST/(J3W'1(,\J]E(Y F_-PE+QJQ758B-
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M#O^NQI>K@,UR6^EC'$'N1\@B7E(&>"-DY<: D8)4I8>.:V;DIHD^* I01Y/
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M"6KR=9U]A5UB!T/8BSQFKU$<EOYNB #G03&GE[VD8C"D";_"T[."!2U./UO
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M.8M#I$(P<@S$BU G'8%*_ /*[G,O1#PKI% P@,2W9 2^A$C)D(3+E!"UN$3
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MQNQ&):4-[<9[^V[/%D9MC;DM\+@4%'#*"$ ,7/WE@,'@ +FB\L+W@8.&"\4
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M&X;0ZV%B4*#!<V;AV%4E=8[2 13'#2!G4(Y,>6X$2'+$>B8;K,CD209EA1@
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M"@@YD5[FLIC*/&4L13G)4L)2!FE<XCGC0L @73&""QG& 0 @0;%([P:[T2
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M_QZ"KFZ"QN#*"6]B%5_+0 J1Q6#+ND2,@7PJ#9)LNBZML#CMQI:GK#@H &"
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M.?;6+Q"W;P/6<1(K_L*"9R/B9VT% &8-0(X663*M+,*N<L7B_YJ6N\1 $M*
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MGDW]]351@4I])]I "(9W$X U6<=4& *6II%]J'5%E 'SW001@C_A)U2(Z@$
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M?<61YUD6)OK?I%^8-\6OJ\XU18#]KNO5C+UL>+<R)KY28:#'1%%9>+X-;WB
MT;TC\ [E[6Q>66L;O+X_Y_W0F6W";E#,92:H$.O=<2L[@=?]]EZ[">VGN;X<
MF:XK1^X!0(QQI8]SY1O4_X##($9M"B8W_Q #_VY"/P#ZIR+_F]0!8Y>[['%(
M>#5QF>8F8I[5W0^# X%5&E1@'HE0[T)ILY^#N):OTS7O@RL[TYJ\)#9UN8Y:
M2OO8O+I3KQVE*#L.$5/VYL>CSZ#$);1SW0L;EC0GQDAC)](1NTY4$9"4#R:)
M<U?%,I@3?I4/+/Z!"'P04B1E8*N*]E.)0$+"J?J(Y#)BO)AA/B(TPV4B,RF"
M"#TX]L4/24UT\;)?65S%J6)Q:A(]JXME6&<36CE19:<R8B$/HAF9J+ K)@,.
M%"<X.UW9T2"29% E!<220051DR<:XHQD\D7X[ EN=T%('FDRRCGNXV(*D>3Y
M4!<C^K7Q:0LID)L7=T4D]>0I+_QZ6T@\]D4&<FH@/#3;1-A#1"P6B7%"7,@F
MR_(VH64"FS#9&2:+Z)*M90]+:)A/$SG2Q('($@!":XZ)E&&G-G6GB>###DP^
M I^:'0PX*11)09J83X@(38'C?(E(X',#.*KD7.=SR7=:5\PBYO-F340(>W+6
M'+%DHB <7=W9*G),EH1A(3SLB*@NJ4./[ =Y#!)#2__I(KJ<BA">X<HFS+K2
M''4Z+:,3@@\5^=@1:/[T.)>4:9OV8SN@\,]\';FB&/)9N_V$(0#V6X;@!@B6
M]#P.J7E9H;S&N$L!L8M$"ORB2GP*#90"T"%Q]95F^G1'3N)K8"1B7%!99KN4
M*0VKQV(3J&)JF-\ B50:;:7]AN=)P/)PJ+O$)MX,RT/$(@9P@<*KS(Z9GIJ=
M2P4NN9A =64A_ESGJH[Y6;X @Q*5(8L+EV&M[NR71Q/=[*'Z[ BW'*).7 Z.
M310SD1CV@U>'& !+G''M/I:;+XGL-B8NJ5E,PR6&RUSW.#OKJ8:Z\MMAS<>Y
M#G'#3048$^2^]4,Y.Q%@HHC_@^&6I8%TG8FZ^AFV^6F'MF%;8_E$M$&8Q#2[
MI4)0PS*#59RZQ(N<0F^;7"*KX!:RB0E<9N+$ABHK,K&X;++FCEY)RYN(,:WR
M$BT836:0(>F#M_\=W3:_U;^\0&29C//BUAK6OVE^J%"&= B5W*:9WS3R+C[%
M)("O4S,%'M9+MG2B:JL&O:P.,,1VB>#2$FR1ZTAL(4C475^:S*#3 JK"4WZ,
M<+PZH65^]5FDA/!J<0@<@7KD,OJ3LU*' <;#O/-F!!KA+C]TW-'=%KC#Z:=S
MY?A%<,YU=%XK7PS#4R0']\E]N-2.<RLWUYWU^3IBH>]__GD9BDYWEC!A)>2B
MI[M&_R/:B>$!FJ<-*A*P,&PF'-5;V"YTD?"\M<C"[%<^5_#*U7[T6R>RCW,Q
M_-3]X:O/!(9:$;L&G_[53%;O=)HZ&<0% :T0NR>K:U+323$T/OO4!/R)W*[)
MOC--CMP2$E4<%VWD\E4.:'D)8JG>VA!D ?)Q:Y:5M\O7*O!V)8**D?,Q^9-/
MOC0,5#<2=TT%5%B[/;I[AVEV4O/I!@ N'(%,3F8"(7Y9B7]1=HM!WOG.RF8G
M*D.=SZOL0%G*$5]^F"-;C7E+UQU*(+^7V%SN%WO$PAEM3=?!IMND!=ET2?ZV
M>!^9<19YNSDL 3V]>3&?3Y],)"ID&:>]V#$J>RC:SRCJ[_\WUYFT?Y2>:HD$
M.B=MW1%,]%6NIF-Q?><L(KT-DAD.?<0E:.!A#,:<3S34;8#*D[MRYQ/3'(;X
MU3C]T)6F>:1IIDC"R:3PA4!UI4#"T"9D?5JUV33MNTOU6WSUJ9S5)I$8&T0@
M@WIW682S<Y3KF67#G"2G%$8B*$/=L4M/5+ZD!!$?WN5B!\]R($4EIA$C4^T7
M,B**E9:FCR@OE(82'1^1S_%;\BO,((\R]+,$;\0@VR,\;UDTCV8P\K_<Y8U=
M<\\M@N7LR1ZGW!W.=/GSH:,AJUP*=6\1@:40[=5/K[8T U06?<(0^>(B*P 6
M#D9UNC=U]K,2M<4>5S4):E81KV;_3FXU.G D)3?C@ OQ(8P':YIE=PH(:P88
M7:Y#;YR1@#AA6PZ!*+;5=IXF!O[%=2D8:[>V,BKS@C>1@W*10?TQ'Q>#8^SE
M._:G&6+#<!?"*>.G>?P!;F$%>L#1=D3!32 #</!G)A)QA3(X0<,U*>G!8X]Q
M;OZC&=0C-"0B<V@U<WCW;I-R.2F2>TIS4WJQ+/[2<FDE*_;$,C7#A! W9BR4
M)L&E&";G5,74AP3UA]<A-A<UB-Z'AA172\3&$I2X(^RA)>WW,MD49BVE/V&6
M)UEH&(7D'C%B1&A0:A0H:+K$1C\E/?MT';33>=,54MGT3I=$#%.H-EC2A$#3
M,!^!>)I1_P\)-1SI,6,Q!"PIV%;W1U0%Y78/,8P2$43%N'D>M0_0P$.T$U>7
MD1&X)#J*Q"0R)SI]IAF<D7DBT2;/E&^EAD GI1+GAC"$-GV75"R(E4WRR'.J
M-R_:X1[PH1%T9EF$!A;-E$G-!QSNQFU F&/N%&X7XF$:\2&3X)!4=FME,6$5
MP1)E%Q)_-9'S,21"$R[E\E+$-7]NT7?YXD-9N'<$:3\.*4A(.!_!Y2K' 4B9
M0&>B1RF,6'W#9EAJY1^7]''CACHB9P QHGR;17OH-F7S)75!"96U\Y22J'[/
MA93EQTP $#BC,V1O*&\'B$T"\AN#TG8>5I7O1TH\%)6*03^AX_^4VC-G/M>*
M!I%K7=%/X<(_QT$G!Q5^_=% M45R_#-3(/%W$R)/8D!ODZ.!!+0G]!,#DY!@
M%Q$A_^1X]%03N981$"=-+^1"I.*7B)EJ&P0V2>5 YE,C$>1X+>4H&'9 (1%7
MU/1L U%/6+5">;1V)R(O_'-3FH5J7 ,Q!X2);@%&OS$C%%&<=)B$OWF0DI@U
MX[13G*<_<?E35%@66V80KPF7<,(3YG@A!-).^616]84^F-1Z8C@Z8]B;>1%!
M>'5PP<5O%,$D^I)[IE,85(*<[K@VBY&>2;4?>YA6'-$[5&E*+Q2(<*A%B$$U
M!I)@_GDQD%24W\<^$E&@3+>?>M$[D8-2:?B2044F9Q%T4U&U#RN 59?S0B#:
M<N%9-+CQ@Z)A<4*A/TN9HC$JHS-*HS5JHS>*HTYAB*&A5$/1HXB8HT$JI$-*
MI$5JI$=Z&E0D&;>),>6&I/]/"J51*J532J55:J57BJ59JJ5;RJ5=ZJ5?"J9A
M*J9C2J9E:J9GBJ9IJJ9KRJ9MZA@[:A3_ QGT$YPV0G?[8%YNJJ=[RJ=]ZJ>O
M\4[W$6*<61-9<RGA(2^M:1.*RE-I J-L0WLK1!(H@9L#=$M_BJF9JJF;RJGZ
MV96$AG(T1!\ND1F:J),B$1**-2'/A'21@QV8> /QR&$:,@G5I1+0U:FYJJN[
MRJN]:A7)-398:1Q1Q';L$8(X05%F,E$1P:0[R!./4R6U2I=8<ZJ^:JW7BJW9
MZJ6U2CWVD37#=JL4*2'F&)HU$5OD@I7#TE)_XA/A=1,[&H,@Y!,5$80:D8T1
M0:E%VJJO4B$&=7H3_6JDF5"M^TJP-$HGCT54'@&>FG$1Z^50/:8,0*,1EVHF
M*G,3]G9#F+A$.I%*!Y,GX9<3"H(0AHHZ"O&H_P7+&WFV*<.&'1C9$I4CL$ZZ
M%I, +  [%  +FCXAL'^C9@M#,L30LU^T$Y=$/2>ILX,SL"BKM-317._#)MIB
M>.AUFUV1K"N(K.G*/]USB>;::#CQ;S$1?R=K$>93C3%&7[DV?4M;&QDB?.W"
M$D)##/ZU(QBI(?GJ.K+Z%JI($S8K%'RK,TG;%,K0MA73(YJD#+BS)V( ,=*:
M%#LKC6H+N33J@@TQ:Y.Z:.0E=AVCLC\U*"0+AA8;*08RN$Y$B2):J!_KK^4S
M'X_8(YE +=+:4)&;&[MH$:H240Y4,3" '2HC!JIRN/V2(C>PC,$J.SG"F3(Q
M(\1P7)S9'V^&(OS3+?^JB*$2TA\D(:>[0A)Z*[VB4[1@V#8[&[-U\H^=V28A
M-&5S1;N[V!\_)4_;(R?4\R%VLFK)!$\W%;X2-)):=+_R!D "N[Z8Q(^R*\"U
MP1G\%7=W=:L3*8C_$6-!:#A&6WQR&;)M2R8VT:P[DKK_V7OQZB@N4ZD#7!NQ
MR[4GDCYR:YGA Q,!U"]A-;"%!D!Q11(4N2NE!A:?<(P-T;LBJ RZ6Q(UFT]N
M4CO$(+@G,8N%(0: ,0DQ'&>I1[A-@K0M!AV42KN/ZVGX:ID3F[[# ;"_:Z[4
M8HT[88DS8B)1O!'VZFA)\XV.VW_?:)$@[,:L(3;C(H!SU43DA7Z&HD,3BZ[_
M1@NG7GD3IT>4A1JV&?Q7\T4S#,27H/O&KC'%S#)>*C1XJ+H]4J(,+86[;GN^
M8,/%=UL/L]@0ZSEY&^81(4&[*^!?(S5WT&"S,IRU*;=I=WL0GZ&W=WM %Z*\
MZ?,9MPS+(0H-4_7)4Y3$(RC$A3'$C]O([&,GVL@3WZ+"3KP2;S7#RE4/CLM(
MCVO--*O!BZS-L6$Z7I:6$T&J#)LB@N%3-GL#\7>N5VNQ8I+#OV3-:06W,V&W
M071N8_FOJ!M+_Q$2S.-+6<BX!]$0S;S-KR'"-$$FL*-&N[O".()5L^P1P=G(
M_;K#Z?/+YGH=F;$C)^$2KM(=#MTO2(D&^6JS'(.3_P<3PP4Q"6[PS/@4*++4
M'9E@5&&B##+,'QV9"8Z[2T(<T LFBTEU4,0<M-C!4_2Q.C*=Q!8!#8ZKMS"-
MR0=Q'$4VT%%]&C]RH(I(;9J!7H+Q-A!&52K(M>'Q=F$Y$ N:$#=E>57-+[5<
M)YTI0SL2(V5(0E)"$2IS?[EFM%(=&L?,$1@MM,H0R7,+O#ABR6=DD8LV'%RE
M3 =A83>\*^-U'$.,T[Y6OD#KK-*8&7UA-0_Q&=4,RR#;+M<!OJLKTW8[@:AZ
MV3^5V%R\LYN\$"1!-'RM$V6$+[J<V:.<KPVERTP]Q;KL!L>AS'@-W*1A@E7A
MP% QW$BA&54;W.AR0 6!JY.-C1V:<$'1X[<P@U59$W\,^40\/,415!:[F&MC
M>RH5A$5]T:_:0S\902 00R#= ;#5/,N933V1EQ*W[+A'K([(5"8_LSY<DKX\
MW8N$EAU(I)-U22UU"6],[3J4<VO&A'AOEQ(*3K-Y)[;+;>&'V,908<:_FL$8
MHQ(,>.%OK->H$5$A;N)_>MQ303U54=)10:?JD=W_)[ZTK)T:WRCC-X[C.:[C
M.\[C/>[C/P[D02[D0T[D16[D1X[D2:[D2\[D3>[D3UZF&4XP+PVX,.@LU;T"
M=UT44OX?-A/4/LOEC!'96=+A4&[F9SX9HSDL%#?B%ESES_KEY$+E1/&8NVS2
M9<,4&KKE'YP8E<QV6AX4,0#H5\M8'BUB\-;6V_'$0#BZ:.[HC_X8-TW"-<$%
M%$?C6!'FSJS+15'=8:,A6;X4>FXLD!'C$Q$5H'X4JP4HV,QV62<1Q&H4:GRJ
MZ0KIM6[K^IEZ]A&K)1L1_U,0Y*-!&X'--)N?&O1>5^4@9?(_LB@3:1LWD,+4
M"AX^Q!!7$R&X6@2P:  8>-[M.J;C$@:01E5]M_G9K9 SWPLD.ZV\XJQF=?E-
M$!A%)]IQ[L9.[UPB$P5Q[[MD.N+J'YM8R72B#/"K0=_-=YKD9RB"4<:IW\BE
M.DLT5_4C1##2U0LQ*7D#&,U;$X+>$;#]$!Z3[._6.N,D3%?COP5")T7H[+>N
M\O\K?Q<%S1&5/JKJL6"@+2 RW-MUMP(7#T=0O!&DO2/+0#N94.I=##-S'O-'
M^1#:L;,X:Q]+KV4DH?' \=L/".(NK P>K:%\6;]V/LL "QQ?7Q E3<V&$@/$
M(.W2/L4"^\5,EV#*039+KQ(9 <./R\6&?A##:-" H1!BW]/4#"@Q()(?_E8D
M@2E>Y+?F(26<W4XBF/<N)>\SH:I6_$W:@KN.>S->?S"?RO*;S_EI@96[/G(R
M,\5\ZTD)]^LJ837;MG)%O8Y\" #ZL,GT>T.DDA#R:_2ASS0RC-_+OBO#8[VP
M4]O87,8)NLL4N<D2S4G!TQT0EWIC[8;K61!?G]_62&G_O![PG)(9P^@U1B1S
M)9[1,-,0&<O7M,O%_+8K9Y0BW_/]?K[XE%K]=*E"VXA5U0P<4\SJ!Z,=M:TU
M'X/J0@L0^P3N(W9#X*1) F\0(R9FX$)E!O=E<DA1H,5]D]#LNP%@X#XQF3Z.
M)%G2Y$F4*56N9-G2Y4N8,67.I%G3YDV<.77NY-G3YT^@084.)5K4Z-%]*T2:
MY+)T7PR1$?<IBR$PY$"/3XD=W(C0:J9Z60=BO/I4V22)*I9!6X%5F<H;":E.
MW-CP(]2I!J%YS K@K<6K5_U.=%C68@QE<TNB64I1ZM>#@\5^%!NCH-RJ5OV6
MQ2JPKT"V^] D))DI\\*+ !JK_\8X$H##?7L=HMZ75>K@@= R%_3\<1* K0=A
M9R)M6N%6L0:F F#^=K1)Q *5[ZN7>9^;A%EY9R0]4EG;@1H%1I]J?:"!X)[?
M?E3\G*.R3!O'*]MND9A\C%X]2Q0C'^E_  ,4<$ ""S3P0 035'!!!AMT4"!E
M<#/I!J=6>$L,AXC)S+B,#.HO/)'<NPJ]C^(3"(W@/)K$H0CI64:UB<P[":])
ME+/(Q($L!$FB&#!4CZ/"0D3NK1L*RPQ& ^JI;;V1Q#A2I,$B_$@P)K&2RR,*
M,YKN.+1<ZZTV"*OB<*1,#(J02?VX(V:R@;8CR"#RM//0OZG FTO**9TJ\\3B
MS)0,PO^V.(O1I"3K/&^I/\L[T2EE8$-#(N&LDB\NDLA;LTJ!MIMD*<0B5%)*
MQ4SD$$?&!OKNN =357555EMU]5588Y5U5EI/$H,YYK+KCB-<-V7NALP, ""A
M6YGS#%=HQ"-5I+"8$Q.VLJ+#509H&NU(0I0B!."&MNQJ;2+FG$QMO=]>VZC4
MJ\K]<+1PYR,(5TA%*U:^-9G;JMC,;HUW'P.*?:M>;GE]32%<W_H,3.JF*Q;&
M')T]"]>,((XX5VV!JYC(%#.5:(6"ZYENNXXP9&Y+ZK)*D^-MD0L3W()!PM4I
MLQ(>J%F&Y>3JHVMEW&LPE&%["%<L@694(O$XVBJ3EK>SJS9EU99&J&)$,:UU
M:JJKMOIJK+/6>FNNNZ9:4*\/I,TE\L .&R?%SE9[;;;;=OMMN..6>^Z2S*9;
M*#=;0IHY\.Y^B3R_ Q=\<,(+-_QPQ!-7?''&&W?\<<@CEWQRRBNW_'+,,]=\
M<\[_._?\<]!#%WUTTDLW_7344U=]==9;=_UUV&.7?7;::[?]=MPQSYNRH;X5
M2E^79220S1RE9FGL I'/?7GFFW?^^5E[A0XXG*G/5O@O50(Z/;U]'DJLK'PD
MLV_MT<:>WY7.-!K5[U=2'M;=H9=_?OKKUSR3J(A7J$A38\"VI/AE+R71P9-+
M? <4Q:3-)H"KB?Z28KP9K8>!0''@2"8(*P7:3X,;Y& '"W>JVNS*,@" QE<(
M^++(O(8_[4*8]M;CEXI)9%CVTHRYCC6P$#+'-,9B#Z[N)3&F 6=G,]2A?GK5
MGE]YIEPB0=EDB$@,8?5->BP3U\0D4BBKD(9Z<PF:L>*2_ZN/%(1C!J,A<8"(
MPKT-*X@&J1?X !"#L7T'#<U)XG*:XS(:MA$DI+E*D096+AGNK4P\#*)("N(_
MC[1Q$A7S8",=^4A(5@V1)Z&0&+3(KR$MAQAX$H-!1 0EEEAF4'=!3D+VQ*$>
M<60I!D@(',%%K%WIZ"#\@=,+%75+$W&&-_EI)8O 0[P_PBA+2O%,)M0G!AO!
MQBN D\IE"(,P\G#!3SV4H"V19I79K$>6R_F2QS3&D81<*C=JO-561&D;\^SI
M!DQ"@WRN(LV+*+.58B)G0M8YGV/*A3\PBV0__?E/@!I(?22!B(H<@A@WA61%
MW[P6&,721A1*AV\#69C!5F;)>&^V\#!O\>8S(42RL0& 9LWIJ&*\@L6\X+%=
M6\K*!&U#M$GL)3R;\IE'%C8P-ODE$[P1@T77]U/ ;:=BS<&(,I0#-)Y)+"MI
M!$!;<!-'\. H)$/U2 PCMIZR]#$X-SUH"3MJ$:321R(FJ@_# GI6M*;_5:TY
MP4NE1 *5%930+PDEAAM@,Q>P57 D.J(4AU"3E="T\R(;>:A#"A4J_U3G+NMA
MBTP_$IHOB8>957%/\;[DTI6)9I'6P<Z>% 4V!H8$3H[-RCW?XZYOEFPD2SL5
MMCZ$,)M1IIH?F0Y&&*,A"T;%.O[;XZ)."Q)^Z@BR)L)6J%ADGEM!<*W+96YS
M =K3'Q'T:-MRUQ9)N":%.&02,M(K;?_ED3VI+ROT., H5[ 12O'KK6\Q+F72
MTR60.(28_<MLJ=KZIE&>IS.8]!)^,\)$1!%C+TH2US5IJZ2Q^&A%L&EI<.+$
M'NN0:"PD! EZ=W45 T=)I#B[$I- 2!8H54E'V>*;CW$B9,[U9()\_/K4AF:S
MJ_KX<B3O<VZ-;7QC^T%-B7=!U"JW4K&MZO T+>ON0$0)SJ3\2F7[B(8*"*8:
M!H,Q9@C[UL4$)I$A5J6C'35BKK:S,";:,F+FB:UXAKB4)4YGCCJ<LI66@ZC4
M8,G!3')3Q9YU1HAE63,&2:-#FE6D]'3T/I!I(Y]_!2<6.DNK UDSC*(CZ"@;
MZS%+$Q9:ZHAC3&=:TYNN\0$Y_6E0AUK4HZ[5H$E]:E2G6M6K9G6K7?UJ6,=:
MUK.F=:UM?6M<YUK7N^9UKWW]:V#_!_MT 11*=XE]H RFY-C"9G:SG?V\WZ1'
MPAGQ&40;_:NA[JHD&21Q@E>"795<$,(_*4MZ8U+D<;L$W<]F=[O=C3D H,%G
MVQ3L1RL5G+"X^23+]G9.C+TOG=CM)<E&";^]<[YW)USA"V=<0QS++S3Y#(2R
MA9!8I"0L7/FG(=?B$\LHA,*%87-;7(88T%";*1].19IWW-N1V%P0(5<\B#8M
M6%EP!1M6LCF-\F'3M3*4\HT3,F?2N=7"O,=PI"==Z73[4%OIK7%<[78]!5S2
M24X,W(RX(2DES&B'3N2AS,P%BG4#I:DH'"%HB+-+<7V(-M.N8<@\Y%Y+Z2-I
M8K"1\W+3_^RWC!1H*+RFM]^+6+#A7]YCL^*E)U[QB^=:;*>]4'N/9-I.1#
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M$+B!X(),U+M1PB+?D3_KR9&EJ#<\\10.XTB:K,EWLPV;FI16$HG?.+QZ# ^
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M=\ZG>>8\9V;>>>><,Z_!:E+2-I<XUUB_ /]/0   # !  @!H   #  ( 0!
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MZ#35\WQ!+))IGE6I\J3XY(C*6J*7;H:^TGS]+J%=4HQENK1#_4MT*ML@XBO
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MRXFL)#"_+\DL\R1EB'ECDC0@BO$L&,V,4\XDC02PGC#GS%-/AY1)X\*X8#C
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M_Q).=J8+,3<PF6"XJ:1TSG-;SUS)\MA227[_[LQ/@KH!(XU82HYH8DUKJN.
MHL')@5;+G0;C30M9J EK6FVBF2.&),1SJ;XX$B/$2,,,_/701R&THY*"94M
ML9Y>XH^(OVQIXH(F*-ZH]%@\I<B:ZB&Y$7GQIM3R9TI2IBE,+14M\BQJNC*!
M@_W]+%^_6L8DR$6NJC$T&B;ZVU.?55'8@15T]$B#;0)PT(T:170(4<:X4CJU
MBC#31!(E*["<*A%EW),R>;TKNOHDE0"(=29O-&D2&;H,K[+TKW(ZJDAP<X!"
MA08P FWLTS01AC" RW3* !A&Z%HBNUYV5805R3#0<"$Q^-20I$4=.-I1P(KT
MR8P22:R)]NG:4_F5+B*:L!#^Q+!6IUA6M^FJ+4+<\0VB*?0@)MUC:$>T#.@6
MMU2//0DTHJK3- B7H]3_/5IW!N(<9=Q &=)@[/,>1EN,<!6WK/6NEU#$E+W:
MY@#V[*KGWKLSNHEA81'!P0HR80L_*%8LN6V()N0%6N(":)WYC11O-S*KN*C@
M4O<UI8-U1HRXE*P\6H&!6UP12:APT[-[O&V)O(GA/5GW)9KP2G_LJ&*/@0(
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M8DNVV:9X(HG&LH@F\<5Y8TG=/CY !'& !KH!QVLQ'CBT@ B^)T;$'>#8B"8
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MPO<J(M"0K<?$S2*FZT/,32E^T 5=X_M(@E+Z#RD:T AKQ.(X0@=-P^9FZR[
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M.6& <, Q&8SP.E;S3_ "AY:M)"]$_6(+@QZX+?$]3(E(;*(3K:2, %2%&#$
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MFVM+7N@3W/PJN1PEMN3,]3M7=!QU+>0;::!BVGS"+:?4MO/1(W$#M/M%;CS
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M,1/A[:DNFJ-&^GO1B.Z/R7U :\Z 8O &XX0V=C)]RR&SV'HFC(2EJ_U]*GT
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M2 PFB)[#\JRO?D4A*!KT&_P1AT@RP8$>&7M9C:AHKN0RH.1(1"(7!<  H@U
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M'DC2\-/=QH\CI]HV>4>S8E%2K3>ZH+XQ:2.^-BZ&>4_9W+^##R^><.^>FF(
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MW$>2'NN2SO\HCX BK$@4&Q.#JL9P:!*[ [#D2Z*R[D.2(JG*=.@[-P4==-
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M S\0!$-0!$>0!$O0!$_PC@(" #M02P,$%     @ 9H)<5JU)(*>)B@  N8H
M !(   !I;6<T,CDW.3<Q,U\Q-BYG:69$=V=4DUT3[0/$T (DU-"4WD(/()W0
M.](%! 242!-1$!%!0P^]EU!#[TCO*$B'T'N5)H(4$>$5L>3ZW?OCSK]9L]:9
M??;><]8<77T=>05GU(T+DA_ _PLD * !  < !  @ @@ 0" !!!I X  $ 4 0
M 2L L$("5FC "@=8$0 K(H !  P2P* !# [ $  ,$:@"@"HD4(4&JG! %0&H
M(@(+ +" !!;0P (.6"  "\1_9P-$)$!$ T0<0"0 Q'_)O]Y()(!& C@D0/A7
M0R( ) *)1*"1"!P204 BB$@K &F%1%JAD58XI!4!:45$8@ D!HG$H)$8'!)#
M0&*(R"H 685$5J&153AD%0%9140N ,@%)'(!C5S (1<(R 4BD@@@B4@D$8TD
MXI!$ I+X#\>_:R/1 !H-X-  X1\L- ) (Y!H!!J-P*$1!#2"B+8"T%9(M!4:
M;85#6Q'05D0T!D!CD&@,&HW!H3$$-(:(K@+054AT%1I=A4-7$=!51/0"@%Y
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MR6Z("(\!9#<5TBPSP(]%V/_ME[YCC%N^C84^;!Y)C0[<]6PP,- KY8!+ YP
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MMAJ,EKVKII!FWK(^FQNIVV-MG'R<@?A--QX0UAW\@/#P&=^NY&;6<DGTZ,F
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MCP R:129446:D2=1IE2YDF5+ER]AQMJTR(Y>0GKL>+532$^83)\_@0:%"2
M1J$OE0&($0/ #8>:@ #AQ>YH5:M7L6;5:I&>.7;U!M+3N95LV9<AS0I,JE1,
MV[9&TR;$&*UD7+MW\>;5JY)>+WT[O=9$2._<7L.'@7)$##$:O6B2<#C<] /(
M)'-@%V?6O)GSOG;FAH7]VIET5;1QE4+3G.FCF-*O8<>6O8_F0G?F> D6/9LW
MXGJ9,A$##D!,<."G24N2X1 .$#4Y>T>7/CUBP=K[Z(6FOGTBW+1+-RL3KRP&
M&N[GT:<76<\@P\_F_H;MI?^>/E!H'_%[1,YYDM.&FG*H#+[Z""Q0KW:@PVY
M ]/;#RME)LDD0HYNB%#"3+S;*P9)&.S00^F$T4VASX;!##NJ/DS1HF54. "&
M & XH,48F<K0)V5N6&HI__911HP8;B!&(C1<:Z@YJ<924<DE73+'G)K$8E(Z
M!Z]B+3_\J,3K  ZE[-++L@B+;R%]ABDGR9N^3',@?98AJ$WLHJE''Q.#JH<X
M-/"<1*VE,N$HRX0FB<$A-=2H;#0U$4WT('J@4Z8]13NS\2IBE(K! !T/T-$
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ML([5J6)-J4/+*E&A?A0&IHLH42,*4, "X*M1C:I ICI1J[ITKP=@J&/<NM7
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M01* (<B"LJ5_)7B$2)&$VZ,"960 ^&<[4N@NZK(/@:8/"__W/VKB$K7#$C=
M=1^Q##=@<2L1-BXA-(\(?!81!MPG$17B$H[8$I!H&IWH'>$G%\4R?C@Q7RP8
M "^H:;XC@Y=A (R!(FTX#&?82ISF7I338Q1W%NO2%H$F7F$P*8O2*A58%M$
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M3 !61D43P"4 FVABH+68,>R-AC=BM$2#=J%=@@!"LJRGUZ%<C'5KW@#@5",
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MT#() ZARI0E9C&0" )K&PFPH3=T58N)ZE&N^EF"I5.E 0BM*C*PE@B))Y41
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MD:2P6%[>=8@#'!^07(PR\5X$@J=TFH0WH&/.DFBH'2ES<<>D:5M,/0S3H.Z
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M,^8.<;#B?=>A_12>_B'2,/4H(U2H# 8 31!GCL[/,)HF37 HP=&?&OW]!T>
M0*CQ X(*CH%@@ \2&*&!]DFTVP$P7-A4<C"U5&%V@TD'V4)0P2<BB *I<,![
M#OFTET!H9 <=8=&]&".,RWWW4R;E"003CDBE454,-0WW5T$"$16D0)(<^5!\
M$,&8W#Y: 05-#"K@J%]^R@R329?$9.*E)EUV&:9((8'D929CA@EF)FXN%O\1
M3-%(A!1BC 6@##0K&. 0C KIA>1/8> 0Q@V%XN 70C@^]Q   >@C49'[6 D
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MJYJBN:R6JAX(^4E2*L:I*VW%GP/<1S1BUAW<E10&J(S_GP.S@Y3L@/->;P4
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M% ", <   !@$ (,#8 @ # 6 80"1 $ D!! )!T0B )$H0"0&@ 0 D!  $@Y
M(@!(% ") : ! #0$@(8#T @ &@5 8_X[&X"! #!P  8!P*  F/^2_WI#(  X
M!("  %#_U2!@  0,@8#A$# " D9!P!@(# "!02 P. 2&@,!0$!@&$@F 1$(@
MD7!() (2B8)$8B!(  0)@2#A$"0"@D1!D!@(&@!!0R!H. 2-@*!1$#0&@@%
M,! (!@[!(" 8% 3SWQS_K0V! ^!P  (.0/TW%AP,@(,A<# <#D; P2@X& .'
M > P"!P&A\,0<!@*#L/ (P'P2 @\$@Z/1, C4?!(#!P)@",A<"0<CD3 D2@X
M$@-' ^!H"!P-AZ,1<#0*CL; ,0 X!@+'P.$8!!R#@F/^0_ ?<0@" $< $ @
MZC\B"#   88@P' $&($ HQ!@# (&0, @"!@< 4,@8"@$#(.(!" B(8A(."(2
M@8A$(2(Q""0 @80@D' $$H% HA!(# (-0* A"#0<@48@T"@$&H/  ! 8" (#
M1V 0" P*@?F/_G]B0U  . J 0 %0_XF! @-08 @*#$>!$2@P"@7&H&  % R"
M@L%1, 0*AD+!,*A( "H2@HJ$HR(1J$@4*A*#0@)02 @*"4<A$2@D"H7$H-
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M[H8+?)^NI>!+L&C\2.8WT,<2+A84!%8A?6]6I>3BX_T=#\? 7.+-X*4PH;N
M@_K/]=@Z>+>_3)"$;<N=L;Z^9<EO2^;9Q5RK\N3-]VL50U")HH5@KGU;:4)G
M12QR-'Z 6-HWH,X[B<[^VRH7G_W,F%--TV7SG7+RH>83#&%NNA75+/;JD2F<
M?$FGO59<W]?%J$<D]17DX%9STWWZ^"Z@S3R>V9'B!WS4=!V3"!9JK:,#6QH1
M;K,^L>ZMJ06.< W^V/*$.W'OR: ^DGDK',(D]?O!+O'2/ZWT]OR45X,G8A.V
MJMU[#_\-SUV"SVAJD*,>@K![IT:9O"A'_1AHFN[FOQ"#IFAH3SHFQ<!2^WM]
MH%.]4FS@N+PT9%;O8&#:X4"V:/$B*#RZJ>(N]?H5A6BO!J8-W#/7_X]<MGWP
MN)UBOP+;N>]WN]M25'W._$=2F1<52>O'Q20DKYQBKCMU9DQ_K4T+)3O([1J;
MS;DNWO(_<6N!63[U-I7M/U46HCR)> Q4T0]R^7)'C?XURL%XK8,G\O37PN^_
MXR64<_>,/ 5]YS"@#0,2GIB21]Z.\35T^$2I"M22_\XW9S>U,<L/#]8FH9>_
M4W9YMJ9.1-[8U#S3\3S<HLLK8-E2D$F J!@[":_/^E=<AYF\YK_G!:"4H%]@
MYI:D@[8]\A'- /NJI\U)*E-=0?O'SI513[.GOC3Y,;UFY<MA>2MI3Q1@0? K
MF&7:+KC&"V_<TR_7(RK <Z]&6?C.1"G23PED:<,=T'44.=(#M:L-)G,.'D3[
M;CNJ/^74S3UB%S%R?#0CG\#GW#5RWB9W>!NH\@??A-'$/K?/H+?65[OG]3QU
M++"2 (LGPD;=VZ_ A43*0;O/8[C'(:TN<+XW!#/E8<%KIQ$M01CC+$$9PY+U
M_(<)OV6,E!2&UA:W3C_,+/3':VO+7IL7O[V5<8,\&]PN9^"=XCRE,X'>($M%
M6YNQJ4"'+LN[0&UY%ZBJF2NA&NADTCO$)/#;K26>LBGKNR#?5>9$GGCJ2F)1
MU>?4/UFE,WU\UA.U\L*KUCT))1U M*Z[CN',@0E)G ::B>837)YIG)8?\_6Q
MT!J-A<&L=1K:KRTV.%\2\)I*QT)BWCU/@K!(S291V;D#LVVA$UKE7 %",!D6
MQ]B>!!/%^O"PJ82R>L^^.(W 1)"-I+V9;Q0";B.]I!F/Z]1MDOQJPZGGV,Y!
MU?;,R3\K('VISQ?NKS#3&3K>R<TK2O '/XVX@[@!S4QMQNM]8YN,F8S@$//#
M,HWM*%2#NKSN^.5]CK8QRW?[9&KN*0G[_,5DP,7P^K79CGHTX;C!<H$! 5?4
M%QJ52T>)R)50Y2-!A_8DPD808Y_8,W.["2Q\(?%@7W@L$.B3C9MSRA7>\\6Z
MK-YC/!#ZIMLE^1:[*-.53LJ2HB?*(""P%B_G%!IAK/F2JM'@ID[CRZR4.E=J
M]]0K\A4AWW<O''ZD*B) OILOX+@N25SVZ9I)#O<NJPX1HA_C56M!6P7Y6"?Y
M[\7?O%0GL+D/3\;%V>6),(&[_:G5>R.69!=@$1>4_,"=\$_MI?Z-&>. 9MJM
MLT4]WW549G C:$&80*A!Z#TYB_>8\IUQ8 )&RWS'Q"+J7NZW1#IVK4-];G1'
MD%LGE<<9U//E0-3R=)1-?-R2F?8I;Z%O8$0-9Y1 GS>V>!Q\DDN\'S)P($%X
ME*-H\32H^OD3#J4W V').#F!"8F9N"&Q6G%L5*&$O"46W;XI]\5Y22&"^:Y>
MK!'S5'F6I@9WIJ6_C",4"\O9XGPE^#33M5Q#..UF)H2%?^I?&48&SUFU^K(9
M^(:I_WA.7&L-2:C:Q#,5.ZFHS?$V-,]YNVZG&VLRTQM.YI:,7<E278\-E[ 4
M^NGQ,)4=@.MJ&Z=H9IJWK>FVOZXW)&[OM8X(FGS%^A'B$E.P9&Z442]&<I]Z
M[*R>PB>?# )4VFIB82J)J+T3?BKA_O>S 8%,!I?J'&5 /H0 OWGORH0:GHVJ
M.6F#? D$-B$<C]#$K"H>?9_H"\^"Q!>]6_<2=K;@I;%HXGV%%VWLXNN\=\R<
M"RK^ Y 6A3RW[69/K:Y/F?<<GB(E5<+U 6G&VN*P39("O/'_"#_E][9\4 (^
M;9<=S&SZTT[4A'R:/-:4[)]N0FD1<Y2QE9!WL%]BF>27*%YZWV43D.!4TV/=
MT)UPP1/K69A^!"R BMN&TY#TGH@P#K)WY08MC7%%YTM]]5&*KLK..$D<"8*:
MM!,D?T8&'^$W%2DF _"Q*X&N6Z18 )4K[WK_HJ8(7#^SP/S? ^'Z16H%F3UY
M>[\"&1(1A+\,]@,3#%SKM.O+4PF</V]YKG/;S]5V!#98W.YK/6()E]BS$LPY
M+P"DC\^X73F\#G\%$]3&W5,0#R3786<1@PWJGD^28K%VC[D]T9 %0<'=]ZJX
MKB^@%;UA4/[&_?@0G8:HU;MJU^F.36Z=F "UT.3@9?["S$;EC/D.03Y7*7XF
MWUOV"W[.9Y@FJ_-&B48CXV]/BNL22TYIG)>%GYH:U%UD-KWG:&>?[(H):'NH
M:,,6>8I] 1T7;F<.S#L&FOYRJ9/<]L,*Y*KFJ?"N("Y9U_1USL/_WE#Q*[9R
MIE"!QE0/)Z$)IV12.LY$%G0)+WM'H_QMOU*CCAARR K($2RC<A NJM;@*<=6
M)GJNT^_\T(UE-QS475<L_!3L36A.V<R*VS13Z_O%Y>7+T,'V OT_MT[RVKQ2
MUR86#&XXQ[$?-%ZS0TM1'ZU7Q1IA4KVNLKW/CS+^C+W*.LPDX8,:UP^%&\O]
M$\7K7T"42Q1)##S]L51':-G-X=\6=32&Q?84&T1"7N+R5P:4X=Z=@JF1< &P
MV%^+L83QLUTRL\GAV=NR&M[F':5@?]/TIJX->TJ5E+9NF75K:!H;.+49G\-C
MFVD1T>7\,LCL+?ZZ><G!"Z_55^8/1LK2TMH0R6\-RD:!H <^G=B*X0>#-H[8
MJ8X:8).;(F#HZ:7P.-8XZ>M!(N)+FY>AK<Q/'"AJ\\CO3()^5K/@E8&*5(*/
MLQMB9PAY6FJD!^"_0@XUBSL#XUNR)PMJ++2QLS@G6',KG&*+!KZ_+)H ##R>
M(Y? W8-%@*&?_4,Y3_E!^ ^9_1K>=;D"<1J4KNBY$"4NE01IT'MN[\^_FDM-
M_7D&DX\2]8B&]"D'_6^:$F=O,\S%D._6P_PQ,TZ061XA*'LQTNKW'V?L+G'R
M32=#WDJN!">SX;:IXKKQBC$ :[_'UJ)U#RGA<%O[_&*FK!_G[_C(I'<R(2$>
M^)Y*,H9K^58-'OI@K:+(A/!K'9/KN+SSG9FI3>\]7GM?"XB1KY0ZQ-U]RNIX
MQ>+4838(-ZH^WC,JM_21FTQ2?>;+;>P<?Z&JC#U*V["T.*6$VD'@2R2JS]I9
M9YFAJ?00&(N$*X[JOB4J!M7A("P39:N.V7.NC7[+LI>(L>3S\Z96ARUQY;!*
M#7#@]!H-S=@C0/,T1@I3%=#^D>U?KUMWIAD2L4DSL1.<S*=-"B<)XFH'(B/5
M0K_@F)"U% [6!@=C3%YF!K=*[W:R4FA5!^F:\'.RTPM_&4C.RUO^I!473/GQ
M L>4NU!%=L?W4Z,.2]  ]U%NG& AFR?BT+VGTKUH[W>65)$EWY;+5**7X%_K
MIC[%IJ&:*KP01?Q&'$/CZ!.U9RNKDMT%B:H<!^SZ7L <QX**^=[M($*;=(*4
MO[!%8L(*FLWXB<)":K[E45R<-5,_:VE#+U ^XY0!1CKN3^"854$'PU1-/+?*
MVIH!'AXS7A@HUQ92K-)%N"BKW,B*U0V&_(A$TF:[#6PWBO7.;%14W]F):R\S
MM&RI%*ZI"!BERGM("H 4)$(0U O/N"VM>>Q7999K7;?;8K?1)OZ0WI'7&-PZ
M '=M*WBR52Q&W.$51PPO=0N']*1 _@%S92ZV"/<JA_ER_488.&E?.< $]S*8
M4AI%6%^!PZ8_1A*^1Q]HD1:B.!C[H4[9#">%2TR-J=4D]; CJF6#P$4;1T)M
M2G.8K3"N,P55Z&($VF5+X9%TBF9UPJG%#\O7K/>8E3"(,Y$QL,ZJ'0I3D#,R
MWAGT)$W01)C<)GSN UH>\.S_ZLW6OH49NR3,34LEM1SF- 6W%R=+RRWA"H$J
M #PX)L;M5H*3F8VS*(%EXL-<L_5"0;<=^%O<5Z/.:1$\<*0+W\;YAC7RYJ2.
M=^4;;:(%WP??RX]+"44_?VLO:Z 6>V8:6R)&,%]=].<LE>/T1GLUQ433/#E8
M;!28B>ED;X[5.7ZD"BGL,UD/;#.U3 UJ/S0<DX>4FM=MN\7/']*B$0-K?BJ>
M8<R>O'2O_7B8\BYBW1B&]EO=YAOU/^V]=BF%;VQMI)E_#@Z0B(M><KEE_K#'
M^*_XK<4[>1%X+^0A.&'1XT?]<JW6X(69G@=P]6_>!RGFU+F(\L;NO*ECU^J/
M.XH&=0]V%WQRAFO9*Z\4O!@^K"/S6ZX+H*[4]H2),.;\!(C':_D]WH+SO;X4
MKJY-L"J+EK YZK/I)^Q=NUZ>([V1K&QD#!,\=M1B(SE7Y_M">QZ6I9+!4Y2,
M(8]%APR(4%?\0LF@+A<S72,YK/<S(2ZG[],5>+#N<8V#*R5LN,KY+*F^:G9H
MG;7_#V/&C"-!SEZX6M9=8X?5MF>HI/]YWR<+EJ5-PB-OH/SXRU*/WO=$A.'S
M8SN.)^:T,,L7TI:,A38OM59FZZL[:_L>TR_&Y2YOBDU.;I1)ZTOQJ(>4=PX?
MLT/K.A\815LAXOR.I)_J2UK6+E_'M(Z\:WFT4\O03>[8P O]9]7Y.E&1?%VS
M& ^GN-W>\>0KT=Y?_:DO;B"F8(4W-E25PGWO2(]'*D9A+WMZ&CV3OR4\[NDY
M&)::25M]3'W-"JCT^*04C4O"#"TTV%>))V%2B*4U/( F4_URI8>H+Q:*.8K"
M=3$0;@W-K"+"E113KW*%/-R7K9SFSS^-NF"[S^_4^\+GH\7Q>QVU<IC'G2"_
M2!:U?GY^GZ=0C:M'GUN_4JA((-,38D '$O>. .P30A%%+$7^CP8.Y/KF4@YB
MGEP_L4DM6+U3R<7X5WGVHM2_K?\<\#OIK(TT.X>&%;(:Q3PCD:T[>\VZ4BE%
M=+ZM8X!0SY26\[T!.J;.B.4"7T)+7]RZK;=824[^_NXWG58-">$\\>87:QIN
M.G%,SNQ[7P0A84"E&+#8Y1F_%#UA8#IQ1?'0_+HE:!F@_VI[6&<E2R,(RBGR
M!6A!:&:Y]6SF4'K5JHL?BDWL#CPV?_A/%$PW.5N=<A5B?'_HL8X*Z/ K_[GT
MNVPLR,]*J\[@+O'._B@T*:Q*(EF32+O$B:J4R%07<^T8(U8];_N4[.Y1NUJ!
M#6K+KZN:5SK].MB$/$Z<1RHV_3-N5UCLC^$@N1E;F1S^N@8XP)\0>P*>9)^*
M)F]I+1(@FV'UC'9M"XF/F6]#158A&\+O0N?K3G"ZTY6+_TUD]=.2L*M#,R3.
M3U4S9GFS5!4Q.&(&R?ESD(D,Z#8D0>'E\#S7)6F)QWA9Q+P(_326ZJN5)F9&
M#]9/@.&+50@3UZQDQ8NBA:;V"-HD<-LIOPB]>*I_GI:IYY4V"=/GTRS^678F
M[Y49O*V,<4:JU<8VR:C#'Q5B5'H"#>;2E:)^K'IN''SXA*KLKH;*;S&XDI:D
M6N>)V\N:]%GD0H9&O=PU-S_$P&)MVQJR4^D_Q&<F@;KG9M.ILIICYS)ZU]-C
MR?+4].P!XC\21"*4=.19*05=FCD&(.0);;/G\[/DBGDHT6=-]B+&4Q7L <_H
M<8?YVBJ(=;V/AI)'B-E2%;834U4"*D!PGS=X,J=)O .>*J5.1%H)6CM<>8N?
MPDSNI'"Y/$VY#"%_UOH^PQ\7&_)TT&)O(__(7&U99*PIYT@>%5\TMP*K\]<3
M#Q=P2)F*4.)7=1U8A?PM%#M]TC'Q*0+\1M^LLM:.BD0?C^ANAU(*LWCES%3>
MSUY;N"Q*?I+KW5I;NI/PGZG@[ K\YF<X&#*%27^EV_;=0>RZWN'A0\/SG%+C
MRPHE^'K]7U0V[8)>8<F*IGC)Z*FFV05[W=7 7*C_W:AYAG1_=DO\EN'X98[V
M9M&%<8<%,HS]9T6QL@['C?P<K,#OUZ>GKR'SKI 7'%$/VQGNP_K59&UM:4-6
MZ0!SD*&K&X^^L98.\5KGA$5RY..<F?(6!_/-Y?D+)SMR\S4#P6]7,;2O#PMW
MQ9X0'GIZ"'$OE_[">4T3***M_%"E%1'&P;EQ%6<;,FZUX+'Q;*LCT5A1)&-Y
MUJGA;OQ#HL8D*-9?G9X;#A4CK]+7'Z:LC_S+I5<O:E6=R*6P(\[#:W-#MMH@
MT5-[C:\I<4B8<YI-?8#Q$8 *^]EV;%%0:V^0D!9OT(;X.E5@KFL<C5 F]Z0-
MU45,I&S?C)CHJCM9JL<2^=-C\9;33<6V4]^_U)QTY$Z0D%DP!$I&B0'3@!]S
MAAU]7M^?O>0(_=&$F]:8R0LAW"$/0CBMJ=(M&,2+NARQE*76@ETV"[F'16E>
M/GE"21JU0EO$R:SW.4NH)]NT_40,Y+3F0+<T=MSPR"-5>0VT27VGZR>DUBG(
MQ)7RHJ;R]]V3KI":C ARWT)/J1QIO?75,B B]G1ZK$NV\AE'BDKA\PKLW ,#
M+QE"Z?4UJ'@[2^4/74C*IEU@ R4*I$J16T@2QUM)8+_D ;9BB\%;L)?\&L:%
M41#^2:=3QM64$L"C9>MJW@HL8 P=CV6F+IUT]EV*(^#BDTSR7_>2 3;'U=5X
M.5:;8#A_+L8J-41(71R%?96&(;]B4_[@3#M6^?6?=W#<!>=1!Y0<-:LE\/B&
M1W37].E(-98^!,KPCA@>&4-WI-3ZNL?=2EJ%.$K P93R9N-%1&/38*Y($7CN
M\\_L&^S[,3'!*5$KL7-.\N'W%43!BQ=.6F:+FHN)HA91\S&L+J)']VK>1N^8
MV]<'H MH]9>A]#%Q2)F7NC(!B>5G/'2^!I,!Y+A.-R\HB/+8>SX+B+LA.<H-
M<@(8&9$_+2"<1997]&;G[Y4X"ZZP2 =9K2[<)C0#,0P95:AL\/!X5("'T;)I
MK@685>R;9K<VT7AF5>KI.JQ+--&=M+_=^-\>K"W<-Y,Z*I=;E^PB)=25;:?"
M:>F'UJI_1_"5Q@]'(87E]8GK8NC[E8+E94,5UM8U>Z.)(A!C:7P H;HML9:%
MU!.(N\>GL*2$9MG#<U.SH4?T9>HM<KIM1\0^59R9A4'*-,B0PLM4--N&;H$*
M'.Q.1]OA]490=I?ND!8??27T(T*LQXZ+4MF#_KLWD<#!EX8Y7MKQU83S K(0
MZXW%S\DD*^]QT6)CE^JYOB+>)12VN 2ZI3,=9E<F1/V&HSAA<_-5J?<I-@,K
M :W;NZY6 :F[_Y(G8=1H'(R0SUQ9G5Z.OBW?LY#\#NH!D;9GHKVMQ($AAX^^
MRBOVF>#FEYX?S^AGU2LG?T;>86V> N)%HG6R)-'TXVR&K99YVT"O3\.72IYX
MR-SM<RX$N[@05[=AN&XZ[;<=U^0#(>,WDX1=+^S+3#3H9R1&+U._-]D,?7T]
M_\H5HC+QV!QN=23K>C1O_A4^'/8LAKQ;_[7E5=-YY'/I79ET]T#GSW9V7!\7
M*O)V649V:6E)7^CE-)*X'VM5ZHAN'VK%@@>O_;NW!-S,^75;)5Y3;EG2I#MU
M_7EYT$WP;%T$3T;!4)V^SO)X0;1H^FY$I":X+$9KJ3GUTR7SQ80>:%P]5< ;
M=!)\BHFFCLJ(^FRH+UF;8.W]=U!-*?_[AZGJ4UO,XIS):,\'J3.N4BEW,">'
M*WNQHL(O8CM.SO9%S5A75<V"T&<;J]T2A4[0S_4BE",5;KECUMG>_%VA7[ R
M_-'5<@[Q'&L6SY3GVS_A<OZ$:LEKS5=D^;OOSGX,>&O%&O1FE^2";O8%WKK@
MKD$]7%OTM5^*D.G9)1DEI[#$@A+6"G0'PL]62E?Z=:8M,8%?*\P_S]VZ*^'?
M9,^F7AGGC*+'UM_9P=U:3V3A'Z-M5*K%A]_^0PIO(:,=32W% WLY%DNLK_PZ
MU1>_98^N:6YIBZ\S?/)C-).95[.I5? 5:<>N4<WN(WW(ID9(8"Q3R%8'9 D(
MDM(^TP6?2QUU*25*]0XO\)+=-\IUC6X/$=4#>X4[Z;_XTN.+UL=JUD_PUD39
MRFDUM3)>#_Q, 5MTM0UF"U96-8@X<+D?TL1<-_UZD./=IWMQ*#V8/1P[)**U
M,+CKRU9#05ZF5'BF3'J23&"H#&+[7M1PW?OA(6EY<XR,+H9T>$S4']B/+*F>
MXQTAR!<:DNBS1X)T.G"^$U'H  -]:G";*7VJZQ[/%=5_OIT-'5G9;E3((I:-
M?6?+5MAH6_ 61)6RS'IK@*<G+$^?$\6- V7:YE/ODKDX'ZM=Z1PS[JBM5F$1
M@VC.=7T7$9.Q:V'CIR_-XH?DJL5MI&+$&$:!1XDV[W*+-0>H+I(6W2EZSUFF
M[\6="0@#V7A][,=2?@^L-D&YA@5>IXR;7%#\/>7_NLJM[B;\;;L3(I+]6_,I
M=Y*R&=%DL^I$^4*;R#5=QSAA(%2&FD(HK!*1PT'<\U*M?9-&X#&7E9Q@0X;>
M?V[<@E*SN('EU3+=A_ZT8->FG"SV? BRHC.C4P9XR"&<S]$ANR.JIRGY^N(M
M_^ID=$S/U7RVF4Q+URIYK!)TDP/(ZYHM-O'65VZ&?D?:O+CU(P.V^M;XG_92
M*NDVO!NU0_8:BF7E9)W$(0B-ZF9.$(,F$6>\Z=I0LV]*T?V@?-B[2()VA]3T
M*<-:!6R&-3H$IO&WH&''8'2H<E2UEC:'AF;.$Z]-LH=K+:G)ISV$B.+KM+^L
M\=]94_I7A'0\5'P9!TN'!$0?\Z1U&^2;27>4"64=*RZT2LL!=.]^MWQ*X?*W
MJYJ+&A,QUX[*96'[42/RF:KR1:,"19.;H3#599>=;/H[1\I*.0Y/\NP: ^SF
MXJ;!HG$ZX_[TU";&HSH:&:&O%&/UP7H%4M2\TAFTNI([)7)S7>-9CQQ8YT\3
M_!;?OA2*]24^K!@I3!0H9Y0D"$56-8ZA2F2U1.<SO O%*( B9UD@.6I:I)0;
M1Z&+J^JHTGBE ,0U9%*$5_&/Z'LN ?F*+J$2L1(PH>3YO7@;@;*]W&!E2B'5
M673W);E,7%,K^N>LB#GC;(?\<\/!O<LI.%DVM5']7LEH$#1Y^ZRB9)/GO=2\
MG*'VM66OU(7^YJE2 K)H-(H!REE^P(N8/^T)<4W-YLM72F$3])'JV"?1#NJ>
MAO3[>8SP^DWW/_"]^J&\(S*,3[[8ESO;5"$470V^)!S4OM2DUVFD*:9 AXE@
MZ1!77 KVE629=*H@M90TYJ3GOP,_V&)8J-5& XW>.7 D?;!0CUJA#,;6=C]*
M^0MDS<,6%+EE0D 2K]TG^/PD.TL,:(]*'QLR?MAQV5A0;_');7+@_4U9^WOQ
M3#OGB5-,<<+-E(0@U^&6_-C9U-L+AC7'#BA4UEWKW38_O6BW,=QON85>03PR
M)]J"J]0$!$7V81]+'"$)HZLFGCR1Q<UFI94S<AU61D/Z5B_&SJN3KQ#)O(ZS
MS 22\0]IU-HQW!Y+*[(Z0X,==#6D1_M=/PAZ>5_D8,M55\Y6[?HGG4PF)7=+
M18/(M,G?B25.65KU+AZE1@O29)CG)OT8K>8G34ZEV1=;:S)G_ +([@I5D0Q0
MQK]=0ZZNM!1C6GMRRLQ>F/:ALJ*R:0((%6^P9?ZY&VQ?/C.OQKG-9>XY$/<B
MK,GW2<4R&IJ$,M(%=XA[,JH$USN\&_I&:8[<2HQ -Q+<HY[$ZOO+*(=<Y:V4
M,..ME+_%7IY^S%"A$'M:)3I;/%<.[A<:X33^B[:;2_4[8)7/V6BNA39=O/4E
MD8+]F7V!#1K;8![#+F'L((OS'%BU@"&H3*X)&(2>)/_L0,TC0(>R6XWL&P0.
M"AG]+%_)1/2H.#-W1[#EE1-)UK%*1C?'/^;ER@7&&,3F=&LL@@-TAP4?QT^&
M:4HSN1)1XA+*R5J9X!\Z(WS84."NSKE;DB'AIG>GONL/Y:GF(L$53/F.SF2.
M' I,7A'3/I6VFE]",#M=R_^VJ L8I:W:O//$<,])?F#=CI^\>Q0EW/%%#=1(
M51&$2^X/'CD4V/U[Q)?)5?V3WMJ=@X7UKPSQL:$]8OHQ69W?;_/JQZP.UMZ_
MORVA:GNMTIF,?!5Q-^Q>5<Q'AKJYAJ-D]T\:8MDO2EN(RD"OV0DR#$A;36RU
MSCA>A]702F]7$M8SCWS$X:::Y]>A'9XL:NY<[0)[\75.Y]:95DE'VGU@TP$Z
MC;WUG^KLQT6;A*ZHUDI^B2:E%<E4(0+/:M:"G.RGDS:DNC=&VF4W"/>KM+!)
M1ZVKTC*T'U)EWKT7#%8L2*+$RTYGI#<IOL54DH132Y"NM\<D7<N^[;*<H"\V
M[7GD^QC,IAA=^]>J*;>+^/QL[4G=HH"X_-"! [U#%O?ZR)SF]I<1S;[AU%H.
MBCPRL.M!>=:M!>9*-V:8Q)+*03>Y:WF_)E*^].,5E<@5DXZ> UZK#2M!<DX.
M79/F6L @F&&R=4ZV'\:A0\D@; 6(=#0]P=E(L#6  P!8T=YP)])( Q<X0!,@
MLH*O!@!PG!+Q:Y[@;VB887]NNUU3)^FW)^YXC2-D+:2T8;&!<S\BJ.HH=5DL
MM'94DYS^=&+J&7-6K9:3'E(M>+Y_00N;@J%6CA$2>L]1;;S71&R@MWC M+<,
MD>%I.Q[D2A,KFL38;?MW%P]OY!G$2O$"7[1'1MGB/VD_"1<^BZG Q;=]\HP
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M/VB+I_%#T<GY='4,]T=>_A5F=8QPC +R^R,,-;X#U8MO&RMPL(8>#+!.):'
MAJ8"VGRAD8OZ(:8ZT?G>G,ZC))D*(K$.+O;.:D"E>((N?=/1'\05ZLL*EV9D
M_+LFC_B"VK/] PUY_+3>!FEO\)#G8OOMZD8)UM"ALUE:.'E6I.;;2(-MG,;>
M[,S/3*FVN-7YYJ#HJ2RL,L[];BHY?KYNLIR[;O=RINEK2O3OL<RT,6:[0E,:
M6_PWX42FN5E=177/1SWR0@YJ%5QPM\C\3]]]17#D[P!SM+,O4IL2XYM676:;
MDUR86PJL16J>_2WNHM^Q'-$H,"$4'4U\DN<A81B=$E6@'$2PB13$5LF*?05?
MBFI1LZ6:Q#P6^T,98:8"W28"*[7KL6<)59I[1*56T@&YGC(6CSCS,OM9U8;J
MR*_9Y+?;*.NGM1W:EK7XK15?@J;G];59)WL71H1GSP6.L.91:+'5&O."JHAY
MX7G/K6Z\_2OG?0N&HS)N8A^".D=V.^ K%:[5#_^6DZ,MT4O-T?;SFP3S>HD<
M?93[[9^MV'VK^RMRRQ<WM4P-E& &2?%&;TJKJG^["Y3R#XC8#8M9E)_/PDQ?
M# 2@)U1>O/_'F/U=?Q-81!_)^JV.Y(?)O#8!CG;DTQ_L2<A4RN\'N7IS8,IU
M>Y?UVDYY/;&!% $\/"Z0'7(N*3(OJWVE*-MBMB*;AS&I!8MZ@Q2#(+I++ONS
M&/F<,[-\WEWC6.?[DP0(UH%PRYFS.+!?R#[9CMQ7\PPOW?G)JO,F$&>.5'C<
M.T<+*N(*]8FA<OMWBMIRXG C_6ZYO/S3H&E8_^-DB_[]7V&;@Z)1K:DI3RK7
M7A'G@=7U3L&.8)-CO@+=&F3>_HR@U50'.6/Y#K34(I<Q]&F-*]SJ>_N!FR!"
MG8=?_BKVFFA^"JCY.YTB)[,'KTVIH@:<7"C-M@FL-NFGLKCDW/\0#*0Z3JXH
M,6I=:G6YXC/WP6\'.;T[<J^5GMZ\K80/$A5R$>PXI2E!J4 1VT_Q&P1.GA.U
M)D\R&Y"JTS#@P[8LO'#Z+N\ 7$BI> PF&F0!=^=RUTZK'0_3GW<IA+Y1U]N(
M<! !;\S?'45?ZS&H\862YJ1-'*RET:ZUYHSLKO!QDXU)H0[OU.:6^&.ZVZ6R
M+%K4W/F/TU<[+$P$/R.8<9OYC,KK*-B<TWQ.TFGY=5C_>S9_U#MT7=D;G"%,
MY_3%R]#Z30HDN)9P)V0.8>UALZT5F5']M#J5O!Y(;_%SLV)5(;["48S_R\+;
M6Q8Q@MR -2/+5"L9#<W4'O):GV6=+@':Z0^;3C<*ECP+E%<? &J3:]WO/EN.
M"17SYZD1E9.3)E]=<\^^>ZP<I&9T8$WMB< AK.L>^\PC\<PG25S<B@^2=&R5
M)W-21B@BS_9C V/*-$T_K\<Z^YY]6MY8Z_%X+!R62)A#1_%/L/PAJ<EG\<6Q
MCLQR C+_,,+1A+ZUY,\@J:9V=O#BC<;,$OFKFY6)M@$L]A?^2X9!#,+6%WT3
MXN-!+QMJ!"8,)EY)X.Y.PF)!"2XIXF6\:<A$GA%AW)-6&M^F_>(L40KJG0)S
MC<;*,JM8(J?8+31!^E!MEL!7UH7Y^7_$*>U'#F;>ST*"$).W)#GF;I>_5Z)Q
M2WW^TO%K^;F,4PL@?/9&FK8.OE2UY$ILW[FMT;IGQRN[%/AT=JQ4,:CB.VI^
M+6=7;Z<>!X?%F;30E60G.E I,.5*/2=ZP,TF63[ZRR&KEQJ":-?0G[["5'X;
M$4SZGESD[(;#&D-Y]RA6%/]!.:] UFA]1GE)7]^AEDXW+'U6":<_LFMZ(O/S
MU=>?Y('?/44-0OL.?ZN[KC_9O2PD-*F:7Y:/UYJ[U(O4.Y:K&MFZ^#\ !T#X
MORW%&,\*FZ4Z")-MS3"%F"3!GN?XR'7N&VIU!5/0'&EVGF/ FGCFZ&ZV41F*
M%N2MI?=L; /:J<T:8I$EZLM-<<H=.:=P$]G '+>EP<YND7_:Q.T<":343(EG
M5+JB9>1-*=8ZDSQI(V$DY"8Y!O:2H[Z-5,@\1RZZ-J<=L:Q^EG$8AF8A'!KS
MERXY=ZG3DWS?8B^;N',Y^8:>Y"<+](Y*Q[NNFWO/]/8U6?#_C(2WOC6DI\C>
M^0XF4]6P:3%^C>>XVI&*Z3=1I5_$DOJGI7KM(!.35OB&##5Y ]!6&-ID >K(
M/*Z.!S=^8Q*-*WI.W#/H 0M5#$]14)&6MR]%#Z1+)M[-49P6_^HA,B'>,B-F
M6121@I<:A+- &'FV<P35?E/='D1_4E*8/!-Q=) P0?8+1F?>81!:CESTE D+
MEBF!6"QBK.Y^)9&]DB,902!$8#E(_W6.SA.F9$_.7^P-\@D HI:5W!6\<5#5
M4.[Z]>"L'+QE16M%P]&PYID.8MS]F&WRZLD-JL3)5E.H!/#'J\@R>&OA@48"
MCS6.]V2Y*OTB;5ZRL?.L,Y^Y<I[S_ZK?SKQTN"XNL! UT3SO)GK6L O(M+IL
MO=">*!-W0^#Q*7K'E(AJ<PSZUQZ4$+FJ35?JD<&=;Z 1@]+9<*QDK&?M)"E#
M28OLOC3QVJL%[_0+3?J+[,+J>!:SB85AI84HERN912BB^=UWT&/*2J*%T/X7
M &Y%5%]]9,,EC9-7\'<WGI!:Z-T2=DAA%]_XY2U+A)CP+ ;_(B?;#MM$VOY$
M#H'GW%G.8BE,\,!^[',$W0:/'/I1935;486T_3P%(A8?0$3;-W"?0(+Z" Y<
MIDP9,67+Z W4%ZT>PGH&ZS%T"-%@08+U!M*+UI#APX3*!D+;!W+?0H<.$5+*
MT64FCBXS<O_,&".#Y@Q-RU0.[)@PVL)E#E$FU,<28<NC)9<-!&E1ZCY]"TF:
M%+IUHD*&8W#>!!LVAXR9,ZZ^?,@R6M."+#,R+,90:<&(!(V69"NQH-N'+X&N
MK.JVZKZ[*YLF12B09<*#@X<.W1>4(&5*8\:0P;PY<^9)41V'%CV:=&G3IU&G
M5FTZC>;,.=1L)I-FC":\%@4N_5A7,,'#5H<VE;P;\4K&;Y5I2J-)#?-,/WLG
MI*>)>G,USS4E91GT*'/FDZAK^MTX>29*<,Y3)P9'ALX9-.'C= ]>$[&/5ZW6
M(Z9I$IS^E*C3SB.%B'G..OJ2RHV@Y#0YS\'Z5&+IKHSX8VZ,FMS_ VNF#7-H
MT+OELKMOP>3.^R_ PA;<CY(T*&F.N@EW8Y"2-TJLSZ ;0;KQ(\H2FHJOJ2YR
MJZW"*A*,*N,(VT<3S&B+;0PGT\B!C"17J]+**[',TK%E:-.,-LQFV\RVT CK
MZL<!'6NKL646,U)"OB;CS2KJE@,0O.; "\H@$OU3KL$Z;6L*I/*NH\1 \."P
MSRJ"J ,03_Z:PVP&FW+"$"RPZGR.S826H=-#0PU5@Q@>]U$FD^:6HP]$1<FS
MLT+P_DLJH4;['..F#<.R*:P9P*/1O#[%0S,Y5!LTCT8;'5/&4>S,.[6^K0;R
M$$10T0LQOX. #*TQCU@"33*X$B)U.'#W_P$%3,YRZ PS1;5LU]UWWU6&R<Z^
M[(P,62.BB,C\@ELI0A2+[$VXK2XJC"*.E"W4ST*=%0^BA3P%,-0&CUVF'FCJ
MJ<Y#&ON\CKJ+(**N/UBK->_27'L""P>=KGO48HR3 W%D]*I-@YB'Z5$6C@IK
M!!#$4J.9CMBA>7Y()!*=G5'#F\1XK](N5GZRV$<]?G@?%<U;>.KG,@K9S_^6
MPW/G4>NAI]/G[FP8O.7LB^K(RHBRB,I%P1U2J")9$G"B@/M2B$DI6Z.MR]K@
M+=SPPTU31C/7-H-R#&]%,[/'X^(F:+BW)&J,L+LP/EO:8A^<!,"HAE753S\-
MU004LY&>^$Y-S'H#D"[8%08Q["5S&DMWIV]*U;F?'N(YZ685UN3B9:@^]=?_
MS .EGHQ%CC[U_OQ4II[NZCP6K*8WE &LE'U*FV*)-:%H6&<SG1A VR!VM%@/
MP9N1DH>B*= ZX7O^R6QH,9)*-ZY \J]%#0DN<WO,MHBSC]@P3C9CH TE$/\7
M00D:;DD.?-)K9).&W>A&@(91T*)$Q!0?!2DZV)**W5:BC/J5J&3-,59Z)O&7
MU"G,=>B17:?"YBSFL1 \%)+8L>17H0N))5=D8=FR &2?ZNA0$S2+7Y^"]RM0
M-:A/$\M.I_[C'YHY*&O+&0D7[02'I>4.96'AV.M"91Z&1*]"?D+/"S,!,8:U
M3&OQ$\^P*I1#L9TN:)F[5DJ(@L"](!!-+0G)1X:R*;[1XS)-PHR3.@.'"4Z2
MDE>ZC+KF%28(@C T^B).CBHRE((Y9ENX@1915H)%T.FP6FNCSC*61\4=\@<.
MIW*(JZ9(+3NJ01F;^,^QJLBQ--QJ4O"Q%*]\Y;/_[, NC#5Z7<-T1K+S=-$[
M_7'(#OL$J_$U*#DD0]T0=W46,N8@ER_TSC*52<>)U2E1RTA;<Z;H2O2\H5/-
M%-ZC0*7"$L8I.G?!C5L(<['BZ*M-?9.3CI24+LYPIDN_J>1#(>H8!VKF!YFI
M%V;&I)#!P.F4 >7G"=W"'5(*ZI!728X6P?A&>+;1.36BY30EAIV%H:^)U%)>
M>.*G/)CRYT(S$ ,Q>](37FD,1++<F31KZ3J<5O.ES]%E>)0Z3Y<6E:DEVA 7
M<N<]]^0 J].D(RWMB#J>'8L^(UMJA:R3B5:RE(DTHR8=V46Y-/5H2U4A57'V
M=4A/-N8PQ+"H9M0 &X:"_R:BA85H-!B7V+^R:H"+@8M [B*2?3J&I/Y+B8^,
MU!'SL:A"L9092BL43&<:U7UEC5[:R)>V:L5S9R?;$$VP:LP<XC)K3P25%'E&
MN_?A\XP>FJDLWQ=$.\;/5TN2SVMSTK2QY%:9RKPGZLZX6M@Y)ZVYY%@0I^@[
M[().$Q@#(56\JYN.")!*A*2L<1[C$8=R::$9U R[#!O?"<K+@E\2G$*_-1H#
MAA<D MV+ 0?4OY#4KXE9I$]S1;:S*=+P0V.EEORV^$86;G-F^>NIAK!*%I[,
MP*9I'5K6G$C+WZ53BD!4*W:I^<L'74>JH(V4>Z V _=D* <J)JMH:XG/VH[O
M6/\*0Y2*<YO%I%U7K?UIV&XNYQOBF-*?D#7(IOI(2LL2#"&*F^B7G*30C,J7
MRX>SLKH6=RY9=21; B0L B.#2/22*UN</ H-2QS&'3K+8_)[ UI/1SWL)M-
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MV$.<PO$TXL,^@!15F'=AIT88)-<@C4E/ =(J<*"(5-5?]1%+:#.Q#M5T6W%
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M+OVER%RZ,:.V5TD9Z>._+SZ223([9O/,FB3Q:Q]/[-;.DL%EH<O@E$T$\I0
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MN!JZ4<RV+-:YB-(H!=#Q-.,%C4C+U"">S#$_V=#JNK&H.ZH69;K6P=3,L=Z
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M/.-Y0*32LCV:G"#N%8#T%D"E?21RD8IB.2T.(;PE,7*1UG1A[&8:2AR+*L&
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M7K/U$$$>DT=BT"!=!,HP8!,2A'+Y80HI(DD"HPEIQKFQ(SJ-&51JRSEUQ&'
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ME$JI&"R*@"S#61C79%4EQ: G1Y2*A60"%TBIDT*IEX(3N;%&-#2"F\K D\K
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MK1&*H;%(_P8I'HEYZFWZ)LFFN@J%B@WM=*3=%N+L;@((\0*>_*LJYN(JU"
MF]!ZO Q0JB+ANN<J#LNA1(IWBD>GL$/]6N+W9LO\XH,F]HS'S.OYWFZS&"W:
M:@Q"9,[[E$Q%E(]HRBU"VLZ(DLOD?.$H<LJZQ&09B.'<),UX3BF)7@TLCN=J
M7LUF^F+T[JIF*N0!M>9K:&(CMD?BP@X_=,T)-[%/?,U#]N6J&.>T0,<$FPPA
MOJ910,^# *E!E*$8E($>AD*D;*ZLE,$=(J.]%,PK:@EY[@H1\<O,4@)4C"7S
M=N+(\,L5;?$\+JY;UH3-6LW-CD>5>FHSL+!Y=,7[5BD]:LG8*/_$8-[BACXK
MP#B1' ?&AT+)AO!F#*3)&N\"3K3(0D[H0BB)POA+ <F"R7B+KHB0P0B-/:PF
M5TBJP3I,ZCY.+/!.5S)NML#C*]!KW  2/D;'IJX+L^"0*6+HJ*9O'H/J0<"'
M+NPFB/ZO'$<23W[(J6Y(>G0-"#.D$%ERLXZG!2OGI+Q0U49OL=COFZ[+C7BQ
M$3NO"-6.3?(+I!KQ XEP?)!(H%C-08S1@Y(/S8+*9FYK+>YB(K'F.-:+(4S2
MO]A&+JB')+]R3_Q%3N8)/SX1;99BAIB-W=1NKQ1*+[R-(B5E/28R/5Z)9-PR
MD)[$HN81XTPHF93L;XH#A,1J:N)0,-__@Z3$I#L^[@T[C7R6S:3B(];>Q2D#
M9]0N)&M4S93,PT=*1BK\B0SFB9_BXOG TC3]P]<,+ K#QS"UQB^L<0BICJZB
MLB+9"^5P\HGBLCODL/#:B29PC+/0$C/!:^HJ<NFD$='PA7W$HS$-S[U$B"H-
MKV$N:R\&#4R(S0-#I[\(D#[";)9.$SP%1!-64_\^R[\TP?SL*^_ 13Q4R$R*
M:C/;(^ (J3/G)<D,4Y&JSEZ\2>-*;6N8,@%Y3S-AX_'V<6'$8I(FY"9BPL6,
MT@N=3.I4HD$KY*# #>[4 YP81&2VYR-3"V&8,#Q#]#^"Z$!6+RZ.2"48\B^_
M\$V*!R-S,[X*_XXI$.U^M*,ZOPJ9TF@!]9(J+Q"SZ %(B6$>AJ$=B+1(B708
MY@$6Z>&C% N_VHVM&.4??:Z $I"RJ+&$>H4YP<8[E.HI#J5HNJ\5KX)$N_/*
M.DY$TY0L6,O6G@KAUG$V%25*GQ0O-11_6.FE:# HA?$P5VWC3&DBIS2R+@_-
M, I(D;0=>H$=>,$<A.$<A*%1S8$7%E52V4%1B?06N89%\8=B@E-LVD4C=3$G
MV:OZ'()JBE#J>%"W( *4Q$PT 84KHT--9S4MFBH</81,W>(HPBLV'A&* ,8P
M3,_:*JRW*B:9=L^DU(FL4LZRBA,VN @[ZH$>BG12&951(748*I47'O^56QT5
M4J\U4I'4+E'%*0R2(R/4IW!/8GAB3D?FG-ZRPXP#?0#S6*TK/$*%7VKE)#])
M)&G57[_BX<1QZ^J#*\> T_!GC<YIOZ[CE.3E0HHH6L?-/!2K_*"OV^2S79H.
M$J%S/^F!2(5A4LTA6X=A4=N!44>V41\U4K_59$U692%5&-JA'5(*(7NE<% L
MZA"V5$LID7*K$*_.:H;0X]0%8]\H!]3QGZX*+K3L7YM6+(XPDY V";6,0E L
MS1HR0"E2,[7#<(!*POJTA1Y4"'/$I"SFL1H$3'Q"&2@54A\57!5U4N%69"5U
M;A45;A=U4;F5%TRV46=VI,*#%UL4*!T*?;3L(V'O[T&_2C^9R%.;E A]9/A0
MDI[L T2=UG+# L!*%+2FXF#A96S:)#Z:=*EP3W RKTSHA3V#$K$Z,RZMDA"-
M+3KWH4CSUEOW=F_GUE&KU61+-G?9065=UENUM62OE1Y< W#,MF0:% C=PSU*
M!K?"+4NKZP+QS"V?KA"99P"G8NPVMRHT\7*_5TL^:6 3QBYV\&I!SE#5Y^PT
M WVR0RG)AX]*"4MC;ECU=#=Y=EI!5E)W=UO9]APF567A5F7!-5MMUW^]]7]W
MMQ?Z=HT:E-]:LQJ]JMIV93U4Q 8'$51;M%,1D"4(I#P]DF#11@;_OY>$LT<N
MO(?BOJQ[F+;@KLL@C\Q)8C=-%B1P-VMYT@LB7X-!<3*ZQ.2<E*%(YY9_7U9E
M"QAO%56(#5AN$1AFS>%N3U92]W;=[#$NX6M"5XU="G/^\O.B#B_E]M3%&+ 0
M4]-,^8D,^K6$+_<;PV[LZ(,D5#'J-+/MF =.>JIF+S H&#*E]LLPCI?Z/,U<
M^+9::3> *35;<Y=OOW5XPQ5WS6%NB7AN2S9EY^$0 _)= P<Z@S'-X(M])?2F
M.*L1V0MP#&8U:4]?Z0*-T_ARQY-#5T\L$<Q!FW6G$M=FELWWHN3M3!5]>*F6
MX,5J;31QO21WCF-ML960FQA;YU9WEQEX_^O6?VV7D>\6;OEW&#*C)P:J"(\)
MC8HP=W@I4A2R'MX.]$97/32D1W%"7S )U\;.E35)E=\Y)3XSM4XR%$71J*"H
M!6G9TV9X3;P/4\[#)PY'6/<-*2IM4=K!4B-UB1/8B?%V;@^YH0T8BB'5;O'6
M=A/9F:V5;]FAFJ4/IAP)B8(O.X&P@@T1*!_0_J#W)(A!E/XK' T6GF,:); ,
M;T)Q[-"SNESCZE)I7I6N66IVL\A6,7G+;%L'[V@B*9<N49=Y>/DWFMDVHA.9
MB)OXHIEYD"=:;]G!("Z$5V9GFCS5I7P5^.+U69OL40@'V8(B? WDR\27_UI/
MIK_7;@J$;?@/8?](XJNMYOTNLI&,KG5R^2V[UGU#Z"\3#:D9!FU;8AB$P7>A
M&:*K&J-1-EL3.G@'N!V26*$MNEN+6'@5M>?*A+J<*"CJS1[3ZR)A".VREHEN
MN2Q\I3NQ0GQK#5#@.JXOERVFHJX+,)/J8G3))FWW% +O$WK!N5M.".H.&U[_
M%$J7\B!(]HDY6YH-69FE.VYI%W?_5[H/.8&K-65A-JLGE5DJC*3')U6LT2"[
M,(26LP\E^%Z 62,LR3QMZ*G@HC1K.XU! F\2CC[(TIZWEIUP+#\AL:R!8JFB
M;UC)S!=+8J?O!R5(=G\E^AR..+/E%F63F67CMKL;N5J)V'8+^5HWVRG_C UQ
M&B:O,<7W+&9W,(H\U MPSOH:3V(  X6>\X,,O->^TU@U0%%\L>KD^/2_Z4\Z
ML:9YXPN1,-A,9A1LZ##'!I<>'OR ,[QE5S;"0Q::$=BBI;JZ%96('3IXF5AX
M-?'LFA$H"@D(VQM_MJJ*$^UW?%4C7AH</;(M4OG&25A?ODSK4H]0V(8DXB\O
M4K70<K#/>S&)Y&_%"?7,D,AP)NM=DX(>>"%X*QJ*,=R[-]S+C7A;>[>1GSBC
M6_;#!UG++SIGR=8E$(,G9Y)GKX:OV\E\5XF<L4Z(*)=#NT=.Y'S.25@9$ :(
M0JM6)L'&V1QV@<=')M$V$\O2*-*&O:-D2-;#_Z6[R[-ZFM^6'1YZ9959@1,:
MHGOWPR&UF:^Z'48<Y!H$6,46>#YW70T-CQ K^MK000I,>VF<.VF]UFW=0^D#
MDR#.GSI7A@@\+"I-(LOE)40J8MOS3U4-:[198E'BLIEZ@8>8HI\\N@7XPIV=
M4H_8NA'9L2?<VMGA&"VTP4"G@'8YQ,O]/CL^U)@":D'+/CQDXM0 WN.=A$&A
M3I"V3&N\*:&H--*+$,-I+'!L1AG+42 12UMI/(8!TCD[>+6[V2]\VH]^Z:7]
M;C.:XB<Z9;F;6=SH0'^=79!<.R48O"@(L1)TO2&"0$A4"D.+:5W^QL^10UUK
MZ])@A#>3:QBR-04\(_\T(S"?%'V7/!'3I"C<@>HS^]*UU;*S';HI.Z+U-K(?
M7,H=E9&3&:)1-M:<CMF Q^U &VOLBJ@343U/JE7'8+5,$M99'NW1?@#G&2[,
M4LP ZKC ':RX]C 5DBWW<TSNS]M[!S@?O_$CE5NC/L*1N'>?V'<A=7BE^[FM
MO-.MW9$;/O##6S/*U?[<DI :$S "]Q[+'<DC9:V1]B3S0XQ&O]9CK[7*/E?7
M_FWR,EUN*\5+"O[2*=0&XR>DDE%JF1\1$R(R_':S7,(G6Z(;N9 7&""$F>O%
MKI>Y@@AYL>/5CJ%"7N:$G9,HD*(YAQ/-#8NHL1V]?2!#UMNG#R2T?2-%A@S_
M67+?R90M5>I+J0QDRV@?4=Z,21(E2&)C@@HEDV8,T3%I<AQ-0T;3RJ=0HTJ=
M2K6JU:M8LVK=RK6KUZ]5ER$-6I0L&:-,QP:E]#$:U90K2T:[&3(:7)1N]RUC
MF?>N3[<S0::$&1>D6[\;%0Y<V+!AQ',.%VJ\6'!RY,N-'R9<6#DQ8X<</1-\
MV'!A1EYM5^85S+?NOIQ[??*T^W2U89\F5\+-&5)3T:-D?@@=.GP,)=M@DRM?
MSKRY\^?/B9U-FW9,#J'5K5.JB1LNS[:#;7K/W=,FZ[^WRZNNG3*V3I4@$8YV
M+-"S0H+S-=]_K'@T?_J0M</19/Y1!!E"_T&44$;#_P@66&!YE9123CRQYZ!)
M,$W(TGGUG.2:3]!04MQ9:!TUEAI&.07=BBRVZ.*+,$JE#(K6#8=B=C0&18Q-
M@-&&TS[(P2?A>>[!%:%YKQ%)TD@2QM227T!*6-]%I8&VT96402210U5V>=]F
M^PE$Q1A@9O:80/AQ9%%^[:PGTI"VM0=26X$AJ=I=JXV$7(8A*2.B66.5%90.
M1@FE8HR()JKHHHR&)!:*)@IUG: T-@7?4QK.!61Z1X9$3U]/'E:;>H[J=N1<
M]:#:9Y:.)59E:(N-9AJ:G!DD#!4  .! @@CMLH(DGYTCF453?FGK9 +=]]VF
M3T'8;%3ZQ$9;2W+E5(\^1_]VR))[^Q!3%HE!D6AB64P=VNBYZ*:KKE;ZF'@6
MI+^-D:-0VQ7F75\7XI;:73==^]2GN'6G'F"71C4/?K-.QAB!G.VW$:W\L4.%
M& (5(LG#BS'T30"2T#?9PQ,=>-EGCR74%F],XO6LJD#**5/!44'YE";AJJ7&
MI-B).P9WZ_;L\\_I+C-)I,35>&-0.=2K%WD!8UHACZPA)]>&K_6XDK6"X0MB
M2NXD*R"MO&14;&:28;S1:.4$,,Q#YB!K62T(3&G?.;#F%W*89^)9'F!Z8OVF
MG4^Y1QM)L>4$*K=^8E>H4)!>-QU1W (M^>240Q=-)F<))R]9FQ<=E"85 @RU
MZ'E;\:RAIW4Q.5B0V.K94Z=R53A/V!6Y;>"7#%&64<BU#_,- &)PJ<BN&Q&"
M SNT'%\+ '$SO"5G&:DIK,,7\=:TS*.>IU=)R\3D[Y+KI4SUC("2D4-1\Q8E
M*,^5M__O_OM<B3A=S8QS#BXEL=WEMVZ>VK;GTYC2WGGJM+2FN:5KO#K6EZ@4
MIM-TAB.*T!5':G& A_S*'%1 P_*.1SN.C.8TF1&;V![S$0]QSSRJ:QGW8J*I
M[S5K-=DJ3ZI6L@R@#.=\].O<6<X"!^S![X= !*)OPH7#SEEG?N BQM.D)CZJ
M)>F)HAH<=W+B(=G QS9TR0D]/C8@ ST/-%.2FP<1I(( \*(7:>N%,%S1@';L
MH@IAX%B92'.FC)6-@1FIHG=<QRRI&.Y2>X&+(*%%$TI<!U!HX5RARJ*&(#KR
MD8XL1G; =;1%+DX3>YG)8:K%+%%ES4WJ62)KL)6UJ3T193S_24:6>">RSY3&
M(*YB&[$6@T$.7O!7O$@;#'9%/3"*[)6;(4C>/F2OGEQK<(,T3).N9AZKS7 E
M-*L9B:JSPR*>Q5R0S*8V);<,](T%",.9WR')M2/U^,4[[AF2RL(#)%2^;(!0
MX=;@N"3+!(U1/PWA7=LP)@Q"!(\=?A"#(AI $+CM8DR5\1KN$C*9,XDL(RQ)
MH2=51C52BH>8%M7:]UJBC&C22'W@(E>XBH+-;9KTI.D2U% $]2YIID@J&^WC
M7ZA5ER>%I(HRY9;+8FC,9#WP;.R U9325#N+6*R@ <A$1 @1@P",)GGLJ$4
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M;B>RMH%*^J:;3GC"UP,.(^5<O(HK]1P1_R.=SVS)E0E(UA/2Q4XPV;H608+
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M+A5.C+.3J9@]0+DT+'1,>U-WJW%J,Z:'!^(V_&8VE.&4"*,8Y]6$H#0U*"=
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M'1*,E*!2TTA$+GATF5DC:*&,T'JO2D8^@->D6$D6.I 6F]EDQE&K-8$<$X6
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MPPC$N#H[B<Z)_R%_<P\5%#V;(SR#_+20(+&12QMPG!;F88K^\#D?RIY^D<A
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M!B Q "064 < U$$!=7! '1I0AP'480%+ , 2%+ $!RRA 4L8P!+VO]X +!2
MA0.P:  6 \#^E_R'#84"X%  &@K _%>#\@.@_% H/QS*CX;R8Z#\6"@, (5!
MH3 X%(:&PC!0&!:*!$"14"@2#D6BH4@,%(F%U@&@=5!H'1Q:AX;68:!U6.@2
M +H$A2[!H4MHZ!(&NH2%8@%0+!2*A4.Q:"@6 \7^-\=_:T/A #@<@(8#,/^-
M!><'P/FA<'XXG!\-Y\? ^;%P&  .@\)A<#@,#8=AX# L' F (Z%P)!R.1,.1
M&#@2"Z\#P.N@\#HXO X-K\/ Z[#P)0!\"0I?@L.7T/ E#'P)"\<"X%@H' N'
M8]%P+ :._8^"_QB'H@%P- "-!F#^8P3-#T#S0]'\<#0_&LV/0?-CT3  &@9%
MP^!H&!H-PZ!A6#02@$9"T4@X&HE&(S%H)!9=!T#70=%U<'0=&EV'0==AT4L
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M5$9"VZ<8?HX>Z*M!B/TL)-/LD33-C[?><^29#86UZ[[D&'/U=VG)T9.?0OG
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M#FH<E"+@'S2>93HZ[HV/C:L&K#.4!X^"?_9+"^3S\SCAF;CV@8$'?/L/M$R
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MK#%Q=N@:'$0FF-?Y6-V9)]/8CY!UJ'/''OVII-1*#)^@K272JVF6"7V*&@:
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MHF._ _$_ C)_YMH:;'L3$[P/!OJ4+)<IL*MR5ZJ:!/=]TQ0:(<%+C'1$]'O
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M:A5P#Q@X !6X6*3V"O=HH "  0 P@!4HZJ)6ZJL&@*B>:@#H:@-0 :L&:P#
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MZNJ*ZCX$B> >Z\)NK] 'AMA3[-IN3]YN%5H&;>QL[OHNRW3A[PIO@/@N.\8
MZ@YO\AY'LX9BOAY/9/8&3SBK8HX(63 'I7V8P3K&,*C&;6BEQ%&N'Z(@#45K
MYT"O;YC:11)#JX[;4GBO@6R'FKT&R&+OY8);MT)/W.# B?P/#D2I=_:$9AC
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MWP-^X O^X!-^X0<;_N&S?$   #M02P,$%     @ 9H)<5C[(/$EAG    O<
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M:L,QE+'(IFA/].ZHMS3H*DX)TQVR/)R4I=&$,B>N.YMZ,A6,!3"_8/A%+MT
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M)1^721?'9H6"+<S*;AUPCU8E;C'Y65'Q!$]ID/F9I$J^TY,P9SRORAS*Y63
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M0J:,6Y6L$#:C7'Y6RK8(3  )*-LA',*JX&/7+MBM2"H!-@/2ES90*KKO9NU
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MH7TN>N\))Q9N^J#UP=4O/N@HX24?67?8/U_8O?Z4^_;+7O_UDUY[\ZU?W?#
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M20-B?1C$'H@<$8^%.QMY,9>_4#5=5O;L#_P/B4LO[B709O5)V<@WMT;3H+8
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M!;&$7)G1;X1,8QDU,4 L2)RJ3&U6@G8!*W%'QLBC&G?/RS#-8XK3R*94? 5
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M&;A&$ 0KK2(?F 24TMD^[6"D?2Q!*.2"F<%BWLO'P><D+PMM$<7N'AA!^3$
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MWM TWF9YN!9QFMW7?U"V[Z_2S,#_H-(,_\OJB7KXL<BY_N'H+,I^,$ZVIMR
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M.)\4#"L]3I5@Z*X8AXY0HQ?;^ ?&OQ_$,.N/X?: G'UB_BR5P2V,69 *6?*
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MEC60J&DW47@PG/RK=78;_O5EFKUWV5J;?Z07Q/"1<LQRV+J'6=A9UNQFL<$
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M% M0*"[%*U"T7W/[W_MPYVW6K#6R]YZSSJBH*4M*V31@VV/> ?Z?@0$ *
M!P"0   :  0 @&  $ H P@% ) "(!D    @8 ($"('  ! F H $P   &!L"@
M !@< $,"8&@  @! @ $(*  !!R"0  0:@ ( 4&  "@I P0$H) "%_I<;@ 8#
MT%  &@Y (P'H?\Z_VF P  H&P,$ Y+\8& @  \%@(!0,A(.!2# 0#88 P! P
M& (%0^!@"!(,08-A # ,#(9!P3 X&(8$P]!@! ", (,14# "#D8@P0@T& 4
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MCXU_D/SKZU_PGQ2  #00C 9"T4 X&HA$ ]%H"  - :,A4#0$CH8@T1 T&@9
MP\!H&!0-@Z-A2#0,C48 T @P&@%%(^!H!!*-0*-1 #0*C$9!T2@X&H5$H_Y7
M[)_0_K']#_)_<__?XO_?6!^P,0" /P#^_SG_VPD 'AIPA\^HVEPR'(%'R?=V
MJKET-(:,7;U M:5L/($6[/)UJJ5\,H5%(9Y1K;5B.H/' /%VNK5R-D?8;J9
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M=70"Z QFD;;57J*&\3_9=: >"O:ZIIE[]?.&CBL7M^9/7#(7K?UG9_S-"Q1
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MC/FEL9E[Z?M9FY;L/62]$.?F&U<OCQ./Y9 EI060^@)+AF@S8*($M#CJ!G#
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M 8\\ ,"PR%+-"@1'AQA$5"M$K1//Z@C=&U(/^2<MSQ-N$S$\10<]G)/L#LD
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M2S&,Z[!#SSJNY[JN[SJO]_H0UW59C^> US"L%[L'#W.K\[*JYP6R_(DRD($
M[@4RMWHP4[L^D\%&A:@O9[M=C#@P+SL]3+M'V+ C$'.R]_*YDT&YV["W7[LP
M6[NZ(W.[JT&R?_NTD_6ZE[!YNB>[D^<[&;3[O_LRO,/[O-<[O=\[N9N[P L\
M60.\MZ/[M,N[+1O\P..[PK\[P[/[#3]\O%>[Q"O[Q"-\#>?[P6/\NS?\QB^\
MQP=SP8=\M5L\R)L\NJ.\QF/\RKN[O8/\RR=\S$/\R=>\NT/\S0=\S-O[SH_\
MQ?O\S ,]T0O]R']\SAL]TO-\SBN]NM-\T'?\T[-\R.O\U']]R5N]OSO\#0_\
M7-<%P(^QL><N,;1]M/^O/?PRLG^D_0U_#C'@L']H@@W_C4K_.1G,"^ $Y+/7
M<%UXQKC7L%FW>PZ,NU"C^1Z;^>-7,N2C>0[7=:TONB)C?J!G_B%K_J!S/B5[
MOM]O/NE_?NF/ONFG/NJO/J*#OB6+?NN??NRK_NRS/JK+_NW3?N[;/NSO?NW_
MON\'?^\;>D5O-$$7.8P',]S++O$0SWB^0]LO/_Q6/@X7.2$3<ETL P[;YA]K
ML1Q_QO;70R ?/K$G"Q\7 _8(NPUC3XK[,+ ;.?Q#=N6GM_S'?V!3?P^_?_WO
M__W;/T"0(:-&8$&# @D>/)A084&&#0="="@1(<6(%!\VS*APXT*+'0V"G(C_
M\6-)DB<EBJR($J+*BRE-PF2I,69+BQXKCB'C:-^RBP_W!14ZE&A1HT>1)E6Z
ME&E3IT^A1I4Z]2B]=NWFN=OWCABQ>E3!AA4[EFS9L<H I,U$%"V M44EQ4@;
MXZU0-&D!X!A&%)H8M6:9CARY;!\EB9KV%=-)1B=A8@<=,WX9D;!/BD$+CL$L
MD##B?041TPNYDB-IG" 3HC8]>@S(-*M'JIX\>G9LF[57RM9]>S=-W#]Y!_?=
MN_3OU,*+$S^-?/EPYK250W]NVWGUY--S8P=NO7EQG! I[7O,V)%!P.?1IU>_
MGFS7H.VLSMNGS!>Q8NSQY]>__ZC?N42)26N2HOS#_PL 28)21BX# 5 F*'T*
M!&! _@1:3+(*R=!GG^-^(F:^@QS<Y" /+:LPH3$\W,="#"/R<#PR[E.F( W)
M(,RP&O?1A,4+&4OHM1U;$^A''H,D8T@+BSPR,Q^96RS)S)84$DH3I02222NK
M)/)*+;-$<DLONXS2R"E[#)/*,;%$DTLUP6133"7/A+-,-^,D\\DTY;QSS3R_
M?-/./NO$\T\SY^234#W;-)3.0@==%%$_!8UT30M_5 /)B'1BR$:#?N3/TT^E
MTJ<>#>G91U0-E=)055-91?5!5H]:U=6GZJEOG_C@VZJKKT#MU==?FTK+/P>%
M:@L-MH2=;\&@)OFKK1B""O]PDDS2.I9"ACC$\<8+%[NOF)4B*S*\:"3J3"!*
MEE%FF70E(RR:=(.*9MM]R"61L4VWF\F[VV22Z5+!^ W8MWX%WG?@@K]#F#:"
M#V[8X(<3=CABB!=6&&")*\;X8HHWGMCCC#F&[>..01Y9Y))_DZA(S#("UF5?
MV2GG&YEIKH7FI-8A1^>==U:G':'HV5F^HMI91YUUUAF:J727B8:>8E*$KQVM
MW/F%&*V8?EGKK?4;)JU]JATJ0 F)N@L H:@% #&YH W*/Z&B$4] 3__ET:@;
M"7)01X/T/BB\93*=<C,R/ NJGH(($]N@\+XE8[/!6;044S+S+*CR0RTG\\*.
M+&3_J.[+'<T<2-&))/US.TVG''7,60^]==!A7]WUV6,?_779:R_]=MMIQ]UW
MWG,_'?C?=>]]^..+SUW.2@,/G._"@.1:>O7T*4=G773>Q1MRRO&FG'*0REEG
M=<@AWWQRE*;'_%*)DD<=8(Q6FBDX-(%CGWK<LPJK4KLJIIYHZI>XZ0V0@%3Q
MR['\LH*AM 5!0[D! -HFMP.!#0#6VD>S )"B!*6E@?L9R;;N!3V(W(<8)\+1
MW@H2GL]$3B"0.Q>]9K3"^ZQ0((AYS!C,!4,>&:0\""E/0GI($$>DIH?GJL@0
M"_)#(T:DB&I0(AE .,1,/;$\04+B0(H(Q2,RY(EXVXE#_[K(0R)>)(@[&6,*
MMYC$BWBQB6%,XAB!F$8L+DZ.7TP(&\&X1C'ZD(QR="(=F<A%/3(QCW?<XQSC
M&$@^HE&1 G&C$ NY1$?"T9%^S"(;!6E(0O)1DY/D9"4;^4=&"C&32X3D)[7X
M1E26\8JB-*49U:C)4R)2DK"DY1?5J$I0[M(@B$'A2@H8S+#,HQSJ^![W=&:]
M9(:O?#P[GSKD 32AM:^8Q62?4S01!TU$HQ[%\$50LH(57?FB5-DDEC#1F<ZB
M_"5MYQQ;78*2EAL42T!MF= ^S'9."<(S/_P*RD,(LA@'-:X@ Z620?6YPONM
MB P.>M'])!,W%.(+,?6P86ZR>/\3C6Y4HRMB:/$X&E*1CI2D)37I25&:4I6N
ME*4M=>E+81I3F:(46R<[CH7^!AMU[I0I1MN%S^;!CGFT@QU8$6=1Z,&.H@YU
M'O(PJE/E<<V@Z>R:^V!',]=1U:9H8A.:6(8^?/&.6QF5?U#[GR:\RE.U!C-M
M0DG6!@&0!J+(4RAC2X,]T986#<XG;!3BUHYLY*2#;.)#13*70?!U$)W\$UPY
MJN&'!!*C"D$N*"142) P&U ,20Y-F!W(8G[D6<Z&5K.C%4Q-28,MT%(I4ZLM
M4VNK)%K7RC:VI9VM;6LK&=.^]K.YA6UG<0M<W=YVN+[MK7!_2]KB(O>XRDTN
M:YL+W=WPTI:YTPVN<Z/+6^LN%[O;?:YVB?M=ZG8WO-D=KW3+ZUWS7A>]QE7O
M7__*V16])K&\7>M]B8(T=;#C*>W0V:R4,E7T"84=Y"-'TK")KGV$@G[<=(\^
MW!'.^]5'K)N 0V?2BE\-^THN8A#*LJ(UMZ&\E:\2PBNSTJ+/L=U3/]EQR!B^
M8AC4XG ?(GK>+Q%3HH;$K1Z:=1P-"6-CPO6D(#H4B(/B9D*3N&2F._RH8IL<
M92E/F<I5MO*5L9QE+5>Y(]E:F(-N].0-X]=H^W6*/G:FU:3H8WOD8-]5=9;5
MIVA"P5S=9JWNH[]Y\&]7.;IP833!_ZLQ#SH_;6'07TILP: \,(+OI* %,:C/
MMLB5/Q]]2'UYY"$9(58\+=I,\Z DE'K B\B<*4R05/A"P*50*"L94LI.&^O4
MROHE#!D29T\47-36FM:[]G6O@3UK8?-ZV+\N=K")G6QC*QO9RW9VLZ%];&DS
M>]K/KG:TJ9UM:VL;V]OV=K<7EA$O&^RBVTD(H=4:C*/QERCZH <]W/WNH B8
M'>ZV][OM713QR0?.5(5*,=)JX3N[9Q]2^]D[O$F/:'0UR)2(&[HAGIZT'1H
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M,8B7'V(0I>@#) 71QT/,/!2#H-DH8S9SF)FRC&@8)!H!+@A2Y^&.?? 3EOO
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MW?]5.K##/J$#/C(CD7UED<I5=3O#)._G,7P8&<$0;NO #IF%5.S@;R=I%/3
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M: B?N$!7!8)3G<T)E8 W??!9Q,N(GK4)H)6@GE@&.HW5=I@'6KW1=T L90
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M0A@AA D6.-"!WLS#CH(,MD3_&%Y Z !-/8[@,I$YYK!3H"^X./).-""&]!:
M,])8HXW[Q   4 7E"  T^R@C4QH[Z5B04 #H%"0 -A6D)!HW6D9==,JU]=1
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MD#:]<F[KQ+<MNY74Z@3G"*7)-DAWU:>[#?/_"FWL8R,;6?42YH<\DNQG1_&
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MXSFB8SJJXSJR8SNZXSO"8SS*XSS28SW:XSWB8S[JXS[R8S_ZXS\"9$ *_^1
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M_W;LQGILR(+LR%8LR6ILR:+LR:ILQ*8LRZYLQKILS,+LS&)LS5ZLOYKKOSZ
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MMVU;='ESM'$/\IT.R3(TL51G]@H10WZ_ YVB_R\IUS?1A@F6*O0^6&GV4NE
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M77]7#U/3&;KUL=_VH:GVC@[*^W*%\4[6<9<[G*;U6K:  J:?LQ=<B.$762:
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M.\*9[Z]8FGF39CD&I?DB9OF&N6, 0V*99:*6Z0^?N5F7N8.>Q=F9J3F78:(
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MS)$.7:8KG=3H)7J=H?YTHC>=U'6&N9YS+M6F"D/D8 _[FR9A@!48( 8P724
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M@D"(A">HYCW8@V\.Z9N^@OO0Z)B.@CL8ZI^>A"7(@I#.Z/J@YBN(YBG8#L-
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M,(P*K&:]1?"6X%:YH(P-!(JG,.95C$&=,.;^U?]-C4SGNNB2)J'A$_1ME&#
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M[_JN&SNRU[JPTT.S'[NOR[JRY_H^M*J2LTJRW*NU;KM/>VFU8@AD#$O,E 7
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MVY%EX1@Q^.?9>M%%E\E! LF0 V."F7B<:O:Q&-V&%@H8XG4[11.? #BH%AN
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MBA(&=P:ER<V^%AYEX8U;:Q'(2+S2LIU];"=!P6F.9IH3GFHD.*X9'$V5=M/
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M2#0-._0D[<@6S] OZ)+!E"(MCSN2'G.U2$21?;22,+(:\>F<!DE$H-A 0L+
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M^[YO_![ES$YN9?!KS3[MU1:#20#PRA;MM28(WN[M?<CN_NZ,%; @_Y;M?3
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M!;OR.=X7Q\F7;R@Y-J@N_ICV%\O^/</\_Q]9]A^&_:==BP T>#B8\^"Q $#
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M@^MX?RO)Y"O*VB7>$S9[(%:,GJ!R^^3UB;"#FPG"C^, 8):V8 &!MV)3'A3
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MY2IY^YBA-UZW!Y;[,(ZU=!W[ZBL_L=/C'[6-2".KDGUL%3:EP#%^SW4E2U!
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M&LSU*9?&[82U,5OJ\S1&@6H.7@OEN<H#(DB^/DL8]%R56FQT>/U"D*DZ1$=
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M4N]7F-*=>\/9;?GX:S%_90H12 =2.1.O*1LLU773? T.?5;H,)T4#Z\ZD]D
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M9</P_8R"ISU',Q+DOJFYU4?QLGG@="U20)AR26Y2U^4R[G1O^:Z,H\H&"48
MWOUSYJ[T$3U6+(PZ)@H/M^;QY15_:.KFKE36&?\;8*2;T/OF)Z%()@RT9.'[
MFV=V73P^K-TJ"-Y#ALQR3Q-X;(WJSXCI@-CO?W,FA,8[[$79#WZWDFQP?1:$
MFZYI8^R2QF-NI[S%^P7&2/6>UQ68<5X(;J'ID6 L90]/\7R_F+XLEO4\QPK-
M!DJ602<^4>S3F#% B;V,6C9)5+B1G1E"$,&4F]&59.=0_5&6WS&8]U5^;$JE
M 6(,/RC0LK+ UL;FE*"189MNKT8PTG&4ZY2-T7S1)^!M^>;[+2*^.-U[(3)0
M?,4RZ 0G7363.M/),_&4JSO/T>B^0\YP;F;C])1"[UI8P%2/;<<VWD7TLKGL
M42C:P=2X-97SJAL+S0,Y2T5W6WD0P5\R(Z9?!-UZV,VLM'=WG%]K]?VEN&L'
M;XGV"L ZE7Z0EILOH79EP'&@7^#9BO03Z]"^))44@<IWW_CIP<'MS/Q);<JY
M8UB[7_I_H=WS%[8Y?<MM 5EBK,5ZVEIQJM MVP@43L4DAKCW^1Z;FYY"T9Z<
M)*135^TU]-Q/*U" [NSBU@_BE11GVO)E\%P=5O1'#XA764V54#LO'4\@K9,P
M"RS3*3[^JX)2:23V?!?6(,5\WQF]$X@I%EYC,'UU5YE9[2UAQ'+9X(4%23,;
MA(=H2ZPH'#W.N;R9.K83+FL69"X8/1R9YU3*/QBEBYP>\&[&:>,]4+?F1.%$
M%^+_K>DAW\(+=)LA*S"TR+X/T/'1_^C;:RGK&N;)[@:Z.CGX5)"KM!+(YVHS
M;GX&$6$.'#R_",V"?(!1=XNKJX&D*@/YM0I+<^VBV\I,4N':78J=<8+ULJAV
M]0(GOM+&@/+"NM= X_20*ES7:]#5LZ6N&C]GD_+,BE6?SFGGP$%9TGRGPZ8<
MDQ6IRUN;J( \L>6F(XB8W:I!EY$AU7&E0+S> EGO/O)<K0"_"4<54X-WYX$&
MR$$!7!==3;8WO9JAX%&<:_X4.N-E<^B,^^?(_5_ER%_$S"IQS6**6M?DNYU!
M#Q10D3J93\[V75QX?69(8-(B2=X61UGO)1_G^&)]F@?J,.+BFE*O03DF!HX=
MYTV V9VRB6\&,!M\Y%L8T9)=:1'J'ZA%U?1PZ.#+!@7(SU\S,M^3VK'V-WZ$
M")?55S)L/FTFC[\?6XHVBH:,M4D?5^4;DM$_[^$QFM!Z_.5<D[?ZWYDSP@1.
MY.R9\/%53;<0>=*^PA (OA_\LG(8/Y$ZLI4O 1C)M8G0TA2+BCSX/H$3(XM_
MU!*A\RCW R]HE00*(,7<4FMM;@TMY(V3;:0^0^G.*EZ' NB:5.O78FP-#W;&
MUC&_N&$^OZR<2EQOA#7OW_]^O/7W@F'0A^/=.('QX 0.OJE4;P2K,:>4'8\_
MUK]Z!E5\46_F]/7P6#KE<R 421>HNJN&177SSG^\&Z*F;A2HW#^!-J561B+B
M(S!@<VO[W699@]*'EO_Z!4_[D\6426A GR/WN_>M7O1']76)MQ 4(U79OB77
MNBQ9%?$"MR*+3!]PILE(YV$..1JF2M@>TUFE7?Z: ZVUL_Y7'T03,\&)U^P<
ML>R-,BV#=Q\:&RBM[#!_Z\B^'-'\,3V# >I+RQ6I%G,H&?O:_S*+V<WUMLCJ
MA'+"X@YST-U1DMCX2JYMD)S$R@VCQC;5YV*)[P)MM6@""LBT$GJ2;IU^2(&+
M2$?%W28[+S4_(2K+Z:%%(/,\S%+QBN31IY01X%EPLI58$<H-=A?D@H_/;10+
MRBK!O$^2-<RJBF%=?T8W6=91L'H7Y9Z"[QF%.3%;0IV-!2N]'_^VQ],Y%X "
M3"],GHO$,AFW#E& ,_-Y\PD6CFD*1 >Q>R\,5K*\MT%*^F6Z][UGM&X&YVCF
M!Z.DXQ 4V'T&;/_9P>%?Q:'ID:O SHLKH]"_U36W*^/K)N89YF>)O:G681WS
M\I,OC7ZNO82!2BI*2H26C/4VRO6EE%E@'E6--Q=Z2U)V;$%18G0_[Y *<LM[
M^2VCV,;%9HK:PZ4[ARU<,?2(H8!A0S#%^=[!]%2;4+R2$@J-M95Z6?$-S.GE
M __.I )& *(-\#T91PPJ@4^$:^7H;BR6GC83^Y2+:[+1%YR=FE-3RM%9NRY?
M!/=%?-6?HMA[# Z$N"_0Y_4BWB-?]$,&]3(<?B#^2N+;WLIB.[ZZKX$T+&BX
MTM\G'B=M>]R#_)_/'F"U07>WZU_-"_Y6U/2'V=LG%1@8/W ?+XH:'6+: N'4
MBPLS_'LH0K\HOQ5(CY67XGBDR?]W;H:<:66W:Z4A!UD%,@$+%$O.TGQS[%=K
M69_EA/7PJ9[BG]:N^!RR>IN,D];]892L+OX_7GP6)O?'0.%%B@T#).[N6K5$
M3 _HB_;)B8GA?FUQ*A;L3>C(5HP1X04\;QU:.0Z=OCT_EG%LRT;?E@2U908_
M:# K8 ^\,Q>MCHR2-O.WI$*8_9JE6&OUJ@[U\Z'XMB%8VE/)",25!4Q!12 E
MP10GO7%]E>Q"A&/FBO4AB,TP/=T9@J.%.U<Z]6+VNG%J^:$QIEU:7$MJ?W5U
M9N'LM#(GBG;7 IL]867^JO1:3>M/F?KYMQ[-<X>(YQ7J[I'J=:=#8"Q?^O;E
M1873^T%B%RVX9W0O7.9=8:*HB&Q(0B*MUW??0I:I\A^B^[EA&]S_K9?-_DUA
M 2L7/7'12FCN(%]S-A#9A1*#7B/5@L7;ZJ4ZPK)FU-I0XP]N?V7*RH #O]27
M/F/-,GMADGV  D23[NW=+-S.GH_JH(#LL..C\'N;OG#WCMY)*&!"O4WZM!<*
M()3("H9@_SD:&/7_:XT$]J[2_YAP(?+RTGP70\C,>N>OH,Q/RJ?68?1KU&Y#
MLB%#T,B(5A$A@-R,EY@T.T(-W9,R:_--#%HI*2_C@I:""(KW/%491RM)9M[&
ML/](IN.H]6H>%%#)>A^@GT&'NYM=47DVJM^/*%T7'O<CS9.?-++*"N? %]]&
M&C>R</$;TMA:\E=0ANE!$X2Q(VIJ>^D "C!)IHAEP^@)>#YM+K@(!H?(0;:!
MHQ8"K'F6J$:%JUP-]A,>-+#:0W^Y7K5RI-DEK.3HVK&Z6^OHPE!E]:;AQ/-(
M=MXY#5_Y0]2I7.U;9');^"B?P_$P%XMK/:PSQD2N[WR5Q-B\Y62$+ &_5DF;
MOY^$FNQ$"P=KMUQ@:,[W$!',<,21*V5V[ ?R-,G(W3UUJ\2J<2Z!PU/[VIR*
M[L4X-?,BQ@9Q;#Z[^O\>!WGV)O4*44Q;V[C0/Q%),9@M.F&]^VH8L[P5;5FS
MF6]\[X+-TL-@_T(0<UAW+@\IQZYP/[I<7[ OG#SBP1Y<(*0/MY4)C#G0GBA
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ML]&A>23$6=WB_3!L:I0D^!MI[V(=PMDAC?M\(&:=M69#$$\W+D;=!@4$2Q3
MF.A.QL8?SI,L[^3P[L9(MFB(E3W:T\09UG7XX101@3U >C"(K,R+_W=HX5]E
M?"[(>0OR.%]N4>2:9+Y:G0,%](MYB-<Z%'$_'8&/9NMS(M\/@*91H(!K+*U-
M4""9QB-^__WXI&]!*TUN,_H_[6GJ7'PT+6KZBC.-+]/?JR<X:2^A>(L5C3)C
M =HS ]"<P+TFVO(LK7SV]5M\B8EMG<H[#7WU=;VW99H1\A]M,E0$'V<[M,$'
MBUYCV6\'5)%;@-NSW?LO8@_AB=$R&T;O_?>%2BQL=@;I/GD/8K/&^G0R[ZEP
M'70=ZN&7WJAMQNHL#3_6Y.1:QAZ^XG"C*1&0\\\VBKZD8W33;)ZF\B./)'*G
M/$6X+E^R.L^DQO%@ZR(9'U)7BE* H0(>2 .NX815<H#2']-S>%%JRD+0SN[7
MRN0W!]3F_=F32RB K;>O4CS@.<<6MVGXLHF<^*N8+G?9F^2FN'.!ZF/D$A)$
M1XVEZ_J.:;(/M-*#6##78!Z R\S4U>U>2M3CA&Q1'_3RS"5U^$R!Q00XWK[7
MD=9YX$<+5IZK,N+F:JP.87,M<[&;J[3D2^C-C"&9"%0VI7L)Y)?"8PIG<#2_
M[<4W5*1WFHAJ4/AU7)5'3_\"+=P?PXNPR'W*<7?N%Y/6)AXW0JPK+%RHZM.T
M8R53S4^^,?KW>FY=%5JF9NS\*$+,R/VDK3:FZS9X=UOBO/0JV3LE?X8R5C#@
MSMAA^DAK<4H:0EFK28DUH&CCR!ZE'9^>)_]X&E9$Z%1APQ"W?W+%I'4X+ZI*
MZ -&B:T>JO?!)( $-9:E3"4D_5+YD-TGTTO6YGTNSN^+_# OIZT8Y^!V:AC^
MS8@CMY59X<\?+VJ&_E4396:5Q\<X/@%B56,P[LNR%GQOL$VW"\MZ<IVL.XDK
M/)$1T[YE*&":$Z(V"MP$1SW277.>/5*P;]Q?YLQF"RH?[UWV7U<.-:\ADU'_
M(GW?("C6!X-R'U@MUVZCNW8PZ+6;OA0H!YY/09K^"Z%$6\K 7CS2;IC5R\=9
MHE4%@(NJ#$9F"/>".$Y\-F./)6L_L9!R 6+V'=&M)[7IZN0X;M]-A\MQMH@J
M33$V"-+6']R%H"@E\%!8(#C=JPMV^CD?:>7&\I>=K52;D)KW(Q_H">**-TB6
MB>UC%Z#RURO.UGLQVHX?S]<D?G2CI^VAO4&JJ1! +EA:[N>86E[Q,*.)XZ'K
M_(HWH_3)2C5L)WR"2AK;S3RO[$#1BL]I09>]W%9XB/BU\*BH1[;6ZKY4_G#G
M0"2>DM]#T&JP4$.)&)6R]*!@ ]$WO=,P>XO&"PO:PF;VI7)?)>Q++9^C=+O@
M5(/D5;W98WO67;SO1C=X\Y-J+V??^6JTL!6@VH:ENJ99%6@55*2+\"2ENU ^
MQBW/H?UX,97?G&HG=(%6KI5@#'#T39B9E.8L%6O,W$K@D:*<ZW.-RSEXI&0D
MB>#G]KFC9EA3T7I,"G ^45&.A6C9&J5^A/>P!:S#'9SHH>/232OO*B@ZK\_3
M:Q.D"H7:Y?8PN%Z.DW_W]YY?B2["2_!:EZ/;/:@DC]T<7=[YA@8 AVRVAM&6
MSN*FQ\V&3@7H5I@;F_L2UTR\,:CUB+@R&O$@HMSB@9@6K[I3R+7/4'=85&XE
MFC) =+^B0=2F)D6JE*0&!37Y%*T2%PD2M4D:HN*XTF/'SD?P66,NUUBZ^HE5
MKE=(Y^6FQ--(#QC/?X;R+N/'.CW,!>(QY6><WM&*T!L;F6?B5T]\R)1A9S(%
ML+@B SP=U%PP$0]:HPH8P;$K$AS-*SO-\-FDF;.3DZIEJLJ[/_*?:!POET39
M929.KM-X*W(2/;!5$ME^2&X1.TCE[[_Q%$IC_/9!ZEU"2M8(^1X%@L,QO7)8
MDK+MG5>D"-V<#GZB$'[]]'5X!Q?!J4!X^BE5D 8%,K&GV@F];-/D]7YY19.'
MPUXB+V5<K)Q>;JAJ>I5;\Q9*O['QHKOOW+!.RZRAQZ<F0' TA:D40KK1C$KV
MA WCS5.D(:&* Y^U":4-?%0ZJ!;V0,'\-0/F[RT4O\?GG,-];'\N+->'I07L
MH"!3'*FD$;E.!WZ+>4C<9"70V*-#XBWC4-Y+B/W1LZ/1,D 6G*I_B7UX0T[]
M 8M\"5Q6,'W]I,<TRFB]B=6= 3CUD3JUG,5S@O4$4VX?.'*0W?.X)2<9ZPT=
M&5/%K[;9N"XQ,)OPM(>[4VVS*H1*;"FUTAP6FJT)COS"EG*3&C(KGTZ!9B0<
MOV&@-%*=&T8#/U*99+(]O+_MVX"G,ZLR/%N9!$EMNBI-F/2'O'B F,FSWX_>
M-6W_U[;^CZ#"E^0/W."9SMWJL*QJBRS59+&QK"5::6BV.!1S1CCHY#O2H86(
MBZ_SSS1.5^.KJLU.ZS6 CL]8W<YH.XGM:1JFM7<7+48N>HF9\(9O[Z" (Z61
MKP5B%C^^U^3*WITSE@=LIR'O"J5YSL@5Z*)++KP(_+G2"61:-G/U895@>Q&)
MYRO'*==>I[TJYOB>($9-^KN@QR'MVH*P]69KZBE-7L(K\L]2U-/P#T^3(U_'
M<L/HOOZM[J/S1(2@V5[/DUC\8\:)&\UX7__V< T%3IO/),;)F%</\S5^@? 3
MZII5&[V>D" 6",,/D4DQO.Y_.J'"T[[M7E,,&&J6_>J(LAYPHFZ>/V4YXA 7
MWJY?*%847&%C)N4]F$_CZ/?[LZ^:+0D7O@MJE;!KHG! \SERTXX&38GJ>J-X
M;)6RAJ,)HZALL!*61_GA9'K9NZXB78L+7;VEY3:A>Z%]Y(";,F<5^_"Y;C73
M6*F3QU.E&8XR&UGJ3'PV9Q,>3HO/D3:!+7J3WQ:"]BCP2V![H->&.A,7%NY)
M\?K^R_ (%67&ZYN//61#5;H6KO-<J*9=B91]*T4Q86UBTO^+MK>,BK-=TH4[
M(4!P=W>'X.X. 8([A !!.HV[2X#@%B#!W6F"N[N[-NX.39!& H?WG6_FS%Y[
MG?GVF37G1_U]Y%XE5]5==54!O#?;2#)U>:J=(9'./7Q=Z]1PHJH2I@0KY\"F
MSN<9LZP/H=>1=_&H  RR9T _6%U%,TA'0;5-[FRM@"6:'2429H\B-(;_3NOZ
M?FZ9L51=^1.=H"+M6M?_:83MWV44"@<_Q<Z];OV"AD+XNE<[:BK\CR/\J=1A
M&3<'H^*M1^*55Q7*6I>G5&IG_7E7Y6Q>E9/'>XX]E7S/ %HG(:M[AMXQ#9SN
M%2E27X>B1V -F,/@&2 )B\Q;#0YI5&-JFZ!Y!GS&6];UHS'1=U>^F/Q=_!_E
MQO$O_VEL5=$3A+?"EV DDX*#P"DS#M=HDH]>1';PVHL9J9(-M!^$!*:.,0QE
M018.F,;DDHIY]-*Z^N<JMQ;H.A*ES>16*=1AH5Z9Q$BV]C&PBV5".@Y#J4T"
M'E?;6%JC>KJ"^/Q#2^C\JH(FZSB6) / XCX54/</U38\G6> >O7T:5_?GQ6^
M7RE:V.\W"1P%X!B:LE&T_HNX[F!"&SDROR>:A7:// R.[+LX;0WZ*'8/>HQ]
M!I@T+4/>_%F2KWF\%G(4*E9N-@T-E,75M?D'H(!0Q^LY>>SGQ-7,&+6K*@_0
M,<:MJ.@\I G%VN(LKMO]5>_)G[/&I4C&"8&6]\8CA'FE+7@;4:%D*NRGCO?A
M,0-,VUQ )*JREJSMGW<1XR>\IH!ECJ75/(,EH@D]>U94>I5>^P<YG6@>9L3:
M=9 )'M;?4F;1U'&"7VZWLXMYD;!.>/IT=9A0$ #[B.Y>$RRU&U$44IRRI,TK
M+^BA[!^N=*ME;[)P#F[^R*>#Y7]1/@.D31I,S#<]VA>VZ[Y8&$H9'CC&_DEM
M$_K5+VI.P3':GUS]O?4%WORGEK/LS,OY93WJS"W&_(QZJ9@-(A*B[N#9[>D
MAMSLQM;ZFLOV&4=<,9<@QL<!E+8)6:(CM0*U?[Z(P9-UC418,)7%B3U]TT"@
M@C[3*UL?.J':JGWTURM:V^IFRG=;VQHCUI;I5FFK?VFK'RD>2N!,O8_0VPNG
M"Y_;=D4%%U$%[F#:_&=5TFWOJ)UA+6AM;XI87J;Z2?^SNS1J.\'Z=1_NM_\]
M[X9;^U]>M01NF>^Q)75XTA\>0^[G81N??G$\ Z9%M,TQU+'/Q5;5KO Z]&;F
MG:RT?9DT8Q/]O05>$OD/U8?)7E_]C]G8X> .,)X!1LC';'N&D=9%:BW4B!12
MW%JN#Q2G; @WLZ@UO4JQ-V$TUZ]K6M%\;]91("6"WDYF]CU%![+NXEY!_L//
M .YQDU.KO0Z:O)<S3_^/+@R6T4?W4O9HJ'S70H6EIP?VVI4GWX>[ZO12=((V
M+TNGU/X0?T\H08_!*&/H<#=*?D9D@&2\%CNBGRS \7X@?*:7 O,1/3+O&)]<
M>V??+<?:#.U'+++BSH+*5K1RGX'O6.]\:E;HU8- BFNK^VY4RAO4.-5=E DX
MHC(3ADG[:S5\#[4/=3) 7[XC&SMEL;<ZL=:=YV/.ND]8\RE]7M=3%S=)%6@J
M*2<IM[\QKGB6&LRD\C?(Y=;:#E[WYT%QM,70+@KK\@]_*;M7K,K;@2R<$/9T
M-_C-FN09ZE0J8)'])L35DQN-84JSKL;RZGP0RG5<0V3LUBK:CS%J(N@_2Y/]
MD.=S+K(":O<C.&JMEZ/<"8+'"+6,[RAO'WHB#D4,<]9M[SM"SMBPB$7%-0CX
MX=-1Z?N)R%OC)7!K[3$](F;Z>WK\:(E=QIP_+R0OX#,>(,PC#W:%BUYBW)'N
M=&#7"3\8_C%7GGWD!9K;7G[C>3BL<G:I2D!B<%@T1+3N.DT]/G=A.7QBL/':
MHB9!\14">A(V#KI]E!B8U&4J]##4O\C7)=;N"*[U]9I4HTU.J9X@U6 6QD=A
MM*"-4R0BV@K@X?6G6#62W0R9MJR>,5\ +3MZES!9;U%)8@6\A1\2'3Q< WMD
M]=ZOA_H(YM=!#H'^WF[UU>MQSP"+!D1';*ST2\!&NL5UG_["QMS.#(@5\2M/
MVZ=^90=V-K_IJG*N>T;7+E.I=T!^A<E'V<W*U_HVXDOX!HM<RC=I2':_JF1&
ME>2B-D)19K*Z X0F,/C RW:ND15B9QI+$5M]^AH*%^\4:#>N#Q0.3?SD(TFV
M71_=4E(_]*>0P"<S(4?Z"VQ\Y+\?;[VZ 2=N[H>>MPJ;E_B6KK$05G(0;ZVK
MA)HS&U !0&@SM$$*I%Y:0N"D+33Q+2&/6(69C5DVL,MU529_$V8MK6*C..49
MH2@BSZNO1;TJ4.^^20_/+^8)RD :MKFS/;T N<ZWC:RJ:@X(+'*0+9GY=8PZ
M8WN=FF^V!L8[J3Z34K 8Q;F@Z/PK#3W2S/3Y^=@<4_U'&2A[#1=E34?H%.7'
M.]K^<A*:!EI= 3'R(_XG+*A)HLLD9,66>&4Y.C&!S+%-'P5#NN&-%S& ]=&[
M9/%X619<5@JSUVR8LX.O4F'6L*A+"AM)KUK[23A!UIXT^:@XAQZ]498V96GC
MH6%-,-02.1IUEJ1+ZQ6UXSV'A@TQ>)JN-:Q\99WJ$!V8>L/R#9)]3%QJ-^XX
M&Z43VZN"_-#KA]HTXS(KW^29[:KKFX?"7+5_@ ;0@!*$B\@BQI2W\N<8ZBG8
ME1/O%K:POGDC-MT+ETRX;3U ZQP1*PO]7/T1:I)1+OO9U?<U)T.:':$L5ZOE
M5'UB_$Q\ZE3CY'D^+,^JDIEAD7K:HN[S&K]GJ$2G^0Q<Q0<U5-O@WDR1-LZ!
M'2!^G.QGGZYDR\"X';>="$"GF!"THB&8U<?&VS*?/DX'O[%69<\M>K@DCL\!
M755J8\.5=\DC];@7LU6EX(B8/L.\ALO85OA'R@1R*7*4>7HB3 >A;!/-Y'S#
MQ00_E#&FM%[GXCL7H"5^LF%L)C=51&TS0\>>>/E8.6<)%CK$"E^M;ZQ:55';
M4FWQ*E SODM@ O=5= 4LSP#*W_4,P%(C.9PRUE,6S3B)2_;8DR&MI27GCH_:
M;[-[!G0KEL&D-[N/FK?UC">JWY[D-:!A5SGDR$3MW HR3!*7Y<$(=-4 'C72
MK3'#T\?:38W)\/7B31)'+1+;5)*$AY/:D1/HL. ^4PR$V%*;F^;/>9\_ C5F
MPK>3MKI6.M%Q-Z*<'*Q?DPD/&$1GA?-4B&O-M0J7=I4JF&GF#[I#E*,")#^O
MA!%.(/*V0'&TA.1#L0_TEXT3O>TI4MP)?F3Q1'#'JF=BV!;E&!XC:M<]Z 9<
M@=@P$WEW=#F;#OSG2@L]!8[D\?RW$,)\MRC0Z&(RO_V.'/'\YH[,EQ^8EI6=
MC?K'O=>/EEPLMH<8KSW39Y7'N*YO[43RH;O@&R+;(CSASKY >1MW;[O8?/X<
M3YDA"!_E#_'GB*-+XU.\'G/&XH!=)T':3*YWHD+B)\+G,(-@T\6LI6? XKK%
M>L?>;Y'3Q8%"X6D/*ZGV&=YG -[J*C6K4-+1F)UV%YV,F2=9TTM,<X92:*9U
MDI-!$=**)&Z;,Q[=G P4=MBWC!70('LF2./P.!XI ZG^X1L7NV/@<%?/$HF9
M92/9/5H=B-I$*[9RP-O^=XHT1;;UY @+H$?$315Z!3,"+[?ZE 9F>D*]K^#>
MX)7-,+RY(R&RZXG>#!S#:,PE WTC:18"0*AOBX/P%<^K6+-M,CL4"H+%HRE]
ML<I-F,ANZJJ>K%"MY>0I R4TB%L32,X]^T4,>PE6R%@Q=C5IH# X[-,Z/$@"
M)_A$$V,#A2G=^.-Z+'O'Q2\>N\5!NBB_-&!Q<=+4(X$-/UPLQ-:)A\VO88&X
M58*$L=Z G&_:^D^I75FJ'"]])Q7-(0!G"3*U;R+R6P*MWJ#-#.3EKJ>I(I+"
MS)-ZRMXT94QT/7, XP #F%F4I/^VOMZ$*;)WRO!/3<\/SYV:-[306N_)8CM)
M2G.B"B87X3U8"4(KEGC-C+RW%.3)_MTP">'5@-?H,^ K\]$S0 ]ZN78:,6 :
M\;9B5P>UYPL=83P$+;8"\#$K/+4B)".YR;\89NM-\I,:Q\8M\:RY7I[R-8GC
MVDA\(XCL>/YXS 7$T(N/N633(/9FDBYAW4*ME!7ZU=7H]0.?_8K$N"APNOC?
M41P<8I^#9^HG):'^9T#.]MU68_-5AM3ZJ9?/A3E=W/8QY+J2[T"AM$?,8,S=
M-'[ZSZ/07\ "\1GPY@5*7*G^3:@##MU:([K2^Z00;T=39QAB:81/1!5X?0+,
MK&AH4P964'\<'DX>3@AP[J+%]$<>=Y_NY)8*I:)JSN1U_8U-.!<J^5GD2:IL
M H1RY!YX1ET?3?>1_[5W)@#/:4O9&Z2L5MV09+"&)!-U1\@ZEMG>\SJ!-P@X
MIC)S,FUTE]]-;_8K*CT^$ZFDO>%U2'\&K8;AMWS#KXW/ *V#MZOCG,'3&<Y%
M W8)& T2OV5OMP#!9Z\.5&Q63.3?I,HD*,+],&Z=0N"K% TH/UX5Z+=J?-"N
MD5&T8*%DO1,%7!?FKX)?K]B86@:: (N#A1 CWB%9#1Z>'JH2B]$9NK<%LD,(
M X)GK^";/Z=H98C7LM')Z6J%LIX*'LYJ_ZS !ND=H7C:L1%+<CI3KN2!^:['
M"-SF J4@RLF;[/KY,10UO[ ]T\W!_DE\>SV#H2S?BI0CW7U;)K%"KRCGT^%=
M24"6/>7*/,7#%@(4'AL42F4.^",*AOS)_)F*O>55OSX&H#KY6FNXO]XK*41I
M^RQYTTB3^J'=2"7!<)=,X5!OTI VFC)S3]@A#-&#-O$$WL9H# OZQ2D<LY\N
M*@65<](]OU[!PE=R&W_:&"GV.P.-W<I?9UB /RM1Q/Z3>072@QK^KHDH?"%@
M/4OIQ^&'/YF>FNHAC['M;T +1;_/#0SG5>3EU&G?0\_6;S[RE4QD'XC?7YOL
M<=,53.O]"4/[/4X9'_D.401NTI=Q[Z/50%%E/&X#OZ,A4L=<69 RAHD0<J4S
MB*Y@I(OQU>3OX*Y;O-J:$5=SFQNY&C9<*4&:=/8-><>6.HOU$9X%\,P0:0(J
MDS6T(1""IPYJDZB0Q=4)P%77KD-JC21*=X4$7HMH*IUU?_^N^64-YHR81E]4
MG+4=)]?Q8D:\X)M?(D1F-Q@H^B6$GO+IZQ?L\H<1ZV#6]W>E]1UE6%)\A>"7
M=.NC[=]U@WT*G//0M$H/9F@%F%U&**TA$43QD^;IY*)L92%O@6FK#?D9H /%
M"+%_P89D0G^*&EDW,$/>;KCO3"+B;7/@#U2N>ZC.N8C:]8+;0 QI_A9FTM$]
M@,2%S"R#4Q$5]RU#8.NBK0G%] D>PE(=V>AEAR#A2H[$=GJB? P/R1\7F/?)
MV^@;MD\H3;?M*W(MU?(E^P5FQWZ$<Q.QE:[QFW^$>_D:W*9D;3FLD%F))-$N
MJ]/+<!)T4P$1IN$&B8^<=5"VBI#6U,!V94%04J3<Z=X)*#KS3_AAYC70$$H0
M]<BQ65QY3<A35O:0(?>6JJY^K11;.ICHL[BW",+A.EX*<(/-#2.T_AZG!WAS
M<%W08ADA07/Y]>&R/=V%# B&KH7Y5MJD?L%_&TM+7% W&IC.3B,_0@$6_H
M*OK6JE[@,:(X]:A(GD)+/*P$6NX5>*=(?,8(B1WE7(\!<IT/W"?GE=I.'=PW
MA%Y!?/DV3Y-X]3N\W:E]3]!&JK@[1?81FL6QK/GO4Z(?Z4H-J4F,^923FS[[
MX&$0:O^5&(1O@G1[O,8K;M20;?RH?LURD%\RT:<*% 9F)<NM%;%DRHE:O[KU
MQRYJN8@-=541!;&B-W &*;=L&:#P&7?5!'$G:Q#08AC,+/@H@F&FG>O+_&.%
MQFMUO0X5L\S'7^); '1Q%G$(GH![9QU7PNO&1U'S+YG8TY5;\43V+G.-6@J_
M!Y>:W'X=IP>>ZIN03OK(;OJ_7>U!CS=WNS4('F\6-GXZ6UX=N,]W>X/]=OPM
M9"@;/:\'^YA;?XB]K-C&ZZN=M*'1X<$PN.T2Y=T])C ,2@A5A T5TJ=Y%A2>
M"CE_88B0RN%*:PCH8<O\:AX!N4 ,M;\REC><9>>!\7B+2FY;\Z1YMO8&%%-E
M4<+#AY-RD&H^:N<?5\%&Y*'LX68(N2!085WJO'(@4L]&**HD*=88P.S(OA(C
MFDLV=\#"WO+B$<AZ*]Q:K#O^R=!Z-USD5?Q"HD&J:2S[*0\&CLJ6 .6#>Y@%
MDV#-H&+_Y* 6/[.J8_!T;46MJ(R/6DHO=A_QTE!N0:',3VIUID^<A\'SU6F=
M"ZGAT-."0P70]1+F\G Y890<@L)I*%P$8%CMVS(XTV557N,E^W&W\A915RE:
M5$N+5&< [#NNU\:W!)X:5\94CJ=L&'^&&1JN_&#3[^7G/(^&+J4T@H%R,ZV2
M=O-\[IEPD_@*^M@@188HFE=1S=DJD&_[Y&W'1=#V)%>P!X/>](FVP='14EZX
M?GW0P'H=X.-Q)M,"*R\&TJ$764A4#1!_.B$1.QQ+1@XQ=A.0B<@ 0-6N1/,(
M,Q)CG!/AW<*K2KB<7^*@;*K6D4G@H_U8ABWYQFO*>7-,20T/QO)!;YOO7KNN
MU]W*8[BFM[21[ ZA*$RR0RW\]OZ8VC<(1"^L!7H&\/^@9943?><UB4AELQU+
MMNZ!\H1#>'*E=P)2WTE8O?W)'D\89DFY*40*E^!X!9[1G:TKJZ#OOI5NFBYG
MLZ/"47$ML;-G?0<O54R)[>3)T.#5,_U(4[;\B)75?=F'.4<^OH<9)*'K7)-T
MU^QBIGW=@61[SA!B%Y,(K( <)HM;-4[OIU,CN3%BHW66804)GDX'T 3W">U_
M\Z':&L'-4@2I*:'AK$+.O#VWK$?LC/BDS6E* -,P99,Y'\Z+"#9OHX3IO6Z(
M2JBRWNG4O&;_ZQ9.R@2EJ,!CG5:&C3\Z(T\X\+.L)SQ7\VYW6/I\YM\((^*C
MT+]>.G YR<H6>>B:S+43KL XC*J">H9JE('>C6"9W,^:2:#LUWF[)A@BJ8 R
M@EY17;6V::O9:S4T4X,C?DZ(HDWAV,]38E7<?<^U5YN-Y'/SC]*S,?$;9.8?
M# T-\]Y0?>57OXOO&$4<;3O&D:M>R&NJ"OK=:8"*05*<I1ZQ)9J/#OZ&XR#:
M*3!080=[!LBU0A$#>4$L:K+>+3^DY, 02>' ([_OKQ*W*'".YTVH+V["<_3U
M1NB+@"R)#DKY=*_)5IRT7ONI#VW'Z\^+44-W;QI*8/IF4RD:,S?*[(5=CXDX
M4=E85F[;@\>!P:<9D Z,(QR/\QZA:FH2%;'A+9+0-2ZB.:D-]P-;%0;I]EI8
MY);H9PM)2U][("DJ*?9[VZYJ85?<5^/*4!)MM5!^XA<<#>JH*Z_L"^E%5HQ>
M>5\,410D0HRZHL\J]L@;\*)O*-0W.;SGG3F6W*X-12(3&V&.7HP?=R\V2I!X
ML[%5JKQA[/I$<2PD$$I1;PRL\,6^RT.@$1)3/'' P)N#I4BWSS[J;ZI(+6%"
M#ANX%9WT.YDKL-0#UU,!>=FP%)/(WM2.,!&)>NPU WVV*P)\V\$$.<4W7%6T
MF/(5TL!M8R7[H-.MFX@56^IAQ1MX,9/=3XA$XP+7%6\NK@]A.?X5@^%_,ASS
M"GZ MMV@5'_;>^,$3+;5';&GI?(UY/#>IB%&\%.DAG?E-12?%5<^-FG<,<&!
M$2Y_0<2P$G),3C##XRW,=,:;IFCA[#!:@L.<9S>X;[VRXBJ"SNP+UT=<2[S7
MD /+.E%Q+(30':WJLS KHE@)ZM &O;TN4MX<4WPTW3B5D:=8NFIA^687 TVR
MBL9S$+Y$$X%].MO>0F\H7J&.YGH&*"A3'FV[G8ZUQ.8<2Y!&/JK/A88_ Y"$
MUF%?])X!Y4]]W,^ 0D)W\W.[@9\Q;J<#=G7'.C,%<^6Z6*0#S(@:OF\'*]]-
MM8IN46 <QEE7;&0@:@/-=F5+>:#]M!)^.BZ,AFZ<Z5:\1PHMYMK=8 "A2?"A
M!/K_KG@&73H"+7GV89CQUZ>*+2Q5^9!JSJN.JTHL6P)C&?\6S7O_D[H.O37B
M@+Z"NXK;/:>=+-6LZ7J@$,I*RW')5*3-G*,AF]@&F*4G"TH/32[+(Z?*NKT(
MOMOP>X'39.#YQ@X26?H,WT)8*/Q=13[62,R1)\7#NT=@ \8YO\J? MB5R/TR
MG=AZBF9M[D_4$A'.,1*[&%G4?'?$>#6P\[_-WI39$H<4)IF)7O_I-ESN+-A)
ME@[(;5I\HH'97#V4[;<TAJ*8LHY:U29SE9[6&:+F,2L>,<*5Y=;4&3NK3IG7
M>A\'$K8V*NN]*XA*$%\%((_8D\-<73M.XCUI5I!"6D3<+GD4F006I^&7241K
M),C8\#HY^L@$Q2A-8%Y.(R!4A:K!^AH"FY$D2P'3EIF]PW/#^_WH6@H,$[:,
M/Y _Q44_)KO@1@^RUCX&G)+O!0@AL^!O]S7C@<- %2,E4CPC*3(1.]@?D@6(
M1)N.,W_L59\^,7B(;8*U@$P4\12I[Z=$_#Y9D>2M($ S$5;VZP"NLSK\8:W:
M>;!<HIUI\/MHNP?Z"(5E01K1!A: '#!M08S!YIX@YO2*);I[X>3LEBO21G]:
M,BC'+?8'IJH"XLM_M^7^JIL@// C5[8_)>G7MTMQP93'&6(-GJ4.6KSMTY]L
ME2WP2.Y=LR$(=T9NDN]D'NPIK8Y#SOK$"*<1T;O0:I@' ^7$JC?&J0G0,U*&
M[,5W'DEE,\") CDT8"%YTAN1ZUB'"U)[ MK;LI=9X=T)6+-H(^/<Z9\"A.Y9
M1BO;.?1Z+@Z.ZT<Z-#'[?I#/FQ&D=V*W5$WZK.R3H@-+&J#S@?QAIH;>_1'#
M_%C"0V^^^70CX&F!]T2B/A(##AG+T1#[#1C"V3_7S9Q9/&@QDRM[;GA8('OQ
M+0#BSY@K%GKMD9>.)@K'2C&$!&6XA+I/<9UP BHH220G".D#A%)90J9=&^JA
MSX 8\=HZ!!6^;A9!7!6&LPU-''R:&8$A<(O2')MK!?NZ>K65MV'(.H[(EY"4
MJAZ @_7K7;Q=$TQ88KY-*EVO">4\?<*I*TI<;WXBH3EV7,%P<)4O=\39M2G^
M@0%=1<9:3HDT?-W>>QQL)8&WIH*DYG#0;+12E@3[<#%"8Z'EVU-WU :ZWG<5
MZ17<IP+FNR&K@?%#A'OYK5#5E#(8A<;<58;[29PT25B;'DI=#8?QU*]Q^1RR
M [B2W*;C=0+K3(J:&;FJLES>N:8$P1VI7%!I01K 074SY+:SY,7"5PGZ*&R(
MM:<2E#^CB'#)3"F2>UGJP04O3B*LXOTLAX4I75RY71XMQ"_W.7(DD28XM-0G
M[UR1,NW,H:$,D)-#R:[JA4!08/',Z*5ER-9GM?-B!WZ.QFSTB(@=<#L=3&/\
M[O3SK+&,TQV7$8HGZMN[_OD4NTGG 8."K<IP/A,BJ%ULON)O:><]WI5,&;"Y
M\4^I-#D2!C!WK"W@K+A2:,''%%3H(SG)#N859+L"1C/;1/!MT'X:JMGI5W;N
M[ =67#P#(GAB<9;'Q))<][Y1C/PD(^8/;R/2>\T(]REB1ZWW_&WD,Z":3,]\
M]-)O:J<COD, LG>ZE-6?.WM^M@VKVWP@/+,T5*P]3DG 7*?YQ1(D[\0(5Y/;
M!#+=8@BY4I$R)%F5;86]LWOS3I$Q@.+N8#"?8UOWF@+_P,LD"5AB9(M55['T
M>BD'02<]/@Y+"WO%"QFPG-L($V/T4/4HB'=%2J*,__1CR(;Y[<\?C*A*%TZR
M+L29#44'EWH#WN+)MPLH(+L<98*X*U)?H:MLM+\;IW^OVBV<>-4>(.#%7-^3
M R?+4J&@3!AUB_HP6?25J+CIOOZX4;36R3, O4B'8,TN\4%I72R,3A97M]SI
MK^O!=W\_A/.O>Y4(QG%&0!ZN:VX 0\3I5DUC/7(! Z0Q,P]11 M77:D3]U,$
M4R!OQ6BR.XN( 'I['F7,5^)?R_%Z.\K>RM[.U*?N4:3Q*ZB9\.JYB8H!'_^]
MTYPY:12MQ#:9V, U5<*4+&7A<NB1^=3D@NQGQ_PYKSM%RU?/#W_4G@&&SP"I
MTJ@FG"S[B9QHD$:8_TC)@4(D*9 8E3D 0!90I"[K*;?Y3UW[SEXIL2*B!;83
MA2MK"G8TS/27%3OQE&PSHY8:!&)[=3RK]FIS^QU!P_Y<ADAC;<-XS.H# OO%
MMZ3$@,G<IA(?W\U!E[I9O[4)N!71<BD!XS4;S,T@1J(OYL6$Y;%XCRHS5_YO
M,KS?TV_ITUYFQWA[:MFAPI5%O<Y_[;6=90 X9RQGL2>T=A>C2#-ZL$\LDE :
MX>U5P]3@7 I@*#X0+#SPXWGQ=)YT&2$S?RIP1M^IP77O<D=W&;W67?F \ =O
MT,1'[2(D<CC1MLGCL\=GO8WX43I#($%W1EDFEX=HC29_KRDR>R7Z#UZ/5)L,
M<T4L_1SV'BJ13CX[0=+/?SD:Q'X3VLCN3/RVN72[!$;(D%34\#2(3AI$!(@?
MVO">\T>!+;R'$H3)%;V V$B7A(LADC[2][ILH0Y<>9ERUG"%N4W&'%O\(76^
M2B0H*K*MQ\&1SJS8,HG/@,;1;/X-8$%34^CXO&':3QU&*JE+A?U76J@)_LB
MY(C=JXYO?L3SO HNQX9+LKUW#^)9(%IE,035?M=7C5?EWO81!E\RA6==B"+9
M:E&():F71XUW:4-U[CP @<$!HF, +WB\3AAPRR\+#,O3G*9P\G1G00LWM)%,
M<K-(H353=5[ R_.$LG37$UP:&-FRMVMEOJ^)M"$FS!)8?HF.Z!['?0#76AVY
MEBU?BIYDAY4C]TAL50B5EB;-L.^+/:T'@*7[UC@:YD2HK(IAWNI)$O-LH%U&
M8@:C07X:)D ,AO2Q!'FT[&?YRL,$6) *,DLLMWH$%D\5=0*-YHSSJP"UCZK
M5*A_KZ$:,BQ-;KJ 2+G(W*T?26^ ?%JK<"J4-@J3.U8)<,98_LU')7_"NW"I
M8,0W3R,0S*:>:\D>\8IVQW'6P<'698'G=N[LJB"+/SFN_+=\[6/Q4M>$].0D
M0@C>@#Q4K:MZR+:DG,DP(<?R,FM$:MW5&%J'=$5+W&2V_0Q /?+:F#KEY4TX
M'7G;X=9%SW+[U4YN8:"*Y]7TE-%>TW8EAH<73&]]37SYQC/Z#:;(>/B?O;?H
M4]=E7!XMDK$])5L8IXQI2DZE#4S)1C7P1 ,TB<&9&0=PMA']DR+:^1Y9I_**
M3<"O]0XQ3YK,]<Y!^0&$#IZD.F/_V.H1MJ7_ R)I27$_$@X8^/4,.-YJ8,EL
M> :$9X7O9I7S!=O>6Q7]'GID(1Z'[AJKEC,KV>4M"ST#4K;L(-WU-]#N+#=>
M9''DA @6BW)G/D@+<E&9#?2H67OL>SK2AP!?#',8J?8P4^%,,UW^W,\A&,&'
M!!4^$/-^9!DB9Y*HVW[LX(Z?]KPN1B7"Q4(D6]UB%WZ*_' S7-7U8X"X-B^D
M#/'#L*0&U]LS%A\IE=+X9=,L36:V_(U;TVG\OXC(S;.@=871Q1Y*-P,F;2^H
M</L+R,&((1D2*)W8>1=PW.=$+'NZ'F[GNO[Z*+4@N<7J3UJ3JZ$L 'RI11NH
M:/K.=S-6Z:II(W2/('2+-IF!T")>F@7#P6N63P@4\Q,I3*VZH?9;^O<@.@FU
M263 I3C<VII'1V\S7FAN#$DWWS3;V6:/\1DGP\*.QM(UKUG=-Q^*DH*!4!%)
ML]+#YLRR>A#>(@]TB&9S5%9U,WA(AQ!O!2;>HTO\^FB!_W>?8_%1RH2K2#P3
M\JM-3*M?<->\E>31!3U^"U";>AN/=:_-C^I4SX! <YY7O6A*(XJPU1)_Z]4>
MZP8AGM=P(H%OOBKU(*MI3JC6!=O=ZE!@/1KB/K$']RP0X/2)2.TMTQ-@GKQ2
M:OWJT!J%GG3,;P"*OJI2=K<$.=(RN*BQ*NUBE"8(/#(UW*NFE3*C2:O5M2#=
MRO:RT*\7RN.^VDF=CRT\? :@G("^7.O5I;'$8O;0J);F\K'QCV=SD#AG(I(!
M"Z#:%;59^"((Y&_3;-= \/(DYO".5R*Q2F?M79]!>?4/M.0R%ERRN]&EDH.4
MYG (F3>3BB*:K9RU4U8C\=_QWU]WG:8"-FL_$FQ;A7=OV,V B*I6'GL8+HI;
M58H-;,0)6OD]BU>E;6R775<^V:Q0VPVGVXE8X:VSU2(YW**@?G+_4,FHWA1P
M@'0D*^]=I'>DSNH^[W:K7K*"[Y'4*=9('2 "LTUUBX:F?6B9!V?71SPH!=@T
MZ*+B<Y6J_8C8#W"2'/#*ZKSL*GF4A(;6%23Y4F] I!('GL">\:HWFI/;E#AK
M+6EC? /J 9+>EO;.;P])IUB*']^69 >16&L04BOD2H8HS#(7W[P.$/ G\,B\
M'.B[=PL&%MO<<ZTLBXX<N0\28I8C?@^HCEX=5U/:]6$]]]T4#P]EV9W-U+>"
M..-*<0KR;>\A"^Q#*@VN1U;Y>C2BS3NJZYMEA9.LPHW@CKB8]4"@TY$?'R.X
MJ>"'*8T7"8D&3  4(0!/L8J2)=OUFGRHS:W#JK)]OF'X=H3$&!:)$R'Z5Y!=
M>V@S!K;'WEI/5SUQ:*1KT:KGK<[-YS/YWY2U[.+SBK706O.HF-P6%A"'6K5B
MPGS_/'SZGCHN<Z[:[2_!1QOJ:9Y%UOSJ,-7:F'DIY<ZX8CF&.<=@"7+#W-4)
M5V@F8(VF9AZ,(_,3=?X7JPW6;]ROPPDD8"]H:M4%I+>=;/*)0KH0J'M3WYQ4
MUUME:K#R[G>J.8L_XMJ7':=7?UBF3UW:Q'KEV%A!V5A,>H_%VFYPLZCHKSH?
M2R@49BPZ#&]G3HFA?J<]4H62SX#7_=9P?8_JA2_&]M"W,"EC?U([5/M0=LI0
MMR-%[8_=X<&T<4]\ R+1_K7 XVVL_/ZG94WFNZGJ>R^LQ9BO;GWZRM8TF?K3
MA//ZCGL*I7!B+XD05!$$M+?"2 2^^2";X"83J,OP5\H]*(*QY8]\*(8"):LO
M\K2Q=^#@(-\B<J@4JOEEG/V2!0_>>4P42-H4*E*$^N$L'DW:^=>?61<:;7QQ
MDY"\(O&XJ31.E)FVM$Y581\:936AGC]RXQ2D=>QB2*UCJ\5I56/E'(3R'2S-
M8H<1#EZ]6+%'2^]MLAC'3"V)L;3:5/+>U)FI9KM$9\A'D7SX[W9G3EZZ2.;B
MRW[D/NHI#Y*\@%OT==L8*N*QAX*[H!@$W^;K2E#;S!=>QGGA!Q9@OF:3SE^J
MGD>=\B V,IS*406Y<X8R>RJ'"PR,<DX T*WAQNL(<[+Z.U UK*=E\1?82S>P
M&B6^4A2+S$?_0()"-)$!Z]E28[%;U)^X_-%9&OB2^_4L^*!$E&]D^A#,WWP\
M%6V\*L"?1$ETHHHRPEVT7.;'&W?,;)RP!?R>B&S UW'TT-A7_S#_X3BN=:,0
M^HLF,>G\_2RO"G^O/[X/[3W:"D&%.?SL0B)$P%7!^'5N#;J@W=RL1UE/XO&M
MP9M?$[C PB/'M4%2G#9M/3S"\]\Z8\D_S0K+*J*CZXKCSAS?**7%EG3N!8C(
M]XFQMT(1 QZE1?L["@[CPC+G>&0;,!P@>E&";'$#YQ;LB 9'(I*>"!F5/CP=
M;9G"WC(X-!,L(;)L=H 1<@3@9)KL=.:18<K,E^4M2R;:0GC6(Z\@QP1FPPRQ
MX9M9@]4ER(0=Y[>";URH+AM1'Q#12DB4GP%1F02-IO1;'"=E/W/BS,*T>YCN
MR=NOTT3;9I\$8$F@PN@&YX.;K7?I.%3AG8]>NH45&:6*N.$@Y%;%W?[N=\@<
MMY(G J2:R<MO&A,VJ:(_QP$NX5_]0 _(+'IQK=@>:=V7/HC$[W5UQCR6/U8;
M"V!:/>BLMOATM+6,[@O<5G@;>J>)?_-#J&NC797.5B%=$A3N[L<X0O,"3%WU
M=?!OJ]82A%5T!OI,/!P3E:&!X%;H>J2),G!+%;3L/G@%> 58PXV*(&Z1(?8T
MB[69;:$\*+.IDBGM*2^>_6 9)0K7 5QN@ ']P-BZIJ:+\=@-ECN12(08D!30
MO#@,,U^#(IEO&4F'V0E=H-*]>>IJY/A[8\M,!3M#[)DR*_)HAY2<K/,3W<5X
MB?>6*'\O,>]JZIJ^-"V%54=X)KXN93*\JG9CO[P=(]S/BZ?8(MA SQ/[;]<V
M_@]M"X1$TUWA$;.EH,A7[5^B7BO"T7IK<[PZXC<1@*HFBE[9881<_48;=)R_
M&XJ.;<="NJ]S\R.]J/B3\JWR4;[<:&FH9+6SOIN%\+W# ''Z+6T-SLH?YH&@
M5F[QT*OC&5\17>+D'$^VW94I)F3]6(!5.@#P> !7\%<9I]CN-/ELVM#]X#CJ
MGKR_,#=15\=<I<C%\^L4#TZKZKO!/H7;0EWYK3;QX4;E60K6+)8'_F> D3_S
M/DL>HG#/4MOVG8L0I[I*:=4+ZOB0&\'RZ]^FYI.7UPQ;O@;AK=*DO_ICRWSJ
MPUWHFS!QRE5(GQ:?6=H6=EU^I!9O]!;D0V,7@38[07.+=%D)FV\5TLE"O&\1
MD+QF2;R?&[952'BM/O?+P2U]XUZ7I(2AA2C+.T?/Y/+BJ__YP&764]O'-0^E
M+?'4:?5W3\>/%4]X15NF.+*;@]EL=C-#G%1:?). ?E5_+(-4WQ.OF"Q[3TPS
MTD%2A"-N55Y+LA_DKJ*M-Q/U'B9\XV*6?;+QQR;A5FRK<WW+)HOYZK+LE$Y=
MK7U/-\+:>2"[I=4W5C2DV17)-,UPH\7@!OV+:2'>OB!XQQ$9(?Z9R04Z0RE;
MVP-)65SM?U][\4I9J_&=?M+[NX2,"$03KX5\&%")F"\89"U'!VDWO9U@N#R$
MZ:)LIF&<KN/ZYO0?"V.D+64U'$]LFN3H?RH8P5/;>P9($_L]KMQ_Z?CK5+_^
M$ZW1I3B6[86'L/J\ZS, #1:KUNC)GO(@+=GX<8)UA>KRPKTL'O*&5%,$5+KB
M0=+'OUR7S_5JRYA[,(+7**GC/:OG?=E3TA%;GHU],9ID+82OC8P=%=F"XH+U
M<]6C[.;/1\DM"HR5$1$:E>DSXC,%Y(3+80*L."\ $GV 8.0+ZCD4H@_;-.;Q
M2$!#,9K^Y%[=]+UPB; 8QU(OH"M\/_VWO@DEE.P\P@_A^#;%L?-R>>4.S=$:
M*737_"<WLU5&4=;@0KFI33)QOC)^CCG(G3C]:V.X!>!^(R()!)I>."EYHVQ'
M8/4=\PWD,.9'-@8W[&>Q9+F'INQL;9L&$<^QBLF:X4B+0P,2,L#/S>0KDR4M
M<56!WK*M'^^4JW#L-_S4L=-T9Q(@T"-;SL6EQ\J, 2YXPM$D$%2DMV105U&1
MT8I_FC$EBUU*>CT(1SJK8\">5#AXJ6=3[P9^!GAF!WYHF V4('?=. 8Z;U22
M-X5R31^E)@Q"Y(P #AA@+G^A@;GLT/6;+].HZO+DV,-&Q7#[7#ELUX(B#PO5
M S8@5"=YLE:%A!J>B&* DU>"<.):ZCR^_>=ZD V<0?$K,\Z@ /0?)ND?$.2C
MMSU;X2L'B)/=9HI>R6L^U!BA-_G;@Q_A0D7I]X1G0)86]E0-<=SEMA^:?R%2
M;AI2WA-?KUA\*ETZK!?RB-/7-X0@J1Z^X62V%RN"2Y0@!VZ/>4M".<)JC;E[
M%N93FJ/[<[[<<!K\LOK*\MHH<!C^@^0XI_%M^+7\E A'R9'C\I^24U"F.N+M
M(!E&0X5^[8L?0UKS%A6:7K,1>XSK+!Z[IG3657B#*2=Y*D%.5'KL;@ NV] _
M>]0L..*:*(5,W)"@..2N8'JU;ZU8V:%SPW2-@26+A_[$=3NS')1U_%ZN14N]
MEV]^*WPF-+H6%.@$+Z/A*-9-+%V-,#I3?K]S8'[<SG,0^CU?T#3SQ9XAU+N,
MQ6;OZQX37;A^GEBIPO9%-CI.MU!&4FRO/?&B\6H/_&K?(\8;KD&\702LZ.S+
M56%=JJU8_#5@.PJ4)X7X*:5 DF3%@#Z*K6=%L3;^-_82ZJH3 5QEA;=6*NAK
MP]3:D.676\<HVE/LG[C>?%Q,L7DV3L9#;O>@-*/! O+/@<K5\4%(_0H#+U&;
MQAN8#YOI3,VLX9(N$@OZ&+3G_&V[D?GK;BRR$C3SVGZ+OJH V(X=?64L120%
M=(L;<K:#@T_TNL20H\0Z$M;-6[&YT77+LFBJ#0)^>;4S1&C1>7@9'V%[F(QD
M0Y:K!V&K_4)$A<4H2[F#R1D@^?*3F[U#.4?$12&\"O.BOO3>#<T,&4I\##@6
MUS0Y9%4:CY+-P6I0J\#*2GIE;X4Z)!W%_(_%(;F4%ID(P&:@H7M3S.Y&.)@&
M7D,CH#IX%F[V<\+9\/S3"F3-4-H9:6> QVSV"3$"\/L<Q[;9-ZMW @'HO":1
M:C2_\*%@TW'7SE*C0US56XL8H<JLXE$-ZCJ?X=" WZ,<Q,GE.\!LA%T$"_48
MW(ZXTK\:04FCJ\[L7W[)"%FQ9<I?%%B#LT^,A439;16M'"LC2"3_HT]P+G31
M GHN0?ZN?O[P@85OT=QXWL_<3&+D;MWC 3K?;$K4@U:^CC[]-H$V5B\02UT"
MN9!OPPL]Z4#\8\T#QF+[$.(29\/@Y4!*K$ICGYBAH>>HG!YU7'?7]EK B=ED
MK/3+D^TW04#%B]NH5J!]I:FAGBV.+86-(OL.UEU]'V)*7=KYJZ!W0KI4OLAC
M%Y%]NO&]FHJS/E(,57+&.=DV6R0!)_G!@2:;WOF'S8DTIH<W#7)B'R:0VU]2
M.3R>^>0%_*TUH$=^@/FM74 EF8"(8Z $1@3C1@A5*&\,XRPS=10\7 #@JFCJ
M'UOOU><J94,S6#L?=T!JM[%W8]+92R2BG"BQ:\H/_1,=:M/%:Q2GT7["O'O+
MD+W$R<SM>S_7*1VLV[W=*>L.37#167&IKTGEU3/@+P(EY[B_7'I.^:$C4$CK
M1@.ZQS&\OFHV^>0:LI&AH5N?)M=^9_\%?92\ !'N\O"JSS6IWZ-^V)?C0W#O
MLM?3)3;^+B*T\GW6CC^&TF'N[$S^_>GQ,^!-=^FN;>YA1]$C7$UNF<WMI*T.
MYIIA_4&!<0]DEL)1!YA1F/&SVEWW)6QI$/Z+A#[_JKPRN9_B*-]I\(L1$ NK
MJA3,1*QO]+ @=!&@;A-JRL(]]/N$ DO94P\'G D3AS$HV9;^_9FEP9J1>>PM
M7L^ KL6=@]R(:TT58](*GI/N",9"&D.)&?%:^V %[C<"5K>B(>Y)HQY2NR)E
MD9H!FZU=9T+$A\<1-78ZYC2IZJAR4N!.S'<1>I>.DUKXQ):%/VK8\DWT4J59
M+E7UKD5FA>9K['-LG@%?FG0M5S"941-4A!7F3EU;L-RM34=6M,Z-,&4_O3[B
MT]'=(O&&<#J%5#>I=+TE4SS5Q<)FG!>8_;=]9$S4/^EUK(>H]$H&:>(<O!8H
MMM3(Z-,<;@Q<;'B['2XY[S#OO5,!)X=$0?\?LW<ES3/@ZW$O^>=G0-U [-D=
M2\2Q#^^V];5G<O\33^@A3,ZTB:%!%*,.X(JO>].<5+JR-%HCU1MP/!.QXZ-8
M0"*<YXK]M&4^+A[2<7^])/F&;^IM=CAUE(O6!\ CBWBOF.D-V<0/><F&XTP6
M)0W'.%(T7'7CK;^16$&)4>V[M[EO)C@7 USWP,+EUN/[R'FTF7/N70;*MLMY
MP!1&GV_H$%=1R,+%D[]2_JQF>KV<ML73V[/QEAYBY@,#5IU>#,%VSV]G X]"
M?GA5LGA[JJI.3MXU"GVRM$$1C"6,_]6LSW]'F$,KB]&$NG80;RLN^T6? ?=S
M'G'9"1)P"2K.]1O'RT--'_T&OC@2BO?Z3X@G6>JHL.N=C4>)\D#2GPC/GTRY
MGD(^?BEW'\D2,V_[/>N%/)L;T2@KQ\PX7""O8>=T]&*ZZG^7RM\G,^Z';"7!
M]1]I?[^BO,:]9X0+GK%,[,JD!C'O+A[J1C>OR8E0W3[)7_"NZ7QNRX4<-YLO
MJP2L>S%Q#O.;ZV7BSN]'N%\\57YO;[@S_RQ^C.M]*_#8YZKB;?T@"V5[!DP\
MCGL\'1G%6C7<^<<OJ,OB#;O\SVY8?!$:YF;<C\B_NA ;"W(#1)X!!M.0]ZU4
MDN\Z.!L:BC;UZP[NH[\:1.=)4G8=5?R9.3;Q=06R)8UT<9U:"MS/F95Z,WDS
M?;EY!G!<"AUQV&-8M]-U9&7=Q4W)XAVD6\PW:"RMRCLB]>1,S+HCM*QRZS3,
M4:]B0:C_P":TGP''NIE:-RE.BZMTO0SH846?A(/UM0H+6SNO@&EZ')3O5KH3
M95;5%RBG.2.&IY9H4$@5]*C9!>"R<0V,"G;S=;'VOT3&8=BF-KH1]4AN-\RZ
M5!C(U%[2-03[O*=PUZRU6J=OW:9-3U 42?!>J#UJIFN])\^QL;+'Y3*B$J>&
M7^F)3_=>B*RN%J8IT=4,U1!$G [ 3C+.<XTG+"M!S7>C*:!3L;'AO5[123XR
MT-=C#GQ)=E9X((G>!<LK#6O)=,[7-*F]T("4D_E>G)USX;!V@:>Z#BN[^N0/
MAAPLN+8!?Q!8:/I^/ T0"8C9;GA=5S#Y6*,S1S""H?"XVBR0G^X%&;D_V?>H
MU'43N%4YG=QDQFV13US<:F#!.K&*=;1RZ,?AB+)PE7?7E3K5-:'=XRS*+DNX
MRG6REC#SGBD/?Q6LBUN-S:+$V7L,,T/7H?#RPCOSZD>?P0+$\MV61Y&_9B[-
M/_X/[XY\D;%Y7LDB2$CL7E/BMX7*;4TFQK+JPYDD1<8!-\UY\$YSADL:]T_:
M%QWJ@<D7P>;;,O+=^$KL,>^T7*]%QS2F:GLL450$5UWYN3CWR>=*]&<B[3,-
M.[I(=-,UM'*J'TW]+U^\3;U@T'^F*6@ZQ_5P?O@$WUQKSZ+1<)<31VHW(*SX
M)%_GPJ/=[?2U*??]1F&3_KB':6^P3GCY.<'0[.F3OKE9].(3I?@/<$R3/P[,
M3GD(1WLZ;6B.\B[01*13F,+_&:!>\LB[97W]'0@,N>0E]$C&WQ8XDH>Y591J
M1FV?,IW.N3T# BR1&ML5SZ=NGP%!+CSJLLXD_[\4>_^W8@GTDCIR>XA[Y1"\
M8V]J;E"K-<RL--KL2J>JI+YR>4?C86&]HP$N>D,^NWS&NXKE2C@Z&=# +'Y>
M=7@-IIO:BAN@3K(4H(Q):J? /#\YLO_[4^UUTJTH@,IV90V/KVK59=U)PXPW
MC15-X,RH>@H-1&[)!C:-2=AW+(>(" >/6$:QEOEUY9B/G C))<$S,@O3?V3;
MNI"<$,ECKVYOP$JS=7O2/#QM(C9N2+;L](W+BK_I0:-.SO._KL_?Z-M>MHVB
M@^Q^[/Y +<MR/#YC*<YMZOPM"P,6_WRW,)\CW@J'<^=_?0R>%&$QSX:C]4P]
M#"6V(MV>1.]N *;-B[S_Q6VX>.J)B,:TPS$S.R>'KCJ(=AQ9S$;SFYU.86$N
MVI%XK]Q5.9MFL"'V#&[E/G4\U=..EDN%1F&_A736=4$U(J;2\<66#"&S-5&.
M[3J;F*[T#8I#2\@:ZKIFOE[U\0%Y/A/=E&? R@OW$(B*=(DM2LN''U:(3_IP
MD./'9FU_) \-!4OB]O*62I(?N69/Q5[QQZ>0XYFZ<DZ\[[HU86-/H1\BT_93
MAOQR9'%UL1K_A]'-BVC-\A+R0)Q9BVC_S)+I38-DC9,(F]KU*F1FZPAK(9JL
M8:P>,F?]-;718OI%0@6PT?-1:_\ 7Z9FORR^/!=>-@7O'J0#1/.(]?)/&?(3
M;,T<LX?I283-#EYMZP=_Y_O_!@C_:0=D*I0BY!E0:V$LKYIXLIQOE!_A0$$6
MV]&Q;\R&YW*DE/ZW196/F_:L,?,G9G#KJ%4?Q6<4Z'U4\&W[T\%\Q$+02TY<
MLY #_PQP=LDZ.L/T&3GQE373\TAX!O3<*A? X@D+'?$.B%!%)_PK30U69Z*U
MQY3]RAZCM%9%F4'KC^-K$18: R+*K*J5)*AE3(,TQVI@S>S_Z?#/0F$PN3T;
M-X*/O8..\?E&?-L0]S],RVA*I-N:KOYG[D]DH71,FZ0#K\Q$^Y*^<(0E^=4X
M='E8Q.;Y%22:SYQTT/&178A_NJX@W.7/<HO[,T#\MQ"=$F\*+QN%]I/ICE9>
MSN!&S)6Z\3Y1E=66X8/,XJZ5R9J5.FSN"AH9(GP2: >QZ'S2'E7_<"AY!6?X
M 8IV>OFC"[/7@SE#;79>!5>;L?@@@#$['3434*K,.U_BQNKR+6HZDUA"3)N\
MZ:DN_]..S)$<BKK=>6N*'I4TVT@ZK2WW1)MK._Y%8$V<K5<]7;N=!O=@Y#.@
M\K'T&1#Z2 ?,X<AB(B X$;-)@_FF/'HMR!I=5R&Q*_GSKS^]POI:>%?JDW(]
M^W(\6_\/B.;*E?\X_&P?**S,<O)8$7P)[A2[ZH+%+#5*6@7JRW1MFCIA*K&(
MMXD-*U&NXJ:V>68%:JX.O&@?SA)+9;PX9OV5LMY/Z2RKU1DW9'FL)(N$B*UO
M&URG!J?M9:T^?;XL(U9.2/YC>N?YXC4-TP/_2_+"RG(V5Q:=^M80R_#F4#+1
MKA/;,=P9FU6D_"LK)/JD"IB4?./4:F7M2K*W[NYW;_]OC[(N0@P1/*>.KWL8
M4IS$KK!)W]U[Q1: =(4K8.)J<^DKLFG**SMJ!$1B^>[WU^ L('*S]M2M:2GG
MC5/1HVB+?_R4NM&[^5;932>:>5#T=9P @;I3IW<6=&"^V9?#9,;UQZV^45X]
ME[F(P'W$N L=_%CS642(WA#$:G'ZQ4AQ_D<W/!>#V3:;O_:)F$U>(Q3DAE;F
M$8.$\Z+F?+AYJVPJN%F-E9X!V,^ Z(^DP<%=E1KE;<J2M;-<#SXEL=#BXVNR
M(S/F[WYHNO:70FWE+#:&\JM^926=4P9"H>&>10GC:5O/@,SPP4=?%GKO;Q5Y
M7.\?M'1!I#+,[=IYI[/#%4B:L6+0L_J7L*FL?5;YL=9H^!G ;T&FPC?.9FCB
ME*I=HN<<[,B +$[Q#- 'C\A<\(:F=F]=_*G_#3Y$'"Y:=+_/FF[^O*D,BS59
M]=\@%9O6G$Z]>\EL@YSN34.O3;'QDK?Y#!QW+'S&1</\*]4JO-A3\I>L;X+6
MAK&(_;&.1GT5SW6MP<R-X5HSEHN-&NKN7NV;LK@Z"#G_*NGEOR1X:'TK^/'G
MF=K1OA.F!?33<]'TJ_&\.JT=];]B?7L#?0F:[I$'$PU:9DE[\B%\0D3I#N(%
M*E:;L'FU6M-!.S &@_LJQ;:^MRX;4V66=(G9MIK!^)JR/PQ>D[Z@$HK)5\]0
M1@X6K[RL*",36E<-&PD4%/><T+F?RP80P@'457&G?29TK#1:$G8B:KW]LQQ>
MU$?S7U6-5V]1WU)B>E#>@JVT+L1^>E-ESKB&3 IB(,*)G[TX#Y:B7# >@\H:
M>^\X5FIM?*]O4=\3^9:'KDZMZ;:J$<;^7;"!D'M,K?<TMB?QN%T( R'@&= V
M\[O/92ZKV-KK<S$&A#4W/A:ZC?8,\$4'V@-5_7MCQ_R3^TW&'6%T+ZCDIQN3
M>2HGK0;K-R^N]&#8S'%42B?(ABI%=@[\!2*XJ$CSF_"/L\KO1_L"1[JV]@+,
M)[K^\QG$*QYO0N6-U+L#\GGE[<@[6[=:7<),<?Q1'.VILU.2'$H+O\8*%GN2
M P(1WX9A>T7UE.M^9LO0TO:)(XU*E6LA8N8HXOD4YU@&]3J?&VRP/^M<7P+_
M [CB2K#<R&"5F#ZSIS@W0OJ_Y^X*:W)]]]2O>0!'S-_OV].^8&3X \F%>4HQ
M?I=#LH@/\'O2KN/N9:+6!S_51C.-;+X/T\!:3;O2)6'H):3_E&J7XNGVI['S
M#Y=-Z$/_<J;.6C>:&/>CD^_FW?Z=3I9V<3L+AX[\/.43F2_ZU*JZLC"\^A#M
M!O)^'0>)=:J')8&XS7=_^,;5B86B8_VR#>^R6XR*8UT"D9T!HNZGC@V6[)E6
MP?Q##[YZ=9;8.^L>9[_/66QO[>[:>!YEQW0,6;S2-V<?=;<P4M2JC?GF&G\7
M/O3ZT=QA](,-/.@%RE.%RPZM,IK8M4#DBT?^0D<'Y:7CO#0CPPE/S6<@^<SO
M3;,9SP!P&NF6/\CZ@ :+;K4:%1#\!J,G:U^7S4?>7!#"PMN:@3PH\'AL4F9T
M>),2?'M!DW5NCO@;;*(XL.GON7!:H@:+;TB=N5C,(*/],#@\[(4GB'O4Y8]V
MQV[2?0-T.PYR$E=2>:*J>1C"6T;?KKS*6Q[R47^HPS!#\D<'[A<]POE%=)+3
MO<MHJ,>1\I7_BQ+,C@+SL!JZ_UTL)E]3NZ0]?P3%0.CRS_*37 &>@:C4L.FU
M^X>&7XZ:87(/Y44'0)F9Q;Y^91>A",9"A?\><J.R-"E'G)U\/?5!T=>&X'[D
MA^[15JERI4T5NIVT-R7;8ZG15L/G^#P-4U3#.V(M'118+CZH?KYF=.W' &S&
M;Z%R]1E04ANSJ@85-UUX9!&WQZBIS&F88^:(F;JVDE" H]W0 <VW%"U;$'V-
M$0\53WL&5&AU_&('-\WR$M&230GY=6P:\#6+1F>BZASI^>,\#ESGI9;7ZURC
M*V'""L8.BUX<]>#HT]3<-3LK2+95_LE@:.'Z&0"G:0ASXV;(\.=>5?+:2?</
MKVAFU-*<MWL&+)B):"74\0ZW-CST#Q#+!-+(RI*]CGJEFANQN/<O[5KZ/XF<
MMNO_FM8I";DC:9O7U=@NOCOG[++;QO45;HQ_CHJ$N@7UG?'3?-=S\@_[ A]/
ML?6"]G>F[E^7;??\X;_)3-.ZJJ_87=+_SR#L*GK7::W[GOGW"J\N9]WD5ET1
M=\OLEO[Z#_8O5_QGX%I4,D?(?HO^C_\,R^[_S=)8]V/;.3?YF_%?!?;_9]@/
M%+'?M/^5(K"W5[__UY7 $(_ZU/HK3O\9_@$%OJ[X!ZR@5@!;PG__@4X0<F7
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M_S[=6K3@D$;@"S;-*X%1<X@Y[9S]_TT 4$L#!!0    ( &:"7%;@[WZ=:#L
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M /7?#"0(  F"0((0D" ,)(@""6) 8  (# *!(2 P# 1&@< 84!@ % 8"A4%
M83!0& H4A@'! 2 X" 2'@. P$!P%@F- :  (#0*A(2 T#(1&@= 8$ 8 PH!
M& @( P-A4"#,?SS^.QL$ 4 @ !@$@/J/%D00 !$$000A$$$81! %$<1 P  (
M& 0!0R!@& 2,@H QD#  ) P$"8- PF"0,!0D# .! R!P$ 0.@<!A$#@* L=
MT  (&@1!0R!H& 2-@J Q$ P @@%!,! (!@;!H""8_R3X3W$0# "! 6 P .H_
M16"" )@@""8(@0G"8((HF" &!@; P" 8& (#PV!@% R,@84!8&$@6!@$%@:#
MA:%@81@8' "#@V!P" P.@\%1,#@&A@; T" 8&@)#PV!H% R-@6$ , P(AH'
M,# 8!@7#_*?^?V:#4  ("@!# 5#_F8$2!* $02A!"$H0AA)$H00Q*#  !0:A
MP! 4&(8"HU!@#"H,@ H#H<(@J# 8*@R%"L.@X  4'(2"0U!P& J.0L$Q*#0
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M6KGD=VI\'WU;.Q#/X^FZ[B[X3LN_!C+C4=?T\,QU-ZB]^<LF#?Z/OC68U<\
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M%@0;P3[]>U!),L3 8]U@*SF]?(P,N_*/5'%_3-*<MZ"XNMS8!<6N=RR8=X/
MCR1NQF5E7]D"+*D'R&D(J0E$2E.4=^G8?@YB[Z3_.$JD-%6:M>^%OTI"QV?2
M^%&[6(F4V]-=9BH5:1&\&R<ZF?SZM)7 C$B(;8'@(W8OW")F74"10Z*0BOAE
MC?T07V_<X=U+2N@0FRG!4P005Y9LND>YJ*:[#(L1.3/T3&+X:5+3M7UB>W["
MDIS*B5T<82);<L30\U85?N8DSMYXUVJV#SW#V!QXG$OIU7S#+R40)[MMC?-
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MT! (&@Y!HR!H# 0#@&! $ P$@H%#,"@(YC\$_Q$'P0$0.  .!Z#^(P(' N!
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M2#@&B<(@,1@T (,&8= 0#!J.0:,PZ/\E^V_0_E/[/^3_]?U_D_]_X_R#BP4
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MG"1[&R%Q"Q>[^ %?%T/%ZU,^42%.\7).'UQB'U>"NL#\CPP":1L5(P+P99G
MDD-Y]9/\5^:52K8:A@I*@: B<^K NFB,AJ6GNA63?OJ80F*@:O^/*C1^]0!W
MM2M3->1,3W/]J7NBYEZ[EG?O4_&7BCY,-1:@&O[*:E^A&H77ZEI'[QB_U$")
MGT7>U[B'@Q?QM>-I''9H(?0=S[4LU)YH,(P/!8()+<TG U%_8@C":L_ EG2G
M[RNT,SZ\?.W-F^%5]2(MD/=^B'V3B/*JYXD/OS O423!4!#U>@F6WZL"1 CG
ME*.K;-8P?91>3T)P=];;+UD D_A:?( BXHFYE05/0H!L+;8$H*&/ J!(&&K
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MA>6C(!'1#_UG8#6X%56=]>@'TIEF&Y>I$CA1O<#<!Z>YW2/I+_7$S1Q,KU#
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M--@;AXO4@/1&;P19E38<,5 SOG"7;GOHN;D>C:[,Z3[Q-* !IP,?P8W2@HR
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M"&TR. 8RO .V0&WJZ(. ,B,Y"*9CRL.>&(UCDN:>E&,X"FJ=/.J?9,T&&RB
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MHE$8Q@ 4 &+?/EXW5!R( 6>90('Z>,6( ># &% +!=*+%,,@#DT5]0T+L\+
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M#KN/,F]MLE"PQ"[+;$6[&)!#40OILP@ T5;4CD&A[+-(2S>$H8( IRPTSQ8
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MB8PH&2,C1XYH(R6.*(DEC6[.\"J>7.!Y9ZJI;I3))#UE(CN$RV1"B445*H
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M&'W1'-W&&9W&SBW='@VLQDW'I+MY8'56&W0G]SPA?BP0FY 6<$T[[= 2!@
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MO872[W]M>=3[.G6^B [^ :W*%_J6/-$EO^68>8_[BUN&YC4/1@!4<  5!,
M*C! #(Y^&W:H  $_1Y,^%A$#AD%$'UM0@0[8_W3\YU^8<'W5<5Q%'192 UBQ
M-36X/[4"#Q+S-07T!>]Z!Z;8"/ 8B7TH!J9HB,GQ$ .\P$8('MBYH4IHF(H0
M%Q]++'IXDH+8+&Z[$4UI'$JP"#+_J \P\@5-$!A'$!'-J0\NPHIP<RB)&IT(
M# F:R('ZH!F$4(9HV+Q)J1C1&YZ/"I*A4BZ9"!G2^Y$QJ(HT(!^BF,&&&(KR
M@8I=@Y*IR(1=0Y6)2T(+R@S+""^80S[$:*]':\-!D:KD&R61RZI7*C3(F Q&
MPQ/!B*4W_)^6T[.N,4-($8,Q9+5=4(N;@A),V((   #+PPUV (#=&A7W X#X
M@X@R,4#]ZT1/!)RHV["[20[GB"8X6"P)(P_%H02N4P]E4< .8[%>\X58')#9
MHH=)H 0P"HHD.Z>ZN[L$T0<$\2?YLZ*_0Z)HXR%W"K)_(HEWP:P@<X1=&X;\
MN):)"!#R_XBLW\F>7>,%^TL8,QRS30N](#&91>*:EDH91FH9B,M%+VR*T=@2
MJ@@*>IBSIT"*5?FI,QR+)*P43R(;!* +P%@4JK$E1%L:5X(EXTL:_CH40QN,
M]=I#2#,:HF'(J]&X1I&>H"HJ3;,4!$@#?:BY=:#$GW._[\O$VGB-2NP4?=""
M $#)3XQ)F?0@Y* $[*BK6HDUZ<@.ZN#$M&HQ]\"%$6N6;R(<,'*'6<Q&8D!*
M7+B/B:B$=2DC@XB7??$Q91,1)!H#H:2<,7#',[(7:!R#V@H/'\.=-!J&8G&8
M,QJ#6P /8BB&CD 0#\DL^2@/$:F)')@$-, ><NQ+X)*+DUFIDO_) 2/!@2Z(
MKC=PQRZQ+B=9O97YB<6:LUQ,@Y:A"E0\%7TTPZ_:"5XZ+SMD-$)!)<98JOT*
MS0#"FH8\30)"JD5C+]1\0UJ:--)LKZUYGSF!GWX,*Y>XEU>;Q 1@OTM</QT1
M@_.S0$G0O#" @1@X -=I!S0( P.0 30@3L:1A#0H2>M<P>RDAT6 @0/  4JB
M!TF( 0"(":L0!C&( 1C @>GL%C1HQH:8A_'\/H+[N7DPNGD+@^\3PIGL3__,
M#0K;E0PKCN@0Q>*,,'!*0!#CJQ)3#Q5;0'>2RY2 .X\HEP/QEXL@"#&XI[4L
M(P1YF XMG1TC#Z?,+&3T'9-@A!MI%H<K>I@'U:<9D4*_Y#**4T*_? DQ$#A#
M,C.181(K=*2C@)G$K(JGL*2J0 KS<?\S5"$&'(B3 9,?2.DD3JL+K!K-SY3(
M/"D42F-(_G(TTYROCYLEP#B:B<1#!CJ,+W4EFNC,C903M&"]5ML%DLR*]#N
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M& .S:%->ZHS!= "ZJ)I$X]C?>\W\L25(>TA3<KZ^0!K_BAH^-)K4+-.$?"4
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M#I)*.JE1<V45Z%B'\G744VQ]^A5;@^K%E**%2HKGGC\1U=-/AKVQGZSJK1,
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MU0^!-764I#,XE(,,E%-^UJB.UT?JX(!]WKE;]47E%@ZK)L;30D+_P2EQPNS
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M\,)X$4\F"@I5;,9UJ8%_^2)5>$5PT,->5*($KM]@A,I5@:7D^,09-<FI'==
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MEQ4-G() 4J1 ,8$1ID8OIC8OON=JL (OA#41<% QBX8KIR)"KR81=^41^O(
M:%56R: O9(4 ^A(N/'00H6<1&]17'%&+W()J"'%!P-=JQ$=Z3*0#@94J@:4O
MH.AX+S%9 O.$W,B-UJ<P$(-]US<M'/(P4"$5HE455T%&2!%^62%;LF5'8;$,
M?*1'[ <7?40,[J=M>T$S-,-(??%;P:4).]-_-7.0^S<8 VAOF51="FF #FF
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M4?&^T9P5[_E:'G._[%C-7G$R9J%^N 6P  I(!%RP^8<7@V&PO<5<#&P9-@.
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MXF(6%MI++_2Z"U]8R"^E!D8P?QE8*(@A,,1 1AE%;%AG)/.PBH&"-(RA&&5
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MR>' '.JH)?%P&>0[*%J1&"8C3H+Y5"8RY("#E/]26D]B6ROJ0-:8T^-(XXY
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MA9C.A/3C^\".2GK55]E:3/K:07I(IM #1@U(- P#]8%?1U3?5)EF:XX?(SS
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MY\:!7!-R_ &0/,?E=#\FI1Z4P4PM2A;%SW^7KW>"1VLSQ\0L;CZVC<2OU.3
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M+?^HZ%MC%U1  !3H $_N;(=,AR60AY<!6&9[5)<!6DS5;J<JJP8:(5O5;ZT
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M1RB,X'<D]8LFGLB@)V*Y) VNJ]ZTW#1 9LYIO3PNBCX((8"#J$4'7UD$  (
M%0"0)8( ."E552"O?:P# ,K;AR(\.A1YJ"#(^KAR &+PK2/+]"D&"  ,E(R
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M]5 2(^H1TC,)>**AR.*D+/BD&/$_$Z5CS(0 5@>AI+,. 4!S0=$.=!D48_$
M#V0N>/B'ZV  9<IV1Z67!L!A0$$/F2 ), 4#*R"8^S")&8064U9ET$ (!T!D
M'O06NQ  ;(%GD;<) [,,>::) A,8!H,8A/9Y8+4PK[AHM4B:;Z6+JZ>:J9<9
MKT$:Q<$:K-$9242,>L57O,=IL\FJQ9$AN7&-8-0CX;$W#7E^;-,=S %N_Z>$
M- 3)69U4-J!4?C_C:Q I?OAXCL6&'H4T-SR3(<)%(:8E6D93GIATD.[Q-O8)
M-PKY',]5(/W76PH21U@$63M2CTSCC=57']/A1R 22;)&D 781UMJKT$Q;PC:
M)%XR2QLHDAVY) 1ZK_<:0 )4$ZISH5 W)[>C.\<".R"1H2Z($1AG$1)#"6I@
M!%,!&(K'$<+C*4]W*0<U+T4Y)_ET+LYA+PPV$;G2!3LG P_Q3PU!E>>B"93@
M&(U23S(@4^@"/&JP3G_B%<K@&$#1$1P*L1S*)TH7EF#)AC<VH1?U7C=&# /[
M.$:6 YDP"9F@M1($='H*94=A%8(X%(3X=E4!!O\KP"B*$ !#-0^+8      K
M8 "7"79K2G+[D'5=D2M&!03Z$D++T'8R@!CY$ -X2E9[,0^%BYEG95:!H1B@
M=ZDOY%8W)&F=^JF/MADC@XNKL1FX<8NS(7L?(QJ Y6FT.3+%:%BQAC)\E)NI
M1ECV\9N_*6U\PWV+]2)8E&J9]39*PZW/*9_EAUO-*C<_TGVI9&O5>1^\RWSO
MH8_).T=2HZT,R45Q1+W-<7T;<I]>,S3,]B#+(2'?F'TV\JZT]47:Z9P >#0C
M$C20U7R:=#:-2+4/N@P%FB5>PJ"3@R51XI'_JB3$8)+Q&Z":X+11)R<%#''X
M];! 8%]@V!(0EQ$=ZB?_$E:T0%"775B6.TD0X90&:C )<+!48N J/_"71$HG
MT3 /";:R]( \O-*(R@#"LO)U^I 1"P8LU44/11>E3^IB"9S *?&P/U!C<;),
M"><3_PO 1S(/<'9F*Z!D '  *K!U\.*E9@J8=3:VA1@4:D%S78< ;7&'AZH)
MR@ -E?>6\+("4>85#(1Y;FD$<1$73X&HCKJH?^&HB)$7!\-"+^2*@>$PE1&+
MF%IZ='5Z%2.JJL<9EU:JP:@)+>,;KKEIQ0%$S7AJNU>;OX4XB*6;U[@=7.2Z
M[^$SO2HW9X2/'V*>EF0?<"2.U-9NFI4V=,1)KA4CT9HC:F-*SVHTR<;*-D(U
M_\9KRT3SD)WTG?0G1A(Y-L\%2,*[O(>%(-%F&VWTG]3!;&<4&T<,P,6 7OJ*
MS4R2"[KT"_Y;D=0LH/J I0-\@@<[$2X8DUX9I?C37Q]A!)SVDK$9/\(#4-KS
MPN=S/3M9$)HP"6D@*98B*5/I<^<S)P4!!_V\/@U!$#^P&G[RP/9C!+<9/^R<
MM$C[)P:%M&09$P:[$S7A !1%H3&@I>\"SD9BBEJ+TIG 9Q/4IGKK8W<YMHGI
MB# 09,'@I8?)=X")%77[I3C=%15AM7-Q9[L  \JS#'SHAV6%9Q(4!V2U>9KY
M0H0&FHT!0Z%9&34D5R6CU:O'&EKMFG:U5Y:!&S]$F_]#]!FH88RC-IO 4<EC
MI#-0%"+,2)S$]YNURH_+^1P)*;X8LDBQE2/<632X)2(-R2%_E*[92X]-8YY4
M$TH) LS1BKV6138<4H_/.6RUM2&_J]BU3(WN(<J<M3C2%B+/64A\[30ZXH['
MM9SR:;SORB ;4=)'7 _SZY'Y2Y)5<H']QB7%L S?'-L0.@9PHCI4=V,FB((>
MD4TN=G1&FR?2E!*ZHSOHC!&\<BLR,*1 "5"I,@D![2H#W7($X7,\N)/(@Z+?
M;2O5 X88O2S-DA+29#L;FL-A&(9/UX97^H8VD5&<^]M#\F,&,%* " .#JF5^
M:!011.!",64]G2N$L+:!2D'!%J3@^1!Y>6JH&*1!=#?%N;(+;N?%;Z$,7 L4
M<CP7RI ,*Q #=S#;*22IA?9Y:>7'I%>YF&N:H('6(X/69NV:D(:Z9WV;R:A[
M;!V;KYI%&0(S-:-KPW$XM %LZ7&]V8$CB--_,Y/:$]*K[9:0H62=8J1;I>5_
MC5VNG+6?KIQ&LJQ<@N1LAMW+[^O9R N/;L-'XI9;.6)MRAE<8*.>KVPC<M2L
M(>*?BI,XP\R\_X$>^QW;LTV@Q/ .&BE+M63-!.K;A/]NKZ#P)BMY41B*SLK2
MP])]Z8#2WC"1Z1'U<=M4A,E34]QCH^7MA..TDXFR/MX]/M4S \>R="\QZ\Z=
M="OX@L$RE@_<AB8(+5#[$T"1&4'A0I".%(E;QE?<Q;EBM?>R"V6[#[4  #\P
MMGDI%&O6 &Z*TP)P+[4@>10TE\ONTWQI>0J^9II8%8$I%/F@[DP1%VA2$?%^
MX4$A[UY1[_..[P]$Q?=B[T;1F')1$77Q[@%#<@$_%UX10@ /0B3W[P6_+N\.
M0O\20B$T%Q ?%&X,%W>[\ -'\1FO\'2A\7#Q5!ST\1EO\@\?\AF_+F:"\BG/
M\2ZO\0$O\R*/\A./\!>/+SG_/_%W^R[&,3?-=C:N]>1J0TFVBA\,:.R03C#$
M4 _%X Z-/F^-/MN/GO3Q6P\2H1/$[8:LXY)':S_-XE#]U=XTB.E*F\Y?^<"R
M$K0,XQ7;G>H^!U  ;4[<'4_<?3S5,_>\$M\,ZV(0:U TJ=X*C"<\/&,2A_6J
MD_55ZH;IPA=#:Q&?8<1)3PM83!1=)W9 (0PG)=)H &>&^10'D 9H, 9LMZ8/
M9/E8%A3YT&=7FPEA8&8G?I@K<  X( EB<!"$J.!A)P-H@ :6M]-[Z)=",0]]
M^)=5;_S'OZ7R,4G3E9![;J[#R36DW8'(3_W5O]_^?!-##"T)>\[)_9(RR>FQ
M,W'Y_V-?+6$L#CW=P^/!0C$,HU[>JCZ5BH(\XATIGA)RKQ[_>M_<? +?*P80
M0 2J 4)0() ?! T>5*/CX$.(0&1,E(& XD2+%BEJ5+;/XT>/T32%ZKAOV<B2
M(%6N9-G2Y4N8,66"U+<H0)R6-0% ^"ALBP$ *@[DB/8QGTT5 !YX9*=B1M&/
M-5<<"*6R70R@ &2 VA6@ZL=(*I(*.+6/'8P$4#WR@F%@15 $<&AN\0HRWQ:J
M,_7NY=O7[U_ @04/)ES8\&'$,#5IB@-'#1S(CQM+=KPI,AQ-<-9 =@RY$IPX
MF3?#69;8]&G4J56O9MW:]6EE&#'&T'BQXL08,B*201CQ1_]!B+^! ]&AT*'P
M@0]_*XQX4 <.&3EP((".0'J.Z YFX-B>@SIV[N$3X,!>/GKX[>D=F">/P"%S
MXLP=)C?XGN%#,@DAJM%_G_E_(+#3B#89#J H-XTT2N.E95)21I--2MLGI=<J
M)&R83#11"R0,-0E,GV$T(>8E>C*4\"4,,P'%0A9;=/%%&&.4T:7.X-CD,<O4
MT.2Q'2_;+([',/NQQ\Z"K&=&))-4<DDFFVPI#=LFNL$B RW*#2,< *1/OX4:
MTG(X_(9;KJ#YMH3ON?)FD"X]]'#0#KTW'SB/S?-DD'--\J([;[P9^KOO(8+2
MB*@^@\8$% C>#JW/.>4.K$TVC0S_E"&W$6=:9A-0]/'H4DTH=/)34$,5=512
M2Q65L1Z!K!'(QCYKK$=--N-1C<8TRRRT$TW5=5=>>[60F"H)C/*V1\M,+J+B
M>GMHOD*U-/0^004R-KD<RH,.NSO;M+8[/=N\<TX<^%Q/AO"P*Y._+L&D;SC^
M!CKW6$/S.TC00)/3 3M)B9UT6(MPZ.M$34#9Y"-EEH'&5X035GAAAAM&+3-:
MX: $M%@QNTQBT"YC+$@=(P/289!#%KE7,2[*2-\K$2 PA^7\)(BWA8"C%[AG
M!Q4(9IN9BU:@',;-=CL[VYSA33:W&\]:/LLEMSOK=*L9(8-RV)(X98]5J&:#
M8H[YSQ],_SY07Y5K\Q"P:##]"$)-CAQY;;;;=OOM"BNNL49:.QZ-UHE5U0RR
MS3Z3"V[  Q<<,4T&Q.WPV[R66MJ"D%LW.'>3F[FAY(0SKNI#I54:3Z;QQ):[
M<<T3W0$]18]N<?J2?9Q9X."S.8>MCVT=S!_(\"YQ FN[DEP#_35,I%!6]"C@
M7 <W_GCDD^\5LHIOM-&QS$#C<33(\IZ82,R4UW[[Y*L#._&*A"47P/?ZLSR^
MV8^=5FM%@<-Y]FI+MU-^T^L'?=O-WZQV=L?5?;RY+_FG..>;#W((@ITK(<@V
M)Q,;8J*Q# DM0V!CFQ#W+'A!#&:0<-3CF/14A3U*L(HSE FA!@)->/_"A&7B
M(KN;U*-:6!'4R2YR6;/9F.HED/X,L#G]@TBUPJ6T;SU@<YLKG77(<[_2Q7!V
MB[K:?A %!$'QYC>L@X\!<<B<]P%A.OJ:B($<L#L%XD!MISE)*"*($A2F48UK
MW%[T_.8\6.T-2$3JD:LZ,S VYE&/2*H'#G)7(/!5"7PR2%:Z:(@Y,J7+9E9;
MXA)U,+D X8];>?KAT+9SI^_,J2KNH)_4#DDUJ#4.E%4$(,V,54AIQ8YQV(F2
M"[G(@DRPQD&AT(2$"N:I/>92E[L,U<:DYS&^50\RC9E,K>Y(05XF4YF)T<2P
M9!,E2>$ A\-9G\P.8CG6X4QURT+D-)LCD ;_E4R(W,)?$L-I2?*491[F>4 ,
M"8+*G/&LD:Z;W<S^U#HN)82587MA[A(8/M^]IHP?*6/QEGE0A";4-,R#WAPK
MTYDY/F9B&%L#Q+ZB4(QF%";1$ .54&8EC\K&DP,9T\S*A#-%6E%R\T0E@!1B
MA&CH8PQM$I?HPJ.#F(J!<SE(PTR[ SL95BV _FO.SDH9RF]J\5&NA!1%D-FB
MD5"P4PW2:%6M>E6/6.9'')L,:";Z2Q%VQJ!8)>M!F_DU<FW$:Q1A%%%5*9"=
M,<=R/YC6-9-Z'&G!(:9=("([PR,G(.P57&LBW?Z.!<EW[L=EA01J8ET*Q7MZ
MB5VL%!\@0ZK6@+XH_QK*P.,^,-79L995M*,U8?0F"L<@\0U6#E6#94)+6MCF
ML63Z$J37PI@^=[7KL0M9#$%"<21E&(0T^] ',5Y6$#B @A*2?8QR?8O'!VE"
M#-U);CUB2@R=1F<Q'B'&8K(+!$TPHEJH X6$ZK$C0(%"$T" 0TF,"Z;D%B4:
MQ+"GLLID'_M8\7:UX><""92;I\HH&@)+B7J%%UL$)_AXONQJQH#DO&!V<+@*
MIO :F^E* DE*@1A!'3WM*L_[%$5#(*&'&B[*W8=4A1@043$0C,"28>  IP3U
MB$QEO"&/#",Z=]B'CA>'DY64&#A'V <].NL1(1?DQ?NHAX16G!R4JDN1FO\S
M&0O[:[(Q:(I)RX!*&8OAD8)56,QC;ACS)-J8B77,,PP-S6C&2&8X6Q!*5ZIM
M4[M($=A-L3?_:>D3!0(5?5 ""'&0[S[>R^-  T?%N@5"69X,FN$Y1CHZ4$8O
MP).#T@Q#36E0 W$GD88TA <GPTA.49*LUR(;9,D3(@BA#7V0%@L$,T%5U@W[
MPQSHW/F9C_JC#'"Y9<X>S"3J#7"<C7UL)6DU8WO[Y=WVQC%D1SMYL7&ARA;H
M-6GB-JF'*LHR%O*5)Q>D*.&.M4%:;)"B"%H-/APG=W+P8GI<"Z?ZX"NW8@T$
M'N\C9D!6-Y%?#>LB/S'=3GS<UA92P'L]$W<)PMT<1!:TJS)"11DDD7;%+>X:
MTT)/XYC!D3#C,+&+A_\<;BJ\3;Y*?N?:L$")!6GL/ ]2%%\\!"="-O>_@5"5
MX*9X'^XX")$3+2T9L FPQ.7"I'-:-![SG"#C_A/3@>!S^,S\(([&K;R0.CLJ
M @=\5FKXOF2#@U^+ZH%I _,F:@EFD:==[7_)4:U&LYFM0C1(:Z<[R):1ZZ:R
M$#<GBXZVE84<0XE8E'^+V;EO_F^%4%TA1:EB#OI$B<4,+-[;F;=/P\-C9;Q\
M'YK(8E7H@1"<U*-+2P8.D.FA"=;)+EET79=PI+/W??'W>Q,I-J\^2]!:"KON
MNZ][:3)NL8H*\WD=.S+OC<^KV(A/@0R\B*2D9L7C1O\A19D$^HB<9(*4A>?_
M G%TX?^M@R/$E!*IQS'1C:Z/0]PO!XL6]SX$?3Z<\^;%^HAZP ^R"4#O"&N*
M<MP!%<[?W<$[VA #A]FLCY@@@@J[XUO ,2,-T?"@U)*,QY",VF- "_P4* D?
M7CL<KL,2>-HVG!&\@YBYQ#J\%?,MQ',(Q6.O@3N(OR&&21B#A"BRFSHZ=SN\
MS'LZXEHO[_N\04LUXO@-J2N4FX.*<'LB@O 3_R .[_F_C<BPVP"[D2FCE(BJ
M"[Q",>.,X%.SS]A"QH",XL-",5R2N[LVTN$[+B*7^1B#@O,?F&L=J&..>V,_
M1;.Y(! _J-$!'J.',1 B:3*_&Y.IZ!".I!,XQ!L(_ZK30?I+#I\[%(?P/#7P
ML"5\",H*'UW;L"B9A+:QKDVA)0G9+*H:0U&TJC2[&+V!J,[XLE%<Q231!&&Q
M-MM0OL3)MLHAJ7L20=!C,A9[-13TP=] ->-*B"6+Q*E[M6J9 2 HLO+0 >*:
M*?O .8#;/OL8GN)X,=$;#KFHA_1!-_>;)C[KDF01D*U3JR<\F<QZ&V*@.),8
MB==B17?<(^DIB-#@D3E",\AHQW?,1]: DGR)E(6[#01A 6EBHE$*L<T;J>MC
M-.W#(9]3M\!",<U[,A3,N0#QO.G"@0<H"DM[B$)L-10SB+)(,JA[B.MSP848
MR5I4CB3$H5:*/9<T.7)1P/6WF;A.V91:DDE]S$GN>8S6^:6(X1A\U$FA3 R\
M<TER/,J^ Y,JHIR'7"X7] CY,#Q4,[2O*(T3% C/VX0'^4%#8PSYHH?L6K\B
M(XD3A,9BG)!:@@I!4S(F0Q?D(JYJ9#+U K?CNAEM\S\-]#K9VQVNJT# @: #
M9$>T&TK"U!Z.Z\DOM)XX",K";,S ( 8[TS60DLP5>#[_.:1ET(?U&K(B2Q2L
MM#GP4POZPPF)'#2U>+)\0S(UB*E[H2M7@T@>NTH4)+&U%(B$)$G[.SR0H,A[
M$@[5>0Y7JHU^W+HQR" K] A:TDK'7$ZX 0TE4X@)O(SR8T[ "?^1C,H$6 2D
MEERKODO"1<D<^ZBA)22(YZDKAK 1'B0.(X 0.&"<B&#/3]H/]&Q/DF(?@QL(
MS$"ON\2MF5*KDQ$?W0&H$P*8X"$8QJ1.!"V5"9P=QYA'($M0D$@&8IC.AJF)
M'W@)$#DPQ "1 ]65,7#"RZHM8<F!=X$DKF&72>2A>DJD;XJ=QP*4K*.G:4F]
MK',KO&J<^^R:D/HG<I24!E*CD_A$L_-+""W24/DX(W@IZ(0,,1.&&,"!"IR'
M+8B!OYD)99A0O= '9? 47HB!!QV92""*CTB&7*F)IS"-JTC&D%&&7,N7)SU*
M3!P*H&I1I7R(:+G/H0H.+3&DI%J(,='_,^AS.;BB-11-'>>(&5;R3R[2NP2)
MI5RB25NZ22.=U%")#!1MSS!$L%V0@1M04Y:(!#_Z4IC0AUT0TYF@ARVH4H^8
MAQ%;FYKPU+M0U1XC4L#0ATSH4%TA!KQCONR4O?-@F2CCCW=Q'TJL3X@XCMW2
M4V1E'$9S'0_+4\<QE*AI0QG*FI*2B#1$G).IDAO C>+<)0GJ,D\D&$HMUR2)
MQ_;\CPFC,':0@4N0@1,SBD)X@U3=BU*E4)9X5>.IA1R(BGI%*.Q$'*_[*)<L
M#V[B'U!:EX-SE_KJIF>=%QAU/>!8G*%RR\>JIB2<%L]D'^>('\2IK>ST&@0@
M0(3B+%#H,C0R_U>5=9$%)4_\=(PFE0%H^%>5X(4<>(8M>- KW1!ZP-*>#5-B
MV-F/H(<KI1!E&(8P4 -B (62(-J5**XM78FHG1 L#3*A;0FBO2YEV)"B+3\M
M#5H2V]JP58M(4-.C35H1*8DP0S*Q[=FPN])DT(1A -NGK=H)45N[]95)^!Z^
ML[*)*)?]<4LG:J+V424L @XV/%0P\<S+K-.VLI?F,):*A:PN00ZC.B#R$"3=
M < TE,*$>J"SH:4$?+.5+=V'<0QV"2;'P$FL:M=3V%0<>U5]H-EVW9!YB(&J
M$ 8_BH$;N $<,#5)X-T;B &QK(GA[=TM4--VO2A]P(0I'5X<J-)7;?^',.#=
M&$@#T>2%XXV!3F,)8?"U11C>[J6'1;#>ZU4+>F $X857C_C>7+G=SEJ$?M4'
M1JC>& B#3O6(,.T)7XL$X17+H?7?X>5='/B!\KL+(-.'6@ "I+5>[$48CD(K
MO1RDBLB3ZW@7USF?MS+1A.4_@MO&QC56=%E6XZ@7(BS(V#&J]ZF/^$E4A7/"
ME)&!2JFJ@?((@3E9T\WAT]B;UHD8B:D5542P[XV&VQ75(9;2!_W>LO@(>6!?
MCRA5E=B%!]Z'>0B#"ZVQ0C#BWZTQ6]B*&E/?^/7=L?E>"OK>KV#5EF '' @#
M-2V**C;@'$O:&I-?J!B&KQABD&CBKR!53]7_AS#X4@7V5#6^ 3)PXS"8XIK
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M,[WDH7@!V<MAV7;$E)E'&"ADF_ L1A^%Z%/?"A$A@4#:).R(P7TM$XD8-&B
MQ"AB<YU8/HL6_TK"2'QL<VM6JLH^UXD][>; 0.F23!!8T;^:E:Q6_$:%5*<P
M8'/QEI11#R;3PYQ+QK.NCMQL9:P25V!3QJV* ;_"W&I+\+NV)K:D;6]OHMOA
M#C>XQ5WN<H\;W>HFMYJ\'9INM^W=[SY3VO;7[OW-.]_XWK?;:AB:EVZFAB\5
MC7D+;O"#(SSA"E\XPQON\(=#/.(2GWC!A_5'M^$OK6X[C2U3:_'RPA1DH]&'
MKBFCCXTH9!CT[8M (I22>8#:.BO/C6Y5,P]*Y'IXT3#@=!%UOE6'TYN0#2&K
M!G?J)BXQA%1C,-(ERR3 14UO)0^6<TQ<FX?0"DL)27:5$@+M;I_"Q?]'I@>3
M[PSE*AV9NRR$=HFE725K<ZU]X<:VW+<==\+@/>_"UD0<X\TF-KT4\( ?^&=J
M>._"UYM-]D[\2_V]/WH#TFWV#/AH1//O&@:Z=X&.$YK4%*<XC5>6H0=]6DE_
M&M.+OO1K.OWJ4W^:VM$P,[T</69P"7O5;XQV&$.3Z^$ >]NW'M"V?ROK<_][
M. 4_^;1?/NZ;S_I UVZU^N.C/?WL2UG2,JV$/@U;VV3+1$^],1JAT+2VX'*4
M,"34X4_)),0XOL=.=40#2V:J;>U8"(/+U!W^W,RD.]P%WD#ZK%^O. Q)C<2L
M(&"O\=H"'ML^P$^-T=BL)-F2-1O:Z4HH0%O_!H8"*,!=W7%)W(%@^WB;L&&;
MM\&/O-U!:&3;'7!-'%@)UZA)N+5-V\3@EJ1-N-';O+5;#N);X&D&XJE-O]5;
MQ7P&H.&/[[W5[>32P"6+/%'<$SJ<+B5+GU5<%9J7%&*A%5+A%6JA_6SA%T)A
M%/90#M7>+!V:Y'$<P0W+VH!A+_417 '8Z>B#ZN@#,2B#Z="A'6($/2C#@)'$
M'/:A'?IA'6[="QW''<K6(.KA'IH.(19$/C2:0I!=;3C+<2QB2M2A8%"+A/2A
M<]3A<,#!(DXB(YK.*%Y$'ZJ/'^Z#'1H/*N:&^LSA)>:&'<8AV2A#^YU:@TW6
M0773@E$8S*0* @75_V0UR6]YB],)E(F(V  "BJ])B$BHV#[D&$:0%)#YVHLE
M1-E-H#::TS*0W9%1X)%A8-H5 [01 P:&PCE2F]SA'0F*F]WAW0K"&][!3[CU
M7;?)6^/=X T"H3X"X>+I&^*IR>+1$VF@"6EH'./]6R\)7 _.4ILP9,!93.S)
M$D4*'_)99.UA).]=9$5RI$8B83SIC_X<VA[Q7EK=WIIXQD:"1N^\WIJHY'H9
M(?'M$@]U#$7R7DH:GTK:)$GRY.SYY$XNBWJQ8: 1BUFY8<;AD4KEWGJU59_E
MTLS5C4;<P7!DQZ4MP@\, V\T1$$,0W)(Q V81VWPPD2$I7(DQ,G!05G>0/](
MT,-N1$1Q.$>";,*#Z$=LR,"!+$3,903*'4=6R@<.@,(BQ&6FC00]?)I$Y,!@
M4EI&,$)<BN5"8$=$M"6+ :9") -8*L?"C)]U:*9O((CY6>5F8@2CQ25H.DA>
MX@=O**8G2@)DGA_?N P.0 ^M@0C3259N]HM56130_:*%U2;-*!$3!:=],".>
MD!3)75U!&. ^T,IY)."0%837*6 ]P)@$BL>*'5N22=DRK)*NJ",ZHMT'RMTZ
M<LTYMF.W%<9Z?IL]<LT^;H(=O)L,WF,HX."MG DHY.>9>!M QIL_SB#@M5N@
M(63E#:&_R=)*X0[(9 QH\9 MF5::4!\;KI3'0:7C_5!HQZVA/,'3:'%H$U8?
MVF1HB.J0$Q8E()GHQ]V3_9#AAK)HL:04BEZHA8X6C58HVKA-[73&OVD,&NH0
M9W!?>WF?1-;D:J&&\)R<&*S,/I1EA-0"#D2B<@['6.[#5_Z'02Q'0;0#A"@$
MHX5!#E0'R?%"&H@$HUWI<?#&RNA#)*BF02#$1<P#?SQ$)!9$).A @<2 &)!I
M1GPI,+&I0^@#+TC$M1Q'GWKE%G1:1LBI0D1">##:&(@$+^! 0D B^8'B0[PF
M;22(D@(JF^JE1NPIDT[J='3E<4CJPM##(H3'0= &/4C_9=DL0_(XP (QG6,=
MD--%6"/%&OY-%X9QF+B$$$_M! X(X'&:!!\:HFHHITG0E(DMJW/R6G6L6+*M
M6 0>&Y0M6P5*F7@J0S%@('DJC'F*8&%PF["Y)]^U#;:EC0C68]_%D9K$4;W%
MZWWN8[ZUV^'QFS[RT Z]FT,*80[-FXX:Y!H&WD/ZWA"NEIJ<X5NUY"ZES4LB
MX<&*9,.V"4INAHZ>Y$HN(>_EY%F=E1F";*");,8Q;,=LS'J=I$L>[+ZZ(;+,
MY,2JU,@>R_7MT9_1+&HA2YL(WYX9:.ZP(<16[/5YGVCP'LBU5QH*CT:,ZD.H
MJD@LP@V0WU\V)JD"ZB+<J4+X_X=(G)QA7LB;]B6D=:9P>"V6TD;8ZD,M$(AP
MQ "5DJKQL&IL("K69IHP>*T\E&I!U *E->IV( 8]^.4F,FV?^"W8^B5W9!IB
MI(>6\N5>+HQ_#% FJ(4NAI*$)=WG%(H3R9I%U=H9$2-P00VNXH!UI="#X$WI
MX@UNF";>W(!]J,>FE6Y'Y9Q\)$>F?24, ( *!,"2!EA):$AS]IJLD$1U)*!X
M *^+%4^UME@T<%VU8NL%<MF5H6,&DN?T<F \BB (QB-A\&<)TB!_PH&ZCAM_
MSF?BS5LHU*M_]F,,JI3B%6B1AMY!/BRSU)".OA1:X=-J^6R(HM?'P)-ZH:AI
M[6]Y]?^OL?BOQ9D6B'HA JNH GOA JNH$V[A T?PBY;HSZZH+:54/>&3!5.H
MG*A-3"5HQ1YM>06IP5+D&U[L#^;/FW37V%0J1K##DM;"F>YEU/(I0=B&RP5#
MACRB^:&$@3PBG09N@;3I7M)&#C.J#H@$$"M$.P@Q1DCJ=@C$M4PQ1MAMV2ZN
MX3[$%A J1D"B=%PQ1F3M/KQP;5C+G'8Q>K3I&)MQG\B&^JT/,1R8P,A:_OTB
M<387TAU)P !C&>G$^Y61_B& ?="##)6# :R  0! #   (BMR#!S!=*C  4PR
M *P   #  <A1)*B (R<R .! +5X$/6A! ,#  Z '#.0N&H3_@>V&\I3X[N\J
MQ',F&S6J6$),:S;B6+6^D3DEVY9UXYU%+SH2@W>>H[1]JP>R([EB[_6^*]_9
M(S3; 0[BW?:*[S636[S9FX "*#?'8.*US5!B', ]'N3]6\3N[PYJ1IP@7H/Z
M4%FY85*>5L<X;-#2DCPS9=!VS,9JK$_VY%L!M$CNWLPFJ,N"K,GVZ)K0I,:I
M[$<6-,@F:%+FSUH=;$7[$,/6<_Y +.R5Z(6FES[G:'GI$J 9K9QPW&:(LMB$
M+1%WZM7*Q]@.L4"X]#XT[4(4[BQF C%(0INN]%\2*MUN!\R5;>%>YG0L[4+<
MK9_0<*%>B]**P5,_=1B4:OJUL4W;_W"7^N6F0354&VI/;V)/Q\;2+@(.;+48
MA,$-".Y8AZH W:(8S&I!-5/1C1#_<1@Q\C$HZ5\PEEHS/5$:5"(=[8(*3&U&
MP  ":.U7KD  ).H^[ ( ](D^/(@*/$#.[0(,X( *&':7BD%P;)IB3XES: B6
M4*/RXC+P^AH"4BL"UL.0D5TW=B,PW]FSK1+8@$(H6%L'5IL'0O,)DEL)9EM\
MAH:5T%MO>UM^_MTT?X;YPJLVSV.]UB /\NC R3/ ]:LL^4]HM.QY[5+[>@RS
MK(T;NHEHC&@@X9-:^>])5W![G<V)2G!J3:$$GRC_E#<"BVA[)TN+>F&,,K!9
MF32(DO>*=O_&>;,-GQ&AQTHLYI7T_1H:&V)W"@^A&^Z1=LGA36<$7Q:UF^HE
MTUYM#$N',-Q&;3SQ<;PF69NU#-3)R44MX#+Q0BQJ&9\MI;TM5M]!2>RMGW0:
MHZ5!)@Q#)F2")JA<F2K(13@NGU[UG%)(#+^!)F3")_1XCV^QRWUUB+/T7Q;,
MDO.XCSL,;<UN2L>.)AQ879M0<%IN-RV3Y]B:,@V7Y/8+66M""\-08P\V.ZQ
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MMB9WKF@)T+:.6&V#$OZN Y1&;7#4]"I7!-3N#&^.,9%0+?S\9IDJ28G_J[9
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M&0EX7?M <3"8#RQ8?;X5!@> @"H  T"P;C0( S\"(3X22CRX#^4@.3,A&BN
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MX T2E821Q/8#90RC3?U1@T2' 2.3U$)F"4&:23[D48F^-*$+[>=(^^F?M,F
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M>-<ZKL,CD')G"+4BAW8HD>[,@:KDBG;5KYM?L!OHCA8$)V:HDM'#CNKY=<9
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M1\+63_>V"_[NGS_ZA^,.*VI0%9AH"L,3-RJM+JW (OT^)(/R!O1"3'!7Z0=
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M(8Y8XHDIKMCBBS'.6..-*PX( #M02P,$%     @ 9H)<5K]JEAT.S   )<P
M !$   !I;6<T,CDW.3<Q,U\T+F=I9D1V=503_AOUE.Y&6F+DR&U(-XQ&:K1(
M3D"0EA(<W9TC!&'4"&DDI7,TD^X4 14P$/WN]?>^?[S/?\]YSGGN?>Z]GW,^
MVKHP63G'['NP>S\!_Z\@   " $ ! %@   \  0 @" "$ (!0 ! 6 ,(#X
M' * (P!P% ".!<#Q "0 @(0 D @ $@5 8@%(/  # & @  P"@$$!,%@ !@_
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M@1.)C . N1E/_SHE,=6..V6UCR3=(!2&2<=NU5?2#5TJI,,4#77U.E,)7UT
M]HK,;I2EWI"46?A+JEG.KT.3QF+ 9BB.,7?ZZ_Y8RD;I7(4GNB]D4G4I#XNJ
MUR<\!.A'[X4_-^N:Q'$^-<ML/[I@@V_T<ZH$=IUZ24&[R$<E.NA0)E!G@.(?
MQLC3J.G V!@6(MZ/:[S-[_T]JUFW0D?$'MEPUUY@DGB\M,S'Y69K\X *SQ5G
MVKH+IK9'CK-?)]FR+<F7J1@)),^D:%K*=!>HX01Y0G2)=1-DW^9)2KMG%YWP
MM+#4+(M":_ &-IBJ+PU*1L?/@T)'O C8YO$5\*H:/K%U(YIO$U5&OJE+9[9
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M?@<I$,4 ;W@;%Y.U)HWC?M1JY9Y7F# V1I^WI_T1W*#O[;357,1,^"ZI-XO
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M2FG/?NC&'KN[2EXNL(W^YU[1]4<-TB#HGWQO*9DR.&*S.76(A39 7(& A92
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MDGT.-#<>_A,;;1X?R6R:;"=9A8X!?[)VL(9K53J[2L2JK6G(&OYD@'X'VI3
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M75-K>KU8>K:6[4I)8%3D1P80 ,[$^KA*V]\'=(_=QX@N!(6;%WW-MB;7?3L
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M)/$H%!,H_KU%ROP?*FG/Z:6DR1 '%[ [R24%1B-,.LD:-W"^*W=$[,V8Y9A
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MKD)88X<&++.HY:\63 73 !.$J4*.J#62!5Y&1'*6AA@9B7&:!$CF+%O.RS\
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MOKSALF,+%MZL6U,FN*Z[#R2_$UZBY?6:1+^1!8-5!PUD@%S*U,-<=RHA1E(
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MC3S%+^21TX +_ SH^A,H''<&G9'-;-M$%2"Z$.H@J6.D7=!FK@&E1L"1[)M
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MDDR&\3EU:D^F'Z=:+$K4(D4Q.-RJ-:A0C,.+,JERK+M0X-FF'JUN+&A3V23
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MBM:2C\MKI:8HF&DB"K]@,M:0KT![,6][KZ% P-# K<[(P*3"LCU9BDDK%H(
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M*$>:(1CJ3F#[4EX&LV%)T_2,SZ%0E'VX1!QYD-J;7&2IYM8++&,:E1IZJ^&
M'>)@G;E"3KLMK79!Y)JP#*I)AC28Y.& JY41V7%5T#4+H)Q61)'UM6)#+>+:
MO-DAS&'(Z$R(#%L^0V9)!E$E,8ZHK0")WZ)8*3M=6..C0%B5IS$FSL[;BYT
MC'>DQS<4L,X0<&V6;/H) WO$EM1VL>+"DOA561PJC#1-"MA6".TBHX=!C ,
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M)8/;WN(UVW_\ITU5@!"#1HQ @@,)BKEQ(\8-A ?%A,$!,>%$@F$H7C0H,./
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M0"Q4B9T,4+\*X8H%C8OR,<E]Z/>0T&4E)*_1K1S_M9/?0,U,:+H<B?*Z#^7
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MS9B#X^*(/#BD(_9C\4)D1'ABFO_VSDBKZC\I8TZ84]H<MS0"UR[.4C' 4VC
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MV[DNH;9@2[=@NS1R$S<RDS2H^[<VFT"B,SI^JQ*G<T(4\C=J&[<<[)(N(1X
MN[FG,[9^4[HGK#FCBP%)T,#7J:4X-#9_DT)=2C9)<\,NR3?R@S;]D4-$/ I'
MTS:@:S-$%!)L,[$CT:T^8S5HZQ(Z"[]!_"\PV39%<T1S4[8K;#!Y^[-M [,J
M"3. T[8O0\2#R*"    [4$L#!!0    ( &:"7%9.K5"]UF0" ,1D @ 1
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M X/YP&$^2)@/ $. 8 @(# &#(> P!!*& & H$ P%@:%@,!0<AD+"4  , ,$
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M*5#YV$=0!%0(H58^HE'6$L5,_&J7 3[+IXE5QTC<JZ:=%S#'6EYO83DVK>=
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MN)%%9-Y-$^P<V=!B.W\R5VQ?5%^]=!:FV*!O6]"O:6"_J#@_YEP9R:ONL%D
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M_6R9<?@R4V0#P$TJRRP&'S?83-MI=S=F^XCR6]1*[(Q9_?$6RH(EWHBH[V9
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MY_OX(_A7<ARY"OUE<@6P=4Y\X1BKOH [X8>'WST 24,EN!;8GX]R;[1W:ID
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M0O.WB)2C&!IH;TBL0,8+!)7O0\I;O)5'^9F'>3/'7B8 @"X/-OY&<XJ)/TA
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MC*<=34%2\^*!I-9%+3K-0F%,VM,FM#(IRN<^T'&9RFI8'O& ;#FM@U$,8G"
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M(B%KG4-F1SMD:40G.3+/]-8S,6@I3%@XV9$;BP<Y,1V,*%.*T!/M A&KT(A
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M;N#M&(0!.RONV ]90ME^\D3,(W'D\'H'(6A,X@;8F?\Q&/?EHWI:=B!WKAV
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M"T"QTBI! 12O>J#[BI17RP1;JS55VKN;,CHXF< .HJM0 3&\V\"WPJOER(0
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MJ]<WX+<MT#3C4()]U;=^9\)[Q5=GJY=G.V)D,\XW-.DW,@Y-X7<N[!=]6?:
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M?^CU,!HWQ3J6F7*S7MCY.9OUTB?3&W:MU2;^.ZL\O'5WQ<TUJS9CW&0::59
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MP/$.?^+]7*VJ#L=O^L?D)F8+NF(A53>)0!:8MEGPQ4EGW>P+>X8%]N"IEIF
M)%+5>%9*B^(2CTC;X-5K/C5,TVD*]VH#6A8KSNH.E^).B['HCL_8 BTX-@U
MUF,7'Z-[TZ/7W0PR[K"MFAD[<ET:BR>>*376>5W60 WZ]?_/HBFQS3UJJ';B
M9I5X&R,1MK8U6??Q;/D=E 2)E$3KHXW2;%GK7$<.( OR69M:%3JK2#X:MMK(
MJ]E:=:WK/-7KY@WE3CCYK2&3[!3E4M8.H' BLPW/]);*=V4O]J0O&J2!P9I3
M,7OV#>1RJ1S (;(Y#$0E#$BV,N]V>D5#IN VJS!)QNX#&L!Y 'R7.(/7FQ_
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M$^A!QQPT,+5]KBLL.O6T$]$DO3IK[#_:?C-N.M9.6RXXQ'CZA!B<@-0DR&%
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MPLR*T+,"F]LL0@@;XQ?%".W-D;$+HR.N.@_K:W"@Y,13+CD)C0MNWLRZ4S%
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M75)TA80DYQQIN4AZKDE]6])@]U9)2AJV<8%M[" !V[C#;BZ2I$OE*4NYE&B
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MU?^].PKS:NZ&-KO_/BOESFD=![0 LU!:)[3B&RDB+W:&^-?SI)0&I;T1SW8
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M]6SH16WE1GLB15(7M5$\(Q_NMC0MA40;]A\9UE(*-GP<QE.;.!]+,R#M47Y
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M=;D@RG # 8!C_S8D[:<B0Q%_#M<4&L* 8V:7ASE'.K5'.C468A4VF_$TNE2
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M#3$D,5OV;/G-@8B98HS6E$GC:-BQ9<^F7=OV;=RY=>_FW1OW4-\?)\4P$ /
M#6+!E2]GWMSY\^7_C>O632E8NN"/AP$?#+GO(D>!!"L2I,Q0IDN8)"]&U#?I
MQB2:"$]*=$^,Y'W5DUYJ=(\&(T3S8$+(IIDX6L\\B#P"C2/*Q%AMI0,'@HF>
M3,30A".-&E(MD_#V06,+32+Z[#X18R!)##$X(B:&3!1#4:+O5#*H._$TFE$D
ME0#,L2/OZ"%PP(*Z@TFU"QDB<$8=&>1.1XK0HPDF(QV:*4"+9.QQ(I4D:FG"
MB%+","()-WK2HX5,0DE&CLZD"$G%%()00AS3-,D@^<IL"2( $Q*((HB"=(FE
MEW3TKB'Y)$J)HI0&G<DF[F9,2+TG!?512LH I%//^"0<TSN)!.)H(JK _V*J
M*U!XNBH3K$XU5:NWSA)U5;-Z2JHKJ6J%ZJNI:,W5J+!P%?77H-KRJ=564=UI
ML</FHJ>ZO);Q$3&#%M/+,6>C-<POOPJ[JZ"[NIW+6=&">S$W8@Y0X8 # D C
M(DD.6.& <"T;!E7HZK7W7GSSU?<RH7H#\*1FE]UW8((+-MBVO JSCB_%'"ML
MKX^N%1/#N,:X(89)A(S/1S )>E(TB";U:+A,UCL0T?H^@LB]C"4L*(8P(AJ0
M(31,!- ]21C= @?%5FRQYAABD"&&=??YC)[/.(/L8TY5 RU$+QE*>2;W,H&(
M,Y6A^2PY-,2X*!/DC!8#T?C G$D,-)1AY&(Q6O_LM,*@VVY3;&62#@TF@> &
MK<6\@KYABZ"5T4<U8B2) 3EHB.DZ:#2(.4@?36(@QCV8]>LN<;LMIPANSMR.
M5-$V#X5QT [5F]3*0G'DTVR0*C7[(HJ,C%0F([L[*$,>1=>3O$$#O7V_14\?
MJ<#106:=I(>(W_0E3U]2DW4R53(>O>_:K%[DWG%RE=:A3DV5JUE#%2O\I\*_
MM7RUB!J5?&!K'3_]\H4U5MBWOI=_J[V4;7;:P^[BZUO_3:9;U"),7W#"+;_P
M16&(:=9R</"&@FG"<@>C8 4M>,'<T*LW!L)@!SWXP> P9B\+F]9T'),=AJ6$
M0/M(0Q@.QZ*9K&X\':+_#)!\MP_52 )+<L(3D7XW.(R!IT$LBA1'-/&> 1D.
M!T\BQGM4Y,3)@682F7"-T60@1?=L@5/E2<CD#B<&8C@/AS'0A K'.(G$@68^
M8PS1AH;Q(K"UZ$ZADQ"*I)B&PQ%#)7ALVR0<U"**=.8&89B$)&[ A36Q$(M_
M3,UGTC!%DC3Q,Y-(0W+"@ ,T9$(25Z3+/B3Y'O>\QTTK>@_<Y%BS/OZ1=S))
ME$G&DQ"+0.ES!\H0[2 DLN3MB8Z?FI$96S*IF%CJATSJCH0PE4@!K>1U>?H1
M+.<CNNEQS"-_H@F<[-0Q*54)3+<K4*:VZ23BA61]W[,?^-9WE%3ERE1K05_[
M_[A7E*7,JE=E(<KV2O5.=AIE*^6$%:K0Z1;[R$4?>0G," V"%Q_A1#O@@@RX
M&%JM_Q&P6MZZBP#CU1MEF(A@\WH-"#WZ47UEHF@X#)&^= )2E*94I1@53'4P
M(D+(/&9NB@%7IYZ$M!C@8 NBI,R9P"23(&FI)I+PS"2FF(9A](@@P^FDD4BV
MGH5L;5!\RJ@8/@*:,$S3/5#SV4OV0;3*1$,,84B#S+9V3)<IAG)@](Y[&!&1
MA&S(DU@#&<LB0KG&K2AC7%K(D\0JRM2 ]8Q=JIM5(3))3DD5B'LMS(M6)KF.
M#2./[(G&7A]+C,W!+#ESM:I!<!"VB R#))G@0M'BXKO81?V4CK&3$$D:,LW3
M_6YN<8*>:BF3(4;)3B%LHM%&"B7,WW*S)B 1DHT>]R0S8NHEU3,)1'0'5^)-
MLTQB?"Z-=L>QUW(J/E*Z:3,5HS[RA44I]=.*>-^I*JV0Q7RU6E6JZI>4>+;S
MG&!154_2MZOS"455\]W5,"S*T+P4Q#'^VY]BDK50G%C++H$9X$ ?PQ?M7+0W
M#O),A27<G-9<>*4;YO!L)L&SB.# ;?G:";[^U6$4IW@WC7GP"&$Z_\+*,,QZ
M$FIA3EDD)QB=3F8 0@GI]C&<BP4Y#67Z,>+:M-C=EF1K2(J=(2.)'!8EI&8+
M:2)\.(*UA!HM!E]:T;K0,Y_R5$B-2+MCTM HR8B-D4/EF<B+AH&#G+9()%=R
MT/"^>C>2^808#H*,E@T"D15)8F0LHB(Q]FRBS=W@0N*I<DDB-)%&>Q*)W'%0
MFK V'N'<@"M\GAE->(NG&0*HE;@K+H]8,M4C9^I+L(NNFXPWO.8!5\>7FU.!
MQ.@05N-IA<NK9DUPC;N9H2=ZN_54<WM7[.)Z+#M8,M.Q;]JC60UK>^@5%OI\
M=5]>=4]65K'OJ]3;%9\$I2I"X6=Z[Q<^G_^8]U=HV0EXS:*)" <,H8Q!*(#_
M<N"8_H7%>.$W701X4)@N1S,W\,QG[F:O84R"S2IF>(K38%41Z="D(VYXQ2U>
M,.J\6($N5EA=(L:8N6%*&6G8:<O8P]M+$5LBL:R'7%DW( I!]DXL"^IA01NH
M[\8@J14R6EF_FC&"R-4C@@709VQWQ(Q]"61IHI"#@%ZW,-Q@;Y %FU7#]:'-
MDL0C1L]HXVIFO*+?($D.$E&0#Q?DS1K=.Y#3=-DY<_;)UL-PR9'0AO"4)I&B
M:)(I 5O+.&+T>F@B#'P#LX."'.0M@"QVMR0([ZBT=M4%$W@J+#: T%,E9=.(
M:<\$=;*O&24DD0?_4&("W>R(UV-';7%*0DJYF( ZS3L!*?4TI)AJ(;7V0D$)
M]OO)R?QZ(JORY>K:ZL:G^-C7/8 FOY^Q>K=:AM_.<:LE+9K@)WGEYUZ=3+1:
M'9>+MB(SEX?Y.\'7&8R^!Q.9OD@KWC'MZ(0A/K#6?.KB\T?IAS\BXGUID/[[
MYS]SII7O_],X&6,(&<,\^?L(QXL\'<&YY)H(EKD[X+DK33LN(/(YZ3F<DG@4
M]HB!LNJ:'\,!?5B1"P&T&TB#)U&C'G.0LM&KVJF4D?@PHL$L**F,K8J(2Y./
MSL@$-HFC(B,)>B BT0FDU5 )L7J0/[(/0S.TC_B,D)FK23@10LN)).24__J0
MB2J;F;IY.ZG#F),(HL2*@9?H,AYYDIK9"4/+B1"A%.XRFS[)$9R[I@A9DB3[
MD]2SG9;()M QGI) GAV1/6XR-6+BF#JQDD2A$T'ID$$4O5!3+64C$%W2D^;R
MKH60CQUYO%^ZM6>;"*TX/DYLIU11GU(!J'5R'^K;B6LC'VF;GV\#+UJYGV))
M17[Z"OI)1;-8((49( ;Z%FAY#&?Q/FI9# ?["V69C/W1/O]9#C3PN8%). WK
M/V<DF+Y[ _<0@S20A$>B..<8B@-\1F[L1MA8F.G@/@#,BYF:EBT"E/]HDSZ9
M$9/ )4S;E,?B$-^!K<J2N>4B&5UJ.2[<$@1YD?_!&R-E< ^9@9PM:)&+N#0C
M43N:0#KA4@E-,#RVZIAB8@@UX@@X<RWO"(/WBQ8N_+$'B0888D.CN8%MJBJ"
M:"&H*8GA(;LF&0; ZIK-0I0I28.;4[-MFD;1\)F>0:(G,;H05",W68^Q2H[8
MX9,WE+7&"Q.5D*9A&I[OH*75DZX;29X F1'12#E+(9W,>QT-#!+1:8C8(R[G
M,A0KX9+JF:, ,9[9TQA&443<NIP[=*X^K$3,T[S>*R?L<Y]4,95L8Y_^DB?N
M>3Y6)$7X$2^H2"=OVYY2G$55K"]7W!X!)"@"4ZC&\);%T,6Z&*AEP4QIN;?[
ML(L%&D#?R*AFA([6:#__;TQ->ZF0@JNPSI";>ND7U9Q-U62Q$;K-R,P:Q( 2
MY.F2;V(F7*LUZ]F=Q7K*-I3 86 >FF"9\B E@9*/< $;$8R(P4.;:I*T-- 3
MLI.2F@F01LM*'-HIMI*3J$$)DJ$/%ID1U4"#+!,;B5 -'P1"E0BD!7F)_H (
MU4@1B< * .E.B8BT_%P=_LPLUY /%N08U4A._!0LO6(0+:LCR5$AT6([KP$3
MK+"UUQJ]-OS*-;(\5ZJE&7/+COB4C;FA.QD](/D<U5E*KP)+LYE$3''0'I/+
M;;(>98(M8CN0&=(\J+)*UK$FCP&4A:@YE2M198)$/0%,)7V?XT-,4I&O=2,^
M_[\4G[90AN+S"FHCEFH#BFIC"_-JB@2RC@/3Q<( /]"<MX4R#&DA1HP8O_3[
MB_\HS=O (P,(@ . @7214]^8EX6C33^]..#X4T'EOX39"V;QM\?@OH_SN-P:
MB&J:&>QIQ\;3DTHAD'J@R:0C$]49CN10#X]$@T*J,1S00TWE+))D"#L*(RSI
MNT&I&5!M&86$G!M+T<HZ.)QCB IYU8M).H2 !A<"50<1@_* AD:X@3/)J*/*
M*I6)JD/"@4E )9 QN&IL(:M*":Z#M/3\.RD"5:"LAR9BD;MAU?7(A"LJ)!QP
M(;[)*#G35C>I.J-RD+2K'#3HFLZZDAS+T7_9F"Y92O\Z$J,7K40<?1/HHB8'
M]11BFA$BB\-&Q#4718]PP9/5\:4I"8_FD50_:<)B:Z4>;<A38[46Q-<.G1)A
M>XA4@1]JFR]K0]F^[*_J4\Q@097V^8G^8HOT(J>L*#?F8U+AH[:;38J!BM.&
MN3>%^=G%J(MZ$T;&2-/R^Y]D@99X$[A,F"*IU3_3I-I!O5KE"$$2TU.L[5J0
MLDT2,J&]@!@+):C/\9(#(=)?N]7;"M(GV1"0$0\ X4'HR@07"K*VZ:2$0-LG
M&4G_R*Q1+1.?^1C#0R,/V0(ZD33].$35VMOY1)$O*I)*"4@ND+HGY(CJ@*%_
MR02="AN'F"8MRT*-=*W8\:/_+WK")7P0$C2Y'X-(-!I+/P*-2+JQ+'FC+UJ&
MCO29UV#"<85(5$D4O1$#A?N26]HQLQ&=GG(E=CS.?B5+VLF1VD-8.)E#AG43
MV"M/9C.F6S6NB0V=M(2K5=(4[<(2UOJ2X?((N:R]Y2G>8,*Q[@*]*\G'DR &
MPS0*[&NWO]05PNQ+E2W,=QJ+JX GZS.W5RP6*UW23B3,L C3OD"_N3#:B((P
M_5F6 KJ696%:ALI,QN ^CZLXCO):$+:-$DL-= G)>CFI$$YAE0K;F!HA<2R,
M146>.3O1 _&I?V6E!?2QK)$(0\RQ0/&JRVB4&B63'ZT,0D' ,#'B%I425\.2
MEUB=_T?##!;U327F1QN.L8]H'K7#8H4 XLI@QQS]%#NS#!JERB^62,PP(U3+
MXA.[C%9B#QJQDR"5O1KEF#:YRGZU$_?-G:R$JM@K-HYYC4RY'AXY7I'=V^'D
MXPAAK9 %"3ZTLX&0)A]KGJ""O48AWCN1(<JX6(]9G8L%7P&+BOLA8,<<S+)H
M%7@"GZE8"I^ 4B9M19B%'Z50/@,F'YL=Q?RB%:*%J/33#IS08 AN*&$<H 6"
MJ&",B_T)P 9:#E6MF[3!E];H4Q6>YDP(@-@IE] 0 WB1C6JN4XFKC!L(  ,X
M  "XJ!&>9G3^H T&VQ)RC.E0&<1XM$%4.1_^Y .ADUB3#_\D>1R0^"UE2PA'
M#9(-M1V/<,$C8Y,L\Y2;8#5$'E'QA8GT]<.#DE\$D9T@^1)!'IYT1!"O(KLV
M:=N[6^A:$M^#FI,@\2F!/KF+YM>5YA,AFI)TA#F9]A$>,Q),(5],<QW)VT\$
MA,3CI.,9JD,^E)-Y!B>7P*Z79N@4A<LBOI)6<E]('AYDTNDL:4,'A;T1Q1L_
M5JHU?*[;<I-.^6K9FEO'5$5EV-]A:&5]>B\LO=GDN]^ROF6R8(L"IL57;#>5
M94S[N>O'1)]YR\6$N98(IN"D[4PXK<QA-B#%!HQMX5K:X+E]N!@XPY=Y<>QT
M_E/('LF/,&',4%>%. !LA$W,0.$+RR[M"EJ80WVI:3G_U(@AQARM2SSFPSK>
MH=]BMDFD6/3E'8N@U))@1Q\UIJQF8O#TU#D2#Y#0%'_6)=/Y")U6WBZV8QW;
M#^IIS['DZN,$O)-+L]CACAFCF#*)+>BJG;'4NNS^V'?LG4V)V'QE'<>EXH"U
M*?(47^&.&JFTUSMT'8?E$5K*+4HUWZIDC[Y52N!9"&AB-B$A[[D1-4'IE(.6
M+>RI'O,-O>YPW,RKZ0@1#TX61$0$$%P[8%&F96F+TOZ--G,K\5$.8%CFV7UZ
MZYIE\>:;95CLV:C(%6&L#OTQ(6UY*'UKEG^C3 7ZZVS!E@A#S=W @>10C8@P
MUGN1H&TT;:^ER8@@!@,H*:/!_T;+L#\1>;\0VZO,L&PG__+HP,T =+&Q#1=P
M20P8R<0ZL2[>D8^3@=[+^U&7-MXH_H^.+;;4X9&4&S7:!NB9\5&.X<.CY&_R
ME9XD&^A?PC0NX>,)7R;ZG,]U/#5'?<>.!:[:@91.-O!U!.4GZ1#'!0_@;EA<
M^O/Y@ C9IN-<JU$S-_#HB<"EGJ$U?[SJI:$=6R[L<N+N<)1,Q]%'P\-@XCR<
M1EX-#>\\Z6)'72'P9LO5"NOC>DJ?)O!>2_#O>EFX-B=JV]_HN[;V*HJ]CO$J
M=>N27=GI2VNM4.L9=R<8-\516;YCT4P( XS'P ED3JBB+6R"^@N$./-EL"BB
M_67T$__LY9 ;,1B#$-NL>N%3, ]A93B 23BB!TER+L>,>?T(**\,',!3=;D,
MTDYXCJ^70K6.%^:X<"FP5'.V0I[$8I^\'![H2\&YHWYNG X7ALZ>^.WTYAIK
M0T[Y?"U8(K1JT%WO3AD085)T(NP.V5XU0W<E+6G$V%H/-)GC##DN8G]#?*91
M'D5Y_4XF3V]J/$^R*&%<XR)U7Q=T&+UGJLS*AP7B/B%8O+G.12PV(B7DZK%A
M>@QK]F9#X(D>V6KY8@+UVKOT&%J]H1<4?Z:U\G")1!^H<6<^Y7/K%_^GZR/E
MG0#@$H=KONZV<_??>>+2^=&5$\?K7RG&=:8H -KQ?0]L-:7_S#25%EU,9L\4
M38RRTQ@8B8>/S2KJ^*ZM9A@8U8\HE]*DQH\@U]'0AP!(5_MH'-Q/?N=@9Q8#
M6[(-B5^.VR,#/:+N[QMJ6UUJP';<H5(OO9^:);^*E"/!Z4KYH;GW,>1-K9!I
M<]=;=HR<CP[QM%/S:=ZQ9(N=:(_QURUI:%*K5(#0MVQ?O7W0ZD43J&\?O7T"
M]Q$T6#!:/6@,'4YL:%$9QH7+]"$$J8_B1HD'H^W[6)!A0H0I1]*CB/(CQ(L/
M":+DN(]DQ(,084*L!S,A38('+<:,^1"D0YDI=[Y$6?#DTWT<#WK<61"DU)U*
MA?9\:57BS)$+8T)$.S#BS8L6HZG5_PH2*<2U&8EZ'*H0I\B+6RN"Q?IT629B
MA3\95E8XDV+#CC4-@RPY<C+(Q! SGCP9E./%ESN#/IQ8M.?2Q"(/ X5:4V7*
MFE?#?BUY]&G5FU.C;LR8M&-EONGY7J:LGF_?T)0!1^Z;.'!ZRYP#%RY=F?3F
MU95#AP9]./6#.FN"#R]^O#[&$#-I&J]^/?M]PR9];R]_/OWZ]N_CSZ]_/_^Q
MX!6WEP8:-4URPWIHX+"/89ED,DDF_4$8H8034EBAA1>&5QQQRGC'G57+<0AB
M32'JQ!%3/*WDDE 4!34615E%%&-#/''$XDMK"7:5?S(!]:)6=,'HEHH8:842
M5S&"-=!"-?^R%5B+2*)D4ET['?D454JRY5940[98$5L?P:75EB4M2>1(*YWH
M$DTU_I45BF(^Q>-3*BZ48DT-<7436 WAU!%.:/EH8D8M^O301'H&=:9%+=HX
ME9IG=;261FBNF*)%>Q*%T:5!E<5BE7N**2E*>,+5%54%\0DJ2BR&J5"83VX*
MI9LNG>K5E$NZ!AMGB^FF6&.8A7;:;9^)-EEGO9I6V&:.(0:9;<'NYAANK-U&
M;:[6.AL;:M!*JTEG @$'5W'/D4N=N>*:*UQQ^BC'+G#L*A.-<L<)!XVZZI*8
MW%H8\@N1)N;U&[#  Q.<'WKB%=;>)&+4A$8:ZXGQ,'@)%URQQ1?_8WPQ=\=M
M6!R('Q=7$[G.94472WNAY:6.6RD)IE)@.IKHR8>NI--* ^%I)U=@N=0JS#]5
M.BI&0A_UU)E"3SJ346,5K=#-D((EJ)\<#6310(U.S71/7#I:YY-K78U0TF/U
M9==92O>U(IXTY4R064E*6735*[U<Y-EQIEIG5Z^Z;+>7?+Y\)I%]ZT7WE$X-
M'5&I1GO),IPSLOQVG3#6/6I"+&'>Z-L.@6DEK4)A6M5$*L=XU=\^?M41WP[=
M. RWI@&;[*^T 6NL9\ B%EMKJM&VK>RD-?98:[-EIJVSKW^&.^VT11N<Q\P=
M]YLR[A8G;W/(39>]N=%QM]WUP!%'W'/Q__6G6!H.3B(QO\-DLE+&[\,??WWT
M'$",>,0<0'Z&!MA/O_UHQ$!! U)0_L(3F87(+X$*7*#\-.0QCG#'-Q_RT'<\
M5A.F7"U58F(*DH#"N2=9:FM6X]2)4D8FN[G,2(P[4@BO9I.PE4E&$B'2J@RW
ML[2(Z5 TZ9F>,F4C2+%-2F&K24&DYJK4T4@B9>H+XR#BE+7Y[6C^X=+<$F*C
MG'RM126,TE\N);2[U6AM@O/)UO36)YNE!6TK8='-R-*729UD+A')F53>@JF1
MV*I1-;1:#/_2%2493FY\L:&D%%>5%T+*:(N+T5K:XB6[T(6,5I',[G+#&\]4
MAAC#0Y[R>!,[9?]H1GB4S!9KF/<ZW?1NE*D)%F9FERQ.=H8Y$72>^-+5O>#8
M:WO8V:6ZDF,N6\H+7]J18(3P%X,#P"  !PB#_BCTKV8R,)K2Y%<F CB>&SR(
M/9DX #>SB0890.28,3" _E@SS?B92Q/JA(,:U  $=P(!"#D @@Y^$,]WOA,.
M<% G*(03I7.><Y;A>V#'.C:<.U'02C3\BJ*8UCBEG2R%)7S<#/<2LXA(+48W
M?$A+\((ZS %2< Z52LE -Q2CD<4F+2$4Z'!(QL @Q"5N8U6;.+<7J'S'3H(Q
MFQ[E@C?5K;!/..1+1"<GHU<%+J)42M%)R:8FBHJ.2 [EE)#TYJK0<43_*:5B
MRI%^AB9(^FU108M(2Q=RQ(N@M860LLB1V)2HRX5DB!P%RESB>CB-''4O1TH*
M2:<H%2PJ8UJ1,:5E>/7*:'42>8=%EF)9Z1C;#.]:D@4-L%9S+.(UAEJF%(UO
MY(4]<*UKE[3<)3WHE<MEY+(YP2QM<X[S/>R92T(.VX<8.*() _6+?= $*&][
M>Y\W,&P\.)C$^M+CVX M Q2:8.<]F^O<>,+SGM&EYSUU$$_KJF&?_=SM<0<6
MH@U%CX(@XA@QK>)9F15DAU-*Z]?6:B?,A610IQ+I#D\:TY)095(+E9D+;?)4
MD:JMKQ.1H:$2AS,LDA%F)%U<2%T4N91BZ2D-[+F+JQ0'Q3 53;\B<8I)G2*H
M.-+$+DUQB>FF%*M"CB6N(DU52];Z4T&^E$Q#\I'[J'*1KGAMA!STDD\>S#.2
MUM<@+AJ,S#I%N@3G4&AN<_#2VN2I@HPN2ART* E%?*/$@10B@FG;)%%CF]4,
M+[*D%+.770<\3Q)CS-4"LV08>TE4FD:5I,3-L7BCJSN',G:&H1Z^0)0][8QO
M7/'297*LDTOE:*^6J!7.]20D!OOAP'[[N(&D,?0O]W4WTYH>3S75$X-L7@@R
MFXZ0O);K3NM*%[JJ=J<:?A!=>+K3U?B$M:J?FUU-[&O4_1+H+!T(_S+W2<]1
M*,+B53V*Q*<M+KY"GI&? 'DI.]HT<4RM2@;K@L>0AJW%2UY94$:(%09;FT<K
M8F\UB;ODE'WQJ:2"VY)C((87\>A5T[:9T&S4)[OZ2!^:B,$;:CHZ!'YI*']A
MJ=?T.C<G:A"D'AQBZ)X$.+C6)% ?/ I370+%GZ&U:'Q)=DKE^*,YX3!G=J0R
MDJ*-5[28KJ\ID^(CS1)$M>A)QE+2"8R6HK;#D=@J9A86F6?3K)Y74C;:XMUA
MA;7SQ):F,8/%\[1Z+MDO5XO,<*Z-[P(+F>FP:Z"NQ8XPGR.NZU5G.H6FSMA]
M*;WHY%*V#T)#-F/ 70CI5M<!"Z9RE\O<Z/_^P+KS7/6MU1E;32\C!@,$SR0*
MB*'(R#T_H(0#=IO+:NGN4Q.;Z,Y <@V>RN<R%.N$PZKQZ7D=[+,8BTK\A$+V
M/.^ MZ#'&=&&M)C&-*$7A$C1-@X74J 8X/X&8H /3M>[<C@54I!+M+C,V)3(
ML,4*(9+X=).LO6TS]0ERBR+&#29A1R,]=(5*@UR9**)[,T'9V&AC&]$J0@QW
M:W%T^\A$&(A[)9@ D!A6?*\;.W?^W.,_N%T+=X$8YC6*L!_NB<&#>,I'@ G+
M;95*T!?K+$V-=)5454[>J!=$N!6BH)$<N1 @8<[&!8Z-:*"\:4I5:%CC= G.
ML8ZC;,J3:=% W%S_G)21?U'@G*F98&E&9'5+8LS@:_!.)S&6[A!/FM'@,/2@
M9;22LAB/T\D@96Q6L/Q&GY&==(27]P@:HQ7'UH5=B'@=V<'%=)S=V]4']2D(
M .  #E@3OVC")  <Z?$'=2@7<Z$:JE%7K3G><]%A/FE"/_E6)@1 ]4'&&]Q
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M#O/A0B5&G&'4!Y>@SU!=AP%;J\Z%I8QF6ELF6BH+_I]^RM&'455#&.V1L%$
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M\->_DMH/>/Y3%&#2B4J)3 \X@%,-S!B91X.(TH$$TRA1Q/ O&J:$"VC(Z%.
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M.186;]H6,HL!)\):#!>K19V4$,PA+3E7-% K!K=^!'85.UN8[NQGKF1"*_6
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M<( 2L_6B0SWV S%-T6[:S+D6Z Z3:Y7^[M+0+1#Y4RZ\KFL.D1YH1.(L)W)
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MJS1OMKXNTVC%PDTM1!?M-!<'C!J[Z>$:SDEN[_^VQ.0.=?Y89TI,[G92YW=
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M.953V,%^U>E7DC'>UI1)-NOJL&D3JE=4B;WX)Y^?"O]O$Z"@^@4*NN:*.YK
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MF(T9)!TW10^!8_]26D&/TSKT263-N4RQXBG,:4>!T8\K^%@G"';>XX/<XY^
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M_N$4Q-!#R0P#.."H_Y$).#!B $"+_\&:/H43&53. 9*SD"E1 ]-$(+1Q]0P
M8A!$I0W:'50/#)<AX3<A.=#"96M!WXAC421R_6MF#FE9[,AD1$&1HH9^AA)I
M"(DX)W@W/VQ' :G5NX6 KL44R$DYT.*?JS)*KH/%_TTXR8:DCV9%H3^HCN)I
M+:,UGYGE)J%[ND_26-GZ2CI7A.OJJYY&=\+$@M;B2D472XRS)SJI5F)A55J5
M*FLLJYLR@*8JQXYT9$8<NMCYJ2CX-@8!++#UR)6KH(6S:HW+1XO2AJMR5NUM
M<]ATL5J)O7UHL+DAE38^'*07OJ6<ON:B>6*9;#I*RE1Y:YX(0<4(>P U19SH
ML@T#S!?SM%*#B0H5'PHUV324"9C=(S#TVPK"0RM ?2$& Y/PBOZ!0B0V!EMA
M(\00!@<PL]:80?+<,6/KBQS\-%N^L[J](.\,YCFE<'Z91+AWBS1B,Y%:>__$
MS\>=5#OF$9-,/'!DK7&T=O]#O$HW][P6^M5$\8&!$G9^2TPBV>A9QY&Q,G?5
M2DQ,A\7/F[M#IBLP47)WD3UO$54+;9)?7$P &CV:JCJ2"W@Y;<7Q"'.=TBFR
MA7AZ-A69BQ.&![ [\70^[=7GW<0RAY!P!4;9PY0<Z:N[I9+=6J&,AM(J,3J'
M=>H0^H&]Q'?(PS;9_ND*K5:J[28/$:/9R["':,KIH^-Y2);+I1NPW*-LS1P"
M5$YOS2]?:4^V 8KX(6X*91XB&S4B^UX+\Z0/3T!P^1XC9^64+<WL+-P:PD,&
ML +A# ,!,'$$L@R2@ .98$,&@6 E-4,\5*4= U-?ZF*?-\UJP-H/D08A4R$\
M):C_).9#8PXB^%P4BOH@KYV+B.YQ$5-C$241M\Q;P[MI6Y4JF@%,F@Z >P*O
M<%0XJCK'D)6Z,7?=EJ3@;YNNF=1VK$N]P#/$)BU6W4U)B"/JMMZ16M,VO!N
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MMP"4K!3\OHBS2+@QP!MTB0*<2(;4-W#L1O$SB;J:JQ4A-,%"D9;4JRUJ&OP
MM"@D- AYFCBRHTRB*_WP0CXBH\JY(Q<4I+S!$2$A&Z[SQK[#2 X$)"&D0WL3
M1I(('$%T'658+T&!MALP"5_+!((X -)!@UESDQ@HB-:1)=.)!C28!%^2I=JY
MG<0)-C[II& 4O?QX-R!('<*[$F68-<K_:SUXNT1)S"1+C YW4XCGBBZ'*+V&
MP"4=>,7FFS1460FU2XE2N<SJ6YRC2T>?(Y*G=+0W?";.PC@EP4/Z:B1!*CH9
M<9N,1!(>8<J]:8I+JQ%$VAM5J21 VANVP4WI>RS/A+IKHI'%R8@HFDU(ZK=*
M$I*ZT<WKV[>><R1$^B;GX1'9M+JB!$ZN0[KO Z15N;1LBB2D-+MX [74C,A"
MLC2D?";&<15GE+>(VTQ'0LXY;)OJ3!4@ 23FA$U[^\#0G,_+9(G6S*SU7+C\
MZT$%M+3X<K30Y!P5O!OE]+^40"0AH2;HV[E1,3IE*$X9-+L'=1*6F#-$6\*N
M62.K 31B4",-_\F0Y!)1JOF9.#-1HP'*$G4K.^(CH+R0.0*CO<HS%,T/Z,O(
MOWO#LF/!@(0^?D,ZC^2_C*-0OIS*A?##]HJ&U$$]+)$E/(F!29B$ R"35G*U
M&$##MQP=W%$F,4!$-K'*4)&EXDN<3)"$-!4)7&(O4$2V]NJD91L4PI)$2200
MX.@4/ER&Q2NU2HFVR*0V*SD<8'S2+H&O<9PW?QL,C(,[F4C'@&3-MH&> @VD
M@Z3'A'NT)!42?"S/RM+ D"2[[D- Z^Q'<W2YBY2;#DPD>S22OE,5=S1(.R1"
MMQ'!8B3"$B3/!,35'[2LT5R[]U(5HY--1'I-!13((.DY"HTW2.+(O/\AU0K<
M0 &\-%*-N5_5UD>=P,C:&V:<34EB3?,L5K)(RNZ#P,FJ$4!BI/ DDMQ\Q_V$
MK!\!TAND3T!:">NL3+A1-#R;D/KHJRYRH[U2R:Y121SMR;HJ43!$PSF#*QQ%
M(Q>MD(2UPH;$F[IA)!;4MTBJO^\\P*J[5".9)$-:5)$('"=='=]2'2Y1)K-D
MD\>CI5?CTDR %&YJ)0-8)F)XKM)9$T/\#;\IC,Q,RX8('3VAR]\21N%Z-W:S
MR],1@\S;J455AMK)!->0A%T+@!NX62@9K>4[V>KK/>?I/GD;1D[+6*BD5+QQ
MT*O#OPZ]N@H$SF@-P!!L3<S"3KMS3Q+L-WK_RT%L--#4Q-N I$$:W#B##,?'
M(D<@F3Z>J\%N?,?H&\CEE%SKTRQRO4C1;-5FE,BW^=8-%$&88\%F!%P/5$!L
M=#1VY3]K75>UD4YIM4_]K%?OY$8?@<#S?%0*?!MG%%9]C;Y8'<E55<'\/,&W
M?0EH@C,2?=@Z6U&'+=@-H=&(E2NF*2.)79 E;-ZMB3,=15@3R:LQ8A'NW8]*
MTE#:G%=/G9N[>0E214]YK,U"0I6PW8AI$C4_^1.5C8AE\(\]M3U:VC7-J9$^
M&0A;B]G1(2_;8:;&G!.$ !#CJQ^&( 8<B,LY4;XG#<QDTQ+\O9),@"[$]%/1
M4X;G@H$QL!)<)*\V#U&WD9!34)#?W<O=1]V]W?^T+W<$.1O<.P$MN(J\5?ED
M./W+N)),3VME0\?R00T<P@.TQD1BI&^=KVR5NG*5./TK%<RM6\T5UR'.QO1U
MT/)-IPU=.CLD5F@EUUUUWY@KW-,572S61X_=1LGJ6+)A)/4,U;OSR!]VE3S\
MS/.LK$?[7(ZDS)';UATT2FK:S&B21WS%5YP34&9,7WX33Q5,QWGKO8BKL_U(
MWB[\WBVBWC::R3@+44VF6%!FM%&&49MLD$,;D3D3PSO+&B0N55V-5M6%GMU[
M7S=^I.XDU7V5RA8&G#)YM]&:T^,2@U?#$_+"';9DE<LI",O#$RRU6M=YV<4T
MF<:Y@6B#T\(! C+ T^;_TP]#W23#^9/5V5(5X,6PI9T#L*V= M%)N>9] .=M
M?E)OU<,G#J28V#D^+I*2M>$,S2:153M8G65\PT%W?<:R88D-%;_JL<WW_>?=
M-,^M<T\BQ3<_9L#B),[+FL8T?F(89,-(:Z31Y4'V<T/K;!NBI$B-?53;I4@V
M7!)8UA$*Q.C+PL-SO6/YL]":D]8-=+^!5,UKG$!+_5:[F1OIE%2!?#^1O1O_
M/#^/YCE*Q50J-M='"U+D7,'[&E(F"=>38,J-W<8\=DU_8T%).5$>5314]J+L
M%>4674+M_9#H[5ZW+F6G$9&V<EXZN^2F*4AQ=&6EM*9\<T.\D]20+B07;N>I
M_Z22SS,U+7E:DJ@394B#24@#3*!$-"BFRXDN 'F]&#B +5B\Q2,3)\F)OPD=
M/.%2X%%FVUG%*_G:174CT5,^>!849;@! O9@4P'A-7FU .!$+CF<U!FVJ7R^
M%]Z_/>R,<6SJ#E4)'D;"[IPT=EP;E/,1MN%IEOM&Z%/&(M;&^W-.X!7D6>5
MJ&S5]37-:$K!/YXLII2[Q1II(^9!2_WHJY9J#<4L"\0['^%H\HQ!2<MJT;7
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M%OH@C%:MB F:Q %B #8*R<P DU"O@\BF _\JL52\#O*-?Q>DC)F6MTSU8&^
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M+$\WDEFCR(5)L.=4_"%:#1W9_2%"AE>U14.25 D0%%B0"!N."&=#)J07=:E
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MJ9WJ.X/\/>,#H;U?.;S'N[Q[%X+$A!96N>2IH^1'[)9N;+HSOK9UN>^84?A
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M1#:Y)C9=JAXWRDY3JH@H DY@(J2N1DT*TK[ZU"-X<^R2#'N\$89X+AZ[*'=
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M:!%05+H7;70*7;<8/:A])ZUHQ*2V6K7#31+;:9,L1@QJZVF[&!SC 3%>-'
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M8%ZXUC"@P?\-@XXDQ4=D E#I'C$<GC*<CM?,W@W\GQ@01'D9C*'@@-<PB'8
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M#/W%39W/5<#,BZ"<:(U<8 60<%:$H"82@;8I%*9F0P1& 7EC@L2)/MR<EL8
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M*6)!F-4CN6491H] U7 ILWA;2NJD-@7W%N38P.W8&@R@-?\EP!8"!VA86.!
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M*TJHM<'"+S2B$>2B),$8DAN>7K([K;JG>](5RBLK[YNU<>&-C7$K V&J I+
MRH,1-N$JP]NGPEL29SDFR,(T47&67 *\(V&IN]N=8,,LU=DKUL&E=(&WHM(^
M1 R3= &*K+L:^ HFVK(:>IH88+FG/<.9M:H6J4$Y[2L5_UF+%^"1L6/KGG([
MB/M;&O59D,@*LE)$.H]*PI Y)</9.YHAO&Z3CL43-@A1JO79#3;Z)O$:$OZ+
M-UBBD&34.F-90631"-#KB*(!/1]\(BP1PM);/%#"CYO2M1!!/'MY'(9K+3>9
M0C"4QWE,"T5),WK$QWQ,"\SB* ![(3U)Q8(!L@ES*J"3Q*QZ$>!0))XC+,I
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MBNXCH-R!VM+R]\T_E3)OY>$4C"QCFZSUTCJ 7&):NO8?(5XV4KE"E5.I,T:
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M6O1WB+3')6.JH@>LQE>JB#JV/]%L3%[%NIQ\<B6Y(%&/"Q:I#/-$)1N&-;=
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MVM@=>/6DH#L[C119$B(B;HIHYF+@D"(S1URQ"Y =]>A'01I2D;+%0@AZ8(O
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M"@,C#:8P%8N)R@1\+&0>8>@G#(XDHQ&ZP,B7\JDW>0K CG$U?HCB$ 6[+L.
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M4>Y#2:I*U"KL*?^XZ]F^L;QXX[>XA:UB)#*EU(LFA33ZA2=[XB6U,$1E+5V
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MD5^^Y6.>E&<^XV6^YG-^XW?^YW&>YX4>Z//_P_:,#D(D"S_#T!9Y=2,ZDNK
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M*>-IH,EU.)1"APGE($6A8JBL>K&V52U"]NU5%H*7A4K8>)29NV!1F=G:Z'/
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M7N$M)6%]N[)YMG,']CK9WS0Y1DR$E66TM>VMVW;YE4C;U.4GTG_4,XC-OC9
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M!#MR!?8H(WW>Y4,Z@_T$:O 4H\)L<.YF\,R2L"R@L)>TJHFP::2HBL<"<"#
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M"5F#(@:"/V3@+W],, G3,.<B%I5D&03B+ZLNCM32'V61(;5R(%./(?KE4V:
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M#,9"P5@$&(L&8_^KX[^VP5  % I 0 'H_\J"@@!0$!@*@D)!""@(#05AH1
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M@-$8*!J#0&/0: P6C06@L6 T%HK&(M!8-!J+_=]!^$^-_Y#\5]=_P?]& 03
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MP*)X>-G$];!8(GO/@AKNL/!H*X6N=@?A$WW_^HB]MX4N_1+!2''/S60F%TV
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M'..V2O9^N1XLOO15'J,[OQJ;I+9C2H)$H1D!N3BA4-SRHM!)/L%+=[_BXQ;
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M^JO%"3&,FD9DA.8WQJ_Z#*.-*-ZG:*N+S:$6T-;'EL\PXRPY!!1:8[&79O,
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MC(9*C4? ^&Q+LZMC-047,A,_GR>E;^>!B1+P>$B0>ONN4K15G"<2%O9S)_!
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M&C*<FA4?!#RLC2UP\(&ICRTT.9NR*XFO<HTLJ1Q\?>/,7OT.X92Y]<+7_!\
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M*;MG 6=++ >Z")]N77ECKXY_B-1KSPH'16%MD1:B&Q>LE LB&TKCHC77=M9
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M<U@BU(G*"(#0(R'1[AW#\S^^:DS-5#_\9G>0RHITB7 >KO^:]F(M/"*J.()
M F#W^O!\)G,?DJ4@INJM,.4MUJ+K]H%0$^+U0&)W#,9K:*.FD@@"5<+12((8
MDL$P_PL-NH<QSL0P;R*J1L0R8NXD3&*&+#,C%NSG.@[<3!$#AY)%11(1[4KY
MK@@7#W1&(H,8#J*Q*(<G ^G*^&IH $B@.M%":(VE(J,X:@HVL%.C?C$7SPX7
M XRY1NQ%1&/)T,Y_L";*.B23..2R?A%O1H<&[8UX,,]VYD3_\HJ-%##4HJ]G
M'NY,]8,)!0)UYM)5U(4@VB( W  A:H\E_C(^)B$Q+I(?PR:4&"=.V,562J96
M$&IZM&5EYBD_>8P[\F?#J!4[O\7_.5DISI[H6.:DQ/S%5[0E8Z:&-8+%!\EM
M5-HQ;%IB[H9/;+Y%/+A)4;JM%-])D=#J^CJ0.]C.:D8K1[!)).DG2G#FIFJ+
M>K;'SEK1T_2GB4@I>10HH2*%3PZ0>5A(D":HM8*J-K8+4WC)\8ZUWTAT5.[.
M&#O1?+Q,R"11':N")0U(EPH24$CDN8;J(6\MCN#U/JHQ;_-6&?RF/N.G2!5D
M+ECFJS0! 'Y"6V@%239B1)3A7Z,A#&Z(-4C"<4K"T"[4,UIB=68N,@LB);X0
MT# E/BP)3A6B'CY!*[(P*I(($#.",>;N2 I1. Q 6ZYPJZ(!+C>E)-8E+1%5
M,_DN#30G8LV"9OGH"-%8%,S$2%I0)9*DAAF/9 R6\WQX;8BTS !1<I"Z$\<R
M+D OI=F$LP!IJWOL#*.F%)4V\[ (E&N5Q$HF*JZPZ25]"UN"\1>#CA;A-B2=
MY#BP]WT:-<"0;'UQI$/,_Y-OY^,F]J)N$@(^E@$3 L DN/)+#N &,V'",N4A
MB=8X/"4J $P3L.XE$&82#& @ H\;*\+1I*MX*L-3<NT+"<XBG><K:&KY?O;C
MDE#!L&)V68+EH*(BK\+FXO#4\JQ4^"039M=XF(_C$B6>-$B#-BLDYT^O*@5&
M*51^"$\$+61UL-1A4I1T(%!-5,T]GK?5ZDQ-B(3\_">48#-7[F1X'&^1L.5[
MP.56PJ,6R36MYDP8>^84+Z1[AN.)3C!8)R<4X1B(0'"+/<U)7@2'T@]L#-@^
MIO*1S50?+FYW?$N,UH(Q<NXEQJDST@ &\.8K9*(C.,)EA4,P"4(&4L(C*L+E
MPO_ C4X',]BS( X"&H)BG'2)D-"Q4+N1(="SZCQB+[J"E>?6KU*N,&O%+<8I
M*@0U)/QKAI0PYH@A .XB(V8.@H!+*<%(EY)WTRS2SO;L$Y$CBW-$$W)5NZS+
M',-V^13E.#Q3K;BML^BN(8\FD7()1D:-RD)T5XDL&/4H?UO4V>BS1.2)3ZYF
MMIJ'$C'9> 29-87IAR9*E,0C;+F+H&%0(&F'8B69/G[7;G @#.8#EQW"4^I0
MUC(AGP1)D9^'MUC"4F_"=>;V*I+P^NKI08ZE9Y2'-SSE6#9+.;)0>)9A?(:V
M)<IT_AAN;E9.OTCHI9>!,4R")#Y52U$J"9=A(P;42SK_=)R#FKY$HD^M>([C
M(H)?@W>GYG_M:#44>8A^%'[4C:WM)^0PRWWD"NQ\*Y^;E +'Q,[TI(V5)R0[
MZ5ZZ!./X&-J\K42/)@*IV"GGU@0OTKHNQ*XJ*K"SI()$\Z!,2H"XXP"9J.V6
MUFBXC\]@U-F8;)(^:J/IPW%,&UZK&BNI!#NCAS( [%G"43F>)1O/1,"09!RU
M9&)"A!XVEQY>[]!0&31J92UFABH@MAY6[*35-ZT^LQ[$$)V/>R1R.T<8%V[I
M97DR@A"/9#$Z3C,@)A-.9%N@X:29FR2415KCZWCXA&>$,12IR&F&,H@ZA9=B
MRIS&P,J8$W]J1"E-$$.FYMXZ_W%GU\CS=C-),V\!_RAHJ<BRBW?'\'FY1JO(
M0/0U=*M$EG6;68A%RA%4(D/ ZWMM97*S## WFL;X@F,ZD:.NI2FUX6,C0(%1
M8(D_"+5?)+@NAH(@)%<^+O3T#/)6-HJ@-B(RYN(]8@-UNNXYKO$]\D<9TH!Q
MDN4R&.<E1L1._,L2,T%RAZ$GCLA;)I.VOB9_;J-@5F(LP 0]%TQ3I@,S(Y7\
MCD@,TK(JQH#*+TZ<M *)"%$,B$%X];R^D#6__A$IMZ91P4L$#=(Z$ONU14O
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M#Z0B^HH;XJ,!M64>XU+2[R)[R.,ALM3)JI$OF43N#=>8<QF^*79L'-E*!4)
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M>Q;KGK!G4S7ZS6KL4_)U)T[DN?<RX/]#K.4HNC.0NGG]A59!*M5S1'/+8N)
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M/REX&,^5FNJK>4FK#+=/ VE[+]S(7Z@C*(Q?5B)8+YY@DG?J=B%E)*;&!Q5
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MC'%*R%@HWPS.PH@T;DF5N8LM,?22>(G%BHL6#LFKDMDR 6$_,^H,_V))/YK
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M,#]D%*!24U6JFM4PIKG:K/[I4G9!\+2G14, #G   QP@  ;8I+KHD0F?#BM
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M;:E"#LAM%!#=#6F$$%\!ZT7655>Z(6+:H%#93,Z8#7D K%J=U#6:81 R'7,
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MSU$\Y413R:AMRU>:IZ%N(JDHPA-S5K%J,AASY%56VI==$=06B:B7&1%/]LF
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MO35\!S*;W?J;;'-)V^86AA)D_1=:.0D<5R-F<9:A7V&77'@:Y4IQ-T ;T?.
ME]>T=4=F@8HQ NA!#R4=OP:O:UA2H+&T,=8<@-)RRL(JSB(;DX04EJ-U+;)E
M:^(UAMI=%;E^D%8[#$I6.F%V!6&7S'>%,R$4ISBL$0LGRL"N"A)BZ01KD@,I
MS.H2CK8DM]:<H@%$-;)$B-8JC5NOT[DU,S8:Z\)TB4(Y5+(P]7-7&LHAPE,R
M35*H"PDA-_^(*R:[9C7$;C+*+-8D&0RB)%]F%UL;$LV+B),7O=Y#KIKV8)-V
M W/Z& F)4K6%*S$%*=Q$#_#S2#[TE 77*MVI&J/1?U,UN^JALR-I))D'-&\W
M.#MDC$^6=SR2CVU%GO9+-MR)8HUS& B0!IA)3@-&EE$#2UY3@CO+BT#E9U.4
M6O+3GNJDDFI9+@YA/D %>A!%>!?5NUO%0++FH_VQG;L3,#GAD($Z48#:CF;)
M*CR)<E/G2 :&>Z5"%AN%3C+4<E>B&\;95FOZO!@!IQ<Q:0]8I_@V$4\EP0-F
M;%KB(;/3<6LG-/3[F]9X) ?7?AN5,%&J0Z8A4B(+LE$CL$A4@L?_PY9GXIR@
M4V/1NL4H*F =FR"ABCCL(1CF9ALM<C;^(S^-L['!2X=9.L5J\65#TWC#.Y_9
MMG^,D<)[O"LFIRC9)AH\&$ JN\4#;!@LT&2:L#(LUEYXBH3H:+_!0I'1-#QL
ME4[ $BDT*E4(?%JYE3HSHB]O.\1$?,2WG!*9@$_0DT_Z=   @)\ED:[_:2HM
M$;@*AT(UB%_SQT TQ\.0^EY@<K<V)C4S*33HXURL!)QA"9^]VI*ZU6I2,C*!
M6!%]DSI"ZU 4Q"S*D .'T62REDUD1X^(MCH\VRSRDF)7TU)\ZV-E8J4>E)0H
MJCK5*B[OJR?*J;9:Z(YOC+*Y<D)_1+$?_YEM:W&B3ZJWI>:EG>E:".U5NUNS
MI+O%$1*7>KQM4]<B=GD5)IO+8",#DB DF1  [9=I88O KC7!]XRX&])7>!F)
M=/5U2@1Z^?J32CMNR$@[ZI9SV+2=#\NT$2VT#$F_R56>#OU>6;729'<OGM9A
M9,&X 0<:A%FT>T$F [2B2J-1I/9>F:4@Q#DDU:6^5ETP@,@TGGG2DCR.NN5'
M&DD@)BT30DF$+'J+FB 8!0V$4VET<IBT1J/5JD21 B)'WV6ID&:\9::,I$9\
M9@I\[+& N4R]+-T0PZ )R: )P^!@^!0#J5@2F=!]&D$/&,@9 ?L77HBIC@&:
M<K9Y7899?A*&P?_Y( "XRM!1H559HYK1BE/%IP1S7 MGJB>'IZF',%%CG:W)
M9!K$:8&*@Z8X4D!*FI5S+K7DDQ+\P]4J.G?YAW%S@!UWK.C9>C[K(YIMSWE"
M%;>[RB86B<'U4 L3L#"G@?TW7CV44;_$18]*K1KEMH37GA4#/^EY)<GQUH;Y
MV1>! Y5&:7X9 S>0V@E6IQ"E98UA8']2<@Z]W ZI6:QY1[Z5P,0Z9%T,I#BF
M;X.V%Z09.;RG1/#SVVI]I&WXDMEVLX$5+E6KC$$+,W7,/VZ1BGU;*_M\4_60
M7,N0BRH=;3/W="AU8XS8C***F@(C&HQ,O^63B5K3E$Z]4&X\HZR1R>__?$&
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MD0D9##%OHH(7C*#C*<Q!I75(I%&.=%FT<(I+0]1AEGY<8\QZCA%EE<7LR6X
MJ,W&H+,XD"/)E%$S$JED.KFCB4UO>JW_VOTH6*=46COW=LGKW/1]$U'EHQ;R
M)6%!"B$J8J$J0^E4:GVOJ1DY%>[$IBO+6/0@PL&A:EK;GE8^[RG"S0J7P .W
MP/ZQI9I)5W&5DMH.RN2AJXQ@WA[SJ='933.SRM)C/J/-FZ$F/G<CVDC^IKG4
MML]9][D6@SS5(/H<UG [0BX'L:+-[/!MB[,K6I58A+@ (NPDMQ/)*S.K,F5<
M=F4XL--)Q!#B?1C/K#>X4PP\G(D]#0.;///0A#)5FEGM"EKM75HF]CG,9^;-
ML)&K#T=&E;4^:GC&H7/*NO)7(,?TI,$J64W7&%0K_KCFQJK[WK;2V\ZO40('
M+)#K7 ,&F)V2_]DNI,0! L'5/ <N@QX^B:/]&DDC!MD$22$")%LFD0;ZQ>\Y
M/YZES03TM)CNJC604LD*H6L7HM2M0[>['A0C,@D<D#(P8]!$"RD2.<[(8";_
MW8_.1*0Y*H;J8\PJ58<\.4.B@9=\XJ,,5\*&ND]O.&7+LW6NS:B<%-[OEWD\
MX4+E:\@BL7)+.F-EE)]".W(Y:B'HX9!*H_45PZID7:U[\ ?)9#@4U5:CY&.V
MJ]J)TJ>)BT&:.%M1,/-KV*2O,Z?5;YDH#+&6QN5AE&0WNS*F+=9*\'WB6Z=;
MS;2>T-GX<4<\)95-),^-].=B3IZ7N$)IO@])BH:=XL\O=_(PM6%EIO_+V8YY
M.[4XJ_GO<\P%S:IKC:HSI4E3$-4UG,3@@Y/<P,,D ]Z?P@ ;3<1 &?@\"3$,
M$-I,J%N/*BDM_:2VM'+)KBM.4=I%+-7#$%;\I?LM<M_<HZWO>,NT]7M;"*O6
M'-+-#=6?;N=CC]35V2R'G"8M.^%64L SRR '^2*&)C*Q9ZN(X>X[)27@ 88O
M!(JAE UT(%%E4\1?&O-&>U/*[99608WC-FWR4^V77&CJ"6]5+F- <\R6VA)X
M=IZ5QGRK3NVRUJ+D4D?":?:.X..DR(Z4Y0+"+?:P;$P->?%[:YF@5JOEU)B7
M3/3%S[4#5[;7M$'N+.B5U'80F2@H<?NU#8W_OB7%MYU8/KS=8A-OH9..DI%S
M!SW8J:-WJ%4Q0=^7)(KIFP2A13-2*B>_]W--=# /)"O1;;O7+AKPPII,81*.
M^8BOP@RIL#C^&)4*\1)ZXR000AR22[6MD8SG$1]-BC#5\)DHFQ*Q2JV3VCJ+
M6Z'$^* *BK$+5"'KXHJ<V:YXBHZC:)W9DITFZ3AL>2T+VQ?EPC7D:Y,Y(:H8
M,(Y/*2$W&3'8 +I]2"-HF(08N)/CF8VBHYM?F3!OZC!B4#ZZ(2MN:HO[\;*E
MP15KTA19^BL4#!RJH1]CBI@'B4"Q>)50>9?4DJ"H,1B?F*2CL RXLHI,(#5%
M@IQRX\":T(0T Z(Q_S"./5N\&%F&H6*@/1D#);J7>RFS,@L\NU BH"(,-B.J
MUJ*?95.?JDB#+W$-X_H5BZ&*A.H6_VN7FV$RQD&100RS@<F.]:.J8W,0QU")
MB+ 7(,H734 2\5$(&=@-$ F2QX 63*HF9OD(BVD4;C.[8*F8 U,GW'J>A@.O
M'O3!-KFY;-0=>G@CH9B$&P" ;229NE*N0L*?TS.2.&PVC.HVV5.( +-&E]*6
MHO*9!W.R&),A6S0M,P&K#^R6L$$?W*J:/WNIQ6$0%&P=WC,\NT@3"/$XK8$Y
MDAK(4$H=(1FWC6@WI;LZ*F,EO!$R"-D)L=*;H!&6>V._N D/UF$L^.N5\O_I
MDHU9QFA\$E3K0[+3D*GIFUF!D47YL5_BF.RX&5><->)SKI :/:TS.XU#F&)+
M#KYXKQ7AQN/HN0.( :L\@!6XRA6X@>LZCC2#C>1A$S1 L4DX@+=(GG""C05"
M)>R)(:^P#"6Z"TJ8'OHQ*E!J#XZP%,9ADJ9BIR41(&N[#UBZE6@)&O[!HQ#$
M%1V$-]S#FY-J#F)[C)P:C)BIOBK21Z4C!KX2# 3(%U (2YA 04JQC45\*P9"
M$ZNXN[\8O+ISS=8,C'O9"W 1JJ%R,]A8IAU$"\E ': ,$$T+P_MZ/%=<EU>:
M"S1;D+#Q.!'S$]AI&V+"&(7P"YYBHM21"QRP0\+_NJ7&PK&GXYN-D!2 BS_J
MJ#%B1*]3F[(!PKBI;)/08L^4&0XZ$8-,N,KBD)G14J8 0BZ2(A!.\9_&8!M/
M[+WY:A 8D3Y;=)CK(D9; 9*A&<@)W,TQK*5XM)%IXZ/QVPZZX:#(*@U8G*L%
MH1Q#FB'RB8X$#=!IDP^E*0\SN3&GZ!^[H16/(3A/0;"$.2?J.DEY&@O^2\P9
M:9JPHRYVV<\_Z[JR6$8^$CX93(E(<YC+Q S%^IRF<Y=$BU']6,'8P1[NV8Z%
M,(G=VH_&2!_)VQDC>4_?&"TTB &Z0@,TF 0VQ4;>\(@1ZR$ X MBB &^4(88
M0(-ZP!,28YYA@*CUHYL0_QK$!X*,7GDSK-@XYLD!$BJ?H+D,SP'&+U%#)GF:
MG5BFDWS#642G7A&54Z+17X2;!>O"D10IT+(9@QL)90LZN3R;FH$,1(2_QS)!
M[*@UV2B:H0*%O(,K!$HS26S-232SN<H!3 27!1HBLTJ3T[(DLHL/,O46T&@1
M:LPD\CO \J TP9!%L3#!6X$G6VFU[V@XU?"72K,+%L [NE$&89R: GPAL?@5
M]S@F_<@=A$G0S:&/ZN#([%@1L\NJ,OV-XP/8DB&& _"3G@L '#@4W4F.3YI2
MIN&25R*1%0*^5AD3?F.0SJ"B<[D:$X'(]VJ<S^&H^%NN)9T/K7/6O6$LLUBO
MI_^H'0 I1E1JBX4P&X 9 X'2/(0L.]BPON(RI%%Q*=A@B_6SD%EEFHE3$B^5
MI53""KVAL3O2V,KIH$W5CA,Y#>+B0*92KG]+I%"#FJQ-$>CCE5B"OY.=F\<9
M0 +ATEB:KF6!3K6#$0EZI/6Y+I^$IV3:CX'UC3@C&6BX2@#(RGUR":PD,>&Q
M2ARXU4H!37[EHT0Y$=B3*OZ(#8TTS(K8RZY#CR<5&Q'5VE4;QNIKVGBK/KM4
M#7&U%@[DFD_:JI-BEF@R$6@8"G5;GV8COSOQ4#/+ =$[,'\2S9%Y&@4-U<-8
MP=G8#+1AB$7T(;VS"DA\S4FLQ+FZB[I:'@1T&)H@B>;_4I?JZ=HW!*"@ ]:[
MN"PG"IE:C(R*Z!:+NYPN5 8O@]X/E0C(G:ZX "S^*EOT)*<8734MM,GF**T^
MRK &&UNTT%LT&F"3R80;>(O-&J-EP(2F8[:2F[&WP+<1E5_UT33,2R7]VR6P
M<Y=Z=8\,@IS_PCWS*-WRD)'+<T#YJ)W62258H[.=X"]E #V[F 09O"X3?+^I
MP&$1U908.PMN98P&_#2\E,@!,QI&:@VYX1Q%N93Y-8^@K!]Q^=U>ZZ0L"<!,
M.2EB-+AMFM#H"YVO0AKYRX\*TK;[*5K].ISEN%29]5GA?6"V6;A450^3U1E#
MK%T(*F#?T!4W&:JR(J([&08Y_X(&Y:L-%KN6(&$:+X6(N1 3QSSC_Z.L&A+<
M37H5J3G/X2+5<+HQ\^N0%VDJ9.33B%Q2P\P95RE2,%%2^!!(P\&!UGMCB(T&
M8LA6P< !63PNE!@A^'M9D T0NWDA;O(*X6B]VM"(1<R[/6$C)?J+[QW6SI0!
MH"*H822[L] 2U-D2E>P28XLRLP(B^\LM'P.101P#@E$=57O1EE5.N-JI'%@@
M=D6ZUQA)22L87U) 3'F-NZI+).KE(8FJSX&4_1' /+X-]Q3H@.U*$?-3W3%'
M(9$P?:T6(?FD>'8B".(_JL4D]!"5>C@B VS6L-O"<QGC[F"LS),J*JT0"%81
M>=JFB_^YSC#+(=0M/_; NK63K9^UWD5R5OTE%L^ PPP$OKKD4I&Q&+O\$B5>
M'<"2(7G1*N^XK6FCO#_[W8:RT599D9"#**K&L_0PS&F48)Z-,M]2F_[0&6D>
MRLA$L%TBCSZ2VUK<MCLJZ-I@0CKQK 4IOIIYL7'KOUL9Q ^<+J^\DPX3%!R8
M@75Z-RW1,FLN[-I:IV!9M@T%%CJ[6#DT1IHRC<:#L/H"EK\9+H*(70+4G,FA
MN\%C9\H!E@!#1#)VK7ZMFW^+&[2](!"*'=JAC9 8*EY%YD<DQ$G,EP72Y00<
M9541EB>*)^/JD1^RV=U091W1BKE@(_O[G(S<'"IU#5UD35K)!E'H23(1;2YY
M]8Y@DSU2>[E6;,M!'19Q%=YYV^.WE@UR5&_>$)[-NH$82-,\L;GEJQG+!L1X
MK9\5@IA1MN8_,HFCZ<1HQ#R>[N!JC![9\B:0]1D@D1BN2VX$U*Z\_*7&XYN9
M<HFST1]XN9A/&>F+^:7]X#;+7D9FG:RH'E=52;9J5>5X6J5I[15WF>*5W@J@
MN>;R@5#&7FTU,8CDJB.M6;(:G6XI?5U27JW?X]F/$YMNBHOF\K>I@)$3=A33
M2*UU&C2RH!@[QDOL_VUOV3#+.ST@ !!86VL>'#T1&#&OEB &M!G9MK 01A24
MGZINP;COD2EQK&N7?NQPDJL> ;02R'':=PSBZ^MO<2(KKYDFYR3,96AEB#E2
M063FP?"KL367J>#=5LJXWQX=!\$:V7G?1F\0_Q+%B/%KV:@(HI)A'+B[Y^U%
MQ9/9+444+CX(05$@33B_=E,]/>$,+0%0BADG\0&6YO+2<94F):2+P)L$Z #R
M,O:B1#<39NW:+0%JTDW $3GJ6?&>#2SU+A_S+L^-GP.Q Q+W,$#5E;&_JJDQ
M*0V<=D5(*R7/J,;H:@&1 00KIA RQ2RF/[S 1 >==V^2>@O/\P29VMT-+O]+
MEY'R1C.[V2DO;Z@+P+SNN&A-**OK.DZ:%R@2BR!UFOMJI_&+-JU(N@KLIB 9
M2(>.2(]ZQVGZ/ADZXA[.V<>&$"YTCE=:+ R//0<_XYTI'"V$R/+6Z**$GXJB
MW6YKEJ%WT47^EWSY[_7T]CQ%@]@0 R>LZX5U6BBKL)/!@>MZWV-^"5=M9EH&
M#$QKECJ")6PCJ8<BW4<7'4#OH*>[HZL"52L6'USZ42TK[*^^$B&*H)"3Y>J.
M35N6V;!ZCP/)W67[NE(4()Q8\E&."./MZH=-0526VH*+C=LA!DK8Q><U1%^L
M<@O-5)28!)\R#HNDA]M%@(6'G,-2S+F%,'9!Q\O_&YWM]A^S^MY0#$$'\ZV-
MIK#1M=HK9Z]^I)2LNM\ ":>4?M,N9V]O]T'F(WY2E3Z/@L,<@2H964C*)AS:
M*6VS/W![;]&*[Y+_L\%'@4BZ;W$07W$6)BR8_TV/NH@UCRZRO2NM&$"1HI_]
M/*?^8)B1IK)JZ]+4!HAH]*+IJ[=OV;YH]?3MTZ<PX4*(^PXFU(>PGD*&!QDJ
MVT>O(<9]':$9W$@1X<:'(>M!H[C/X#*''V-&=&@R9#2/(B>R7!CR8\Z/'_>1
M+/I2X$Z;& MZ1#H1X4.2/)L.C>ET:<R)%F5.'+GP(5&?"84V/#KP9<.8"#5V
M[.BPI+))FN1.?$E28]V\_WKW\NWK]R]@O\IB$,L[N&/@Q(K[9B*FL"5,B!E_
M-B6&(Y.F-&/&X.@L0P:"SZ)%AY;1F?-H&6.4H>SY>.),B0P1NG5MMQ[&D!UG
M%LPI56?+NEZ#4BQ:,C;%K0J)6TS(\VU8ABS1+L-1V&5#3:A'XZ"$N*74K\<)
MBARC>0RQK12GWSVZ<SK4DE9+&BQFG?K8G%_/TGXY.VU#.0DTX$=II*%5/<K,
MU5EIW(VAB3+2Z0=94P6QA0-B8"F3QF@Y9"*@04A19M10N1UEX4XY)16B03VY
MA!!4:"%&#QS<%:8>1K$QU)Q^O3$TT%+B]9@<2D+EE!5^6''55(O*$/.D,D@%
MA__88E5:>>5>5&*Y)9==>HFE/I,HLQ)3^D'4$D) .A?B6" 1U.)#!;7$%(RP
MO9=?;\))I!58&TWGHT\\VOG444%"IZ9+'3W49VT2657BFP ^AY8F.(B&@R;B
MX7@3B429=21:H;:55IX@N=?<;S0QI5-S!FTEGT,_$MK3?P,-9*%![=&ZJ&1E
MA@A4H#OY1]Y9@2+Y$ZC+1)3C3D!5&%)+:IZ54T?T$3?10[4)R%-[M^KFZ4G2
MX0GK15U-->&=08&XG'0RF6E0M=@:])&6X^[Y);Y=1A-#)GEE<D!)^6XYR2?<
M@M0M<2IJDAK#J5F*@WER$</:/IGD( 9WF80$&[H1\;?_ZL8^Y<351VP"FA]%
M]*@UZ5JA[J2HG*'FRJ*=7DG:WW3*R !S@I4R;)V*)KKF:GRA:F2F6VC!)RM$
MLAI%=*S*B&$5KNJ.I]%\_[78G'O[C#&)<RJ^1(S%EC8HFH?IT=?2HB$1DP-O
M(BT\VFK^B45M4TKC/2=-H.H4;U8?4?CCFX0K-9%EW&FBITV]&;JQM(0&'I:D
M'15)J%?0H?4:>ZAA2NA9 HN.9;^CFRXPV5UE,LGJ]>*[C"2[]3K=1TPQ-/)"
M:OFJ'T%9D61F5A8.R"U];2*VGT!KK>QHWG'F?F9$VB:G;NU9Y2ZGB8]%S].
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MJ:#IF!KOOH.J$H@CW$CJ":C8_S:B["ZG7KO+IP^'*V^B" L3B#*?5BQHO/=
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M86Y%G!%#8\2GESK6I4.6--*4[L,A&I)%7_:$W\6*]+ RG68M5M++8K1V(<Q
M17N6T]*SO@(3Q%@T6:YDB5_XA"Q\Z<QD#=4>T?[%F*BH*&(]RQ^4M.4^CI*S
M11=[C54RNIKDL61RW<+BI#1F%K\,U"IB0E45+V3/.\G2,O2K29\(IJTT"8^$
MRX2F;I01@QM,(A-O8$[1R+.,57G5/9H0C;C6"M>XRG6NQ8%&)EHHAKMF8J^\
MFL3F+DFB3NI#&>!\ TA20Y/_A80,9'=2J6,TM5.L&"V'TR)@-)0A@P*9-#(
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M7+>5@J7SG2*JH[T"*<N%BB4J<-L;3_=U$H*E;F-P?%8+K_DC *&D+]0RC<4
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M&NW1-H<^9+V2T!YCW'#L;= 9 @0MTE)MU8H9=$F"K1P  !S RQ('M^)&0LJ
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MV-/K27I@*V;BJ2P&CH?*>(9U^Q9N7+ESZ1[-) 8-7KQCT*#A6T]I6X;T9,A
M,*EN8L6+&3=VS)788XEI4@I,$P-G9(QB8I ="%A9)L^229<V?1K_=>G+:6/8
M;&U3K=),FA<J,RQ#9VK=NWGW]HTT]^Y,*T )S 0 QZ0;,696Q!&[]J0T@G]7
MMWX=>_;$DSXU!%68A5/MX\F7-]]X-&KE] 3*N,%>68#*%36I",X0&O7S^_GW
M]Y\T&K/$PVJVAHA!P##:_EN0P08=W$C!U-*X0:!) ,@MFIPL0@L-B-B"YL$0
M11QQ1'IN",  Y-)+2K^!-"D,@15)G)'&&JN[+S6TDL,))F4,&%"B96ZX89F(
M6K01R225?"R-%43+) ;$KGHCP@H1E$'&);7<DLNM@-1M$LS"((NSBI0) P?
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M2)-)HQ)*>-(WTJ->FL->ENO9)N)LIF]CT"( OI% (>(R. XY0V(9&HTDPN\
M*&[W7'55+^+N<.(3]T%/14(3 (!IO,T4O2U5V50C;@ YK"[PU,9FQ(!3:0(
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MF23T04<5XHA'XK/9TB3XL/LXVR,LCAG=T\_DA./$^G;_ UDB@QZV^2(:T#@
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M $, 8"@ # -  @!($  )!2 1 "0*@,0 T   &@1 0P%H! "- J Q_YT-P(
M&"@ @P!@4 #,?\E_V" 0  H"($  U'\U$!   H) 0"@(B  !42 @!@0!@" @
M$ 0*@B! $!0(@@'! " 8" 2#@F ($ P%@F% 2  ("0(AH2 D H1$@9 8$!H
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M'-$%:QQ7ID2E*B+S#.,(_M^D_>*<8WI=+G@RH\R"I^6C14PT<IRQ6<<;A2U
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MQA^/?/+*+\]\\\X_#WWTTD]/??767X]]]MIOSWWWWG\/_D<! 0 [4$L#!!0
M   ( &:"7%:2'-I1LJT  ,ZM   1    :6UG-#(Y-SDW,3-?.2YG:69$=W<X
MV^\7]H<001"S1NP]BX3:7WM3N_:6HA2EBJ*Q8\\BJ-I[:]4>M0FUHO:FI;2J
MI8,V;W_O^\=[_CO7N:XS[OL\UW-N'3UM.7D71M(EHA_ _S,$ *    L .  @
M *( ((H 1%& *!80Q0&B!, 2 "P1@"4*L,0"ECC D@"@ 0"- - H (T%T#@
M30#J * . =2A@#HL4(<#Z@@ '@#P" "/ O!8 (\#\(1_N0$" B"@  (6(.
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MN[=X%PF+V&?F7TP'3=!S%;%FTRM4;&6<G%P=H4'G6N2CV.0T#(E0<S82RQ"
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M]%TA'9[.YZQ!>PDGSIW@YGNZ_C1?#7D)/C?RL4_EA7R%+6@D?$_G!MPY)Z=
MPV1)6M$@T^'!MQ<B9.KG9M8C"RHBD%Q*Z@HQ_B)GF-Z5^I/7?K:/IITOQ[@
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MGZ0U[)6U7T,4D:9$E1#9/HCK:XPAE:[<:(X18PK+[O3=P#R>:$X/*A4)>L#
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M9\7:X1$EQ3SH(&TXU3M.<D*S#!S02HB4&L.^3H5$W(1/BUV<#%TXU[89)K"
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MYZH!UV/^<C0]PQ2%5HK;4HXKQJ#GBDI")%,".;/_4 S*E,IF_!+,EN%J#L
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M6Z$@I_O#IKR]9%X%12?7)$26TN.R\ Z31(Z,_Q)%BH&RIYV> 6*,F!PX!N+
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M\K/!)I7!BX9II+/5/;1*OLM4_016D.:J]YB<'X-TZ4N;(L,:E9QI\V$ ,7
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MS>!(@QAP+)C  85\D4EH,#P3)>EDRJB#L\%9%IC$S5-23+(L+;#RQB04Q;<
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MX_^;R0PRZ\*BFA,P^^.E0;+4-.Q0%;,LQ" D$U3$8U5$?? Z@IB+;?VV- B
M&UC1EF@<GR$*/PW$R+1*[?*U5ZNA:.PS)_51Y7.]E/S0^7$Y7,6L5GV:CER0
MJ\3)ES2VB_01E[TZA5U*@QB#?QR#[8P6:>L(>KH[OQ.)G3&6]9S8G7!/ #@
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M&M/68^/V>C.YCR]_/OWZ=)=E M];+':=D7\'IYEG/,TF6UM"L34:?^9U5UR
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M29*U!>WE&]2N7*DHQ5Q,#/O:V&G*F"/*VKO$)F*%$=6618]ZK8E(!AYS\[8
MF6YP(8B.7Z$1#XWV;PQ0'H=N5KP]%'PQWIB)DT>8TGSQ#W&%GP$L'((IV@'
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M=[C*HT:QNJGHH&@\6!]3A.:M>^P:"PE,8?SJM62O=MIE-Y,>!Q.(9.NQ_Z]
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M,324805T341PJZ>6DBDYD=3Z91^8"32PD2HEK4,RH1&=R-,T 09PP/-DP-K
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M #M02P$"% ,4    " !F@EQ6CY\IX#TK! "7/#< $0              @ $
M    86QE8RTR,#(R,3(S,2YH=&U02P$"% ,4    " !F@EQ6>VJ56'T0  "R
ML@  $0              @ %L*P0 86QE8RTR,#(R,3(S,2YX<V102P$"% ,4
M    " !F@EQ6S>#AQF(0  "(Y@  %0              @ $8/ 0 86QE8RTR
M,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ 9H)<5@9%53:Z*   7/0" !4
M             ( !K4P$ &%L96,M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( &:"7%:G6"UU0)D  /)!!P 5              "  9IU! !A;&5C+3(P
M,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !F@EQ6>1(@+PE"  ! *04 %0
M            @ $-#P4 86QE8RTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%
M  @ 9H)<5JH6]M[)%0  1_<  !               ( !25$% &%L96,M97@Q
M,%\Q,2YH=&U02P$"% ,4    " !F@EQ6M.VW.E4'  !X7@  $
M    @ % 9P4 86QE8RUE>#$P7S$X+FAT;5!+ 0(4 Q0    ( &:"7%::GSW>
MI@,  ,4?   /              "  <-N!0!A;&5C+65X,C-?,2YH=&U02P$"
M% ,4    " !F@EQ69;RN0:\(  "E40  #P              @ &6<@4 86QE
M8RUE>#,Q7S$N:'1M4$L! A0#%     @ 9H)<5O^*8"#$"   JE$   \
M         ( !<GL% &%L96,M97@S,5\R+FAT;5!+ 0(4 Q0    ( &:"7%8$
M\MH/^@0  ',K   /              "  6.$!0!A;&5C+65X,S)?,2YH=&U0
M2P$"% ,4    " !F@EQ6R/?_$0@%   @+   #P              @ &*B04
M86QE8RUE>#,R7S(N:'1M4$L! A0#%     @ 9H)<5O)B=3RN80$ NF$! !$
M             ( !OXX% &EM9S0R.3<Y-S$S7S N9VEF4$L! A0#%     @
M9H)<5DZ"4'CAN $ ZK@! !$              ( !G/ & &EM9S0R.3<Y-S$S
M7S$N9VEF4$L! A0#%     @ 9H)<5K3<##3G@P  /KX  !(
M ( !K*D( &EM9S0R.3<Y-S$S7S$P+FIP9U!+ 0(4 Q0    ( &:"7%90Z;S:
MXEX! .Y> 0 2              "  <,M"0!I;6<T,CDW.3<Q,U\Q,2YG:690
M2P$"% ,4    " !F@EQ6D<UV_:<F 0"L)@$ $@              @ '5C H
M:6UG-#(Y-SDW,3-?,3(N9VEF4$L! A0#%     @ 9H)<5H'54K((/0  MT8
M !(              ( !K+,+ &EM9S0R.3<Y-S$S7S$S+FIP9U!+ 0(4 Q0
M   ( &:"7%9&ICY91B(! %4B 0 2              "  >3P"P!I;6<T,CDW
M.3<Q,U\Q-"YG:6902P$"% ,4    " !F@EQ6<0<R"/6@   'H0  $@
M        @ %:$PT :6UG-#(Y-SDW,3-?,34N9VEF4$L! A0#%     @ 9H)<
M5JU)(*>)B@  N8H  !(              ( !?[0- &EM9S0R.3<Y-S$S7S$V
M+F=I9E!+ 0(4 Q0    ( &:"7%8;O9VBE<X  *;.   2              "
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M,U\R,"YJ<&=02P$"% ,4    " !F@EQ6X.]^G6@[  "%.P  $@
M    @ %F^A$ :6UG-#(Y-SDW,3-?,C$N9VEF4$L! A0#%     @ 9H)<5E4'
M<(Y]F $ BI@! !$              ( !_C42 &EM9S0R.3<Y-S$S7S,N9VEF
M4$L! A0#%     @ 9H)<5K]JEAT.S   )<P  !$              ( !JLX3
M &EM9S0R.3<Y-S$S7S0N9VEF4$L! A0#%     @ 9H)<5DZM4+W69 ( Q&0"
M !$              ( !YYH4 &EM9S0R.3<Y-S$S7S4N9VEF4$L! A0#%
M  @ 9H)<5HA_FV4Q6P  0EL  !$              ( ![/\6 &EM9S0R.3<Y
M-S$S7S8N9VEF4$L! A0#%     @ 9H)<5G;BS1#Z50$ _E4! !$
M     ( !3%L7 &EM9S0R.3<Y-S$S7S<N9VEF4$L! A0#%     @ 9H)<5F(7
MKGI=6P  =%L  !$              ( !=;$8 &EM9S0R.3<Y-S$S7S@N9VEF
M4$L! A0#%     @ 9H)<5I(<VE&RK0  SJT  !$              ( ! 0T9
H &EM9S0R.3<Y-S$S7SDN9VEF4$L%!@     C ", K0@  .*Z&0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
